Ovarian Cancer by unknown
Ovarian Cancer 
Clinical and Therapeutic Perspectives
Edited by Samir A. Farghaly
Edited by Samir A. Farghaly
Worldwide, Ovarian carcinoma continues to be responsible for more deaths than all 
other gynecologic malignancies combined. International leaders in the field address 
the critical biologic and basic science issues relevant to the disease. The book details 
the molecular biological aspects of ovarian cancer. It provides molecular biology 
techniques of understanding this cancer. The techniques are designed to determine 
tumor genetics, expression, and protein function, and to elucidate the genetic 
mechanisms by which gene and immunotherapies may be perfected. It provides an 
analysis of current research into aspects of malignant transformation, growth control, 
and metastasis. A comprehensive spectrum of topics is covered providing up to date 
information on scientific discoveries and management considerations.
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204,449 new cases of ovarian cancer are diagnosed worldwide each year, with an 
estimated 124,860 disease-related deaths. Ovarian cancer is the second most 
gynecological cancer in the United States of America, but most common cause of 
gynecological cancer related death, primarily because most patients present with 
advanced disease. 65-70 % of patients are diagnosed at an advanced stage, conferring a 
5-year survival rate of 30-55%. Ovarian cancer is associated with such a significant 
burden of disease for the individual and for society. The ovarian cancer statistics for 
incidence, indicate it is highest in the USA and Northern Europe and lowest in Africa 
and Asia. The approach to women with ovarian cancer has become multidisciplinary, 
with many professionals contributing to the excellent care and outcome that we wish 
to see for those individuals we are privileged to look after. 
This book discusses a range of diagnostic and therapeutic considerations, including 
epidemiologic, pathologic, open surgical, minimally invasive surgical, and 
chemotherapeutic aspects.  
The most current and comprehensive statistics associated with ovarian cancer 
incidence is detailed in Chapter 1. Screening for epithelial ovarian cancer (EOC), and 
the development of novel diagnostic tests such as bead-based ELISA assays using 
recombinant anti bodies produced by yeast is presented in Chapter 2. Screening for 
ovarian cancer in the general and increased-risk population is reviewed in Chapter 3. 
Macroscopic, histology grading, immunohistochemistry, and differential diagnosis of 
malignant and borderline surface epithelial-stromal tumors of the ovary is discussed 
in Chapter 4. Clinico-pathological features of the central nervous system involvement 
in epithelial ovarian cancer and the different therapeutic approaches for such a disease 
are discussed in Chapter 5. Comprehensive review of peripheral neuropathy relative 
to ovarian cancer, including symptoms, pathogenesis, incidence, risk factors, 
diagnosis, and management is covered in Chapter 6. A therapeutic strategy for the 
treatment of primary and secondary ovarian cancer which involves surgery, 
chemotherapy, radiation therapy, biological therapy, and hormones is presented in 
Chapter 7. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for 
the treatment of locally advanced ovarian cancer is described in Chapter 8. Recent 
advances and state-of-the-art minimally invasive surgical techniques for advanced and 
recurrent ovarian cancer, in reference to involvement of lower urinary tract, 
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gastrointestinal tract, spleen, and liver are presented in Chapter 9. The medical and 
surgical management principals of recurrent and persistent ovarian cancer are 
reviewed in Chapter 10. Feasibility of repositioning antiprogestins, originally designed 
for contraceptive purposes, for ovarian cancer therapy is covered in Chapter 11. 
Current status and aspects of intraperitoneal radioimmunotherapy (RIT) of ovarian 
cancer is reviewed in Chapter 12. Efficacy and safety of Vitamin K2 as a chemotherapy 
agent for the treatment of ovarian cancer is reviewed in Chapter 13. Second-line 
combination therapy for platinum and taxane-resistant epithelial ovarian cancer is 
described in Chapter 14. HER2 as a therapeutic target for ovarian cancer inidentifying 
and treating the right patient is presented in Chapter 15. Sexual functions and body 
image of patients with ovarian cancer following therapy is detailed in Chapter 16. 
Finally, Scale structures, psychometric properties, and clinical validities of extrinsic 
instruments for the assessment of health related quality of life of patients with ovarian 
cancer is detailed in Chapter 17. 
This book is intended for all clinicians caring for women with ovarian cancer, 
including attending surgeons and physicians, fellows, and residents in the disciplines 
of gynecologic oncology, surgical oncology, medical oncology, and primary care. 
Allied medical staff, palliative services, and nurse specialists will also find it a useful 
adjunct to getting current information on ovarian cancer. 
I hope that you enjoy this book, and benefit from the extensive experience of the 
contributors to this book from the USA, Europe, and Asia who have authored its 
contents. 
 
Samir A. Farghaly, MD, PhD 
The Joan and Sanford Weill Medical College of Cornell University 
 The New York Presbyterian Hospital 
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Ovarian Cancer Incidence: Current  
and Comprehensive Statistics  
Sherri L. Stewart 
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention 
USA 
1. Introduction 
Ovarian cancer is a commonly diagnosed and particularly deadly gynecologic malignancy 
worldwide. It ranks among the top ten diagnosed cancers and top five deadliest cancers in 
most countries (Ferlay et al., 2010). Several cancer incidence data sources have been used to 
measure ovarian cancer burden across the world; however, the statistics presented are often 
not population-based, which can lead to misrepresentation of the burden due to incomplete 
or inaccurate data. An accurate assessment of ovarian cancer burden is essential as incidence 
data are used for many purposes including to generate hypotheses regarding etiology, 
allocate resources and funding toward  new treatment discovery and clinical trials, and 
determine which populations of women may benefit from more education or greater 
surveillance for the disease.  The purpose of this chapter is to present global comprehensive 
ovarian cancer incidence data. Data collected are from several resources, and every effort is 
made to present only high-quality data from population-based data sources. Because of 
changing age structures of populations and differences in data quality and coverage of 
various data sources over time, only the most recent data are presented. This will aid in 
preventing misinterpretation of temporal trends. 
2. Data sources and interpretation 
Data on the incidence of ovarian cancer (the number of new cases per year) is collected by 
population-based cancer registries; however, only certain countries have national registries 
that collect this information. In the United States, a law passed in 1992 established nationwide 
cancer surveillance. This law resulted in the establishment of the National Program of Cancer 
Registries (NPCR), which is administered by the Centers for Disease Control and Prevention 
(CDC), and provides cancer incidence data for 96% of the U.S. population (U.S.Cancer 
Statistics Working Group, 2010). When combined with data  from the existing Surveillance, 
Epidemiology, and End Results (SEER) program, administered by the National Cancer 
Institute (NCI), 100% of the U.S. population is accounted for. Several other countries including 
Canada, Singapore, Denmark, Finland, Iceland, Norway, and Sweden have nationwide 
registry systems (Thun et al., 2011). Many other countries base their incidence on cancers 
collected in certain regions or groups of regions, and therefore these results vary in quality 
(Thun et al., 2011).  Cancer registries typically require a period of one to two years to collect all 
required information on cancer diagnoses in the geographic areas covered. For that reason, 
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Incidence rates take into account the number of new cases of cancer (numerator), and also 
the population at risk for the cancer (denominator). Most incidence rates are age-adjusted or 
standardized in order to allow comparisons across populations with differing age 
structures. Several age distributions are available for standardization. In international data, 
which is compiled from population-based registries by the International Agency for 
Research on Cancer (IARC), the 1960 world standard population is used (Ferlay et al., 2010). 
Within specific countries, such as the United States, the 2000 U.S. standard population is 
used (Thun et al., 2011; U.S.Cancer Statistics Working Group, 2010). Differences in age 
standardization methodology can result in a variance of rates reported from the same 
country. Age-specific rates for certain age poulations (e.g., children) are often reported; 
these rates are often not age-adjusted or standardized. Most rates are expressed per 100,000 
persons, and in the case of ovarian cancer per 100,000 women. 
In this chapter, data are presented from a variety of sources, including monographs and 
peer-reviewed literature. Data are presented from the IARC public-use monograph 
(GLOBOCAN 2008) on case counts and rates for countries around the world (Ferlay et al., 
2010). Since the United States also produces a comprehensive monograph annually, data are 
also presented for this country from the public-use United States Cancer Statistics (USCS) 
website (U.S.Cancer Statistics Working Group, 2010).  Overall case and rate data from peer-
reviewed articles are also included for countries (including the United States) that have 
published ovarian cancer incidence information from population-based registries. These 
articles may be a better source of data for some countries than monographs, as they may 
contain more complete or up-to-date information. Demographic- and clinical factor-specific 
data, and temporal trends are presented from monographs when available, and are 
supplemented with data from the most recent peer-reviewed publications for all countries 
available. Clinical factor data  and temporal trends especially (histology, stage, laterality) are 
most often contained in peer-reviewed publications as opposed to monogaphs.  To prevent 
misinterpretation, only data from the most recent publications (monograph or peer-
reviewed publication) are presented. Table 1 lists data sources, years and population 
covered for each.   
3. Global ovarian cancer incidence 
A total of 224,747 new cases of ovarian cancer were reported worldwide in 2008, with 99,521 
cases being diagnosed in more developed regions, and 125,226 being diagnosed in less 
developed regions (Ferlay et al., 2010). Ovarian cancer was the seventh most common cancer 
diagnosis among women in the world overall, and fifth most common cancer diagnosis 
among women in more developed regions (Ferlay et al., 2010). The world rate is estimated 
to be 6.3 per 100,000, and is higher in developed countries and regions (9.3) compared to 
others (Ferlay et al., 2010).  Incidence rates for selected regions, continents and countries are 
shown in Table 2. Rates range from 3.8 in the Southern and Western African regions  to 11.8 
in the region of Northern Europe. Continental rates are highest in Europe (10.1), followed by 
North America (8.7), Australia (including New Zealand, 7.8), South America (6.2), Asia (5.1), 
and Africa (4.2). 
Figure 1 displays a categorization of ovarian cancer incidence rates around the world. Rates 
for individual countries range from 1.8 in Samoa to 14.6 in Latvia (Ferlay et al., 2010). 
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Author and publication year Data year(s) Population* 
Ferlay et al., 2010 2008 World 
U.S. Cancer Statistics 
Working Group, 2010 
2007 United States (99.1%) 
Koper et al., 1996 1989-1991 Netherlands  
Ioka et al., 2003 1975-1998 Osaka, Japan 
Mahdy et al., 1999 1988-1997 Alexandria, Egypt 
Zambon et al., 2004 1986-1997 Several regions in Italy 
Kohler et al., 2011 Rates: 2003-2007;  
Trends: 1998-2007 
United States (93%) 
Tamakoshi et al., 2001 1975-1993 Several regions in Japan 
Jin et al.,1993 1979-1989 Shanghai, China 
Dey et al., 2010 1999-2002 Tanta, Egypt 
Minelli et al., 2007 1998-2002 Umbria, Italy 
Goodman & Howe, 2003 1992-1997 United States (52%) 
Goodman et al., 2003 1992-1997 United States (52%) 
Boger-Megiddo & Weiss, 
2005 
1992-2000 United States (26%) 
Stiller, 2007 NR World 
Brookfield et al., 2009 1973-2005 United States (9%) 
Poynter et al., 2010  1975-2006 United States (9%) 
Smith et al., 2006 1973-2002 United States (9%) 
Goodman and Shvetsov, 
2009 
1995-2004 United States (64%) 
Jaaback et al., 2006 1993-2003 Royal United Hospital, UK 
Stewart et al, 2007 1998-2003 United States (83.1%) 
Riska et al., 2003 1953-1997 Finland 
Pfeiffer et al., 1989 1978-1983 Denmark 
 
Table 1. Data years and populations covered for monographs and articles cited throughout 
this chapter. *The population coverage for a particular country or region is provided when 
available from reports. NR=not reported. 
In the United States, 20,749 ovarian cases were diagnosed in 2007 (the most recent year for 
which data are available), for an incidence rate of 12.2 per 100,000 women (U.S.Cancer 
Statistics Working Group, 2010). Koper et al. reported a rate of 14.9 in the Netherlands, 
similar to that found in the United States (Koper et al., 1996). In Osaka, Japan the overall rate 
reported was 5.4 (Ioka et al., 2003), and in Alexandria, Egypt, the rate was 3.16 (Mahdy et al., 
1999). An Italian network of cancer registries reported 7,690 cases of ovarian cancer from 
1986 through 1997 (Zambon et al., 2004).  Few countries publish trends in ovarian cancer 
incidence over time. This may be due to differing methods of data collection and data 
quality issues, especially for countries that do not have a national registry. In the United 
States, a recent report estimates that ovarian cancer incidence has been decreasing since 
1998, with a significant decline of 2.3% per year from 2003-2007 (Kohler et al., 2011). The 
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reasons for this decrease are unclear, but are likely not artefactual due to the long-standing 
high-quality data available for the United States. A Japanese analysis based on data from 
several regional cancer registries reported a 1.5 fold increase in ovarian cancer rates from 
1975 to 1993 (Tamakoshi et al., 2001).  The Chinese Shanghai Cancer Registry also reported 
an increase in ovarian cancer incidence from 1979-1989 (Jin et al., 1993). Some of these 
increases may be due to increases in population coverage or completeness of data within the 
registry; however, the Chinese increase is thought to be a birth cohort effect in women born 
between 1925-1935 (Jin et al., 1993). 
 
 
Region  Case count Rate 
World 224747   6.3   
More developed regions 99521   9.3   
Less developed regions 125226   5.0   
Africa 13976   4.2   
Sub-Saharan Africa 9961   4.0   
Eastern Africa 3840   4.0   
Middle Africa 1728   4.3   
Northern Africa 4015   4.8   
Southern Africa 893   3.8   
Western Africa 3500   3.8   
Latin America and Caribbean 16981   5.9   
Caribbean 1005   4.3   
Central America 3571   5.2   
South America 12405   6.2   
Northern America 23895   8.7   
Asia 102408   5.1   
Eastern Asia 40831   4.3   
South-Eastern Asia 18580   6.6   
South-Central Asia 38797   5.5   
Western Asia 4200   4.8   
Europe 65697   10.1   
Central and Eastern Europe 27071   11.0   
Northern Europe 10256   11.8   
Southern Europe 11751   8.4   
Western Europe 16619   8.9   
Oceania 1790   7.6   
Australia/New Zealand 1601   7.8   
Melanesia 161   5.1   
Micronesia/Polynesia 28   5.5   
Micronesia 15   6.1   
Polynesia 13   5.0   
Table 2. Ovarian cancer incidence counts and rates for selected regions and continents 
worldwide. Rates are per 100,000 women and age-standardized to the 1960 world standard 
population. Source: Ferlay et al., 2011. 
 





Fig. 1. Map of ovarian cancer rates worldwide. Rates are per 100,000 women and are age-
standardized to the 1960 world standard population. Data were not included for white areas 
on the map. Source: Ferlay et al., 2011. 
Incidence patterns stratified by region can assist with assessment of environmental or 
cultural factors that may increase risk. Regional variation in ovarian cancer rates exists, and 
this variation can sometimes be substantial. Percentages of ovarian cancer cases in World 
Health Organization regions are shown in Figure 2, these percentages range from 4.4% in 
the Eastern Mediterranean region (EMRO) to 31.0% in the European region (EURO) (Ferlay 
et al., 2010).   
 
 
Fig. 2. Percentage of ovarian cancer cases by World Health Organization (WHO) health 
organization region. SEARO=Southeast Asia Regional Office, EURO=European Regional 
Office; EMRO=Eastern Mediterranean Regional Office; WPRO=Western Pacific Regional 
Office; AFRO=Africa Regional Office; PAHO=Pan American Health Organization. Source: 
Ferlay et al., 2011. 
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These numbers do not take into account the population, and may likely be reflective of the 
population coverage of cancer registration in these areas. In the United States, ovarian 
cancer incidence rates are similar among the Northeast, Midwest, and South U.S. Census 
regions (11.7-12.9), and individual state rates range from 7.3 to 15.4 (U.S.Cancer Statistics 
Working Group, 2010).   Studies in Egypt (Dey et al., 2010) and Italy (Minelli et al., 2007) 
have found ovarian cancer rates to be higher in urban compared to rural areas.  Table 3 
displays the ovarian cancer case counts and incidence rates by U.S. census region and 




Geographic Area Case count Rate 
United States 20,749 12.2 
Northeast 4,375 12.9 
New England 1,057 11.9 
Connecticut 268 12.1 
Maine 98 11.8 
Massachusetts 473 11.8 
New Hampshire 99 12.5 
Rhode Island 77 11.8 
Vermont 42 10.8 
Middle Atlantic 3,318 13.3 
New Jersey 696 13.3 
New York 1,516 13 
Pennsylvania 1,106 13.7 
Midwest 4,724 12.3 
East North Central 3,318 12.4 
Illinois 896 12.6 
Indiana 428 11.7 
Michigan 755 13.1 
Detroit 320 13.7 
Ohio 827 12 
Wisconsin 412 12.7 
West North Central 1,406 12.1 
Iowa 248 13.7 
Kansas 196 12.6 
Minnesota 352 12.1 
Missouri 403 11.5 
Nebraska 108 10.4 
North Dakota 46 12.9 
South Dakota 53 11.4 
South 7,298 11.7 
South Atlantic 4,045 11.9 
Delaware 78 15.4 
District of Columbia 31 9.4 
Florida 1,391 11.8 
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Geographic Area Case count Rate 
Georgia 638 13.2 
Atlanta 191 12.1 
Maryland 367 11.2 
North Carolina 612 12 
South Carolina 295 11.4 
Virginia 491 11.3 
West Virginia 142 11.9 
East South Central 1,187 11.2 
Alabama 312 11.1 
Kentucky 278 11.3 
Mississippi 173 10.3 
Tennessee 424 11.8 
West South Central 2,066 11.6 
Arkansas 188 11 
Louisiana* 237 9.6 
Oklahoma 272 13 
Texas 1,369 11.8 
West  NR NR  
Mountain  NR NR  
Arizona 397 11.6 
Colorado 334 13.3 
Idaho 119 15 
Montana 65 11 
Nevada  NR NR  
New Mexico 129 11.9 
Utah 103 9.1 
Wyoming 22 7.3 
Pacific 3,183 12.4 
Alaska 37 13.1 
California 2,319 12.3 
San Francisco-Oakland 317 12.8 
San Jose-Monterey 158 12.8 
Los Angeles 626 12.6 
Hawaii 92 12.2 
Oregon 280 12.7 
Washington 455 12.5 
Seattle-Puget Sound 332 13.2 
 
Table 3. Ovarian cancer incidence counts and rates for the United States, U.S. Census regions 
and divisions and individual states. Rates are per 100,000 women and age-adjusted to the 
2000 U.S. standard. Data presented cover 99.1% of the U.S. population. *Indicates that data 
differ from that presented by the Louisiana Tumor Registry and the SEER Program. NR=not 
reported.  Source: (U.S.Cancer Statistics Working Group, 2010). 
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3.1 Clinical factors (histology, stage, laterality) and ovarian cancer incidence 
Ovarian cancers are classified into three main histologic groups: epithelial tumors, sex 
cord-stromal tumors, and germ cell tumors (Cannistra et al., 2011). Epithelial tumors are 
believed to originate from the surface epithelium of the ovary (Chen et al., 2003). There 
are four main subtypes of epithelial tumors: serous, mucinous, endometrioid, and clear 
cell adenocarcinomas (Chen et al., 2003). Sex cord-stromal tumors originate in granulosa 
or thecal cells, or other stromal cells. Germ cell tumors are formed by cells that are 
believed to be derived from primordial germ cells, and they include the subtypes 
dysgerminomas, teratomas, and yolk sac tumors, among other subtypes (Chen et al., 
2003). Several histologic-specific ovarian cancer incidence studies are published in the 
peer-reviewed literature, and most are based on populations in the United States. In a 
2003 publication, Goodman et al. reported that 91.9% of ovarian tumors were epithelial, 
1.2% were sex cord-stromal, and 1.9% were germ cell (Goodman & Howe, 2003). Serous 
adenocarcinoma was the most incident epithelial subtype, accounting for 37.7% of all 
ovarian tumors (Goodman & Howe, 2003). These U.S. data are consistent with those from 
the Netherlands, where 89% of all ovarian cancer diagnoses were reported to be epithelial 
tumors (Koper et al., 1996).   
Effective early detection methods for ovarian cancer do not currently exist, and symptoms 
for ovarian cancer can be vague and gastrointestinal (as opposed to gynecologic) in nature. 
Because of this, many ovarian tumors are diagnosed at advanced stages. In the United 
States, studies show that about 20% of all ovarian cancer cases are localized stage at 
diagnosis, about 13% are regional stage, and the majority are distant stage (58%) (Goodman 
et al., 2003). This distribution differs by histologic type. Sex cord-stromal and germ cell 
tumors are more often diagnosed at localized stages (>50%) compared to epithelial tumors 
(19%) (Goodman et al., 2003). In the Netherlands, two thirds of all ovarian cancers were 
found to be extended to the pelvis or beyond at diagnosis (Koper et al., 1996).    
There is a paucity of analyses on laterality.  In a U.S. population, serous adenocarcinomas 
were were found to be bilateral at diagnoses in 57.5% of cases, and other epithelial tumors 
ranged in bilaterality from 13.3% to 35.6%  (Boger-Megiddo & Weiss, 2005).  
3.2 Demographic factors (age and race/ethnicity) and ovarian cancer incidence 
Age is commonly reported in most ovarian cancer incidence publications. Globally, 
ovarian cancer incidence rates increase with advancing age and range from 0.2 among 
those aged 0-14 to 29.2 among those aged 75 years and older (Ferlay et al., 2010). A similar 
pattern is seen in more developed countries;  however, the incidence rates are higher and 
range from 0.3 to 42.6 (Ferlay et al., 2010). In the United States, ovarian cancer incidence 
rates range from 0.3 in those aged 5-9 years to 44.2 in women aged 85 and older 
(U.S.Cancer Statistics Working Group, 2010). The peak ovarian cancer incidence rate of 
50.6 is found among women aged 80-84 in the United States (U.S.Cancer Statistics 
Working Group, 2010). In developing countries, ovarian cancer occurs in younger women. 
In Ghana, the mean age of ovarian cases seen in a teaching hospital was 46.4 years 
(Nkyekyer, 2000), and in Kyrgyzstan, the average age of ovarian cancer patients was 37.9, 
with the highest incidence rate (11.2 per 60,0000 women) observed among those aged 40-
49 (Igisinov & Umaralieva, 2008).    
Several published studies limit their age-specific ovarian cancer analyses to children and 
adolescents, and many of these specifically report on ovarian germ cell tumors, which are 
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diagnosed in high numbers among children and adolescents (Young et al., 2003). In an 
international study of cancer among adolescents, ovarian germ cell tumors were found in 
the highest rates among those aged 15-19 (Stiller, 2007). A study from the United States 
reported an overall ovarian cancer incidence rate of 0.102 for girls aged 9 years and younger, 
and 1.072 for girls aged 10-19 years (Brookfield et al., 2009). Other studies in the United 
States comparing germ cell tumor rates concluded that the incidence of ovarian germ cell 
tumors was significantly higher in Hispanic compared to non-Hispanic girls aged 10-19 
(Poynter et al., 2010; Smith et al., 2006), and Asian/Pacific Islanders (0.059) compared to 
other ethnicities (Smith et al., 2006). Consistent with international studies, girls aged 15-19 
years had the highest germ cell rates in the United States and it was reported that these rates 
are increasing (Smith et al., 2006).  
Most reports examining ovarian cancer by race and/or ethnicity are in the United States 
population. This is likely due to the diversity in the racial and ethnic make-up of the 
United States. In 2007,  it was reported that ovarian cancer incidence rates were highest 
among U.S. white women (12.6), followed by black (9.1), Asian/Pacific Islander (A/PI) 
(9.0), and  American Indian/Alaska Native (AI/AN) women (8.0) (U.S.Cancer Statistics 
Working Group, 2010). Rates were lower in Hispanic women (10.2) compared to non-
Hispanic women (11.3) (U.S.Cancer Statistics Working Group, 2010). Some U.S. studies 
have used enhanced population denominator data to probe race-specific rates further in 
an attempt to provide more accurate or meaningful rates. Studies using denominator data 
adjusted for Indian Health Service delivery regions in the United States  (Espey et al., 
2007; Kohler et al., 2011) report ovarian cancer incidence rates of 11.3 (Kohler et al., 2011) 
among AI/AN women. The most recent report examining trends concluded that ovarian 
cancer incidence rates have been decreasing at about 1.0% per year since 1998 among most 
racial and ethnic groups in the United States, with the exception of A/PI women (Kohler 
et al., 2011).    
4. Primary peritoneal and primary fallopian tube cancers 
Primary peritoneal cancer (PPC) and primary fallopian tube cancer (PFTC) are rare 
malignancies, but share many similarities to ovarian cancer. These three cancers are 
clinically managed in a similar manner (Cannistra et al., 2011). Due to their rarity, these 
cancers are generally not reported as a distinct or separate category in statistical 
monographs; reports of their incidence are limited to relatively few peer-reviewed 
publications. In the United States, the incidence rate of PPC is estimated to be 0.678 
(Goodman & Shvetsov, 2009a). PPCs were diagnosed at later ages (mean age 67 years) and 
more  advanced stages (85% regional/distant diagnoses) than ovarian cancer (mean age 
63, 75% regional/distant diagnoses) in this same population (Goodman & Shvetsov, 
2009a). In contrast, a study from a UK cancer center examining PPC found that age and 
tumor characteristics (stage and grade) were similar among ovarian and primary 
peritoneal tumors (Jaaback et al., 2006). The U.S. incidence rate of PFTC is 0.41 (Stewart et 
al., 2007). The vast majority of PFTCs (89%) are unilateral at diagnosis, and about 30% are 
diagnosed at each localized, regional and distant stages (Stewart et al., 2007). U.S. PFTC 
rates are  similar to those reported from Finland (0.3) (Riska et al., 2003) and Denmark 
(0.5)  (Pfeiffer et al., 1989). U.S. studies have suggested that the rates of both PPC 
(Goodman & Shvetsov, 2009a; Howe et al., 2001) and PFTC  (Goodman & Shvetsov, 2009a; 
Stewart et al., 2007) are increasing. It is thought that some of this increase may be due to 
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reduction in the misclassification of PPC and PFTC as ovarian cancer (Stewart et al., 2007, 
Goodman & Shvetsov, 2009b). 
5. Discussion 
Ovarian cancer incidence rates reported from countries with nationwide cancer registration 
and those from more developed countries are generally similar to each other.  In less 
developed countries and regions, ovarian cancer rates are relatively lower, and this is likely 
due in part to the lack of quality data from large portions of the population in these 
countries. Additionally, cancers that are related to infectious agents (i.e. not ovarian cancer), 
are some of the most incident cancers in developing countries (Thun et al., 2011). It should 
be noted; however, that while cancer overall has typically been more incident in 
industrialized and comparatively wealthy nations, it is suggested that cancer incidence is 
increasing in low and medium resource countries (Thun et al., 2009). This increase may be a 
result of an increased lifespan due to advances in medical treatment in these countries, as 
well as the adoption of Western patterns of diet, physical activity, and tobacco use (Thun et 
al., 2011).  
Several factors, including  genetic, reproductive, hormonal and behavioral factors have been 
suggested to increase risk for ovarian cancer.  Genetic factors perhaps have the strongest 
and most consistent association with increased risk for ovarian cancer. At least 10% of all 
epithelial ovarian cancers are reported to be hereditary, with the majority (about 90%) of 
these related to mutations in BRCA genes and 10% related to mutations associated with 
Lynch syndrome (Prat et al., 2005).  Hereditary ovarian cancers have distinct patterns from 
sporadic ovarian cancers. Many are diagnosed at younger ages and less advanced stages 
than sporadic ovarian cancers (Prat et al., 2005). Regarding reproductive factors, studies 
over several years have consistently associated nulliparity with increased risk of ovarian 
cancer (Modan et al., 2001; Risch et al, 1994; Vachon et al., 2002). It is estimated that 
nulliparity may increase risk only slighty in the average-risk population (relative risk 
[RR]=1.4, 95% confidence interval [CI] 1.9-2.4), but may have a more substantial effect in 
women with a family history of ovarian cancer (Vachon et al., 2002).  Hysterectomy and 
tubal ligation have been consistently associated with conferring a decreased risk for ovarian 
cancer.   Tubal ligation has been estimated to decrease risk substantially  (RR= 0.33, 95% CI 
0.16 to 0.64), while hysterectomy may have a weaker, but still protective association (RR= 
0.67, 95% CI 0.45 to 1.00) (Hankinson et al., 1993). Oral contraceptive use has been suggested 
to decrease risk for ovarian cancer, while post-menopausal hormone replacement therapy 
use is suggested to increase risk for ovarian cancer.  However, conclusions from hormonal 
studies have generally been less consistent and more difficult to interpret than genetic and 
reproductive factor studies.  Although some studies have shown a protective effect of oral 
contraceptives on ovarian cancer (Beral et al., 2008), IARC classifies estrogen, combined 
estrogen-progesterone oral contraceptives, and combined estrogen-progesterone hormone 
replacement therapy as class one carcinogens, concluding there is sufficient evidence for 
their carcinogenicity in humans (IARC 2007).  The relationship between behavioral factors, 
such as tobacco use, physical activity, and obesity and ovarian cancer has been less reported 
compared to the other factors mentioned. Available results are generally inconclusive. Some 
studies have suggested a modest increased risk of ovarian cancer in obese women 
(Leitzmann, et al., 2009); however, others have found no relationship between body mass 
index and ovarian cancer (Fairfield et al., 2002). Similarly with physical activity, one study 
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concluded there was a modest inverse association of physical activity and ovarian cancer 
risk (Biesma et al., 2006), while another concluded there was no association (Hannan et al., 
2004). Smoking has been shown to increase risk for the epithelial subtype mucinous 
adenocarcinoma, but does not increase risk for other more incident subtypes (Jordan et al., 
2006).  
6. Conclusion 
Although ovarian cancer patterns vary widely around the world, incidence rates are high in 
several regions. The etiology and natural history of ovarian cancer are poorly understood, 
and much more research is needed to elucidate factors that may increase or decrease risk for 
ovarian cancer. The analysis of incidence patterns both within and between populations is 
essential to revealing potential causes of and risk factors for ovarian cancer. Incidence rates 
from countries with high-quality data should continue to be analyzed with respect to 
histology and stage variation, as these types of analyses may provide clues to the 
pathogenesis of the disease.  Currently, a major goal of ovarian cancer research is to develop 
an effective test that can detect the disease at its earliest stages, which would ultimately 
result in decreased mortality. Increased knowledge of ovarian cancer etiology and 
pathogenesis would greatly enhance the development of this tool. Expansions in ovarian 
cancer incidence registration and analyses will be very valuable in this endeavor.  
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1. Introduction 
Despite advances in surgery and chemotherapy, epithelial ovarian cancer (EOC) remains the 
most lethal gynecologic malignancy 1. Due to lack of a specific prodromal symptomatology 
as well as effective screening strategies, the vast majority of EOC patients present with 
advanced stage disease will ultimately die from their disease 1. Furthermore, while up to 
80% of patients will respond to conventional primary platinum/taxane chemotherapy, 
greater than 60% will experience disease recurrence, and current reports indicate 
discouraging response rates of 20% in women with resistance to platinum-based 
chemotherapy 2. Preventive strategies, including improvements in early detection of disease 
as well as in preventing disease recurrence, are, therefore, crucial to improving prognosis.  
Ovarian cancer prevention can be defined by two main strategies: 1) early detection of 
cancer in at-risk patients and 2) prevention of recurrent disease in patients with an 
established diagnosis of cancer. Through the use of screening tools, such as serum 
biomarkers and medical imaging, early disease detection offers the promise of identifying 
cancer while still localized and potentially curable 3. Secondary preventive approaches aim 
to maintain patients without evidence of active disease and thereby extend their disease-free 
survival. Surveillance methods including serial biomarker measurements as well as 
therapeutic vaccinations have been examined for their impact on survival outcomes. Finally, 
risk stratification is critical to the success of any cancer prevention strategy; capitalizing on 
risk-reducing behaviors and intensive screening is most likely to improve individuals at 
greatest risk for disease-related morbidity and mortality. 
Current research in the early detection of ovarian cancer largely focuses on biomarker 
discovery, using transcriptome analysis, proteomics, epigenomics, metabolomics and 
glycomics of differentially expressed molecules between women with disease and healthy 
controls. Biomarkers already approved by the FDA (i.e., CA125 and HE4) or those under 
investigation, including osteopontin, MUC1 and mesothelin, offer hope for women at risk 
for disease development, especially those with predisposing genetic mutations 4. As part of 
this effort, we have generated site-specific biotinylated recombinant antibodies secreted by 
yeast (Biobodies 5) to cost- and time-effectively generate antibodies for developing screening 
tools for large populations of women 6. In addition, biomarkers, especially tumor associated 
antigens, may also serve as targets for vaccination 7. 
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Immune-driven therapies are currently under investigation for the prevention of ovarian 
cancer recurrence8-12. Therapeutic vaccinations, targeting molecules specific to an 
individuals’ disease through the use of whole tumor lysates and tumor-pulsed dendritic 
cells, are currently under investigation for women with recurrent disease; such 
immunotherapeutic strategies are an additional research interest in our group 
(NCT00683241, NCT01132014, NCT00603460) 13, 14. Preventive approaches targeting 
individuals at risk for ovarian cancer as well as those with advanced stage disease may 
significantly impact disease incidence and prognostic outcomes. In this chapter, we will 
discuss these current approaches in detail. 
2. Challenges in ovarian cancer prevention 
In 1968, the World Health Organization (WHO) established guidelines for disease screening, 
including that the screened condition should be an important health problem with available 
treatment 15. Ovarian cancer arguably satisfies these principles as it ranks as one of the top 
ten most common cancers amongst women in the US with more than 21,000 diagnosed 
annually 1. Further, ovarian cancer is the fifth most common cause of cancer mortality and 
remains the most lethal gynecologic cancer 1. Platinum/taxane chemotherapy is available 
for women with this disease, and approximately 70-80% will respond to this regimen 1. 
However, more than 75% of women are diagnosed when disease has already spread from 
the ovary, and advanced stage disease at presentation carries an overall poor prognosis 1. 
Improved ovarian cancer screening methods are therefore needed to detect disease in its 
earliest stages when treatment is more effective, translating into improved overall five year 
survival rates ranging from 60% to 90% 3, 16, 17. 
The prevention strategy applied in cervical cancer demonstrates that successful disease 
screening significantly diminishes disease-related morbidity and mortality. The 
understanding of the natural history of cervical cancer led to the introduction of screening 
cervical cytology via Papnicolaou smears and guidelines for the early detection of 
preneoplastic cervical lesions. Since the introduction of these strategies, the incidence of 
cervical cancer has declined by more than 75% 18. Furthermore, vaccination against the 
oncogenic Human papillomavirus (HPV) will also aid in eliminating this disease.  
However, preventive strategies in ovarian cancer, unlike those in cervical cancer, have been 
met with several challenges. First, compared to cervical cancer which ranks as the second most 
common gynecologic cancer worldwide, ovarian cancer has a low prevalence with 40 cases per 
year per 100,000 women over the age of 50 years; this mandates that an effective screening test 
for ovarian cancer has both a high sensitivity and specificity in order to significantly impact 
disease incidence 19.  Second, current screening methods for early detection of ovarian cancer, 
including routine physical examination, CA125 serum assessment, and transvaginal 
ultrasound, have high false-positive rates and low positive predictive values (Table 1) 20.  In 
fact, for a positive predictive value (PPV) of 10%, an ovarian cancer screening test would 
require a sensitivity of at least 75% and a specificity of greater than 99% 22. Further, current 
methods of screening have not resulted in a significant impact on disease morbidity or 
mortality 21. 
While it is known that persistent HPV infection is responsible for virtually all cervical cancer 
and its immediate precursors worldwide 23, the exact etiology for ovarian cancer remains 
largely debated. Precursors for ovarian cancer should be “morphologically recognizable 
lesions that are reproducible thereby permitting early clinical intervention” 24. It has been 
 
Preventive Strategies in Epithelial Ovarian Cancer 17 
generally accepted that ovarian cancer originates from the ovarian surface epithelium (OSE) or 
from postovulatory inclusion cysts, and one hypothesis is that incessant ovulation is the main 
pathogenic mechanism 25, 26. Yet, recent evaluation of pathologic specimens has also suggested 
that a greater proportion of “ovarian” cancers may actually originate in the fimbriated end of 
the fallopian tube with metastasis to the ovary 26, 27. Further, a dualistic classification system 
has been proposed in which ovarian cancers are divided into two groups: type I tumors which 
consist of low-grade neoplasms and type II tumor which are aggressive and progress rapidly 
28. Precursor lesions, including borderline malignant tumors and endometriosis, have been 
identified for type I tumors and may serve to improve early detection of these ovarian tumors 
especially given their indolent nature; a slower transition time between early and later stage of 
disease may afford opportunities to detect disease when it is still localized to the ovary. 
However, type II tumors do not have well-characterized precursor lesions, which is perhaps 
due to their high level of genetic instability 24. Because the transition time between stage I and 
stage III is unknown, it is uncertain whether these tumors rapidly progress from an early stage 
to an advanced stage or whether these tumors develop as a result of a diffuse peritoneal 
process 19. At this point in time and despite a large body of work, no consensus has been 
reached regarding ovarian cancer precursors, which contributes to the challenge of creating an 
effective preventive strategy for ovarian cancer. 
Finally, screening can carry some significant disadvantages, including an increased cost to 
society for over-utilized medical resources as well as psychological stress/anxiety especially 
in cases of false positive screening resulting in unnecessary operative intervention for 
benign pathology. However, thanks to stratifying approaches based on reproducible risk 
factors enabling maximized efficiency and balanced cost-effectiveness, this last hurdle may 
be easier to overcome.  
 
Method Sensitivity Specificity PPV 
Symptomatology 57-83%31, 75 86.7-90% 31, 75 1% 34 
Bimanual Exam 28%145 93%145 64%145  
Ultrasound 75-95%54, 56, 58  73-98.7% 54, 56, 58 1-46% 54, 58 
CA125 57%68 85-93%68 96-100%68 
Table 1. Current Ovarian Cancer Screening Methods. 
3. Available modalities in prevention of late stage ovarian cancers and of 
disease recurrence 
The goal of preventive strategies is to reduce ovarian cancer-related morbidity and 
mortality. Disease screening aims to detect ovarian cancer while it is still confined to the 
ovary and the five-year survival rates are 80-90% 1, thus to prevent incurable, late stage 
disease. Disease surveillance following conventional adjuvant chemotherapy allows for 
early detection of recurrent ovarian cancer and therefore permits prevention of clinically 
apparent recurrence. Current screening modalities include symptom recognition, bimanual 
exam, serial CA125 levels and pelvic ultrasound, while disease surveillance typically relies 
on physical exam, CA125 levels and imaging. 
3.1 Do symptoms correspond with the onset of disease or with recurrence? 
Ovarian cancer is referred to as the “silent killer” due to non-specific symptoms which 
often go unrecognized until the disease has significantly spread. Although there is limited 
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data to support symptomatology as a sole screening modality for ovarian cancer, 
recognition of ovarian cancer symptoms by both patients and caregivers may help to 
identify individuals with early stage disease 29 and in 2007 the Gynecologic Cancer 
Foundation, American Cancer Society and Society of Gynecologic Oncologists issued a 
consensus statement supporting the recognition of symptoms as a modality in the 
evaluation of ovarian cancer 30. 
Patient symptoms have been correlated with the onset of disease 31-33. Symptoms commonly 
attributed to ovarian cancer include abdominal bloating, increased abdominal size and 
urinary symptoms 32. In a case-control study of women at risk for developing ovarian cancer 
symptoms, specifically pelvic/abdominal pain, urinary urgency/frequency, increased 
abdominal size/bloating and difficulty eating/early satiety, were significantly associated 
with ovarian cancer when they occurred more than 12 days per month for less than one year 
duration 31. Further, a symptom index was more sensitive in women with advanced stage 
disease (79.5% vs. 56.7% early stage disease) and more specific in women greater than 50 
years of age (90% vs. 86.7% for women less than 50 years old). The authors also applied this 
symptom index to a sample of 1709 women at average risk and reported a positive screening 
rate of 2.6%.   
In a large population-based study 34, Rossing and colleagues reported a positive symptom 
index in 62.3% of women with early stage disease compared to 70.7% with late-stage disease 
and 5.1% of controls. While symptoms were more likely to occur in women with ovarian 
cancer, there only was a short interval (less than 5 months) from symptom onset to 
diagnosis. This suggests that the symptom index may not provide a critical help to diagnose 
early stage ovarian cancer. In addition, the PPV of the symptom index was approximately 
1%; thus the use of a positive symptom index alone would only result in the diagnosis of 
ovarian cancer in 1 out of 100 women in the general population presenting with the same 
symptoms. 
Further complicating this screening technique is the fact that symptom presentation and 
duration may be influenced by the histological subtype of ovarian cancer 35. In a recent 
population-base study, women with serous histology (the major histologic subtype ) were 
less likely to report symptoms, were more often diagnosed at advanced stage (compared to 
mucinous tumors) and had a shorter duration of symptoms compared to women with early 
stage disease. This study also further highlights the difficulty in diagnosing ovarian cancer 
at an early stage due to rapid progression of disease. 
Finally, monitoring symptoms in women with established ovarian cancer has also been 
considered for early intervention for disease recurrence. However, in a recent systematic 
review 36, approximately 67% of a patients identified with recurrent disease had no 
concurrent clinical symptoms. Other surveillance modalities, including clinical examination, 
biomarker determination and imaging, should therefore be used in conjunction with 
symptoms in order to diagnose recurrent ovarian cancer. 
3.2 Can bimanual examination diagnose early stage ovarian cancer and/or recurrent 
disease? 
Routine pelvic examination is a key component of annual gynecologic health assessment. 
Palpation of the uterus and ovaries by bimanual examination may allow for the earlier 
detection of ovarian cancer; exam findings may initiate further evaluation with ultrasound 
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and ultimately surgery, potentially detecting cancers before they become clinically evident.  
Further, a pelvic exam has little adverse consequences 37.   
However, pelvic examination is generally recommended only for the evaluation of 
symptomatic patients and only in conjunction with ultrasonography 38. Routine pelvic exam 
is considered as being neither a sensitive nor a specific means for detecting ovarian cancer in 
asymptomatic women 39, 40 and may thus result in unnecessary surgical intervention for 
benign ovarian lesions. Further supporting this view, bimanual examination, which was 
originally included in the screening protocol of asymptomatic, postmenopausal women in 
the Prostate, Lung, Colorectal and Ovarian Screening Trial of the National Cancer Institute 
(NCI), was eliminated as a screening modality from the trial as it became evident that it 
failed to detect the first onset of ovarian cancer 41. 
In contrast, pelvic examination is recommended for disease surveillance of ovarian cancer 
per the NCCN guidelines, as 26-50% of recurrences occur within the pelvis 42. Physical 
examination is an inexpensive, safe and practical tool that can trigger further evaluation 
with other modalities, but it must be kept in mind that the detection rates of recurrent 
ovarian cancer vary widely 43, 44 and physical examination may fail to detect common sites of 
recurrence, including the upper abdomen, the retroperitoneum and the thorax 45.   
3.3 How effective is ultrasound in detecting early stage ovarian cancer? 
Pelvic ultrasound has been utilized for predicting the likelihood of malignancy, especially in 
women with a known pelvic mass. Transvaginal ultrasound (TVUS) can detect changes in 
ovarian size and morphology and is superior to physical examination in evaluating ovarian 
size, especially in women who are postmenopausal, obese or who have an enlarged uterus46. 
Primary screening studies with TVUS in both asymptomatic and symptomatic at-risk 
women have been successful in identifying early stage ovarian cancers 47-50. 
Ovarian volume is inversely related to age; thus an enlarged ovary in post-menopausal 
women can be a sign of an evolving ovarian cancer. Mean ovarian volume is significantly 
greater in premenopausal women compared to postmenopausal women 51; the upper limit 
of normal ovarian volume is 20 cm3 and 10cm3 in premenopausal and postmenopausal 
women, respectively. Other ovarian characteristics, including complex or solid morphology, 
cyst papillations, septae and increased blood flow, have also been suggested as findings 
suspicious for malignancy 52, 53. 
To decrease the number of false-positive results, morphology scoring indices have been 
introduced for ovarian cancer screening. Investigators at the University of Kentucky have 
developed a morphology scoring index based on ovarian volume, wall structure and septal 
structure as a means to improve the PPV of TVUS for ovarian cancer screening 54. In a multi-
institutional sample of patients undergoing surgical intervention for ovarian tumors, this 
morphology index implemented during preoperative ultrasound evaluation, yielded a 
sensitivity of 89%, a specificity of 73%, and a positive predictive value of 46% 55.   
The International Ovarian Tumor Analysis (IOTA) study has also provided a reproducible 
standardized methodology for the ultrasound evaluation of adnexal masses and has further 
identified features with increased risk of malignancy: the presence of an irregular solid tumor, 
the presence of papillary or solid components, the presence of ascites, an irregular multilocular 
solid tumor and the presence of pronounced blood flow 53. Prospective validation of these 
simple ultrasound rules in a sample of women with adnexal masses yielded a sensitivity of 
95%, a specificity of 91%, positive likelihood ratio of 10.37 and negative likelihood ratio of 0.06 
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data to support symptomatology as a sole screening modality for ovarian cancer, 
recognition of ovarian cancer symptoms by both patients and caregivers may help to 
identify individuals with early stage disease 29 and in 2007 the Gynecologic Cancer 
Foundation, American Cancer Society and Society of Gynecologic Oncologists issued a 
consensus statement supporting the recognition of symptoms as a modality in the 
evaluation of ovarian cancer 30. 
Patient symptoms have been correlated with the onset of disease 31-33. Symptoms commonly 
attributed to ovarian cancer include abdominal bloating, increased abdominal size and 
urinary symptoms 32. In a case-control study of women at risk for developing ovarian cancer 
symptoms, specifically pelvic/abdominal pain, urinary urgency/frequency, increased 
abdominal size/bloating and difficulty eating/early satiety, were significantly associated 
with ovarian cancer when they occurred more than 12 days per month for less than one year 
duration 31. Further, a symptom index was more sensitive in women with advanced stage 
disease (79.5% vs. 56.7% early stage disease) and more specific in women greater than 50 
years of age (90% vs. 86.7% for women less than 50 years old). The authors also applied this 
symptom index to a sample of 1709 women at average risk and reported a positive screening 
rate of 2.6%.   
In a large population-based study 34, Rossing and colleagues reported a positive symptom 
index in 62.3% of women with early stage disease compared to 70.7% with late-stage disease 
and 5.1% of controls. While symptoms were more likely to occur in women with ovarian 
cancer, there only was a short interval (less than 5 months) from symptom onset to 
diagnosis. This suggests that the symptom index may not provide a critical help to diagnose 
early stage ovarian cancer. In addition, the PPV of the symptom index was approximately 
1%; thus the use of a positive symptom index alone would only result in the diagnosis of 
ovarian cancer in 1 out of 100 women in the general population presenting with the same 
symptoms. 
Further complicating this screening technique is the fact that symptom presentation and 
duration may be influenced by the histological subtype of ovarian cancer 35. In a recent 
population-base study, women with serous histology (the major histologic subtype ) were 
less likely to report symptoms, were more often diagnosed at advanced stage (compared to 
mucinous tumors) and had a shorter duration of symptoms compared to women with early 
stage disease. This study also further highlights the difficulty in diagnosing ovarian cancer 
at an early stage due to rapid progression of disease. 
Finally, monitoring symptoms in women with established ovarian cancer has also been 
considered for early intervention for disease recurrence. However, in a recent systematic 
review 36, approximately 67% of a patients identified with recurrent disease had no 
concurrent clinical symptoms. Other surveillance modalities, including clinical examination, 
biomarker determination and imaging, should therefore be used in conjunction with 
symptoms in order to diagnose recurrent ovarian cancer. 
3.2 Can bimanual examination diagnose early stage ovarian cancer and/or recurrent 
disease? 
Routine pelvic examination is a key component of annual gynecologic health assessment. 
Palpation of the uterus and ovaries by bimanual examination may allow for the earlier 
detection of ovarian cancer; exam findings may initiate further evaluation with ultrasound 
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and ultimately surgery, potentially detecting cancers before they become clinically evident.  
Further, a pelvic exam has little adverse consequences 37.   
However, pelvic examination is generally recommended only for the evaluation of 
symptomatic patients and only in conjunction with ultrasonography 38. Routine pelvic exam 
is considered as being neither a sensitive nor a specific means for detecting ovarian cancer in 
asymptomatic women 39, 40 and may thus result in unnecessary surgical intervention for 
benign ovarian lesions. Further supporting this view, bimanual examination, which was 
originally included in the screening protocol of asymptomatic, postmenopausal women in 
the Prostate, Lung, Colorectal and Ovarian Screening Trial of the National Cancer Institute 
(NCI), was eliminated as a screening modality from the trial as it became evident that it 
failed to detect the first onset of ovarian cancer 41. 
In contrast, pelvic examination is recommended for disease surveillance of ovarian cancer 
per the NCCN guidelines, as 26-50% of recurrences occur within the pelvis 42. Physical 
examination is an inexpensive, safe and practical tool that can trigger further evaluation 
with other modalities, but it must be kept in mind that the detection rates of recurrent 
ovarian cancer vary widely 43, 44 and physical examination may fail to detect common sites of 
recurrence, including the upper abdomen, the retroperitoneum and the thorax 45.   
3.3 How effective is ultrasound in detecting early stage ovarian cancer? 
Pelvic ultrasound has been utilized for predicting the likelihood of malignancy, especially in 
women with a known pelvic mass. Transvaginal ultrasound (TVUS) can detect changes in 
ovarian size and morphology and is superior to physical examination in evaluating ovarian 
size, especially in women who are postmenopausal, obese or who have an enlarged uterus46. 
Primary screening studies with TVUS in both asymptomatic and symptomatic at-risk 
women have been successful in identifying early stage ovarian cancers 47-50. 
Ovarian volume is inversely related to age; thus an enlarged ovary in post-menopausal 
women can be a sign of an evolving ovarian cancer. Mean ovarian volume is significantly 
greater in premenopausal women compared to postmenopausal women 51; the upper limit 
of normal ovarian volume is 20 cm3 and 10cm3 in premenopausal and postmenopausal 
women, respectively. Other ovarian characteristics, including complex or solid morphology, 
cyst papillations, septae and increased blood flow, have also been suggested as findings 
suspicious for malignancy 52, 53. 
To decrease the number of false-positive results, morphology scoring indices have been 
introduced for ovarian cancer screening. Investigators at the University of Kentucky have 
developed a morphology scoring index based on ovarian volume, wall structure and septal 
structure as a means to improve the PPV of TVUS for ovarian cancer screening 54. In a multi-
institutional sample of patients undergoing surgical intervention for ovarian tumors, this 
morphology index implemented during preoperative ultrasound evaluation, yielded a 
sensitivity of 89%, a specificity of 73%, and a positive predictive value of 46% 55.   
The International Ovarian Tumor Analysis (IOTA) study has also provided a reproducible 
standardized methodology for the ultrasound evaluation of adnexal masses and has further 
identified features with increased risk of malignancy: the presence of an irregular solid tumor, 
the presence of papillary or solid components, the presence of ascites, an irregular multilocular 
solid tumor and the presence of pronounced blood flow 53. Prospective validation of these 
simple ultrasound rules in a sample of women with adnexal masses yielded a sensitivity of 
95%, a specificity of 91%, positive likelihood ratio of 10.37 and negative likelihood ratio of 0.06 
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56. This study has also demonstrated that although pattern recognition of ultrasound findings 
by an experienced examiner can not only reproducibly discriminate between benign and 
malignant adnexal masses, it is superior to serum CA125 57 .   
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is a 
randomized control trial evaluating the effect of screening on mortality 58. Patients are 
randomized to screening with CA125 and transvaginal ultrasound or with transvaginal 
ultrasound alone. At the prevalence screen, the results were promising for transvaginal 
ultrasound, which yielded a sensitivity, specificity and PPV of 75.0%, 98.2%, and 2.8%, 
respectively, for primary invasive epithelial ovarian and tubal cancers 58. The impact of 
ultrasound screening on mortality is still pending at this time.  
Ultrasound has also been examined for its role in the detection of ovarian cancer recurrence 
45. While sensitivity ranges 45-85% and specificity ranges 60-100% 45, ultrasound has user 
variability and limited visibility 59. For this reason, CT scans are often employed in 
surveillance protocols 42 and are typically only performed when indicated by clinical 
findings. In summary, although it is not the imaging modality of choice for ovarian cancer 
surveillance, TVUS is a useful tool to prevent the discovery of late stage ovarian cancer in 
women who are at increased risk for developing ovarian cancer.   
3.4 What role do biomarkers play in the screening of ovarian cancer and the detection 
of disease recurrence? 
Biomarkers are substances which help to indicate the presence of a disease. Soluble 
biomarkers differentially expressed between individuals with disease and normal controls 
are convenient tools of disease detection. The perceived advantages of biomarkers 
compared to other disease screening modalities such as physical exam or ultrasound, 
include availability, reproducibility, objectivity (operator-independent) and cost-
effectiveness. Biomarkers for early detection aim to identify ovarian cancer in individuals 
who are symptomatic (Phase II specimens) or who are asymptomatic before a clinical 
diagnosis is made (Phase III specimens). However, the identification of such biomarkers is 
challenging. Discovery methods often use patient samples with clinically diagnosed and 
advanced stage disease, thus making it necessary to extrapolate findings of advanced 
disease to early-stage disease, and biomarkers discovered in diagnostic samples may not be 
validated in prediagnostic samples 60.   
CA125 (or MUC16) glycoprotein is the most studied tumor marker, alone and/or in 
combination with other biomarkers, for ovarian cancer screening.  Approximately 80% of 
ovarian cancer tumors are CA125 positive 61. Elevated serum CA125 levels (>35 units/mL) 
can be detected in asymptomatic women with ovarian cancer using a monoclonal antibody 
(OC 125) 62 and carry a specificity of 98.5% for postmenopausal women 63. An elevation in 
CA125 levels, especially twice the upper limits of normal, can often occur 2 to 5 months 
prior the clinical detection of an ovarian cancer recurrence 45, with sensitivity and specificity 
for recurrence detection ranging from 62-94% and 91-100% 45, 64-66. Recent work has further 
shown that CA125 levels may begin to rise as early as 3 years prior to clinical diagnosis, but 
will likely only reach detectable levels in the final year before diagnosis 67. 
While CA125 is the most predictive marker of ovarian cancer 67 and remains the single-best 
marker 68, studies have generally indicated that CA125 serum testing performs poorly in the 
detection of early stage disease 69. CA125 levels are only elevated in approximately 50% of 
stage I ovarian cancers 62. Further, false positive CA125 levels can occur in women with 
 
Preventive Strategies in Epithelial Ovarian Cancer 21 
benign conditions, including menstruation, appendicitis, benign ovarian cysts, 
endometriosis and pelvic inflammatory disease, as well as with other malignancies, 
including breast, lung, endometrial and pancreatic cancers 61. Thus, multimodal strategies, 
particularly the combination of CA125 with pelvic ultrasound, have been examined in order 
to improve sensitivity and PPV of ovarian cancer screening.   
The combination of CA125 and ultrasound has been examined in several studies 70.  In a 
prospective pilot study, 144 women with an elevated risk of ovarian cancer, as defined by a 
Receiver Operating Characteristic (ROC) curve based on age and CA125, underwent TVUS 
71. Sixteen women were recommended for surgery and 3 women were found to have 
primary invasive ovarian cancer, thus yielding a specificity of 99.8% and a PPV of 19%. This 
algorithm was subsequently incorporated into the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening, which is a randomized controlled trial designed to assess the 
effect of screening on mortality 58. Women are randomized to three arms: no treatment, 
CA125 with TVUS screening or TVUS alone screening. At the prevalence screen, CA125 
combined with TVUS achieved sensitivity, specificity, and positive-predictive values of 
89.5%, 99.8% and 35.1%, respectively 58. The specificity was higher in this combined 
screening group compared to the TVUS alone group (89.4% vs. 75.0%), suggesting that this 
screening would result in lower rates of repeat testing and surgery. In an additional study, 
an elevated serum CA125 (≥35 units/mL) and preoperative ultrasound findings of solid or 
complex tumors yielded a PPV of 84.7%, a NPV of 92.4% and correctly identified 77.3% of 
patients with early stage disease 70. 
Additional potential serum biomarkers have been identified 72-74 and extensively examined 
for the detection of ovarian cancer 75-77. Human epididymis protein 4 (HE4) is a biomarker 
overexpressed by both serous and endometrioid ovarian cancers 78 and is expressed by 32% 
of ovarian cancers lacking CA125 expression 76. HE4 has been FDA approved to monitor for 
disease recurrence (June 2008) and was recently incorporated into the clinical evaluation of 
ovarian cancer patients. Studies have also indicated that HE4 may also improve prediction 
of malignancy in ovarian masses when combined with CA125 measurements 75-76. 
Furthermore, Anderson and colleagues have demonstrated an increase in CA125, HE4 and 
mesothelin in ovarian cancer patients compared to matched controls, with a differential 
expression noted as early as 3 years preceding diagnosis; these results suggest that a 
multimarker profile may improve detection of early stage disease 67. 
Several panels of biomarkers have been published during the past ten years. One of them, a 
multiplex, bead-based, immunoassay system, examined serum concentrations of leptin, 
prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor and CA125.  
This blood test, called OvaSure™, was reported to achieve a sensitivity of 95.3% and specificity 
of 99.4%, providing a significant improvement over CA125 alone for ovarian cancer detection 
in a cohort of women newly diagnosed with ovarian cancer compared to healthy controls 79. 
OvaSure™ was proposed as a screening tool for women at risk for ovarian cancer, but, due to 
some concerns 80, further investigation is warranted prior to the commercial use of this 
biomarker panel as a screening tool for the early detection of ovarian cancer. 
The use of CA125 for detection of relapsed disease is not supported by the recent results of a 
randomized control trial 81. This multi-institutional European randomized control trial failed 
to demonstrate a survival advantage for women with recurrent disease who received early 
intervention based on rising CA125 levels compared to those who received treatment when 
symptoms developed 81. The authors thus questioned the value of routine CA125 
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56. This study has also demonstrated that although pattern recognition of ultrasound findings 
by an experienced examiner can not only reproducibly discriminate between benign and 
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randomized control trial evaluating the effect of screening on mortality 58. Patients are 
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ultrasound alone. At the prevalence screen, the results were promising for transvaginal 
ultrasound, which yielded a sensitivity, specificity and PPV of 75.0%, 98.2%, and 2.8%, 
respectively, for primary invasive epithelial ovarian and tubal cancers 58. The impact of 
ultrasound screening on mortality is still pending at this time.  
Ultrasound has also been examined for its role in the detection of ovarian cancer recurrence 
45. While sensitivity ranges 45-85% and specificity ranges 60-100% 45, ultrasound has user 
variability and limited visibility 59. For this reason, CT scans are often employed in 
surveillance protocols 42 and are typically only performed when indicated by clinical 
findings. In summary, although it is not the imaging modality of choice for ovarian cancer 
surveillance, TVUS is a useful tool to prevent the discovery of late stage ovarian cancer in 
women who are at increased risk for developing ovarian cancer.   
3.4 What role do biomarkers play in the screening of ovarian cancer and the detection 
of disease recurrence? 
Biomarkers are substances which help to indicate the presence of a disease. Soluble 
biomarkers differentially expressed between individuals with disease and normal controls 
are convenient tools of disease detection. The perceived advantages of biomarkers 
compared to other disease screening modalities such as physical exam or ultrasound, 
include availability, reproducibility, objectivity (operator-independent) and cost-
effectiveness. Biomarkers for early detection aim to identify ovarian cancer in individuals 
who are symptomatic (Phase II specimens) or who are asymptomatic before a clinical 
diagnosis is made (Phase III specimens). However, the identification of such biomarkers is 
challenging. Discovery methods often use patient samples with clinically diagnosed and 
advanced stage disease, thus making it necessary to extrapolate findings of advanced 
disease to early-stage disease, and biomarkers discovered in diagnostic samples may not be 
validated in prediagnostic samples 60.   
CA125 (or MUC16) glycoprotein is the most studied tumor marker, alone and/or in 
combination with other biomarkers, for ovarian cancer screening.  Approximately 80% of 
ovarian cancer tumors are CA125 positive 61. Elevated serum CA125 levels (>35 units/mL) 
can be detected in asymptomatic women with ovarian cancer using a monoclonal antibody 
(OC 125) 62 and carry a specificity of 98.5% for postmenopausal women 63. An elevation in 
CA125 levels, especially twice the upper limits of normal, can often occur 2 to 5 months 
prior the clinical detection of an ovarian cancer recurrence 45, with sensitivity and specificity 
for recurrence detection ranging from 62-94% and 91-100% 45, 64-66. Recent work has further 
shown that CA125 levels may begin to rise as early as 3 years prior to clinical diagnosis, but 
will likely only reach detectable levels in the final year before diagnosis 67. 
While CA125 is the most predictive marker of ovarian cancer 67 and remains the single-best 
marker 68, studies have generally indicated that CA125 serum testing performs poorly in the 
detection of early stage disease 69. CA125 levels are only elevated in approximately 50% of 
stage I ovarian cancers 62. Further, false positive CA125 levels can occur in women with 
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benign conditions, including menstruation, appendicitis, benign ovarian cysts, 
endometriosis and pelvic inflammatory disease, as well as with other malignancies, 
including breast, lung, endometrial and pancreatic cancers 61. Thus, multimodal strategies, 
particularly the combination of CA125 with pelvic ultrasound, have been examined in order 
to improve sensitivity and PPV of ovarian cancer screening.   
The combination of CA125 and ultrasound has been examined in several studies 70.  In a 
prospective pilot study, 144 women with an elevated risk of ovarian cancer, as defined by a 
Receiver Operating Characteristic (ROC) curve based on age and CA125, underwent TVUS 
71. Sixteen women were recommended for surgery and 3 women were found to have 
primary invasive ovarian cancer, thus yielding a specificity of 99.8% and a PPV of 19%. This 
algorithm was subsequently incorporated into the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening, which is a randomized controlled trial designed to assess the 
effect of screening on mortality 58. Women are randomized to three arms: no treatment, 
CA125 with TVUS screening or TVUS alone screening. At the prevalence screen, CA125 
combined with TVUS achieved sensitivity, specificity, and positive-predictive values of 
89.5%, 99.8% and 35.1%, respectively 58. The specificity was higher in this combined 
screening group compared to the TVUS alone group (89.4% vs. 75.0%), suggesting that this 
screening would result in lower rates of repeat testing and surgery. In an additional study, 
an elevated serum CA125 (≥35 units/mL) and preoperative ultrasound findings of solid or 
complex tumors yielded a PPV of 84.7%, a NPV of 92.4% and correctly identified 77.3% of 
patients with early stage disease 70. 
Additional potential serum biomarkers have been identified 72-74 and extensively examined 
for the detection of ovarian cancer 75-77. Human epididymis protein 4 (HE4) is a biomarker 
overexpressed by both serous and endometrioid ovarian cancers 78 and is expressed by 32% 
of ovarian cancers lacking CA125 expression 76. HE4 has been FDA approved to monitor for 
disease recurrence (June 2008) and was recently incorporated into the clinical evaluation of 
ovarian cancer patients. Studies have also indicated that HE4 may also improve prediction 
of malignancy in ovarian masses when combined with CA125 measurements 75-76. 
Furthermore, Anderson and colleagues have demonstrated an increase in CA125, HE4 and 
mesothelin in ovarian cancer patients compared to matched controls, with a differential 
expression noted as early as 3 years preceding diagnosis; these results suggest that a 
multimarker profile may improve detection of early stage disease 67. 
Several panels of biomarkers have been published during the past ten years. One of them, a 
multiplex, bead-based, immunoassay system, examined serum concentrations of leptin, 
prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor and CA125.  
This blood test, called OvaSure™, was reported to achieve a sensitivity of 95.3% and specificity 
of 99.4%, providing a significant improvement over CA125 alone for ovarian cancer detection 
in a cohort of women newly diagnosed with ovarian cancer compared to healthy controls 79. 
OvaSure™ was proposed as a screening tool for women at risk for ovarian cancer, but, due to 
some concerns 80, further investigation is warranted prior to the commercial use of this 
biomarker panel as a screening tool for the early detection of ovarian cancer. 
The use of CA125 for detection of relapsed disease is not supported by the recent results of a 
randomized control trial 81. This multi-institutional European randomized control trial failed 
to demonstrate a survival advantage for women with recurrent disease who received early 
intervention based on rising CA125 levels compared to those who received treatment when 
symptoms developed 81. The authors thus questioned the value of routine CA125 
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measurements for surveillance of women with ovarian cancer who attain a complete 
response after first line therapy. Yet, the conclusions of this study have been underplayed by 
several concerns, including failure to address the role of secondary cytoreduction, lack of 
stratification by residual disease following primary cytoreduction, lack of radiographic 
confirmation of recurrence and non-standardized second-line therapies. Thus, the 
prevention of clinically detectable relapses using serial CA125 measurements will likely 
continue at the discretion of the patient and her physician 82. 
4. Biomarker discovery for ovarian cancer prevention 
Various techniques are currently under investigation in order to identify new biomarkers 
which may improve the detection of early stage ovarian cancer as well as improve the 
detection of recurrent disease 83-87. Proteomic analysis of serum and ascites samples by mass 
spectrometry is a strategy under investigation for the detection of differentially expressed 
proteins or protein fragments in women with ovarian cancer compared to healthy controls 
83, 88, 89. Biomarkers and respective panels identified with proteomics have the potential to 
influence ovarian cancer prevention; further development and validation, however, are 
necessary before they may introduced into clinical practice 89. 
Evolving technologies, including transcriptomics 84, epigenomics 85, 86, metabolomics 90 and 
glycomics 87, are also under investigation in ovarian cancer. Transcriptomics, or expression 
profiling, studies the impact of RNA molecules, including mRNA, rRNA, tRNA and non-
coding RNAs, in diseases. Using techniques based on DNA microarrays, these molecules 
can be identified to help pinpoint genes which may be differentially expressed in ovarian 
cancer compared to normal tissue 84. Gene expression profiling can be performed using both 
serum and formalin-fixed paraffin-embedded tissue biopsies and may help to identify genes 
associated with early-stage disease thereby improving screening 84. 
Epigenomics focuses on the role of DNA methylation, histone modifications, RNA 
interference and nucleosome remodeling in the development and progression of ovarian 
cancer 86. Epigenetic alterations can be used as candidate targets for early detection and 
for monitoring of ovarian cancer recurrence 85. Aberrant DNA hypermethylation of CpG 
islands in the promoter of tumor suppressor genes and other cancer genes as well as 
microRNAs (miRNAs) are currently being identified in both body fluids and tissue 
biopsies and may help to demonstrate the importance of specific genes involved in 
ovarian tumorigenesis 85. 
Metabolomics examines the role of small molecules (“metabolites”) which are unique to a 
specific cellular process.  Metabolic fingerprints of ovarian cancer can be measured in serum 
and/or other bodily fluids using mass spectrometry and has the potential to improve 
detection of early stage and recurrent disease 90. Lysophosphatidic acid 91 and lipid 
associated sialic acid 92 are metabolites which are currently under investigation for ovarian 
cancer detection. 
Glycosylation is the most common post-translational modification of proteins. Aberrant 
glycosylation patterns of proteins, such as MUC1 93, have been identified in ovarian cancer 
and may play a key role in promoting tumor cell invasion and metastasis as well as 
stimulating anti-tumor immune responses 94. Therefore, glycoproteins are currently being 
examined for their potential as biomarker as well as for treatment 87. 
In addition to these efforts, we have generated a cost- and time-effective method for 
generating site-specific in vivo biotinylated recombinant antibodies secreted by yeast 
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(Biobodies 5, 95). Biobodies have been generated against HE4 95 and mesothelin 96. We have 
also demonstrated that this technology can be used reliably in a highly-sensitive bead-based 
ELISA assay for screening large populations of women for ovarian cancer 5, 67 and for serum 
biomarker discovery 6. 
These novel approaches to biomarker discovery offers promise for improved ovarian cancer 
screening and for detection of recurrences. The impact of these biomarkers on clinical 
outcomes warrants further investigation in prospective clinical trials. 
5. Current recommendations for ovarian cancer prevention 
Given its low prevalence in the general population, universal screening for ovarian cancer 
is neither feasible nor cost-effective. Risk assessment is inherent to the success of any 
screening approach, and women at highest risk for disease are likely to benefit the most 
from preventive strategies. Several risk factors have been identified for epithelial ovarian 
cancer (Table 2) 25, and current screening recommendations are often stratified by an 
individual’s risk of developing disease. While the exact pathogenesis of this disease is still 
unclear, it is generally postulated that an increase in ovulation and/or an increase in 
estrogen exposure is associated with an increased lifetime risk of disease. Thus, factors, 
such as nulliparity, menarche at an early age, menopause at a late age, fertility drug use 
and hormone replacement therapy use, are believed to put individuals at risk for disease 
25, 97-101. Age, Caucasian race, ethnicity (especially Ashkenazi Jewish heritage), living in an 
industrialized country, and a history of endometriosis are other factors predisposing to 
ovarian cancer 25. In addition, several factors, particularly multiparity, oral contraceptive 
use, breastfeeding and tubal ligation, have been linked with a decreased incidence of 
ovarian cancer and are therefore believed to be protective against developing ovarian 
cancer 102, 103.   
 
Protective Factors Risk Factors 
Hysterectomy Age 
Tubal Ligation Caucasian race 
Multiparity Early menarche 
Lactation Ethnicity (Ashkenazi Jewish, Icelandic, Hungarian) 
Oral Contraceptive use Family history 
 Fertility drug use 
 Hormone replacement therapy 
 Late menopause 
 Nulliparity 
 Personal history of breast cancer 
 Residence in North America and Northern Europe 
 Talc 
 Endometriosis 
Table 2. Protective and Risk factors for Ovarian Cancer 25. 
Perhaps, the single most important risk factor for ovarian cancer is family history. 
Hereditary ovarian cancers account for approximately 10% of all EOC cases. Compared to 
controls, women with one first or second-degree relative with ovarian cancer have a three-
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necessary before they may introduced into clinical practice 89. 
Evolving technologies, including transcriptomics 84, epigenomics 85, 86, metabolomics 90 and 
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coding RNAs, in diseases. Using techniques based on DNA microarrays, these molecules 
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cancer compared to normal tissue 84. Gene expression profiling can be performed using both 
serum and formalin-fixed paraffin-embedded tissue biopsies and may help to identify genes 
associated with early-stage disease thereby improving screening 84. 
Epigenomics focuses on the role of DNA methylation, histone modifications, RNA 
interference and nucleosome remodeling in the development and progression of ovarian 
cancer 86. Epigenetic alterations can be used as candidate targets for early detection and 
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islands in the promoter of tumor suppressor genes and other cancer genes as well as 
microRNAs (miRNAs) are currently being identified in both body fluids and tissue 
biopsies and may help to demonstrate the importance of specific genes involved in 
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Metabolomics examines the role of small molecules (“metabolites”) which are unique to a 
specific cellular process.  Metabolic fingerprints of ovarian cancer can be measured in serum 
and/or other bodily fluids using mass spectrometry and has the potential to improve 
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(Biobodies 5, 95). Biobodies have been generated against HE4 95 and mesothelin 96. We have 
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Given its low prevalence in the general population, universal screening for ovarian cancer 
is neither feasible nor cost-effective. Risk assessment is inherent to the success of any 
screening approach, and women at highest risk for disease are likely to benefit the most 
from preventive strategies. Several risk factors have been identified for epithelial ovarian 
cancer (Table 2) 25, and current screening recommendations are often stratified by an 
individual’s risk of developing disease. While the exact pathogenesis of this disease is still 
unclear, it is generally postulated that an increase in ovulation and/or an increase in 
estrogen exposure is associated with an increased lifetime risk of disease. Thus, factors, 
such as nulliparity, menarche at an early age, menopause at a late age, fertility drug use 
and hormone replacement therapy use, are believed to put individuals at risk for disease 
25, 97-101. Age, Caucasian race, ethnicity (especially Ashkenazi Jewish heritage), living in an 
industrialized country, and a history of endometriosis are other factors predisposing to 
ovarian cancer 25. In addition, several factors, particularly multiparity, oral contraceptive 
use, breastfeeding and tubal ligation, have been linked with a decreased incidence of 
ovarian cancer and are therefore believed to be protective against developing ovarian 
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fold increase in risk 104. Hereditary ovarian cancers are commonly attributed to genetic 
mutations which are transmitted in families in an autosomal dominant fashion. Germline 
mutations in BRCA1 and BRCA2, tumor suppressors which participate in homologous 
recombination repair of double-stranded DNA breaks, account for approximately 95% of 
all hereditary EOC cases 105 and carry a 25 to 50% lifetime risk of ovarian cancer 106. 
Further, BRCA1/2 mutations are highly prevalent amongst women of Ashkenazi Jewish 
descent; 35-40% of Ashkenazi women with ovarian cancers have a BRCA1 or BRCA2 
mutation 107. These mutations may also be suspected in individuals with a personal 
history of breast cancer before age 50, dual breast cancer or ovarian cancer 108. Women 
with BRCA- associated ovarian cancer typically present with high grade serous cancers at 
an earlier age compared to non-hereditary controls; however, these individuals more 
often have higher response rates to platinum-based chemotherapy and improved overall 
survival 109.  
The remaining hereditary EOC cases are attributed to Lynch Syndrome II, also referred to as 
hereditary nonpolyposis colorectal cancer (HNPCC) syndrome; these individuals with 
mutations in DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2  are at increased 
risk for colon cancer as well as numerous other cancers, including endometrial and ovarian 
cancer 110. Women with this autosomal dominant genetic background have a 3 to 14% 
lifetime risk of ovarian cancer 110.  
5.1 Recommendations for ovarian cancer prevention in women at average risk 
In the absence of significant risk factors, a typical woman carries a 1 in 72 lifetime risk of 
ovarian cancer 111 and is considered at average risk of developing ovarian cancer.   
5.1.1 Prevention by risk reducing behaviors 
Epidemiologic studies of women with ovarian cancer risk have identified several protective 
factors, including oral contraceptive pill use (OCP), parity, lactation, and tubal ligation (Table 
2). These protective factors should be considered for women with any risk of ovarian cancer as 
an additional preventive strategy. Patients should be counseled regarding the impact of these 
factors on their risk of ovarian cancer. Specifically, (1) the use of OCPs for 5 or more years 
results in a 50% reduction in the incidence of ovarian cancer 102, and this benefit may last for 
up to 30 years following use 112. This benefit has also been reported in women with BRCA1 or 
BRCA2 mutations 113 and for most histological subtypes 114. It is estimated that OCPs have 
prevented 200,000 ovarian cancers and 100,000 deaths 25. (2) Parity is a protective factor for 
ovarian cancer 25. The risk for ovarian cancer decreases with each live birth, but there is no 
additional benefit once a women achieves grand multiparity 115. Parous women with BRCA1 
mutations can also experience a reduced risk of ovarian cancer with each additional full-term 
pregnancy 116. (3) Lactation also results in a decreased incidence of ovarian cancer117. However, 
there is no additional benefit for individual episodes of lactation beyond 12 months. The 
relative risk of ovarian cancer decreases by 2% for each month of breastfeeding 118. (4) Tubal 
ligation may also substantially reduce the risk of ovarian cancer 119. Given a greater than 60% 
risk reduction, women with BRCA1 mutations should be counseled regarding this option 
especially when they have completed childbearing 120.   
5.1.2 Prevention by routine screening 
Given a low incidence and prevalence of ovarian cancer in the general population, large 
study cohorts are necessary to evaluate the utility of an ovarian cancer screening test 121. The 
 
Preventive Strategies in Epithelial Ovarian Cancer 25 
results of initial clinical trials, while failing to evaluate the impact of screening on cancer-
related mortality, emphasize limitations on the specificity and PPV of available screening 
strategies for women at average risk.   
A pilot randomized control trial evaluated a multimodal screening approach with serial 
CA125 and pelvic ultrasound in a sample of almost 22,000 postmenopausal women 121. 
Combined CA125 and ultrasound (US) screening was not only feasible but also 
preliminarily resulted in a survival advantage (median survival 72.9 months in the 
screened group vs. 41.8 months in the control group, p = 0.0112). Data from this trial have 
paved the way for larger randomized-control trials 21, 58, 122 which aim to examine the 
impact of screening on mortality. 
The Shizuoka Cohort Study of Ovarian Cancer Screening (SCSOCS) trial was a prospective, 
randomized trial examining ovarian screening, via CA125 and US, in asymptomatic 
postmenopausal Japanese women between 1985 and 1999 122. Of more than 41,000 women 
who underwent screening, only 27 had detected ovarian cancer; at the prevalent screen, 
screening produced a detection rate of 0.31 per 1000. Ovarian cancer screening also 
identified a higher proportion of stage I cancers (63% vs. 38%, p=0.23) when compared to 
the control group. 
The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial is a randomized 
controlled cancer screening trial evaluating screening tests for the 4 PLCO cancers 41. More 
than 78,000 healthy women between 55 and 74 years of age from across the United States 
were randomized to a screening or usual care arm at 10 screening sites between 1993 and 
2001. The primary objective of this trial was to determine whether routine screening via 
transvaginal ultrasound (TVUS) and/or CA125 can reduce ovarian cancer-specific mortality.  
Twenty-nine neoplasms were identified in almost 29,000 women who received any 
screening test, producing a PPV for TVUS of 1.0%, 3.7% for CA125, and 23.5% for combined 
TVUS and CA125. Overall, these screening tests were associated with a high number of 
false-positive tests, especially for women who were younger, heavier, and had a history of 
prior hysterectomy 123. Further, TVUS and CA125 failed to produce a significant impact on 
ovarian cancer mortality, and 15% of women with false-positive screening experienced 
serious resulting complications 21. The results of this trial suggest that routine screening 
with CA125 and TVS should not be performed in asymptomatic women at low-risk for 
ovarian cancer.   
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is a large 
randomized control trial evaluating TVUS and/or CA125 versus no screening in sample of 
more than 200,000 postmenopausal women between 2001 and 2005 58. The primary objective 
of this study is to determine whether screening affected ovarian cancer-related mortality. In 
the prevalence screen, 42 primary ovarian and 45 fallopian tube cancers were identified with 
48.3% of these cancers reported as stage I or II disease. The sensitivity, specificity and PPV 
for primary invasive epithelial ovarian and tubal cancers were 89.5%, 99.8% and 35.1% for 
combined TVUS and CA125 versus 75.0%, 98.2%, and 2.8% for TVUS alone, respectively. 
Thus, combination screening methods yielded the lowest number of false-positive screens, 
translating into lower rates of repeat testing and surgery. While this initial screen indicates 
that these screening strategies are feasible, the impact of these tests on mortality is still 
pending at this time. 
In summary, the latest studies suggest that risk reducing behaviors can provide significant 
prevention of ovarian cancer, while routine screening for ovarian cancer in women at 
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often have higher response rates to platinum-based chemotherapy and improved overall 
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The remaining hereditary EOC cases are attributed to Lynch Syndrome II, also referred to as 
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mutations in DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2  are at increased 
risk for colon cancer as well as numerous other cancers, including endometrial and ovarian 
cancer 110. Women with this autosomal dominant genetic background have a 3 to 14% 
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In the absence of significant risk factors, a typical woman carries a 1 in 72 lifetime risk of 
ovarian cancer 111 and is considered at average risk of developing ovarian cancer.   
5.1.1 Prevention by risk reducing behaviors 
Epidemiologic studies of women with ovarian cancer risk have identified several protective 
factors, including oral contraceptive pill use (OCP), parity, lactation, and tubal ligation (Table 
2). These protective factors should be considered for women with any risk of ovarian cancer as 
an additional preventive strategy. Patients should be counseled regarding the impact of these 
factors on their risk of ovarian cancer. Specifically, (1) the use of OCPs for 5 or more years 
results in a 50% reduction in the incidence of ovarian cancer 102, and this benefit may last for 
up to 30 years following use 112. This benefit has also been reported in women with BRCA1 or 
BRCA2 mutations 113 and for most histological subtypes 114. It is estimated that OCPs have 
prevented 200,000 ovarian cancers and 100,000 deaths 25. (2) Parity is a protective factor for 
ovarian cancer 25. The risk for ovarian cancer decreases with each live birth, but there is no 
additional benefit once a women achieves grand multiparity 115. Parous women with BRCA1 
mutations can also experience a reduced risk of ovarian cancer with each additional full-term 
pregnancy 116. (3) Lactation also results in a decreased incidence of ovarian cancer117. However, 
there is no additional benefit for individual episodes of lactation beyond 12 months. The 
relative risk of ovarian cancer decreases by 2% for each month of breastfeeding 118. (4) Tubal 
ligation may also substantially reduce the risk of ovarian cancer 119. Given a greater than 60% 
risk reduction, women with BRCA1 mutations should be counseled regarding this option 
especially when they have completed childbearing 120.   
5.1.2 Prevention by routine screening 
Given a low incidence and prevalence of ovarian cancer in the general population, large 
study cohorts are necessary to evaluate the utility of an ovarian cancer screening test 121. The 
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results of initial clinical trials, while failing to evaluate the impact of screening on cancer-
related mortality, emphasize limitations on the specificity and PPV of available screening 
strategies for women at average risk.   
A pilot randomized control trial evaluated a multimodal screening approach with serial 
CA125 and pelvic ultrasound in a sample of almost 22,000 postmenopausal women 121. 
Combined CA125 and ultrasound (US) screening was not only feasible but also 
preliminarily resulted in a survival advantage (median survival 72.9 months in the 
screened group vs. 41.8 months in the control group, p = 0.0112). Data from this trial have 
paved the way for larger randomized-control trials 21, 58, 122 which aim to examine the 
impact of screening on mortality. 
The Shizuoka Cohort Study of Ovarian Cancer Screening (SCSOCS) trial was a prospective, 
randomized trial examining ovarian screening, via CA125 and US, in asymptomatic 
postmenopausal Japanese women between 1985 and 1999 122. Of more than 41,000 women 
who underwent screening, only 27 had detected ovarian cancer; at the prevalent screen, 
screening produced a detection rate of 0.31 per 1000. Ovarian cancer screening also 
identified a higher proportion of stage I cancers (63% vs. 38%, p=0.23) when compared to 
the control group. 
The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial is a randomized 
controlled cancer screening trial evaluating screening tests for the 4 PLCO cancers 41. More 
than 78,000 healthy women between 55 and 74 years of age from across the United States 
were randomized to a screening or usual care arm at 10 screening sites between 1993 and 
2001. The primary objective of this trial was to determine whether routine screening via 
transvaginal ultrasound (TVUS) and/or CA125 can reduce ovarian cancer-specific mortality.  
Twenty-nine neoplasms were identified in almost 29,000 women who received any 
screening test, producing a PPV for TVUS of 1.0%, 3.7% for CA125, and 23.5% for combined 
TVUS and CA125. Overall, these screening tests were associated with a high number of 
false-positive tests, especially for women who were younger, heavier, and had a history of 
prior hysterectomy 123. Further, TVUS and CA125 failed to produce a significant impact on 
ovarian cancer mortality, and 15% of women with false-positive screening experienced 
serious resulting complications 21. The results of this trial suggest that routine screening 
with CA125 and TVS should not be performed in asymptomatic women at low-risk for 
ovarian cancer.   
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is a large 
randomized control trial evaluating TVUS and/or CA125 versus no screening in sample of 
more than 200,000 postmenopausal women between 2001 and 2005 58. The primary objective 
of this study is to determine whether screening affected ovarian cancer-related mortality. In 
the prevalence screen, 42 primary ovarian and 45 fallopian tube cancers were identified with 
48.3% of these cancers reported as stage I or II disease. The sensitivity, specificity and PPV 
for primary invasive epithelial ovarian and tubal cancers were 89.5%, 99.8% and 35.1% for 
combined TVUS and CA125 versus 75.0%, 98.2%, and 2.8% for TVUS alone, respectively. 
Thus, combination screening methods yielded the lowest number of false-positive screens, 
translating into lower rates of repeat testing and surgery. While this initial screen indicates 
that these screening strategies are feasible, the impact of these tests on mortality is still 
pending at this time. 
In summary, the latest studies suggest that risk reducing behaviors can provide significant 
prevention of ovarian cancer, while routine screening for ovarian cancer in women at 
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average risk does not improve the prevention of late-stage disease and is currently not 
recommended by any professional society 25.   
5.2 Recommendations for ovarian cancer prevention in women at increased risk 
Women with a strong family history of either ovarian or breast cancer alone are considered 
to be at higher-than-average risk, while women with confirmed mutations in BRCA1 or 
BRCA2 and those with Lynch syndrome are at the highest risk of developing ovarian cancer. 
Genetic risk assessment should be performed in individuals to provide “individualized and 
quantified assessment of risk as well as options for tailored screening and prevention 
strategies” 108. The Society of Gynecologic Oncologists recommends genetic screening in 
women with a 20-25% risk of having an inherited predisposition to breast and ovarian 
cancer: (1) women with a personal history of both breast and ovarian cancer (including 
those with primary peritoneal or fallopian tube cancers; (2) women with ovarian cancer and 
a close relative with breast cancer at ≤ 50 years or ovarian cancer at any age; (3) women with 
ovarian cancer at any age who are of Ashkenazi Jewish ancestry; (4) women with breast 
cancer at ≤50 years and a close relative with ovarian or male breast cancer at any age; (5) 
women of Ashkenazi Jewish ancestry and breast cancer at ≤ 40 years; or (6) women with a 
first or second degree relative with a known BRCA1 or BRCA2 mutation 108. Further, risk 
assessment is recommended if women have a 20-25% of having an inherited predisposition 
to endometrial, colorectal and related cancers, including: those patients meeting the revised 
Amsterdam criteria 124 and those with personal or family history concerning for Lynch 
Syndrome 108.  
5.2.1 Prevention by risk reducing behaviors and surgery 
In addition to the risk reducing behaviors described earlier for women at average risk,, 
prophylactic surgery should be strongly considered in women at high risk for ovarian 
cancer.  Risk-reducing salpingo-oophorectomy (RRSO) is associated with an 80% risk 
reduction in BRCA1/2-associated ovarian, fallopian tube or primary peritoneal cancer 125, 126. 
Women with BRCA germline mutations have a significant survival advantage following 
risk-reducing surgery compared to disease surveillance 125, 126. This approach has also been 
reported as a cost-effective strategy 127, 128. Women with BRCA1/2 germline mutations should 
be counseled on risk-reducing strategies, and RRSO should be recommended upon 
completion of childbearing or by age 40 25.   
Risk-reducing hysterectomy and bilateral salpingo-oophorectomy is also a feasible 
preventive approach in women with Lynch Syndrome, with risk reduction approaching 
100% 129 . Recent cost-effective analyses demonstrated that risk-reducing surgery is the most 
cost-effective gynecologic cancer prevention strategy in this patient population 128, 130. 
5.2.2 Prevention by routine screening 
Current opinion suggests that screening may be appropriate for women in these increased 
risk categories. However, while intensive screening is recommended for women with 
BRCA1 and 2 mutations, studies have indicated that screening with CA125 and TVUS are 
ineffective 131, 132 because the majority of cancers are still detected at advanced stages. In a 
retrospective study of 241 women with confirmed BRCA1 or BRCA2 mutations, surveillance 
with annual pelvic exam, transvaginal ultrasound and serum CA125 level failed to 
effectively identify women with early stage disease 131.   
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Currently, women with HNPCC/Lynch Syndrome are offered active disease surveillance 
including annual TVUS, endometrial biopsy and CA125 108. Auranen and colleagues 
performed a systematic review of the literature to determine the role of screening in women 
with HNPCC or with a family history of HNPCC 133. Of five studies meeting inclusion 
criteria, only three examined the utility of CA125 surveillance for ovarian cancer in this 
patient population. In total, five ovarian cancer cases, none of which were reported as early 
stage disease, were detected by CA125 surveillance. Based on the current available 
published evidence, the authors concluded that there is no benefit for ovarian cancer 
screening in this patient population. 
In summary, while studies have failed to demonstrate a benefit for screening in high risk 
patients, risk-reducing surgery is the most cost-effective gynecologic cancer prevention 
strategy and screening with serial CA125 levels and TVUS is generally recommended until 
risk-reducing surgery can be performed.   
5.3 Recommendations for ovarian cancer prevention in women with pelvic masses 
Several investigators have introduced risk models which would allow for the preoperative 
risk assessment of women with pelvic masses 134-137. The Risk of Malignancy Index (RMI) is 
a diagnostic model combining CA125 levels, imaging and menopausal status; at a cutoff 
level of 200, the RMI produced a sensitivity of 85% and a specificity of 97% and was an 
effective model for discriminating between cancer and benign lesions 137. The Risk of 
Ovarian Malignancy Algorithm (ROMA) is another model which predicts the likelihood of 
ovarian cancer in women with pelvic masses by the combination of HE4 and CA125 serum 
levels with menopausal status 136. This algorithm has shown promising diagnostic 
performance for the detection of ovarian cancer in postmenopausal women, with a 
sensitivity of 82.5% 136, and has also been shown to perform better than the RMI model for 
risk prediction of ovarian cancer 134, 135. This model may therefore be an effective strategy for 
triaging patients with pelvic masses. 
5.4 Current recommendations for preventing disease recurrence 
5.4.1 Role of disease surveillance 
Active disease surveillance aims to detect recurrent ovarian cancer in asymptomatic women 
in order to provide opportunities for early intervention and ultimately improved outcomes. 
However, current surveillance recommendations are often based on expert opinions and 
practice patterns. The National Comprehensive Cancer Network (NCCN) recommends 
routine visits every 2 to 4 months for 2 years, then every 3 to 6 months for 3 years, followed 
by annual visits after 5 years 42. A physical examination, serum CA125 and laboratory and 
imaging (as clinically indicated) are to be performed at each visit. 
In response to the MRC OV05/EORTC 55955 trial 81, the Society of Gynecologic Oncologists 
issued a statement on the use of CA125 for monitoring ovarian cancer in June 2009: 
“Although there may not presently be a major survival advantage to the use of CA125 
monitoring for earlier diagnosis of recurrence, patients and their physicians should still have 
the opportunity to choose this approach as integral to a philosophy of active management” 
and that “patients and their physicians should be encouraged to actively discuss the pros 
and cons of CA125 monitoring and the implications for subsequent treatment and quality of 
life” 82. 
A systematic review of the literature demonstrated that routine surveillance was able to 
detect 67% of asymptomatic recurrences with a lead time of 3 months but that published 
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average risk does not improve the prevention of late-stage disease and is currently not 
recommended by any professional society 25.   
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women of Ashkenazi Jewish ancestry and breast cancer at ≤ 40 years; or (6) women with a 
first or second degree relative with a known BRCA1 or BRCA2 mutation 108. Further, risk 
assessment is recommended if women have a 20-25% of having an inherited predisposition 
to endometrial, colorectal and related cancers, including: those patients meeting the revised 
Amsterdam criteria 124 and those with personal or family history concerning for Lynch 
Syndrome 108.  
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In addition to the risk reducing behaviors described earlier for women at average risk,, 
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cancer.  Risk-reducing salpingo-oophorectomy (RRSO) is associated with an 80% risk 
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Women with BRCA germline mutations have a significant survival advantage following 
risk-reducing surgery compared to disease surveillance 125, 126. This approach has also been 
reported as a cost-effective strategy 127, 128. Women with BRCA1/2 germline mutations should 
be counseled on risk-reducing strategies, and RRSO should be recommended upon 
completion of childbearing or by age 40 25.   
Risk-reducing hysterectomy and bilateral salpingo-oophorectomy is also a feasible 
preventive approach in women with Lynch Syndrome, with risk reduction approaching 
100% 129 . Recent cost-effective analyses demonstrated that risk-reducing surgery is the most 
cost-effective gynecologic cancer prevention strategy in this patient population 128, 130. 
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Current opinion suggests that screening may be appropriate for women in these increased 
risk categories. However, while intensive screening is recommended for women with 
BRCA1 and 2 mutations, studies have indicated that screening with CA125 and TVUS are 
ineffective 131, 132 because the majority of cancers are still detected at advanced stages. In a 
retrospective study of 241 women with confirmed BRCA1 or BRCA2 mutations, surveillance 
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effectively identify women with early stage disease 131.   
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Currently, women with HNPCC/Lynch Syndrome are offered active disease surveillance 
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with HNPCC or with a family history of HNPCC 133. Of five studies meeting inclusion 
criteria, only three examined the utility of CA125 surveillance for ovarian cancer in this 
patient population. In total, five ovarian cancer cases, none of which were reported as early 
stage disease, were detected by CA125 surveillance. Based on the current available 
published evidence, the authors concluded that there is no benefit for ovarian cancer 
screening in this patient population. 
In summary, while studies have failed to demonstrate a benefit for screening in high risk 
patients, risk-reducing surgery is the most cost-effective gynecologic cancer prevention 
strategy and screening with serial CA125 levels and TVUS is generally recommended until 
risk-reducing surgery can be performed.   
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Several investigators have introduced risk models which would allow for the preoperative 
risk assessment of women with pelvic masses 134-137. The Risk of Malignancy Index (RMI) is 
a diagnostic model combining CA125 levels, imaging and menopausal status; at a cutoff 
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sensitivity of 82.5% 136, and has also been shown to perform better than the RMI model for 
risk prediction of ovarian cancer 134, 135. This model may therefore be an effective strategy for 
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5.4 Current recommendations for preventing disease recurrence 
5.4.1 Role of disease surveillance 
Active disease surveillance aims to detect recurrent ovarian cancer in asymptomatic women 
in order to provide opportunities for early intervention and ultimately improved outcomes. 
However, current surveillance recommendations are often based on expert opinions and 
practice patterns. The National Comprehensive Cancer Network (NCCN) recommends 
routine visits every 2 to 4 months for 2 years, then every 3 to 6 months for 3 years, followed 
by annual visits after 5 years 42. A physical examination, serum CA125 and laboratory and 
imaging (as clinically indicated) are to be performed at each visit. 
In response to the MRC OV05/EORTC 55955 trial 81, the Society of Gynecologic Oncologists 
issued a statement on the use of CA125 for monitoring ovarian cancer in June 2009: 
“Although there may not presently be a major survival advantage to the use of CA125 
monitoring for earlier diagnosis of recurrence, patients and their physicians should still have 
the opportunity to choose this approach as integral to a philosophy of active management” 
and that “patients and their physicians should be encouraged to actively discuss the pros 
and cons of CA125 monitoring and the implications for subsequent treatment and quality of 
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A systematic review of the literature demonstrated that routine surveillance was able to 
detect 67% of asymptomatic recurrences with a lead time of 3 months but that published 
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studies failed to demonstrate a survival advantage of early detection of ovarian cancer by 
routine surveillance 36. The authors suggest that routine surveillance should be reconsidered 
in current practice.   
5.5 Immunoprevention of disease recurrence 
While 70-80% of patients with advanced EOC will initially respond to conventional 
platinum/taxane therapy, more than 60% will experience a recurrence of disease and 70-
90% will ultimately die of their disease 2. Immune-driven vaccines are currently under 
investigation for the prevention of ovarian cancer recurrence 8-12.   
Host anti-tumor immune responses have the potential to significantly influence prognosis in 
ovarian cancer patients. The presence of tumor-infiltrating lymphocytes (TILs) has been 
correlated with significantly improved progression-free and overall survival rates in women 
with advanced stage ovarian cancer compared to women without TILs 138, 139. Thus, given 
that ovarian cancer is intrinsically immunogenic, it may be possible to enhance host anti-
tumor immune responses by using vaccines which strengthen TIL responses and thereby 
improve patient outcomes by preventing recurrent disease.   
Therapeutic vaccinations derived from autologous whole tumor cell lysates may help to 
enhance host antigen-specific anti-tumoral immune responses 14. The main advantages of 
these vaccines are “the opportunity to induce immunity to a personalized and broad range 
of antigens” and the incorporation of yet unidentified tumor antigens 140. A recent meta-
analysis of 173 immunotherapy trials, including ovarian and other primary cancers, 
demonstrated a higher objective clinical response in individuals receiving whole tumor 
antigen-based vaccines compared to those receiving synthetic antigens (8.1% vs. 3.6%, 
respectively; p <0.001) 141. The Penn Ovarian Cancer Research Center is currently 
conducting a phase I/II randomized study to determine the feasibility, safety and 
immunogenicity of a vaccine derived from autologous oxidized tumor cell lysate (OC-L) in 
combination with Ampligen, a Toll-like receptor 3 agonist (NCT01312389).   
Vaccination with antigen-specific dendritic cells (DCs) can enhance anti-tumor immunity 
via specific tumor-antigen presentation and activation of effector T cells 142. There are 
several approaches to DC-based vaccines, including exposure of DCs to whole tumor cell 
lysates, defined ovarian tumor peptides, and ovarian tumor cells, to induce a cytotoxic T 
lymphocyte (CTL) response 143. In a phase I trial, three of six patients with progressive or 
recurrent ovarian cancer experienced stabilization of disease following administration of 
autologous tumor antigen-pulsed DCs with reported progression-free intervals of 8-45 
months 144. Given these promising data, DC-based vaccines are currently the focus of 
several new trials (NCT00703105, NCT00683241, and NCT01132014) which will hopefully 
demonstrate an impact on long-term prognosis. The Penn Ovarian Cancer Research 
Center is currently examining the feasibility and immunogenicity of a DC vaccine loaded 
with autologous tumor lysate administered intranodally, alone or in combination with 
intravenous Bevacizumab (NCT01132014). A phase I/II trial is also underway at our 
institution in which patients with recurrent EOC or primary peritoneal cancer will 
undergo adoptive transfer of ex vivo CD3/CD28-costimulated autologous peripheral 
blood T cells along with tumor lysate-pulsed DC vaccination (DCVax®-L) (NCT00603460) 
in order to determine the feasibility and safety of this combination and progression-free 
survival at 6 months. 
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6. Conclusion 
Ovarian cancer is the most lethal gynecologic cancer in the United States. Given the low 
prevalence of this disease in the general population, risk assessment is crucial to the success 
of available preventive strategies. However, current primary preventive strategies, even in 
women at high risk, have not proven reliable in the detection of early stage disease nor have 
they significantly impacted disease related mortality. Thus, risk-reducing behaviors and 
surgery should be considered in women at high risk for ovarian cancer. 
In the near future, novel technologies may help to better characterize critical pathways in 
ovarian carcinogenesis and therefore result in biomarkers and/or multimarker panels more 
effective than CA125 alone, in both detecting early stage disease as well as recurrences. 
Validations of proposed strategies are under investigation in ongoing studies (Table 3). 
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studies failed to demonstrate a survival advantage of early detection of ovarian cancer by 
routine surveillance 36. The authors suggest that routine surveillance should be reconsidered 
in current practice.   
5.5 Immunoprevention of disease recurrence 
While 70-80% of patients with advanced EOC will initially respond to conventional 
platinum/taxane therapy, more than 60% will experience a recurrence of disease and 70-
90% will ultimately die of their disease 2. Immune-driven vaccines are currently under 
investigation for the prevention of ovarian cancer recurrence 8-12.   
Host anti-tumor immune responses have the potential to significantly influence prognosis in 
ovarian cancer patients. The presence of tumor-infiltrating lymphocytes (TILs) has been 
correlated with significantly improved progression-free and overall survival rates in women 
with advanced stage ovarian cancer compared to women without TILs 138, 139. Thus, given 
that ovarian cancer is intrinsically immunogenic, it may be possible to enhance host anti-
tumor immune responses by using vaccines which strengthen TIL responses and thereby 
improve patient outcomes by preventing recurrent disease.   
Therapeutic vaccinations derived from autologous whole tumor cell lysates may help to 
enhance host antigen-specific anti-tumoral immune responses 14. The main advantages of 
these vaccines are “the opportunity to induce immunity to a personalized and broad range 
of antigens” and the incorporation of yet unidentified tumor antigens 140. A recent meta-
analysis of 173 immunotherapy trials, including ovarian and other primary cancers, 
demonstrated a higher objective clinical response in individuals receiving whole tumor 
antigen-based vaccines compared to those receiving synthetic antigens (8.1% vs. 3.6%, 
respectively; p <0.001) 141. The Penn Ovarian Cancer Research Center is currently 
conducting a phase I/II randomized study to determine the feasibility, safety and 
immunogenicity of a vaccine derived from autologous oxidized tumor cell lysate (OC-L) in 
combination with Ampligen, a Toll-like receptor 3 agonist (NCT01312389).   
Vaccination with antigen-specific dendritic cells (DCs) can enhance anti-tumor immunity 
via specific tumor-antigen presentation and activation of effector T cells 142. There are 
several approaches to DC-based vaccines, including exposure of DCs to whole tumor cell 
lysates, defined ovarian tumor peptides, and ovarian tumor cells, to induce a cytotoxic T 
lymphocyte (CTL) response 143. In a phase I trial, three of six patients with progressive or 
recurrent ovarian cancer experienced stabilization of disease following administration of 
autologous tumor antigen-pulsed DCs with reported progression-free intervals of 8-45 
months 144. Given these promising data, DC-based vaccines are currently the focus of 
several new trials (NCT00703105, NCT00683241, and NCT01132014) which will hopefully 
demonstrate an impact on long-term prognosis. The Penn Ovarian Cancer Research 
Center is currently examining the feasibility and immunogenicity of a DC vaccine loaded 
with autologous tumor lysate administered intranodally, alone or in combination with 
intravenous Bevacizumab (NCT01132014). A phase I/II trial is also underway at our 
institution in which patients with recurrent EOC or primary peritoneal cancer will 
undergo adoptive transfer of ex vivo CD3/CD28-costimulated autologous peripheral 
blood T cells along with tumor lysate-pulsed DC vaccination (DCVax®-L) (NCT00603460) 
in order to determine the feasibility and safety of this combination and progression-free 
survival at 6 months. 
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6. Conclusion 
Ovarian cancer is the most lethal gynecologic cancer in the United States. Given the low 
prevalence of this disease in the general population, risk assessment is crucial to the success 
of available preventive strategies. However, current primary preventive strategies, even in 
women at high risk, have not proven reliable in the detection of early stage disease nor have 
they significantly impacted disease related mortality. Thus, risk-reducing behaviors and 
surgery should be considered in women at high risk for ovarian cancer. 
In the near future, novel technologies may help to better characterize critical pathways in 
ovarian carcinogenesis and therefore result in biomarkers and/or multimarker panels more 
effective than CA125 alone, in both detecting early stage disease as well as recurrences. 
Validations of proposed strategies are under investigation in ongoing studies (Table 3). 
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1. Introduction 
Of all the gynecologic cancers, ovarian malignancy represents the greatest clinical challenge 
because it is difficult for early detection, difficult to cure, and it has the highest fatality to 
case ratio of all the gynecologic malignancies. Many studies have been tried to find a novel 
strategy on early detection of ovarian cancer. Ultimately, successful screening in 
asymptomatic women could increase cure rate and prolong survival among patients who 
have to live with ovarian cancer. 
 
 
*Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. 
GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 
[Internet]. 
Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr, accessed on day/month/year. 
Fig. 1. Estimated age-standardised incidence rate per 100,000 women-year of ovarian cancer, 
all ages. 
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2. Epidemiology and impact  
Higher than two hundred thousand women were diagnosed ovarian cancer in 2008 
worldwide(Ferlay, Shin et al. 2010). As a result, more than one hundred and forty thousand 
women accounting for more than fifty percent fatality to case ratio died in this year. Major 
incidences are in Northern America and Europe. In Asia, higher trend of incidence grows 
significantly. Unfortunately, ovarian cancer remains mysterious for early detection and cure. 




Region   
Ovarian cancer Cervical cancer Uterine cancer 
New cases Death  New cases Death  New cases Death  
World* 224,747 140,163 530,232 275,008 288,387 73,854 
US** 21,990 15,460 12,710 4,290 46,470 8,120 
Thailand*** 1,384 - 6,954 - 745 - 
*Ferlay, Shin et al. 2010 
**American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011.  
***Attasara P, Srivatanakul, P, Sriplung, H. cancer incidence in Thailand. In: Khuhaprema T, 
Srivatanakul P, Attasara P, Sriplung H, Wiangnon S, Sumitsawan Y, editor. Cancer in Thailand 2001-
2003 vol.V. 1st ed.  Bangkok: Bangkok Medical Publisher. 2010: 3-76. 
Table 1. Number of new cases and deaths from ovarian, cervical and uterine cancer in a 
year. 
2.1 The incidence and prevalence of ovarian cancer including the stage distribution  
World age-specific incidence rate of ovarian cancer was 6.3 per 100,000 women with a 
cumulative risk 0-74 year-old of 0.7 in 2008 (Ferlay, Shin et al. 2010).  It does not seem to 
significant lower from the year 2002. The distant and regional stage distributions are higher 
than localized ovarian cancer in both developed and developing countries as shown in table 










Percent  of 
cases 
5 year  
survival (%) 
Localized  15 94 26 90 
Regional  23 73 39 80 
Distant  62 28 35 15-25 
* American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society; 2011. 
**modified from Wilailak S. Epidemiologic report of gynecologic cancer in Thailand. J Gynecol 
Oncol. 2009;20: 81–83. 
Table 2. The ovarian cancer distribution and percent of five-year survival. 
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2.2 The sequelae and impact of ovarian cancer 
Eventually, ovarian cancer impacts on patients’ survival and their quality of life. Suffering 
from gut obstruction and malnutrition, renal failure, liver failure, respiratory failure, severe 
chronic pain, infection and sepsis are expected during lifetime and at the end of life in 
women diagnosed with ovarian cancer. Impacts of ovarian cancer are direct from cancer and 
metastases and indirect from treatments and complications. 
Direct sequelae from cancer and metastases 
- Primary tumor: intractable pain 
- Secondary tumor: Brain, Bone, Lung, Liver, KUB system, GI system, lymph nodes 
Indirect sequelae from treatments and complications. 
- Surgery: hemorrhage, internal organ injury, gut obstruction. 
- Chemotherapy: Leukopenia, thrombocytopenia, sepsis, renal failure, cardiotoxicity, 
hypersensitivity reaction 
- Molecular therapy: hypertension, bowel perforation. 
3. Challenges of ovarian cancer 
Challenges toward early ovarian cancer diagnosis could increase cure rate, prolong survival 
and delay suffering from cancer and decreased interventive complications.  
3.1 Pre-Cancer lesion has not yet been identified 
Ovarian cancer pathogenesis has been hypothesized, but it and also pre-cancerous lesion 
have not yet been identified.  
3.2 Most cases are diagnosed in advanced stage 
Asymptomatic women with intra-abdominal concealing of ovarian cancer are most likely 
having late ovarian cancer diagnosis. Eighty-five percent of patients with ovarian cancer are 
diagnosed when the cancer cells already metastases out of the ovary to the whole abdomen. 
Survival and prognosis directly relate to extent of disease. Asymptomatic or nonspecific 
symptoms always found in women with early ovarian cancer.  
3.3 Symptoms are non-specific 
Ninety percent of patients with ovarian cancer had non-specific symptoms which mostly 
were misdiagnosed and delayed proper treatments for some periods.  
3.4 Difficulty in palpation by either patients or physicians 
Women could not feel abdominal mass or even any abnormalities before the mass enlarged 
to beyond her pubic symphysis. Physicians could palpate any mass of ovarian cancer during 
pelvic examination.  
3.5 Result of the treatment is poor in advanced stage 
Contemporary standard primary treatment is surgery and adjuvant combined 
chemotherapy for early stages cancer. In advanced cancer, initially exploratory laparotomy 
with biopsy followed by palliative chemotherapy and/or secondary cytoreductive surgery 
or neo-adjuvant chemotherapy followed by primary cytoreductive surgery is decided 
depending on individualized patient. The most reliable prognosis depends on the residual 
tumor after every attempted surgery.  
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women diagnosed with ovarian cancer. Impacts of ovarian cancer are direct from cancer and 
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- Molecular therapy: hypertension, bowel perforation. 
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3.3 Symptoms are non-specific 
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pelvic examination.  
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Contemporary standard primary treatment is surgery and adjuvant combined 
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3.6 The present tumor markers are non-specific 
Tumor markers are non-specific. Currently, CA125 is widely used as the most promising 
tool along with contemporary standard primary treatment. CA125 is a tumor-associated 
antigen which is detected in 80-85 percent of epithelial ovarian cancer. Only fifty percent of 
patients with FIGO stage I and 60% of patients with FIGO stage II has shown an increased 
CA125 level. Moreover, CA125 test has low specificity among women with reproductive 
age, pregnancy and benign diseases including myoma uteri, endometriosis, and pelvic 
infection. Data suggest that combined CA125 and transvaginal ultrasonography improved 
specificity for ovarian cancer screening. 
4. Screening target population 
Currently, there are no effective screening methods that could decrease mortality from 
ovarian cancer. They are evidences for ovarian cancer screening in both general and high 
risk population. 
4.1 General population 
Mass screening in asymptomatic and general risk population seems to be ineffective and 
associated with increased rates of surgery and patient anxiety(Fung, Bryson et al. 2004). Two 
large studies in Europe and Northern America (Menon, Gentry-Maharaj et al. 2009; Buys, 
Partridge et al. 2011) have shown currently data. The prostate, lung, colorectal and ovarian 
(PLCO) cancer screening randomized controlled trial was conducted in the United States. 
Asymptomatic women aged 55-74 years who had no previous diagnosis of lung, colorectal or 
ovarian cancer were recruited between 1993-2001. Thirty-nine thousand one hundred and five 
participants received annual screening with transvaginal ultrasounds for four years and 
CA125 blood tests for six years. On comparison, Thirty-nine thousand one hundred and eleven 
participants received usual medical care. The positive predictive value was only 23.5%. Sixty 
percent of invasive cancers would not have been detected by the screening. Only 21 percent of 
the participants, who were detected cancer by the screening, were stage I/II.  It was shown 
that women who were screened for ovarian cancer with annual transvaginal ultrasound and 
CA125 blood test had not reduced ovarian cancer mortality. In addition, the screening 
increased invasive medical procedures and associated harms (Buys, Partridge et al. 2011). 
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was 
studied between 2001-2005 (Menon, Gentry-Maharaj et al. 2009). Post-menopausal women 
aged 50—74 years were randomly assigned to no treatment (control; n=101 359); annual 
CA125 screening with transvaginal ultrasound scan as a second-line test (multimodal 
screening [MMS]; n=50 640); or annual screening with transvaginal ultrasound (USS; 
n=50 639) alone in a 2:1:1 ratio (Menon, Gentry-Maharaj et al. 2009).  
Forty-two women with the annual CA125 screening and transvaginal ultrasound scan and 
45 women with annual transvaginal ultrasound were detected primary ovarian and tubal 
cancers including 28 borderline tumors (eight MMS, 20 USS). 28 (16 MMS, 12 USS) of 58 
(483%) of the invasive cancers were stage I/II, with no difference in stage distribution 
between the groups. For primary invasive epithelial ovarian and tubal cancers, the 
sensitivity, specicity, and positive-predictive values were 895%, 998%, and 351% for 
MMS, and 750%, 982%, and 28% for USS, respectively. Specicity was higher in the 
annual CA125 screening with transvaginal ultrasound scan than in the annual screening 
with transvaginal ultrasound alone group, resulting in lower rates of repeat testing and 
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surgery. The screening strategies might be feasible. However, the results of ongoing 
screening are awaited to determine the effect of the screening on mortality from ovarian 
cancer (Menon, Gentry-Maharaj et al. 2009). 
4.2 Increased-risk population 
Prevalence of ovarian cancer is higher in high risk population. Positive family history of 
specific cancers, menopause and having adnexal mass are higher probabilities for ovarian 
cancer.  Screening benefits should be more pronounced and encourage. In addition, 
screening by gynecologic oncologists is feasible and cost effective.  
4.2.1 Menopause 
Senescence is significantly caused genetic aberration inducing cancer. Postmenopause are 
high risk for ovarian cancer (Hensley, Robson et al. 2003).  
4.2.2 Positive family history 
Women with certain family histories have higher risks of ovarian cancer than general 
population. Ten percent of women with epithelial ovarian cancer have mutations in the 
BRCA1 and BRCA2 genes with located on chromosome 17 and 13 respectively. Lynch II 
syndrome is a less common genetic cause of ovarian cancer and endometrial cancer, which 
is known as the hereditary nonpolyposis colorectal cancer syndrome (HNPCC syndrome). 
There is a very limited benefit, of screening even in high-risk women with BRCA1 and 
BRCA2 mutation carriers (Hermsen, Olivier et al. 2007; Woodward, Sleightholme et al. 
2007). In addition, annual gynecological screening is unlikely to reduce mortality in women 
with BRCA1 and BRCA2 mutation carriers (Hogg and Friedlander 2004; Hermsen, Olivier et 
al. 2007). 
4.2.3 Having adnexal mass 
Malignant ovarian masses are pathological diagnosed. Occasionally, it is possible to 
differentiate benign from malignant tumors on the basis of history and physical examination 
findings. 
5. General characteristics of a good cancer screening 
Screening for ovarian cancer is a method for secondary prevention by early detection 
followed with definite treatment. Efficacy screening depends on 5 factors including 
incidence of disease, effective early treatment, available cost effectiveness method and 
adequate population target. Impact of ovarian cancer burden and surgically and adjuvant 
chemotherapeutic effective early treatments are significantly propagated the development of 
a good ovarian cancer screening. There are general characteristics to consider. 
a. High sensitivity, specificity and predictive value 
Accuracy for screening is necessary. Ideally, a good cancer screening for ovarian cancer could 
decrease mortality rate significantly. As this result, it could detect ovarian cancer among 
women who have the cancer. It could discrete non-ovarian cancer women among truly non-
ovarian cancer women. Moreover, the test should be accurate on the results of the tests, it 
means that truly non-ovarian cancer women would be among negative tests’ women and truly 
asymptomatic women with ovarian cancer would be among positive tests’ women. More than 
75 percent sensitivity and more than 99 percent specificity of the most effective test is required 
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surgery. The screening strategies might be feasible. However, the results of ongoing 
screening are awaited to determine the effect of the screening on mortality from ovarian 
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4.2.2 Positive family history 
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to achieve a positive predictive value of 10 percent(Moore, MacLaughlan et al. 2010). These 
mean ten operations of each case of ovarian cancer detected. 
b. Safe 
Safety set as a priority for mass screening in asymptomatic women. 
c. Simple 
Simple method screening which is easy and noninvasive is suitable to coverage the target 
population.  
d. Inexpensive 
Cost of the screening should be paid on attention other than its effectiveness. Cost could be 
one of the obstacles to be refused and ignore from the target population.  
6. The aim of ovarian cancer screening is an attempt to detect early-stage 
asymptomatic individuals 
6.1 Tools for ovarian cancer screening 
Beyond pelvic examination, various tools are proposed including tumor markers, 
ultrasonography and abdominal imaging. 
6.2 Tumor markers 
The most extensively evaluated and available tumor marker currently is Cancer Antigen 125 
(CA125). It has been firstly introduced as OC125 since 1981(Bast, Feeney et al. 1981). Up to 
eighty percent of patients with advanced epithelial ovarian cancer had high CA125 levels 
during diagnosis. However, only 50 percent of patients at early staged ovarian cancer were 
found higher levels than serum thresholds. Low specificity and variable levels of CA125 
resulted in low accurate for screening. Many benign gynecologic and medical conditions 
compromised the specificity. However, CA125 remains valuable for follow up in women 
with epithelial ovarian cancer who have ever had high CA125 level. 
6.3 Imaging 
6.3.1 Ultrasonography 
Utrasonographic results could discriminate patients with ovarian malignancy including 
bilaterality, large cystic structure, any solid lesions (as shown in picture 1), and papillary 
vegetation on the cyst wall or ascites. Accuracy of ultrasonography is still low for detecting 
ovarian cancer. 
6.3.2 Computerized tomography (CT), Magnetic resonance imaging (MRI) 
High false positive rate for detecting ovarian cancer using imaging technology have been 
reports. Individualized patients who should have benefits from the imaging should be 
judged by their physicians. 
7. Single modality of screening or multiple modalities 
7.1 Single/multiple tumor markers 
Various types of tumor markers have been study both early staged and late staged of 
ovarian cancer (Table 3)(Rein, Gupta et al. 2011). High serum levels of HE4, Osteopontin, 
Mesothelin, B7-H4, Prostatin and VEGF were found in both early staged and late staged 
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ovarian cancer. A number of tumor markers were detected only in late staged of cancer as 
shown in table 3.  
 
 
Picture 1. Transabdominal ultrasonography of 44 year-old, single woman with palpable 
pelvic mass has shown mixed solid cystic mass sized 11.8 cm. Postoperative pathologic 
diagnosed clear cell adenocarcinoma of ovary, FIGO stage IC. 
 
Tumor markers* 
Early staged Advanced  and late-staged 
HE4 HE4 
Osteopontin Osteopontin 








IL-6, IL-8 Haptoglobin 
Eosinophil-derived neurotoxin and COOH-osteopontin fragments M-CSF 
OVX1 Sat2-Chr1, Satα 
APOA1 and transthyretin MCJ 
 P53 
*modified from Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers 
for detection and monitoring of ovarian cancer. J Oncol 2011;2011: 475983. (Rein, Gupta et al. 
2011)  
Table 3. The tumor markers detect during early staged and late staged of ovarian cancer. 
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Human epididymis protein 4 (HE4) is elevated in ovarian cancer, especially endometrioid 
adenocarcinoma and serous cystadenocarcinoma (Scholler, Crawford et al. 2006). 
Osteopontin is a glycoprotein and secreted from vascular endothelial cells and osteoblasts. It 
has an ability to inhibit apoptosis and correlates with metastasis(Denhardt and Noda 1998). 
Mesothelin expresses on the surface of mesothelial cells. It is overexpressed in ovarian 
cancer, mesotheliomas and pancreatic cancer (Hassan, Remaley et al. 2006). 
B7-H4 over expressed in T-cells and ovarian cancer including serous cystadenocarcinoma, 
endometrioid adenocarcinoma and clear cell carcinoma. Its levels were elevated 45% of 
patients with early stage ovarian cancer (Simon, Zhuo et al. 2006). 
Hepatoglobin originated from the liver. It has been shown expression in ascetic fluid and 
serum of patients with ovarian cancer. Higher levels of hepatoglobin have been associated 
with poor prognosis(Zhao, Annamalai et al. 2007). The levels also decreased during 
chemotherapy.  
CA125 is only promising tumor marker currently, but it is low specificity. In combination 
with CA125, other serum tumor markers have been evaluated to improve the accuracy with 
some limitations (Visintin, Feng et al. 2008; Amonkar, Bertenshaw et al. 2009; Nosov, Su et 
al. 2009). The study in 2008 evaluated various combinations of 9 markers including CA125, 
HE4, SMRP, CA72-4, Osteopontin, ERBB2, Inhibin, Activin, and EGFR. Dual marker 
combination of CA125 and HE4 had a greater sensitivity than either marker alone (Moore, 
Brown et al. 2008). However, the dual markers are limited in detecting epithelial ovarian 
cancer of mucinous cell type. Human epididymis protein4 (HE4) has equivalent sensitivities 
to CA125 for detecting malignancy in women with pelvic masses (Shah, Lowe et al. 2009).  
In addition, HE4 has greater specificity in premenopausal women due to it does not 
influence by benign gynecologic conditions. Contrary, another study has shown that in 
combination of HE4 and CA125 test was no benefit in clinical practice(Jacob, Meier et al. 
2011). HE4 is going on studies for ovarian cancer screening. 
7.2 The risk of malignancy index (RMI) 
The risk of malignancy index (RMI) was introduced for discriminating ovarian cancer from 
other ovarian mass (Jacobs, Oram et al. 1990). The RMI score is calculated from 
menstruation status, ultrasonographic result and CA125 level. RMI cut-off level of 200 has 
85% sensitivity and 97% specificity to identify ovarian cancer. 
RMI indices followed by Histoscanning study, a novel computer aided diagnostic tool, were 
assessed in 199 women with adnexa masses. A cutoff RMI value of 250 resulted in 74% 
sensitivity and 86% specificity. The RMI indices  with cutoff values between 105-2100 
followed by Histoscanning study improved diagnostic accuracy in women with adnexal 
masses with 88% sensitivity and 95% specificity (Vaes, Manchanda et al. 2011). 
7.3 Risk of malignancy algorithm (ROMA) 
The risk of malignancy algorithm (ROMA) is a scoring system in combination of CA125 and 
HE4 which shows excellent diagnostic performance for the detection of epithelial ovarian 
cancer in post-menopausal women presenting with pelvic mass (Montagnana, Danese et al. 
2011).  
Using ROMA, 389 women with pelvic mass were measured serum levels of HE4 and CA125 
preoperatively. A cutoff of 12.5% for pre-menopausal patients had 67.5% sensitivity and 
87.9% specificity. A cutoff of 14.4% for postmenopausal patients had 90.8% sensitivity and 
66.3% specificity. However, HE4 and ROMA did not increase the detection of ovarian cancer 
comparing to CA125 alone (Van Gorp, Cadron et al. 2011).  
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On comparison, the dual markers using HE4 and CA125, calculated a ROMA value were 
evaluated preoperatively (Moore, Jabre-Raughley et al. 2010). This study used the following 
predictive probability algorithm (ROMA): 
Premenopausal Predictive index (PI) = -12+2.38*LN (HE4) +0.0626*LN (CA125) 
Postmenopausal Predictive index (PI)  = -8.09+1.04*LN (HE4) +0.732*LN (CA125) 
Predicted probability       = exp (PI)/ [1+exp (PI)] 
The following equation was used to calculate RMI: 
    RMI = U X M X serum CA125 
  Where   U = 0 for imaging score of 0 
    U = 1 for imaging score of 1 
    U = 3 for imaging score of 2-5 
    M = 1 if premenopausal 
    M = 3 if postmenopausal 
It shows significant higher sensitivity for detecting epithelial ovarian cancer than RMI as 

























98.8 93.0 0.0350 52.1 50.3 99.6 97.5 
*modified from Moore. Comparison of a novel multiple marker assay versus the RMI. Am J 
Obstet Gynecol 2010. 
Table 4. The sensitivity, positive predictive value and negative predictive value between 
Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) of 
benign tumor and epithelial ovarian cancer (EOC) stage I-IV at a set specificity of 75%. 
LMP= low malignant potential. 
Receiver operating characteristic (ROC) analysis of individual tumor markers and their 
combinations were evaluated and summarized(Jacob, Meier et al. 2011). HE4 performed best 
83.3% sensitivity and 84.6% specificity. Whereas ROMA were 85.4% sensitivity and 85.6% 
specificity (Table 4).  
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On comparison, the dual markers using HE4 and CA125, calculated a ROMA value were 
evaluated preoperatively (Moore, Jabre-Raughley et al. 2010). This study used the following 
predictive probability algorithm (ROMA): 
Premenopausal Predictive index (PI) = -12+2.38*LN (HE4) +0.0626*LN (CA125) 
Postmenopausal Predictive index (PI)  = -8.09+1.04*LN (HE4) +0.732*LN (CA125) 
Predicted probability       = exp (PI)/ [1+exp (PI)] 
The following equation was used to calculate RMI: 
    RMI = U X M X serum CA125 
  Where   U = 0 for imaging score of 0 
    U = 1 for imaging score of 1 
    U = 3 for imaging score of 2-5 
    M = 1 if premenopausal 
    M = 3 if postmenopausal 
It shows significant higher sensitivity for detecting epithelial ovarian cancer than RMI as 

























98.8 93.0 0.0350 52.1 50.3 99.6 97.5 
*modified from Moore. Comparison of a novel multiple marker assay versus the RMI. Am J 
Obstet Gynecol 2010. 
Table 4. The sensitivity, positive predictive value and negative predictive value between 
Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) of 
benign tumor and epithelial ovarian cancer (EOC) stage I-IV at a set specificity of 75%. 
LMP= low malignant potential. 
Receiver operating characteristic (ROC) analysis of individual tumor markers and their 
combinations were evaluated and summarized(Jacob, Meier et al. 2011). HE4 performed best 
83.3% sensitivity and 84.6% specificity. Whereas ROMA were 85.4% sensitivity and 85.6% 
specificity (Table 4).  
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Tumor markers and their 
combinations 
Borderline tumors and cancer group versus  
non-malignant group 
AUC Sensitivity (%) Specificity (%) 
HE4 0.89 83.3 84.6 
CA125 0.87 60.4 91.3 
CA125*HE4 0.90 70.8 94.2 
ROMA 0.90 85.4 85.6 
RMIHE4 0.93 79.1 86.5 
RMICA125 0.95 66.7 97.1 
RMICA125*HE4 0.95 75.0 98.1 
*modified from Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and 
CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121(3): 487-91. 
(Jacob, Meier et al. 2011) 
Table 5. The AUC, sensitivity and specificity of individual tumor markers and their 
combinations between borderline tumors and cancer group versus non-malignant group. 
8. Economic evaluation: Cost effectiveness analysis 
During economic crisis around the world, the cost effectiveness should be evaluated. It is 
estimated the cost-effectiveness of different screening strategies using a stochastic 
simulation model (Skates and Singer 1991). On prediction, a multimodel strategy would cost 
51,000 US dollars per year of life saved. Therefore, it would be potentially cost-effective for 
ovarian cancer screening (Sfakianos and Havrilesky 2011).  
9. Conclusion and recommendations 
In conclusion, screening for ovarian cancer would be emerged as a promising strategy to 
increase cure rate, prolong survival and decrease morbidities in the future. Further 
evaluations for ovarian cancer screening and early detection should be encouraged. 
Understanding preclinical ovarian cancer and development of novel effective strategy could 
lead for early detection, ultimately it will decrease incidence and mortality from ovarian 
cancer. 
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1. Introduction 
Epithelial ovarian carcinoma (EOC) is the fourth leading cause of cancer mortality among 
women in western countries. The incidence of newly diagnosed EOC in the US is estimated to 
be 22,430 cases per year with 15,280 deaths (Jamel A et al., 2006). Surface epithelial-stromal 
tumors are the most common neoplasms of the ovary. Their origin is likely the epithelium 
lining the ovarian surface and/or invaginations of this lining into the superficial cortex of the 
ovary. They occur in women of reproductive age and older. They are usually subclassified as 
benign, borderline and malignant. Due to the numerous histologic types of ovarian neoplasms, 
we will limit our discussion to the most common epithelial stromal tumors. We will be 
discussing the gross appearances, microscopic patterns and differential diagnosis.  
Based on the 2002 World Health Organization (WHO) classification of ovarian tumors 
(Tavassoli FA and Devilee P, 2003), Borderline and Malignant Surface-epithelial stromal 
tumors are classified as: 
1.1 WHO classification 
Serous tumors 
 Malignant  
  Adenocarcinoma 
  Surface papillary adenocarcinoma 
  Adenocarcinofibroma 
 Borderline tumor 
  Papillary cystic tumor 
  Adenofibroma and cystadenofibroma 
Mucinous tumors 
 Malignant 
  Adenocarcinoma 
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1. Introduction 
Epithelial ovarian carcinoma (EOC) is the fourth leading cause of cancer mortality among 
women in western countries. The incidence of newly diagnosed EOC in the US is estimated to 
be 22,430 cases per year with 15,280 deaths (Jamel A et al., 2006). Surface epithelial-stromal 
tumors are the most common neoplasms of the ovary. Their origin is likely the epithelium 
lining the ovarian surface and/or invaginations of this lining into the superficial cortex of the 
ovary. They occur in women of reproductive age and older. They are usually subclassified as 
benign, borderline and malignant. Due to the numerous histologic types of ovarian neoplasms, 
we will limit our discussion to the most common epithelial stromal tumors. We will be 
discussing the gross appearances, microscopic patterns and differential diagnosis.  
Based on the 2002 World Health Organization (WHO) classification of ovarian tumors 
(Tavassoli FA and Devilee P, 2003), Borderline and Malignant Surface-epithelial stromal 
tumors are classified as: 
1.1 WHO classification 
Serous tumors 
 Malignant  
  Adenocarcinoma 
  Surface papillary adenocarcinoma 
  Adenocarcinofibroma 
 Borderline tumor 
  Papillary cystic tumor 
  Adenofibroma and cystadenofibroma 
Mucinous tumors 
 Malignant 
  Adenocarcinoma 
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  Adenocarcinofibroma 
 Borderline tumor 
  Intestinal type 
  Endocervical type 
 Mucinous cystic tumor with mural nodules 
 Mucinous cystic tumor with pseuodomyxoma peritonei 
Endometrioid tumors including variants with squamous differentiation 
 Malignant  
  Adenocarcinoma, NOS 
  Adenocarcinofibroma 
  Malignant mullerian mixed tumor (carcinosarcoma) 
  Adenosarcoma 
  Endometrial stromal sarcoma, low grade 
  Undifferentiated sarcoma  
 Borderline tumor 
  Cystic tumor 
  Adenofibroma and cystadenofibroma 
Clear cell tumors 
 Malignant 
  Adenocarcinoma 
  Adenocarcinofibroma 
 Borderline tumor 
  Cystic tumor 
  Adenofibroma and cystadenofibroma 
Transitional cell tumors 
 Malignant 
  Transitional cell carcinoma (non-Brenner type) 
  Malignant Brenner tumor 
 Borderline  
  Borderline Brenner tumor 
Squamous cell tumors 
 Squamous cell carcinoma 
Mixed epithelial tumors 
Undifferentiated and unclassified tumors. 
2. Serous tumors 
2.1 Borderline tumors 
Serous borderline tumors (SBT) represent 25% to 30% of non benign serous tumors and 
occur in women 30-50 years of age. In the majority of cases they are unilateral and usually 
present at an early stage (stage I) (Prat J and de Nictolis M., 2002). The WHO defines SBT as 
an “ovarian tumor of low malignant potential exhibiting an atypical epithelial proliferation 
of serous type cells greater than that seen in its benign counterpart but without destructive 
stromal invasion”.  
Grossly, the mass is usually partially cystic and partially solid. Polypoid excrescences are 
present on the outer surface of the ovary or within the cyst lumen Fig.2.1.a,b.  
 









Fig. 2.1.b. BST. In another case, instead of polypoid excrescences on the outer surface of the 
ovary, papillary projections are seen within the cyst lumen of the ovary.  
The papillary structures are yellowish, soft and friable. Grossly, SBT should be 
differentiated from the hard, stocky, white excrescences that are usually a characteristic of 
serous cystadenofibroma.  
SBTs are divided into typical and micropapillary patterns.  
2.1.1 Typical SBT 
Typical SBT makes up the majority of SBT (90%). Microscopically, the papillae are lined 
by stratified cuboidal to columnar epithelial cells. These papillae show branching and 
complex structure. The epithelial cells have high nuclear cytoplasmic ratio (N/C), and the 
nuclei are hyperchromatic with prominent nucleoli. Mitotic figures are frequently present 
Fig 2.1.1 a,b.  
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ovary, papillary projections are seen within the cyst lumen of the ovary.  
The papillary structures are yellowish, soft and friable. Grossly, SBT should be 
differentiated from the hard, stocky, white excrescences that are usually a characteristic of 
serous cystadenofibroma.  
SBTs are divided into typical and micropapillary patterns.  
2.1.1 Typical SBT 
Typical SBT makes up the majority of SBT (90%). Microscopically, the papillae are lined 
by stratified cuboidal to columnar epithelial cells. These papillae show branching and 
complex structure. The epithelial cells have high nuclear cytoplasmic ratio (N/C), and the 
nuclei are hyperchromatic with prominent nucleoli. Mitotic figures are frequently present 
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Fig. 2.1.1.b. BST: At higher magnification, the papillae are lined by epithelial cells exhibiting 
severe pleomorphism with moderate to severe atypia and with high nuclear/cytoplasmic 
ratio. They have big round nuclei and prominent nucleoli.  
Caution should be practiced when one sees what appears to be epithelial proliferation 
without cytologic atypia, because tangential sectioning of the lining of a benign serous 
cystadenoma can give the impression of proliferation of the epithelial lining.  
By definition, SBT lack stromal invasion. This is a major criterion to differentiate SBT from 
serous adenocarcinoma. Careful gross examination, as well several sections (1 section/1 cm 
of the tumor diameter) is needed. Finally, invasion of the stalk of the papillae should not be 
considered as ovarian stromal invasion. 
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2.1.2 SBT with micropapillary pattern or micropapillary SBT (MSBT) 
SBT with micropapillary pattern or micropapillary SBT (MSBT) accounts 5-10% of all 
SBTs. The significance of this subtype has generated a lot of debate in pathology. Some 
authors have found a close association between MSBT and invasive implants and urged to 
call this entity as “micropapillary serous carcinoma”. Yet others prefer the terminology of 
MSBT, avoiding the use of the term of “carcinoma”, to minimize the possibility of over 
treating patients (Chang SJ et al., 2008; Sehdev S et al., 2003). The general agreement on 
the significance of micropapillary architecture in SBTs is that there is a significant increase 
in incidence of invasive peritoneal implants (Burks R et al., 1996). Molecular studies show 
that MSBT has a similar gene expression profile as low-grade serous carcinoma (LG-
serous carcinoma) and distinct from typical SBT [May T et al., 2010]. The underlying 
genes involved in the pathogenesis of LG-serous carcinoma, and in MBST include 
mutations in a number of different genes including KRAS and BRAF.  Actually, MSBT is 
the only surface-epithelial stromal tumor with a well defined adenoma-carcinoma 
sequence, where LG serous is thought to arise in a stepwise fashion from a benign 
cystadenoma through BST to an invasive LG-serous carcinoma (Kurman RJ et al., 2008). 
Microscopically, MSBTs shows highly complex micropapillary growth in a filigree 
pattern, growing in a nonhierarchical fashion from stalk. It has been described as 
“Medusa head” like appearance. Micropapillae are at least five times as long as they are 








Fig. 2.1.2.a. Micropapillary SBT: Microscopic examination shows highly complex 
micropapillary growth in a filigree pattern, which is defined by a growth in a 
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Fig. 2.1.1.b. BST: At higher magnification, the papillae are lined by epithelial cells exhibiting 
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2.1.2 SBT with micropapillary pattern or micropapillary SBT (MSBT) 
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SBTs. The significance of this subtype has generated a lot of debate in pathology. Some 
authors have found a close association between MSBT and invasive implants and urged to 
call this entity as “micropapillary serous carcinoma”. Yet others prefer the terminology of 
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genes involved in the pathogenesis of LG-serous carcinoma, and in MBST include 
mutations in a number of different genes including KRAS and BRAF.  Actually, MSBT is 
the only surface-epithelial stromal tumor with a well defined adenoma-carcinoma 
sequence, where LG serous is thought to arise in a stepwise fashion from a benign 
cystadenoma through BST to an invasive LG-serous carcinoma (Kurman RJ et al., 2008). 
Microscopically, MSBTs shows highly complex micropapillary growth in a filigree 
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Fig. 2.1.2.b. Micropapillary SBT: The micropapillae are at least five times as long as they are 
wide. 
Micropapillary foci should occupy an area of at least 5 mm, since micropapillary foci of less 
than 5 mm have no bearing on clinical outcome (Slomovitz MB et al., 2002).  
2.1.3 Peritoneal implants 
Peritoneal implants are classified into epithelial invasive and non-invasive implants, and 
desmoplastic invasive and non-invasive implants. Implants are a hetergenous group and 
various types may coexist, therefore, multiple biopsies of numerous foci of suspicious 
lesions at the time of surgery and extensive tumor sampling by the pathologist, is the main 
key to exclude an invasive implant. 
Epithelial non-invasive implants are characterized by the presence of branching, complex 
papillae within cystic spaces with no stromal reaction or destruction Fig 2.1.3.a. 
 
 
Fig. 2.1.3.a. Non-invasive peritoneal implant: The implant is defined by papillary structure 
in a space like structure with no evidence of invasion or destruction of the ovarian stroma. 
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SBT with non-invasive implants have been considered indolent, with 5-year survival rate of 
95% and recurrence rate ranging from 8% to 32% (Silva EG et al., 2006). 
Epithelial invasive implants are characterized by haphazardly distributed glands and 
clusters of branching papillae infiltrating the adipose tissue and stroma. The epithelial cells 
should have marked cytologic atypia. The associated stroma is composed of dense fibrous 
tissue Fig 2.1.3.b. Patients with SBT with invasive implants may develop low grade 
carcinomas many years after initial diagnosis. (McCluggage WG, 2010) 
 
 
Fig. 2.1.3.b. Invasive implant: it is defined by complex structure of papillae where the 
neoplastic cells exhibit severe cytologic atypia and they seem to infiltrate a very dense stroma. 
Desmoplastic non invasive implants are defined by clusters of tumor cells that are present 
in a loose fibrous stroma. The stroma may have granulation tissue like features with 
neutrophilic infiltrates and hemorrhage. 
Differential diagnosis: Implants should be distinguished from benign epithelial inclusions or 
endosalpingiosis. Inclusions are defined by small glands lined by a single cell layer without 
atypia. Endosalpingiosis is characterized by a lining typical for tubal epithelium such as 
ciliated and intercalated cells. 
2.1.4 SBT with microinvasion 
Microinvasion is defined as single cells or few clusters of cells similar to those seen in the 
overlying SBT that infiltrate the stroma. One or more foci may be present but none should 
exceed 10 mm2. SBT with microinvasion appears to have no significance on disease 
outcome, with 10 year survival rate is of 86% (Slomovitz BM et al, 2002). 
2.1.5 Implants in a lymph node  
Approximately 27% of surgically staged patients with SBT present with lymph node 
involvement by tumor. The most common lymph nodes involved are the pelvic and paraaortic 
groups. Recent molecular and morphologic data suggest that although most nodal implants 
are indeed metastatic from a concurrent ovarian neoplasms, small subsets arises de novo from 
nodal endosalpingiosis. It has also been suggested that the route of spread from an ovarian 
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SBT to lymph nodes might be via a peritoneal route and not lymphatic. The morphology of the 
implant is similar to that occurring in the ovary. Lymph node involvement does not adversely 
impact the overall survival of patients with SBT of the ovary [Fadare O, 2009]. The major 
differential diagnosis is endosalpingiosis and the criteria are cited previously in the text. 
2.2 Serous carcinoma 
Serous adenocarcinoma occurs in women a bit older than women with SBT, with an average 
age of 56 years. Patients with serous adenocarcinoma often present with advanced stage 
disease (stage III and IV) at first presentation.  
Grossly, the tumor varies considerably in size from a few cm to 30 cm. The cut surface may 
be partially cystic and partially solid or it may be solid with areas of necrosis and 
hemorrhage Fig 2.2.a. When infiltrating the omental adipose tissue, the tumor creates what 
is called “omental caking” Fig 2.2.b.  
 
 
Fig. 2.2.a. Serous adenocarcinoma: the ovarian mass is solid with few cystic areas. The cut 
surface is firm, white with areas of necrosis and hemorrhage.  
 
Fig. 2.2.b. Omentum: The tumor involves the omentum and create “omental cake” which is 
characterized by tumoral seeding of the adipose tissue. The cut surface is white, firm and 
homogenous.  
 




Grading of surface epithelial stromal tumors is still performed haphazardly with several 
systems and non-systems used in different institutes and in different research studies. The 
lack of uniformity in grading has resulted in little consensus as to whether ovarian tumor 
grade has any significance in predicting disease outcome. The grading systems used most 
commonly worldwide are the International Federation of Gynecology and Obstetrics (FIGO) 
system, and the World Health Organization (WHO) system. The FIGO grading system for 
the ovary is similar to the grading system used in the uterus. It is based on architectural 
features. The grade depends on the ratio of glandular or papillary structures versus solid 
tumor growth. Grade 1 is equivalent to <5% solid growth, grade 2 to 5-50% solid growth 
and grade 3 to =>50% solid growth (International federation of Gynecology & Obstetrics, 
1971). In the WHO system, the grade is assessed by both the architectural and cytologic 
features, without any quantitative values (Tavassoli FA and Devilee P., 2003). The 
Gynecologic Oncology (GOG) system is the most commonly used system in the United 
States (Benda JA et al., 1994). It employs a method based on the histologic type. For 
example, ovarian carcinoma of endometrioid type is graded similarly to the endometrial 
adenocarcinoma of endometrioid type. Ovarian carcinoma of transitional type is graded 
similar to transitional cell carcinoma (TCC) of the bladder. Clear cell carcinomas are not 
graded at all. Silverberg’s et al proposed a new grading system similar to that used in breast 
carcinoma and it depends on architectural features (glandular 1, papillary 2 and solid 3), 
cytologic atypia (mild 1, moderate 2, severe 3), and mitotic rate (1 0-9 mitosis/10HPF, 2 10-
24, 3 >25). A score is given by adding the parameters, a score of 3-5, is grade 1, a score of 6-7 
is grade 2, and a score of 8 -9 is grade 3 (Silverberg S, 200). Fig 2.2.1a and Fig 2.2.1.b are 







Fig. 2.2.1.a. Low grade serous carcinoma: The tumor has papillary features. The neoplastic 
cells have mild to moderate atypia and rare mitotic figures. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
62
SBT to lymph nodes might be via a peritoneal route and not lymphatic. The morphology of the 
implant is similar to that occurring in the ovary. Lymph node involvement does not adversely 
impact the overall survival of patients with SBT of the ovary [Fadare O, 2009]. The major 
differential diagnosis is endosalpingiosis and the criteria are cited previously in the text. 
2.2 Serous carcinoma 
Serous adenocarcinoma occurs in women a bit older than women with SBT, with an average 
age of 56 years. Patients with serous adenocarcinoma often present with advanced stage 
disease (stage III and IV) at first presentation.  
Grossly, the tumor varies considerably in size from a few cm to 30 cm. The cut surface may 
be partially cystic and partially solid or it may be solid with areas of necrosis and 
hemorrhage Fig 2.2.a. When infiltrating the omental adipose tissue, the tumor creates what 
is called “omental caking” Fig 2.2.b.  
 
 
Fig. 2.2.a. Serous adenocarcinoma: the ovarian mass is solid with few cystic areas. The cut 
surface is firm, white with areas of necrosis and hemorrhage.  
 
Fig. 2.2.b. Omentum: The tumor involves the omentum and create “omental cake” which is 
characterized by tumoral seeding of the adipose tissue. The cut surface is white, firm and 
homogenous.  
 




Grading of surface epithelial stromal tumors is still performed haphazardly with several 
systems and non-systems used in different institutes and in different research studies. The 
lack of uniformity in grading has resulted in little consensus as to whether ovarian tumor 
grade has any significance in predicting disease outcome. The grading systems used most 
commonly worldwide are the International Federation of Gynecology and Obstetrics (FIGO) 
system, and the World Health Organization (WHO) system. The FIGO grading system for 
the ovary is similar to the grading system used in the uterus. It is based on architectural 
features. The grade depends on the ratio of glandular or papillary structures versus solid 
tumor growth. Grade 1 is equivalent to <5% solid growth, grade 2 to 5-50% solid growth 
and grade 3 to =>50% solid growth (International federation of Gynecology & Obstetrics, 
1971). In the WHO system, the grade is assessed by both the architectural and cytologic 
features, without any quantitative values (Tavassoli FA and Devilee P., 2003). The 
Gynecologic Oncology (GOG) system is the most commonly used system in the United 
States (Benda JA et al., 1994). It employs a method based on the histologic type. For 
example, ovarian carcinoma of endometrioid type is graded similarly to the endometrial 
adenocarcinoma of endometrioid type. Ovarian carcinoma of transitional type is graded 
similar to transitional cell carcinoma (TCC) of the bladder. Clear cell carcinomas are not 
graded at all. Silverberg’s et al proposed a new grading system similar to that used in breast 
carcinoma and it depends on architectural features (glandular 1, papillary 2 and solid 3), 
cytologic atypia (mild 1, moderate 2, severe 3), and mitotic rate (1 0-9 mitosis/10HPF, 2 10-
24, 3 >25). A score is given by adding the parameters, a score of 3-5, is grade 1, a score of 6-7 
is grade 2, and a score of 8 -9 is grade 3 (Silverberg S, 200). Fig 2.2.1a and Fig 2.2.1.b are 







Fig. 2.2.1.a. Low grade serous carcinoma: The tumor has papillary features. The neoplastic 
cells have mild to moderate atypia and rare mitotic figures. 
 








Fig. 2.2.1.b. High grade serous carcinoma: The tumor cells are arranged in solid sheets with 
very rare foci of papillary architecture. The cells exhibit severe atypia and frequent mitotic 
figures.  
This grading system was confirmed to be reproducible in subsequent studies (Ishioka SI et 
al., 2002). Another study from MD Anderson cancer center group suggested adopting a two-
tier system that is based primarily on the assessment of nuclear atypia (uniformity vs. 
pleomorphism) in the worst area of the tumor (Malpica A et al., 2004). The tumor is graded 
into low grade and high grade. A few years after its introduction, the authors confirmed its 
reproducibility and urged its use to facilitate the clinical trials and protocols (Malpica A et 
al., 2007).  
3. Mucinous tumors 
3.1 Mucinous borderline tumors 
Mucinous borderline tumors (MBT) (mucinous tumors of low malignant potential) as 
defined by the WHO, are tumors exhibiting an epithelial proliferation of mucinous type 
cells greater than that seen in their benign counterparts but without evidence of stromal 
invasion. MBT can be of intestinal type or endocervical-like type.  
3.1.1 Mucinous borderline tumors of intestinal type 
The intestinal type tumors are the most common type of MBTs, accounting for 85-90% of 
cases. They are not associated with peritoneal implants or lymph node involvement. Similar 
to low- grade serous tumors, intestinal type MBTs are thought to arise from a cystadenoma 
and to progress to carcinoma, following the adenoma-carcinoma sequence model. Grossly, 
they are usually a very large unicystic or multicystic mass filled with mucoid-gelatinous 
material Fig 3.1.1a.  
 






Fig. 3.1.1.a. Mucinous borderline tumor (MBT): The cut surface of the ovarian mass shows 
multiple cysts filled with gelatinous material. However in some areas the wall of the cyst 
seemed to be thickened. 
Histologically, the lining of the cyst is composed of stratified lining of epithelial cells having 
high N/C ratio and prominent nucleoli Fig 3.1.1.b,c. Goblet cells and Paneth cells are 





Fig. 3.1.1.b. MBT: At low magnification, the tumor is composed of proliferation of glands 
which some are cystically dilated separated by abundant intervening stroma.  
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Fig. 3.1.1.b. MBT: At low magnification, the tumor is composed of proliferation of glands 
which some are cystically dilated separated by abundant intervening stroma.  
 




Fig. 3.1.1.c. Higher magnification showed that the glands are lined by mucin secreting cells 
exhibiting moderate to severe atypia, big nuclei and prominent nucleoli. In some areas, the 
cytoplasm shows mucin depletion. Mitotic figures are frequently present.  
3.1.2 Mucinous borderline tumors of endocervical type 
The endocervical type tumors are a less common and make up 10-15% of MBTs. They are 
usually smaller in size than their intestinal type counterparts and they are commonly 
bilateral (40%). They are thought to arise from endometriosis. Microscopically, the epithelial 
cells lining the cyst wall contain intracytoplasmic mucin, resembling endocervical cells.  
3.1.3 Mucinous tumors with mural nodules 
Mucinous tumors of the ovary, whether benign, borderline or malignant, may contain one or 
more nodules. These nodules are morphologically different than the overlying mucinous 
neoplasm. Grossly, nodules are yellow, pink with areas of hemorrhage and necrosis Fig 3.1.3.a.  
 
 
Fig. 3.1.3.a. Mural nodules: Mural nodules are grossly characterized by a well defined mass 
within the wall of the cyst. The cut surface is often hemorrhagic.  
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Microscopically, the mural nodules may be malignant (anaplastic, sarcoma or 
carcinosarcoma) or benign (sarcoma-like). It is important to distinguish between benign and 
malignant mural nodules, because benign mural nodules are of no prognostic significance. 
Immunohistochemistry is a very helpful tool for this purpose. Sarcoma-like nodules are 
composed of a heterogenous cell population of cells including spindle cells, giant cells, 
mononuclear cells and inflammatory cells. The cells of the sarcoma- like nodules are 
negative or very weakly positive for cytokeratin Fig3.1.3.b.  
 
 
Fig. 3.1.3.b. Sarcoma-like nodules: They are composed of heterogenous cell population 
including spindle cells, giant cells, mononuclear cells and inflammatory cells.  
Anaplastic sarcoma mural nodules are composed of diffuse sheets of spindled or large 
rhabdoid-looking cells with abundant eosinophilic cytoplasm and prominent nucleoli fig 
3.1.3.c,d. These cells are usually strongly positive for cytokeratin fig 3.1.3.e.  
 
 
Fig. 3.1.3.c. Anaplastic nodules: They are characterized by proliferation of spindle cells. 
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Fig. 3.1.3.d Anaplastic nodules: At higher magnification, the spindle cells exhibit severe 




Fig. 3.1.3.e. Anaplastic nodules: The spindle cells in are strongly positive for total 
cytokeratin immunostain.  
Lastly Sarcoma nodules exhibit a variety of patterns such as fibrosarcoma, 
rhabdomyosarcoma and undifferentiated sarcoma.  
3.2 Mucinous adenocarcinoma 
Mucinous adenocarcinomas (MAC) are very large tumors; many are 15 to 30 cm in diameter 
and weigh as much as 4 kgs. The cut surface can be cystic or solid and the content is 
composed of gelatinous, mucoid material Fig 3.2a.  
 








Fig. 3.2.a. Mucinous cystadenocarcinomas: Grossly, they are characterized by partially cystic 
and partially solid mass. The cysts content is composed of gelatinous material. 
These tumors are defined by invasion and adequate sampling is a key factor to document 
invasion process. Numerous sections (2 to 3 sections /1cm of tumor diameter) are required. 
Invasion can be defined as infiltration of ovarian stroma by neoplastic cells arranged in nests 






Fig. 3.2.b. Mucinous adenocarcinoma: It is also defined by proliferation of back to back 
glands with no or little interfering stroma.  
 





Fig. 3.1.3.d Anaplastic nodules: At higher magnification, the spindle cells exhibit severe 




Fig. 3.1.3.e. Anaplastic nodules: The spindle cells in are strongly positive for total 
cytokeratin immunostain.  
Lastly Sarcoma nodules exhibit a variety of patterns such as fibrosarcoma, 
rhabdomyosarcoma and undifferentiated sarcoma.  
3.2 Mucinous adenocarcinoma 
Mucinous adenocarcinomas (MAC) are very large tumors; many are 15 to 30 cm in diameter 
and weigh as much as 4 kgs. The cut surface can be cystic or solid and the content is 
composed of gelatinous, mucoid material Fig 3.2a.  
 








Fig. 3.2.a. Mucinous cystadenocarcinomas: Grossly, they are characterized by partially cystic 
and partially solid mass. The cysts content is composed of gelatinous material. 
These tumors are defined by invasion and adequate sampling is a key factor to document 
invasion process. Numerous sections (2 to 3 sections /1cm of tumor diameter) are required. 
Invasion can be defined as infiltration of ovarian stroma by neoplastic cells arranged in nests 






Fig. 3.2.b. Mucinous adenocarcinoma: It is also defined by proliferation of back to back 
glands with no or little interfering stroma.  
 





Fig. 3.2.c. Mucinous adenocarcinoma: These glands are cytologically malignant with severe 
atypia, large nucleoli, loss of cytoplasmic mucin and numerous mitosis.  
However, one needs not to see typical stromal invasion with desmoplastic reaction to 
diagnose MAC, because invasion can also be defined as neoplastic glands which are back to 
back with no intervening stroma Fig 3.2d. Similar to MBTs, the epithelial lining in MAC can 
be of intestinal or endocervical type. MAC should be distinguished from metastatic 
adenocarcinoma from colonic origin. Metastatic colonic carcinomas are usually bilateral. 
Morphologically, they are characterized by glandular proliferation with abundant dirty 
necrosis and nuclear debris within amorphous necrotic tissue. The glands are lined by 




Fig. 3.2.d. Mucinous cystadenocarcinoma: It is defined by invasion of the ovarian stroma by 
small glands and nests of tumor cells .  These glands are cytologically malignant and 
infiltrate the stroma in disorderly fashion. 
 




Fig. 3.2.e. Metastatic colon carcinoma: It is characterized by large glands with center “dirty” 
necrosis and nuclear debris within amorphous necrotic tissue. 
3.3 Pseudomyxoma peritonei 
Pseudomyxoma peritonei (PP) is a clinical term used to describe the finding of mucoid, 
gelatinous material in the abdominal cavity, often accompanied by an ovarian or 
gastrointestinal tumor. In 1995, Ronnett et al classified PP into low-grade variety “diffuse 
peritoneal adenomucinosis” (DPAM) and to high-grade variety “peritoneal mucinous 
carcinomatosis” (PMCA) (Ronnett BM et al, 1995). DPAM is defined as pools of mucin with 
few strips of mucinous epithelium exhibiting minimal cytologic atypia and rare mitotic 
figures Fig3.3.a. On the other hand, PMCA is characterized by abundant mucinous 




Fig. 3.3.a. Peritoneal mucinosis; It is characterized by pool of acellular mucin.  
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Fig. 3.3.a. Peritoneal mucinosis; It is characterized by pool of acellular mucin.  
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This classification is prognostically significant with 5-year survival rates of 84% for DPAM 
and 6.7% for PMCA (Ronnett BM et al, 2001).  PP may originate from an ovarian primary or 
from an appendiceal primary. An appendectomy is necessary in those circumstances. 
Grossly, the appendix shows a dilated lumen filled with mucinous material. Histologically, 
depending upon the cytologic atypia, the appendiceal tumor may be a mucinous 





Fig. 3.3.b. Peritoneal adenocarcinomatosis: It is characterized by pool of mucin and clusters 




Fig. 3.3.c. Appendiceal mucinous tumor: The appendiceal lumen is dilated and filled with 
mucin which is dissecting the entire thickness of the wall. 
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In many cases, the appendix is encased by a very large mucinous mass, and histologically, 




Fig. 3.3.d. Appendiceal mucinous tumor: The appendiceal mucosa shows proliferation of 
mucin-secreting cells that they are not frankly malignant. Due to the absence of glandular 
cribriform and submucosal invasion, this lesion is classified as mucinous tumor of low 
malignant potential. 
Not so long ago, there was a considerable controversy about the origin of mucin in PP, in 
women with concomitant mucinous tumors of the appendix and the ovaries. Recent 
immunohistochemical, molecular, and genetic evidence supports the appendix as the 
primary tumor and secondary involvement of the ovary (Ronnet BM et al, 2004)  In difficult 
cases, immunohistochemistry study including cytokeratin 7 (CK7), cytokeration 20 (CK20) 
and CDX2 are useful to discriminate between primary appendix from primary ovarian 
mucinous tumors. At first CDX2 seemed to be a promising marker and its positivity was 
found to be very specific for lower gastrointestinal carcinomas but as more studies have 
been published, more cases of ovarian mucinous tumors have been found to be positive for 
CDX2 rendering its use of little value. On the other hand CK7/CK20 is more useful, as 
ovarian mucinous tumor are CK7+/CK20+ and appendiceal/ colon tumors are CK7-
/CK20+. Thus, CK7/CK20 is the most useful and reliable combination in distinguishing 
appendiceal versus ovarian primary (Chu P et al., 2000; Kaimaktchiev et al., 2004).  
4. Endometrioid tumors 
4.1 Endometrioid adenocarcinoma 
Endometrioid adenocarcinoma (EAC) account for 10-20% of ovarian carcinomas. They 
occur in postmenauposal women, with average age of 56 years. The frequent association 
with endometriosis and endometrioid adenocarcinoma of the endometrium suggested 
that some EAC of the ovary might have the same risk factors as those occurring in the 
endometrium.  In contrary to serous carcinomas, about half of EAC cases present as early 
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stage disease (stage I and II). They are bilateral in 20% of cases. Microscopically, these 
tumors are usually well differentiated tumors (grade I). The tumor is microscopically very 
similar to those occurring in the endometrium, where back to back glands with no 
intervening stroma and squamous differentiation in the form of squamous morules and 
keratin pearls are present. Fig 4.1a., b 
 
 
Fig. 4.1.a. Endometrioid adenocarcinoma (EAC): The morphologic features of this tumor are 
very similar to those occurring in the endometrium where back to back glands with no 
intervening stroma.  
 
Fig. 4.1.b. EAC: The glands are cribriform and they are cytologcially malignant. 
Rare examples of mucin-rich, secretory, ciliated, and oxyphilic types have been described. 
Occasionally the tumor may resemble granulosa cell tumor, with the cells arranged in 
ribbons, and small glands, creating the illusion of Call-Exner bodies. Also, rare cases exhibit 
tubular glands resembling a Sertoli-Leydig cell tumor. In both cases alpha-inhibin is 
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excellent marker to differentiate between EAC and sex-cord tumors, where it is negative in 
EAC of the ovary and it is positive in sex-cord stromal tumors such as Sertoli-Leydig tumors 




Fig. 4.1.c.  Sertoli-Leydig cell tumor: They may be arranged in irregular tubules lined by 




Fig. 4.1.d. Sertoli-Leydig cell tumor: Tumor cells are positive for inhibin immunostain. 
4.2 Carcinosarcoma (mixed malignant mullerian tumor/MMMT) 
Carcinosarcomas account for <1% of all ovarian cancers and occur in the sixth to eight 
decades. They are composed of two components; a malignant epithelial component and 
sarcomatous elements. The sarcomatous component may be homologous (tissue native to 
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the ovary) or heterologous elements (skeletal muscle, cartilage and bone). Molecular studies 
support a clonal origin of both components, leading some to propose designating 
carcinosarcoma as a “metaplastic carcinoma” (Thompson L et al, 1996; Mayall F et al, 1994). 
The epithelial component is usually of endometrioid type adenocarcinoma but other types 
like serous or mucinous may be found Fig 4.2.a. The sarcomatous component may be a 
homologous type such as fibrosarcoma, high-grade endometrial stromal sarcoma, or a 




Fig. 4.2.a. MMMT: the tumor is composed of two components which are malignant, the 




Fig. 4.2.b. MMMT: the mesenchymal component (sarcoma) is composed of very atypical, 
hyperchromatic cells. These cells have a high mitotic rate.    
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5. Clear cell tumors 
Clear cell carcinoma 
Clear cell carcinomas (CCC) represent 6% of surface-epithelial tumors. They occur in 
postmenopausal women, with a mean age of 57 years. CCC of the ovary has a few notable 
characteristics 1- they are almost always unilateral, 2- they are admixed with 
endometrioid type adenocarcinoma in 20-25% of cases, 3- they are often accompanied by 
endometriosis of the same ovary, 4- they may be associated with paraneoplastic 
hypercalcemia and 5- they have frequent mutations of ARID1A and PIK3CA genes 
(Anglesio MS et al., 2011). Histologically, CCC may exhibit various patterns of growth, 
including tubulo-cystic, papillary and solid patterns Fig 5.a. The papillae of CCC are 
unique in that they are composed of an extensive hyaline core which is different from the 
small, fibrovascular core papillae as seen in serous adenocarcinoma. In addition, CCC can 
display numerous cell types such as clear, hobnail, cuboidal, flat, oxyphilic and signet-cell 
types. The most common type, clear cell type, is defined by round to polygonal cells with 
a clear cytoplasm, eccentric nuclei and prominent nucleoli Fig5.b, c. The cytoplasm 
contains abundant glycogen which is Periodic acid-Schiff (PAS) positive, diastase 
digestion resistant. Numerous intracytoplasmic hyaline globules may be seen. Mucin can 
be found in the lumens of tubules and cysts and it is very abundant in the cytoplasm of 










Fig. 5.a. Clear cell carcinoma (CCC): low magnification shows proliferation of neoplastic 
cells in form of solid sheets and papillary patterns. 
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cells in form of solid sheets and papillary patterns. 
 















Fig. 5.c. CCC: some cells contain inspissated secretion that is mucicarmine positive creating 
a targetoid appearance.  
Due to these various patterns, CCC can be mistaken for germ cell tumors including 
dysgerminoma, yolk sac tumors, endometrioid adenocarcinoma with secretory changes, and 
with metastatic renal cell carcinoma (RCC) Fig 5.d,e.  
 












Fig. 5.e. Yolk sac tumor: The tumor cells have abundant eosinophilic cytoplasm and contain 
hyaline bodies.  
Alpha-fetoprotein (AFP), placenta alkaline phosphatse (PLAP), cytokeratins and epithelial 
membrane antigen (EMA) are helpful immunohistochemistry stains to distinguish CCC 
from germ cell tumors. In germ cell tumors, AFP and PLAP are positive and cytokeratin and 
EMA are negative, while CCC cells are negative for AFP and PLAP and positive for 
cytokeratin and EMA (Mittal k et al 2008).  
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Metastatic RCC to the ovary, though rare, creates a major diagnostic challenge, when CCC 
of the ovary is of clear cell type. It is almost impossible to differentiate the two based solely 
on morphology. Therefore, IHC is helpful as RCC is usually negative for CK7 and positive 
for CD10 and CCC of the ovary is typically positive for CK7 and negative for CD10. In 
addition, correlation with radiologic findings is necessary to rule out metastatic RCC (Mittal 
K et al, 2008).  
6. Transitional cell tumors 
Transitional cell carcinoma and malignant Brenner tumors 
The group of transitional cell tumors includes benign Brenner tumors, borderline and 
malignant Brenner tumors, and transitional cell carcinoma. By definition, transitional cell 
carcinoma of the ovary (TCC-O) and malignant Brenner tumors are composed of epithelial 
cells morphologically resembling urothelium. TCC-O is the least common surface epithelial 
tumor of the ovary, accounting 1-2% of all ovarian tumors. It may sometimes be associated 
with germ cell tumors. They are bilateral in 15% of the cases. Grossly they are cystic with 








Fig. 6.a. Transitional cell carcinoma of the ovary (TCC-O): The mass is mostly composed of 
one large cystic where a large vegetating tumoral mass protrudes in the lumen. 
TCC-O can be already widespread disease at the time of diagnosis, however, malignant 
Brenner tumors are usually stage I disease at first presentation.  Histologically, TCC-O and 
malignant Brenner tumors resemble TCC occurring in the urinary tract. They are composed 
of papillary projections protruding into a cystic lumen, lined by multilayered malignant 
transitional epithelium Fig 6.b.c. 
 





Fig. 6.b. TCC-O: The tumor is composed of broad undulating macropapillae with smooth 
borders. 
 
Fig. 6.c. TCC-O: At higher magnification, the macropapillae are composed of multilayered 
transitional cells resembling that of papillary transitional cell carcinoma of the bladder. 
These cells have high grade nuclei and numerous mitotic figures. 
Foci of glandular differentiation and squamous metaplasia may also be seen. Very often, 
TCC can be mixed with serous adenocarcinoma. At matched stage, TCC-O has a worse 
prognosis compared to malignant Brenner tumors. Therefore, TCC-O should be 
differentiated from malignant Brenner tumors. Morphologically, TCC-O lack an associated 
benign or borderline Brenner tumor, whereas, malignant Brenner tumors are always 
accompanied by benign or borderline Brenner tumors (Eichhorn JH et al., & Young RH, 
2004). Thus, extensive tumor sampling is needed to make an accurate diagnosis. The major 
differential diagnosis is metastatic TCC from the urinary tract and immunohistochemistry 
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can be very helpful. Numerous studies have dealt with this issue and concluded that the 
best IHC panel is CK20, uroplakin, and Wilm’s tumor (WT). TCC-O are CK20-, uroplakin- 
and WT1+, whereas, metastatic TCC from the bladder are CK20+, Uroplakin + and WT1- ( 
Logani S et al., 2003; Delair D et al., 2011 ; Ordonez NG, 2000). 
7. Squamous cell carcinoma 
Squamous cell carcinomas (SCCs) of the ovary are very rare. They arise most commonly 
from the lining of a dermoid cyst, endometrioisis or a Brenner tumor (Acien P et al, 2010; 
Bal A et al, 2007). They have similar morphology to squamous cell carcinoma occurring in 
the cervix or vagina. Fig 7.a   
 
 
Fig. 7.a. Squamous cell carcinoma. Tumor cells are arranged in large nests. Keratin pearls 
and necrotic debris is also present. The tumor cells resembling squamous cell carcinoma of 
the cervix or squamous cell carcinoma of any origin.  
Before the diagnosis of primary squamous cell carcinoma of the ovary is made, metastatic 
SCC from the cervix should be excluded. In addition, primary SCCs of the ovary should be 
distinguished from endometrioid adenocarcinoma with extensive squamous differentiation. 
Thus, extensive sampling is recommended. Cases of primary SCCs of the ovary frequently 
have spread beyond ovary at the time of presentation, leading to poor prognosis.  
8. Ovarian carcinoma after neoadjuvant therapy 
Traditionally, advanced stage ovarian carcinoma is treated by debulking surgery followed 
by chemotherapy. In some circumstances, neoadjuvant chemotherapy followed by 
debulking surgery may be done. Neoadjuvant chemotherapy is increasingly being used in 
the management of patients with advanced ovarian cancer and pathologists should be 
aware of the morphologic changes in ovarian cancer after neoadjuvant chemotherapy. For 
the inexperienced or those with no knowledge of the patients’ history, treated tumors may 
be mistaken for metastatic carcinoma from breast primary or other sites. The morphologic 
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changes seen in response to neoadjuvant chemotherapy include small groups or single 
tumor cells in a densely fibrotic stroma Fig 8.a. The tumor cells are characterized by 
nuclear and cytoplasmic alteration making the grading and sometimes the tumor typing 
impossible and inaccurate. Nuclear changes include nuclear enlargement, 
hyperchromasia, irregular nuclear outlines and chromatin smudging. Cytoplasmic 
alterations include eosinopholic cytoplasm, vacuolation and foamy cell changes Fig 8.b. 
The stroma may have pronounced fibrosis, inflammation, foamy histiocytic infiltrates, 
hemosiderin deposits, necrosis, calcification and numerous free psammoma bodies 
(McCluggage WG et al., 2002; Chew I et al., 2009).  
 
 
Fig. 8.a. Ovarian carcinoma after neoadjuvant therapy: The tumor presents extensive areas 
of fibrosis with few areas of remaining viable tumor cells. 
 
 
Fig. 8.b. Ovarian carcinoma after neoadjuvant therapy  The nuclear changes seen including 
nuclear enlargement, hyperchromasia, irregular nuclear outlines and chromatin smudging.  
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The immunohistochemistry profile is similar to that of native untreated tumors. Ck7, 
CA125, WT1, ER, p53 and p16 may be of value in identifying residual tumor cells [Miller 
K et al., 2008].  
9. Conclusion 
Ovarian tumors are often complex and heterogenous in nature. In this book chapter we 
limited our discussion to the most common ovarian tumors in adult women. This is a 
concise histological description of these tumors that clinicians will find useful in their daily 
practice.  
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The immunohistochemistry profile is similar to that of native untreated tumors. Ck7, 
CA125, WT1, ER, p53 and p16 may be of value in identifying residual tumor cells [Miller 
K et al., 2008].  
9. Conclusion 
Ovarian tumors are often complex and heterogenous in nature. In this book chapter we 
limited our discussion to the most common ovarian tumors in adult women. This is a 
concise histological description of these tumors that clinicians will find useful in their daily 
practice.  
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1. Introduction 
Ovarian cancer represents the leading cause of death from gynaecological cancers especially 
because it relapses in most of the cases. 
Central nervous system and especially the encephalon are very often involved in 
metastatic process arising from malignancies coming from many different sites in the 
whole body. 
The incidence of brain involvement in metastatic tumours was estimated to be around 25%, 
that represents a very large proportion and moreover, around 20% of the lesions found 
within the central nervous system are diagnosed as secondary locations of a wide spread 
cancer. 
The most common tumours that present brain involvement are lung, breast cancers and 
melanomas, while the gynaecological malignancies contribute around 2% of all the brain 
metastases, except the trophoblastic diseases that involve the central nervous system in 
around 30% of the cases. 
Anyway, although it was believed that central nervous system involvement from epithelial 
ovarian cancer was very uncommon, it is increasing of incidence. 
Moreover, the comprehension of how to diagnose and treat these metastases is very 
important because they are usually characterized, more than the most common liver or 
lung metastases, by symptomatology that can severely affect the quality of life of these 
patients. 
This new finding points out whether or not is appropriate to ask for a brain image 
technique in the follow up of ovarian cancer patients, and which therapy should these 
women receive. 
Today, there are new possible therapeutic approaches including stereotactic radiosurgery, 
the administration of new effective and with less side effect chemotherapy agents, moreover 
the improvement in the neurosurgery techniques makes craniotomy from brain metastases a 
less riskful procedure with better outcomes.  
Aim of his chapter is to analyse the clinicopathological features of these patients, the 
diagnosis and the different therapeutic approaches based on our experience and on all the 
series published in literature in the last 15 years. 
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Central nervous system involvement from ovarian cancer is an uncommon event, but many 
studies published in literature agree that it is increasing in incidence. (Cormio, 2011a; 
Cormio 2011b; Pectasides, 2006) 
The analysis of two reports present in literature about the biological behaviour of ovarian 
cancer in autopsied patients reveals that 1 out of 158 women with this tumour actually 
present a brain involvement. (Bergman, 1966; Julian, 1974) 
In literature, the reported incidence ranges from 0.29 to 4.5%. (Larson, 1986; Stein, 1986; 
Leroux, 1991; Rodriguez, 1992; Geisler J.P. & Geisler H.E., 1995; Kaminsky-Forrett, 2000) In 
our recent series of 20 patients the incidence estimated was 5%. (Cormio, 2011a)  
This increased incidence can be the result of three different aspects. First of all the advances in 
the production and management of the new chemotherapy agents have guaranteed in the last 
years a prolongment of life of these patients; this increased time allows the tumour to implant 
and grow in distant sites. Secondly, the improvement of brain image techniques allowed 
detecting very small lesions. Finally, the use of chemotherapy agents that seem to pass poorly 
the blood brain barrier results in the growth of cancer cells within the nervous tissue.  
3. Ways of spread to the central nervous system 
Ovarian cancer usually spreads locally into the peritoneal cavity, while the lymphatic and 
haematogenous route are possible but rare. Distant metastases are found in about 30% of 
patients and the most common localizations are liver, lungs and pleura. (Cormio, 2003a) 
The dissemination of the ovarian cancer into the brain seems to occur in three possible way: 
via the haematogenous spread, by direct invasion of the nervous tissue after bony 
involvement, or in case of leptomeningeal carcinomatosis, through retrograde lymphatic 
spread (Pectasides, 2006)  
The mechanism of meningeal dissemination is still not known, but hypothetically it should 
be caused by a direct invasions of the liquor through the choroid plexus, by a rupture of the 
brain lesions into the ventricles or subarachnoid space, or by infiltration either of the small 
veins in the arachnoid membrane, either of the lymphatic vessels. (Cormio, 2007). 
4. Clinicopathological characteristics of the primary tumour 
Different series published in literature in the last 15 years, agree that most commonly these 
metastases arise in patients with an advanced stage (FIGO stage III or IV), serous hystotype 
and poorly differentiated (G3) primary ovarian cancer (see Table 1). (Anupol, 2002; Brown 
III, 2005; Chen, 2009; Cohen, 2004; Cormio, 1995, 2003b, Cormio, 2011a; D'Andrea, 2005; 
Kastritis, 2006; Kim, 2007; Kumar, 2003; Lee, 2008; Sanderson, 2002; Sehouli, 2010; Tay & 
Rajesh, 2005). However Kolomainen et al. demonstrated in their series that a brain 
involvement could be seen quite frequently (one third of their patients) also in patients with 
FIGO stage I. (Kolomainen, 2002) 
The median age at presentation of the ovarian cancer in patients who present brain 
involvement in the same series is 55,1 years, ranging from 46,7 to 60,3 years. 
In most of these studies, patients were treated with the standard procedure consisting in 
primary optimal debulking surgery followed by platin-based chemotherapy; in particular 
patients of our recent study received six courses of taxol and carboplatin (Cormio, 2011a) 
 























(1995) 23 - 59 20 (87%) 17 (74%) 14 (61%) 
Anupol 
(2002) 15 
1,4% 58 15 (100%) 12 (80%) 14 (93,3%) 
Pothuri 
(2002) 14 - 59,3 13 (92,8%) 10 (71,4%) 9 (64,3%) 
Sanderson 
(2002) 13 1,1% 55 13 (100%) - 3 (23%) 
Cormio 
(2003) 20 - 54 20 (92%) 12 (55%) 15 (68%) 
Kumar 
(2003) 18 2,7% 54 16 (88,9%) 11 (55,5%) 13 (72,2%) 
Cohen 
(2004) ¹ 72 0,9% 50,4 52 (81%) 52 (83%) 14 (24%) 
D'Andrea 




4 0,66% 52,5 3 (75%) - 2 (50%) 
Brown III  
(2005) 3 - 46,7 3 (100%) - 2 (66,7) 
Kastritis  
(2006) ² 8 3%² 59 8 (100%) 6 (75%) 6 (75%) 
Kim (2007) 13 2,7% 52 12 (92,3%) 7 (53,8%) 9 (69,2%) 
Lee (2008) 15 1% 55 14 (93,3%) - 8 (53,3%) 
Sehouli  
(2010) 74 1,7% 53,9 62 (83,8%) 43 (58,1%) 53 (71,6%) 
Chen (2011) 10 1,9% 56,6 9 (90%) 6 (60%) 7 (70%) 
Cormio  
(2011a) 20 5% 55.5 19 (95%) 15 (75%) 14  (70%) 
 
- data not available 
¹ this study analyses all the ovarian cancer patients and not just the epithelial ones. Anyway most of 
patients with CNS metastases, when data were available, had a epithelial hystotype (about 93%) 
² this study analyses only patients presented with brain involvement as isolated site of relapse, for this 
reason we decided not to include the incidence here calculated in the final results 
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5. Clinicopathological characteristics of brain metastases 
5.1 Pathology 
Metastatic tumour to the brain can involve the Dura Mater and the cranial bones arising 
especially from breast or prostatic cancer, the leptomeninges leading to a meningeal 
carcinomatosis, the encephalon or the spinal cord. Metastases in the encephalon usually 
involve the cerebral and cerebellar hemispheres, less frequently the brainstem and the basal 
ganglia. Brain metastases usually arise in the zone within the cortex and the white substance 
that is very vascularized, only rarely they arise deeply.  
Macroscopically brain metastases usually appear as grey-red nodular lesions, with or 
without necrotic or haemorrhagic areas. (Maiuri, 1992) 
Central nervous system metastases from epithelial ovarian cancer are usually multiple and 
localized into the brain hemispheres, followed by the cerebellum; rarely they involve the 
spinal cord or a leptomeningeal dissemination is discovered. The median interval from the 
time of primary cancer diagnosis to the brain involvement findings is 32 months in 
published studies, but in some patients the brain metastases can be found as the first 
manifestation of the tumour, and only a deep investigation can reveal the ovarian origin. 
The majority of these women usually present extracranial localizations of the disease, within 
or not the peritoneal cavity. (See Table 2, Figures 1, 2, 3, 4) 
 
 
Fig. 1. Cerebral metastases from epithelial ovarian cancer. 
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- data not available 
¹ this study analyses all the ovarian cancer patients and not just the epithelial ones. Anyway most of 
patients with CNS metastases, when data were available, had a epithelial hystotype (about 93%) 
² this study analyses only patients presented with brain involvement as isolated site of relapse, for this 
reason we decided not to include the incidence here calculated in the final results 
³ in this value are excluded two patients whose brain involvement was discovered at the same time of 
the ovarian cancer findings 
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5. Clinicopathological characteristics of brain metastases 
5.1 Pathology 
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ganglia. Brain metastases usually arise in the zone within the cortex and the white substance 
that is very vascularized, only rarely they arise deeply.  
Macroscopically brain metastases usually appear as grey-red nodular lesions, with or 
without necrotic or haemorrhagic areas. (Maiuri, 1992) 
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spinal cord or a leptomeningeal dissemination is discovered. The median interval from the 
time of primary cancer diagnosis to the brain involvement findings is 32 months in 
published studies, but in some patients the brain metastases can be found as the first 
manifestation of the tumour, and only a deep investigation can reveal the ovarian origin. 
The majority of these women usually present extracranial localizations of the disease, within 
or not the peritoneal cavity. (See Table 2, Figures 1, 2, 3, 4) 
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Fig. 2. Cerebellar metastases from epithelial ovarian cancer. 
 
















Fig. 3. Single brain metastases from epithelial ovarian cancer. 
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Fig. 4. Multiple brain metastases from epithelial ovarian cancer. 
5.2 Clinical manifestations 
The symptoms at the diagnosis of these metastases, like all central nervous system tumours, 
can be mild usually with an unspecific symptomatology or severe with, for example 
epilepsy or focal neurological deficit. 
In some cases the metastases can be diagnosed after a stroke, caused by an embolism of 
cancer cells; in these cases usually the patients at first complain of some sort of neurological 
deficit that can resolve in few days, but some weeks after the clinical manifestations get 
quickly worse for the implant and growth of the cancer. (Maiuri, 1992) 
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Patients with central nervous system dissemination from ovarian cancer most commonly 
complain of headache, which is probably a consequence of the increased intracranial 
pressure caused by the oedema or the hydrocephalus, more then a consequence of the mass 
of the lesion itself.  
Other symptoms that are often described are vomiting, confusions, visual disturbances, 
paresis, and weakness, loss of consciousness, seizures, and dizziness. (Cohen, 2004; Cormio, 
2003; Cormio, 2011a; D'Andrea, 2005; Lee, 2008; Pectasides, 2006; Tay &Rajesh, 2005) 
The leptomeningeal involvement usually causes an arise of the intracranial pressure 
associated with hydrocephalus; these patients more frequently than the others complain also 
for bowel of bladder dysfunctions, while the involvement of cranial nerves can also be 
possible. (Pectasides, 2006; Vitaliani R, 2009) 
In our recent series of 20 patients, all patients were symptomatic at the moment of the 
diagnosis; most of them complain of headache, vomiting and dizziness with or without 
balance disturbances, less frequent symptoms were diplopia, convulsions, amnesia, 
confusion and pain. One patient had a left hemiparesis caused by a metastases localized in 
the right parietal lobe. (Cormio, 2011a) 
6. Diagnosis 
The diagnosis is usually suspected when a patient with ovarian cancer complains about any 
neurological symptoms, although asymptomatic cases are not infrequent. The symptoms 
themselves can already also suggest the localization of the lesions in some cases.  
6.1 Imaging features  
It is necessary, in our opinion, to perform either a computed tomography (CT) scan or a 
magnetic resonance imaging (MRI) in any patient with a history of ovarian cancer, who has 
any neurological defect. 
Usually the first diagnosis is done both by the clinical examination that reveals neurological 
signs and by pre and post contrast CT scan, less commonly clinicians ask for an MRI. 
The two image techniques are both effective, even if MRI seems to be the modality of choice 
because it has an higher resolution than CT scan, it is able to detect lesions as small as 1,9 
mm; moreover MRI seems to be more effective especially for the image study of the lesions 
localized in the posterior fossa. (Pectasides, 2006).  
In a CT scan, metastatic lesions appear as ring areas, singular or multiple, slightly hyper 
dense, homogeneous or not and commonly surrounded by oedema. Sometimes the 
metastases can have a hypo dense core for the presence of central necrosis or of a central 
abscess, which can sometimes simulate the diagnosis of an inflammatory abscess. 
The administration of an intravenous contrast medium has been shown to enhance the 
sensitivity of the technique, moreover Davis et al also demonstrated that a delaying imaging 
after the administration and an increased volume of contrast also can increase the detection 
rate. (Davis, 1991) 
In MRI the brain metastases appear as hypo intense nodular areas, the administration of the 
contrast medium (gadolinium) enhances the intensity in the image.  
The most important differential diagnosis should be done with primary brain tumours, 
vascular conditions like strokes or haemorrhages and intracranial abscess.  
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Metastatic lesions, usually, can be differentiated from primary central nervous system 
tumours, because more frequently they are multiple and surrounded by larger areas of 
oedema (larger than primary tumours of the same size). Finally, the metastatic lesions  
Further studies should investigate the benefits of using new image techniques as positron 
emission tomography or magnetic resonance spectroscopy for the diagnosis of central 
nervous system involvement from epithelial ovarian cancer. 
6.2 Leptomenigeal carcinomatosis  
The meningeal carcinomatosis from epithelial ovarian cancer is often difficult to diagnose, in 
fact CT scans even with contrast medium injection can be negative.  
CT images usually show the presence of solid areas in the parenchyma and hydrocephalus 
(Chung, 2001), but not directly the presence of leptomeningeal metastases. For this reason 
the presence of meningeal involvement should be suspected in patient with ovarian cancer 
and hydrocephalus, and further investigations should be performed.  
The image of choice in these patients is the contrast enhanced MRI, while the non-contrast 
one has been showed to be as ineffective as CT scan. (Collie, 1999)  
In patients with meningeal carcinomatosis the diagnosis can be done also by the cytological 
analysis of the cerebrospinal fluid that reveal the presence of ovarian cancer malignant cells. 
(Pectasides, 2006) 
6.3 The role of Ca125  
The serum marker Ca125 is the strongest tumour marker for the presence of ovarian cancer. 
An increased value of Ca125 can be or not observed in patients with brain involvement from 
ovarian cancer.  
In our experience we noticed that usually it arises in patients with brain involvement, who 
were already found to have high concentration of the tumour marker at the first diagnosis of 
the ovarian cancer, even if sometimes it arises also in patients without an history of 
increased Ca125, or it does not arise in patients for whom this lab value was used as a strong 
and efficient marker of the presence of the cancer during the previous therapies.  
In any case, as for the primary ovarian cancer in patients with positive Ca125, this marker can 
be used during and after the therapy of the brain metastases in order to assess the response of 
the cancer to the treatment and the presence or absence of the disease during the follow up. 
7. Therapy 
7.1 Treatments options and clinical decisions  
When it comes to decide about the different types of treatments, the first things to think 
about is the quality of life of these patients, in fact in very few cases limited to those patients 
with a good performance status, single metastases and without any sign of extracranial 
disease the intent of the therapy can be curative.  
As already showed, a large proportion of these patients present with extracranial disease 
and multiple metastases, in these women it is very unlikely that any treatment of central 
nervous system metastases chosen can be curative, so the primary roles of the therapy must 
be the improvement of symptoms, the avoidance of life threatening conditions and the 
increase of life expectance.  
Moreover, other important things to consider are the patients performance status, age, 
status of the disease, previous treatments and their results. All these aspects added to the 
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clinicopathological characteristics of the metastatic brain lesions should be strictly studied to 
assess the risk-benefit of each treatment modality. 
Treatment options are: in emergency the therapy of the life threatening complications like 
increased intracranial pressure, obstructing hydrocephalus and severe epilepsy, no 
treatment in patients not eligible of any therapy, corticosteroids, radiotherapy administrated 
as whole brain radiotherapy or stereotactic radiosurgery, surgery and chemotherapy.  
Due to the rarity of these metastases, this condition has not already had any guidelines that 
can be followed in the choice of treatment, for this reason is very important that the expert 
gynaecologist oncologist cooperate with the neuroradiologist and the neurosurgeon in order 
to decide what is best management for each patients with brain involvement from epithelial 
ovarian cancer.  
7.2 Corticosteroids, mannitol and antiepileptic agents 
The intracranial oedema is very common in women with brain metastases from epithelial 
ovarian cancer; it results from the damage of the blood brain barrier caused by the tumour 
itself that leads to an increase of the barrier permeability, with a passage of sodium and 
water molecules into the brain tissues.  
For this reason almost all patients with this condition is eligible of receiving corticosteroids 
therapy just after the first diagnosis of brain involvement. In fact, corticosteroids are very 
effective drugs especially in reducing the surrounded oedema of these metastatic lesions, 
resulting in a decrease of intracranial pressure.  
The mechanism of action of corticosteroids is to decrease the oedema by decreasing the 
permeability of the blood brain barrier and the passage of water and ions into the cerebral 
parenchyma. This drugs in long term administrations can lead to severe side effects like 
diabetes and hyperglycaemia, osteoporosis, hypertension, thyroid deficiency, 
hypogonadism and male impotence, cataract and several others.  
The preferred molecule is the dexamethasone because of its lower mineralocorticoids effects 
that results in fewer side effects. The starting dose is usually 4 mg administered 
intravenously or orally 4 times daily, after the stabilization of the clinical manifestations the 
dose should be gradually decreased in a long period of few weeks, to reduce the side effects 
of a long corticosteroid treatment on the entire metabolism of the patients.  
Corticosteroids administered in patients with metastatic brain involvement from epithelial 
ovarian cancer, results in few hours (usually 6- 24 hours) in the improvement of the 
headache and the generalized neurological symptoms, while the focal neurological deficits 
are less effectively improved.  
The maximum result is seen usually after few days of corticosteroids treatment, but in a 
large number of patients their action lasts after some days from the end of the 
administration.   
Mannitol is an osmotic diuretic that administered intravenously is effective in reducing 
intracranial pressure in acute cases, but with repeated administration can give a rebound 
effect and worsen the oedema, for this reason is used only for acutely decompensating 
patients in association to corticosteroids. 
Some patients with brain involvement from ovarian cancer can develop convulsions and 
epilepsy. The prophylactic use of anticonvulsant agents is not indicated, but in patients who 
present epilepsy these should be administered; the most common drugs used in the clinical 
practice are the valproate, phenobarbital, phenytoin and carbamazepine. Phenytoin is our 
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anticonvulsant of choice because it is usually effective, well tolerated and it can be 
administered both parenterally and orally.  
Corticosteroids and mannitol with or without valproate or other antiepileptic drugs are 
usually administered in patients with multiple metastases and bad clinical conditions. 
Several studies present in literature demonstrated that the median survival after brain 
metastases involvement diagnosis in patients treated with corticosteroids alone is about 2 
months, and that this value is similar to the median survival obtained in patients treated 
with palliative therapy with any kind of central nervous system metastatic disease. (Cohen, 
2004; Kaminsky-Forrett, 2000; Pectasides, 2005; Pectasides, 2006; Markesbery, 1978; 
Ruderman, 1965) 
7.3 Radiotherapy  
The irradiation of the entire brain (whole brain radiotherapy) has been considered for years 
alone or after surgery, or with chemotherapy the modality of choice in the treatment of 
metastatic malignancies to the brain with or without extracranial disease. The standard dose 
for patients who are not eligible of surgery is 30 Gy administered in 10 fractions over a 
period of 2 weeks. Higher daily doses can be administered to reduce the duration of the 
treatment, but they cause more commonly a late onset encephalopathy, a severe condition 
that should be avoided especially in patients with a higher life expectancy. (Dropcho, 1991; 
Rottenberg, 1977).  
This therapeutic approach can actually increase survival and relieve symptoms by reducing 
the oedema. It is effective in most patients on the headache, convulsions, cognitive and other 
neurological deficiency, moreover it also let to decrease the corticosteroids doses. Series of 
patients present in literature who received a uni modal treatment consisting only in whole 
brain radiotherapy revealed that it leads to a median survival of about 5 months, ranging 
from 1,5 to 27 months. (Cohen, 2004; Kaminsky-Forrett, 2000; Kumar, 2003; Pectasides, 2006; 
Sood, 1996) 
7.4 Stereotactic radiosurgery  
Stereotactic radiosurgery represents an important alternative to the surgical approach. It is a 
special form of radiotherapy where high doses of radiatons are delivered to the metastases 
using a linear accelerator or, in gamma knife radiosurgery, using a gamma knife without 
any surgical incision. (Edwend, 2001; Lassman, 2003; Monaco, 2008; Yo Kyung Lee, 2008) 
The administered dose is inversally proportioned to the diameter of the lesion; usually for 
lesions smaller than 3 cm the dose is 18-20 Gy. These metastases are usually small, circular 
and with radiological margins well defined. More than primary brain tumours, metastatic 
brain tumours are suitable of being treated with stereotactic radiosurgery. (Soffietti, 2002) 
Stereotactic surgery has been proven in several reports to be a good therapeutic approach 
for patients with brain metastases, because these cause rapid reduction of the 
symptomatology and of the dimensions of the lesions, with lower invasiveness. 
This radiotherapy technique has a lower morbidity than surgical approach and so can be 
admistered also in local anesthesia in patients with systemic clinical conditions that are not 
suitable for general anesthesia; moreover it has also economic advantages because it does 
not required hospitalization. 
When comparing radiosurgery with whole brain radiotherapy, it is proven that the first one 
has less long term side effects, such as cognitve problems. 
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Patients who are eligible for it are especially those with small metastases, deep seated and so 
surgically inaccesible lesions. (Monaco, 2008; Combs, 2004) 
Anyway, there are some controversial in literature about the role of stereotactic 
radiosurgery, for example studies showing that these techniques does not have any impact 
on survival (Andrews, 2004) or that it improves outcomes only in patients with single 
metastases and not with multiple ones. (Pectasides, 2006) 
In conclusion, for these reasons stereotactic radiosurgery is now preferred for those patients 
who are not eligible for surgery, with single lesions or with deep seated surgically 
inaccesible metastases. 
7.5 Surgery  
Surgical management can be used with different aims. First of all it can be used in case the 
diagnosis is not clear, in fact the histological examination done after surgery can clarify the 
diagnosis especially in those cases where the brain involvement is the first sign of the 
ovarian cancer and there is no clear evidence of the presence of the primary disease. 
Secondly, surgical approach can be also used to reduce the symptoms by removing the 
lesions and so the pressure that the mass causes on the brain parenchyma. Finally, surgery 
can be used with curative aims or in every case it is necessary to control the local 
intracranial disease to improve the clinical conditions and let clinicians administer other 
treatments for the systemic disease. 
Many studies demonstrated that the surgical approach represents the best treatment 
modality for patients with brain involvement from epithelial cancer that are eligible for it. 
(Cormio, 2003; Cormio, 2011a; Cormio, 2011b; Pothuri, 2002) 
For patients who are not good candidates, with extracranial sign of disease or multiple 
metastases, craniotomy can control symptomatology, avoid life-threatening complications; 
improve quality of life and also overall survival. (Buckner, 1992; Pectasides, 2006) 
In a series of 56 patients, treated in our centre, with a diagnosis of central nervous system 
metastases from ovarian carcinoma, 22 underwent surgical resection of solitary brain 
metastases and survived 16 months, while the other 34 women, who were not eligible for 
surgery, survived only 4 months. (Cormio, 2003) 
In conclusion the surgical approach should be chosen always if there are the following 
conditions:  
 the cerebral metastases are single and superficial 
 There are no radiological signs of the presence of the disease at other sites, or the 
activity of the primary tumour is well control 
 The clinical conditions of the patients are good 
7.6 Chemotherapy 
The role of chemotherapy in the treatment of brain metastases from ovarian cancer is still 
on debate. As already précised above, the increasing rate of these metastases observed in 
the last few years has been attributed to chemotherapy drugs. (Lassman, 2003; Lesser, 
1996). 
This therapeutic approach has some advantages, such as the simple way of administration 
that in most cases can be done on outpatient basis or with few days hospitalization, its 
action on cancer cells that can be eventually presents in the whole body and the fact that it 
does not damage the brain tissues causing dementia or brain atrophy (Pectasides, 2006) 
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On the other side, the poor clinical conditions of some patients, the aggressivity of these 
treatments and the fact that many chemotherapy agents seem not to pass the blood brain 
barrier can contraindicate this procedure. 
Many authors demonstrated that chemotherapy actually results in a remission of the disease 
and in an increased survival (Cooper, 1994; Cormio, 1995, Rodriguez, 1992; Watanabe, 2005) 
An analysis conducted on 15 studies by Mc Meekin et al showed that chemotherapy has an 
important role because is the only therapeutic approach that, as the surgical treatment, 
really improves survival. (Mc Meekin, 2001). 
The best choice for their ability to pass the blood brain barrier seem to be cisplatin and other 
platin-based drugs, etoposide, gemcitabine, docetaxel (Cormio, 1995; Melichar, 2004; 
Rodriguez, 1992; Vlasved, 1990; Salvati, 1994; Watanabe, 2005) 
7.7 Multimodal approaches 
In our experience but also in several series reported in literature the best approach for 
patients with brain involvement from epithelial cancer seems to be the multimodal 
approach; in our recent study, we demonstrated that craniotomy followed by 
radiotherapy and/or chemotherapy results in median survival of about 18 months. 
(Cormio, 2011a). 
The best multimodal approach is supposed to have a double effect, on one side a local 
therapy such as craniotomy or stereotactic radiosurgery or whole brain radiotherapy is 
administered to remove and control the local spread of the cancer within the brain, on the 
other side the systemic treatment is able to control the wide spread of the disease. 
In conclusion, the best combinations of therapies, from our experience, are surgery plus 
radiotherapy and eventually chemotherapy that in our opinion is the best choice for patients 
with extracranial disease, stereotactic radiotherapy plus whole brain radiotherapy and 
eventually chemotherapy. 
7.8 Therapy of neoplastic meningitis  
The neoplastic meningitis has been reported in very few studies, for this reason the 
therapeutic approach that should be chosen for this patients is currently not defined. 
The therapy of neoplastic neoplastic meningitis usually consists in radiotherapy and 
intracerebrospinal fluid chemotherapy like intrathecal methotrexate (Chamberlain, 2005; 
Cormio, 2007). 
Most patients who present leptomenigeal dissemination of ovarian cancer have also a wide 
spread dissemination of the disease, with poor clinical conditions and aggressive treatments 
that are usually indicated in these conditions can give more damages than benefits; for this 
reason plus the fact that the choice of any clinical approach must take into account first of all 
the improvement of the quality of life of these patients, the treatment choice is usually very 
difficult and must be decided for each patients. 
8. Survival and prognostic factors 
Although many efforts and improvements in diagnosis and treatment of central nervous 
system metastases from epithelial ovarian cancer have been already reached, the prognosis 
of this condition is still poor. In the studies present in literature the overall survivals 
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calculated from the time of the diagnosis of the brain involvement range from 4 to 10 
months. (Table 3, Figure 5) 
 
Clinical series (year) Survival (months) ¹ 
Cormio (1995) 5 
Anupol (2002) 6 
Pothuri (2002) 18 
Sanderson (2002) 4 
Cormio (2003) ² 16 
Kumar (2003) 4 
Cohen (2004) 6,27 
D'Andrea (2005) ³ 28 
Tay & Rajesh (2005) 19,5 
Brown III (2005) - 
Kastritis (2006) - 
Kim (2007) 7 
Lee (2008) 14 
Sehouli (2010) 6,2 
Chen (2011) 3 
Cormio (2011a) 17,6 
 
 
- data not available 
¹ the survival was calculated from the time of diagnosis of CNS metastases 
² this study analyses only patients with solitary brain metastases who underwent surgical resection 
³ this study analyses only patients treated with surgical en bloc removal and postoperative radio-
chemotherapy 
Table 3. Survival in the series present in literature. 
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Fig. 5. Survival in the series present in literature. 
Different studies present in literature demonstrated that the prognostic factors that 
significantly affect survival of patients with brain involvement from ovarian cancer are the 
presence of extracranial disease, the number of brain metastases and the treatment 
approaches (multi-modal therapy prolong survival in most of the studies. The prognostic 
factors of each study analysed are shown in Table 4. 
9. Changes from the past and future prospective 
In a recent study (Cormio, 2011b), we compared the a series of patients from 1995 and a 
series of patients from 2010 all with diagnosis of epithelial ovarian cancer and brain 
metastases in order to assess the difference in management and outcomes of this condition. 
We demonstrated that, even if the clinicopathological features both of the primary tumour 
and the metastases were similar in the two groups, the survival triplicate in the last 15 years 
going from 5 months to 18 months. This difference can be attributed to the change in the 
therapeutic approach. In fact, while in 1995 the therapy was given more with palliative 
intent, nowadays clinicians are more likely to administer more aggressive and multimodal 
treatments, with the intent of both improving the quality of life and the overall survival. 
(Anupol, 2002; Brown III, 2005; Chen, 2009; Cohen, 2004; Cormio, 1995; Cormio, 2003b; 
Cormio, 2011a; D'Andrea, 2005; Kastritis, 2006; Kim, 2007; Lee, 2008;  Sanderson, 2002; 
Sehouli, 2010; Tay & Rajesh, 2005) 
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Study Prognostic factors  
Cormio (1995) 
- number of lesions 
- extracranial disease 
- treatment (P vs RT vs O RT) 
Anupol (2002) 
- extracranial disease 
- treatment (survival with RT+O+CT > RT+O 
>RT+CT>RT) 
Cormio (2003) 
- extracranial disease 
- interval between ovarian cancer diagnosis and brain 
involvement findings 
- treatment ( survival with O > no O) 
Kumar (2003)  
- serous hystotype  
- grade (survival in I-II > III- IV) 
- optimal primary surgery  
- extracranial disease 
Cohen (2004) 
Univariate analysis 
- extracranial disease 
- treatment (RT+O > RT or O alone> P)  
Multivariate analysis  
- treatment (RT+O > RT or O alone> P)  
Kim (2007) 
Univariate analysis 
- Karnofsky performance status > 70 better prognosis 
- primary lesion (controlled vs not controlled) 
- number of CNS metastases (single > multiple) 
- RPA prognostic classification (I >II>III) 
- extracranial disease 
- treatment (GKRS vs without GKRS)  
Multivariate analysis 
- RPA prognostic classification (I >II>III) 
- treatment (GKRS vs without GKRS)  
Lee (2008) - treatment (GKRS > WBRT) 
Sehouli (2010)  
- number of CNS metastases (single > multiple) 
- Karnofsky performance status > 60 better prognosis 
- platinum sensitive diseases have better survival 
- grading  
- FIGO stage 
NB: no multimodal therapy and extracranial 
metastases  
Cormio (2011a) 
- FIGO stage 
- extracranial disease 
- treatment (O >no O; multimodal>unimodal 
treatment) 
- response after brain metastases therapy (complete > 
incomplete or absent)  
 
Table 4. Prognostic factors in the studies present in literature. 
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Future efforts can be put on one side, on the improvement of early diagnosis by the 
investigation of the role of new imaging techniques such as positron emission tomography 
and magnetic resonance spectroscopy in the detection of brain metastases, and on the other 
side on the improvement of treatment modality with higher efficacy and lower morbidity 
like the new radio surgical techniques. Although many authors agree that a multimodal 
approach results in better prognosis, further studies should be done to fix some guidelines 
for the treatment of these patients.  
Finally, further studies are also needed to investigate the role of chemotherapy especially in 
patients with both brain metastases and extracranial metastases from ovarian cancer, in 
order to find a therapy that can control both the local and systematic manifestations of these 
cancer. 
10. Conclusions 
In conclusion, even if brain metastases from ovarian cancer have always been considered an 
uncommon event, they are increasing of incidence. All patients with ovarian cancer who 
present neurological symptoms must undergo a CT or MRI scan of the brain.  
The treatment choice must take into account the clinicopathological characteristics of the 
metastases and of primary cancer, the presence of extracranial disease and obviously the 
performance status of the patients. Moreover the therapy should be aim both to have a 
remission of the disease and to improve the quality of life.  
Patients with poor performance status and/or multiple and not isolated metastases usually 
undergo palliative therapy consisting in mannitol, corticosteroids and anticonvulsant. In 
patients who are eligible for therapy the possibilities include: craniotomy, stereotactic 
radiosurgery (including the new gamma knife one), whole brain radiotherapy and 
chemotherapy. These approaches can be combined in multi-modal treatments. 
Although older studies suggested that these patients should undergone only palliative 
management, in the last 15 year's published studies many authors agree that a multi-modal 
treatment is the modality of choice in selected patients and can achieve a long-term 
remission and a better quality of life. (Anupol, 2002; Brown III, 2005; Chen, 2009; Cohen, 
2004; Cormio, 1995; Cormio, 2003b; Cormio, 2011a; D'Andrea, 2005; Kastritis, 2006; Kim, 
2007; Lee, 2008; Sanderson, 2002; Sehouli, 2010; Tay & Rajesh, 2005). 
An aggressive multimodal approach should be aimed both to cure local and systemic 
disease and leads to an improvement in duration and quality of life.  
Multi centre studies should investigate the better combination of surgery, radiotherapy and 
chemotherapy giving particular attention to the role of different antineoplastic drugs in 
order to find a standard treatment for these patients. 
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1. Introduction 
Peripheral neuropathy is not uncommon in ovarian cancer. The incidence density of 
peripheral neuropathy was 21.5 per 1000 person-years in ovarian cancer, 15.3 per 1000 
person-years in breast cancer and 18.3 per 1000 person-years in lung cancer for patients who 
received platinum-taxane combination chemotherapy (Nurgalieva et al., 2010). 
Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, which 
has been reported to associate with chemotherapy induced neurotoxicity in as high as 54% 
of patients after their first-line 6 cycles of treatment and with 23% of patients with residual 
neuropathy after a median follow up of 18 months (Pignata et al., 2006 ). However, 
peripheral neuropathy in ovarian cancer is not always due to chemotherapeutic agents. 
Other etiologies of neuropathy in ovarian cancer patients are focal compression, nutritional 
deficiency, metabolic abnormalities, endocrine disorders, and paraneoplastic neurological 
syndromes.  
A detailed medical history is most important for the diagnosis of neuropathy including 
symptoms, distribution, duration and course of the neuropathy. The past medical and 
social history may reveal a possible cause such as diabetes, inflammation, or a toxic or 
nutritional etiology. A positive family history may suggest a hereditary neuropathy. A 
neurologic examination is required to confirm the presence of neuropathy. 
Electrodiagnostic studies, including nerve conduction study and electromyography, are 
used to reveal the severity and its distribution pattern; underlying process demyelination 
or axonal loss; sensory, motor or a combination. One limitation of nerve conduction study 
is that it assess the function of only the large diameter nerve fibers, and not small fibers. 
Quantitative sensory testing, epidermal nerve fiber density, or autonomic function testing 
are used to evaluate small fiber neuropathy. Blood tests may reveal the etiology of 
nutritional, metabolic, endocrine, inflammatory, paraneoplastic, infectious, toxic, or 
hereditary neuropathies.  
2. Chemotherapy-induced neuropathy 
Seven cytotoxic chemotherapy agents have been approved by the FDA for advanced 
ovarian cancer since 1978. They are cisplatin, carboplatin, altretamine, paclitaxel, 
topotecan, liposomal doxorubicin and gemcitabine. Among them, cisplatin, caboplatin, 
altretamine, and paclitaxel have significant neurotoxicity. Although bone marrow 
suppression and neurotoxicity are the major side-effects related to chemotherapy, 
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symptoms, distribution, duration and course of the neuropathy. The past medical and 
social history may reveal a possible cause such as diabetes, inflammation, or a toxic or 
nutritional etiology. A positive family history may suggest a hereditary neuropathy. A 
neurologic examination is required to confirm the presence of neuropathy. 
Electrodiagnostic studies, including nerve conduction study and electromyography, are 
used to reveal the severity and its distribution pattern; underlying process demyelination 
or axonal loss; sensory, motor or a combination. One limitation of nerve conduction study 
is that it assess the function of only the large diameter nerve fibers, and not small fibers. 
Quantitative sensory testing, epidermal nerve fiber density, or autonomic function testing 
are used to evaluate small fiber neuropathy. Blood tests may reveal the etiology of 
nutritional, metabolic, endocrine, inflammatory, paraneoplastic, infectious, toxic, or 
hereditary neuropathies.  
2. Chemotherapy-induced neuropathy 
Seven cytotoxic chemotherapy agents have been approved by the FDA for advanced 
ovarian cancer since 1978. They are cisplatin, carboplatin, altretamine, paclitaxel, 
topotecan, liposomal doxorubicin and gemcitabine. Among them, cisplatin, caboplatin, 
altretamine, and paclitaxel have significant neurotoxicity. Although bone marrow 
suppression and neurotoxicity are the major side-effects related to chemotherapy, 
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neurotoxicity is often the decisive factor limiting the dose of chemotherapy agent since 
bone marrow suppression can be overcome with growth factors, blood transfusion, or 
bone marrow transplantation. Chemotherapy-induced peripheral neuropathy is clearly 
related to the dose per cycle, as well as the cumulative dose. However, pre-existing nerve 
abnormalities (debates mellitus, hereditary neuropathies, alcoholism, previous neurotoxic 
treatments, or malnutrition) make nerves more susceptible to chemotherapy-induced 
neuropathy. The incidence of chemotherapy-induced neuropathy varies in the literature 
due to a wide range of individual drug doses, cumulative doses, treatment schedules, and 
the combined use with other drugs. The other challenge is different grading systems that 
have been utilized, including Eastern Cooperative Oncology Group (ECOG), National 
Cancer Institute–Common Toxicity Criteria (NCI-CTC), and World Health Organization 
(WHO) toxicity criteria. The common toxicity scales are designed to allow a rapid 
examination of the patients with peripheral neurotoxicity by oncologists based on clinical 
symptoms and signs. Total Neuropathy Score (TNS) also includes neurological 
examination and nerve conduction study, which grade accurately and correlated well 
with NCI-CTC and ECOG scores (Cavaletti et al., 2006). The Functional Assessment of 
Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) 
questionnaire is used to evaluate symptoms and concerns associated specifically with 
chemotherapy-induced neuropathy, which was found to be reliable for assessing quality 
of life in ovarian cancer patient with neuropathy (Calhoun et al., 2003). 
2.1 Platinum agents 
Platinum agents cisplatin, carboplatin, and oxaliplatin have been used for the treatment of 
ovarian cancer. Cisplatin was approved for the treatment of ovarian cancer in 1978, and is 
currently administered for advanced ovarian cancer intravenously and intraperitoneally 
(Armstrong et al., 2006, Markman et al., 2001). Carboplatin was approved in 1989, and 
subsequently became a part of the first-line therapy for ovarian cancer in combination with a 
taxane. It was found to be less neurotoxicity than cisplatin (du Bois et al., 2003). In 2002, a 
third-generation platinum drug, oxaliplatin, was approved for treatment of metastatic 
colorectal cancer; however, 70% of the patients receiving oxaliplatin were affected by some 
degree of sensory neuropathy (McWhinny et al., 2009). Oxaliplatin in combination with 
variety of chemotherapy agents (cyclophosphamide, gemcitabine, paclitaxel and pegylated 
liposomal doxorubicin) has been reported in phase II clinical trials of ovarian cancer 
(Harnett et al., 2007, Misset et al., 2001, Nicoletto, 2006, Recchia et al., 2007, Viens et al., 
2006). 
Platinum-induced peripheral neuropathy has elements common to all three agents with 
some distinctive patterns. The severity of neurotoxicity in platinum agents from greatest 
to least is cisplatin, oxaliplatin, and carboplatin (McWhinny et al., 2009). Cisplatin 
produces a predominantly sensory neuropathy characterized by painful paresthesia, 
numbness, and diminished vibratory sense. Symptoms often begin in the feet, and 
typically occur during the first few cycles of treatment. When severe, gait ataxia may 
appear. Lhermitte sign may occur. Large fiber function is more affected than small fiber 
function. Autonomic neuropathy in general is not prominent. Weakness and motor 
neuropathy are less common. Sensory disturbance is typical in a symmetrical stocking 
and glove distribution, with decreasing proprioception and vibratory sensation. Deep 
tendon reflexes are reduced or absent. Peripheral neuropathy is often not completely 
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reversible. Symptoms may be worse transiently after therapy is discontinued (coasting 
effect). Neurotoxicity has been reported in 47% of the patients treated with cisplatin 
compared with 25% of those treated with the non-cisplatin regimen in 387 patients with 
ovarian cancer. The severity was much higher at cumulative doses of cisplatin between 
500 and 600 mg/m2 (Van Der Hoop et al., 1990). Carboplatin induced neuropathy has 
similar symptoms to those of cisplatin, but absent Lhermitte sign. The neurotoxicity of 
carboplatin is generally considered to be less frequent, and less severe than cisplatin. 
Grade 3/4 sensory neuropathy was 13.5% in the cisplatin regimen versus 7.2% in the 
carboplatin regimen (du Bois et al., 2003). In addition to chronic sensory neuropathy 
similar to cisplatin, oxaliplatin also causes acute cold-aggravated transient painful 
paresthesia, which occurs within hours of each infusion, and typically resolves within 
hours to days. These symptoms can be accompanied by jaw and eye pain, possibly due to 
muscle cramps.  
Cisplatin and oxaliplatin undergo hydrolysis to a greater extent than carboplatin, and may 
associate with more severe patterns of neurotoxicity (McWhinny et al., 2009). In addition, 
cisplatin produces about three times more platinum-DNA adducts in the dorsal root 
ganglion than does oxaliplatin and with greater neurotoxicity (Ta et al., 2006). The 
neurotoxicity is the result of platinum compounds accumulating in the dorsal root ganglia, 
leading to shrinking or loss of dorsal root ganglia neurons and a resultant sensory 
neuronopathy (Krarup-Hansen et al., 1999), which is likely why the motor fibers are 
primarily spared. Platinum-DNA-protein cross-links have been proposed as a mechanism 
for the platinum antitumor activities (Chválová et al., 2007). Platinum compounds interfere 
with DNA replication and metabolic function of the dorsal root ganglia. The "coasting" 
phenomenon may result from platinum accumulation in the dorsal root ganglia over a long 
period time. Cisplatin also induces apoptosis in dorsal root ganglion by binding to nuclear 
DNA and mitochondrial DNA (Podratz et al., 2011). There is also the secondary 
degeneration of the posterior columns, which likely accounts for the Lhermitte sign. 
Oxaliplatin affects nerve excitability through voltage-dependent mechanisms, with specific 
effects mediated through axonal Na+ channel inactivation. It may be the cause of the acute 
neurotoxicity of oxaliplatin (Park et al., 2011a). 
2.2 Taxanes (paclilaxel / Docetaxel) 
Paclitaxel and docetaxel are frequently used taxanes in ovarian cancer. Paclitaxel combined 
with carboplatin is now considered as a standard first-line therapy for advanced ovarian 
cancer, but neurological toxicity is a clinically significant adverse effect (Mayerhofer et al., 
2000). Docetaxel combined with carboplatin has been suggested to be a promising 
alternative, particularly in terms of minimizing the incidence and severity of peripheral 
neuropathy (Pfisterer et al., 2004 and Vasey et al., 2004). Nab-paclitaxel is an albumin-bound 
paclitaxel that has lesser hypersensitivity reactions, but seems to be similar to paclitaxel for 
inducing neuropathy. 
Paclitaxel induces a progressive, predominantly sensory neuropathy. Symptoms can 
occur after the first dose, and include painful paresthesia as well as numbness of the 
hands and feet. Transient myalgia is common after each dose, which usually resolves 
within days. Sensory loss presents in a stocking-glove distribution. Ankle jerks and other 
reflexes may be diminished or absent, which progresses with cumulative doses. Both 
small and large fiber sensory functions are affected. Muscle strength is frequently 
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neurotoxicity is often the decisive factor limiting the dose of chemotherapy agent since 
bone marrow suppression can be overcome with growth factors, blood transfusion, or 
bone marrow transplantation. Chemotherapy-induced peripheral neuropathy is clearly 
related to the dose per cycle, as well as the cumulative dose. However, pre-existing nerve 
abnormalities (debates mellitus, hereditary neuropathies, alcoholism, previous neurotoxic 
treatments, or malnutrition) make nerves more susceptible to chemotherapy-induced 
neuropathy. The incidence of chemotherapy-induced neuropathy varies in the literature 
due to a wide range of individual drug doses, cumulative doses, treatment schedules, and 
the combined use with other drugs. The other challenge is different grading systems that 
have been utilized, including Eastern Cooperative Oncology Group (ECOG), National 
Cancer Institute–Common Toxicity Criteria (NCI-CTC), and World Health Organization 
(WHO) toxicity criteria. The common toxicity scales are designed to allow a rapid 
examination of the patients with peripheral neurotoxicity by oncologists based on clinical 
symptoms and signs. Total Neuropathy Score (TNS) also includes neurological 
examination and nerve conduction study, which grade accurately and correlated well 
with NCI-CTC and ECOG scores (Cavaletti et al., 2006). The Functional Assessment of 
Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) 
questionnaire is used to evaluate symptoms and concerns associated specifically with 
chemotherapy-induced neuropathy, which was found to be reliable for assessing quality 
of life in ovarian cancer patient with neuropathy (Calhoun et al., 2003). 
2.1 Platinum agents 
Platinum agents cisplatin, carboplatin, and oxaliplatin have been used for the treatment of 
ovarian cancer. Cisplatin was approved for the treatment of ovarian cancer in 1978, and is 
currently administered for advanced ovarian cancer intravenously and intraperitoneally 
(Armstrong et al., 2006, Markman et al., 2001). Carboplatin was approved in 1989, and 
subsequently became a part of the first-line therapy for ovarian cancer in combination with a 
taxane. It was found to be less neurotoxicity than cisplatin (du Bois et al., 2003). In 2002, a 
third-generation platinum drug, oxaliplatin, was approved for treatment of metastatic 
colorectal cancer; however, 70% of the patients receiving oxaliplatin were affected by some 
degree of sensory neuropathy (McWhinny et al., 2009). Oxaliplatin in combination with 
variety of chemotherapy agents (cyclophosphamide, gemcitabine, paclitaxel and pegylated 
liposomal doxorubicin) has been reported in phase II clinical trials of ovarian cancer 
(Harnett et al., 2007, Misset et al., 2001, Nicoletto, 2006, Recchia et al., 2007, Viens et al., 
2006). 
Platinum-induced peripheral neuropathy has elements common to all three agents with 
some distinctive patterns. The severity of neurotoxicity in platinum agents from greatest 
to least is cisplatin, oxaliplatin, and carboplatin (McWhinny et al., 2009). Cisplatin 
produces a predominantly sensory neuropathy characterized by painful paresthesia, 
numbness, and diminished vibratory sense. Symptoms often begin in the feet, and 
typically occur during the first few cycles of treatment. When severe, gait ataxia may 
appear. Lhermitte sign may occur. Large fiber function is more affected than small fiber 
function. Autonomic neuropathy in general is not prominent. Weakness and motor 
neuropathy are less common. Sensory disturbance is typical in a symmetrical stocking 
and glove distribution, with decreasing proprioception and vibratory sensation. Deep 
tendon reflexes are reduced or absent. Peripheral neuropathy is often not completely 
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reversible. Symptoms may be worse transiently after therapy is discontinued (coasting 
effect). Neurotoxicity has been reported in 47% of the patients treated with cisplatin 
compared with 25% of those treated with the non-cisplatin regimen in 387 patients with 
ovarian cancer. The severity was much higher at cumulative doses of cisplatin between 
500 and 600 mg/m2 (Van Der Hoop et al., 1990). Carboplatin induced neuropathy has 
similar symptoms to those of cisplatin, but absent Lhermitte sign. The neurotoxicity of 
carboplatin is generally considered to be less frequent, and less severe than cisplatin. 
Grade 3/4 sensory neuropathy was 13.5% in the cisplatin regimen versus 7.2% in the 
carboplatin regimen (du Bois et al., 2003). In addition to chronic sensory neuropathy 
similar to cisplatin, oxaliplatin also causes acute cold-aggravated transient painful 
paresthesia, which occurs within hours of each infusion, and typically resolves within 
hours to days. These symptoms can be accompanied by jaw and eye pain, possibly due to 
muscle cramps.  
Cisplatin and oxaliplatin undergo hydrolysis to a greater extent than carboplatin, and may 
associate with more severe patterns of neurotoxicity (McWhinny et al., 2009). In addition, 
cisplatin produces about three times more platinum-DNA adducts in the dorsal root 
ganglion than does oxaliplatin and with greater neurotoxicity (Ta et al., 2006). The 
neurotoxicity is the result of platinum compounds accumulating in the dorsal root ganglia, 
leading to shrinking or loss of dorsal root ganglia neurons and a resultant sensory 
neuronopathy (Krarup-Hansen et al., 1999), which is likely why the motor fibers are 
primarily spared. Platinum-DNA-protein cross-links have been proposed as a mechanism 
for the platinum antitumor activities (Chválová et al., 2007). Platinum compounds interfere 
with DNA replication and metabolic function of the dorsal root ganglia. The "coasting" 
phenomenon may result from platinum accumulation in the dorsal root ganglia over a long 
period time. Cisplatin also induces apoptosis in dorsal root ganglion by binding to nuclear 
DNA and mitochondrial DNA (Podratz et al., 2011). There is also the secondary 
degeneration of the posterior columns, which likely accounts for the Lhermitte sign. 
Oxaliplatin affects nerve excitability through voltage-dependent mechanisms, with specific 
effects mediated through axonal Na+ channel inactivation. It may be the cause of the acute 
neurotoxicity of oxaliplatin (Park et al., 2011a). 
2.2 Taxanes (paclilaxel / Docetaxel) 
Paclitaxel and docetaxel are frequently used taxanes in ovarian cancer. Paclitaxel combined 
with carboplatin is now considered as a standard first-line therapy for advanced ovarian 
cancer, but neurological toxicity is a clinically significant adverse effect (Mayerhofer et al., 
2000). Docetaxel combined with carboplatin has been suggested to be a promising 
alternative, particularly in terms of minimizing the incidence and severity of peripheral 
neuropathy (Pfisterer et al., 2004 and Vasey et al., 2004). Nab-paclitaxel is an albumin-bound 
paclitaxel that has lesser hypersensitivity reactions, but seems to be similar to paclitaxel for 
inducing neuropathy. 
Paclitaxel induces a progressive, predominantly sensory neuropathy. Symptoms can 
occur after the first dose, and include painful paresthesia as well as numbness of the 
hands and feet. Transient myalgia is common after each dose, which usually resolves 
within days. Sensory loss presents in a stocking-glove distribution. Ankle jerks and other 
reflexes may be diminished or absent, which progresses with cumulative doses. Both 
small and large fiber sensory functions are affected. Muscle strength is frequently 
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preserved or only minimally affected. Docetaxel presents similar clinical manifestations as 
paclitaxel, but with different toxicity profiles. Docetaxel/carboplatin was associated with 
11% grade 2 or higher sensory neuropathy compared with 30% in paclitaxel/carboplatin. 
Motor neuropathy grade 2 or higher was 3% in Docetaxel/carboplatin versus 7% in 
paclitaxel/carboplatin. However, docetaxel/carboplatin was associated with significantly 
more grade 3-4 neutropenia as 94% versus 84% (Vasey et al., 2004). Docetaxel was 
tolerated better by patients because of less neuropathic pain and myalgia (Pan & Kao 
2007). Overall, either single or cumulative dose is the most important factor to consider in 
taxanes-induced neuropathy. Most symptoms usually improve or resolve after 
discontinuation of treatment, however, severe symptoms may persist for a long period of 
time (Argyriou et al., 2008). 
The taxanes block tubulin depolymerisation, leading to the inhibition of microtubule 
dynamics and cell cycle arrest. Paclitaxel and docetaxel accumulate microtubules in axon, 
dorsal root ganglia, and Schwann cells. These defective microtubules inhibit axonal 
transport, axonal sprouting, or nerve regeneration  (Manfredi & Horwitz 1984, Rowinsky 
and Donehower 1995). In rat model, both paclitaxel and docetaxel equally induced severe 
and dose-dependent neuropathy measured with neurophysiological methods, however, 
the morphometric examination demonstrated more detrimental effect of paclitaxel on 
nerve fibers (Persohn et al., 2005). In patients, paclitaxel produced early sensory 
dysfunction in 4 weeks as increasing in stimulus threshold and reduction in sensory 
amplitudes on neurophysiological and nerve excitability studies; 71% of patients 
developed symptoms by 6 weeks after administration of about 500 mg/m2 (Park et al., 
2011b). Reduced sensory amplitudes or abolishment of sensory responses on 
neurophysiology studies were also found in patients treated with docetaxel (New et al., 
1996, Pan & Kao 2007). Taxanes-induced peripheral neuropathy is a predominant axonal 
sensory neuropathy.  
2.3 Altretamine 
Altretamine was approved by the FDA to treat refractory ovarian cancer in 1990. It is an 
alkylating agent, binding to and cross-linking of nucleic acid chains. Altretamine induces a 
mild sensorimotor axonal polyneuropathy that is reversible on cessation of the drug. The 
neuropathy consists of paresthesia, decreased position and vibrating sense, hyporeftexia, 
and motor weakness. The incidence of neuropathy (primarily sensory) was between 5-
10%(Manetta et al., 1990, Olver et al., 2001, Vergote et al., 1992). Prognosis is usually good 
with the reversal of the neuropathy upon discontinuation of treatment.  
2.4 Neuroprotection 
There is currently no standard treatment for the prevention of chemotherapy induced 
neuropathy. However, neuroprotection studies revealed some potential agents although 
none of them are commonly employed at present. The ideal candidate for neuroprotection 
should be safe, well-tolerated, and effective. Most importantly it should not interfere with 
the cytotoxic activity of chemotherapy. 
2.4.1 Acetyl-L-carnitine 
Acetyl-L-carnitine, the acetyl ester of L-carnitine, naturally occurs in plants and animals. 
Acetyl-L-carnitine plays an essential role in metabolism to facilitation of fatty acid 
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utilization. Acetyl-L-carnitine has demonstrated neuroprotective and neurotrophic actions 
in other neuropathies. In a multicenter, randomized, double-blind, placebo-controlled, 
diabetic neuropathy study with 333 patients, acetyl-L-carnitine or placebo was administered 
intramuscularly at a dosage of 1000 mg/day for 10 days and continued orally at a dosage of 
2000 mg/day for 355 days (De Grandis & Minardi 2002). Acetyl-L-carnitine showed a 
statistically significant improvement in mean nerve conduction velocity and amplitude 
compared with placebo. The greatest changes were observed in sural and ulnar sensory 
nerves, and the peroneal motor nerve. After 12 months of treatment, pain was reduced 39% 
from baseline in the acetyl-L-carnitine group, but only 8% in the placebo group (De Grandis 
& Minardi 2002). Acetyl-L-carnitine also showed significant improvements in sural nerve 
fiber numbers and regenerating nerve fiber clusters in two 52-week randomized placebo-
controlled clinical diabetic neuropathy trials (Sima et al., 2005). Low levels of serum acetyl-
L-carnitine were found in patients with antiretroviral toxic neuropathy (James 1997). After 6 
months of acetyl-L-carnitine (1500 mg twice daily, oral), small sensory fibers increased from 
skin biopsy in HIV-positive patients with antiretroviral toxic neuropathy. Improvement of 
innervation continued in the epidermis and dermis after 24 months of treatment (Hart et al., 
2004). In a randomized study, acetyl-L-carnitine treatment produced a significantly greater 
reduction in pain compared with placebo (P=0.022) when administered 500 mg 
intramuscularly twice daily for 14 days, followed by orally 1000 mg twice daily for 42 days 
in patients with antiretroviral toxic neuropathy (Youle et al., 2007). 
Acetyl-L-carnitine was found to be able to reduce the neurotoxicity of cisplatin and 
paclitaxel without interfering with antineoplastic effects of either medication (Pisano et al., 
2003) as well as the neurotoxicity of oxaliplatin in rat models (Ghirardi et al., 2005). It was 
also confirmed that acetyl-L-carnitine does not affect the cytotoxicity of paclitaxel or 
carboplatin on ovarian cancer cells (Engle et al., 2009). In rats, acetyl-L-carnitine prevented 
paclitaxel-induced neuropathic pain, the swollen and vacuolated mitochondria caused by 
paclitaxel in C-fibers, but not in A-fibers (Jin et al., 2008). In addition, acetyl-L-carnitine 
decreased the spontaneous discharge of A-fibers and C-fibers, and blocked the development 
of the paclitaxel-evoked pain in the sural nerve of rats (Xiao and Bennett 2008). Acetyl-L-
carnitine has been investigated in 2 open label clinical trials in chemotherapy-induced 
neuropathy. Acetyl-L-carnitine was administrated orally 1g 3 times a day for 8 weeks in 25 
patients with neuropathy during paclitaxel or cisplatin therapy (Bianchi et al. 2005). All 
patients except one reported symptomatic relief, and only two reported nausea. Sensory 
neuropathy improved in 15 of 25 patients, and motor neuropathy improved in 11 of 14 
patients. Total neuropathy score that included neurophysiological studies improved in 23 
(92%) patients. Symptomatic improvement persisted in 12 of 13 evaluable patients at median 
13 months. Acetyl-L-carnitine (1 g intravenous infusion over 1-2 hours) was also 
investigated in 26 patients with paclitaxel and/or cisplatin-induced neuropathy (Maestri et 
al. 2005). At least one WHO grade improvement in the peripheral neuropathy severity was 
shown in 73% of the patients. Insomnia related to acetyl-L-carnitine was reported in one 
patient. At present, there is no double-blind, placebo controlled studies to confirm the effect 
of acetyl-L-carnitine in chemotherapy-induced neuropathy. 
2.4.2 Amifostine 
Amifostine is approved as a cytoprotective adjuvant for use in cancer chemotherapy and 
radiotherapy involving DNA-binding chemotherapeutic agents including platinum and 
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preserved or only minimally affected. Docetaxel presents similar clinical manifestations as 
paclitaxel, but with different toxicity profiles. Docetaxel/carboplatin was associated with 
11% grade 2 or higher sensory neuropathy compared with 30% in paclitaxel/carboplatin. 
Motor neuropathy grade 2 or higher was 3% in Docetaxel/carboplatin versus 7% in 
paclitaxel/carboplatin. However, docetaxel/carboplatin was associated with significantly 
more grade 3-4 neutropenia as 94% versus 84% (Vasey et al., 2004). Docetaxel was 
tolerated better by patients because of less neuropathic pain and myalgia (Pan & Kao 
2007). Overall, either single or cumulative dose is the most important factor to consider in 
taxanes-induced neuropathy. Most symptoms usually improve or resolve after 
discontinuation of treatment, however, severe symptoms may persist for a long period of 
time (Argyriou et al., 2008). 
The taxanes block tubulin depolymerisation, leading to the inhibition of microtubule 
dynamics and cell cycle arrest. Paclitaxel and docetaxel accumulate microtubules in axon, 
dorsal root ganglia, and Schwann cells. These defective microtubules inhibit axonal 
transport, axonal sprouting, or nerve regeneration  (Manfredi & Horwitz 1984, Rowinsky 
and Donehower 1995). In rat model, both paclitaxel and docetaxel equally induced severe 
and dose-dependent neuropathy measured with neurophysiological methods, however, 
the morphometric examination demonstrated more detrimental effect of paclitaxel on 
nerve fibers (Persohn et al., 2005). In patients, paclitaxel produced early sensory 
dysfunction in 4 weeks as increasing in stimulus threshold and reduction in sensory 
amplitudes on neurophysiological and nerve excitability studies; 71% of patients 
developed symptoms by 6 weeks after administration of about 500 mg/m2 (Park et al., 
2011b). Reduced sensory amplitudes or abolishment of sensory responses on 
neurophysiology studies were also found in patients treated with docetaxel (New et al., 
1996, Pan & Kao 2007). Taxanes-induced peripheral neuropathy is a predominant axonal 
sensory neuropathy.  
2.3 Altretamine 
Altretamine was approved by the FDA to treat refractory ovarian cancer in 1990. It is an 
alkylating agent, binding to and cross-linking of nucleic acid chains. Altretamine induces a 
mild sensorimotor axonal polyneuropathy that is reversible on cessation of the drug. The 
neuropathy consists of paresthesia, decreased position and vibrating sense, hyporeftexia, 
and motor weakness. The incidence of neuropathy (primarily sensory) was between 5-
10%(Manetta et al., 1990, Olver et al., 2001, Vergote et al., 1992). Prognosis is usually good 
with the reversal of the neuropathy upon discontinuation of treatment.  
2.4 Neuroprotection 
There is currently no standard treatment for the prevention of chemotherapy induced 
neuropathy. However, neuroprotection studies revealed some potential agents although 
none of them are commonly employed at present. The ideal candidate for neuroprotection 
should be safe, well-tolerated, and effective. Most importantly it should not interfere with 
the cytotoxic activity of chemotherapy. 
2.4.1 Acetyl-L-carnitine 
Acetyl-L-carnitine, the acetyl ester of L-carnitine, naturally occurs in plants and animals. 
Acetyl-L-carnitine plays an essential role in metabolism to facilitation of fatty acid 
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utilization. Acetyl-L-carnitine has demonstrated neuroprotective and neurotrophic actions 
in other neuropathies. In a multicenter, randomized, double-blind, placebo-controlled, 
diabetic neuropathy study with 333 patients, acetyl-L-carnitine or placebo was administered 
intramuscularly at a dosage of 1000 mg/day for 10 days and continued orally at a dosage of 
2000 mg/day for 355 days (De Grandis & Minardi 2002). Acetyl-L-carnitine showed a 
statistically significant improvement in mean nerve conduction velocity and amplitude 
compared with placebo. The greatest changes were observed in sural and ulnar sensory 
nerves, and the peroneal motor nerve. After 12 months of treatment, pain was reduced 39% 
from baseline in the acetyl-L-carnitine group, but only 8% in the placebo group (De Grandis 
& Minardi 2002). Acetyl-L-carnitine also showed significant improvements in sural nerve 
fiber numbers and regenerating nerve fiber clusters in two 52-week randomized placebo-
controlled clinical diabetic neuropathy trials (Sima et al., 2005). Low levels of serum acetyl-
L-carnitine were found in patients with antiretroviral toxic neuropathy (James 1997). After 6 
months of acetyl-L-carnitine (1500 mg twice daily, oral), small sensory fibers increased from 
skin biopsy in HIV-positive patients with antiretroviral toxic neuropathy. Improvement of 
innervation continued in the epidermis and dermis after 24 months of treatment (Hart et al., 
2004). In a randomized study, acetyl-L-carnitine treatment produced a significantly greater 
reduction in pain compared with placebo (P=0.022) when administered 500 mg 
intramuscularly twice daily for 14 days, followed by orally 1000 mg twice daily for 42 days 
in patients with antiretroviral toxic neuropathy (Youle et al., 2007). 
Acetyl-L-carnitine was found to be able to reduce the neurotoxicity of cisplatin and 
paclitaxel without interfering with antineoplastic effects of either medication (Pisano et al., 
2003) as well as the neurotoxicity of oxaliplatin in rat models (Ghirardi et al., 2005). It was 
also confirmed that acetyl-L-carnitine does not affect the cytotoxicity of paclitaxel or 
carboplatin on ovarian cancer cells (Engle et al., 2009). In rats, acetyl-L-carnitine prevented 
paclitaxel-induced neuropathic pain, the swollen and vacuolated mitochondria caused by 
paclitaxel in C-fibers, but not in A-fibers (Jin et al., 2008). In addition, acetyl-L-carnitine 
decreased the spontaneous discharge of A-fibers and C-fibers, and blocked the development 
of the paclitaxel-evoked pain in the sural nerve of rats (Xiao and Bennett 2008). Acetyl-L-
carnitine has been investigated in 2 open label clinical trials in chemotherapy-induced 
neuropathy. Acetyl-L-carnitine was administrated orally 1g 3 times a day for 8 weeks in 25 
patients with neuropathy during paclitaxel or cisplatin therapy (Bianchi et al. 2005). All 
patients except one reported symptomatic relief, and only two reported nausea. Sensory 
neuropathy improved in 15 of 25 patients, and motor neuropathy improved in 11 of 14 
patients. Total neuropathy score that included neurophysiological studies improved in 23 
(92%) patients. Symptomatic improvement persisted in 12 of 13 evaluable patients at median 
13 months. Acetyl-L-carnitine (1 g intravenous infusion over 1-2 hours) was also 
investigated in 26 patients with paclitaxel and/or cisplatin-induced neuropathy (Maestri et 
al. 2005). At least one WHO grade improvement in the peripheral neuropathy severity was 
shown in 73% of the patients. Insomnia related to acetyl-L-carnitine was reported in one 
patient. At present, there is no double-blind, placebo controlled studies to confirm the effect 
of acetyl-L-carnitine in chemotherapy-induced neuropathy. 
2.4.2 Amifostine 
Amifostine is approved as a cytoprotective adjuvant for use in cancer chemotherapy and 
radiotherapy involving DNA-binding chemotherapeutic agents including platinum and 
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alkylating agents. The cytoprotective activity of amifostine is proposed to decrease DNA 
interstrand crosslinks of platinum and alkylating agents, and to scavenge free radicals. 
Common side effects are hypotension, nausea and vomiting. 
Amifostine cytoprotection was investigated in a multicenter randomized controlled trial in 
242 advanced ovarian carcinoma patients with the first-line treatment of cisplatin and 
cyclophosphamide.  The study demonstrated a significant reduction in hematologic, renal, 
and neurologic toxicities with equivalent therapeutic response and survival (Rose 1996). 
Later, a phase II study was conducted by the Gynecologic Oncology Group. Twenty-seven 
patients received intravenous paclitaxel (175 mg/m2) followed by amifostine (740 mg/m2) 
and cisplatin (75 mg/m2). Four of 27 patients developed grade 2 to 4 neurotoxicity based on 
clinical assessments, Cancer Institute–Common Toxicity Criteria and the Functional 
Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity. The 
neuropathic events exceeded the predetermined threshold level, and the study was closed 
(Moore et al., 2003). In a double-blind randomized placebo-controlled amifostine study of 72 
patients in first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel with 
or without epirubicin, amifostine improved sensory neuropathy according to Cancer 
Institute–Common Toxicity Criteria with objective neurological assessment. The 
improvement included two-point discrimination, vibration perception and tendon reflex, 
but there were almost no differences in self-estimated specific sensory or motor symptoms 
comparing with placebo. In addition, amifostine failed to improve the global health status 
quality of life score, and worsened nausea and vomiting (Hilpert et al., 2005). The other 
randomized study in 90 ovarian cancer patients treated with standard 
carboplatin/paclitaxel with or without amifostine reported no symptoms of neurotoxicity 
in 40% of the carboplatin/paclitaxel group versus 49% of the carboplatin/paclitaxel/ 
amifostine group. Grad II sensory neuropathy was in 12% of the carboplatin/paclitaxel 
group versus 2% of the carboplatin/paclitaxel/amifostine group. Amifostine was 
temporarily interrupted in five patients due to hypotension. Quality of life questionnaires 
showed no difference in neurotoxicity scores between both study arms (De Vos et al., 
2005). 
American Society of Clinical Oncology published 2008 clinical practice guideline. 
Amifostine may be considered for prevention of cisplatin-associated nephrotoxicity, 
reduction of grade 3 to 4 neutropenia. It is not recommended for protection against 
platinum or paclitaxel associated neuropathy (Hensley et al., 2009). 
2.4.3 Glutamate 
The amino acid glutamate is naturally in many foods. Glutamate is the most abundant 
excitatory neurotransmitter in the vertebrate nervous system. Like the closely related amino 
acid glutamine, glutamate was investigated in a randomized, placebo-controlled, double-
blinded clinical and electrodiagnostic study. Forty-three ovarian cancer patients were 
available for analysis following six cycles of paclitaxel treatment. Twenty-three patients 
were supplemented by glutamate at a daily dose of 500 mg three times, while 20 patients 
received a placebo. The only statistical difference was found in lower pain scores in the 
glutamate group. There was no significant difference in neurological examinations, 
questionnaires and sensory-motor nerve conduction studies between the two groups (Loven 
et al., 2009). Therefore, based on limited study, glutamate has not demonstrated 
neuroprotective properties against peripheral neurotoxicity. 
 




Glutamine is a neutral amino acid that plays a critical role in protein synthesis, as a source 
of cellular energy, and nitrogen donation. The neuroprotective role in chemotherapy 
induced neuropathy has not been reported in ovarian cancer. Two non-randomized, 
controlled studies investigated the effect of glutamine (10 g orally three times a day) in 
single high-dose paclitaxel (825 mg/m2 ) induced peripheral neuropathy in breast cancer 
with a total of 91 patients (Stubblefield et al., 2005, Vahdat et al., 2001). Both paired pre- 
and post-paclitaxel evaluations shown that the glutamine group had a statistically 
significant reduction in the incidence and severity of peripheral neuropathy, reduced 
symptoms and sign in dysesthesias, numbness, weakness and abnormal vibration sense. 
There were significant reductions in the amplitude and conduction velocity of the motor 
and sensory nerves from the baseline in both groups, and glutamine did not appear to 
exert a protective effect (Stubblefield et al., 2005, Vahdat et al., 2001). The role of oral 
glutamine in preventing oxaliplatin-induced neuropathy was evaluated in 86 patients 
with colorectal cancer (wang et al., 2007). Patients were randomized to receive or not 
receive glutamine (15 g twice a day). Glutamine had significantly lower incidence of 
grade 1-2 peripheral neuropathy, reduced interference with activities of daily living, and 
did not result in a need for oxaliplatin dose reduction. There were no significant 
differences between groups in electrophysiological abnormalities, or survival (wang et al., 
2007).  All 3 clinical trials found that oral glutamine reduces the symptoms of 
chemotherapy-induced neuropathy, but it does not prevent declining nerve function as 
measured by nerve conduction study. In addition, none of these studies was randomized, 
or placebo-controlled. There is a lack of sufficient evidence to recommend oral glutamine 
for the prevention of chemotherapy induced neuropathy. 
2.4.5 Glutathione 
Glutathione is a tripeptide. It is an antioxidant to prevent cellular damage by reactive 
oxygen species such as free radicals. Glutathione was postulated to reduced the toxicity of 
cisplatin, and a multi-center, double-blind, randomized, placebo controlled phase III trial 
was conducted in 151 ovarian cancer patients with 74 patients in cisplatin/glutathione 
group, and 77 patients in cisplatin/placebo group (Smyth et al.,1997). The objective was to 
determine whether glutathione would enhance the feasibility of giving six cycles of cisplatin 
at 100 mg/m2. Glutathione (3 g/m2) or placebo was given with cisplatin every 3 weeks. 
Fifty-eight percent of patients completed 6 cycles of treatment in the glutathione group 
versus 39% of patients in the control group (P = 0.04). The glutathione group also showed 
significantly less nephrotoxicity, and better quality of life scores. Glutathione only suggested 
a trend towards less neurotoxicity. Sensory neuropathy was 39% in the glutathione group 
versus 49% in the control group.  Motor neuropathy was 9% in the glutathione group versus 
12% in the control group measured with common toxicity criteria.  
Shortly before the clinical trial for ovarian cancer, glutathione showed efficacy in the 
prevention of cisplatin induced neurotoxicity, and did not reduce the clinical activity of 
cisplatin in a randomized double-blind placebo-controlled trial with 50 gastric cancer 
patients (Cascinu et al., 1995). Glutathione was given intravenously at a dose of 1.5 g/m2 
immediately before cisplatin administration, and at a dose of 600 mg by intramuscular 
injection on days 2 to 5. Normal saline was administered to patients in the placebo group. 
Clinical neurologic evaluation and electrophysiologic investigations were performed at 
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alkylating agents. The cytoprotective activity of amifostine is proposed to decrease DNA 
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prevention of cisplatin induced neurotoxicity, and did not reduce the clinical activity of 
cisplatin in a randomized double-blind placebo-controlled trial with 50 gastric cancer 
patients (Cascinu et al., 1995). Glutathione was given intravenously at a dose of 1.5 g/m2 
immediately before cisplatin administration, and at a dose of 600 mg by intramuscular 
injection on days 2 to 5. Normal saline was administered to patients in the placebo group. 
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baseline, after 9 (cisplatin cumulative dose, 360 mg/m2) and 15 (cisplatin cumulative dose, 
600 mg/m2) weeks of treatment. At the 9th week, no patients showed clinically evident 
neuropathy in the glutathione group, compared to 16 patients in the placebo group. After 
the 15th week, 4 of 24 patients in the glutathione group suffered from neurotoxicity versus 
16 of 18 in the placebo group (P = .0001). Neurophisiologic studies showed a significant 
reduction of sensory nerve amplitude in the placebo group but not in the glutathione group 
(Cascinu et al., 1995). Later, glutathione in oxaliplatin-induced neurotoxicity was also 
demonstrated in a randomized, double-blind, placebo-controlled trial by the same authors 
with a similar study design (Cascinu et al., 2002). After 12 cycles (oxaliplatin cumulative 
dose 1,200 mg/m2), grade 2 to 4 neurotoxicity was observed in 3 of 21 patients in the 
glutathione group, and in 8 of 19 patients in the placebo group (P=.004). Sural sensory nerve 
conduction study showed a statistically significant reduction in the placebo group but not in 
the glutathione group. This study provides evidence that glutathione is a promising drug 
for the prevention of oxaliplatin induced neuropathy without a reduction of the clinical 
activity of oxaliplatin. The results from above clinical trials on the efficacy of glutathione are 
encouraging, but it should be further confirmed in large scale randomized, double-blind, 
placebo-controlled trials. 
2.4.6 Vitamin E  
Vitamin E is a fat soluble vitamin with antioxidant property. Low plasmatic levels of 
vitamin E had been found in patients with severe cisplatin induced neurotoxicity (Bove et 
al., 2001). Supplementation of vitamin E has shown neuroprotection in patients receiving 
cisplatin, paclitaxel, or their combination.  
Pace and colleagues performed both preclinical study and a pilot clinical trial to evaluate the 
neuroprotective effect of vitamin E in cisplatin induced neuropathy (Pace et al., 2003). In 
preclinical studies, nude mice carrying the human melanoma tumor were treated with 
cisplatin alone or in combination with vitamin E. Cisplatin combined with vitamin E 
showed no differences in tumor growth, tumor weight, or life span of nude mice as 
compared to treatment with cisplatin alone. Forty-seven patients were randomly assigned to 
the vitamin E group during cisplatin chemotherapy, or the control group with cisplatin 
chemotherapy alone. Vitamin E 300 mg daily was administered orally before cisplatin 
chemotherapy and continued for 3 months after the suspension of treatment in the vitamin 
E group. Twenty-seven patients completed six cycles of cisplatin chemotherapy: 13 patients 
in the vitamin E group and 14 patients in the control group. The incidence of neurotoxicity 
was significantly lower in the vitamin E group (30.7%) than it was in the control group 
(85.7%). The severity of neurotoxicity, measured with a comprehensive neurotoxicity score 
based on clinical and neurophysiological parameters, was significantly lower in patients of 
the vitamin E group than in patients in the control group (2 versus 4.7) (Pace et al., 2003). 
Later, Pace and colleagues performed a 2 center, double-blind, randomized, placebo 
controlled study of cisplatin induced neuropathy in solid tumor patients (Pace et al., 2010). 
A total of 108 patients treated with cisplatin chemotherapy were randomly assigned to 
receive vitamin E (400 mg/day) or placebo orally. Only 41 patients who received a 
cumulative dose of cisplatin higher than 300 mg/m2 were eligible for statistical analysis 
with 17 in the vitamin E group and 24 in the placebo group. The incidence of neurotoxicity 
was significantly lower in the vitamin E group (5.9%) than in the placebo group (41.7%) (p< 
0.01). Neurotoxicity was measured with Total Neuropathy Score, and revealed a mean score 
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of 1.4 in the vitamin E group versus 4.1 in the placebo group (p < 0.01). On sensory nerve 
conduction study, mean sural and median sensory amplitudes were both significantly 
reduced in the control group, while only mildly reduced in the sural nerve and unchanged 
in the median nerve in the vitamin E group (Pace et al., 2010).  
Argyriou and colleagues conducted 3 randomized, open label with blind assessment, 
controlled trials to determine whether vitamin E has a neuroprotective effect in chemotherapy-
induced peripheral nerve damage. In 3 trials, a total 93 patients treated with six cycles of 
cisplatin, paclitaxel, or their combination were randomly assigned to a vitamin E group or a 
control group. Patients were followed by neurologic examination and electrophysiologic 
study. Patients assigned to the vitamin E group received oral vitamin E at a daily dose of 600 
mg/day during chemotherapy and 3 months after its cessation were compared to patients of 
the control group. The incidence of neurotoxicity differed significantly between the two 
groups. The percentage of patients with neurotoxicity was 18.7-25% in the vitamin E group 
and in 62.5-73.3% in the control group. Mean peripheral neuropathy scores were 2.25-4.99 for 
patients of the vitamin E group and 10.62-11.5 for patients of the control group (Argyriou et al., 
2005, 2006a, 2006b). Their studies showed that vitamin E effectively protects patients with 
cisplatin/paclitaxel induced peripheral neuropathy. Interestingly, vitamin E supplement at 
dose from 300 mg to 600 mg daily in all above clinical trials seems to have a similar range of 
reduction of the incidence of peripheral neurotoxicity. The promising results warrant 
additional double-blind, randomized, placebo controlled trials in ovarian cancer with 
carboplatin/paclitaxel treatment for the safety, and efficacy.  
Acetyl-L-carnitine, amifostine, glutamate, glutamine, glutathione and vitamin E, reviewed 
here, are only some of the possible neuroprotective agents investigated for chemotherapy 
induced neuropathy. Other agents, such as acetylcysteine, calcium and magnesium, 
diethyldithiocarbamate, and Org 2766 have been investigated , but only limited data is 
available. At present, the neuroprotection data is insufficient to conclude that any of these 
agents prevent or limit the neurotoxicity in chemotherapy-induced neuropathy (Albers et 
al., 2011). 
Future research for neuroprotective agents needs well designed clinical trials in 
chemotherapy-induced neuropathy with a validated grading system, quality of life 
measurement and evidence of improvement in nerve structure or function, such as 
epidermal nerve fiber density or electrophysiology study. Otherwise, clinical measurement 
alone may be symptomatic treatment instead of neuroprotection. 
2.4.7 Symptomatic treatment of neuropathic pain 
Chemotherapy induced sensory neuropathy may cause neuropathic pain reported as 
burning, tingling, pins and needles sensation, shooting, cramping, and deep aching. 
Neuropathic pain is frequently treated with antidepressants, anticonvulsants, topical agents, 
and analgesics. This treatment must be individualized. Combinations of different agents 
should be considered in some patients. Slow dose escalation may improve drug tolerability 
(Pan and Thomas 2001). A new evidence-based guideline for treating painful diabetic 
neuropathy was issued by the American Academy of Neurology, the American Association 
of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical 
Medicine and Rehabilitation based on a systematic review of literature from 1960 to 2008 
(Bril et al., 2011). This guideline recommends using pregabalin for painful diabetic 
neuropathy if clinically appropriate; venlafaxine, duloxetine, amitriptyline, gabapentin, 
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baseline, after 9 (cisplatin cumulative dose, 360 mg/m2) and 15 (cisplatin cumulative dose, 
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with a similar study design (Cascinu et al., 2002). After 12 cycles (oxaliplatin cumulative 
dose 1,200 mg/m2), grade 2 to 4 neurotoxicity was observed in 3 of 21 patients in the 
glutathione group, and in 8 of 19 patients in the placebo group (P=.004). Sural sensory nerve 
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2.4.6 Vitamin E  
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showed no differences in tumor growth, tumor weight, or life span of nude mice as 
compared to treatment with cisplatin alone. Forty-seven patients were randomly assigned to 
the vitamin E group during cisplatin chemotherapy, or the control group with cisplatin 
chemotherapy alone. Vitamin E 300 mg daily was administered orally before cisplatin 
chemotherapy and continued for 3 months after the suspension of treatment in the vitamin 
E group. Twenty-seven patients completed six cycles of cisplatin chemotherapy: 13 patients 
in the vitamin E group and 14 patients in the control group. The incidence of neurotoxicity 
was significantly lower in the vitamin E group (30.7%) than it was in the control group 
(85.7%). The severity of neurotoxicity, measured with a comprehensive neurotoxicity score 
based on clinical and neurophysiological parameters, was significantly lower in patients of 
the vitamin E group than in patients in the control group (2 versus 4.7) (Pace et al., 2003). 
Later, Pace and colleagues performed a 2 center, double-blind, randomized, placebo 
controlled study of cisplatin induced neuropathy in solid tumor patients (Pace et al., 2010). 
A total of 108 patients treated with cisplatin chemotherapy were randomly assigned to 
receive vitamin E (400 mg/day) or placebo orally. Only 41 patients who received a 
cumulative dose of cisplatin higher than 300 mg/m2 were eligible for statistical analysis 
with 17 in the vitamin E group and 24 in the placebo group. The incidence of neurotoxicity 
was significantly lower in the vitamin E group (5.9%) than in the placebo group (41.7%) (p< 
0.01). Neurotoxicity was measured with Total Neuropathy Score, and revealed a mean score 
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of 1.4 in the vitamin E group versus 4.1 in the placebo group (p < 0.01). On sensory nerve 
conduction study, mean sural and median sensory amplitudes were both significantly 
reduced in the control group, while only mildly reduced in the sural nerve and unchanged 
in the median nerve in the vitamin E group (Pace et al., 2010).  
Argyriou and colleagues conducted 3 randomized, open label with blind assessment, 
controlled trials to determine whether vitamin E has a neuroprotective effect in chemotherapy-
induced peripheral nerve damage. In 3 trials, a total 93 patients treated with six cycles of 
cisplatin, paclitaxel, or their combination were randomly assigned to a vitamin E group or a 
control group. Patients were followed by neurologic examination and electrophysiologic 
study. Patients assigned to the vitamin E group received oral vitamin E at a daily dose of 600 
mg/day during chemotherapy and 3 months after its cessation were compared to patients of 
the control group. The incidence of neurotoxicity differed significantly between the two 
groups. The percentage of patients with neurotoxicity was 18.7-25% in the vitamin E group 
and in 62.5-73.3% in the control group. Mean peripheral neuropathy scores were 2.25-4.99 for 
patients of the vitamin E group and 10.62-11.5 for patients of the control group (Argyriou et al., 
2005, 2006a, 2006b). Their studies showed that vitamin E effectively protects patients with 
cisplatin/paclitaxel induced peripheral neuropathy. Interestingly, vitamin E supplement at 
dose from 300 mg to 600 mg daily in all above clinical trials seems to have a similar range of 
reduction of the incidence of peripheral neurotoxicity. The promising results warrant 
additional double-blind, randomized, placebo controlled trials in ovarian cancer with 
carboplatin/paclitaxel treatment for the safety, and efficacy.  
Acetyl-L-carnitine, amifostine, glutamate, glutamine, glutathione and vitamin E, reviewed 
here, are only some of the possible neuroprotective agents investigated for chemotherapy 
induced neuropathy. Other agents, such as acetylcysteine, calcium and magnesium, 
diethyldithiocarbamate, and Org 2766 have been investigated , but only limited data is 
available. At present, the neuroprotection data is insufficient to conclude that any of these 
agents prevent or limit the neurotoxicity in chemotherapy-induced neuropathy (Albers et 
al., 2011). 
Future research for neuroprotective agents needs well designed clinical trials in 
chemotherapy-induced neuropathy with a validated grading system, quality of life 
measurement and evidence of improvement in nerve structure or function, such as 
epidermal nerve fiber density or electrophysiology study. Otherwise, clinical measurement 
alone may be symptomatic treatment instead of neuroprotection. 
2.4.7 Symptomatic treatment of neuropathic pain 
Chemotherapy induced sensory neuropathy may cause neuropathic pain reported as 
burning, tingling, pins and needles sensation, shooting, cramping, and deep aching. 
Neuropathic pain is frequently treated with antidepressants, anticonvulsants, topical agents, 
and analgesics. This treatment must be individualized. Combinations of different agents 
should be considered in some patients. Slow dose escalation may improve drug tolerability 
(Pan and Thomas 2001). A new evidence-based guideline for treating painful diabetic 
neuropathy was issued by the American Academy of Neurology, the American Association 
of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical 
Medicine and Rehabilitation based on a systematic review of literature from 1960 to 2008 
(Bril et al., 2011). This guideline recommends using pregabalin for painful diabetic 
neuropathy if clinically appropriate; venlafaxine, duloxetine, amitriptyline, gabapentin, 
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valproate, opioids, capsaicine and percutaneous electrical nerve stimulation are probably 
effective and should be considered. This guideline can be used for the treatment of 
chemotherapy induced neuropathic pain.  
Pregabalin is an anticonvulsant, which does not bind to plasma proteins or interact with 
other drugs. It has demonstrated efficacy in 4 randomized, double-blind, multicenter 
studies of painful diabetic neuropathy (Frampton & Scott 2004, Satoh et al., 2011). 
Pregabalin is given 2 to 3 times daily. From an initial dose of 50 or 75 mg/day, may be 
increased to 300 mg/day gradually, and later, to 600 mg/day as needed. Adverse effects 
of pregabalin include dizziness, somnolence, peripheral edema, headache, blurred vision, 
and constipation. 
Venlafaxine is an antidepressant. It is a serotonin, norepinephrine, and dopamine reuptake 
inhibitor. A moderate effect of pain relief was found compared with placebo (Rowbotham et 
al., 2004). Venlafaxine XR 75 mg daily may be increased to 150 mg daily. Venlafaxine is well 
tolerated; the adverse events are nausea, headache, somnolence, dry mouth, and dizziness.  
Duloxetine is an antidepressant, a reuptake inhibitor of serotonin and norepinephrine. 
Duloxetine at doses of 60 and 120 mg a day improved neuropathic pain in several 
randomized, double-blind studies of diabetic neuropathy and was rather well tolerated 
(Goldstein et al., 2005). A more common initial side effect, nausea, can be curtailed if the 
drug is started at a low dose of 20 or 30 mg during the first week. 
Amitriptyline has been investigated in several double-blind, randomized trials. 
Amitriptyline, desipramine, and fluoxetine were compared at a mean daily dose of 105, 111, 
and 40 mg respectively in 2 randomized, double-blind, crossover studies of painful diabetic 
neuropathy. Amitriptyline and desipramine relieved pain in 74% and 61% of 38 patients 
respectively, whereas fluoxetine showed no difference compared with placebo in 46 patients 
(Max et al., 1992). Amitriptyline should be started at a dosage of 10 to 25 mg/day and 
increased by 10 to 25 mg/week to the maximum effect or tolerated dosage. Bedtime 
administration may help to reduce day time sedation. The adverse events most commonly 
reported are dry mouth, sedation, constipation, nausea, and urinary retention as well as 
orthostatic hypotension and tachycardia in elderly patients. Amitriptyline should be 
administrated with caution in patients with urinary retention, glaucoma, constipation, 
impaired liver function, or cardiovascular disease.  
Gabapentin is currently the most frequently used anticonvulsant for painful neuropathy, 
and also does not bind to plasma proteins or interact with other drugs. A double-blind, 
placebo-controlled trial demonstrated pain reduction with gabapentin at 900 to 3600 
mg/day in 165 patients with diabetic neuropathy (Backonja et al., 1998). Gabapentin can 
reduce chemotherapy-induced neuropathic pain at a low dose of 800 mg/day (Tsavaris et 
al., 2008). Adverse events may include fatigue, dizziness, somnolence, and weight gain. 
Gabapentin should be started at a dose of 100 to 300 mg/day and slowly increased to the 
maximum effect or tolerated dosage. Occasionally, a previously effective dose needs to be 
increased to maintain pain control in the absence of objective evidence of disease 
progression, possibly due to habituation.  
3. Entrapment neuropathy 
Entrapment neuropathy is caused by focal compression, restriction, or mechanical 
distortion of a nerve in a fibrous or fibro-osseous tunnel. Chemotherapy-induced 
peripheral neuropathy can make nerves more vulnerable to compression or to stretching 
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nerve injury. Minor compression may lead to focal demyelination or axonal injury. 
Entrapment neuropathy should be suspected if symptoms are focal or unilateral instead 
of symmetrical, length dependent or generalized. Positive Tinel’s sing may be found at 
the entrapment site. Nerve conduction study and electromyography can localize the 
abnormality and reveal the severity. Several common entrapment neuropathies should be 
recognized as below.  
Median nerve entrapment at the wrist is the most common entrapment neuropathy as 
median nerve passes the carpal tunnel. Symptoms involve the thumb, index and middle 
fingers with numbness, tingling and burning, but referred pain can radiate to forearm or 
arm. Symptoms may be worse at night, or after using of the hand. Examination may reveal 
sensory deficit for light touch in the median nerve distribution distal to carpal tunnel. 
Thenar weakness and atrophy are seen in the severe entrapment cases. Nerve conduction 
study frequently demonstrates prolonged sensory nerve latency, reduced amplitude, and 
prolonged distal motor latency. The initial treatment is wrist splint in neutral position. 
Severe entrapment needs surgical carpal tunnel release. 
Ulnar nerve entrapment at the elbow is the second most common entrapment neuropathy.  
The ulnar nerve may be directly compressed in the retrocondylar grove or entrapped 
through cubital tunnel. Symptoms present as tingling or numbness in the fifth and part of 
the fourth fingers, hypothenar eminence and the dorsum of the hand.  Weakness or atrophy 
of the interossei muscles causes clawing of the fourth and fifth fingers in severe entrapment. 
Nerve conduction study reveals slow conduction velocity across the elbow segment. 
Electromyography may reveal acute and chronic denervation in ulnar nerve innervated 
muscles. Elbow protector, avoidance of repetitive elbow flexion and extension, and direct 
pressure from excessive elbow leaning may resolve the symptoms. Surgical release of 
compression or anterior translocation may be considered if symptoms persist after 
conservative treatment. 
Common peroneal nerve entrapment at the fibular head is the most common entrapment 
neuropathy in the leg. Direct pressure to the fibular head, or habitual leg crossing can result 
foot drop, inversion, and sensory deficits at the lateral lower leg. Nerve conduction study 
may reveal slow motor conduction velocity across the fibular head. Electromyography may 
reveal acute and chronic denervation in common peroneal or deep nerve innervated 
muscles. Ankle-foot orthosis can improve the gait when foot drop is present.  
Posterior tibial nerve is more frequently entraped distally at the tarsal tunnel instead of the 
proximal segment. The most common pathology relates to external compression from shoes 
that are too tight or to plaster casts. Others include posttraumatic fibrosis, tendon sheath 
cysts, and rheumatoid arthritis. The plantar nerves may be damaged within the tarsal tunnel 
or more distally as they course through the arch and sole of the foot. The medial plantar 
nerve is injured more commonly than the lateral, and may cause burning pain in the toes 
and the sole of the foot, which is difficult to deferential from chemotherapy-induced 
neuropathy if it involves both feet. Nerve conduction study may confirm entrapment at 
the tarsal tunnel, however, planter nerve sensory response is not easy to elicit, may be 
absent even without tarsal tunnel syndrome. If the sural sensory study is abnormal, 
absent planter nerve sensory response may be due to generalized peripheral neuropathy. 
Tarsal tunnel syndrome treatment, at least initially, should be conservative to remove 
possible outside compression, such as shoes. When conservative measures fail, surgical 
release may be considered. 
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valproate, opioids, capsaicine and percutaneous electrical nerve stimulation are probably 
effective and should be considered. This guideline can be used for the treatment of 
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(Goldstein et al., 2005). A more common initial side effect, nausea, can be curtailed if the 
drug is started at a low dose of 20 or 30 mg during the first week. 
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Amitriptyline, desipramine, and fluoxetine were compared at a mean daily dose of 105, 111, 
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respectively, whereas fluoxetine showed no difference compared with placebo in 46 patients 
(Max et al., 1992). Amitriptyline should be started at a dosage of 10 to 25 mg/day and 
increased by 10 to 25 mg/week to the maximum effect or tolerated dosage. Bedtime 
administration may help to reduce day time sedation. The adverse events most commonly 
reported are dry mouth, sedation, constipation, nausea, and urinary retention as well as 
orthostatic hypotension and tachycardia in elderly patients. Amitriptyline should be 
administrated with caution in patients with urinary retention, glaucoma, constipation, 
impaired liver function, or cardiovascular disease.  
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nerve injury. Minor compression may lead to focal demyelination or axonal injury. 
Entrapment neuropathy should be suspected if symptoms are focal or unilateral instead 
of symmetrical, length dependent or generalized. Positive Tinel’s sing may be found at 
the entrapment site. Nerve conduction study and electromyography can localize the 
abnormality and reveal the severity. Several common entrapment neuropathies should be 
recognized as below.  
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proximal segment. The most common pathology relates to external compression from shoes 
that are too tight or to plaster casts. Others include posttraumatic fibrosis, tendon sheath 
cysts, and rheumatoid arthritis. The plantar nerves may be damaged within the tarsal tunnel 
or more distally as they course through the arch and sole of the foot. The medial plantar 
nerve is injured more commonly than the lateral, and may cause burning pain in the toes 
and the sole of the foot, which is difficult to deferential from chemotherapy-induced 
neuropathy if it involves both feet. Nerve conduction study may confirm entrapment at 
the tarsal tunnel, however, planter nerve sensory response is not easy to elicit, may be 
absent even without tarsal tunnel syndrome. If the sural sensory study is abnormal, 
absent planter nerve sensory response may be due to generalized peripheral neuropathy. 
Tarsal tunnel syndrome treatment, at least initially, should be conservative to remove 
possible outside compression, such as shoes. When conservative measures fail, surgical 
release may be considered. 
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Lateral femoral cutaneous nerve entrapment is usually entrapped at the inguinal ligament 
with obesity, direct compression by a belt, but rarely in the proximal segment of femoral 
nerve by retroperitoneal tumor, hematoma, ascites or other conditions with increased intra-
abdominal pressure. This nerve is a pure sensory nerve and entrapment causes numbness, 
burning, and/or pain on the anteriorlateral thigh. Most patients with lateral femoral 
cutaneous nerve neuropathy, except for those with iliacus or retroperitoneal hematoma that 
might require surgical intervention, are treated conservatively, while waiting for 
spontaneous remyelination or reinnervation. 
Dellon and colleagues reported clinical success of surgical decompression in 80 percent of 
their patients, including chemotherapy-induced neuropathy if patients had positive Tinel’s 
sign on the known anatomic compression sites. Five of 9 in the report were ovarian cancer 
patients treated with cisplatin or paclitaxel or both. Three patients had complaints of pain 
localized in a single extremity with single nerve compression. Single nerve decompression 
was successful for those patients. The other 2 ovarian cancer patients had multiple 
decompression in lower extremities. Surgical decompression has resulted in restoration of 
sensation and relief of pain. (Dellon et al., 2004).  
4. Neurologic paraneoplastic syndromes 
Paraneoplastic syndromes are rare, and occur as a remote effect of tumor, not by mass 
lesions, metastases, or anti-tumor treatment. The prevalence of paraneoplastic syndromes is 
very low, as only one patient was found with neurological paraneoplastic syndrome as 
cerebellar degeneration in 908 patients with primary ovarian malignancy (Hudson et al., 
1993). Neurologic paraneoplastic disorders are autoimmune diseases, and can affect any 
part of the central (cerebellar degeneration, limbic encephalitis, opsoclonus-myoclonus, and 
brainstem encephalitis), or peripheral nervous system (subacute sensory neuronopathy, and 
autonomic insufficiency). Unlike chemotherapy-induced neuropathy, subacute sensory 
neuronopathy can begin in arm, legs, or face, and spread proximally to trunk, with 
progressively loss all sensations. Neurological paraneoplastic syndromes are caused by an 
autoimmune response to proteins (onconeural antigents) that are shared by the cancer and 
the peripheral or central nerve systems. They are Hu, Yo, Ri, CV2, amphiphysin, Ma, Ta, Tr, 
NMDA. Ovarian cancer patients may express proteins Hu, Yo, Ri and anti-amphiphysin 
(Titulaer et al., 2011). Therefore, test antibodies for Hu, Yo, Ri and anti-amphiphysin can 
help to diagnose neurological paraneoplastic syndrome in ovarian cancer. In a retrospective 
study of 73 Hu-antibody positive patients, neurological paraneoplastic syndromes are 55% 
sensory neuropathy, 22% cerebellar degeneration, 15% limbic encephalitis, and 16% 
brainstem encephalitis (Sillevis Smitt et al., 2002). 
Treatment of paraneoplastic syndromes in ovarian cancer should primarily treat the 
malignancy. Corticosteroids, cyclophosphamide and other immunosuppressant may be 
used. Intravenous immune globulin or plasma exchange can be tried.  However, all 
treatment may not be beneficial to subacute sensory neuronopathy. 
5. Conclusion  
Peripheral neuropathy in ovarian cancer is complex. When patients develop neuropathy 
symptoms in ovarian cancer, we cannot simply conclude that it is chemotherapy-induce 
neuropathy. It is a challenge to treat this condition. Diagnosis of the etiology of the 
neuropathy, treating the underlying disease, correction of metabolic, nutritional, and 
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endocrine abnormalities, and decompression of the nerve entrapment will preserve nerve 
function. The goals of treatment are reduction of symptoms, improvement of function and 
patient’s quality of life. 
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1. Introduction 
Therapeutic management for ovarian cancer (OC) requires effective treatment methods such 
as optimization in terms of technical variability, dosage, or administration period and the 
introduction of new therapeutic methods in the existing protocols, all in order to improve 
immediate results, especially of the long term. Establishing therapeutic strategies are based 
on the main factors that influence cancer development and prognosis of primary starting 
point of the ovary. Studies have established even a prognostic profile of OC and a profile of 
the degree of response to chemotherapy [Spentzos, 2005]. 
Complex treatment should involve the main therapeutic methods to combat both the 
primary ovarian tumor and secondary determinations: 
- Surgery 
- Chemotherapy 
- Radiation therapy and recently 
- Biological therapy and 
- Hormone 
The main prognostic factor and therapeutic attitude that divides into two different 
directions is the set of FIGO stage of disease. With FIGO, a number of other factors require 
the combination of several methods of therapeutic treatment in the same direction.  
2. Therapeutic strategies in early ovarian cancer 
OC is confined to early stages I-IIa FIGO. In this stage of OC, therapeutic strategies differ 
depending on the presence of several prognostic factors, according to which natural 
evolution of the disease progresses differently. They are represented mainly by: 
- FIGO stage  
- Grading 
- Histology 
- Increased amount of ascites 
- Preoperative or intraoperative tumor intrusion 
- Development of the primary extracapsular tumor 
- Patient age 
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For early stages of OC, Vasey established in 2008 a range of risk depending on the 
therapeutic attitude that fits (Table 1) [Vasey, 2008]. 
 













Table 1. Range in early OC [Vasey-2008]. 
However, Virgote considered the main prognostic factor tumor grading in tumor recurrence 
risk, followed in order by preoperative tumor, intraoperative tumor rupture, namely age 
[Vergote, 2001]. 
2.1 Radiation 
Radiotherapy, either whole abdomen teletherapy or intraperitoneal with 32P brachytherapy 
is a method that initially had similar results with combined-modality therapy (CMT), when 
it was not done with chemotherapy based on platinum ions. Lately it was abandoned due to 
inferior results and increased risk to platinum-based CMT, in which the rate of major 
complications locally was increased. Thus, these procedures are currently strict historical 
interest method [Vergote, 1992; Young, 2003]. 
2.2 Surgery 
OC surgery for early stages follow both the primary tumor, complete excision to the limits 
cancer and dissemination in the main sires, to their excision or biopsy of their evaluation by 
sampling [Zoung, 1983; Cass, 2001]. 
Surgery methods are the following: 
- Abdominal hysterectomy with bilateral anexectomy by median approach 
- Total omentectomy 
- Biopsy pelvic peritoneum (a Pap smear test form the peritoneum fragments from 
diaphragm is accepted as an alternative method) [Chhieng, 2011].  
- Sampling bilateral pelvic and paraaortic lymph nodes  
- Lavage cytology of peritoneal cavity 
- Appendectomy in all patients with OC epithelial origin, especially if they have 
mucinous histology or clear cell [Ozols, 2005]. 
Controversy and debate regarding surgery has occurred for the patients came seeking 
preservation of reproductive function in these stages. Conservative surgery consisting of 
unilateral anexectomy is accepted as a therapeutic method in young patients with OC in 
first stage, with favorable histological structure (low malignant potential, stromal tumors, 
germinomas) and seeking fertility preservation [Ozols, 2005]. Literature data for carefully 
and properly selected cases, do not report an increased risk of relapse, or a lower survival 
rate in patients treated conservatively compared to those treated aggressively [Young, 2003]. 
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If the inspection is suspecting lesion on contralateral ovary in patients treated conservatively, 
surgical treatment, in addition to unilateral anexectomy should be supplemented by targeted 
biopsy of suspicious areas [Ozols, 2005]. The presence of tight adhesions between adjacent 
organs and regional annexes requires the overstaging and the right therapy approach by 
aggressive surgery and the introduction of adjuvant chemotherapy [Ozols, 2005]. Minimally 
invasive approach to OC (laparoscopic or robotic) is a therapeutic method that tends to win 
ever more ground in early stages of OC. Larger studies are needed to analyze the laparoscopic 
approach compared to the staging and treatment of early OC [Medeiros, 2011]. For patients 
with favorable prognostic factors (std. Ia, Ib, G1) surgery is considered sufficient as the only 
therapeutic approach without requiring the association of adjuvant chemotherapy [Young, 
2003]. For patients with moderate (std. Ib, G2, suboptimal staging), or with poor prognostic 
factors (std. Ic, IIa, G3, clear cell carcinoma, close adhesions, break tumor near the operation) 
surgery is insufficient, requiring adjuvant CMT compulsory association as a therapy method 
complementary to the management of these cases [Trimbos, 2003]. 
2.3 Chemotherapy 
Chemotherapy as an adjuvant in the treatment protocol of early OC has always been an 
issue that concerns the role and selection of cases where its use proves its real efficiency in 
terms of median progression-free survival (PFS) and especially overall survival (OS). The 
controversies about the application of OC in the early stages CMT year refer specifically to: 
- The group of patients to be associated 
- Type of CMT and the timing  
- Regimens (monotherapy/polytherapy) 
- The administration (number of series) 
Initially addressed to the patients with the increased prognostic risk groups of early OC, the 
indication of the application of CMT was extended to patients with moderate risk group due 
to significant differences in overall survival and median progression-free survival [Young, 
2003]. Regarding the timing of CMT in patients with early OC, both technically and as a 
result, CMT is totally adjuvant; its administration is in fact a therapy nonsense, which would 
require an initial biopsy laparatomy for a resectable case in radical limits. As an 
extrapolation of the results obtained with different regimens applied to patients with 
advanced OC, it was concluded that the most effective combination therapy is the combined 
protocol Carboplatin AUC 5 to 7.5 mg/ml/min + Paclitaxel 175mg/m2/3h [Kyrgiou, 2006]. 
Some studies that compared adjuvant CMT versus "watchful waiting”, established that the 
use of adjuvant CMT improves OS and PFS in high-risk patients with early stages of OC. 
This was confirmed recently by a metanalysis comprising five prospective randomized 
studies. Its final conclusion was that the patients who received platinum-based adjuvant 
chemotherapy had better OS [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.53-0.93] 
and PFS (HR 0.67, 95% CI 0.53- 0.84) than patients who did not receive treatment adjuvant 
[Colombo, 2010]. One of the conclusions of mentioned metanalysis surprised by considering 
early adjuvant CMT as a factor influencing the final results in OC, but was very important in 
the further development of specific cases and suboptimal staging. Later was observed that 
two thirds of the studies that classified patients of having early stages OC, could classified 
that patients in higher stages. In these cases there was a significant difference in OS and PFS 
terms considering association or not adjuvant CMT at initial surgery resection. However, in 
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suboptimal staged group with unfavorable prognostic factors, adjuvant CMT could address 
and properly stage the group of patients [Trimbos, 2003]. The controversy regarding the 
duration of the adjuvant CMT tried to be clarified in GOG-157 study which demonstrated 
that 6 cycles of Carboplatin + Paclitaxel have the same therapeutic effect (OS and PFS) with 
only 3 cycles with the same combination, but only with an increased cumulative toxicity 
[Bell, 2003]. A 33 percent reduction in the risk of loco-regional relapse, demonstrated using 
the same 6-cycle regimens, compared with 3 cycles, led to the routine use of CMT under 
standard adjuvant 6 cycles [Bell, 2003].  
3. Therapeutic strategies in advanced ovarian cancer 
There is a significant difference between the management of early stages and advanced 
stages of OC management and the latter, there is a difference between stages II B - III C, 
respectively, stage IV. The inclusion of stage II was made considering prognosis of patients 
with OC at this stage, and data showed that are closer to those of stage III. For stage II B - III 
C of OC, therapeutic methods are represented by chemotherapy and surgery, radiotherapy 
with more historical significance and biological therapy. 
3.1 Radiation 
Radiotherapy (either WAR or intraperitoneal brachytherapy) was analyzed in several 
studies, the last completed in 2003. The studies have underlined the utility of this method 
but also the increased risks of major complications [Verheijen, 2006]. 
3.2 Surgery 
In the early stages of OC, surgery proposed a radical intervention intended to remove the 
entire tumor, on the one hand, and to estimate the peritoneal dissemination of cancer in any 
sites for a more accurate staging, on the other hand. In advanced stages, cytoreductive 
surgery (CRS) has the main purpose not to excise the whole tumor, but to obtain a small 
volume of residue lesions. Direct proportionality between the individual and the extent of 
cytoreduction evolution was demonstrated by multiple studies. In 2002, Bristov even 
proposed a mathematical model, showing that the ultimate goal of surgery is to obtain 
under 1 cm of residual tumor, which can involve, if feasible, multivisceral resections, 
peritonectomy, stripping diaphragm, pelvic radical dissection, splenectomy [Marszalek, 
2010]. A review on the subject showed an increased OS from 17 to 39 months [Bristow, 
2002]. Discussions regarding aggressive surgical risk refer to the degree that is vital for the 
patient. Thus, if the patient is suitable for CRS at primary laparatomy, then the biopsy is 
followed by neoadjuvant CMT and subsequently secondary CRS [Tangjitgamol, 2010]. It is 
preferable that secondary CRS be performed after three cycles of CMT and be followed by 
three cycles of adjuvant with the same regimen CMT. In patients with complete response to 
treatment, a second look surgery has not proven be beneficial of the OS. Secondary CRS 
scheduled after neoadjuvant CMT does not show a clear increased of OS [Winter, 2008]. 
3.3 Chemotherapy 
Chemotherapy is a mandatory means in the treatment of advanced OC. Over time there 
have been many controversies concerning: 
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- When administered CMT 
- Therapeutic regimes 
- Simultaneous therapy versus sequential therapy 
- Duration of therapy (no. of cycles) 
- Route of administration 
- Tumor residue 
3.3.1 Timing CMT 
The debate is limited not only about using CMT as adjuvant, but also about the possibility of 
its association as neoadjuvant therapy. Administration of preoperative CMT (preferably 3 
cycles) has proven useful only in cases where primary optimal CRS surgery was impossible 
to perform, and response to treatment favorable, allowing a secondary CRS [Vergote, 2010]. 
Survival, however, in these cases proved to be a less than optimal in primary CRS cases 
followed by adjuvant CMT [Kumar, 2010]. The remaining cases that could benefit from 
primary CRS will receive mandatory six cycles of adjuvant CMT 3 weeks each. 
3.3.2 Regimens 
Since 1996 it was formulated the standard scheme for CMT in advanced OC, combination of 
platinum and taxane ions, causing abandonment included Cyclofosfamide regimens, 
doxorubicin or 5-fluorouracil [McGuire, 1996]. The response rates to this combination in 
patients with advanced OC were different, depending on the degree of primary CRS: 70% 
for suboptimal CRS and over 80% for primary optimal CRS [Ozols, 2003].  
Usefulness of paclitaxel-based chemotherapy potentiation of platinum ions was 
demonstrated in Gynecologic Oncology Group (GOG) 111 study and European-Canadian 
(OV-10) trial, but it has not been confirmed by following studies: The Third International 
Collaborative Ovarian Neoplasm Study (ICON-3) and GOG 132 [McGuire, 1996; Stuart, 
1998; Muggia, 2000]. GOG 114 study underlines the effectiveness of carboplatin and 
cisplatin same regimes combined with a top low toxicity for carboplatin [Ozols, 2003]. In 
combination with paclitaxel chemotherapy comparing the study above demonstrates 
increased efficiency of carboplatin in terms of OS and PFS. This is another argument in 
favor of regime 7.5 Carboplatin/Paclitaxel 175 mg/m2/3h, as concluded in GOG 158 
study [Ozols, 2003]. 
3.3.3 Simultaneous versus sequential therapy 
Sequential administration of cytostatics in combination regimens is also an important 
controversy in the treatment of advanced OC. In GOG-132 study and The European-
Canadian study, one of the conclusions was that the benefit of platinum ions taxane 
association is found both in the system simultaneously, and in the sequence [Vermorken, 
2000, Piccart, 2000]. In GOG 132 study was also demonstrated that OS was similar in 
regimens combined platinum + taxane type ions, regardless of the combination 
simultaneously, or sequentially, resulting less encouraging for monotherapy (regimes 
based exclusively platinum ions showing a 5-year OS 67%). The weakest cytostatic agent 
used as monotherapy was paclitaxel (exclusive regimes showing a 5-year OS 42%) 
[Vermorken, 2000; Muggia, 2000]. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
132 
suboptimal staged group with unfavorable prognostic factors, adjuvant CMT could address 
and properly stage the group of patients [Trimbos, 2003]. The controversy regarding the 
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surgery (CRS) has the main purpose not to excise the whole tumor, but to obtain a small 
volume of residue lesions. Direct proportionality between the individual and the extent of 
cytoreduction evolution was demonstrated by multiple studies. In 2002, Bristov even 
proposed a mathematical model, showing that the ultimate goal of surgery is to obtain 
under 1 cm of residual tumor, which can involve, if feasible, multivisceral resections, 
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2010]. A review on the subject showed an increased OS from 17 to 39 months [Bristow, 
2002]. Discussions regarding aggressive surgical risk refer to the degree that is vital for the 
patient. Thus, if the patient is suitable for CRS at primary laparatomy, then the biopsy is 
followed by neoadjuvant CMT and subsequently secondary CRS [Tangjitgamol, 2010]. It is 
preferable that secondary CRS be performed after three cycles of CMT and be followed by 
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- Route of administration 
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GOG-111 386 III, IV  
Paclitaxel (135 mg/m2) 51 18 38 
Cisplatin (75 mg/m2) P = .0002 P = .0001 
Cyclosphosphamide 
(750 mg/m2)   31 13 24 
Cisplatin (75 mg/m2)
OV10  668 IIB IV    
Paclitaxel (175 mg/m2) 50 16 35 
Cisplatin (75 mg/m2) P = .0005 P = .0016 
Cyclophosphamide (750 mg/m2) 36 12 25 
Cisplatin (75 mg/m2)
ICON-3 2074 Ia IV    
Paclitaxel (175 mg/m2) NA 17.3 36.1 
Carboplatin (AUC 5 to 6) P = .19 P = .74 
Carboplatin (AUC 5 to 6) NA 16.1 35.4a 
Cisplatin (50 mg/m2)
Doxorubicin (50 mg/m2) 
Cyclophosphamide (500 mg/m2)
     
GOG-132 614 III IV  
Paclitaxel (135 mg/m2) NA 16 35b 
Cisplatin (75 mg/m2)  
Cisplatin (100 mg/m2) NA 16.4 30.2 
Paclitaxel (200 mg/m2) NA 11.4 26 
Table 2. Randomized Trials of Paclitaxel versus Non-Paclitaxel First-Line Therapy in 
Advanced Epithelial Ovarian Cancer [De Vita, 2008]. 
3.3.4 Duration of therapy (number of cycles) 
Three randomized trials that analyzed the effectiveness of increasing the number of cycles of 
CMT on the OS have concluded unanimously that the results are similar, but increased the 
frequency of complications (especially neurological). The cumulative toxicity was directly 
proportional with the number of cycles. It was established that the optimal number of cycles 
is 6, each separated by 3 weeks of rest between them [Colombo, 2010]. 
3.3.5 Route of administration 
Until recently, the route of administration of the CMT was systemic intravenous peripheral 
or central. Increasing concentration in the peritoneal cavity of CMT after primary CRS, 
without causing systemic side effects, is believed to be a result of the ratio of cisplatin, 
paclitaxel, respectively, between the peritoneum and systemic circulation central. Since then, 
it appeared the idea of intraperitoneal CMT [Rothenberg, 2003]. Since 1980 analyzed in 
numerous randomized trials, intraperitoneal administration of CMT was shown to improve 
OS and PFS in optimal cytoreduced patients and in terms of pathological complete 
remission in patients in whom cytoreduction was actually, suboptimal (residual tumor < 2 
cm was accepted as optimal at that time), compared with only intravenous administration of 
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CMT [Alberts, 1987]. GOG-172 (Armstrong, 2006) study pointed out that the combination of 
CMT to the intravenous intraperitoneal resulting OS rise from 49.7 to 65.6 months (35%) and 
PFS from 19 to 24 months (with 26%), but with a greatly increased associated toxicity. In 
58% of cases resulted the abandonment of intraperitoneal administration of CMT, making 
only 42% complete the 6 cycles (given on day 2 and day 8). Cochrane's metanalysis, 
balancing risks and benefits, reported in eight randomized trials of systemic administration 
of CMT (intraperitoneal association and administration) concluded that effect is beneficial in 
terms of OS (hazard ratio 0.799) and PFS (hazard ratio 0.792) [Jaaback, 2006]. Despite these 
favorable results, many authors have remained skeptical about this therapy, which was still 
considered at an experimental level [Gore, 2006; Ozols, 2006]. Since 1994, the efficiency of 
intraperitoneal CMT is questioned, by administering in hyperthermia. In this respect, there 
were a lot series of studies that examined the usefulness of this method in the management 
of OC. CMT administration at 39 to 44,5 degrees Celsius, in addition to increased 
locoregional and systemic toxic effect, translated into a major complication rate of 28.3% 
[Ryu, 2004] and a perioperative mortality of 3.7% [Gori, 2005]. 
HIPEC indications can be summarized in: 
- Recurrent or persistent disease: the use of intraperitoneal CMT extended the period of 
progression of OC lesion from 10 to 21.8 months [Zanon, 2004; Helm, 2007]. 
- As first-line therapy: although logical, it is recommended an aggressive approach of OC, 
but when it was applied, the number of cases was too small for a conclusion [Piso, 2004]. 
- When CRS is scheduled after neoadjuvant CMT, it is preferably an optimal 
cytoreduction followed by HIPEC. The number of cases remained was insufficient to 
have a clear conclusion [Reichman, 2005; Yoshida, 2005]. 
- CMT as consolidation therapy, when it is applicable second look surgery or after a 
partial response in these cases.  
One study observed an improvement from 19.8 to 48.7 months and OS of 52, 8 to 63.4 
months (Ryu - cisplatin + interferon treatment) [Ryu, 2004]. These results are relative, since, 
although in large numbers, the patients from this study were not homogeneous in terms of 
progress including early cases. Another study obtained a recurrence rate of 69.9% for HIPEC 
compared with 63.1% in the control group, a difference of OS from 64.4 to 46.4 months, but 
proved to be insignificant (p = 0.29), due to lots of inhomogeneity [Gori, 2005]. 
Several ways to amend the standard treatment protocols were tried in order that adjuvant 
CMT to increase: 
- Addition of the third chemotherapy 
- Management of locoregional chemotherapy 
- Maintenance Chemotherapy 
- Increasing doses 
- The combination of biological therapy 
GOG-111 and OV-10 studies identified the need to improve therapeutic strategies 
considering long-term adverse outcomes [McGuire, 1996; Stuart, 1998].  
Combination of the third drug 
The combination of the third drug joins the regimen used to treat OC (Carboplatin - 
Paclitacsel). Other chemotherapy gemcitabine Dacsil, topotecan achieved an improvement 
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or central. Increasing concentration in the peritoneal cavity of CMT after primary CRS, 
without causing systemic side effects, is believed to be a result of the ratio of cisplatin, 
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CMT [Alberts, 1987]. GOG-172 (Armstrong, 2006) study pointed out that the combination of 
CMT to the intravenous intraperitoneal resulting OS rise from 49.7 to 65.6 months (35%) and 
PFS from 19 to 24 months (with 26%), but with a greatly increased associated toxicity. In 
58% of cases resulted the abandonment of intraperitoneal administration of CMT, making 
only 42% complete the 6 cycles (given on day 2 and day 8). Cochrane's metanalysis, 
balancing risks and benefits, reported in eight randomized trials of systemic administration 
of CMT (intraperitoneal association and administration) concluded that effect is beneficial in 
terms of OS (hazard ratio 0.799) and PFS (hazard ratio 0.792) [Jaaback, 2006]. Despite these 
favorable results, many authors have remained skeptical about this therapy, which was still 
considered at an experimental level [Gore, 2006; Ozols, 2006]. Since 1994, the efficiency of 
intraperitoneal CMT is questioned, by administering in hyperthermia. In this respect, there 
were a lot series of studies that examined the usefulness of this method in the management 
of OC. CMT administration at 39 to 44,5 degrees Celsius, in addition to increased 
locoregional and systemic toxic effect, translated into a major complication rate of 28.3% 
[Ryu, 2004] and a perioperative mortality of 3.7% [Gori, 2005]. 
HIPEC indications can be summarized in: 
- Recurrent or persistent disease: the use of intraperitoneal CMT extended the period of 
progression of OC lesion from 10 to 21.8 months [Zanon, 2004; Helm, 2007]. 
- As first-line therapy: although logical, it is recommended an aggressive approach of OC, 
but when it was applied, the number of cases was too small for a conclusion [Piso, 2004]. 
- When CRS is scheduled after neoadjuvant CMT, it is preferably an optimal 
cytoreduction followed by HIPEC. The number of cases remained was insufficient to 
have a clear conclusion [Reichman, 2005; Yoshida, 2005]. 
- CMT as consolidation therapy, when it is applicable second look surgery or after a 
partial response in these cases.  
One study observed an improvement from 19.8 to 48.7 months and OS of 52, 8 to 63.4 
months (Ryu - cisplatin + interferon treatment) [Ryu, 2004]. These results are relative, since, 
although in large numbers, the patients from this study were not homogeneous in terms of 
progress including early cases. Another study obtained a recurrence rate of 69.9% for HIPEC 
compared with 63.1% in the control group, a difference of OS from 64.4 to 46.4 months, but 
proved to be insignificant (p = 0.29), due to lots of inhomogeneity [Gori, 2005]. 
Several ways to amend the standard treatment protocols were tried in order that adjuvant 
CMT to increase: 
- Addition of the third chemotherapy 
- Management of locoregional chemotherapy 
- Maintenance Chemotherapy 
- Increasing doses 
- The combination of biological therapy 
GOG-111 and OV-10 studies identified the need to improve therapeutic strategies 
considering long-term adverse outcomes [McGuire, 1996; Stuart, 1998].  
Combination of the third drug 
The combination of the third drug joins the regimen used to treat OC (Carboplatin - 
Paclitacsel). Other chemotherapy gemcitabine Dacsil, topotecan achieved an improvement 
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of the OS or PFS, but with a toxicity increased as studies ICON-5 and GOG 182 have shown. 
The role of the third combination chemotherapy was relevant for mucinous adenocarcinoma 
OC type or clear cell [Bookman, 2006]. 
Locoregional administration of CMT 
Results of studies on intraperitoneal chemotherapy have been mentioned previously. 
Increasing doses of CMT 
The concept of increasing doses of CMT has been divided in two: on the one hand, the 
concept of increasing the dose (increasing the effective dose per chemotherapy cures the 
same secventiality) and, on the other hand, the concept of dose densification (the same dose 
in more frequent cycles). Increasing the desired effect by increasing the dose of 
chemotherapy was ruled out by the study AGO-Ovar/AIO and EBMT in 2007. The study 
showed that there were no significant differences in OS and PFS terms [Mobus, 2007]. In 
2008, Isonishi and collaborators demonstrated, however, through a study on 631 patients 
randomized, that in the second year, OS and PFS are significantly influenced (77.7 versus 
83.6, respectively 17.1 versus 27.9) after the densification of Carboplatin dosage scheme - 
Paclitaxel, when these were administered weekly [Ionishi, 2008]. 
Maintenance therapy 
The maintenance therapy requires long term administration, after six cycles of combined 
CMT or variable number of cycles of CMT administered as monotherapy. Most studies that 
examined the maintenance therapy with ions of platinum, taxanes, topotecan, epirubicin, 
surprised no significant differences in OS and PFS terms. One study reported that 
maintenance therapy for 12 months with Paclitaxel 7 months improved PFS [Markman, 
2003; Markman, 2009]. 
4. Therapeutic strategies in recurrent ovarian cancer 
Patients that experienced disease relapse or are refractory to first-line treatment are 
candidates for second-line chemotherapy. An ideal agent will provide broad antitumor 
activity, demonstrate a favorable toxicity profile, and have generally convenient 
administration, among other factors. Additionally, many of the more active agents used in 
second-line treatment (e.g., gemcitabine, liposomal doxorubicin, and topotecan) are non–
cross-resistant to first-line therapies. They exhibit novel mechanisms of action relative to 
cisplatin/carboplatin and paclitaxel, thereby targeting a different aspect of cell division. The 
agents include members of the platinum and taxane families, such as carboplatin and 
paclitaxel (every 3 weeks and weekly schedules), respectively; the topoisomerase I inhibitor 
topotecan; the liposome-encapsulated anthracycline doxorubicin (liposomal doxorubicin); 
and the novel antimetabolite gemcitabine. The clinical utility (benefit-risk ratio) of these 
agents in the recurrent ovarian cancer setting will be reviewed briefly below. 
Hexamethylmelamine 
Hexamethylmelamine (altretamine; Hexalen; MGI Pharma, Bloomington, MN) is an 
approved single-agent therapy for ovarian cancer. It has the advantage of oral 
administration, which may be preferable for some patients. However, it has been 
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demonstrated only limited activity in patients with relapsed platinum-refractory ovarian 
cancer [Markman, 2003]. 
Platinum 
Patients that were found to be platinum sensitive at first-line therapy are likely to benefit 
from reintroduction of platinum on disease recurrence. Both cisplatin (Platinol; Bristol-
Myers Squibb, Princeton, NJ) and carboplatin (Paraplatin; Bristol-Myers Squibb) are FDA-
approved for the treatment of recurrent ovarian cancer and are often used as monotherapy 
or in combination with paclitaxel. Carboplatin is considerably less nephrotoxic than 
cisplatin; however, because the primary route of clearance is renal, the potential for acute 
renal toxicity should be monitored when it is established the dosage. In clinical trials of 
single-agent carboplatin, overall tumor response rates ranged from 21% to 30% in platinum-
resistant or platinum-refractory patients and from 27% to 53% in platinum-sensitive 
patients [Williams, 1992; Kavanagh J, 1995; Bolis G, 2001]. Furthermore, the proportion of 
patients with stable disease was approximately 18% to 33%. 
Gemcitabine plus Platinum 
Gemcitabine (Gemzar; Eli Lilly and Co., Indianapolis, IN) has received approval in other 
indications but is still investigational in the treatment of ovarian cancer. Gemcitabine can be 
safely combined with carboplatin for the treatment of patients with relapsed ovarian 
cancer [du Bois, 1995]. The gemcitabine plus carboplatin regimen recently compared 
favorably with carboplatin alone in a randomized trial in patients with relapsed platinum-
sensitive ovarian cancer, producing significant improvements in quality of life, significantly 
faster palliation of abdominal symptoms, significant improvements in response rate, and a 
significant increase in progression-free survival. 
Paqclitaxel 
 Every three weeks  
Paclitaxel (Taxol; Bristol-Myers Squibb) is indicated as first-line (with cisplatin or 
carboplatin) and subsequent therapy for the treatment of ovarian cancer. The taxane is 
administered in two different schedules; however, the FDA-approved dosing is intravenous 
administration over 3 or 24 hours once every 3 weeks. In studies of paclitaxel administered 
on this schedule, overall tumor response rates were approximately 22% in platinum-
resistant or platinum-refractory patients and 45% in platinum-sensitive patients [Cantu 
2002; Gore, 1995; Trimble, 1993]. Median survival in platinum-resistant or refractory 
patients ranged from 6 to 9 months and was 26 months in 47 evaluable platinum-sensitive 
patients is generally less favorable than it is when the agent is administered weekly; 
therefore, partly because of the sometimes debilitating toxicity associated with the approved 
schedule, investigators have developed interest in evaluating the antitumor activity and 
tolerability of weekly schedules. 
 Weekly 
Although weekly paclitaxel is not an approved regimen in ovarian cancer therapy, overall 
tumor responses were at least comparable and potentially higher than those achieved with 
the every-3-week’s schedule in preliminary studies in patients with recurrent 
disease [Rosenberg, 2002]. 
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resistant or platinum-refractory patients and from 27% to 53% in platinum-sensitive 
patients [Williams, 1992; Kavanagh J, 1995; Bolis G, 2001]. Furthermore, the proportion of 
patients with stable disease was approximately 18% to 33%. 
Gemcitabine plus Platinum 
Gemcitabine (Gemzar; Eli Lilly and Co., Indianapolis, IN) has received approval in other 
indications but is still investigational in the treatment of ovarian cancer. Gemcitabine can be 
safely combined with carboplatin for the treatment of patients with relapsed ovarian 
cancer [du Bois, 1995]. The gemcitabine plus carboplatin regimen recently compared 
favorably with carboplatin alone in a randomized trial in patients with relapsed platinum-
sensitive ovarian cancer, producing significant improvements in quality of life, significantly 
faster palliation of abdominal symptoms, significant improvements in response rate, and a 
significant increase in progression-free survival. 
Paqclitaxel 
 Every three weeks  
Paclitaxel (Taxol; Bristol-Myers Squibb) is indicated as first-line (with cisplatin or 
carboplatin) and subsequent therapy for the treatment of ovarian cancer. The taxane is 
administered in two different schedules; however, the FDA-approved dosing is intravenous 
administration over 3 or 24 hours once every 3 weeks. In studies of paclitaxel administered 
on this schedule, overall tumor response rates were approximately 22% in platinum-
resistant or platinum-refractory patients and 45% in platinum-sensitive patients [Cantu 
2002; Gore, 1995; Trimble, 1993]. Median survival in platinum-resistant or refractory 
patients ranged from 6 to 9 months and was 26 months in 47 evaluable platinum-sensitive 
patients is generally less favorable than it is when the agent is administered weekly; 
therefore, partly because of the sometimes debilitating toxicity associated with the approved 
schedule, investigators have developed interest in evaluating the antitumor activity and 
tolerability of weekly schedules. 
 Weekly 
Although weekly paclitaxel is not an approved regimen in ovarian cancer therapy, overall 
tumor responses were at least comparable and potentially higher than those achieved with 
the every-3-week’s schedule in preliminary studies in patients with recurrent 
disease [Rosenberg, 2002]. 
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Platinum plus paclitaxel 
Patients who responded to combination first-line therapy may benefit from reintroduction 
of platinum and paclitaxel on disease recurrence. In the largest study to date conducted in 
collaboration with the International Collaborative Ovarian Neoplasm (ICON4) and three 
cooperative groups, 802 relapsed patients with ovarian cancer were randomized to 
treatment with platinum plus a taxane or single-agent platinum [Parmar, 2003] . Overall 
tumor response rate in the combination group was 66% compared with 54% in the platinum 
treatment group (P = 0.06). Notably, the hazard ratios for progression-free survival and 
overall survival were 0.76 and 0.82, respectively, favoring platinum plus paclitaxel over 
single-agent platinum in both cases. Thus, there was a statistically significant difference in 
survival favoring the platinum plus paclitaxel combination compared with single-agent 
platinum (P = 0.023) [Parmar, 2003]. 
Topotecan 
Topotecan (Hycamtin; GlaxoSmithKline, Philadelphia, PA) is an active and well-established 
agent currently indicated [topotecan (1.5 mg/m2) on days 1 through 5 of a 21-day cycle] for 
the treatment of relapsed metastatic ovarian cancer after failure of initial or subsequent 
chemotherapy. 
Docetaxel 
Although docetaxel (Taxotere; Aventis Pharmaceuticals Inc., Bridgewater, NJ) is more 
commonly used in the treatment of non–small-cell lung cancer and breast cancer, recent 
studies have been conducted in patients with relapsed ovarian cancer [Rose, 2003; 
Markman, 2003]. In the largest study, with 60 paclitaxel-resistant ovarian cancer patients 
receiving docetaxel (100 mg/m2) every 21 days, Rose and collaborators reported a 
response rate of 22%, including 5% and 17% complete and partial response rates, 
respectively [Rose, 2003]. 
Gemcitabine 
Although is not currently FDA-approved for the treatment of ovarian cancer, gemcitabine 
(Gemzar; Eli Lilly and Co.) has typically been administered as monotherapy in pretreated 
patients with ovarian cancer. 
Etoposide 
Etoposide (VePesid; Bristol-Myers Squibb) inhibits topoisomerase II and thus inhibits DNA 
synthesis. In a phase II study in patients with recurrent ovarian cancer investigated 
etoposide (150 mg/m2) on days 1 through 3 of a 28-day cycle [Eckhardt, 1990]. Of the 71 
patients evaluable for response, 1 achieved a complete response, and 5 achieved a partial 
response. An additional 48 patients had stable disease. 
5. Conclusions 
The questions of optimal treatment duration and whether patients should receive treatment 
to disease progression remain unanswered. However, in the absence of definitive evidence 
addressing optimal treatment duration in patients with relapsed disease, it should be 
recognized and appreciated that a number of agents are available that offer a level of 
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flexibility and treatment customization heretofore unseen in the management of recurrent 
ovarian cancer in this generally poor-prognosis patient population. These agents should be 
wielded with the critical goal of balancing the efficacy and toxicity of particular agents and 
schedules with their effect on symptoms and quality of life. 
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1. Introduction 
Ovarian cancer is the leading cause of death from gynecologic cancer and the fifth cause 
of cancer deaths in women in developed countries (Yancik, 1993; Cannistra, 1993). The 
number of deaths seems to increase the last few years. More than 70% of the patients with 
ovarian cancer have advanced disease at the time of initial diagnosis because they remain 
asymptomatic in early stages (Roberts, 1996). Ovarian cancer is the most frequent 
intraceolomic malignancy presenting with peritoneal spread. In the past debulking 
surgery combined with systemic chemotherapy offered long-term survival in less than 
10% of the patients (Smith & Day, 1979). The standard treatment of advanced ovarian 
cancer is cytoreductive surgery followed by systemic chemotherapy (Hacker et al, 1983; 
Neijt et al, 1991; Hoskins et al, 1992). Despite systemic chemotherapy based on platinum 
and taxanes 5 and 10-year survival rate do not exceed 20% and 10% respectively because 
the majority of the patients develop recurrence (Mc Guire & Ozols, 1998; Piccart et al, 
2000). The disease remains characteristically confined to the peritoneal surfaces for most 
of its natural course (Bergmann, 1996). Surgical resection of the tumor may not be 
complete and microscopic or even macroscopic residual tumor may be left behind. In 
these situations the intraperitoneal route of administration of cytostatic drugs is a logical 
approach. 
Patients with diseases that have similar biological behavior to ovarian cancer are offered 
significant survival benefit when they are treated with perioperative intraperitoneal 
chemotherapy integrated in cytoreductive surgery. In pseudomyxoma peritonei 
(Sugarbaker, 2006), peritoneal sarcomatosis (Rossi et al, 2004), peritoneal mesothelioma 
(Yan et al, 2007), colorectal cancer with peritoneal dissemination (Elias et al, 2009; 
Mahteme et al, 2004; Verwaal et al, 2008), as well as in gastric cancer with peritoneal 
carcinomatosis (Yonemura et al, 1996; Yu et al, 1998) survival is improved with this 
treatment strategy. The last two decades the method has been used in ovarian cancer with 
promising results. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
142 
Vergote, I.; Trope, C.G.; Amant, F. et al. (2010). Neoadjuvant chemotherapy or primary 
surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, Vol. 363, 
No.10, (September, 2010), pp. 043-953. 
Vergote, I.B.; Vergote-De Vos, L.N. Abeler, V.M. et al. (1992). Randomized trial comparing 
cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant 
treatment of ovarian cancer. Cancer, Vol. 69, No.3, (February, 1992), pp. 741-749. 
Verheijen, R.H.; Massuger, L.F.; Benigno, B.B. et al. (2006). Phase III trial of intraperitoneal 
therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients 
with epithelial ovarian cancer after a surgically defined complete remission. Journal 
of Clinical Oncology, Vol. 24, No.4, (February, 2006), pp. 571-578. 
Vermorken, J.B. (2000). Optimal treatment for ovarian cancer: taxoids and beyond, Annals of 
Oncology, Vol. 11, Suppl 3, pp. 131-139. 
Winter, W.E. 3rd, Maxwell, G.L. Tian, C. et al. (2008). Tumor residual after surgical 
cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: 
a Gynecologic Oncology Group Study. Journal of Clinical Oncology, Vol. 26, No.1, 
(January, 2008), pp. 83–89. 
Yoshida, Y.; Sasaki, H.; Kurokawa, T.; et al. (2005). Efficacy of intraperitoneal continuous 
hyperthermic chemotherapy as consolidation therapy in patients with advanced 
epithelial ovarian cancer: a long-term follow-up. Oncology Reports, Vol.13, No.1, 
(January, 2005), pp. 121–125. 
Young, R.C.; Brady, M.F.; Nieberg, R.K. et al. (2003). Adjuvant treatment for early ovarian 
cancer: a randomized phase iii trial of intraperitoneal 32P or intravenous 
cyclophosphamide and cisplatin a Gynecologic Oncology Group Study. Journal of 
Clinical Oncology, Vol.21, No.23, (December, 2003), pp. 4350-5355. 
Young, R.C.; Decker, D.G.; Wharton, J.T.; Piver, M.S. et al. (1983). Staging laparotomy in 
early ovarian cancer. The Journal of American Medical Association, Vol. 250, No. 22, 
3072–3076. 
Young, R.C. (2003). Early-stage ovarian cancer: to treat or not to treat. Journal of National 
Cancer Institute, Vol. 95, No.2, (January, 2003), pp. 94-95. 
Zanon, C.; Clara, R.; Chiappino, I. et al. (2004). Cytoreductive surgery and intraperitoneal 
chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. 
World Journal of Surgery, Vol. 28, No.10, (October, 2004), pp. 1040–1045. 
8 
Combined Cytoreductive  
Surgery and Perioperative  
Intraperitoneal Chemotherapy for the  
Treatment of Advanced Ovarian Cancer 
Antonios-Apostolos K. Tentes1,  
Nicolaos Courcoutsakis2 and Panos Prasopoulos2 
1Didimotichon General Hospital, 
 2Alexandroupolis University Hospital 
Greece 
1. Introduction 
Ovarian cancer is the leading cause of death from gynecologic cancer and the fifth cause 
of cancer deaths in women in developed countries (Yancik, 1993; Cannistra, 1993). The 
number of deaths seems to increase the last few years. More than 70% of the patients with 
ovarian cancer have advanced disease at the time of initial diagnosis because they remain 
asymptomatic in early stages (Roberts, 1996). Ovarian cancer is the most frequent 
intraceolomic malignancy presenting with peritoneal spread. In the past debulking 
surgery combined with systemic chemotherapy offered long-term survival in less than 
10% of the patients (Smith & Day, 1979). The standard treatment of advanced ovarian 
cancer is cytoreductive surgery followed by systemic chemotherapy (Hacker et al, 1983; 
Neijt et al, 1991; Hoskins et al, 1992). Despite systemic chemotherapy based on platinum 
and taxanes 5 and 10-year survival rate do not exceed 20% and 10% respectively because 
the majority of the patients develop recurrence (Mc Guire & Ozols, 1998; Piccart et al, 
2000). The disease remains characteristically confined to the peritoneal surfaces for most 
of its natural course (Bergmann, 1996). Surgical resection of the tumor may not be 
complete and microscopic or even macroscopic residual tumor may be left behind. In 
these situations the intraperitoneal route of administration of cytostatic drugs is a logical 
approach. 
Patients with diseases that have similar biological behavior to ovarian cancer are offered 
significant survival benefit when they are treated with perioperative intraperitoneal 
chemotherapy integrated in cytoreductive surgery. In pseudomyxoma peritonei 
(Sugarbaker, 2006), peritoneal sarcomatosis (Rossi et al, 2004), peritoneal mesothelioma 
(Yan et al, 2007), colorectal cancer with peritoneal dissemination (Elias et al, 2009; 
Mahteme et al, 2004; Verwaal et al, 2008), as well as in gastric cancer with peritoneal 
carcinomatosis (Yonemura et al, 1996; Yu et al, 1998) survival is improved with this 
treatment strategy. The last two decades the method has been used in ovarian cancer with 
promising results. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
144 
2. Prognostic indicators of advanced ovarian cancer 
2.1 Peritoneal Cancer Index (PCI) 
The clinical utility of the FIGO staging system has been well established since its first report 
in 1964 (Odicino et al, 2001) but does not provide clear details about the extent and 
distribution of the peritoneal spread. 
In contrast the peritoneal cancer index is a useful clinical variable by which the evaluation of 
the extent and distribution of the peritoneal malignancy is clear and accurate and has been 
continuously used in pseudomyxoma peritonei (Sugarbaker, 2006), peritoneal mesothelioma 
(Yan et al, 2007), colorectal cancer with peritoneal dissemination (Elias, 2001; Sugarbaker, 
1999; Gomez-Portilla et al, 1999), and peritoneal sarcomatosis (Rossi et al, 2004; Esquivel & 
Sugarbaker, 1998). 
The calculation of the peritoneal cancer index is possible with the division of the abdomen 
and pelvis in 13 different regions (Figure 1). Two transverse and two sagittal planes are used 
to divide the abdomen and pelvis in nine regions. The upper transverse plane is the lowest 
part of the costal margin and the lower plane is the anterior superior iliac spine. The sagittal 
planes divide the abdomen in three equal sectors. The abdominopelvic region 0 (AR-0) 
includes the midline incision, the greater omentum and the transverse colon. The 
abdominopelvic region 1 (AR-1) includes the superior surface of the right lobe of the liver, 
the undersurface of the right hemidiaphragm, and the right retrohepatic space. The 
epigastric fat, the left lobe of the liver, the lesser omentum and the falciform ligament are 
included in the abdominopelvic region 2 (AR-2). The abdominopelvic region 3 (AR-3) 
includes the undersurface of the left hemidiaphragm, the spleen, the tail of the pancreas, as 
well as the anterior and posterior surface of the stomach. The descending colon and the left 
abdominal gutter are included in abdominopelvic region 4 (AR-4). The left pelvic side wall 
and the sigmoid colon are included in the abdominopelvic region 5 (AR-5). The 
abdominopelvic region 6 (AR-6) includes the internal female genitalia, the cul-de-sac of 
Douglas, and the rectosigmoid colon. The abdominopelvic region 7 (AR-7) includes the right 
pelvic side wall, the base of the cecum, and the appendix. The abdominopelvic region 8 (AR-
8) includes the ascending colon and the right paracolic gutter. The small bowel and its 
mesentery are divided in four additional regions in upper jejunum (AR-9), lower jejunum 
(AR-10), upper ileum (AR-11), and lower ileum (AR-12). The peritoneal cancer index is the 
summation of the tumor volume in each one of the 13 different regions in which the 
abdomen and the pelvis are divided. 
Although the inclusion of the anatomic structures in the abdominopelvic regions is arbitrary 
the assessment of the distribution and extent of the peritoneal dissemination is detailed. 
2.2 Tumor volume 
The tumor volume is assessed as LS-0 (lesion size) when no visible tumor is detected, as LS-
1 when tumor nodules are < 0.5 cm in their largest diameter, as LS-2 when tumor nodules 
are 0.5-5 cm in their largest diameter, and as LS-3 when tumor nodules are > 5 cm in their 
largest diameter, or there are confluent any size nodules. LS-0, LS-1, and LS-2 are considered 
small volume tumors, and LS-3 large volume tumors (Figure 1) (Jacquet & Sugarbaker, 
1996). 
The tumor volume is a significant prognostic indicator of survival in advanced ovarian 
cancer (Tentes et al, 2003; Piso et al, 2004; Raspagliesi et al; 2006, Di Giorgio et al, 2008). 
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The extent of peritoneal dissemination in ovarian cancer may also be assessed with the 
use of the Lyon staging system, and the Dutch simplified peritoneal carcinomatosis index 
(SPCI) (Gilly et al, 2006). The assessment of the extent and distribution of peritoneal 
carcinomatosis using anyone of the above staging systems is helpful in excluding from 
surgery those patients who are not expected to be offered any benefit from cytoreductive 
surgery. 
In patients with high-grade tumors and high PCI complete cytoreduction is not feasible. In 
contrast, patients with low-grade tumors such as pseudomyxoma peritonei, grade I sarcoma 
and cystic peritoneal mesothelioma may easily undergo complete cytoreduction even if they 
have very high PCI. Therefore, in these situations the prognosis is related only to the 
completeness of cytoreduction. In addition, in very aggressive high grade tumors such as 
unresectable common bile duct cancer or unresectable cancer of the head of the pancreas the 
peritoneal cancer index is of no prognostic significance, even if it is low. In addition, the 
lymph node involvement in groups of lymph nodes that have no anatomic relation to the 
primary tumor the prognosis is poor despite a low PCI, because the favorable PCI is 








Fig. 1. Assessment of PCI by summation of the lesion size in the 13 regions in which the 
abdomen and pelvis are divided. 
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2.3 Prior Surgical Score (PSS) 
Prior surgical score is a useful prognostic indicator of survival for patients with peritoneal 
malignancy. If surgery has not been performed or only biopsy or laparoscopy has been 
performed then the score is 0 (PSS-0). In patients that have undergone surgery in one 
abdominopelvic region the score is 1 (PSS-1). For those patients that have undergone 
surgery in 2-5 abdominopelvic regions the score is 2 (PSS-2) and for those patients that have 
undergone surgery in > 5 abdominopelvic regions the score is 3 (PSS-3) (Jacquet & 
Sugarbaker, 1996). 
Prior surgical score is a significant prognostic indicator of survival in peritoneal 
sarcomatosis, appendiceal cancer, and peritoneal mesothelioma (Rossi et al, 2004; Jacquet & 
Sugarbaker, 1996; Sebbag et al, 2000). The significance of PSS has been questioned by other 
studies for pseudomyxoma peritonei and peritoneal mesothelioma (Brigand et al, 2006; 
Deraco et al, 2006; Miner et al, 2005; Baratti et al, 2007). In ovarian cancer PSS has been 
identified as a significant prognostic indicator of survival in one study (Look et al, 2004). 
The value of PSS in ovarian cancer is currently under investigation. 
2.4 Completeness of cytoreduction score 
In ovarian cancer the residual tumor is the most significant indicator for long-term survival 
(Hacker et al, 1983; Neijt et al, 1991; Hoskins et al, 1992; Eisenkop et al, 2003; Hunter et al, 
1992; Bristow et al, 2002; Tentes et al, 2006; Piso et al, 2004; Raspagliesi et al, 2006; Di Giorgio 
et al, 2008; Look et al, 2004). Gynecologists oncologists use the terms optimal and 
suboptimal cytoreduction to define the quality of the surgical result. The level of optimal 
cytoreduction has been arbitrarily set from 5 mm to 3 cm. The Gynecologic Oncology Group 
has shown that survival progressively decreases as the residual tumor increases from 
microscopic to 2 cm (Hoskins et al, 1994). As a consequence optimal cytoreduction is defined 
as the operation with no macroscopic residual disease. Survival is not improved if the 
residual tumor is more than 2 cm in its largest diameter and these patients do not survive 
longer than patients with 10 cm residual disease, which means that aggressive surgery such 
as bowel resection is not indicated if the residual tumor can not be less than 2 cm (Hoskins 
et al, 1994). 
The completeness of cytoreduction is a different approach to residual disease. For 
gastrointestinal cancer the completeness of cytoreduction score is defined as CC-0 if no 
macroscopically tumor is left after cytoreductive surgery, as CC-1 if nodules less than 2.5 
mm are left after surgery, as CC-2 if the residual nodules are > 2.5 mm and < 2.5 cm, and as 
CC-3 if tumor nodules > 2.5 cm or a confluence of tumor nodules in the abdomen or in the 
pelvis are left behind after cytoreductive surgery. For high-grade tumors only CC-0 surgery 
is considered to be complete cytoreductive surgery. For low-grade tumors CC-0 and CC-1 
cytoreductions are considered complete cytoreductive operations. 
The completeness of cytoreduction score is the most significant prognostic indicator of 
survival in patients with pseudomyxoma peritonei (Sugarbaker, 2006; Miner et al, 2005; 
Baratti et al, 2007) peritoneal mesothelioma (Yan et al 2007; Sebbag et al, 2000; Brigand et al, 
2006; Deraco et al, 2006), colorectal cancer with peritoneal carcinomatosis (Sugarbaker, 1999; 
Gomez-Portilla et al, 1999) gastric cancer with peritoneal carcinomatosis (Yonemura et al, 
2003), and peritoneal sarcomatosis (Rossi et al, 2004; Berthet et al, 1999). 
The completeness of cytoreduction score in advanced ovarian cancer has been demonstrated 
to be a significant prognostic indicator of survival (Tentes et al, 2003; Tentes et al, 2006; Piso 
et al, 2004; Raspagliesi et al, 2006; Di Giorgio et al, 2008). 
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2.5 Performance status 
Long-term survival in ovarian cancer is related to patient’s performance status (Tentes et al, 
2006). Patients with poor performance status can not tolerate extensive surgery such as 
cytoreductive surgery because of increased morbidity and hospital mortality. The 
preoperative performance status and the extent of the peritoneal carcinomatosis are 
prognostic indicators of hospital morbidity (Reuter et al, 2008) 
3. Treatment of advanced ovarian cancer 
3.1 Cytoreductive surgery-standard peritonectomy procedures 
The most powerful tool in the treatment of the diseases that have already disseminated at 
the peritoneal surfaces is surgical resection of the macroscopically visible tumor. For this 
purpose standard peritonectomy procedures have been used. The initially described six 
peritonectomy procedures (Sugarbaker, 1995) have recently been modified to the: 1) 
epigastric peritonectomy, 2) right subdiaphragmatic peritonectomy, 3)) left 
subdiaphragmatic peritonectomy, 4) greater omentectomy + splenectomy 5) lesser 
omentectomy, 6) pelvic peritonectomy,  7) cholecystectomy and resection of the omental 
bursa, 8) right parietal peritonectomy, 9) left parietal peritonectomy, and 10) resection of 
other organs (antrectomy, colectomy other than low anterior, subtotal colectomy, total 
gastrectomy, segmental intestinal resection) (Sugarbaker, 1999). 
In retrospective studies the residual tumor has been identified as the most significant 
prognostic indicator of survival (Hacker et al, 1983; Neijt et al, 1991; Hoskins et al, 1992; 
Eisenkop, 2003). Meta-analyses have documented the same finding (Hunter et al, 1992; 
Bristow et al, 2002) but no prospective trial has been performed. The feasibility of complete 
cytoreduction using standard peritonectomy procedures in ovarian cancer is 78.4% (Tentes 
et al, 2006; Chi et al, 2004). 
3.1.1 Patient’s position 
The patient is placed in modified lithotomy position. This place provides access to the 
perineum. A hyperthermia blanket is placed on the operating table to warm the patient 
during surgery. A midline incision from xyphoid process to the symphysis pubis is used for 
maximal exposure of the abdominal cavity. 
3.1.2 Epigastric peritonectomy procedure 
Epigastric peritonectomy procedure is used in re-operations and includes wide resection of 
the old scar with the round and the falciform ligament of the liver. Sometimes resection of 
the xyphoid process is required for maximal exposure of the subdiaphragmatic areas. 
3.1.3 Right subdiaphragmatic peritonectomy procedure 
The peritoneum beneath the right hemidiaphragm is stripped until the bare area of the liver 
is encountered. If tumor has seeded the anterior surface of the liver then it is removed 
beneath or through the Glisson’s capsule until the liver surface free of tumor is encountered. 
The tumor beneath the right hemidiaphragm, the right subhepatic space and the surface of 
the liver is removed en-bloc forming an envelope. Laterally on the right the dissection 
includes the peritoneum that covers the right perirenal fat as well as the anterior surface of 
the right adrenal. Eventually the vena cava, and the right hepatic vein form the base of the 
specimen (Figures 2, 3). 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
146 
2.3 Prior Surgical Score (PSS) 
Prior surgical score is a useful prognostic indicator of survival for patients with peritoneal 
malignancy. If surgery has not been performed or only biopsy or laparoscopy has been 
performed then the score is 0 (PSS-0). In patients that have undergone surgery in one 
abdominopelvic region the score is 1 (PSS-1). For those patients that have undergone 
surgery in 2-5 abdominopelvic regions the score is 2 (PSS-2) and for those patients that have 
undergone surgery in > 5 abdominopelvic regions the score is 3 (PSS-3) (Jacquet & 
Sugarbaker, 1996). 
Prior surgical score is a significant prognostic indicator of survival in peritoneal 
sarcomatosis, appendiceal cancer, and peritoneal mesothelioma (Rossi et al, 2004; Jacquet & 
Sugarbaker, 1996; Sebbag et al, 2000). The significance of PSS has been questioned by other 
studies for pseudomyxoma peritonei and peritoneal mesothelioma (Brigand et al, 2006; 
Deraco et al, 2006; Miner et al, 2005; Baratti et al, 2007). In ovarian cancer PSS has been 
identified as a significant prognostic indicator of survival in one study (Look et al, 2004). 
The value of PSS in ovarian cancer is currently under investigation. 
2.4 Completeness of cytoreduction score 
In ovarian cancer the residual tumor is the most significant indicator for long-term survival 
(Hacker et al, 1983; Neijt et al, 1991; Hoskins et al, 1992; Eisenkop et al, 2003; Hunter et al, 
1992; Bristow et al, 2002; Tentes et al, 2006; Piso et al, 2004; Raspagliesi et al, 2006; Di Giorgio 
et al, 2008; Look et al, 2004). Gynecologists oncologists use the terms optimal and 
suboptimal cytoreduction to define the quality of the surgical result. The level of optimal 
cytoreduction has been arbitrarily set from 5 mm to 3 cm. The Gynecologic Oncology Group 
has shown that survival progressively decreases as the residual tumor increases from 
microscopic to 2 cm (Hoskins et al, 1994). As a consequence optimal cytoreduction is defined 
as the operation with no macroscopic residual disease. Survival is not improved if the 
residual tumor is more than 2 cm in its largest diameter and these patients do not survive 
longer than patients with 10 cm residual disease, which means that aggressive surgery such 
as bowel resection is not indicated if the residual tumor can not be less than 2 cm (Hoskins 
et al, 1994). 
The completeness of cytoreduction is a different approach to residual disease. For 
gastrointestinal cancer the completeness of cytoreduction score is defined as CC-0 if no 
macroscopically tumor is left after cytoreductive surgery, as CC-1 if nodules less than 2.5 
mm are left after surgery, as CC-2 if the residual nodules are > 2.5 mm and < 2.5 cm, and as 
CC-3 if tumor nodules > 2.5 cm or a confluence of tumor nodules in the abdomen or in the 
pelvis are left behind after cytoreductive surgery. For high-grade tumors only CC-0 surgery 
is considered to be complete cytoreductive surgery. For low-grade tumors CC-0 and CC-1 
cytoreductions are considered complete cytoreductive operations. 
The completeness of cytoreduction score is the most significant prognostic indicator of 
survival in patients with pseudomyxoma peritonei (Sugarbaker, 2006; Miner et al, 2005; 
Baratti et al, 2007) peritoneal mesothelioma (Yan et al 2007; Sebbag et al, 2000; Brigand et al, 
2006; Deraco et al, 2006), colorectal cancer with peritoneal carcinomatosis (Sugarbaker, 1999; 
Gomez-Portilla et al, 1999) gastric cancer with peritoneal carcinomatosis (Yonemura et al, 
2003), and peritoneal sarcomatosis (Rossi et al, 2004; Berthet et al, 1999). 
The completeness of cytoreduction score in advanced ovarian cancer has been demonstrated 
to be a significant prognostic indicator of survival (Tentes et al, 2003; Tentes et al, 2006; Piso 
et al, 2004; Raspagliesi et al, 2006; Di Giorgio et al, 2008). 
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2.5 Performance status 
Long-term survival in ovarian cancer is related to patient’s performance status (Tentes et al, 
2006). Patients with poor performance status can not tolerate extensive surgery such as 
cytoreductive surgery because of increased morbidity and hospital mortality. The 
preoperative performance status and the extent of the peritoneal carcinomatosis are 
prognostic indicators of hospital morbidity (Reuter et al, 2008) 
3. Treatment of advanced ovarian cancer 
3.1 Cytoreductive surgery-standard peritonectomy procedures 
The most powerful tool in the treatment of the diseases that have already disseminated at 
the peritoneal surfaces is surgical resection of the macroscopically visible tumor. For this 
purpose standard peritonectomy procedures have been used. The initially described six 
peritonectomy procedures (Sugarbaker, 1995) have recently been modified to the: 1) 
epigastric peritonectomy, 2) right subdiaphragmatic peritonectomy, 3)) left 
subdiaphragmatic peritonectomy, 4) greater omentectomy + splenectomy 5) lesser 
omentectomy, 6) pelvic peritonectomy,  7) cholecystectomy and resection of the omental 
bursa, 8) right parietal peritonectomy, 9) left parietal peritonectomy, and 10) resection of 
other organs (antrectomy, colectomy other than low anterior, subtotal colectomy, total 
gastrectomy, segmental intestinal resection) (Sugarbaker, 1999). 
In retrospective studies the residual tumor has been identified as the most significant 
prognostic indicator of survival (Hacker et al, 1983; Neijt et al, 1991; Hoskins et al, 1992; 
Eisenkop, 2003). Meta-analyses have documented the same finding (Hunter et al, 1992; 
Bristow et al, 2002) but no prospective trial has been performed. The feasibility of complete 
cytoreduction using standard peritonectomy procedures in ovarian cancer is 78.4% (Tentes 
et al, 2006; Chi et al, 2004). 
3.1.1 Patient’s position 
The patient is placed in modified lithotomy position. This place provides access to the 
perineum. A hyperthermia blanket is placed on the operating table to warm the patient 
during surgery. A midline incision from xyphoid process to the symphysis pubis is used for 
maximal exposure of the abdominal cavity. 
3.1.2 Epigastric peritonectomy procedure 
Epigastric peritonectomy procedure is used in re-operations and includes wide resection of 
the old scar with the round and the falciform ligament of the liver. Sometimes resection of 
the xyphoid process is required for maximal exposure of the subdiaphragmatic areas. 
3.1.3 Right subdiaphragmatic peritonectomy procedure 
The peritoneum beneath the right hemidiaphragm is stripped until the bare area of the liver 
is encountered. If tumor has seeded the anterior surface of the liver then it is removed 
beneath or through the Glisson’s capsule until the liver surface free of tumor is encountered. 
The tumor beneath the right hemidiaphragm, the right subhepatic space and the surface of 
the liver is removed en-bloc forming an envelope. Laterally on the right the dissection 
includes the peritoneum that covers the right perirenal fat as well as the anterior surface of 
the right adrenal. Eventually the vena cava, and the right hepatic vein form the base of the 
specimen (Figures 2, 3). 
 




Fig. 2. The peritoneum beneath the right hemidiaphragm with the tumor, and the Glisson’s 




Fig. 3. Specimen of the right subdiaphragmatic peritonectomy procedure. The right lobe of 
the liver has been turned to the left. The muscular segment of the right hemidiaphragm is 
exposed free of tumor as well as the anterior surface of the right adrenal and the right 
kidney. The subhepatic inferior vena cava is visualized. 
3.1.4 Left subdiaphragmatic peritonectomy procedure 
All the tumor tissue beneath the left hemiaphragm is stripped until the muscular segment of 
the left hemiaphragm, the anterior surface of the left adrenal, the left kidney, and the tail of 
the pancreas are visualized free of tumor (Figure 4). 
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Fig. 4. Specimen of the left subdiaphragmatic peritonectomy procedure. The spleen has been 
removed. The tail of the pancreas, the undersurface of the left hemidiaphragm, the anterior 
surface of the left adrenal and the left kidney are exposed. 
3.1.5 Greater omentectomy and splenectomy 
The greater omentum dissected from the transverse colon and transverse mesocolon permits 
the exposure of the anterior surface of the body and tail of the pancreas. The branches of the 
right and left gastroepiploic vessels and the short splenic vessels on the greater curvature of 
the stomach are clamped and ligated. The splenic artery and vein at the tail of the pancreas 
are visualized, clamped, divided, and ligated. If the spleen is adherent by tumor of the left 
hemiaphragm then left subdiaphragmatic peritonectomy procedure must be completed 
before the spleen and the greater omentum are released (Figure 5, 6). 
 
 
Fig. 5. Omental cake. 
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Fig. 6. The base of greater omentectomy and splenectomy (greater curvature of the stomach). 
3.1.6 Cholecystectomy and resection of the omental bursa 
The gallbladder is removed from its fundus toward the cystic artery and the cystic duct 
which are ligated, and divided. The anatomical structures of the hepatoduodenal ligament 
are skeletonized and the covering peritoneum is released. The peritoneum that covers the 
anterior surface of the inferior vena cava is stripped with the tumor that seeds the foramen 
of Winslow (Figure 7). 
 
 
Fig. 7. The skeletonized hepatoduodenal ligament and the anterior surface of the inferior 
vena cava below the portal vein are exposed free of tumor. 
3.1.7 Lesser omentectomy 
The lesser omentum is released from the fissure between liver segments 1, 2, and 3, and 
from the arcade of the right to left gastric artery along the lesser curvature of the stomach. 
Combined Cytoreductive Surgery and Perioperative  
Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer 
 
151 
The fat of the lesser omentum with the tumor are separated and released from the vascular 
arcade. The anterior vagus must be preserved as much as possible. An accessory left hepatic 
artery originating from the left gastric artery must also be preserved. After the release of the 
lesser omentum the complete resection of the omental bursa is possible by division of the 
peritoneal reflection of the liver to the left of the subhepatic vena cava which is stripped 
from the superior recess of the omental bursa, from the crus of the right hemidiaphragm, 
and from beneath the portal vein (Figure 8). 
 
 
Fig. 8. The base of lesser omentectomy. The arcade of the right gastric and left gastric artery 
has been preserved. 
3.1.8 Pelvic peritonectomy procedure 
The peritoneum stripped from the posterior surface of the lower abdominal incision allows 
the exposure of the posterior muscular wall of the bladder. The urachus is identified, 
divided, and used for traction of the bladder. In female patients the round ligaments are 
divided at the point they enter the internal inguinal canal bilaterally. Superiorly the 
peritoneum is stripped to the duodenum and the ligament of Treitz. The ureters are 
identified and preserved. In females the ovarian veins are identified and ligated at the lower 
pole of the kidneys while in males the spermatic veins are preserved. The inferior 
mesenteric vein is identified and ligated. The inferior mesenteric artery is also identified and 
ligated just above its origin from the aorta. The colon is divided at the junction of the 
descending to sigmoid colon and this allows the complete separation of the upper and the 
lower abdomen. The mesorectum can be easily dissected with the use of a ball-tip 
electrocautery. The surgeon working in a centripetal fashion may free-up the entire pelvis. 
The uterine vessels are ligated and divided above the ureters and close to the base of the 
bladder. The bladder is freed from the cervix and the vagina is encountered. The vagina is 
divided, the perirectal fat is divided beneath the peritoneal reflection and the tumor 
occupying the cyl-de-sac of Doudlas is removed en-bloc with the specimen. The mid-rectum 
is skeletonized and divided (Figure 9). 
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Fig. 9. The base of pelvic peritonectomy procedure. The vaginal stump has not been sutured 
and is visualized. The bladder is raised by a clamp. The ureters, the sacral bone, and the 
rectal stump are also visualized. 
3.1.9 Bilateral lateral peritonectomy procedure 
The peritoneum behind the rectus abdominal muscle is stripped and the base of the 
specimen is the posterior sheath of the rectus abdominal muscle and the posterior surface of 
the lateral abdominal muscles. 
3.1.10 Resection of other organs 
Antrectomy in addition to other peritonectomy procedures is required if the gastric antrum 
is seeded by tumor. Total gastrectomy is infrequently required in an attempt to achieve 
complete cytoreduction. Segmental intestinal resection or subtotal colectomy with end-
ileostomy may also be performed in order to achieve complete or near complete 
cytoreduction (Stamou et al, 2003). 
3.2 Perioperative intraperitoneal chemotherapy 
Even if the macroscopically visible tumor has been completely removed after maximal 
cytoreductive surgery the microscopic residual tumor will possibly be present at the 
peritoneal surfaces. The disseminated cancer cells adhere to the peritoneal surfaces and are 
covered by fibrin, platelets, polymorphonuclear cells, and monocytes that infiltrate fibrin 
during the healing process. Growth factors released in large amounts stimulate fibroplast 
proliferation and local collagen production, eventually modulating wound healing promote 
cancer proliferation and give rise to secondary tumors within 2-3 years after initial surgery 
(Roberts & Sporn, 1989). In recurrent ovarian cancer it has been demonstrated that in 90% of 
the patients tumor is found in the vaginal cuff and in 60% tumor is found in the lower part 
of the abdominal incision (Sugarbaker TA et al, 1996). 
The concept about the use of intraperitoneal chemotherapy is based upon the properties of 
the peritoneal-plasma barrier. Peritoneal plasma barrier is an anatomical and functional 
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structure. It is consisted by the fluid in the abdominal cavity, the mesothelium, the 
intervening interstitium, and the blood vessel wall (Jacquet et al, 1994; Sugarbaker, 1991). 
Most of the cytostatic drugs are large molecular weight substances that are confined for long 
at the peritoneal surfaces and exert intensively their pharmacologic properties before their 
absorption into the systemic circulation. 
The penetration of intraperitoneal chemotherapy is limited to approximately 1-2 mm into 
tissues and may result in the eradication of the microscopic residual tumor. 
3.2.1 Hyperthermic Intraperitoneal Intraoperative Chemotherapy (HIPEC) 
Hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) enhances cytotoxicity 
and improves drug penetration. The heat itself has antitumor properties. If HIPEC is 
performed with the open abdominal technique (Coliseum technique) the surgeon may 
distribute uniformly the heat and the cytotoxic drugs to the entire peritoneal cavity 
manually (Figure 10). Renal toxicity of intraperitoneal chemotherapy is avoided by careful 
monitoring of urine output during perfusion. Side-effects of systemic chemotherapy 
(nausea, vomiting) are avoided because the patient is under general anesthesia. The time 
that elapses during hyperthermic perfusion normalizes a number of parameters 
(hemodynamics, hemostasis, temperature etc) (Sugarbaker, 2005). 
 
 
Fig. 10. The surgeon distributes heat and cytotoxic drugs manually to all the peritoneal 
surfaces. 
3.2.2 Early Postoperative Intraperitoneal Chemotherapy (EPIC) 
Early postoperative intraperitoneal chemotherapy under normothermia (EPIC) is used with 
the same intent as HIPEC before intra-abdominal adhesions are formed. The method is used 
during the first five postoperative days (Sugarbaker, 2005), because the formation of 
adhesions after days 7-8 do not permit uniform distribution of the cytostatic drugs. The 
distribution of cytostatic drugs is imperfect with EPIC because the undersurface of the right 
hemidiaphragm, the corresponding surface of the right lobe of the liver, the anterior surface 
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of the stomach, the folds of small bowel mesentery, and adherent bowel surfaces, the male 
pelvis, and the abdominal wall are not adequately exposed to cytostatic drugs (Averbach & 
Sugarbaker, 1996). 
The effectiveness of the peritoneal-plasma barrier persists despite extensive stripping of the 
peritoneal surfaces and the pharmacokinetics of intraperitoneal drug delivery is not 
changed (Jacquet.& Sugarbaker, 1996a). These results have been reproduced and confirmed 
by studies on peritoneal transport in experimental animals (Rubin et al, 1988). 
3.2.3 Drugs used in HIPEC 
The combination of cis-platin (50 mg/m2) and doxorubicin (15 mg/m2) is the ideal treatment 
for both primary and recurrent ovarian cancer. For platinum resistant patients gemcitabine 
(1000 mg/m2) or mitomycin-C (10-20 mg/m2) or oxaliplatin (130 mg/m2) or melphalan (50-
70 mg/m2) may alternatively be used. The doses are 33% reduced if aggressive 
chemotherapy has been previously used or the renal function is marginal or the patient is 
above 60 years of age or there has been extensive intraoperative trauma to the small bowel 
surfaces or if irradiation has been previously used (Sugarbaker, 2005). 
3.2.4 Drugs used in EPIC 
5-FU (600 mg/m2) (maximum dose=1400 mg) with 50 meq sodium bicarbonate or 
alternatively paclitaxel (20-40 mg/m2) (maximum dose=80 mg) or docetaxel (20 mg/m2) 
(maximum dose=100 mg) are currently in use during EPIC (Sugarbaker, 2005). 
4. Patient selection for cytoreductive surgery and perioperative 
intraperitoneal chemotherapy 
The combined treatment with the use of cytoreductive surgery and perioperative 
intraperitoneal chemotherapy does not offer benefit to all patients. Therefore proper patient 
selection is required. 
4.1 Inclusion criteria 
Patients are included for cytoreductive surgery and perioperative intraperitoneal 
chemotherapy if they meet the following criteria: 1) performance status > 50% according to 
Karnofsky performance scale, 2) no recent cardiovascular accident, 3) normal hematologic 
profile, 4) normal hepatic and renal function, 5) absence of a second malignancy at risk for 
recurrence (except for skin basal-cell carcinoma or in-situ cancer of the cervix adequately 
treated), 6) absence of chronic or recent acute pulmonary disease, 7) absence of multiple and 
unresectable extra-abdominal metastases. 
4.2 Exclusion criteria 
Patients with: 1) performance status < 50%, 2) severe cardiovascular or pulmonary disease, 
3) white blood cell count < 4000, 4) platelets < 150.000, 5) urea > 50 mg/dl, 6) creatinine level 
> 1.5 mg/dl, 7) abnormal hepatic function, 8) presence of a second malignancy at risk for 
recurrence, 9) pregnancy, 10) drug addiction, 11) presence of tumor at the ligament of Treitz, 
12) multiple segmental intestinal obstruction, 13) presence of multiple and unresectable 
distant metastases, 14) extensive disease at the peritoneal surfaces of the small bowel 
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making impossible a complete or near-complete cytoredution are excluded from treatment 
for cytoreductive surgery and perioperative intraperitoneal chemotherapy. 
Complete hematological and biochemical profile is preoperatively required as well as whole 
body bone scanning for the exclusion of osseous metastases. 
The presence of resectable distant metastases is not an absolute contraindication for 
cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. It has 
been demonstrated that patients with colorectal cancer, peritoneal carcinomatosis, and 
hepatic metastases who may undergo complete cytoreduction, and R0 resection of the 
metastatic lesions are offered significant survival benefit although their long-term 
survival is not equivalent to survival of patients without distant metastases (Elias et al, 
2001). 
4.3 Imaging modalities used to detect the extent and distribution of peritoneal 
malignancy 
All imaging modalities have been used in the past to detect peritoneal malignancy. Plain 
films, ultrasound, magnetic resonance imaging, and CT-scan have been used in excess. CT-
scan of the abdomen and pelvis with oral and intrarectal contrast plus intravenous contrast 
has been the state-of-the-art modality for detecting the extent of the implants of peritoneal 
malignancy (Archer et al, 1996). 
4.3.1 Abdominopelvic Ultrasonography (US) 
The first imaging evaluation of women with ovarian cancer and suspected peritoneal 
carcinomatosis was performed with US (Raptopoulos & Gourtsigiannis, 2001). There is a 
lack of radiation, the examination is easily accepted from the patient and the availability of 
the modality is wide. The accuracy of the method is high in detecting ascites and/or 
peritoneal implants especially at the pelvic walls (Raptopoulos & Gourtsigiannis, 2001; 
Gonzalez-Moreno et al, 2009). The detailed mapping of cancerous implants in entire 
peritoneal cavity is time consuming with low specificity. The results of the examination are 
operator – depended and consequently not always reproducible (Gonzalez-Moreno et al, 
2009). 
4.3.2 Computed Tomography (CT), Computed Tomography-Enteroclysis (CTE) 
CT is the established and worldwide most used imaging method in staging and follow-up of 
patients with peritoneal carcinomatosis because of high image quality, fast throughput of 
examinations and lower cost, than other imaging modalities (i.e. MRI, PET, PET/CT) 
(Raptopoulos & Gourtsigiannis, 2001; Gonzalez-Moreno et al, 2009; Woodward et al, 2004; 
Coakley et al, 2002; Marin et al, 2010). The last few years the development of technology 
with the multi-detectors CT (MDCT) has improved significantly the ability to obtain in 
short-image acquisition very thin slices with high spatial resolution including multiplanar 
or tridimensional reconstructions (Forstner 2007). The ability of CT to detect peritoneal 
dissemination depends on the size and morphology of the peritoneal implants. The 
diagnostic accuracy of CT even MDCT for detecting peritoneal implants is decreased 
dramatically for lesions smaller than 0.5 cm or for those with a “layered – type” form 
covering the gastrointestinal tube and especially the small bowel (Gonzalez-Moreno et al, 
2009; Coakley et al, 2002). 
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of the stomach, the folds of small bowel mesentery, and adherent bowel surfaces, the male 
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recurrence, 9) pregnancy, 10) drug addiction, 11) presence of tumor at the ligament of Treitz, 
12) multiple segmental intestinal obstruction, 13) presence of multiple and unresectable 
distant metastases, 14) extensive disease at the peritoneal surfaces of the small bowel 
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making impossible a complete or near-complete cytoredution are excluded from treatment 
for cytoreductive surgery and perioperative intraperitoneal chemotherapy. 
Complete hematological and biochemical profile is preoperatively required as well as whole 
body bone scanning for the exclusion of osseous metastases. 
The presence of resectable distant metastases is not an absolute contraindication for 
cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. It has 
been demonstrated that patients with colorectal cancer, peritoneal carcinomatosis, and 
hepatic metastases who may undergo complete cytoreduction, and R0 resection of the 
metastatic lesions are offered significant survival benefit although their long-term 
survival is not equivalent to survival of patients without distant metastases (Elias et al, 
2001). 
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scan of the abdomen and pelvis with oral and intrarectal contrast plus intravenous contrast 
has been the state-of-the-art modality for detecting the extent of the implants of peritoneal 
malignancy (Archer et al, 1996). 
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The first imaging evaluation of women with ovarian cancer and suspected peritoneal 
carcinomatosis was performed with US (Raptopoulos & Gourtsigiannis, 2001). There is a 
lack of radiation, the examination is easily accepted from the patient and the availability of 
the modality is wide. The accuracy of the method is high in detecting ascites and/or 
peritoneal implants especially at the pelvic walls (Raptopoulos & Gourtsigiannis, 2001; 
Gonzalez-Moreno et al, 2009). The detailed mapping of cancerous implants in entire 
peritoneal cavity is time consuming with low specificity. The results of the examination are 
operator – depended and consequently not always reproducible (Gonzalez-Moreno et al, 
2009). 
4.3.2 Computed Tomography (CT), Computed Tomography-Enteroclysis (CTE) 
CT is the established and worldwide most used imaging method in staging and follow-up of 
patients with peritoneal carcinomatosis because of high image quality, fast throughput of 
examinations and lower cost, than other imaging modalities (i.e. MRI, PET, PET/CT) 
(Raptopoulos & Gourtsigiannis, 2001; Gonzalez-Moreno et al, 2009; Woodward et al, 2004; 
Coakley et al, 2002; Marin et al, 2010). The last few years the development of technology 
with the multi-detectors CT (MDCT) has improved significantly the ability to obtain in 
short-image acquisition very thin slices with high spatial resolution including multiplanar 
or tridimensional reconstructions (Forstner 2007). The ability of CT to detect peritoneal 
dissemination depends on the size and morphology of the peritoneal implants. The 
diagnostic accuracy of CT even MDCT for detecting peritoneal implants is decreased 
dramatically for lesions smaller than 0.5 cm or for those with a “layered – type” form 
covering the gastrointestinal tube and especially the small bowel (Gonzalez-Moreno et al, 
2009; Coakley et al, 2002). 
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The assessment of the extent and distribution of the peritoneal carcinomatosis is possible 
with CT which provides sufficient sensitivity and specificity. However, the sensitivity and 
specificity at the peritoneal surfaces of the small bowel and its mesentery are not sufficient 
(Raptopoulos & Gourtsigiannis, 2001; Gonzalez-Moreno et al, 2009; de Bree et al, 2004). 
Disease at the small bowel constitutes a sentinel, limiting criterion in the decision making 
process involved cytoreduction because sufficient length of small bowel must remain in 
place to allow for adequate oral nutrition in the future. Once the extent of peritoneal 
malignancy at the small bowel is the limit of cytoreductive surgery, the evaluation of the 
small bowel is a crucial component in the preoperative imaging assessment. Experience tells 
us that even the most sophisticated CT technology usually underestimates actual small 
bowel involvement revealed at surgical exploration (Gonzalez-Moreno et al, 2009; de Bree et 
al, 2004). 
Implants of less than 1 cm in size are detected with sensitivity 25-50% when helical-CT is 
used (Gonzalez-Moreno et al, 2009; de Bree et al, 2004). Multi-detectors CT yield a mean 
sensitivity of 89% for implants larger than 0.5 cm. The sensitivity decreases to 43% for 
lesions less than 0.5 cm (Marin et al, 2010). 
CTE has been defined as “small bowel distention” by administration of high volume of 
contrast medium via a naso-gastro-jejunal catheter followed by axial CT acquisition 
(Maglinte et al, 2007). Thus, CTE is a hybrid technique combining the advantages of 
conventional enteroclysis and those of CT. The cancerous implants attached to the 
partially distended intestinal loops, sometimes with insufficient quantity of enteral 
contrast on conventional CT are very difficult to be depicted. Severe involvement of the 
entire segments of the small bowel manifested as remarkable wall thickness cannot be 
revealed, if the intestinal loops are not well-distended. Thus, the study of the small bowel 
and its mesentery could be more accurate, in detail and facilitated having simultaneously 
information for both the extent and the distribution of cancerous implants within the 
peritoneal cavity. At the surface of the stretched loops, the tiny or small in size implants 
may be depicted. Even, the “layered-type” of small bowel involvement may be 
demonstrated as remarkable thickness of the strongly enhancing intestinal wall. Small 
bowel loops dilatation allows mesentery unfolding and consequently the easier 
demonstration of implanted cancerous lesions. 
CTE in patients with peritoneal malignancy is currently under extensive investigation. In a 
prospective study, forty-five consecutive patients (34 women, 11 males, mean age=57.02 
years) with peritoneal malignancy of different primaries who were candidates for 
cytoreductive surgery and HIPEC underwent CTE before surgery. A modified CTE-
Peritoneal Carcinomatosis Index (CTE-PCI) was applied to score the lesion size of the 
nodules at the small bowel surfaces.  CTE-PCI was correlated with surgical–PCI.  High 
sensitivities and specificities were estimated for each part of the small bowel. The sensitivity 
was 87.5%, 91.3%, 92.3%, 90%, and the specificity was 95.2%, 95.4%, 94.7%, 100% for 
proximal jejunum, distal jejunum, proximal ileum, and distal ileum respectively. The 
average sensitivity was 90.3±2.1%, and the average specificity was 96.3±2.5% for the entire 
small bowel. The kappa coefficient of agreement was found to be statistically significant 
(p<0.0001) in all four parts ranging from 0.597 for proximal jejunum, 0.663 for distal 
jejunum, 0.470 for proximal ileum, to 0.752 for distal ileum (mean kappa=0.621 ± 0.119) 
(Courcoutsakis et al, 2010a; Courcoutsakis et al, 2010b) (Figures 11, 12). 
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4.3.3 Magnetic Resonance Imaging (MRI) 
There are few studies comparing CT to MRI in the peritoneal carcinomatosis evaluation. It 
has been shown that MRI has significantly improved sensitivity for depicting tumor 
involving the peritoneum even the subtle peritoneal implants (Forstner, 2007; Low, 2000). 
In patients with ascites the evaluation of visceral and parietal peritoneum is allowed 
(Gonzalez-Moreno et al, 2009; Forstner, 2007; Low, 2000). Compared with CT scan, MRI 
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has lower spatial resolution, the acquisition time is longer and influenced by respiratory 
movement artifacts. On MRI may be obtained multiplanar and tridimensional 
reconstructions. The clinicians find it harder to interpret, the availability is limited, and 
the cost is higher. For the evaluation of cancerous implants within the peritoneal cavity 
specific sequences are needed (i.e. fat-suppression techniques, spoiled-gradient–echo 
sequence) and the i.v. infusion of gadolinium for tissue enhancement (Gonzalez-Moreno 
et al, 2009).  
The recently introduced MR technique “diffusion-weighted imaging” (DWI) provides 
quantitative information about tissue cellularity and exploits the restricted water mobility 
within hypercellular tumors to increase the contrast between these lesions and surrounding 
tissue.  DWI of the peritoneum in patients with ovarian cancer may be helpful for mapping 
the disease sites, their extent and differentiating tumors from treatment – induced changes 
(Kyriazi et al, 2010).  Larger cohorts are needed to establish the role of the MRI-DWI in 
peritoneal carcinomatosis. 
4.3.4 18 Fluoro Deoxyglucose Positron Emission Tomography (PET), PET/CT 
PET has been introduced in the clinical praxis the last decade provoking an innovation in 
diagnostic oncology. PET uses nuclear medicine in measuring the metabolic assessment of 
the tumors by counting the selective uptake of the intravenously administrated 18 Fluoro-
Deoxyglucose. The disadvantages of the method are the poor anatomic resolution, and the 
non infrequent false positive results. The deficit of the poor spatial resolution is overcome 
by PET/CT. It has been reported that this hybrid technique is more accurate than PET or CT 
alone (Gonzale-Moreno et al, 2009, Satoh et al, 2011).  This hybrid technique PET/CT may 
not be commonly used because of disadvantages such as the large size and the high cost of 
the system, the high cost of the examination, and time expended by the patient (Satoh et al, 
2011). There have been only few reports of comparisons of DWI and PET, and the 
conclusions are controversial (Satoh et al, 2011). 
5. Hospital morbidity-mortality 
Cytoreductive surgery with perioperative intraperitoneal chemotherapy is associated with 
high morbidity rate and low mortality rate. The majority of postoperative complications are 
due to surgery itself. The last decade systemic chemotherapy integrated in this combined 
treatment has increased the rate of chemotherapy complications which are frequently easily 
reversed. A large multi-institutional study in patients with peritoneal malignancy of 
colorectal cancer origin revealed that major complications occurred in approximately 23% of 
the patients (Glehen et al, 2004). The extent of peritoneal carcinomatosis, and the use of EPIC 
significantly increase the risk of major complications, as well as the combination of HIPEC 
and EPIC (Glehen et al 2003; Stephens et al, 1999; Glehen et al, 2003). The most frequent 
complications are anastomotic leaks or bowel perforation (Glehen et al 2004; Stephens et al, 
1999; Glehen et al, 2003; Younan et al, 2005; Kusamura et al, 2006). Other important variables 
related to postoperative morbidity are the duration of surgery and the number of the 
performed anastomoses (Stephens et al, 1999). Hematological toxicity is low and does not 
usually exceed 4% (Stephens et al, 1999). 
The rate of postoperative complications in cytoreductive surgery combined with HIPEC 
does not usually exceed 30-35% although a morbidity rate of 54% has been referred in one 
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study (Elias et al, 2001). The same high rate of morbidity has been recorded in patients with 
ovarian cancer treated with cytoreduction and perioperative intraperitoneal chemotherapy 
(Tentes et al, 2003; Tentes et al, 2006; Raspagliesi et al, 2006; Di Giorgio et al, 2008; Tentes et 
al, 2010). 
In properly selected patients the mortality rate is not high and does not exceed 5% (Piso et 
al, 2004; Raspagliesi et al, 2006; Tentes et al, 2010). However, if the patients are not properly 
selected the mortality rate increases dramatically (Tentes et al, 2006). In non-properly 
selected patients the age > 65 years and the performance status were found to be related to 
mortality, in addition to extensive peritoneal carcinomatosis that was not completely 
cytoreduced (Table 1). 
 
 






fistula bleeding sepsis mor-tality 
Ryu 57 - 7% - - 5% 3% 
Rufian 33 - 3% - 3% - 0% 
Di 
Giorgio 47 NR - 7% 4% NR 4.2% 
Ras-
pagliesi 40 7.5% 2.5% - - - 8% 
Piso 19 - 10% - 5% 5% 5% 
Zanon 30 6% 6% - 5% - 3.3% 
de Bree 19 0% - -   10% 
Bae 67 13% NR NR NR NR 0% 
Tentes 29 .9% 10.3% 0% 0% 0% 3.4% 
Ceelen 42 NR NR NR NR NR 0% 
NR=not reported 
Table 1. Major morbidity and mortality rates in cytoreductive surgery combined with 
HIPEC in patients with primary or recurrent ovarian cancer. 
6. Survival 
Several clinical variables have been identified to be related to long-term survival. The 
completeness of cytoreduction, and the extent of peritoneal dissemination are consistently 
found to be significant prognostic indicators of survival (Tentes et al, 2003; Piso et al, 2004; 
Gilly et al, 2006; Di Giorgio et al, 2008; Tentes et al, 2010; Zanon et al, 2004; Rufian et al, 
2006). Prior surgical score has been identified as a prognostic indicator of survival in one 
study (Look et al, 2004). 
Median and 5-year survival rate varies from 18-54 months and 12-66% respectively (Piso et 
al, 2004; Raspagliesi et al, 2006; Di Giorgio et al, 2008; Tentes et al 2010, Ryu et al, 2004; 
Zanon et al, 2004; Rufian et al, 2006; de Bree et al, 2003; Bae et al, 2007; Ceelen et al, 2009) 
(Table 2). All these studies are prospective but not randomized (evidence level 4) and 
demonstrate that the method is feasible, well tolerated by the patients, and the results are 
equivalent or even improved if compared to historical data. 
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study (Elias et al, 2001). The same high rate of morbidity has been recorded in patients with 
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1st author year Patients No Median FU Median survival 5-year 
survival 
Ryu 2004 57 47 NR 54 
Rufian 2006 33 NR 48 37 
Di Giorgio 2008 47 NR 24 16.7 
Raspagliesi 2006 40 26 32 12 
Piso 2004 19 24 18 15 
Zanon 2004 30 19 28 12 
de Bree 2003 19 30 54 42 
Bae 2007 67 NR NR 66 
Tentes 2010 29 34 34 30 
Ceelen 2009 42 NR 37 41.3% 
NR=not reported 
Table 2. Median follow-up, median and 5-year survival rate in cytoreductive surgery 
combined with HIPEC for ovarian cancer. 
7. Recurrence 
The incidence of recurrence is high in ovarian cancer and varies from 42-48% (Di Giorgio et 
al, 2008; Tentes et al, 2010). The majority of recurrences are loco-regional. The extent of 
peritoneal carcinomatosis is a prognostic indicator of recurrence (Tentes et al, 2010), and less 
than 30% of patients with low PCI (<13) develop recurrence. 
8. Conclusions 
Maximal cytoreductive surgery using standard peritonectomy procedures combined with 
perioperative intraperitoneal chemotherapy is an effective and promising treatment strategy 
in women with locally advanced epithelial ovarian cancer. The extent of peritoneal 
carcinomatosis and the completeness of cytoreduction are the most significant prognostic 
variables of survival. Proper patient selection is required for women with primary or 
recurrent ovarian cancer because only those women with limited peritoneal carcinomatosis 
may undergo complete cytoreduction and may be offered significant survival benefit. A 
useful tool in patient selection is CT-enteroclysis that shows to have higher sensitivity and 
specificity in the detection of peritoneal malignancy at the peritoneal surfaces of the small 
bowel compared to CT-scan. 
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1st author year Patients No Median FU Median survival 5-year 
survival 
Ryu 2004 57 47 NR 54 
Rufian 2006 33 NR 48 37 
Di Giorgio 2008 47 NR 24 16.7 
Raspagliesi 2006 40 26 32 12 
Piso 2004 19 24 18 15 
Zanon 2004 30 19 28 12 
de Bree 2003 19 30 54 42 
Bae 2007 67 NR NR 66 
Tentes 2010 29 34 34 30 
Ceelen 2009 42 NR 37 41.3% 
NR=not reported 
Table 2. Median follow-up, median and 5-year survival rate in cytoreductive surgery 
combined with HIPEC for ovarian cancer. 
7. Recurrence 
The incidence of recurrence is high in ovarian cancer and varies from 42-48% (Di Giorgio et 
al, 2008; Tentes et al, 2010). The majority of recurrences are loco-regional. The extent of 
peritoneal carcinomatosis is a prognostic indicator of recurrence (Tentes et al, 2010), and less 
than 30% of patients with low PCI (<13) develop recurrence. 
8. Conclusions 
Maximal cytoreductive surgery using standard peritonectomy procedures combined with 
perioperative intraperitoneal chemotherapy is an effective and promising treatment strategy 
in women with locally advanced epithelial ovarian cancer. The extent of peritoneal 
carcinomatosis and the completeness of cytoreduction are the most significant prognostic 
variables of survival. Proper patient selection is required for women with primary or 
recurrent ovarian cancer because only those women with limited peritoneal carcinomatosis 
may undergo complete cytoreduction and may be offered significant survival benefit. A 
useful tool in patient selection is CT-enteroclysis that shows to have higher sensitivity and 
specificity in the detection of peritoneal malignancy at the peritoneal surfaces of the small 
bowel compared to CT-scan. 
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1. Introduction 
Estimated, 225,000 new cases of ovarian cancer in the world in 2011, with approximately 
140,000 deaths. In the United States of America, ovarian cancer is the second most 
gynecological cancer. It is the most common cause of gynecological cancer related death 
primarily because most patients present with advanced disease. 65-70% of patients are 
diagnosed at an advanced stage, conferring a 5-year survival rate of 30-55%. Epithelial 
ovarian cancer (EOC) remains the most lethal gynecologic cancer in the United States. In 
2010, approximately 21,880 new cases and 13,850 deaths occurred. There is no proven 
screening test for this disease. Many women present with vague symptoms, including 
abdominal bloating, change in bowel or bladder habits, early satiety, or abdominal pain. It is 
diagnosed at advanced stage for about 75% of patients [1]. It spreads along the peritoneal 
surfaces to the upper abdomen by direct extension or by peritoneal implantation [2]. 
Metastases to the diaphragm, especially to the right hemi-diaphragm, are common in 
patients with advanced ovarian cancer. About 40% of patients with advanced ovarian cancer 
present with bulky metastatic diaphragmatic disease. About 19% of patients are diagnosed 
with International Federation of Obstetrics and Gynecology (FIGO) [Table 1.] stage I disease, 
in which the tumor is confined to one or both ovaries. (1). Stage I disease is usually 
diagnosed incidentally during laparoscopic or laparotomy surgery for benign-looking 
ovarian tumors, but, following complete staging, it is upstaged in 30% of patients due to 
microscopic metastatic disease.(2,3 ). FIGO guidelines have stated that the standard 
management for apparent early-stage disease is complete surgical staging, including total 
abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph 
node dissection, infracolic omentectomy, multiple peritoneal washing, and multiple 
peritoneal biopsies (4). Initial evaluation includes a thorough history and physical 
examination, imaging studies such as MRI and computerized tomography scanning, 
assessment of tumor markers such as CA-125, biopsies, cystoscopy and colonoscopy. The 
standard treatment for primary ovarian cancer consists of maximum cytoreductive effort to 
reduce residual tumor (RT), followed by platinum-based chemotherapy (3, 4). It has been 
shown that cytoreduction has a more significant influence on survival than the extent of a 
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metastatic disease observed before surgery (5). This target has value in the primary 
cytoreduction (3), and in interval debulking surgery after neoadjuvant chemotherapy (6), in 
addition to in secondary cytoreduction in platinum-sensitive recurrent ovarian cancer 
patients (7). Extensive upper abdominal debulking surgery increases the rate of optimal 
cytoreduction and it is related with improved survival rates in advanced ovarian cancer 
undergoing primary cytoreduction and interval debulking surgery (8). Hepatic resection (9), 
splenectomy (10) and (11), video-assisted thoracic surgery (12), and diaphragmatic resection 
(13), (14), (15), (16), (17), (18) and (19) have been considered as components of primary 
cytoreduction when necessary.  
 
Stage I: Growth limited to the ovaries 
IA Growth limited to one ovary: no ascites present containing malignant cells. No tumor 
on the external surface; capsule intact. 
IB Growth limited to both ovaries: no ascites present containing malignant cells. No 
tumor on the external surfaces; capsules intact. 
IC* Tumor either stage IA or IB, but with tumor on surface of one or both ovaries, or with 
capsule ruptured, or with ascites present 
containing malignant cells, or with positive peritoneal washings. 
Stage II: Growth involving one or both ovaries with pelvic extension. 
IIA Extension and/or metastases to the uterus and/or tubes. 
IIB Extension to other pelvic tissues. 
IIC* Tumor either stage IIA or IIB, but with tumor on surface of one or both ovaries, or 
with capsule(s) ruptured, or with ascites present 
containing malignant cells, or with positive peritoneal washings. 
Stage III: Tumor involving one or both ovaries with histologically confirmed peritoneal 
implants outside the pelvis and/or positive retroperitoneal 
or inguinal nodes. Superficial liver metastases equals stage III. Tumor is limited to the 
true pelvis but with histologically proven 
malignant extension to small bowel or omentum. 
IIIA Tumor grossly limited to the true pelvis, with negative nodes, but with histologically 
confirmed microscopic seeding of abdominal 
peritoneal surfaces, or histologic proven extension to small bowel or mesentery. 
IIIB Tumor of one or both ovaries with histologically confirmed implants, peritoneal 
metastasis of abdominal peritoneal surfaces, none 
exceeding 2 cm in diameter; nodes are negative. 
IIIC Peritoneal metastasis beyond the pelvis > 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
Stage IV: Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a 
case to stage IV. Parenchymal liver metastasis equals stage IV. 
* In order to evaluate the impact on prognosis of the different criteria for allotting cases to 
stage IC or IIC, it would be of value to know if rupture of the 
capsule was spontaneous, or caused by the surgeon; and if the source of malignant cells 
detected peritoneal washings, or ascites. 
 
Table 1. Carcinoma of the ovary:  figo classification ( rio de janerio 1988) 
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2. Minimally invasive surgery in advanced ovarian cancer 
Laparoscopic assisted surgery can be utilized in the surgical management of apparent early-
stage ovarian cancer, in assessing resectability of advanced disease prior to laparotomy, and 
also in second-look procedures. 
Several studies showed that laparoscopy is safe and feasible in the surgical management of 
apparent early-stage ovarian cancer. (20-23) In a Study comparing laparoscopic treatment of 
gynecologic malignancies with traditional laparotomy for early-stage ovarian cancer, it was 
observed (24) that the acceptable survival rates with decreased morbidity and shorter 
hospitalization: 91.6% with disease-free survival and overall survival of 100% at 46 months. 
The advantages of laparoscopy are faster recovery with early return of bowel function and a 
shorter hospital stay. Laparoscopy can be useful, when deciding whether to proceed with 
primary cytoreductive surgery or neoadjuvant chemotherapy in advanced epithelial ovarian 
cancer. In a study of 87 patients who underwent diagnostic laparoscopy, 53 were considered 
resectable.(25). Of these 53 patients, 96% were optimally cytoreduced. Laparoscopy seems to 
be an acceptable method for assessing disease resectability. Operative time of 120 to 240 
minutes has been reported with laparoscopic staging of ovarian cancer (26). Surgical 
complications could include vascular and gastrointestinal injuries, and possibly port site 
metastases (27). There is a concerqn that ovarian cancer mass my rupture while trying to 
remove it. Ovarian cyst rupture has been reported in 12% to 25% of patients undergoing 
laparoscopy(,28,29) and rupture may cause intra-abdominal dissemination. Several studies 
have suggested that cyst rupture increase recurrence rate and decrease survival (30,31). To 
avoid any spillage, the ovarian mass should be placed in a laparoscopic bag and retrieved 
through the umbilical port or through a colpotomy. Minimally invasive robot- assisted 
laparoscopic surgery, utilizing da Vinci surgical system ( Figures 1 and 2), has been 
employed to duplicate traditional open procedures via small incisions in the skin with 
surgical outcomes equivalent or superior to a traditional surgical approach. Robotic surgery 
enables the operator to control the robotic system alone and to perform more precise and 
complex operations. The da Vinci Surgical System provides surgeons with 1) intuitive 
translation of the instrument handle to the tip movement, thus eliminating the mirror-image 
effect, 2) visualization with high quality 3-dimensional images and stable camera platform, 
3) scaling, 4) tremor filtering, 5) coaxial alignment of eyes, hand, and tooltip images, 6) 




Fig. 1. Da Vinci Surgical System 
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Fig. 1. Da Vinci Surgical System 
 




Fig. 2. Robotic platform docked off patient’s right shoulder in 10 degree reverse 
Trendelenburg position, and 10 degree rotation to left. 
It has been demonstrated that minimally invasive surgery is associated with less blood loss , 
shorter hospital stay, less post operative pain , improved cosmesis, and faster recovery 
compared to traditional approaches (32), (33). 10 cases were reported with an operative time 
of 207 minutes, blood loss of 355 cc and nodal yield of 27 (34). It was observed that the 
operative time in robotic radical hysterectomy was 241 minutes and blood loss of 71 cc, and 
no conversion to laparotomy reported (35). 
3. Laparoscopic assesment of disease extent and potential for resectability 
Staging laparoscopy (S-LPS) has been shown to predict optimal cytoreduction in primary 
and recurrent ovarian cancer (36), (37), (38), (39). It has been shown that an objective 
evaluation of the complete debulking is available for primary advanced cases utilizing a 
laparoscopic predictive index score (40- 41). In addition, the inclusion of S-LPS can reduce 
the risk of explorative laparotomies to about 10%, with respect to 20% and 30% obtained 
with the classical criteria of evaluation of response. S-LPS could increase optimal 
cytoreduction in 20% of patients with stable disease. The explanation to this, could be the 
presence of radiological artifacts due to the effects of chemotherapy, such as adherences or 
fibrosis secondary to tumor shrinkage, which would probably alter the diagnostic 
performances of conventional images. The laparoscopic predictive score of surgical outcome 
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has been shown to be reliable in selected group of patients (41-42). The laparoscopic 
parameters meeting the inclusion criteria have been mesenteral retraction, bowel and 
stomach infiltration, and superficial liver metastases. Excluding bowel infiltration, these 
results confirmed others (43-44). It is clear that, S-LPS has an important role in the prediction 
of optimal cytoreduction in advanced ovarian cancer patients at primary diagnosis. 
4. Laparoscopic re-assesment and 2nd look surgery 
Second-look surgical reassessments in patients with advanced ovarian cancer have been 
performed to identify patients who had a complete pathologic response to chemotherapy, as 
demonstrated by numerous biopsies that were negative for persistent cancer. . The surgical 
method involved a laparotomy with extensive exploration of the abdomen, including 
multiple peritoneal washings, multiple biopsies, and, more than often, additional 
retroperitoneal lymph node sampling (45). With the current chemotherapy regimens, 75 - 
80% of patients with optimally cytoreduced disease have a complete clinical response to 
primary chemotherapy, but only 50% of these patients are found to have a negative second 
look (46),(47). About one-half of all patients, who achieve a negative second look develop 
recurrent disease. It has been shown that, there is no survival benefit to the second-look 
procedure (48-51). Laparoscopy had been used to perform second-look evaluations in 
patients with ovarian cancer. Initial studies of second look by laparoscopy reported 
inadequate visualization; a high false-negative rate of between 11 and 55%; a high rate of 
complications, primarily bowel injuries, of 2 to 9%; and a higher recurrence rate following 
negative second-look laparoscopy (52 –55). More recent studies, however, have shown that 
laparoscopic second-look evaluations are equivalent to those performed by laparotomy, but 
are associated with significantly lower blood loss, decreased operating time, short hospital 
stay, and decreased hospital charges (56), (57). The current purpose of laparoscopic second-
look surgery is to identify 3 patients categories: (1) those with microscopic diseases, (2) those 
with resectable disease that can successfully be rendered microscopic, and (3) those with 
gross, unresectable disease. In general, laparoscopy is an efficient and accurate technique for 
surgical reassessment following primary therapy in advanced ovarian cancer patients. 
Despite initial good response rates with primary chemotherapy, the majority of patients 
with advanced ovarian cancer will die of their disease. As approximately 50% of patients 
with a pathologically negative second look will eventually suffer from recurrent disease, as 
these patients all have microscopic disease. Studies have found, that patients with 
microscopic disease at second-look surgical reassessment have a good prognosis and a 5-
year survival rate of 50 to 70% with continued therapy. Furthermore, patients who are 
successfully cytoreduced to microscopic disease at the time of second look have a prognosis 
equivalent to those found to have microscopic disease (58–61). Therefore, this group 
represents a subset of patients who have an overall better prognosis and may potentially be 
curable with effective therapy. Studies have suggested a potential benefit to 
consolidation/salvage therapy in this group of patients (62,63). It appears that microscopic 
disease may be missed by laparoscopy compared with laparotomy, but as all patients in this 
group (both negative-second-look and microscopically positive second-look patients) may 
benefit from consolidation therapy, the small advantage of a more accurate diagnosis of 
microscopic disease does not warrant laparotomy. It has been shown that, the rate of 
positive retroperitoneal nodes as the only evidence of disease at second look was only 3.8% 
(64). Several studies have shown that second-look laparoscopy was considered a promising 
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candidate to replace second-look laparotomy which has been considered as standard 
treatment (65-67). In most initial studies which were conducted involving a small number of 
patients, second look laparoscopy did not produce satisfactory results and inappropriate 
operative field was reported to reach up to 12% and resulted in a false negative rate between 
29.1% and 55% (65,68,69). It has been shown that patients in complete remission after 
chemotherapy underwent laparotomy and histological examination right after suspicious 
lesions were detected by second-look laparoscopy. As a result, the positive and negative 
predictive values of laparoscopy were 100% (six of six cases) and 86% (two false-negative 
out of 14 cases), respectively. Thorough observation of intraperitoneal lesions was available 
in 95% of patients in the LT group and only in 41% of patients in the LPS group due to 
intraperitoneal adhesions after previous surgeries. Though this study has some limitations 
in which postoperative survival rates were not compared with the results of the operation, it 
suggested that second look laparoscopy was less reliable than second-look laparotomy (67). 
Russo reported similar results (70). In a retrospective study by Husain on 150 cases of 
second look laparoscopy (71), the procedure was reported to be safe and accurate as a 
second-look operation. Also, the authors observed that the complication rates were 
reportedly low when laparoscopy was performed on patients who had received a primary 
debulking operation, and the recurrence rates of laparoscopic 
second-look in patients with histologically negative findings and a negative predictive value 
were also reported to be equivalent to those in patients who 
underwent laparotomic second-look (71). Second-look laparoscopy is thought to have 
disadvantages including limited access to lesions due to adhesions formed after previous 
surgeries, inappropriate operative fields and difficulty in manual examination of lesions. 
However, it has several advantages to offset these disadvantages. These are: 
1. When using second-look laparoscopy not for removal of lesions but for diagnosis, the 
preoperative imaging procedure enables the extent and duration of operation to be 
predicted equivalently to those in non-invasive surgery, 
2. Enlarged laparoscopic images enable the detection of minute lesions, 
3. A certain degree of adhesion due to previous surgeries does not affect the performance 
of experienced laparoscopists (76), (77). 
Currently, advanced laparoscopic procedures are increasingly being 
utilized as an alternative to laparotomy in gynecological surgery.(72-74). A meta-analysis of 
27 prospective randomized trials has proven the benefits of laparoscopic compared with 
abdominal gynecologic surgery: decreased pain, decreased surgical-site infections 
(decreased relative risk 80%), decreased hospital stay (2 days less), quicker return to activity 
(2 weeks sooner), and fewer postoperative adhesions (decreased 60%).(75) 
5. Minimally invasive thoracic surgery for patients with advanced ovariian 
cancer 
In advanced and recurrent ovarian cancer, the presence of macroscopic intrathoracic disease 
may alter patient management, particularly if less than 1–2 cm intrathoracic tumor deposits. 
That would leave the patient with suboptimal residual disease at the conclusion of 
maximum intra-abdominal cytoreduction. It has been reported that rate of optimal primary 
debulking ranges from 27% to 51% (78), (79) and (80). The benefits of debulking in patients 
with malignant pleural effusions compared with other stage IV disease criteria have been 
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evaluated. In a study of 84 patients with stage IV disease, including 38% of those patients 
with malignant pleural effusions, in a study it was reported a median survival of 38.4 
months in optimally debulked patients (≤ 1 cm) and 10.3 months for patients with 
suboptimal residual disease (P = 0.0004) (79). On univariate analysis, there was no difference 
in median survival comparing patients with pleural effusion and other stage IV criteria. 
Although several retrospective reviews have demonstrated a survival benefit to optimal 
intra-abdominal debulking in patients with malignant pleural effusions, these patients still 
have decreased survival when compared with patients who have disease confined to the 
abdomen. Evaluating optimally cytoreduced stage IIIC and stage IV patients, it has been 
reported (82) reported a median survival of 58 months for patients who had stage IIIC 
disease and 30 months for patients with stage IV disease (p = 0.016). In patients with 
symptomatic malignant pleural effusions, video-assisted thoracic surgery (VATS) provides 
therapeutic benefits, as thoracoscopic pleurodesis is an effective technique for performing 
pleurodesis, particularly when using talc as the sclerosant. It was observed that the use of 
more extensive ablative techniques and radical upper abdominal procedures is required to 
achieve optimal cytoreduction (83). The involvement of the diaphragm in patients with 
ovarian cancer is the limiting factor preventing optimal cytoreduction (84). Diaphragmatic 
superficial tumor studding can be ablated or resected using diaphragmatic peritonectomy. 
Several authors have described the use of extensive diaphragmatic resections for full 
thickness or deeply invasive diaphragmatic disease (85, (86). VATS may be helpful in 
evaluating the extent of superficial and full thickness diaphragmatic disease and can then be 
used to plan appropriate intra-abdominal surgical approaches. In patients with isolated 
pleural-based disease, VATS can also facilitate intrathoracic cytoreduction. The outcomes of 
30 patients who underwent thoracoscopy either by a transdiaphragmatic approach at 
laparotomy was observed, or through the chest wall prior to a planned abdominal 
procedure (81). In this series, 33% (10/30) underwent pleural implant ablation and/or 
tumor excision, which influenced the final cytoreductive outcome (87). VATS should be 
considered for incorporation into the standard management algorithm for patients with 
advanced ovarian cancer and pleural effusion. The rate of pleural involvement is 
underestimated in patients with advanced ovarian cancer. Preoperative computed 
tomography (CT) identified only one third of patients who had macroscopic pleural nodules 
by video-assisted thoracoscopy (VAT) (88). Occult pleural involvement may be present in up 
to 84% of patients with abdominal diaphragmatic involvement. (89). Without routine pleural 
exploration, failure to remove thoracic lesions occurs in up to one third of patients (89). It has 
been reported that VAT is feasible and safe in patients with advanced ovarian cancer (87).  
Pleural metastases are common in patients with ovarian malignancies and pleural effusions. 
Previously reported rates range from 42% to 65%, Video-assisted thoracoscopy is better than 
CT for evaluating pleural involvement. In a retrospective study of 12 patients with large 
pleural effusions, chest CT detected pleural lesions in only 2 of 6 patients who had pleural 
disease by VAT.(87).  
Routine examination of the pleural cavity may improve staging accuracy, even in patients 
with limited abdominal involvement. In another study, the result of VAT influenced 
treatment decisions in 33% of patients, (87).  
Pleural involvement has been shown to influence patient outcomes (90). In a retrospective 
study, median survival after optimal cytoreductive surgery was 58 months in patients with 
stage IIIC disease and 30 months in those with stage IV disease (P = 0.016). This survival 
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difference may be attributed to residual intrathoracic disease responsible for decreased 
efficacy of complete abdominal cytoreduction or to tumor aggressiveness in patients with 
stage IV disease. Extensive thoracic cytoreductive surgery has been suggested in 
combination with abdominal surgery. It has been reported (91) that performing VAT may 
translate into therapeutic benefits in 30% of cases. Other studies found better survival in 
patients who underwent complete cytoreductive surgery (91), (92).  
Ovarian cancer usually spreads along different routes: lymphatic, haematogenous and 
transcaelomic. One of its features is the possible peritoneal and pleural dissemination. 
Mediastinal lymph node metastasis predicts poor prognosis (93). CPLN colonization is 
frequently associated with intrathoracic disease, which presents as right-sided pleural 
effusion. This is explained by the anatomic arrangement of abdominal lymphatic drainage, 
which follows a clockwise route, involving first the thoracic lymphatic stations on the right 
side. Metastatic calcification of supradiaphragmatic nodes from ovarian primary, is an 
interesting phenomenon, and is reported with an incidence up to 35%. Calcified 
intrathoracic nodes in patients with previous ovarian serous adenocarcinoma cannot be 
ruled out as granulomatous disease, but metastatic deposits must be excluded. Progressive 
growth of the involved station will point out to the latter. FDG-PET scan proves to be 
unreliable because granulomatous lymphadenitis which show an increased FDG-uptake. 
Surgery for patients with ovarian cancer is carried to achieve histologic diagnosis, disease 
staging, and prolonged survival, and Videothoracoscopy is a reliable procedure for that. The 
minimally invasive approach enables thorough exploration of the entire pleural cavity, easy 
resection of any small nodes sited within the pericardial fat, and removal of bilateral CPLN 
growths. Resection of isolated node metastases could improve outlook for slow growing 
tumors. It has been shown that ovarian tumor growth rate seems a sound parameter (93).  
6. Laparooscopic assisted diaphragmatic and hepatic surgery in patients 
with advanced ovarian cancer 
Advanced ovarian cancer spreads along the peritoneal surfaces to the abdomen, and often it 
involves the upper abdomen by direct extension or by peritoneal implantation. Metastases 
to the diaphragm, especially to the right hemi-diaphragm, are common in patients with 
advanced ovarian cancer, and up 40% of patients with advanced ovarian cancer present 
with bulky metastatic diaphragmatic disease. The current standard treatment for primary 
ovarian cancer consists of maximum cytoreductive effort to reduce residual tumor (RT), 
followed by platinum-based chemotherapy (94), (95). It has been observed that 
cytoreduction has a more significant influence on survival than the extent of a metastatic 
disease observed before surgery(96); this target has value not only in the primary 
cytoreduction (94), but also in interval debulking surgery after neoadjuvant chemotherapy 
(97), and in secondary cytoreduction in platinum-sensitive recurrent ovarian cancer patients 
(98). It is accepted that upper-abdominal spread of disease represents a major limit to 
achieve an optimal residual disease after primary cytoreduction (99). Extensive upper 
abdominal debulking surgery increases the rate of optimal cytoreduction and it is related 
with improved survival rates in advanced ovarian cancer undergoing primary 
cytoreduction and interval debulking surgery (100). Thus, hepatic resection(99), 
splenectomy [102] and [103], video-assisted thoracic surgery [104], and diaphragmatic 
resection [105], [106], [107], [108], [109], [110] and [111] have been advocated as components 
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of radical primary cytoreduction . The aim of surgery in advanced or recurrent ovarian 
cancer patients should be the removal of any macroscopic intra-abdominal disease. It has 
been shown (94) that each decrease of 10% in residual tumor volume is followed by an 
increase of 5.5% in median survival in advanced ovarian cancer patients. The diaphragmatic 
implants can be resected with various surgical techniques, as ABC, peritonectomy or muscle 
resection. As previously suggested [112], [115]. The complete understanding of the upper 
abdominal anatomy and of the liver mobilization maneuvers are essential to allow 
exploration and radical debulking of the diaphragm, and minimizing the risk of major 
vessels injuries (retro-hepatic caval vein, supra-hepatic veins, diaphragmatic vessels) with 
severe haemorrhage. It has been reported that the most frequent complication is pleural 
effusion (42.5%) (114). It was observed, using multivariate analysis, that pleural effusion 
was statistically well predicted only by hepatic mobilization. Data from 2 reports [107], [113] 
showed that pulmonary complications represented the main morbidity of diaphragmatic 
surgery and suggest that the respiratory status of patients with diaphragmatic perforation 
should be carefully observed postoperatively. The insertion of intra-operative chest tube 
should be considered in patients undergoing complete liver mobilization and large 
diaphragmatic peritoneal or full thickness resection. Moreover, a strict early post-operative 
pulmonary follow-up should reduce the rate of chest complications. In metastatic ovarian 
carcinoma, involving the dome of the right hepatic lobe are encountered, and this requires 
radical full-thickness resection of a portion of the muscular diaphragm. Secondary 
cytoreductive surgery is an acceptable treatment paradigm for patients with platinum 
sensitive [progression-free survival (PFI) at least 6 to 12 months], recurrent ovarian cancer, 
who have a good performance status and can subsequently undergo platinum-based 
salvage chemotherapy [116]. Optimally resected patients have an 18 to 25 months survival 
advantage over those left with bulky disease ([117), (118] and completely resected patients 
have overall median survival in excess of 44 months [119], (120). Hepatic resection of 
recurrent ovarian and fallopian tube cancers has been reported by Yoon et al [119} with a 
series of 24 patients collected over 14-years in a single institution. Most (88%) were 
completely resected and the median survival was 62 months (range, 6 to 94). Fifty percent of 
patients also required diaphragm resection in this series [121]. Robotic-assisted major and 
minor hepatic resections have been described for management of benign and malignant 
liver lesions. It has been reported that conversion to laparotomy was low (5.7%), mean 
estimated blood loss 262 ml, mortality 0%, and morbidity 21.4% [122]. The majority of the 
malignant lesions were hepatobiliary primary or metastatic cancers, and only two cases 
required a partial diaphragm resection. 
Port placement for this procedure requires careful preoperative planning based on the 
anatomic location of the hepatic lesion. The camera should be triangulated 11 cm from the 
operative table. The laparoscopic Habib 4X® can be useful for cauterization of surrounding 
parenchyma, especially for lesions deeper in the liver. Diaphragm resection performed by 
laparotomy results in a pneumothorax that can be evacuated using a red rubber tube and 
suction from a syringe applied just prior to tying the running suture, while the lung is 
temporarily hyperinflated. A study [121] reported on management and outcomes from 9 
laparoscopic diaphragm injuries or resections accumulated over a 10-year experience. In all 
cases, a 14 Fr rubber catheter was introduced through a port and placed to water seal while 
the anesthesiologist hyperinflated the lungs, expelling excess CO2 from the chest cavity 
prior to tying the final diaphragm suture. Only one patient had a pneumothorax on post-
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translate into therapeutic benefits in 30% of cases. Other studies found better survival in 
patients who underwent complete cytoreductive surgery (91), (92).  
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which follows a clockwise route, involving first the thoracic lymphatic stations on the right 
side. Metastatic calcification of supradiaphragmatic nodes from ovarian primary, is an 
interesting phenomenon, and is reported with an incidence up to 35%. Calcified 
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ruled out as granulomatous disease, but metastatic deposits must be excluded. Progressive 
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with bulky metastatic diaphragmatic disease. The current standard treatment for primary 
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followed by platinum-based chemotherapy (94), (95). It has been observed that 
cytoreduction has a more significant influence on survival than the extent of a metastatic 
disease observed before surgery(96); this target has value not only in the primary 
cytoreduction (94), but also in interval debulking surgery after neoadjuvant chemotherapy 
(97), and in secondary cytoreduction in platinum-sensitive recurrent ovarian cancer patients 
(98). It is accepted that upper-abdominal spread of disease represents a major limit to 
achieve an optimal residual disease after primary cytoreduction (99). Extensive upper 
abdominal debulking surgery increases the rate of optimal cytoreduction and it is related 
with improved survival rates in advanced ovarian cancer undergoing primary 
cytoreduction and interval debulking surgery (100). Thus, hepatic resection(99), 
splenectomy [102] and [103], video-assisted thoracic surgery [104], and diaphragmatic 
resection [105], [106], [107], [108], [109], [110] and [111] have been advocated as components 
 
Minimally Invasive Surgical Procedures for Patients with Advanced and Recurrent Ovarian Cancer 
 
175 
of radical primary cytoreduction . The aim of surgery in advanced or recurrent ovarian 
cancer patients should be the removal of any macroscopic intra-abdominal disease. It has 
been shown (94) that each decrease of 10% in residual tumor volume is followed by an 
increase of 5.5% in median survival in advanced ovarian cancer patients. The diaphragmatic 
implants can be resected with various surgical techniques, as ABC, peritonectomy or muscle 
resection. As previously suggested [112], [115]. The complete understanding of the upper 
abdominal anatomy and of the liver mobilization maneuvers are essential to allow 
exploration and radical debulking of the diaphragm, and minimizing the risk of major 
vessels injuries (retro-hepatic caval vein, supra-hepatic veins, diaphragmatic vessels) with 
severe haemorrhage. It has been reported that the most frequent complication is pleural 
effusion (42.5%) (114). It was observed, using multivariate analysis, that pleural effusion 
was statistically well predicted only by hepatic mobilization. Data from 2 reports [107], [113] 
showed that pulmonary complications represented the main morbidity of diaphragmatic 
surgery and suggest that the respiratory status of patients with diaphragmatic perforation 
should be carefully observed postoperatively. The insertion of intra-operative chest tube 
should be considered in patients undergoing complete liver mobilization and large 
diaphragmatic peritoneal or full thickness resection. Moreover, a strict early post-operative 
pulmonary follow-up should reduce the rate of chest complications. In metastatic ovarian 
carcinoma, involving the dome of the right hepatic lobe are encountered, and this requires 
radical full-thickness resection of a portion of the muscular diaphragm. Secondary 
cytoreductive surgery is an acceptable treatment paradigm for patients with platinum 
sensitive [progression-free survival (PFI) at least 6 to 12 months], recurrent ovarian cancer, 
who have a good performance status and can subsequently undergo platinum-based 
salvage chemotherapy [116]. Optimally resected patients have an 18 to 25 months survival 
advantage over those left with bulky disease ([117), (118] and completely resected patients 
have overall median survival in excess of 44 months [119], (120). Hepatic resection of 
recurrent ovarian and fallopian tube cancers has been reported by Yoon et al [119} with a 
series of 24 patients collected over 14-years in a single institution. Most (88%) were 
completely resected and the median survival was 62 months (range, 6 to 94). Fifty percent of 
patients also required diaphragm resection in this series [121]. Robotic-assisted major and 
minor hepatic resections have been described for management of benign and malignant 
liver lesions. It has been reported that conversion to laparotomy was low (5.7%), mean 
estimated blood loss 262 ml, mortality 0%, and morbidity 21.4% [122]. The majority of the 
malignant lesions were hepatobiliary primary or metastatic cancers, and only two cases 
required a partial diaphragm resection. 
Port placement for this procedure requires careful preoperative planning based on the 
anatomic location of the hepatic lesion. The camera should be triangulated 11 cm from the 
operative table. The laparoscopic Habib 4X® can be useful for cauterization of surrounding 
parenchyma, especially for lesions deeper in the liver. Diaphragm resection performed by 
laparotomy results in a pneumothorax that can be evacuated using a red rubber tube and 
suction from a syringe applied just prior to tying the running suture, while the lung is 
temporarily hyperinflated. A study [121] reported on management and outcomes from 9 
laparoscopic diaphragm injuries or resections accumulated over a 10-year experience. In all 
cases, a 14 Fr rubber catheter was introduced through a port and placed to water seal while 
the anesthesiologist hyperinflated the lungs, expelling excess CO2 from the chest cavity 
prior to tying the final diaphragm suture. Only one patient had a pneumothorax on post-
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extubation chest X-ray and it resolved spontaneously. Based on their experience and, they 
recommended reserving chest tubes only for patients symptomatic with greater than 30% 
pneumothorax. In general, performance of hepatic and diaphragm resections for recurrent 
ovarian cancer can be associated with considerably extended patient survival when 
followed by platinum-based chemotherapy. This procedure is successfully performed with 
robotic-assisted laparoscopy. The technique involves, general anesthesia, the patient is 
placed in a supine position, and 5 trocars are used. Pneumoperitoneum to 12 mmHg is 
established. A 12-mm trocar for the robotic camera is placed above or below the umbilicus 
by the Hassen method. Three additional 8-mm trocars are placed at the left upper quadrant 
(LUQ) epigastric, and right upper quadrant (RUQ) areas under the laparoscopic guidance, 
respectively. A 12-mm trocar for an assistant was also placed at the LUQ area. Insertion sites 
of trocars are slightly different for each case because of additional procedures. The 4-arm da 
Vinci surgical robot system is brought into position and docked following port placement. 
The operator moved to the console to control the robotic arms. The assistant remained at the 
patient's left side to change robotic instruments and perform clipping, stapling, 
intraoperative ultrasonography, and choledochoscope through the 12-mm LUQ trocar site. 
30° robotic camera was used. After exploration of the abdominal cavity, intraoperative 
ultrasonography is used to examine the remaining liver to search for undetectable lesions 
and obtain adequate surgical resection margins, and hepatic resection is performed.  
A closed suction drain catheter is placed in the subhepatic space. The specimen was placed 
in an endoscopic retrieval bag and removed through a left subcostal mini-laparotomy 
incision extending from the port site. 
Robotic surgery enables the operator to control the robotic system alone and to perform 
more precise and complex operations, and possibility of remote site surgery (123- 124). 
Robotic liver surgery provides access to fine structures of the liver and allows visualization 
of blood vessels and ducts. Three-dimensional vision offers the advantage of improved 
depth-perception and accuracy. Robotic surgery has several limitations: 1) high cost, 2) 
inadequate coverage by medical insurance, 3) lack of tactile sense, that can impair surgeons' 
capacity to make intuitive decisions, 4) lack of training systems, 5) heavy robotic arms and 
equipments, 6) time-consuming set up, and 7) difficulty in converting to open surgery. (125-
126).  
In addition, resected hepatic parenchymal metastasis in patients with primary epithelial 
ovarian carcinoma have favorable outlook with an actuarial 3 year cancer survival of 78% 
after resection. From surgical standpoint, the use of parenchymal –sparing segmental 
resections and decrease in the number of hepatic segments resected have substantial 
influence on decline in blood loss, the use of blood products and, hospital stay (3). 
Moreover, laparoscopic surgery or robotic assisted laparoscopic surgery is ideal for these 
cases. The same oncologic rules would apply, including “non –touch technique, RO radical 
resection and, the achievement of tumor-free surgical margin. Moreover, it was observe that 
overall morbidity, biliary leakage, transfusion rates, and mortality revealed no difference 
between the clamp crushing and other alternative transaction techniques (127), (128). 
7. Minimally invasive Splenectomy in advanced ovarian cancer 
To achieve optimal cytoreductive results in patients with advanced-stage ovarian cancer, 
splenectomy may be required when disease involves the hilum, capsule, or parenchyma of 
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the spleen. In patients with extensive omental involvement extending into the splenic hilum, 
complete removal of the omentum can be safer, with less blood loss, if the spleen is removed 
en bloc with the omentum. 
With the focus on attempting radical cytoreduction to less than 5 mm residual tumor, The 
frequency with which splenectomy is conducted has increased. The major associated 
complications of splenectomy include pleural effusions, pneumonia, thrombocytosis with 
thromboembolism, pancreatic injury, and postoperative sepsis. 
The benefit of ultra- radical surgical cytoreduction in the management of ovarian cancer, 
with the goal of microscopic or minimal residual disease, has been established.  
- The minimally invasive robotic surgical technique for splenectomy, involves placing the 
patient in an incomplete lateral right decubitus position with an anti-Trendelenbourg 
inclination of about 30°. A patient-side cart with robotic arms is positioned on the left 
side of the operating table. A 12 mm Hg pneumoperitoneum is created using an open 
technique and by inserting a Verses needle in the same point and the needle is then 
replaced with a 15 mm trocar. A 30° laparoscope is used in all cases. Three additional 
trocars are used. A lateral approach is used. At the start of the procedure the abdominal 
cavity is examined to detect any accessory spleens, which are identified and removed. 
The first step consists of the dissection of the inferior splenic pole and ligature of the 
lower polar vessels, followed by the dissection and ligature of the short gastric vessels. 
The second step is to approach the splenic pedicle next to the hilum; the ligature of hilar 
vessels is performed as far as possible from the pancreatic tail. 
- This part of the procedure is more precise. The splenorenal ligaments are divided up to 
the splenodiaphragmal attachments. The splenic ligament dissection is performed using 
an ultrasonic device , and the hilar and short gastric vessels are dissected using an 
endovascular stapler. The surgical specimens are removed, laparoscopically, through an 
enlarged median supra or subumbilical incision using an endobag, and the drain is 
removed within 48 hours, to avoid the risk of postoperative infections. 
For optimal laparoscopic splenectomy, first, a gentle dissection to avoid incidental 
hemorrhages or parenchymal rupture due to traction on the spleen and cellular 
dissemination; second, accurate hemostasis and transection of the hilar vessels, and the 
identification and removal of accessory spleens that can cause the failure of the surgical 
procedure. For successful laparoscopic splenectomy, the semi lateral right decubitus 
position associated with a lateral approach to the splenic hilum reduces the risks of 
intraoperative bleeding, which is an important reason for conversion to laparotomy. 
Vaccination in the splenectomized is an important topic. Streptococcus pneumonia is the 
major pathogen in postsplenectomy sepsis, accounting for 50% to 90% of all infections 
(129). It has been observed that 31% of patients who had an overwhelming 
postsplenectomy infection (OPSI) had previously received the appropriate 
pneumococcal vaccine. OPSIs are rare but well-described, life-threatening events that 
can occur after splenectomy (131), (132). The incidence of postoperative infection has 
been estimated to be 3.2%, with a mortality rate of 1.3% (131). When an OPSI occurs, the 
mortality rate increases to 50% or higher (130). Aggressive early management of 
postoperative infection is critical to patient survival (129). The interval from the time of 
a splenectomy to an episode of OPSI varies, from 24 days to 65 years (130). The classic 
manifestation of OPSI is a brief episode of fever with mild nonspecific symptoms that 
rapidly evolve into overwhelming septic shock. It is important to initiate empiric broad-
spectrum antibiotic therapy against Serratia pneumonia, Haemophilus influenzae, and 
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respectively. A 12-mm trocar for an assistant was also placed at the LUQ area. Insertion sites 
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A closed suction drain catheter is placed in the subhepatic space. The specimen was placed 
in an endoscopic retrieval bag and removed through a left subcostal mini-laparotomy 
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the spleen. In patients with extensive omental involvement extending into the splenic hilum, 
complete removal of the omentum can be safer, with less blood loss, if the spleen is removed 
en bloc with the omentum. 
With the focus on attempting radical cytoreduction to less than 5 mm residual tumor, The 
frequency with which splenectomy is conducted has increased. The major associated 
complications of splenectomy include pleural effusions, pneumonia, thrombocytosis with 
thromboembolism, pancreatic injury, and postoperative sepsis. 
The benefit of ultra- radical surgical cytoreduction in the management of ovarian cancer, 
with the goal of microscopic or minimal residual disease, has been established.  
- The minimally invasive robotic surgical technique for splenectomy, involves placing the 
patient in an incomplete lateral right decubitus position with an anti-Trendelenbourg 
inclination of about 30°. A patient-side cart with robotic arms is positioned on the left 
side of the operating table. A 12 mm Hg pneumoperitoneum is created using an open 
technique and by inserting a Verses needle in the same point and the needle is then 
replaced with a 15 mm trocar. A 30° laparoscope is used in all cases. Three additional 
trocars are used. A lateral approach is used. At the start of the procedure the abdominal 
cavity is examined to detect any accessory spleens, which are identified and removed. 
The first step consists of the dissection of the inferior splenic pole and ligature of the 
lower polar vessels, followed by the dissection and ligature of the short gastric vessels. 
The second step is to approach the splenic pedicle next to the hilum; the ligature of hilar 
vessels is performed as far as possible from the pancreatic tail. 
- This part of the procedure is more precise. The splenorenal ligaments are divided up to 
the splenodiaphragmal attachments. The splenic ligament dissection is performed using 
an ultrasonic device , and the hilar and short gastric vessels are dissected using an 
endovascular stapler. The surgical specimens are removed, laparoscopically, through an 
enlarged median supra or subumbilical incision using an endobag, and the drain is 
removed within 48 hours, to avoid the risk of postoperative infections. 
For optimal laparoscopic splenectomy, first, a gentle dissection to avoid incidental 
hemorrhages or parenchymal rupture due to traction on the spleen and cellular 
dissemination; second, accurate hemostasis and transection of the hilar vessels, and the 
identification and removal of accessory spleens that can cause the failure of the surgical 
procedure. For successful laparoscopic splenectomy, the semi lateral right decubitus 
position associated with a lateral approach to the splenic hilum reduces the risks of 
intraoperative bleeding, which is an important reason for conversion to laparotomy. 
Vaccination in the splenectomized is an important topic. Streptococcus pneumonia is the 
major pathogen in postsplenectomy sepsis, accounting for 50% to 90% of all infections 
(129). It has been observed that 31% of patients who had an overwhelming 
postsplenectomy infection (OPSI) had previously received the appropriate 
pneumococcal vaccine. OPSIs are rare but well-described, life-threatening events that 
can occur after splenectomy (131), (132). The incidence of postoperative infection has 
been estimated to be 3.2%, with a mortality rate of 1.3% (131). When an OPSI occurs, the 
mortality rate increases to 50% or higher (130). Aggressive early management of 
postoperative infection is critical to patient survival (129). The interval from the time of 
a splenectomy to an episode of OPSI varies, from 24 days to 65 years (130). The classic 
manifestation of OPSI is a brief episode of fever with mild nonspecific symptoms that 
rapidly evolve into overwhelming septic shock. It is important to initiate empiric broad-
spectrum antibiotic therapy against Serratia pneumonia, Haemophilus influenzae, and 
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Neisseria meningitides, and await blood culture results. Preoperatively, patients should 
receive the pneumococcal vaccine (Pneumovax), H influenzae vaccine (if available), and 
meningococcal vaccinations approximately 10 to 14 days before surgery to maximize 
immunity (131). Patients who do not receive the vaccine preoperatively should receive 
the appropriate vaccinations in the immediate postoperative period.  
Minor lacerations to the tail of the pancreas that do not involve the major ducts are managed 
with closed suction drainage. The splenic capsule should not be closed as there is no 
evidence that will decrease morbidity (132). 
8. Minimally invasive colorectal surgery in patients with advanced ovarian 
cancer 
Several studies have compared laparoscopic versus open rectal excision for rectal cancer 
(133). There were no difference in morbidity, rate of pelvic sepsis and mortality in both 
groups (134), (135). Histopathologic assessment of the rectal reflects the quality of resection 
in rectal cancer surgery. Both distal and circumferential resection margins are risk factors of 
recurrence after rectal excision. (136), (137). It has been shown that laparoscopic approach 
for rectal cancer is an oncologic safe procedure (138). The surgical technique for rectal 
metastatic involvement , secondary to advanced ovarian cancer is as follows: patients have a 
mechanic bowel preparation the day before the operation and prophylactic antibiotics are 
given at the time of surgery. High ligation of the inferior mesenteric artery and mobilization 
of the splenic flexure are performed. For upper third rectal tumors, a 5-cm mesorectal 
excision with end-to-end colorectal anastomosis is performed, for mid and low rectal 
tumors, TME with pouch supra-anal or anal anastomosis is performed, and 
abdominoperineal excision is performed when the levator muscle is invaded. Mesorectal 
excision includes complete removal of the mesorectum circumferentially with preservation 
of the hypogastric and pelvic plexuses. Extra facial anatomic dissection of the mesorectum is 
performed. The rectum is transected with a linear stapler, or transanally according to the 
level of the tumor. For very low tumors, intersphincteric resection is performed to achieve 
sphincter preservation with clear distal margin. The anastomosis is fashioned using a 
mechanical circular stapler. A colonic pouch is performed when feasible. A loop ileostomy is 
performed when the anastomosis is below 5 cm from the anal verge. Pelvic suction drain is 
inserted. In addition, the distal part of rectal dissection is performed by the perineal 
approach and a manual coloanal anastomosis is done. The goal of this minimally invasive 
procedure is to optimize obtaining distal and circumferential safe margins, and to decrease 
pitfalls due to a difficult laparoscopic low stapling.  
Postoperative analgesia is ensured by intravenous morphine chloridrate (patient-controlled 
administration) at a maximum of 4 mg per hour with a single dose of 1 mg and free interval 
of 10 minutes for 1 to 2 days. Nasogastric tube is removed at the end of the surgical 
procedure, fluids intake on postoperative day 1, oral solid food at postoperative day 2 or 3, 
and bladder catheter removal on postoperative day 3.  
The rectal specimen is examined in the operative room to assess distal resection margin, then 
addressed freshly to the pathologic department pinned on a cork board with moderate 
tension. The surface of the mesorectum is inked before slicing to assess the circumferential 
resection margin. Microscopic assessment included tumor infiltration through the bowel wall 
(pT), presence of positive lymph nodes, and distal and circumferential resection margins. The 
resection margin is considered as negative if >1 mm (R0) and positive if <=1 mm (R1).  
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9. Minimally invasive lower urinary tract surgery in invasive ovarian cancer 
In patients with advanced or recurrent ovarian cancer, who have metastatic lower urinary 
tract involvement, robotic assisted laparoscopic surgery is beneficial. The advantage of 
using the robotic system is that it enables the surgeon to dissect deeply in the narrow pelvic 
floor. Also, it offers a better visualization with the binocular optics generating 3-D 
stereoscopic vision. The utilization of harmonic scalpel allows for control of the pelvic 
sidewall vessels and transaction of the ligaments attachments around the pelvic structures. 
The articulating wristed robotic instrument allows for fine sewing. Robotic surgery for 
advanced ovarian cancer can be achieved by rotating the operating table and relocking the 
robot at the patient’s head. This position will allow dissection and removal of the paraaortic 
lymph nodes, resection of the upper abdominal metastases, and debulking of diaphragm 
and live involvement (139). It has been shown that robotic radical prostatectomy; provide a 
significant advantage in terms of its learning curve especially to surgeons with little or no 
advanced laparoscopic experience (140). It required only 12 cases to achieve proficiency in 
performing robotic assisted radical prostatectomy. Total cystectomy with urinary diversion 
remains the treatment of choice for organ –confined muscle invasive cancer of the urinary 
bladder. Gil et al. (141) reported laparoscopic radical cystectomy, bilateral 
lymphadenectomy, and ileal conduit diversion, with the entire procedure carried out by 
intracorporeal laparoscopic technique. There have been few case reports of laparoscopic 
anterior pelvic exenteration (142), (143). It has been shown that the procedure is feasible and 
if combined with intracorporal urinary diversion. The overall morbidity and hospitalization 
considerably decreased. It is worth noting that, the goal of extensive surgery; anterior pelvic 
exenteration should always be resection of the tumor with tumor free margin. Farghaly 
(144) described the following Technique for urinary bladder invasion in advanced and 
recurrent ovarian cancer: Once the patient is anesthetized, she is placed in the low lithotomy 
position in yellowfin stirrups and her arms tucked at her side. After prepping and draping 
the patient, a standard V-care ® Uterine Manipulator (Conmed Endosurgery, Utica, NY) is 
placed and a foley catheter is inserted into the urinary bladder. A 3-cm incision is made at 
the umbilicus, a Gelport ® is inserted into the incision and trocars are introduced through 
the port with robotic instruments. The patient is then placed in the steep trendelenberg 
position and the da Vinci ® surgical system (Intitutive Surgical, Sunnyvale, CA) is docked 
between her legs. A 10-mm robotic 30 degree scope is used through the 10-mm port and 
robotic monopolar Hook and bipolar Maryland instruments are used through the 
triangulated robotic ports to perform the procedure. The assistant intermittently places an 
endoscopic suction device directly through the port. Ovarian cancer tumor and local 
metastases are debulked to less than 1cm in diameter. The round ligaments are ligated 
bilaterally, and retroperitoneal spaces are developed. The infundibulopelvic ligaments are 
skeletonized and transected. A bladder flap is developed, and the uterine arteries and their 
tributaries are skeletonized and ligated. Pelvic and para-aortic lymph nodes are dissected. 
The anatomical margins for the lymph node dissection were: medially the ureter, laterally 
the body of the psoas muscle and genitofemoral nerve, posteriorly, the obturator nerve, 
inferiorly, the deep circumflex iliac vein, and cephalic of the midportion of the common iliac 
artery. The superior limit of the para-aortic dissection is the inferior mesenteric artery. The 
bladder is dissected with its covering. Peritoneum in the cave of Retzius and ureters are 
clipped and cut. The vagina is cut with harmonic shears and this cut is extended anteriorly 
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Neisseria meningitides, and await blood culture results. Preoperatively, patients should 
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performed when the anastomosis is below 5 cm from the anal verge. Pelvic suction drain is 
inserted. In addition, the distal part of rectal dissection is performed by the perineal 
approach and a manual coloanal anastomosis is done. The goal of this minimally invasive 
procedure is to optimize obtaining distal and circumferential safe margins, and to decrease 
pitfalls due to a difficult laparoscopic low stapling.  
Postoperative analgesia is ensured by intravenous morphine chloridrate (patient-controlled 
administration) at a maximum of 4 mg per hour with a single dose of 1 mg and free interval 
of 10 minutes for 1 to 2 days. Nasogastric tube is removed at the end of the surgical 
procedure, fluids intake on postoperative day 1, oral solid food at postoperative day 2 or 3, 
and bladder catheter removal on postoperative day 3.  
The rectal specimen is examined in the operative room to assess distal resection margin, then 
addressed freshly to the pathologic department pinned on a cork board with moderate 
tension. The surface of the mesorectum is inked before slicing to assess the circumferential 
resection margin. Microscopic assessment included tumor infiltration through the bowel wall 
(pT), presence of positive lymph nodes, and distal and circumferential resection margins. The 
resection margin is considered as negative if >1 mm (R0) and positive if <=1 mm (R1).  
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9. Minimally invasive lower urinary tract surgery in invasive ovarian cancer 
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tract involvement, robotic assisted laparoscopic surgery is beneficial. The advantage of 
using the robotic system is that it enables the surgeon to dissect deeply in the narrow pelvic 
floor. Also, it offers a better visualization with the binocular optics generating 3-D 
stereoscopic vision. The utilization of harmonic scalpel allows for control of the pelvic 
sidewall vessels and transaction of the ligaments attachments around the pelvic structures. 
The articulating wristed robotic instrument allows for fine sewing. Robotic surgery for 
advanced ovarian cancer can be achieved by rotating the operating table and relocking the 
robot at the patient’s head. This position will allow dissection and removal of the paraaortic 
lymph nodes, resection of the upper abdominal metastases, and debulking of diaphragm 
and live involvement (139). It has been shown that robotic radical prostatectomy; provide a 
significant advantage in terms of its learning curve especially to surgeons with little or no 
advanced laparoscopic experience (140). It required only 12 cases to achieve proficiency in 
performing robotic assisted radical prostatectomy. Total cystectomy with urinary diversion 
remains the treatment of choice for organ –confined muscle invasive cancer of the urinary 
bladder. Gil et al. (141) reported laparoscopic radical cystectomy, bilateral 
lymphadenectomy, and ileal conduit diversion, with the entire procedure carried out by 
intracorporeal laparoscopic technique. There have been few case reports of laparoscopic 
anterior pelvic exenteration (142), (143). It has been shown that the procedure is feasible and 
if combined with intracorporal urinary diversion. The overall morbidity and hospitalization 
considerably decreased. It is worth noting that, the goal of extensive surgery; anterior pelvic 
exenteration should always be resection of the tumor with tumor free margin. Farghaly 
(144) described the following Technique for urinary bladder invasion in advanced and 
recurrent ovarian cancer: Once the patient is anesthetized, she is placed in the low lithotomy 
position in yellowfin stirrups and her arms tucked at her side. After prepping and draping 
the patient, a standard V-care ® Uterine Manipulator (Conmed Endosurgery, Utica, NY) is 
placed and a foley catheter is inserted into the urinary bladder. A 3-cm incision is made at 
the umbilicus, a Gelport ® is inserted into the incision and trocars are introduced through 
the port with robotic instruments. The patient is then placed in the steep trendelenberg 
position and the da Vinci ® surgical system (Intitutive Surgical, Sunnyvale, CA) is docked 
between her legs. A 10-mm robotic 30 degree scope is used through the 10-mm port and 
robotic monopolar Hook and bipolar Maryland instruments are used through the 
triangulated robotic ports to perform the procedure. The assistant intermittently places an 
endoscopic suction device directly through the port. Ovarian cancer tumor and local 
metastases are debulked to less than 1cm in diameter. The round ligaments are ligated 
bilaterally, and retroperitoneal spaces are developed. The infundibulopelvic ligaments are 
skeletonized and transected. A bladder flap is developed, and the uterine arteries and their 
tributaries are skeletonized and ligated. Pelvic and para-aortic lymph nodes are dissected. 
The anatomical margins for the lymph node dissection were: medially the ureter, laterally 
the body of the psoas muscle and genitofemoral nerve, posteriorly, the obturator nerve, 
inferiorly, the deep circumflex iliac vein, and cephalic of the midportion of the common iliac 
artery. The superior limit of the para-aortic dissection is the inferior mesenteric artery. The 
bladder is dissected with its covering. Peritoneum in the cave of Retzius and ureters are 
clipped and cut. The vagina is cut with harmonic shears and this cut is extended anteriorly 
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into the urethera and the entire specimen is disconnected. The paracolpos is cut with 
Ligasure till the levator ani muscle with endopelvic fascia is seen. The entire specimen; 
uterus, ovarian tumor tissues, fallopian tubes and all lymph nodes removed through the 
vagina by placing it in endocatch bag, and the vagina is packed to prevent carbon dioxide 
gas leak. The urinary resvoir is formed by dissecting the terminal ileum about 12 cm from 
the ileocecal valve and the large colon is dissected 15-20 cm distal to the hepatic flexure. The 
transection site of the large colon is performed before the middle colonic artery. The distal 
portion of the ileum is used for continent mechanism of the resvoir. The isolated bowel tract 
is washed using normal saline solution, ringer lactate and antiseptic proidone-iodine 
solution. The isolated bowel tract is then filled with 200 ml. of normal saline, and 6 
teniamyotomies are performed. The tenia is sectioned across the whole width to the 
subumblical layer with, 6 cm between each teniamyotomy. The teniamyotomies are left 
open in order to increase the resvoir capacity of the pouch. The spatulated ureters are 
sutured together at the medial side of spatulation to create a trapezoidal plane which is 
anastomosed to the resvoir as the distal ileum is used as efferent segment of the pouch. The 
distal ileum is cannulated with 14 Fr catheter. The ileocecal valve is reinforced with 2/0 
prolene suture. The tapered ileum is then brought to the anterior abdominal wall. 
Pelvic drain is introduced through the 10mm port and ports were removed under vision. 
The vagina is closed by intracorporeal suturing with 2-0 vicryl and by taking continuous 
interlocking sutures. The fascia is closed using 0 vicryl suture and the skin is closed with 
running 4-0 monocryl subcuticular stitch. Estimated operative time 4.6 hours, and average 
blood loss 210 ml. The pelvic drain is kept for 24-48 hours depending on the drainage. 
Hospital stay is about 5 days. 
This technique offers benefits such as improved surgeon dexterity, enhanced ergonomics 
and 3-D optics. The utilization of ileal conduit formation for urinary diversion is technically 
feasible with good result. Also, it is safe, cost effective, with acceptable operative, 
pathological and short and long term clinical outcome. It retains the advantage of minimally 
invasive surgery 
10. Minimally invasive Surgery for small bowel involvement in patients with 
ovarian cancer 
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have an important 
role in the management of patients with peritoneal surface and small bowel involvement in 
patients with advanced stage ovarian cancer. The patterns of intraceolomic dissemination, 
combined with loco-regional cancer therapies directed at small microscopic residual disease 
constitute the basis of this therapy. Heat and intraperitoneal chemotherapy given at the time 
of surgery after a cytoreduction of the peritoneal tumors has resulted in a significant 
improvement of quality and a prolongation of life in selected patients. The robot –assisted 
laparoscopic or laparoscopic technique involves greater omentectomy. The greater 
omentum is mobilized off the transverse colon and its hepatic and splenic flexures are 
excised using the Harmonic scalpel (Ethicon Inc, Guaynabo, Puerto Rico). The gastrosplenic 
ligament is transected close to the splenic hilum. Bowel resections are performed with an 
Endo GIA 3.5/60 mm cartridge (US Surgical, Norwalk, Connecticut). The bowel mesentery 
is transected with the Harmonic scalpel (Ethicon Inc, Guaynabo, Puerto Rico). At the end of 
the laparoscopic stage of the procedure, a 5 cm periumbilical midline laparotomy is 
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performed and the specimens are extracted. Two inflow and 2 outflow perfusion catheters 
are placed and the skin at the laparotomy and port sites is closed with a running Nylon 
stitch. Hyperthermic intraperitoneal chemotherapy with cisplatin and adriamycin or 
mitomycin C for 90 minutes at 43°C is administered using Thermasolutions 
(Thermasolutions Inc, Pittsburgh, Pennsylvania) perfusion system. At the completion of the 
heated perfusion, gastrointestinal anastomosis is performed. 
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into the urethera and the entire specimen is disconnected. The paracolpos is cut with 
Ligasure till the levator ani muscle with endopelvic fascia is seen. The entire specimen; 
uterus, ovarian tumor tissues, fallopian tubes and all lymph nodes removed through the 
vagina by placing it in endocatch bag, and the vagina is packed to prevent carbon dioxide 
gas leak. The urinary resvoir is formed by dissecting the terminal ileum about 12 cm from 
the ileocecal valve and the large colon is dissected 15-20 cm distal to the hepatic flexure. The 
transection site of the large colon is performed before the middle colonic artery. The distal 
portion of the ileum is used for continent mechanism of the resvoir. The isolated bowel tract 
is washed using normal saline solution, ringer lactate and antiseptic proidone-iodine 
solution. The isolated bowel tract is then filled with 200 ml. of normal saline, and 6 
teniamyotomies are performed. The tenia is sectioned across the whole width to the 
subumblical layer with, 6 cm between each teniamyotomy. The teniamyotomies are left 
open in order to increase the resvoir capacity of the pouch. The spatulated ureters are 
sutured together at the medial side of spatulation to create a trapezoidal plane which is 
anastomosed to the resvoir as the distal ileum is used as efferent segment of the pouch. The 
distal ileum is cannulated with 14 Fr catheter. The ileocecal valve is reinforced with 2/0 
prolene suture. The tapered ileum is then brought to the anterior abdominal wall. 
Pelvic drain is introduced through the 10mm port and ports were removed under vision. 
The vagina is closed by intracorporeal suturing with 2-0 vicryl and by taking continuous 
interlocking sutures. The fascia is closed using 0 vicryl suture and the skin is closed with 
running 4-0 monocryl subcuticular stitch. Estimated operative time 4.6 hours, and average 
blood loss 210 ml. The pelvic drain is kept for 24-48 hours depending on the drainage. 
Hospital stay is about 5 days. 
This technique offers benefits such as improved surgeon dexterity, enhanced ergonomics 
and 3-D optics. The utilization of ileal conduit formation for urinary diversion is technically 
feasible with good result. Also, it is safe, cost effective, with acceptable operative, 
pathological and short and long term clinical outcome. It retains the advantage of minimally 
invasive surgery 
10. Minimally invasive Surgery for small bowel involvement in patients with 
ovarian cancer 
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have an important 
role in the management of patients with peritoneal surface and small bowel involvement in 
patients with advanced stage ovarian cancer. The patterns of intraceolomic dissemination, 
combined with loco-regional cancer therapies directed at small microscopic residual disease 
constitute the basis of this therapy. Heat and intraperitoneal chemotherapy given at the time 
of surgery after a cytoreduction of the peritoneal tumors has resulted in a significant 
improvement of quality and a prolongation of life in selected patients. The robot –assisted 
laparoscopic or laparoscopic technique involves greater omentectomy. The greater 
omentum is mobilized off the transverse colon and its hepatic and splenic flexures are 
excised using the Harmonic scalpel (Ethicon Inc, Guaynabo, Puerto Rico). The gastrosplenic 
ligament is transected close to the splenic hilum. Bowel resections are performed with an 
Endo GIA 3.5/60 mm cartridge (US Surgical, Norwalk, Connecticut). The bowel mesentery 
is transected with the Harmonic scalpel (Ethicon Inc, Guaynabo, Puerto Rico). At the end of 
the laparoscopic stage of the procedure, a 5 cm periumbilical midline laparotomy is 
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performed and the specimens are extracted. Two inflow and 2 outflow perfusion catheters 
are placed and the skin at the laparotomy and port sites is closed with a running Nylon 
stitch. Hyperthermic intraperitoneal chemotherapy with cisplatin and adriamycin or 
mitomycin C for 90 minutes at 43°C is administered using Thermasolutions 
(Thermasolutions Inc, Pittsburgh, Pennsylvania) perfusion system. At the completion of the 
heated perfusion, gastrointestinal anastomosis is performed. 
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Management of Recurrent  
or Persistent Ovarian Cancer 
Constantine Gennatas 
Areteion Hospital, University of Athens 
Greece 
1. Introduction 
Approximately 70-80% of patients with epithelial ovarian cancer will relapse after first-line 
chemotherapy with a platinum and taxane-based combination. These patients require 
further treatment and they may benefit from local and/or systemic therapy. The prognosis 
is poor and the management of relapsed ovarian cancer remains a difficult problem open to 
research [National Cancer Institute (NCI), 2010].  
Most patients with epithelial ovarian carcinoma receive postoperative chemotherapy, either 
as adjuvant treatment after complete removal of all visible disease or because of residual 
tumor. Evaluation after chemotherapy completion includes CA 125 and imaging with chest-
X-Ray or CT scanning of the chest and CT scanning or MRI of the abdomen. The limitations 
of this evaluation are well known. In the past several institutions practiced a “second-look 
laparotomy”, which several times revealed widespread intra-abdominal disease in patients 
with a negative metastatic work-up.  Early detection of persistent disease by second-look 
laparotomies after completing first-line treatment is no longer practiced, as it had no effect 
on patients’ outcome. The time to first relapse varies from a few months to several years 
(NCI, 2010). The median interval to first recurrence is 18 to 24 months. Half of the 
recurrences occur more than 12 months from the end of the first-line therapy, and one 
quarter of all recurrences occur at less than 6 months.  Regarding recurrent sites at first 
relapse, the primary disease site is involved in fifty-five percent of the patients. Recurrence 
can also been noted in retroperitoneal or distant nodes, liver, spleen, brain, and bones. In 
order to clarify prognostic factors and to determine the best treatment approach grouping of 
recurrent patients has been applied. The results are not clear yet and more publications are 
needed. (Martin 2009; NCI 2011; Ushijima, 2010). 
2. The management of patients with persistent or recurrent disease 
Patients with persistent detectable disease after surgery and first-line chemotherapy with a 
platinum derivative and taxane combination are candidates for further treatment. They have 
a partial response of residual disease or they have developed progressive disease during 
first-line chemotherapy. Another group includes patients in complete remission after 
surgery and first-line chemotherapy who eventually relapse. The management of patients 
with persistent or recurrent disease is very difficult. In the case of persistent disease the 
question is what is the proper next step including surgery, chemotherapy and research 
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recurrences occur more than 12 months from the end of the first-line therapy, and one 
quarter of all recurrences occur at less than 6 months.  Regarding recurrent sites at first 
relapse, the primary disease site is involved in fifty-five percent of the patients. Recurrence 
can also been noted in retroperitoneal or distant nodes, liver, spleen, brain, and bones. In 
order to clarify prognostic factors and to determine the best treatment approach grouping of 
recurrent patients has been applied. The results are not clear yet and more publications are 
needed. (Martin 2009; NCI 2011; Ushijima, 2010). 
2. The management of patients with persistent or recurrent disease 
Patients with persistent detectable disease after surgery and first-line chemotherapy with a 
platinum derivative and taxane combination are candidates for further treatment. They have 
a partial response of residual disease or they have developed progressive disease during 
first-line chemotherapy. Another group includes patients in complete remission after 
surgery and first-line chemotherapy who eventually relapse. The management of patients 
with persistent or recurrent disease is very difficult. In the case of persistent disease the 
question is what is the proper next step including surgery, chemotherapy and research 
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protocols. In the case of relapse after a complete response to upfront therapy the first 
question related to these patients is the best follow-up, the second the time to start treatment 
and the third the choice of treatment. The goal of treatment today is not the cure but the 
maintaining or improving the quality of life and prolonging patients’ survival. (NCI, 2010; 
Ushijima, 2010). 
As the results of the recurrent disease management remain disappointing the question of 
maintenance therapy after initial therapy has been raised. After the completion of the initial 
therapy, surgery and chemotherapy, the majority of patients are in complete remission. This 
remission in most cases does not last and patients develop recurrent disease. Instead of 
terminating therapy at this point, the question is if a maintenance, low toxicity therapy, can 
improve disease free progression and the overall survival. (Gardner & Jewell 2011). Two 
studies examined the use of paclitaxel in maintenance or consolidation treatment without 
significant results. There are two ongoing studies with paclitaxel or CT-2103, a 
polyglutamated taxane and the second with the addition of bevacizumab. Finally vaccines 
are being studied and they represent a hope to improve today’s results (Gardner & Jewell 
2011).  
2.1 The follow-up of patients completing postoperative chemotherapy 
History, physical examination and serial CA 125 determinations at intervals of 1 to 3 months 
have been accepted as a reasonable follow-up program for patients who are in clinical 
complete remission. Increases in CA 125 represent a common method to detect disease 
relapse but as its limitations are well known imaging procedures are also included in many 
Institutions. (NCI, 2010). 
2.2 Detection of disease recurrence and the proper time to start treatment 
A well-known analysis of a trial by the Medical Research Council and European 
Organization for Research and Treatment of Cancer examined the consequences of early 
institution of treatment for recurrence versus treatment delayed until clinical symptoms 
appeared. The median survival of all patients registered was 70.8 months. The study 
concluded that there was no benefit in the detection of early presence of disease by CA 125 
(NCI, 2010; Ozols et al., 2003). This is also consistent with the failure of currently tested 
therapeutic modalities to alter outcome by routine second-look laparotomies and early 
detection of persistent disease after initial treatment. However it is difficult in everyday 
practice to follow-up patients with evidence of recurrent disease without treatment and 
most Oncologists treat their patients without waiting for the symptoms of their disease. 
2.3 Therapeutic options 
Therapeutic options include local modalities, surgery and radiation therapy, and systemic 
therapy. 
2.3.1 Local modalities: Surgery 
Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the 
initial treatment for epithelial ovarian cancer. Despite advances in the use of 
chemotherapeutic and biologic agents, surgery remains an important modality in the 
treatment of recurrent disease as well. (Ramirez et al., 2011). Surgery for clinical recurrence 
is defined as secondary cytoreductive surgery and it is similar to surgery for persistent 
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disease at the completion of chemotherapy. The role of secondary cytoreductive surgery for 
persistent and/or recurrent disease remains unclear.  Complete response to chemotherapy 
for recurrent ovarian cancer is rare, and shrinkage of the tumor does not always prolongs 
survival while a surgical approach may offer a clear clinical benefit to properly selected 
patients. So while the results of chemotherapy remain unsatisfactory, especially in platinum 
resistant patients, several authors have published encouraging results with surgery and the 
question remains what are the selection criteria for secondary debulking.  Are the theoretical 
and clinical benefits of primary cytoreduction the same in patients with recurrent disease? 
Do they apply to platinum sensitive and platinum resistant patients as well? What is the 
definition of limited recurrent disease? How much we can trust the preoperative work-up? 
What are the results of the cytoreductive surgery in terms of complete resection, optimal 
resection (residual < 1 cm) or suboptimal resection (residual >1 cm) and what is the relation 
of these results to the post recurrence survival?  Several authors have reported a significant 
median survival benefit in patients with no or minimal residual disease that ranges from 38 
to 61 months compared to 4.5 months to 27 months for suboptimal cytoreduction. In a 
retrospective study fifty five patients were included who met the following inclusion 
criteria: A complete clinical response to primary therapy, > 12 months between initial 
diagnosis and recurrence, and < 5 recurrence sites on preoperative imaging studies. The 
conclusions of this study were the definition of localized recurrent ovarian cancer as 
patients with 1 or 2 radiographic recurrence sites and that in a select population with a 
diagnosis-to-recurrence interval > 18 months and complete secondary cytoreduction the 
associated median post recurrence survival was approximately 50 months. (Salani et al., 
2007).   
Due to a lack of large randomized trials, conclusive and universally accepted data are 
limited regarding the benefits of secondary cytoreductive surgery. A patient with a rapid, 
multifocal recurrence is unlikely to obtain any clinical benefit from surgery. Secondary 
cytoreduction should be considered for the subgroup of patients with progressive –free 
interval of >12 to 18 months from completion of adjuvant chemotherapy, localized 
recurrence amenable to complete cytoreduction, potential chemosensitive disease, and good 
performance status. As with primary debulking, resection to no gross residual disease is the 
most important prognostic factor. Patients with optimal secondary cytoreduction survived 
for 16 to 60 months, compared to 8 to 27 months for those patients with residual diseases >1 
cm. However the benefit of surgery, compared to chemotherapy alone, is unclear because of 
a lack of data. The biology of the cancer is certainly another significant cofounding factor 
(Bae et al., Hoskins et al., 1989; Markman et al, 2004; Frederick et al.; Harter et al; Munkarah 
& Coleman, 2004).  
A subgroup of patients may be candidates for tertiary debulking, based on similar selection 
criteria used for secondary debulking. (Fotopoulou et al., 2010; Frederick et al 2011). At 
secondary reduction, bowel or other organ resections are often also performed. More than 
30% of surgeries included bowel resection and some of them accompanied considerable 
morbidity, such as colostomy or pelvic exenteration (Ushijima, 2010).       
2.3.2 The management of complications 
Small and/or large bowel obstruction is a rather common complication in patients with 
advanced disease.  Surgery in these cases remains controversial and requires careful patient 
selection. Patients are usually end-stage and malnourished after a period of nausea, 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 192 
protocols. In the case of relapse after a complete response to upfront therapy the first 
question related to these patients is the best follow-up, the second the time to start treatment 
and the third the choice of treatment. The goal of treatment today is not the cure but the 
maintaining or improving the quality of life and prolonging patients’ survival. (NCI, 2010; 
Ushijima, 2010). 
As the results of the recurrent disease management remain disappointing the question of 
maintenance therapy after initial therapy has been raised. After the completion of the initial 
therapy, surgery and chemotherapy, the majority of patients are in complete remission. This 
remission in most cases does not last and patients develop recurrent disease. Instead of 
terminating therapy at this point, the question is if a maintenance, low toxicity therapy, can 
improve disease free progression and the overall survival. (Gardner & Jewell 2011). Two 
studies examined the use of paclitaxel in maintenance or consolidation treatment without 
significant results. There are two ongoing studies with paclitaxel or CT-2103, a 
polyglutamated taxane and the second with the addition of bevacizumab. Finally vaccines 
are being studied and they represent a hope to improve today’s results (Gardner & Jewell 
2011).  
2.1 The follow-up of patients completing postoperative chemotherapy 
History, physical examination and serial CA 125 determinations at intervals of 1 to 3 months 
have been accepted as a reasonable follow-up program for patients who are in clinical 
complete remission. Increases in CA 125 represent a common method to detect disease 
relapse but as its limitations are well known imaging procedures are also included in many 
Institutions. (NCI, 2010). 
2.2 Detection of disease recurrence and the proper time to start treatment 
A well-known analysis of a trial by the Medical Research Council and European 
Organization for Research and Treatment of Cancer examined the consequences of early 
institution of treatment for recurrence versus treatment delayed until clinical symptoms 
appeared. The median survival of all patients registered was 70.8 months. The study 
concluded that there was no benefit in the detection of early presence of disease by CA 125 
(NCI, 2010; Ozols et al., 2003). This is also consistent with the failure of currently tested 
therapeutic modalities to alter outcome by routine second-look laparotomies and early 
detection of persistent disease after initial treatment. However it is difficult in everyday 
practice to follow-up patients with evidence of recurrent disease without treatment and 
most Oncologists treat their patients without waiting for the symptoms of their disease. 
2.3 Therapeutic options 
Therapeutic options include local modalities, surgery and radiation therapy, and systemic 
therapy. 
2.3.1 Local modalities: Surgery 
Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the 
initial treatment for epithelial ovarian cancer. Despite advances in the use of 
chemotherapeutic and biologic agents, surgery remains an important modality in the 
treatment of recurrent disease as well. (Ramirez et al., 2011). Surgery for clinical recurrence 
is defined as secondary cytoreductive surgery and it is similar to surgery for persistent 
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disease at the completion of chemotherapy. The role of secondary cytoreductive surgery for 
persistent and/or recurrent disease remains unclear.  Complete response to chemotherapy 
for recurrent ovarian cancer is rare, and shrinkage of the tumor does not always prolongs 
survival while a surgical approach may offer a clear clinical benefit to properly selected 
patients. So while the results of chemotherapy remain unsatisfactory, especially in platinum 
resistant patients, several authors have published encouraging results with surgery and the 
question remains what are the selection criteria for secondary debulking.  Are the theoretical 
and clinical benefits of primary cytoreduction the same in patients with recurrent disease? 
Do they apply to platinum sensitive and platinum resistant patients as well? What is the 
definition of limited recurrent disease? How much we can trust the preoperative work-up? 
What are the results of the cytoreductive surgery in terms of complete resection, optimal 
resection (residual < 1 cm) or suboptimal resection (residual >1 cm) and what is the relation 
of these results to the post recurrence survival?  Several authors have reported a significant 
median survival benefit in patients with no or minimal residual disease that ranges from 38 
to 61 months compared to 4.5 months to 27 months for suboptimal cytoreduction. In a 
retrospective study fifty five patients were included who met the following inclusion 
criteria: A complete clinical response to primary therapy, > 12 months between initial 
diagnosis and recurrence, and < 5 recurrence sites on preoperative imaging studies. The 
conclusions of this study were the definition of localized recurrent ovarian cancer as 
patients with 1 or 2 radiographic recurrence sites and that in a select population with a 
diagnosis-to-recurrence interval > 18 months and complete secondary cytoreduction the 
associated median post recurrence survival was approximately 50 months. (Salani et al., 
2007).   
Due to a lack of large randomized trials, conclusive and universally accepted data are 
limited regarding the benefits of secondary cytoreductive surgery. A patient with a rapid, 
multifocal recurrence is unlikely to obtain any clinical benefit from surgery. Secondary 
cytoreduction should be considered for the subgroup of patients with progressive –free 
interval of >12 to 18 months from completion of adjuvant chemotherapy, localized 
recurrence amenable to complete cytoreduction, potential chemosensitive disease, and good 
performance status. As with primary debulking, resection to no gross residual disease is the 
most important prognostic factor. Patients with optimal secondary cytoreduction survived 
for 16 to 60 months, compared to 8 to 27 months for those patients with residual diseases >1 
cm. However the benefit of surgery, compared to chemotherapy alone, is unclear because of 
a lack of data. The biology of the cancer is certainly another significant cofounding factor 
(Bae et al., Hoskins et al., 1989; Markman et al, 2004; Frederick et al.; Harter et al; Munkarah 
& Coleman, 2004).  
A subgroup of patients may be candidates for tertiary debulking, based on similar selection 
criteria used for secondary debulking. (Fotopoulou et al., 2010; Frederick et al 2011). At 
secondary reduction, bowel or other organ resections are often also performed. More than 
30% of surgeries included bowel resection and some of them accompanied considerable 
morbidity, such as colostomy or pelvic exenteration (Ushijima, 2010).       
2.3.2 The management of complications 
Small and/or large bowel obstruction is a rather common complication in patients with 
advanced disease.  Surgery in these cases remains controversial and requires careful patient 
selection. Patients are usually end-stage and malnourished after a period of nausea, 
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vomiting and constipation. The causes of obstruction are often multifactorial and include 
mechanical blockage, dense mesenteric infiltration, peritoneal carcinomatosis and adhesions 
from previous surgery (Ramirez et al., 2011). Surgical procedures include bowel resection, 
colostomy and intestinal bypass.  Even with palliative surgery to remove obstruction, the re-
obstruction rate ranges between 10 and 50% (Ramirez et al., 2011). Several patients will 
definitely benefit from palliative surgery and the absence of the following factors have been 
associated with successful palliation: 1) More than 3 liters of ascites, 2) Multifocal 
obstruction, 3) palpable bulky tumors, and 4) preoperative weight loss more than 9 Kg. 
There are authors who do not agree with these criteria and it remains very important to 
individualize the approach to a patient with bowel obstruction. Certain patients are 
candidates for percutaneous gastrostomy only or intravenous hydration and end-stage care 
(Pothuri et al., 2003; Ramirez et al, 2011). 
2.3.3 Local modalities: Radiation therapy 
The role of radiation therapy in patients with recurrent ovarian cancer has not been defined. 
It can be used in selected cases for symptoms palliation. 
2.4.1 Systemic therapy 
Chemotherapy options for patients with persistent or recurrent disease are subdivided as 
follows: 1) Platinum-sensitive recurrence: for patients whose disease recurs more than 6 
months after cessation of the induction (usually retreated with a platinum (cisplatin or 
carboplatin) and referred to as potentially platinum sensitive. 2) Platinum-refractory or 
platinum-resistant recurrence: for patients who progress prior to cessation of induction 
therapy (platinum refractory) or within 6 months after cessation (platinum resistant); in 
these patients, platinum derivatives are generally deemed toxic and not sufficiently useful to 
be part of the treatment plan (NCI, 2010). 
2.4.2 Platinum-sensitive recurrence 
It has long been recognized that individuals with malignant disease who respond to 
chemotherapy and who experience a long treatment-free interval before initiation of a 
second-line treatment program may respond again to the same drug(s) as used in the initial 
treatment regimen. Ovarian cancer is no exception to this highly clinically relevant 
observation. (Markman et al, 2004). A number of studies have revealed that secondary 
responses to platinum-based chemotherapy occur in this setting in as many as 50% to 80% of 
patients, based on the duration of the treatment-free interval. (Markman et al, 2004). A 
retrospective study conducted at the Cleveland Clinic has addressed the following 
question:” Can the duration of the second response in an individual patient be reasonably 
accurately predicted based on knowledge of the length of the prior response or treatment-
free interval?” This study has confirmed the importance of the duration of prior response in 
defining the opportunity for secondary responses to platinum-based treatment. It has also 
demonstrated that the duration of response to the initial or prior platinum-based 
chemotherapy regimen is highly predictive of the upper limit of the duration of response to 
a subsequent platinum treatment program, assuming that the same or similar drugs are 
used as in the previous treatment program. The authors note that the large majority of 
patients in these series received either single-agent carboplatin in the second-line setting or 
the same drug regimen (carboplatin-paclitaxel) used in the previous course of 
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chemotherapy. For patients who exhibited an objective response, treatment was frequently 
discontinued after six courses of therapy. Therefore, it is possible that if platinum had been 
delivered in combination with an agent not previously administered to that individual or if 
the drug had been continued in the responding patient population, the duration of response 
might have been longer. (Markman et al, 2004). They suggest that more data are required. 
However, they note, although prolonging second-line therapy or adding a new drug may 
improve the duration of response, either approach also has the potential to increase both the 
toxicity and the cost of treatment without having any meaningful impact on the patient’s 
quality of life, time to symptomatic disease progression, or overall survival. (Markman et al, 
2004). These series have been unable to accurately predict the duration of secondary 
response to platinum chemotherapy for individual patients based on the length of the initial 
or immediately preceding remission. Although this may have been because of the limited 
number of patients in each previous response duration category, it is also possible that 
inherent substantial heterogeneity associated with the recurrent tumor (e.g. the rate of 
growth of platinum-resistant cells present within the sensitive tumor cell population) makes 
it unrealistic that a reliable predictive model for individual patient management can be 
developed. (Markman et al, 2004). This study has several potential implications for clinical 
trials design for second-line chemotherapy.  
Several studies that have been conducted in patients with recurrent platinum sensitive 
ovarian carcinoma, have reinforced using carboplatin as the treatment core for patients with 
platinum-sensitive recurrences (Muggia, 1989). Cisplatin is occasionally used, particularly in 
combination with other drugs, because of its lesser myelosuppression, but this advantage 
over carboplatin is counterbalanced by its greater intolerance. Oxaliplatin, initially 
introduced with the hope that it would overcome platinum resistance, has activity mostly in 
platinum-sensitive patients (Piccart et al., 2000) but has not been compared with carboplatin 
alone or in combinations. With all platinums, outcome is in generally better the longer the 
initial interval without recurrence from the initial platinum-containing regimens (Markman 
M et al., 2004).  
However the clinical benefit based on the progression free survival (PFS) and the overall 
survival (OS) is in generally limited.  
The combination of Carboplatin and pegylated-liposomal doxorubicin have resulted in a 
median PFS of 9 months and a median OS of 31 months (Ferrero et al, 2007).  The 
combination of Carboplatin and Epirubicin versus Carboplatin produced a very limited 
difference in OS 17 versus 15 months (Bolis et al, 2001). A triple combination of Cisplatin, 
doxorubicin and cyclophosphamide (CAP) that has been used in the past as first-line 
treatment of choice versus paclitaxel revealed a significant difference in both PFS 15.7 versus 
9 months and in OS 34.7 versus 25.8 months (Cantù et al., 2002). The addition of 
Gemcitabine to Carboplatin was compared to Carboplatin alone. The PFS was 8,6 versus 5.8 
month and the OS 18 versus 17 months (Pfisterer et al, 2006).  
In an international, multicenter trial 802 patients were randomized to receive paclitaxel plus 
platinum chemotherapy or conventional platinum-based chemotherapy. The paclitaxel plus 
platinum combination seems superior in terms of PFS and median OS. The PFS was 11 
versus 9 months and the OS 24 versus 19 months in the two groups (Parmar et al, 2003). 
Accordingly, because of this randomized experience, carboplatin plus paclitaxel is 
considered the standard regimen for platinum-sensitive recurrence in the absence of 
residual neurotoxicity. 
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vomiting and constipation. The causes of obstruction are often multifactorial and include 
mechanical blockage, dense mesenteric infiltration, peritoneal carcinomatosis and adhesions 
from previous surgery (Ramirez et al., 2011). Surgical procedures include bowel resection, 
colostomy and intestinal bypass.  Even with palliative surgery to remove obstruction, the re-
obstruction rate ranges between 10 and 50% (Ramirez et al., 2011). Several patients will 
definitely benefit from palliative surgery and the absence of the following factors have been 
associated with successful palliation: 1) More than 3 liters of ascites, 2) Multifocal 
obstruction, 3) palpable bulky tumors, and 4) preoperative weight loss more than 9 Kg. 
There are authors who do not agree with these criteria and it remains very important to 
individualize the approach to a patient with bowel obstruction. Certain patients are 
candidates for percutaneous gastrostomy only or intravenous hydration and end-stage care 
(Pothuri et al., 2003; Ramirez et al, 2011). 
2.3.3 Local modalities: Radiation therapy 
The role of radiation therapy in patients with recurrent ovarian cancer has not been defined. 
It can be used in selected cases for symptoms palliation. 
2.4.1 Systemic therapy 
Chemotherapy options for patients with persistent or recurrent disease are subdivided as 
follows: 1) Platinum-sensitive recurrence: for patients whose disease recurs more than 6 
months after cessation of the induction (usually retreated with a platinum (cisplatin or 
carboplatin) and referred to as potentially platinum sensitive. 2) Platinum-refractory or 
platinum-resistant recurrence: for patients who progress prior to cessation of induction 
therapy (platinum refractory) or within 6 months after cessation (platinum resistant); in 
these patients, platinum derivatives are generally deemed toxic and not sufficiently useful to 
be part of the treatment plan (NCI, 2010). 
2.4.2 Platinum-sensitive recurrence 
It has long been recognized that individuals with malignant disease who respond to 
chemotherapy and who experience a long treatment-free interval before initiation of a 
second-line treatment program may respond again to the same drug(s) as used in the initial 
treatment regimen. Ovarian cancer is no exception to this highly clinically relevant 
observation. (Markman et al, 2004). A number of studies have revealed that secondary 
responses to platinum-based chemotherapy occur in this setting in as many as 50% to 80% of 
patients, based on the duration of the treatment-free interval. (Markman et al, 2004). A 
retrospective study conducted at the Cleveland Clinic has addressed the following 
question:” Can the duration of the second response in an individual patient be reasonably 
accurately predicted based on knowledge of the length of the prior response or treatment-
free interval?” This study has confirmed the importance of the duration of prior response in 
defining the opportunity for secondary responses to platinum-based treatment. It has also 
demonstrated that the duration of response to the initial or prior platinum-based 
chemotherapy regimen is highly predictive of the upper limit of the duration of response to 
a subsequent platinum treatment program, assuming that the same or similar drugs are 
used as in the previous treatment program. The authors note that the large majority of 
patients in these series received either single-agent carboplatin in the second-line setting or 
the same drug regimen (carboplatin-paclitaxel) used in the previous course of 
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chemotherapy. For patients who exhibited an objective response, treatment was frequently 
discontinued after six courses of therapy. Therefore, it is possible that if platinum had been 
delivered in combination with an agent not previously administered to that individual or if 
the drug had been continued in the responding patient population, the duration of response 
might have been longer. (Markman et al, 2004). They suggest that more data are required. 
However, they note, although prolonging second-line therapy or adding a new drug may 
improve the duration of response, either approach also has the potential to increase both the 
toxicity and the cost of treatment without having any meaningful impact on the patient’s 
quality of life, time to symptomatic disease progression, or overall survival. (Markman et al, 
2004). These series have been unable to accurately predict the duration of secondary 
response to platinum chemotherapy for individual patients based on the length of the initial 
or immediately preceding remission. Although this may have been because of the limited 
number of patients in each previous response duration category, it is also possible that 
inherent substantial heterogeneity associated with the recurrent tumor (e.g. the rate of 
growth of platinum-resistant cells present within the sensitive tumor cell population) makes 
it unrealistic that a reliable predictive model for individual patient management can be 
developed. (Markman et al, 2004). This study has several potential implications for clinical 
trials design for second-line chemotherapy.  
Several studies that have been conducted in patients with recurrent platinum sensitive 
ovarian carcinoma, have reinforced using carboplatin as the treatment core for patients with 
platinum-sensitive recurrences (Muggia, 1989). Cisplatin is occasionally used, particularly in 
combination with other drugs, because of its lesser myelosuppression, but this advantage 
over carboplatin is counterbalanced by its greater intolerance. Oxaliplatin, initially 
introduced with the hope that it would overcome platinum resistance, has activity mostly in 
platinum-sensitive patients (Piccart et al., 2000) but has not been compared with carboplatin 
alone or in combinations. With all platinums, outcome is in generally better the longer the 
initial interval without recurrence from the initial platinum-containing regimens (Markman 
M et al., 2004).  
However the clinical benefit based on the progression free survival (PFS) and the overall 
survival (OS) is in generally limited.  
The combination of Carboplatin and pegylated-liposomal doxorubicin have resulted in a 
median PFS of 9 months and a median OS of 31 months (Ferrero et al, 2007).  The 
combination of Carboplatin and Epirubicin versus Carboplatin produced a very limited 
difference in OS 17 versus 15 months (Bolis et al, 2001). A triple combination of Cisplatin, 
doxorubicin and cyclophosphamide (CAP) that has been used in the past as first-line 
treatment of choice versus paclitaxel revealed a significant difference in both PFS 15.7 versus 
9 months and in OS 34.7 versus 25.8 months (Cantù et al., 2002). The addition of 
Gemcitabine to Carboplatin was compared to Carboplatin alone. The PFS was 8,6 versus 5.8 
month and the OS 18 versus 17 months (Pfisterer et al, 2006).  
In an international, multicenter trial 802 patients were randomized to receive paclitaxel plus 
platinum chemotherapy or conventional platinum-based chemotherapy. The paclitaxel plus 
platinum combination seems superior in terms of PFS and median OS. The PFS was 11 
versus 9 months and the OS 24 versus 19 months in the two groups (Parmar et al, 2003). 
Accordingly, because of this randomized experience, carboplatin plus paclitaxel is 
considered the standard regimen for platinum-sensitive recurrence in the absence of 
residual neurotoxicity. 
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Platinum derivatives remain the most important drugs in the management of recurrent 
ovarian carcinoma. It is of interest that on occasion, patients with platinum-sensitive 
recurrences relapsing within 1 year have been included in trials of nonplatinum drugs. In 
one such trial, comparing the pegylated liposomal doxorubicin (PLD) to topotecan, the 
subset of patients who were platinum sensitive had better outcomes with either drug (and 
in particular with PLD) relative to the platinum-resistant cohort (Gordon et al., 2004).  
2.4.3 Platinum-refractory or platinum-resistant recurrence 
Clinical recurrences that take place during or within 6 months of completion of a platinum-
containing regimen are considered platinum-refractory or platinum-resistant recurrences 
respectively.  Patients with originally platinum- sensitive disease eventually also become 
platinum-resistant. Anthracyclines (particularly when formulated as PLD), taxanes, 
topotecan, and gemcitabine are used as single agents for these recurrences. These agents in 
generally convey a marginal benefit. Patients with platinum-resistant disease should be 
encouraged to enter clinical trials. Treatment with paclitaxel historically provided the first 
agent with consistent activity in patients with platinum-refractory or platinum-resistant 
recurrences (Kohn et al., 1994; McGuire et al., 1989, Einzig et al., 1992, Thigpen JT et al., 1994, 
Trimble EL et al., 1993).  
Subsequently, randomized studies have indicated that the use of topotecan achieved results 
that were comparable to those achieved with paclitaxel. In phase II studies, topotecan 
administered intravenously 1.5mg/m2 on days 1 to 5 of a 21-day cycle yielded objective 
response rates ranging from 13% to 16.3% and other outcomes that were equivalent or 
superior to paclitaxel (Ten Bokkel Huinink W et al, 1997, Kudelka AP et al.; 1996, Creemers 
et al.; 1996, Bookman et al., 1998). Substantial myelosuppression follows administration in 
most cases. Other toxic effects include nausea, vomiting, alopecia, and asthenia. A number 
of schedules are under evaluation in an effort to decrease hematologic toxicity (NCI, 2010). 
Topotecan was compared with pegylated liposomal doxorubicin in a randomized trial of 
474 patients and demonstrated similar response rates, PFS, and OS at the time of the initial 
report, contributed primarily by the platinum-resistant subsets (Gordon et al., 2001). 
A phase II study of Pegylated liposomal doxorubicin (PLD) given IV  50mg/m2 once every 
21 to 28 days demonstrated one complete response and eight partial responses in 35 patients 
with platinum-refractory or paclitaxel-refractory disease (response rate = 25.7%). In general, 
liposomal doxorubicin has few acute side effects other than hypersensitivity. The most 
frequent toxic effects are usually observed after the first cycle and are more pronounced 
following dose rates exceeding 10 mg/m2 per week and include stomatitis and hand-foot 
syndrome. Neutropenia and nausea are minimal, and alopecia rarely occurs. (Muggia et al., 
1997). Liposomal doxorubicin and topotecan have been compared in a randomized trial of 
474 patients with recurrent ovarian cancer. Response rates (19.7% versus 17.0%; P = .390), 
PFS (16.1 weeks vs. 17.0 weeks; P = .095), and OS (60 weeks versus. 56.7 weeks; P = .341) did 
not differ significantly between the liposomal doxorubicin and topotecan arms, respectively. 
Survival was longer for the patients with platinum-sensitive disease who received liposomal 
doxorubicin (Gordon et al., 2001,2004). 
Docetaxel has shown activity in paclitaxel-pretreated patients and is a reasonable alternative 
to weekly paclitaxel in the recurrent setting (Berkenblit et al., 2004). 
Several phase II trials of gemcitabine as a single agent administered IV on days 1, 8, and 15 
of a 28-day cycle have been reported. The response rate ranges from 13% to 19% in 
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evaluable patients. Responses have been observed in patients whose disease are platinum 
refractory and/or paclitaxel refractory as well as in patients with bulky disease. Leukopenia, 
anemia, and thrombocytopenia are the most common toxic effects. Many patients report 
transient flu-like symptoms and a rash following drug administration. Other toxic effects, 
including nausea, are usually mild (Friedlander et al., 1998; Lund et al., 1994; Mutch et al., 
2007, Shapiro et al., 1996).  
Ovarian cancer patients generally receive paclitaxel in front-line induction regimens. 
Retreatment with paclitaxel, particularly in weekly schedules, indicates an activity 
comparable to those of the preceding drugs. If there is residual neuropathy upon recurrence, 
this may shift the choice of treatment towards other agents. In a phase III study, 235 patients 
who did not respond to initial treatment with a platinum-based regimen but who had not 
previously received paclitaxel or topotecan, were randomly assigned to receive either 
topotecan as a 30-minute infusion daily for 5 days every 21 days or paclitaxel as a 3-hour 
infusion every 21 days. The overall objective response rate was 20.5% for those patients who 
were randomly assigned to treatment with topotecan and 13.2% for those patients who were 
randomly assigned to treatment with paclitaxel (P = .138). Both groups experienced 
myelosuppression and gastrointestinal toxic effects. Nausea and vomiting, fatigue, and 
infection were observed more commonly following treatment with topotecan, whereas 
alopecia, arthralgia, myalgia, and neuropathy were observed more commonly following 
paclitaxel (Ten Bokkel Huinink et al., 1997).  
2.4.4 Other drugs used to treat platinum-refractory or platinum-resistant recurrence 
This group includes drugs that have limited activity in platinum-resistant cases but they are 
in use in every day practice as there are patients who need successive chemotherapeutic 
regimens. 1) Etoposide. It can be given intravenously or orally.  It has limited activity. 2) 
Cyclophosphamide. It was used as first-line therapy in combination with platinum 
derivatives in the before the paclitaxel era. It has uncertain activity in platinum resistant 
cases. 3) Hexamethylmelamine (Alteramine) is an alkylating prodrug, has also uncertain 
activity in platinum resistant cases. 4) Irinotecan. It is cross - resistant to topotecan. 5) 
Oxaliplatin. Partially cross -resistant to the other platinum derivatives. 6) Vinorelbine. 25-
30mg/m2 IV on days 1 and 8 every 21 days.  Vinorelbine can also be given orally. It has 
erratic activity. 7) 5-fluorouracil and capecitabine. May be useful in mucinous tumors. 
(Vasey et al., 2003). 8) Tamoxifen. Has minimal activity. May be useful in certain cases either 
after chemotherapy or in older patients who do not tolerate or refuse to receive 
chemotherapy 9) Trabectedin (Yondelis) a new drug for advanced soft-tissue sarcomas in 
combination with liposomal doxorubicin has shown significant activity in patients with 
relapsed ovarian carcinoma and has been approved for use in certain countries. It was 
however rejected by a US Food and Drug Administration (FDA) advisory committee. 
Further clinical trials are needed. 10) Thalidomide an antiangiogenic agent in combination 
with Topotecan appears to improve response rate in patients with recurrent ovarian cancer. 
The results of phase III are needed (Downs Jr LS 2007). 
2.4.5 Hyperthermic intraperitoneal chemotherapy 
Patients with widespread peritoneal carcinomatosis present a very difficult problem as 
cytoreductive surgery has limited results. A retrospective study suggests that the 
combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is 
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Platinum derivatives remain the most important drugs in the management of recurrent 
ovarian carcinoma. It is of interest that on occasion, patients with platinum-sensitive 
recurrences relapsing within 1 year have been included in trials of nonplatinum drugs. In 
one such trial, comparing the pegylated liposomal doxorubicin (PLD) to topotecan, the 
subset of patients who were platinum sensitive had better outcomes with either drug (and 
in particular with PLD) relative to the platinum-resistant cohort (Gordon et al., 2004).  
2.4.3 Platinum-refractory or platinum-resistant recurrence 
Clinical recurrences that take place during or within 6 months of completion of a platinum-
containing regimen are considered platinum-refractory or platinum-resistant recurrences 
respectively.  Patients with originally platinum- sensitive disease eventually also become 
platinum-resistant. Anthracyclines (particularly when formulated as PLD), taxanes, 
topotecan, and gemcitabine are used as single agents for these recurrences. These agents in 
generally convey a marginal benefit. Patients with platinum-resistant disease should be 
encouraged to enter clinical trials. Treatment with paclitaxel historically provided the first 
agent with consistent activity in patients with platinum-refractory or platinum-resistant 
recurrences (Kohn et al., 1994; McGuire et al., 1989, Einzig et al., 1992, Thigpen JT et al., 1994, 
Trimble EL et al., 1993).  
Subsequently, randomized studies have indicated that the use of topotecan achieved results 
that were comparable to those achieved with paclitaxel. In phase II studies, topotecan 
administered intravenously 1.5mg/m2 on days 1 to 5 of a 21-day cycle yielded objective 
response rates ranging from 13% to 16.3% and other outcomes that were equivalent or 
superior to paclitaxel (Ten Bokkel Huinink W et al, 1997, Kudelka AP et al.; 1996, Creemers 
et al.; 1996, Bookman et al., 1998). Substantial myelosuppression follows administration in 
most cases. Other toxic effects include nausea, vomiting, alopecia, and asthenia. A number 
of schedules are under evaluation in an effort to decrease hematologic toxicity (NCI, 2010). 
Topotecan was compared with pegylated liposomal doxorubicin in a randomized trial of 
474 patients and demonstrated similar response rates, PFS, and OS at the time of the initial 
report, contributed primarily by the platinum-resistant subsets (Gordon et al., 2001). 
A phase II study of Pegylated liposomal doxorubicin (PLD) given IV  50mg/m2 once every 
21 to 28 days demonstrated one complete response and eight partial responses in 35 patients 
with platinum-refractory or paclitaxel-refractory disease (response rate = 25.7%). In general, 
liposomal doxorubicin has few acute side effects other than hypersensitivity. The most 
frequent toxic effects are usually observed after the first cycle and are more pronounced 
following dose rates exceeding 10 mg/m2 per week and include stomatitis and hand-foot 
syndrome. Neutropenia and nausea are minimal, and alopecia rarely occurs. (Muggia et al., 
1997). Liposomal doxorubicin and topotecan have been compared in a randomized trial of 
474 patients with recurrent ovarian cancer. Response rates (19.7% versus 17.0%; P = .390), 
PFS (16.1 weeks vs. 17.0 weeks; P = .095), and OS (60 weeks versus. 56.7 weeks; P = .341) did 
not differ significantly between the liposomal doxorubicin and topotecan arms, respectively. 
Survival was longer for the patients with platinum-sensitive disease who received liposomal 
doxorubicin (Gordon et al., 2001,2004). 
Docetaxel has shown activity in paclitaxel-pretreated patients and is a reasonable alternative 
to weekly paclitaxel in the recurrent setting (Berkenblit et al., 2004). 
Several phase II trials of gemcitabine as a single agent administered IV on days 1, 8, and 15 
of a 28-day cycle have been reported. The response rate ranges from 13% to 19% in 
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evaluable patients. Responses have been observed in patients whose disease are platinum 
refractory and/or paclitaxel refractory as well as in patients with bulky disease. Leukopenia, 
anemia, and thrombocytopenia are the most common toxic effects. Many patients report 
transient flu-like symptoms and a rash following drug administration. Other toxic effects, 
including nausea, are usually mild (Friedlander et al., 1998; Lund et al., 1994; Mutch et al., 
2007, Shapiro et al., 1996).  
Ovarian cancer patients generally receive paclitaxel in front-line induction regimens. 
Retreatment with paclitaxel, particularly in weekly schedules, indicates an activity 
comparable to those of the preceding drugs. If there is residual neuropathy upon recurrence, 
this may shift the choice of treatment towards other agents. In a phase III study, 235 patients 
who did not respond to initial treatment with a platinum-based regimen but who had not 
previously received paclitaxel or topotecan, were randomly assigned to receive either 
topotecan as a 30-minute infusion daily for 5 days every 21 days or paclitaxel as a 3-hour 
infusion every 21 days. The overall objective response rate was 20.5% for those patients who 
were randomly assigned to treatment with topotecan and 13.2% for those patients who were 
randomly assigned to treatment with paclitaxel (P = .138). Both groups experienced 
myelosuppression and gastrointestinal toxic effects. Nausea and vomiting, fatigue, and 
infection were observed more commonly following treatment with topotecan, whereas 
alopecia, arthralgia, myalgia, and neuropathy were observed more commonly following 
paclitaxel (Ten Bokkel Huinink et al., 1997).  
2.4.4 Other drugs used to treat platinum-refractory or platinum-resistant recurrence 
This group includes drugs that have limited activity in platinum-resistant cases but they are 
in use in every day practice as there are patients who need successive chemotherapeutic 
regimens. 1) Etoposide. It can be given intravenously or orally.  It has limited activity. 2) 
Cyclophosphamide. It was used as first-line therapy in combination with platinum 
derivatives in the before the paclitaxel era. It has uncertain activity in platinum resistant 
cases. 3) Hexamethylmelamine (Alteramine) is an alkylating prodrug, has also uncertain 
activity in platinum resistant cases. 4) Irinotecan. It is cross - resistant to topotecan. 5) 
Oxaliplatin. Partially cross -resistant to the other platinum derivatives. 6) Vinorelbine. 25-
30mg/m2 IV on days 1 and 8 every 21 days.  Vinorelbine can also be given orally. It has 
erratic activity. 7) 5-fluorouracil and capecitabine. May be useful in mucinous tumors. 
(Vasey et al., 2003). 8) Tamoxifen. Has minimal activity. May be useful in certain cases either 
after chemotherapy or in older patients who do not tolerate or refuse to receive 
chemotherapy 9) Trabectedin (Yondelis) a new drug for advanced soft-tissue sarcomas in 
combination with liposomal doxorubicin has shown significant activity in patients with 
relapsed ovarian carcinoma and has been approved for use in certain countries. It was 
however rejected by a US Food and Drug Administration (FDA) advisory committee. 
Further clinical trials are needed. 10) Thalidomide an antiangiogenic agent in combination 
with Topotecan appears to improve response rate in patients with recurrent ovarian cancer. 
The results of phase III are needed (Downs Jr LS 2007). 
2.4.5 Hyperthermic intraperitoneal chemotherapy 
Patients with widespread peritoneal carcinomatosis present a very difficult problem as 
cytoreductive surgery has limited results. A retrospective study suggests that the 
combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is 
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feasible and has potential benefits. A randomized trial is needed to establish its role in the 
management of these difficult cases (Chua, et al 2009). Similar results were reported in a 
pilot study of Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent 
epithelial ovarian cancer. It proved to be feasible, relatively safe and effective in 
combination with chemotherapy and surgery in cases with peritoneal carcinomatosis 
(Frenel, et al 2011). Larger studies are needed (Roviello, et al 2010).   
2.4.6 New drugs – Targeted therapy 
Certain studies evaluating the efficacy of antiangiogenic agents in ovarian cancer have been 
reported including vascular endothelial growth factor (VEGF) pathway inhibitors, 
monoclonal antibodies, tyrosine kinase inhibitors and inhibitors of other angiogenic factors 
and vascular disrupting agents. Angiogenesis is a critical component of tumor development 
and proliferation. Agents that target the angiogenic process are of considerable interest in 
the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody against 
VEGF and possesses minimal single-agent activity in common epithelial cancers such as 
colorectal, non-small-cell lung cancer and breast cancer. The combination of Bevacizumab 
with chemotherapy has revealed significant improvement in the outcome in several tumors, 
leading to registration. Bevacizumab possesses more single-agent activity in epithelial 
ovarian cancer than in any other epithelial tumor, apart from renal cancer, where the 
vascular biology is specifically relevant to this therapeutic approach. Clinical trials have 
confirmed Bevacizumab effectiveness but that also revealed significant toxicity including 
bowel perforation. (Kaye ., 2007; Teoh et al., 2011; Monk et al., 2006).  
Three phase II studies have shown activity for Bevacizumab, an antibody to vascular 
endothelial growth factor (VEGF). The first study included 62 patients who had received 
only one or two prior treatments (these last patients had received one additional platinum-
based regimen because of an initial interval of 12 months or greater after first-line regimens 
and also had to have a performance status of 0 or 1)(Burger et al., 2007). Patients received a 
dose of 15 mg/kg every 21 days; there were two complete responses and 11 partial 
responses, a median PFS of 4.7 months, and an OS of 17 months. This activity was noted in 
both platinum-sensitive and platinum-resistant subsets. The second study only included 
patients with platinum-resistant disease using an identical dose schedule, but the study was 
stopped because five of 44 patients experienced bowel perforations, one of them fatal; seven 
partial responses had been observed (Cannistra et al., 2007). This increased risk of bowel 
perforations was associated with three or more prior treatments (Monk et al., 2006; Kaye 
2007). The third study included 70 patients who received 50 mg of oral cyclophosphamide 
daily, in addition to bevacizumab (10 mg/kg every 2 weeks); 17 partial responses were 
observed and four patients had intestinal perforations. (Garcia et al., 2008). Studies by the 
Gynecologic Oncology Group are evaluating the efficacy of the drug added to the initial 
treatment and at first recurrence in the platinum-resistant setting. Bevacizumab will 
probably be approved for clinical use in the near future. As neovascularization is a 
complicated process other antiangiogenic agents have been developed to overcome 
resistance to VEGF blockade, and several are undergoing clinical trials (Teoh et al., 2011). 
Future studies must answer to the following questions: The role of bevacizumab in first-line 
treatment and in the management of recurrent disease, the results of the combination with 
chemotherapy, risk factors for bowel perforation, the appropriate dose 15mg/Kg every 
three weeks or less and criteria for patient selection for bevacizumab treatment. (Kaye., 2007; 
Teoh et al., 2011; Monk et al., 2006).  
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Several targeted therapeutic agents are under evaluation in ongoing studies. They include 
the following groups of agents: 1) Antiangiogenic agents, 2) mTOR inhibitors, 3) PARP 
inhibitors and 4) Histone Deacetylase inhibitors.  
1. Antiangiogenic agents include: a) Bevacizumab which has already been presented and 
will probably be approved for clinical use in the near future. b) VEGF-Trap a potent 
angiogenesis inhibitor fusion protein is under study. c) Agents that block the VEGF 
receptor. These agents include sorafenib and sunitinib, small molecules that block 
tyrosine kinase activity located in the cytoplasmic domain of VEGF receptor (VEGFR). 
Some of these molecules block VEGFR specifically, whereas others, such as sorafenib 
and sunitinib, block both VEGFR and the platelet-derived growth factor (PDGFR), 
thought to be involved in later phases of tumor angiogenesis relating to vessel 
maturation. (Gardner & Jewell, 2011).  
2. mTOR inhibitors. Dysregulation of mTOR signaling occurs in many tumors and has 
been found to be activated in gynecological cancers. Increased AKT/PI3K activity with 
constitutive downstream activation of the mTOR pathway has been found in ovarian 
tumor specimens and ovarian cancer cell lines. Inhibition of mTOR by agents such 
temsirolimus, everolimus and deforolimus are in clinical trials.(Gardner & Jewell, 2011). 
3. PARP inhibitors. Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase 
(PARP), a key enzyme in the DNA repair, may lead to the accumulation of breaks in 
double-stranded and cell death. Therefore, PARP inhibitors have been developed and 
are potentially exciting agents in the treatment of ovarian cancer, especially cancers 
with BRCA1 and BRCA2 mutations. Initial reports have been encouraging A phae II, 
randomized double-blind, multicenter study is assessing the efficacy of an oral PARP 
inhibitor olaparib (AZD2281) in the treatment of patients with platinum-sensitive 
serous ovarian cancer following treatment with two or more platinum-containing 
regimens. (Gardner & Jewell, 2011). 
4. Histone Deacetylase Inhibitors. Aberrant histone modifications such as hypoacetylation 
have been associated with malignancy through the transcriptional silencing of tumor 
suppressor genes. Belinostat is a histone deacetylase inhibitor (HDAC) that can alter the 
acetylation level of histone and nonhistone proteins. Such epigenetic modulation may 
sensitize drug-resistant tumor cells to other antineoplastic agents, as suggested in 
preclinical studies. A phase II study is examining the use of belinostat in combination 
with carboplatin among patients with recurrent or persistent platinim-resistant disease. 
(Gardner & Jewell, 2011). These new targeted biologic agents, particularly those 
involved with the vascular endothelial growth factor pathway and those targeting the 
poly (ADP-ribose) polymerase (PARP) enzyme, hold great promise for improving the 
outcome of ovarian cancer. (Jelovac & Armstrong 2011). 
2.4.7 Microarray – Based gene expression studies in ovarian cancer 
Despite recent improvements in treatment, ovarian cancer remains the No. 1 cause of death 
among gynecologic cancer in the United States. In more than 90% of patients with localized 
disease, surgery alone is curative. However, in most patients, the tumor has disseminated 
beyond the ovaries by the time the cancer is diagnosed. For these patients combined 
modality treatment, surgery and chemotherapy, is necessary and first-line chemotherapy 
has yielded response rates of greater than 80%. Unfortunately the median progression-free 
survival has been only 18 months in these patients and, in most with advanced cancer, the 
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feasible and has potential benefits. A randomized trial is needed to establish its role in the 
management of these difficult cases (Chua, et al 2009). Similar results were reported in a 
pilot study of Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent 
epithelial ovarian cancer. It proved to be feasible, relatively safe and effective in 
combination with chemotherapy and surgery in cases with peritoneal carcinomatosis 
(Frenel, et al 2011). Larger studies are needed (Roviello, et al 2010).   
2.4.6 New drugs – Targeted therapy 
Certain studies evaluating the efficacy of antiangiogenic agents in ovarian cancer have been 
reported including vascular endothelial growth factor (VEGF) pathway inhibitors, 
monoclonal antibodies, tyrosine kinase inhibitors and inhibitors of other angiogenic factors 
and vascular disrupting agents. Angiogenesis is a critical component of tumor development 
and proliferation. Agents that target the angiogenic process are of considerable interest in 
the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody against 
VEGF and possesses minimal single-agent activity in common epithelial cancers such as 
colorectal, non-small-cell lung cancer and breast cancer. The combination of Bevacizumab 
with chemotherapy has revealed significant improvement in the outcome in several tumors, 
leading to registration. Bevacizumab possesses more single-agent activity in epithelial 
ovarian cancer than in any other epithelial tumor, apart from renal cancer, where the 
vascular biology is specifically relevant to this therapeutic approach. Clinical trials have 
confirmed Bevacizumab effectiveness but that also revealed significant toxicity including 
bowel perforation. (Kaye ., 2007; Teoh et al., 2011; Monk et al., 2006).  
Three phase II studies have shown activity for Bevacizumab, an antibody to vascular 
endothelial growth factor (VEGF). The first study included 62 patients who had received 
only one or two prior treatments (these last patients had received one additional platinum-
based regimen because of an initial interval of 12 months or greater after first-line regimens 
and also had to have a performance status of 0 or 1)(Burger et al., 2007). Patients received a 
dose of 15 mg/kg every 21 days; there were two complete responses and 11 partial 
responses, a median PFS of 4.7 months, and an OS of 17 months. This activity was noted in 
both platinum-sensitive and platinum-resistant subsets. The second study only included 
patients with platinum-resistant disease using an identical dose schedule, but the study was 
stopped because five of 44 patients experienced bowel perforations, one of them fatal; seven 
partial responses had been observed (Cannistra et al., 2007). This increased risk of bowel 
perforations was associated with three or more prior treatments (Monk et al., 2006; Kaye 
2007). The third study included 70 patients who received 50 mg of oral cyclophosphamide 
daily, in addition to bevacizumab (10 mg/kg every 2 weeks); 17 partial responses were 
observed and four patients had intestinal perforations. (Garcia et al., 2008). Studies by the 
Gynecologic Oncology Group are evaluating the efficacy of the drug added to the initial 
treatment and at first recurrence in the platinum-resistant setting. Bevacizumab will 
probably be approved for clinical use in the near future. As neovascularization is a 
complicated process other antiangiogenic agents have been developed to overcome 
resistance to VEGF blockade, and several are undergoing clinical trials (Teoh et al., 2011). 
Future studies must answer to the following questions: The role of bevacizumab in first-line 
treatment and in the management of recurrent disease, the results of the combination with 
chemotherapy, risk factors for bowel perforation, the appropriate dose 15mg/Kg every 
three weeks or less and criteria for patient selection for bevacizumab treatment. (Kaye., 2007; 
Teoh et al., 2011; Monk et al., 2006).  
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Several targeted therapeutic agents are under evaluation in ongoing studies. They include 
the following groups of agents: 1) Antiangiogenic agents, 2) mTOR inhibitors, 3) PARP 
inhibitors and 4) Histone Deacetylase inhibitors.  
1. Antiangiogenic agents include: a) Bevacizumab which has already been presented and 
will probably be approved for clinical use in the near future. b) VEGF-Trap a potent 
angiogenesis inhibitor fusion protein is under study. c) Agents that block the VEGF 
receptor. These agents include sorafenib and sunitinib, small molecules that block 
tyrosine kinase activity located in the cytoplasmic domain of VEGF receptor (VEGFR). 
Some of these molecules block VEGFR specifically, whereas others, such as sorafenib 
and sunitinib, block both VEGFR and the platelet-derived growth factor (PDGFR), 
thought to be involved in later phases of tumor angiogenesis relating to vessel 
maturation. (Gardner & Jewell, 2011).  
2. mTOR inhibitors. Dysregulation of mTOR signaling occurs in many tumors and has 
been found to be activated in gynecological cancers. Increased AKT/PI3K activity with 
constitutive downstream activation of the mTOR pathway has been found in ovarian 
tumor specimens and ovarian cancer cell lines. Inhibition of mTOR by agents such 
temsirolimus, everolimus and deforolimus are in clinical trials.(Gardner & Jewell, 2011). 
3. PARP inhibitors. Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase 
(PARP), a key enzyme in the DNA repair, may lead to the accumulation of breaks in 
double-stranded and cell death. Therefore, PARP inhibitors have been developed and 
are potentially exciting agents in the treatment of ovarian cancer, especially cancers 
with BRCA1 and BRCA2 mutations. Initial reports have been encouraging A phae II, 
randomized double-blind, multicenter study is assessing the efficacy of an oral PARP 
inhibitor olaparib (AZD2281) in the treatment of patients with platinum-sensitive 
serous ovarian cancer following treatment with two or more platinum-containing 
regimens. (Gardner & Jewell, 2011). 
4. Histone Deacetylase Inhibitors. Aberrant histone modifications such as hypoacetylation 
have been associated with malignancy through the transcriptional silencing of tumor 
suppressor genes. Belinostat is a histone deacetylase inhibitor (HDAC) that can alter the 
acetylation level of histone and nonhistone proteins. Such epigenetic modulation may 
sensitize drug-resistant tumor cells to other antineoplastic agents, as suggested in 
preclinical studies. A phase II study is examining the use of belinostat in combination 
with carboplatin among patients with recurrent or persistent platinim-resistant disease. 
(Gardner & Jewell, 2011). These new targeted biologic agents, particularly those 
involved with the vascular endothelial growth factor pathway and those targeting the 
poly (ADP-ribose) polymerase (PARP) enzyme, hold great promise for improving the 
outcome of ovarian cancer. (Jelovac & Armstrong 2011). 
2.4.7 Microarray – Based gene expression studies in ovarian cancer 
Despite recent improvements in treatment, ovarian cancer remains the No. 1 cause of death 
among gynecologic cancer in the United States. In more than 90% of patients with localized 
disease, surgery alone is curative. However, in most patients, the tumor has disseminated 
beyond the ovaries by the time the cancer is diagnosed. For these patients combined 
modality treatment, surgery and chemotherapy, is necessary and first-line chemotherapy 
has yielded response rates of greater than 80%. Unfortunately the median progression-free 
survival has been only 18 months in these patients and, in most with advanced cancer, the 
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disease eventually relapses and the patient dies. Studies evaluating various cytotoxic agents 
in recurrent ovarian cancer have generally shown responses of 10% to 28% with limited 
effect on overall survival. This has prompted the search for novel strategies for treatment of 
ovarian cancer. (Chon & Lancaster, 2011). 
Since 1987 microarray technology has been deeply incorporated in research settings and is 
developing an increasing presence in clinical arenas. Prior to the era of microarrays, the 
approach to understanding carcinogenesis largely focused on studying one gene at a time. 
Measuring the expression of thousands of genes at the same time using microarrays has 
answered many questions that were impossible to resolve previously. Gene expression 
assays are now used in daily clinical practice in the care of many patients who are newly 
diagnosed with breast cancer. In ovarian cancer, gene expression profiles have so far been 
used to examine differential gene expression patterns between histology subtypes. Several 
studies have sought to identify gene expression signatures that correlate with clinical 
outcome, to determine which genes affect survival and relapse, and to generate biomarkers 
that could predict patient response to chemotherapy.  Data from these studies have 
deepened and widened our understanding of the biology of ovarian cancer despite some 
challenges. Studies on the role of microarray analysis to identify gene expression profiles 
associated with prognostic values and prognostic and predictive molecular markers will 
help identify patient groups who could benefit more from individualized treatment rather 
than the current standard first-line chemotherapy. In addition, identification of biomarkers 
associated with early detection of disease and molecular subsets will also improve overall 
survival for patients with ovarian cancer, as the early signs of the disease are often 
undetectable. (Chon & Lancaster, 2011). 
2.4.8 Ovarian cancer: The future 
Over the last several decades, clinical trials have led in 2006, for the first time, to a median 
overall survival of greater than 5 years in advanced – stage patients treated in a randomized 
controlled trial (Gardner & Jewell, 2011). Clinical trials continue to address important 
questions including the following issues: 1) The combination of surgery and chemotherapy. 
2) The identification of new targeted therapeutics. 3) The route and timing of chemotherapy 
administration.  4) The quality of life endpoint 5) Tissue acquisition for translational studies. 
(Gardner & Jewell, 2011).  
Quality of life studies. Persistent or recurrent ovarian cancer is not a curable disease today. 
The first aim of the Oncologist must be the improvement or maintenance of the quality of 
patients’ life and the second the survival increase. There are at least 78 ongoing studies on 
quality of life today. The burden of disease and the effects of treatment have been 
increasingly recognized.  Clinical trials are increasingly including quality of life components 
in trial designs in an effort to increase the duration of life and improve its quality at the 
same time. (Gardner & Jewell, 2011). Health – related quality of life (HRQOL) addresses 
important aspects of the patient’s life including physical, social, psychological, financial, and 
sexual issues, as well as the side effects of the chemotherapeutic medications that we rely on 
for treatment. (Grzankowski & Carney, 2011). HRQOL assessment plays an important role 
in medical care, and this is especially significant in ovarian cancer treatment as 80% of 
newly diagnosed patients present with advanced disease and require extensive surgical and 
chemotherapeutic treatment regimens that are associated with significant morbidity. 
(Grzankowski & Carney, 2011). HRQOL data can be utilized in clinical trials, with an 
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endpoint of improvement of HRQOL. The data can also be used as a tool in standardizing 
the efficacy and tolerability of treatment. In addition, information from the HRQOL 
assessments may help identify the need for changes in treatment regimens that may have 
otherwise been overlooked and can aid in the deciding when to pursue need for further 
treatment versus palliative care. (Grzankowski & Carney, 2011). Prolongation of life, 
without regard for the quality of that life, is not a universally desired goal. When 
considering aggressive, life-prolonging treatments and end-of-life decisions, it is necessary 
to consider each individual’s assessment of what makes life worth living. Overall HRQOL 
assessment can help patients with ovarian cancer maintain autonomy when faced with the 
difficult decision between aggressive, life – prolonging treatments versus end-of-life 
decisions. As medical, pharmaceutical, and surgical techniques continue to prolong life 
much longer than our predecessors would have imagined, it is now the role of today’s 
physicians to encompass quality of life into their ever-changing role as health care providers 
and patient advocates. To reach such positive outcomes, the use of an interdisciplinary 
treatment team approach is vital to each patient’s needs. To optimize treatment decisions for 
patients with ovarian cancer, clinicians need to be familiar with differences between 
regimens in terms of toxicity, dosage, and administration, and emerging data from HRQOL 
assessments. (Grzankowski & Carney, 2011). 
While decisions surrounding the diagnosis and treatment of cancer are difficult and cost is 
not usually the most pressing concern of decision makers, the increasing burden of the 
rising cost of healthcare demands attention. As newer, higher-cost therapies become 
available, formal evaluation of the costs and benefits of these new treatments in comparison 
to existing and established strategies should be a high priority. (Sfakianos et al, 2011). 
2.5.1 Treatment options for patients with persistent or recurrent disease 
There are today three available treatment options, as presented above, for patients with 
persistent or recurrent disease than can be used alone or in combination: 
a.  Secondary cytoreduction.  
b. Chemotherapy. For patients with platinum-sensitive disease treatment with a 
cisplatinum or carboplatin combination is indicated. For patients with platinum-
refractory or platinum-resistant disease treatment with other effective drugs must be 
used. 
c. Clinical trials.  
3. Conclusions 
Patients with persistent or recurrent ovarian cancer have a lethal chronic disease. Treating 
them is challenging, and despite the recent advances many controversies remain. Research 
findings continue to resolve many of these issues. Secondary cytoreduction, especially 
complete, combined with further adjuvant therapy at the time of relapse may improve 
clinical outcome in selected patients. There are several treatment choices from first relapse to 
terminal state; however these choices cannot be made uniformly. They should be decided on 
an individual basis depending directly on the patients’ condition. Patients with recurrent 
platinum-sensitive ovarian cancer have significant response rates and longer PFS when 
treated with combination platinum-based chemotherapy. Most recurrent patients with 
platinum resistant disease have little chance for a long PFS, but treatment may contribute to 
extending their overall survival.  
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disease eventually relapses and the patient dies. Studies evaluating various cytotoxic agents 
in recurrent ovarian cancer have generally shown responses of 10% to 28% with limited 
effect on overall survival. This has prompted the search for novel strategies for treatment of 
ovarian cancer. (Chon & Lancaster, 2011). 
Since 1987 microarray technology has been deeply incorporated in research settings and is 
developing an increasing presence in clinical arenas. Prior to the era of microarrays, the 
approach to understanding carcinogenesis largely focused on studying one gene at a time. 
Measuring the expression of thousands of genes at the same time using microarrays has 
answered many questions that were impossible to resolve previously. Gene expression 
assays are now used in daily clinical practice in the care of many patients who are newly 
diagnosed with breast cancer. In ovarian cancer, gene expression profiles have so far been 
used to examine differential gene expression patterns between histology subtypes. Several 
studies have sought to identify gene expression signatures that correlate with clinical 
outcome, to determine which genes affect survival and relapse, and to generate biomarkers 
that could predict patient response to chemotherapy.  Data from these studies have 
deepened and widened our understanding of the biology of ovarian cancer despite some 
challenges. Studies on the role of microarray analysis to identify gene expression profiles 
associated with prognostic values and prognostic and predictive molecular markers will 
help identify patient groups who could benefit more from individualized treatment rather 
than the current standard first-line chemotherapy. In addition, identification of biomarkers 
associated with early detection of disease and molecular subsets will also improve overall 
survival for patients with ovarian cancer, as the early signs of the disease are often 
undetectable. (Chon & Lancaster, 2011). 
2.4.8 Ovarian cancer: The future 
Over the last several decades, clinical trials have led in 2006, for the first time, to a median 
overall survival of greater than 5 years in advanced – stage patients treated in a randomized 
controlled trial (Gardner & Jewell, 2011). Clinical trials continue to address important 
questions including the following issues: 1) The combination of surgery and chemotherapy. 
2) The identification of new targeted therapeutics. 3) The route and timing of chemotherapy 
administration.  4) The quality of life endpoint 5) Tissue acquisition for translational studies. 
(Gardner & Jewell, 2011).  
Quality of life studies. Persistent or recurrent ovarian cancer is not a curable disease today. 
The first aim of the Oncologist must be the improvement or maintenance of the quality of 
patients’ life and the second the survival increase. There are at least 78 ongoing studies on 
quality of life today. The burden of disease and the effects of treatment have been 
increasingly recognized.  Clinical trials are increasingly including quality of life components 
in trial designs in an effort to increase the duration of life and improve its quality at the 
same time. (Gardner & Jewell, 2011). Health – related quality of life (HRQOL) addresses 
important aspects of the patient’s life including physical, social, psychological, financial, and 
sexual issues, as well as the side effects of the chemotherapeutic medications that we rely on 
for treatment. (Grzankowski & Carney, 2011). HRQOL assessment plays an important role 
in medical care, and this is especially significant in ovarian cancer treatment as 80% of 
newly diagnosed patients present with advanced disease and require extensive surgical and 
chemotherapeutic treatment regimens that are associated with significant morbidity. 
(Grzankowski & Carney, 2011). HRQOL data can be utilized in clinical trials, with an 
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endpoint of improvement of HRQOL. The data can also be used as a tool in standardizing 
the efficacy and tolerability of treatment. In addition, information from the HRQOL 
assessments may help identify the need for changes in treatment regimens that may have 
otherwise been overlooked and can aid in the deciding when to pursue need for further 
treatment versus palliative care. (Grzankowski & Carney, 2011). Prolongation of life, 
without regard for the quality of that life, is not a universally desired goal. When 
considering aggressive, life-prolonging treatments and end-of-life decisions, it is necessary 
to consider each individual’s assessment of what makes life worth living. Overall HRQOL 
assessment can help patients with ovarian cancer maintain autonomy when faced with the 
difficult decision between aggressive, life – prolonging treatments versus end-of-life 
decisions. As medical, pharmaceutical, and surgical techniques continue to prolong life 
much longer than our predecessors would have imagined, it is now the role of today’s 
physicians to encompass quality of life into their ever-changing role as health care providers 
and patient advocates. To reach such positive outcomes, the use of an interdisciplinary 
treatment team approach is vital to each patient’s needs. To optimize treatment decisions for 
patients with ovarian cancer, clinicians need to be familiar with differences between 
regimens in terms of toxicity, dosage, and administration, and emerging data from HRQOL 
assessments. (Grzankowski & Carney, 2011). 
While decisions surrounding the diagnosis and treatment of cancer are difficult and cost is 
not usually the most pressing concern of decision makers, the increasing burden of the 
rising cost of healthcare demands attention. As newer, higher-cost therapies become 
available, formal evaluation of the costs and benefits of these new treatments in comparison 
to existing and established strategies should be a high priority. (Sfakianos et al, 2011). 
2.5.1 Treatment options for patients with persistent or recurrent disease 
There are today three available treatment options, as presented above, for patients with 
persistent or recurrent disease than can be used alone or in combination: 
a.  Secondary cytoreduction.  
b. Chemotherapy. For patients with platinum-sensitive disease treatment with a 
cisplatinum or carboplatin combination is indicated. For patients with platinum-
refractory or platinum-resistant disease treatment with other effective drugs must be 
used. 
c. Clinical trials.  
3. Conclusions 
Patients with persistent or recurrent ovarian cancer have a lethal chronic disease. Treating 
them is challenging, and despite the recent advances many controversies remain. Research 
findings continue to resolve many of these issues. Secondary cytoreduction, especially 
complete, combined with further adjuvant therapy at the time of relapse may improve 
clinical outcome in selected patients. There are several treatment choices from first relapse to 
terminal state; however these choices cannot be made uniformly. They should be decided on 
an individual basis depending directly on the patients’ condition. Patients with recurrent 
platinum-sensitive ovarian cancer have significant response rates and longer PFS when 
treated with combination platinum-based chemotherapy. Most recurrent patients with 
platinum resistant disease have little chance for a long PFS, but treatment may contribute to 
extending their overall survival.  
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Finding the optimal treatment remains a research goal. 
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1. Introduction 
The overall goal of this chapter is to provide evidence for the feasibility of repositioning 
antiprogestin compounds originally utilized for reproductive medicine toward ovarian cancer 
therapy. This disease is the most deadly of the female reproductive track; at the time of 
diagnosis, in the majority of cases abnormal growths have progressed outside the ovaries and 
into the nearby fallopian tubes, uterus, and peritoneal cavity. Thus, the majority of diagnosed 
patients require cytoreductive surgery followed by platinum-based chemotherapy (Bukowski 
et al.,2007; DiSaia&Bloss,2003; Martin,2007; Naora&Montell,2005; Ozols,2006a). The efficacy of 
this therapy, however, is limited by the elevated toxicity of the platinum derivatives (Cepeda 
et al.,2007), the development of mechanisms to escape drug toxicity (Cepeda et al.,2007; 
Kelland,2007), and the repopulation or regrowth of cells between treatment intervals 
(Kim&Tannock,2005), all of which lead to the recurrence of the disease. The majority of 
relapsing patients are platinum-resistant, with very limited chemotherapeutic options, and a 
median survival time of about only two years (Gordon et al.,2004; Modesitt&Jazaeri,2007; 
Ozols,2006b; Pectasides et al.,2006; Wilailak&Linasmita,2004). The five-year survival for 
ovarian cancer patients is extremely disappointing, ranging from 37% to 45% (Jemal et 
al.,2006). Hence, new therapeutic interventions to overcome the limitations of platinum-based 
therapy for ovarian cancer patients are greatly needed. 
2. Mifepristone: A prototypical antiprogestin 
The synthetic steroid RU-38486 or simply RU-486, now named mifepristone, was first 
synthesized in the mid-1980s when investigators were in the pursuit of synthesizing an  
antiglucocorticoid agent to treat Cushing’s syndrome (Spitz,2006); however, because in 
preclinical studies with pregnant animals the compound had a remarkable capacity to 
interrupt pregnancy, its ability to oppose progesterone action in the uterus was inferred. As 
a result, mifepristone was rapidly repositioned for reproductive medicine, to exploit largely 
its antiprogesterone and, consequently, contraceptive properties. Mifepristone became the 
first prototypical antiprogestin clinically approved for early termination of pregnancy in the 
United States in 2000. In this context, mifepristone blocks progesterone receptors in the 
uterus (Philibert et al.,1985), thus increasing the sensitivity to myometrial contractions 
induced by prostaglandin analogues, leading to early interruption of pregnancy (Benagiano 
et al.,2008a).  
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its antiprogesterone and, consequently, contraceptive properties. Mifepristone became the 
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Mifepristone has also been used for other reproductive indications, such as oral 
contraception, menstrual regulation, and emergency contraception (Benagiano et al.,2008b; 
Ho et al.,2002). More recently, mifepristone emerged as a treatment of endocrine-related 
diseases such as endometriosis and uterine leiomyoma (Moller et al.,2008); it diminishes the 
pain associated with pelvic endometriosis (Fedele&Berlanda,2004; Kettel et al.,1994) and 
reduces the size of uterine fibroids, improving quality of life without evidence of 
endometrial hyperplasia (Eisinger et al.,2009; Murphy et al.,1995; Steinauer et al.,2004). 
3. Mifepristone is a valuable therapeutic alternative in oncology 
The antiprogestin activity of mifepristone has been extensively studied; however, it is 
evident that the contraceptive effect of the compound jeopardized its investigation for other 
medical uses, in particular, its application in oncology, which is now emerging. In non-
reproductive tissues, it was reported that mifepristone inhibited the growth of gastric cancer 
cells (Li et al.,2004), meningioma cells in vitro and in vivo (Grunberg et al.,2006; Grunberg et 
al.,1991; Matsuda et al.,1994; Tieszen et al.,2011), glioblastoma and osteosarcoma cells 
(Tieszen et al.,2011), and non-small lung cell carcinoma cell lines (Weidner, Hapon & 
Telleria, unpublished observations).  
In reproductive tissues, mifepristone blocked the growth of cervical adenocarcinoma cells in 
vitro and in vivo (Jurado et al.,2009), and inhibited cell proliferation killing benign and 
malignant endometrial cancer cells (Han&Sidell,2003; Murphy et al.,2000; Narvekar et 
al.,2004; Schneider et al.,1998). In prostate cancer, the antiprogestin blocked growth of 
androgen-sensitive and androgen-insensitive LNCaP and PC-3 cells (El Etreby et al.,2000a; 
El Etreby et al.,2000b; Liang et al.,2002; Tieszen et al.,2011). In breast cancer, mifepristone 
inhibited the growth of T-47D (Musgrove et al.,1997), MCF-7, and MDA-MB-231 cells 
(Tieszen et al.,2011); particularly in MCF-7 cells, mifepristone had an additive lethal effect 
when associated with the antiestrogen tamoxifen (El Etreby et al.,1998), as well as a 
synergistic lethal interaction with the Chk-1 inhibitor 7-hydroxystaurosporine (UCN-01) 
(Yokoyama et al.,2000) and with 4-hydroxytamoxifen (Schoenlein et al.,2007). Mifepristone 
also blocked the growth of MCF-7 sublines made resistant to 4-hydroxytamoxifen (Gaddy et 
al.,2004) and was lethal to MDA-MB-231 cells that are devoid of estrogen and progesterone 
receptors (Liang et al.,2003). In p53/BRCA1-deficient mice, mifepristone prevented the 
formation of breast tumors (Poole et al.,2006), indicating its efficacy not only impairing the 
growth of established mammary tumors but also inhibiting mammary tumorigenesis. In 
mice with spontaneous lung cancer or leukemia, mifepristone was also found to improve 
longevity and quality of life (Check et al.,2009; Check et al.,2010b). Most recently, case 
studies of patients with widely metastatic thymic, renal, colon, or pancreatic cancers no 
longer responding to chemotherapy, reported that chronic daily treatment with 200 mg 
mifepristone had a significant improvement in their qualities of life (Check et al.,2010a). 
4. Mifepristone in ovarian cancer therapeutics 
The action of antiprogestins on ovarian cancer has received limited attention. First in 1996, it 
was revealed that the antiprogestin mifepristone arrested OVCAR-3 and A2780 ovarian 
cancer cells at the G1 phase of the cell cycle (Rose&Barnea,1996). In a small clinical trial 
conducted with patients having recurrent epithelial ovarian cancer whose tumors had 
become resistant to standard chemotherapy, mifepristone administration showed promising 
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effects against some of the tumors (Rocereto et al.,2000). Years later, it was reported that 
mifepristone enhanced the toxic effect of cisplatin on COC1 ovarian cancer cells in vitro and 
in xenografted immunosuppressed mice (Liu et al.,2003; Qin&Wang,2002).  
These initial studies indicated an anti-ovarian cancer activity of mifepristone, yet the 
molecular target(s) involved in mediating such an effect remained obscure. In 2007, we 
described some molecular mediators of growth inhibition induced by mifepristone as a 
single agent in ovarian cancer cells, and further defined its efficacy in an in vivo preclinical 
setting (Goyeneche et al.,2007). We also proved that cytostatic doses of mifepristone added 
after a lethal dose of cisplatin prevents repopulation of remnant ovarian cancer cells 
surviving a platinum insult (Freeburg et al.,2009b). We showed that cell cultures exposed to 
mifepristone after cisplatin had a remarkable increase in the percentage of cells expressing 
the cell death marker cleaved poly (ADP-ribose) polymerase (PARP) and the mitotic marker 
phospho-histone H3 suggesting that mifepristone potentiates cisplatin lethality and that the 
cells likely die as a consequence of mitotic failure (Freeburg et al.,2009b). We also reported 
that the effect of mifepristone in ovarian cancer cells is independent of p53 functionality and 
platinum sensitivity (Freeburg et al.,2009a), making mifepristone an even more interesting 
chemotherapeutic candidate for ovarian cancer as the majority of tumors in relapsing 
patients are platinum resistant and p53 mutant (Ozols,2006b). Finally, we have shown in 
ovarian cancer cells that mifepristone potentiates the lethality of otherwise sub-lethal doses 
of cisplatin, and synergizes with cisplatin growth inhibiting ovarian cancer cells of different 
genetic backgrounds and platinum sensitivities (Gamarra-Luques&Telleria,2010).  
4.1 Mifepristone-induced cytostasis vs. lethality in ovarian cancer cells 
Antiprogestin mifepristone is toxic towards ovarian cancer cells, with cytostasis manifested at 
lower micromolar concentrations and lethality taking place when the compound is used at 
higher micromolar doses (Freeburg et al.,2009a; Goyeneche et al.,2007; Goyeneche et al.,2011; 
Tieszen et al.,2011). When mifepristone was used at doses up to 20 M, the effect was limited 
to cytostasis demonstrated by the reversibility of the growth inhibition observed when the 
drug was removed from the culture media, in association with the lack of measurable cell 
death (Goyeneche et al.,2007). In all ovarian cancer cell lines we investigated, concentrations of 
mifepristone 30 M or higher were lethal (Freeburg et al.,2009a; Goyeneche et al.,2011; Tieszen 
et al.,2011).  This lethality was illustrated by the reduced viability of the cells, the increase in 
cellular particles with hypodiploid fragmented DNA content, and the cleavage of the cell 
death associated caspase, caspase-3, in parallel with the cleavage of the widely accepted 
marker of cell death and a substrate for caspase-3, PARP (Scovassi&Poirier,1999). The lethality 
of concentrations of mifepristone over 40 M towards ovarian cancer cells was first suggested 
in OVCAR-3 and A2780 cells (Rose&Barnea,1996). Yet, our studies demonstrate that the 
lethality of mifepristone monotherapy towards ovarian cancer cells is related to a caspase-
associated apoptotic process.  
The dose-dependent cytostatic and lethal effects of mifepristone towards ovarian cancer 
cells, which we globally refer to as cytotoxicity, occur also in breast cancer cells. In the MCF-
7 breast cancer cell line the combination of mifepristone and antiestrogen 4-
hydroxytamoxifen had greater cytostatic and lethal activities than either monotherapy, 
whereas the lethality of the treatment was associated with genomic DNA fragmentation and 
cleavage of PARP (Schoenlein et al.,2007). In addition, it has been shown that MCF-7 cells 
made resistant to 4-hydroxytamoxifen also respond to mifepristone monotherapy 
undergoing apoptotic death (Gaddy et al.,2004); finally, although at higher concentrations, 
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effects against some of the tumors (Rocereto et al.,2000). Years later, it was reported that 
mifepristone enhanced the toxic effect of cisplatin on COC1 ovarian cancer cells in vitro and 
in xenografted immunosuppressed mice (Liu et al.,2003; Qin&Wang,2002).  
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setting (Goyeneche et al.,2007). We also proved that cytostatic doses of mifepristone added 
after a lethal dose of cisplatin prevents repopulation of remnant ovarian cancer cells 
surviving a platinum insult (Freeburg et al.,2009b). We showed that cell cultures exposed to 
mifepristone after cisplatin had a remarkable increase in the percentage of cells expressing 
the cell death marker cleaved poly (ADP-ribose) polymerase (PARP) and the mitotic marker 
phospho-histone H3 suggesting that mifepristone potentiates cisplatin lethality and that the 
cells likely die as a consequence of mitotic failure (Freeburg et al.,2009b). We also reported 
that the effect of mifepristone in ovarian cancer cells is independent of p53 functionality and 
platinum sensitivity (Freeburg et al.,2009a), making mifepristone an even more interesting 
chemotherapeutic candidate for ovarian cancer as the majority of tumors in relapsing 
patients are platinum resistant and p53 mutant (Ozols,2006b). Finally, we have shown in 
ovarian cancer cells that mifepristone potentiates the lethality of otherwise sub-lethal doses 
of cisplatin, and synergizes with cisplatin growth inhibiting ovarian cancer cells of different 
genetic backgrounds and platinum sensitivities (Gamarra-Luques&Telleria,2010).  
4.1 Mifepristone-induced cytostasis vs. lethality in ovarian cancer cells 
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et al.,2011).  This lethality was illustrated by the reduced viability of the cells, the increase in 
cellular particles with hypodiploid fragmented DNA content, and the cleavage of the cell 
death associated caspase, caspase-3, in parallel with the cleavage of the widely accepted 
marker of cell death and a substrate for caspase-3, PARP (Scovassi&Poirier,1999). The lethality 
of concentrations of mifepristone over 40 M towards ovarian cancer cells was first suggested 
in OVCAR-3 and A2780 cells (Rose&Barnea,1996). Yet, our studies demonstrate that the 
lethality of mifepristone monotherapy towards ovarian cancer cells is related to a caspase-
associated apoptotic process.  
The dose-dependent cytostatic and lethal effects of mifepristone towards ovarian cancer 
cells, which we globally refer to as cytotoxicity, occur also in breast cancer cells. In the MCF-
7 breast cancer cell line the combination of mifepristone and antiestrogen 4-
hydroxytamoxifen had greater cytostatic and lethal activities than either monotherapy, 
whereas the lethality of the treatment was associated with genomic DNA fragmentation and 
cleavage of PARP (Schoenlein et al.,2007). In addition, it has been shown that MCF-7 cells 
made resistant to 4-hydroxytamoxifen also respond to mifepristone monotherapy 
undergoing apoptotic death (Gaddy et al.,2004); finally, although at higher concentrations, 
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mifepristone was also cytotoxic to progesterone receptor- and estrogen receptor-negative 
MDA-MB-231 breast cancer cells (Liang et al.,2003; Tieszen et al.,2011).  
4.2 The inhibition of ovarian cancer growth by mifepristone occurs regardless of 
histopathological classification, platinum sensitivity, or p53 genetic background 
Ovarian cancer is very heterogeneous from histopathological and genetic viewpoints 
(Cannistra,2004; Despierre et al.,2010). Furthermore, mutations of the p53 tumor suppressor 
gene occur at extremely high frequencies in ovarian cancer (Havrilesky et al.,2003), whereas  
most recurrent patients with ovarian cancer are platinum-resistant, consequently being left 
with therapeutic alternatives that have very disappointing outcomes (DiSaia&Bloss,2003; 
Herzog,2006; Vasey,2003). Thus, if the histopathological and genetic backgrounds, 
sensitivity to platinum, and p53 status of the ovarian cancer cells would not condition their 
response to the growth inhibition activity of mifepristone, such findings would have 
pronounced clinical relevance.  
We showed that the cytostatic effect of mifepristone displayed similar potency among the 
ovarian cancer cells representing various histopathological origins (Freeburg et al.,2009a; 
Goyeneche et al.,2007; Tieszen et al.,2011), such as clear cell adenocarcinoma (SK-OV-3), 
papillary ovarian adenocarcinoma (Caov-3 cells), glandular with mixed differentiation 
(IGROV-1), undifferentiated (A2780), and endometrioid (OV2008) cells (Shaw et al.,2004).   
We proved that the growth inhibition induced by mifepristone occurred irrespective of the 
p53 background of the ovarian cancer cell lines studied, with IC50s ranging between ~ 7 to 12 
M (Freeburg et al.,2009a; Goyeneche et al.,2007) in p53 wild type cells [e.g. OV2008, 
OV2008/C13, A2780, and IGROV-1; (Casalini et al.,2001; Fraser et al.,2003; Sasaki et al.,2000; 
Siddik et al.,1998)], p53 mutant cells [A2780/CP70 and Caov-3 (Lu et al.,2001; Reid et 
al.,2004; Yaginuma&Westphal,1992)], or p53 null cells [SK-OV-3; (O'Connor et al.,1997; 
Yaginuma&Westphal,1992)]. 
We observed that mifepristone displayed similar growth inhibition potency among SK-OV-
3, OV2008, and Caov-3 cell  lines (Goyeneche et al.,2007), which have different sensitivities 
to platinum agents. OV2008 cells were reported as being highly sensitive to cisplatin 
(Katano et al.,2002), SK-OV-3 cells were originally obtained from a patient with intrinsic 
resistance to clinically achievable doses of cisplatin and considered, in vitro, as semi-resistant 
to platinum (Ormerod et al.,1996), whereas Caov-3 cells were shown to be resistant to 
cisplatin (Arimoto-Ishida et al.,2004; Hayakawa et al.,1999). Furthermore, when we studied 
the action of mifepristone among ovarian cancer cell line pairs consisting of cisplatin-
sensitive parental lines and stable cisplatin-resistant sublines derived by in vitro selection 
with stepwise exposure to cisplatin, the toxicity of mifepristone did not discriminate among 
the cell lines, as we could not find a correlation between the IC50s for mifepristone and the 
IC50s for cisplatin obtained for the ovarian cancer cell lines studied (Freeburg et al.,2009a). 
These results confirm that mifepristone growth inhibits ovarian cancer cells regardless of 
their sensitivities to cisplatin.  
5. Anti-ovarian cancer effect of antiprogestins other than mifepristone: ORG-
31710 and CDB-2914 (Ulipristal) 
ORG-31710 and CDB-2914 (a.k.a. ulipristal) are two members of a family of selective 
progesterone receptor modulators with a similar structure to RU-38486, as they all contain a 
dimethylaminophenyl substitution at the 11-position that confers antiprogestin activity 
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(Belanger et al.,1981; Benagiano et al.,2008a; Moller et al.,2008) (Fig. 1). ORG-31710 and CDB-
2914, however, were designed with the aim to decrease the antagonistic effect of RU-38486 on 
the glucocorticoid receptor by substitutions made at the 17side chain (Moller et al.,2008). 
 
 
Fig. 1. Chemical structure of antiprogestins [Adapted from (Goyeneche et al.,2011)] 
Limited information is available on the oncologic value of CDB-2914 and ORG-31710. Both 
chemicals were effective in rats, reducing the growth of established DMBA-induced breast 
tumors (Kloosterboer et al.,2000; Wiehle et al.,2007). In cultured human uterine leiomyoma 
cells, CDB-2914 inhibited cell proliferation down-regulating PCNA expression and inducing 
apoptosis (Xu et al.,2005). Moreover, a randomized controlled clinical trial revealed that 
CDB-2914 reduced leiomyoma growth (Levens et al.,2008).  ORG-31710, on the other hand, 
was effective in increasing apoptosis in human periovulatory granulosa cells (Svensson et 
al.,2001). We have proved that mifepristone, ORG-31710 and CDB-2914, are all cytostatic at 
lower concentrations and lethal at higher doses towards OV2008 and SK-OV-3 ovarian 
cancer cells (Goyeneche et al.,2011). 
6. Mechanisms of antiproliferation of ovarian cancer cells by antiprogestins  
It is apparent that different antiprogestin compounds are cytotoxic to ovarian cancer cells 
displaying two main effects: (i) a cytostatic effect at lower concentrations blocking cell 
growth at the G1 phase of the cell cycle; and (ii) a lethal effect at higher doses associated 
with morphological features of apoptosis and fragmentation of the genomic DNA. The 
overall toxicity of antiprogestins involves a dose-dependent decline in the activity of the cell 
cycle regulatory protein cyclin dependent kinase 2 (Cdk-2).  
6.1 Cell cycle arrest  
Exposure of ovarian cancer cells to concentrations of mifepristone likely to be achieved in 
vivo inhibits their growth by inducing G1 cell cycle arrest without triggering cell death. This 
is consistent with the dose-dependent tumor growth inhibition achieved by mifepristone 
monotherapy in vivo in nude mice carrying subcutaneous tumors derived from human 
ovarian cancer cells (Goyeneche et al.,2007).  
The growth inhibitory effect of mifepristone on ovarian cancer cells is associated with 
inhibition of DNA synthesis, down-regulation of the transcription factor E2F1 needed for 
S phase progression, and inhibition of the activity of Cdk-2. This cell cycle regulatory 
protein is critical to promote the transition of cells in the cell cycle from G1 to S phase 
(Conradie et al.,2010). For instance, the activity of Cdk-2 is needed for the stimulation of 
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mifepristone was also cytotoxic to progesterone receptor- and estrogen receptor-negative 
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to platinum agents. OV2008 cells were reported as being highly sensitive to cisplatin 
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resistance to clinically achievable doses of cisplatin and considered, in vitro, as semi-resistant 
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with stepwise exposure to cisplatin, the toxicity of mifepristone did not discriminate among 
the cell lines, as we could not find a correlation between the IC50s for mifepristone and the 
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These results confirm that mifepristone growth inhibits ovarian cancer cells regardless of 
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(Belanger et al.,1981; Benagiano et al.,2008a; Moller et al.,2008) (Fig. 1). ORG-31710 and CDB-
2914, however, were designed with the aim to decrease the antagonistic effect of RU-38486 on 
the glucocorticoid receptor by substitutions made at the 17side chain (Moller et al.,2008). 
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Limited information is available on the oncologic value of CDB-2914 and ORG-31710. Both 
chemicals were effective in rats, reducing the growth of established DMBA-induced breast 
tumors (Kloosterboer et al.,2000; Wiehle et al.,2007). In cultured human uterine leiomyoma 
cells, CDB-2914 inhibited cell proliferation down-regulating PCNA expression and inducing 
apoptosis (Xu et al.,2005). Moreover, a randomized controlled clinical trial revealed that 
CDB-2914 reduced leiomyoma growth (Levens et al.,2008).  ORG-31710, on the other hand, 
was effective in increasing apoptosis in human periovulatory granulosa cells (Svensson et 
al.,2001). We have proved that mifepristone, ORG-31710 and CDB-2914, are all cytostatic at 
lower concentrations and lethal at higher doses towards OV2008 and SK-OV-3 ovarian 
cancer cells (Goyeneche et al.,2011). 
6. Mechanisms of antiproliferation of ovarian cancer cells by antiprogestins  
It is apparent that different antiprogestin compounds are cytotoxic to ovarian cancer cells 
displaying two main effects: (i) a cytostatic effect at lower concentrations blocking cell 
growth at the G1 phase of the cell cycle; and (ii) a lethal effect at higher doses associated 
with morphological features of apoptosis and fragmentation of the genomic DNA. The 
overall toxicity of antiprogestins involves a dose-dependent decline in the activity of the cell 
cycle regulatory protein cyclin dependent kinase 2 (Cdk-2).  
6.1 Cell cycle arrest  
Exposure of ovarian cancer cells to concentrations of mifepristone likely to be achieved in 
vivo inhibits their growth by inducing G1 cell cycle arrest without triggering cell death. This 
is consistent with the dose-dependent tumor growth inhibition achieved by mifepristone 
monotherapy in vivo in nude mice carrying subcutaneous tumors derived from human 
ovarian cancer cells (Goyeneche et al.,2007).  
The growth inhibitory effect of mifepristone on ovarian cancer cells is associated with 
inhibition of DNA synthesis, down-regulation of the transcription factor E2F1 needed for 
S phase progression, and inhibition of the activity of Cdk-2. This cell cycle regulatory 
protein is critical to promote the transition of cells in the cell cycle from G1 to S phase 
(Conradie et al.,2010). For instance, the activity of Cdk-2 is needed for the stimulation of 
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histone gene transcription (Zhao et al.,2000), which is one of the major events marking the 
entry into the S phase. To drive cell cycle progression, Cdk-2 should be free of p21cip1 and 
p27kip1 binding (Conradie et al.,2010), bound to cyclin E, and allocated to the nucleus to 
phosphorylate cell cycle regulatory proteins (Brown et al.,2004; Lents et al.,2002). 
Mifepristone, ORG-31710 and CDB-2914 affect the nucleocytoplasmic trafficking of Cdk 
inhibitors p21cip1 and p27kip1, Cdk-2 and its co-factor cyclin E. The antiprogestins also 
increase p21cip1 and p27kip1 abundances in both cytoplasm and nuclear compartments in 
correlation with decreased Cdk-2 and cyclin E nuclear levels, increased cytoplasmic cyclin 
E, and a remarkable decline in the activity of Cdk-2 in both subcellular compartments 
(Goyeneche et al.,2007; Goyeneche et al.,2011). 
Because Cdk-2 is frequently up-regulated in ovarian tumors as compared to non-cancerous 
cells (Sui et al.,2001), the potent inhibition of Cdk-2 elicited by antiprogestins may be 
critically important from a translational therapeutics viewpoint. Moreover, because 
cytoplasmic localization of Cdk inhibitor p27kip1 in ovarian cancer patients has been 
associated with poor prognosis (Rosen et al.,2005), by promoting an increase in p27kip1 in the 
nucleus, antiprogestins may be able to rescue the tight inhibitory control of Cdk inhibitors 
on Cdk-2 activity that is mostly lost in ovarian cancer.  
The magnitude of inhibition of Cdk-2 activity is related to the growth inhibition potency 
of the antiprogestins with mifepristone>ORG-31710>CDB-2914 (Goyeneche et al.,2011). 
Supporting our results, a decline in cyclin E-associated kinase activity (presumably Cdk-
2) was reported for T-47D breast cancer cells in response to ORG-31710 in the absence of 
significant changes in cyclin E and Cdk levels, but in the presence of elevated amounts of 
p21cip1, suggesting that p21cip1 contributes to the reduction in Cdk-2 activity after 
antiprogestin treatment (Musgrove et al.,1997). In ovarian cancer cells, we provide 
evidence that not only the increased association of p21cip1 and p27kip1 to Cdk-2 may 
account for the reduced Cdk-2 activity in the nucleus in response to antiprogestins, but 
also a reduction in Cdk-2 and cyclin E nuclear levels and redistribution of cyclin E to the 
cytoplasm, are related variables leading to blunt Cdk-2 nuclear activity needed for the 
cells to transit from G1 to S phase. A recent study using LNCaP prostate cancer cells 
revealed that targeting Cdk-2 to the nucleus is sufficient to prevent growth inhibition 
triggered by 1,25 (OH)2 D3 (Flores et al.,2010), suggesting that antiprogestin-mediated 
growth inhibition and growth arrest triggered by metabolites of vitamin D may share 
common molecular intermediaries. 
6.2 Cell death  
At high concentrations, the antiprogestins mifepristone, ORG-31710 and CDB-2914 blunt the 
activity of Cdk-2 leading to ovarian cancer cell death in association with morphological 
features of apoptosis, hypodiploid DNA content, fragmentation of the DNA, and cleavage 
of the executer caspase substrate PARP (Goyeneche et al.,2011). Such effects may be the 
consequence of Cdk-2 inhibition. For instance, in addition to regulating cell cycle 
progression, Cdk-2 is involved in cell survival after DNA damage (Deans et al.,2006; Huang 
et al.,2006). As a survival factor, Cdk-2 phosphorylates the FOXO1 transcription activator of 
pro-apoptotic genes, keeping them in the cytoplasm (Huang et al.,2006; 
Huang&Tindall,2007) . If the activity of Cdk-2 is abolished by an antiprogestin, then FOXO1 
may not be retained in the cytoplasm, consequently migrating to the nucleus where it 
promotes the expression of pro-apoptotic genes (Huang et al.,2006; Huang&Tindall,2007).  
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The lethality of high concentration antiprogestins has features of apoptosis similar to that of 
platinum-induced lethality in the same cell lines in terms of nuclear and DNA 
fragmentation (Goyeneche et al.,2011); however, the molecular mediators of antiprogestin-
induced cell death vary among the steroids. Cleavage of the caspase-3 substrate PARP is a 
commonality among mifepristone, ORG-31710 and CDB-2914. CDB-2914 also causes an up-
regulation of PARP which was previously observed in cultured human uterine leiomyoma 
cells (Xu et al.,2005). In addition, CDB-2914 causes up-regulation of the anti-apoptotic 
proteins XIAP and Bcl-2, yet cell death still ensues but with less effectiveness than that 
observed after exposure to high concentrations of mifepristone or ORG-31710, in which both 
XIAP and Bcl-2 are down-regulated after 3 days of treatment (Goyeneche et al.,2011). Thus, 
the extended up-regulation of XIAP and Bcl-2 upon CDB-2914 treatment but not after 
mifepristone or ORG-31710 may account for the reduced cytotoxic potency of CDB-2914. 
Although with different potencies, high concentrations of antiprogestins lead the cells to 
cross a cell death threshold or point of no return in which the pro-apoptotic load of the cell 
surpasses its anti-apoptotic buffering capacity. 
6.3 Progesterone receptors are not essential for the growth arrest induced by 
antiprogestins in ovarian cancer  
Because several tumors of both gynecologic and non-gynecologic origin are steroid 
hormone-dependent and express progesterone receptors, antiprogestins have been 
investigated as potential anti-cancer therapeutic agents largely based on their capacity to 
modulate progesterone receptors. However, whether the mechanism(s) through which 
antiprogestins act to induce cytostasis and lethality in cancer cells actually requires 
progesterone receptor expression remains obscure.  
When targeting cancer cells mifepristone has progesterone-like activity. For example, in T-
47D breast cancer cells and HeLa cervical adenocarcinoma cells, mifepristone induced 
progesterone-regulated reporter genes mainly when the cyclin AMP pathway was activated 
(Kahmann et al.,1998; Sartorius et al.,1993). In ovarian cancer cells, progesterone blocked cell 
growth (Syed&Ho,2003; Syed et al.,2007; Syed et al.,2001); likewise, mifepristone also 
induced cell growth arrest, though with greater potency than synthetic progestins 
(Goyeneche et al.,2007). These data suggest that the cytostatic effect of mifepristone might be 
mediated by an agonistic action on progesterone receptors.  
Nonetheless, there is ample evidence suggesting that the efficacy of antiprogestins as anti-
cancer agents may not require progesterone receptor expression. Liang and colleagues 
reported that micromolar doses of mifepristone monotherapy were able to inhibit the 
growth of estrogen receptor- and progesterone receptor-negative MDA-MB-231 breast 
cancer cells (Liang et al.,2003). In another report mifepristone, instead of blocking growth 
inhibition induced by progesterone, potentiated progesterone-mediated growth retardation 
and apoptosis (Moe et al.,2009). Such potentiation of cytotoxicity of progesterone by 
mifepristone was also observed in progesterone receptor positive MCF-7 breast cancer cells 
and progesterone receptor negative C4-I cervical carcinoma cells, suggesting that the 
presence of progesterone receptor is not essential for the anti-growth properties of both 
progesterone and mifepristone (Fjelldal et al.,2010).   
The reported level of expression of progesterone receptors in ovarian cancer cell lines is 
controversial. Progesterone receptor immuno-reactive proteins A (PR-A) and B (PR-B) were 
identified in OVCA-429 and OVCA-432 ovarian cancer cells—derived from patients with 
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histone gene transcription (Zhao et al.,2000), which is one of the major events marking the 
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features of apoptosis, hypodiploid DNA content, fragmentation of the DNA, and cleavage 
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late-state serous ovarian cancer—at levels higher than those found in immortalized human 
ovarian surface epithelial cells (Mukherjee et al.,2005). Papillary adenocarcinoma Caov-3 
ovarian cells were reported to express progesterone receptor mRNA in one study (Akahira 
et al.,2002) but not in another report (Hamilton et al.,1984). Similarly, studies in clear 
adenocarcinoma SK-OV-3 ovarian cells showing some and no expression of progesterone 
receptor mRNA have been published (Hamilton et al.,1984; Keith Bechtel&Bonavida,2001; 
McDonnel&Murdoch,2001). We have found low levels of progesterone receptor immuno-
reactive proteins in endometrioid OV2008 ovarian cancer cells when compared with MCF-7 
breast cancer cells used as positive control (Fig.2A). Moreover, utilizing ten cell lines 
expanding cancers from the nervous system (meningioma IOMM-Lee cells and glioblastoma 
U87MG cells), breast (estrogen-responsive MCF-7 and estrogen-unresponsive MDA-MB-231 
cells), prostate (androgen-responsive LNCaP and androgen-unresponsive PC-3 cells), bone 
(osteosarcoma U-2OS and SAOS-2 cells), and ovary (OVCAR-3 and SK-OV-3 cells), and two 
anti-progesterone receptor antibodies, we failed to detect progesterone receptor immuno-
reactive proteins in all but MCF-7 cells, yet all cell lines studied were growth inhibited by 
mifepristone (Tieszen et al.,2011). Even in MCF-7 cells carrying progesterone receptors, 
mifepristone reduced their expression, further discouraging the role of these nuclear 
receptors as mediators of the growth inhibitory effect of mifepristone given that the 
cytostatic property of mifepristone can be maintained long after the receptors are down-
regulated (Tieszen et al.,2011). 
These data rule out progesterone receptors as essential mediators of the growth inhibitory 
effect of antiprogestins. Mainstream literature on the anti-cancer effect of antiprogestin 
mifepristone assumes that it acts as a progesterone receptor antagonist, implying that the 
presence of progesterone receptors in the target tissues is a pre-requisite for mifepristone’s 
anti-growth activity. Our work challenges such a dogma (Tieszen et al.,2011), opening the 
field of study to alternate, non-classical mechanisms whereby antiprogestins operate as cell 
growth inhibitors without the necessity of nuclear progesterone receptors being present or 
operational. If these results were translated into the clinic, the presence or absence of 
classical, nuclear progesterone receptors would not be relevant and would not impact the 
usage of this drug for cancer therapy.  
6.4 Glucocorticoid receptors and the growth inhibitory activity of antiprogestins  
Antiprogestins, mainly mifepristone, may drive their anticancer action through glucocorticoid 
receptors. This is because: (i) mifepristone can bind to glucocorticoid receptors with an affinity 
similar to that of progesterone receptors (Mao et al.,1992); and (ii) ovarian cancer cells have 
been reported to express glucocorticoid receptors (Tieszen et al.,2011; Xu et al.,2003). In this 
regard, we have detected abundant levels of glucocorticoid receptor immuno-reactive proteins 
alpha (GR) and beta (GR) in SK-OV-3, OVCAR-3, and  OV2008 cells [(Tieszen et al.,2011) 
and (Fig.2B)]. When we cultured OV2008 cells in the presence of the glucocorticoid agonist 
dexamethasone at concentrations equimolar to cytostatic mifepristone, ORG-31710 or CDB-
2914, however, the antiprogestins up-regulated Cdk inhibitors p21cip1 and p27kip1 and blocked 
cell growth, but dexamethasone did not, though its activity is demonstrated by the down-
regulation of glucocorticoid receptors (Fig.2B). These data suggest that even if antiprogestins 
bind glucocorticoid receptors in the ovarian cancer cells, they may not trigger receptor 
transactivation. Supporting our observations with ovarian cancer cells, mifepristone blocked 
the growth of LNCaP prostate cancer cells that were either androgen-sensitive or -refractory, 
while competition for glucocorticoid receptors with equimolar doses of mifepristone and 
 
Antiprogestins in Ovarian Cancer 
 
215 
hydrocortisone could not reverse the degree of growth inhibition achieved by mifepristone 






                                                 
Fig. 2. (A) Expression of progesterone receptor isoforms (PR-A and PR-B) and glucocorticoid 
receptors (GR and GR) in OV2008 ovarian cancer cells. Whole cell extracts (WCE) from 
MCF-7 cells were used as positive control for progesterone receptor expression. To detect 
progesterone receptor proteins in OV2008 cells, we worked with cells growing exponentially 
and increased the WCE loading 4-fold with respect to MCF-7. (B) Effect of equimolar 
concentrations of antiprogestins and dexamethasone (DEX) on OV2008 ovarian cancer 
growth. Cells were exposed to vehicle (VEH), 20 M mifepristone (RU-38486), ORG-31710, 
CDB-3914 (ulipristal) or DEX for 72 h. Cell growth (B, upper panel) was analyzed by 
microcytometry and protein expression (B, lower panel) by Western blot. Bars, mean± SEM.  
Mifepristone has potent anti-glucorticoid activity (Baulieu,1991; Benagiano et al.,2008c) . 
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potency depending on the concentration of glucocorticoid receptors in the cell (Zhang et 
al.,2007). Although GR has been considered a dominant-negative regulator of GR(Oakley 
et al.,1999; Taniguchi et al.,2010; Yudt et al.,2003),  it was also reported that mifepristone was 
the only compound of 57 potential natural and synthetic ligands to bind the GR receptor 
isoform, and that interaction of GRβ with mifepristone led to its nuclear translocation 
(Lewis-Tuffin et al.,2007). This latter study also found that despite its classification as a 
dominant-negative isoform lacking transcriptional activity, GR was able to regulate gene 
expression in the absence of GR, and this activity was modulated by the interaction with 
mifepristone. A more recent study also reported intrinsic transcriptional activity of GR 
independent of GR, but neither found an association between mifepristone binding and 
nuclear translocation of GR nor could detect modulation of GR transcriptional activity by 
mifepristone (Kino et al.,2009), adding controversy to the actual activity of mifepristone on 
GR. This evidence and our results encourage performing more studies to underscore a role, 
if any, for either isoform of the glucocorticoid receptor on the anti-growth activity of the 
antiprogestin mifepristone. 
6.5 Other potential targets of antiprogestins when operating as cell growth inhibitors 
A possibility exists that antiprogestins may have an effect that does not involve specific 
hormone receptors. In this regard, mifepristone was shown to have a potent antioxidant 
activity reflected at micromolar concentrations and likely caused by the dimethylamino 
phenyl side chain of the molecule (Parthasarathy et al.,1994). Furthermore, the growth 
inhibitory action of mifepristone in endometrial cells and macrophages was attributed, at 
least in part, to the antioxidant property of the compound (Murphy et al.,2000; Roberts et 
al.,1995). A putative antioxidant effect of mifepristone on ovarian cancer cells could be 
interesting in the context of G1 arrest associated with p21cip1 upregulation, because p21cip1 
can be induced in response to some antioxidants in a p53 independent manner 
(Liberto&Cobrinik,2000; Liu et al.,1999). We have shown that growth arrest caused by 
mifepristone is associated with p21cip1 increase in p53 wild type OV2008 cells and in p53 null 
SK-OV3 cells, opening the possibility for mifepristone acting as an antioxidant to drive G1 
arrest through a p53-independent up-regulation of p21cip1.  
Another potential target of antiprogestin action is the ubiquitin-proteasome system (UPS). 
This idea is based on the following facts:  (i) to transition from G1 to S phase and to commit 
to DNA synthesis, the cells must degrade the Cdk-2 inhibitors p27kip1 and p21cip via the 
Skp1-Cullin-F-box protein/Skp2 (SCFSkp2) E3 ubiquitin ligase complex (Bornstein et al.,2003; 
Tsvetkov et al.,1999). This requires the Cdk-2-dependent phosphorylation of p27kip1 on 
Thr187 (Tsvetkov et al.,1999) and p21cip1 on Ser130 (Bornstein et al.,2003); (ii)  antiprogestins 
have a dual effect blocking Cdk-2 activity and triggering the accumulation of p21cip1 and 
p27kip1, and these Cdk-2 inhibitors rely on the UPS for their disappearance to enforce the 
orderly progression of the cell cycle from G1 to the S phase;  (iii) there are remarkable 
similarities in the behavior of antiprogestins and proteasome inhibitors in inducing p21cip1 
and p27kip1 accumulation before triggering caspase-associated lethality (Bazzaro et al.,2006; 
Freeburg et al.,2009a; Goyeneche et al.,2007).  It is therefore possible that antiprogestins 
induce G1 growth arrest by interfering with the proteasome-mediated degradation of 
p27kip1/p21cip1, leading to Cdk-2 inhibition. It is also reasonable that the sustained levels of 
p27kip and p21cip1 in response to cytostatic doses of antiprogestins are the consequence of a 
reduced recognition of the Cdk inhibitors by the UPS.  Because ovarian cancer cells function 
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with high activity of the UPS (Bazzaro et al.,2006), this proteolytic machinery may be 
degrading Cdk inhibitors at a high rate, causing the reduced basal levels we found in 
ovarian cancer cells, thus favoring their proliferation. Antiprogestins may mitigate this 
process.  
An additional potential mechanism mediating the anti-cell growth activity of 
antiprogestins is the induction of stress of the endoplasmic reticulum. A recent study 
showed that mifepristone induced an atypical unfolded protein response (UPR) in non-
small lung cell carcinoma cells (Dioufa et al.,2010). The role of the endoplasmic reticulum 
responding to antiprogestins triggering the UPR, which could lead to either survival or 
death depending on the concentration of antiprogestins, is a provoking hypothesis that 
should be explored.  
The newly discovered progesterone receptor membrane component 1 (PGRMC1) 
(Gellersen et al.,2009; Rohe et al.,2009) or the family of membrane PRs (mPR 
(Dressing et al.,2011; Gellersen et al.,2009; Thomas et al.,2007) may also mediate the anti-
tumor effect of antiprogestins. For instance, PGRMC1 expression increases while cognate, 
nuclear progesterone receptor decreases in advanced stages of ovarian cancer, and 
overexpression of PGRMC1 interferes with the lethality of cisplatin,  suggesting a survival 
role for PGRMC1 in ovarian cancer development (Peluso et al.,2008).  In a panel of 
ovarian cancer cell lines expressing mPR, mPR, and mPR, but not cognate nuclear 
progesterone receptors, exposure to progesterone mediated the expression of pro-
apoptotic proteins via activation of JNK and p38 MAPKs (Charles et al.,2010). Given that 
at micromolar concentrations the antiprogestin mifepristone operates as an agonist on 
both mPR and mPR when expressed in yeast (Smith et al.,2008), it is conceivable that 
antiprogestins carrying a similar structure (Fig.1) may mediate antiproliferation of cancer 
cells acting as agonists of mPRs.   
7. Strategy to utilize antiprogestins in ovarian cancer therapeutics 
7.1 Blockage of ovarian cancer re-growth after platinum therapy 
We validated an in vitro model of ovarian cancer cell repopulation taking place among 
courses of lethal cisplatin therapy. Using this in vitro model system, we demonstrated that  
intertwining cytostatic concentrations of the antiprogestin mifepristone in between courses 
of cisplatin treatment is an efficacious strategy to prevent repopulation of ovarian cancer 
cells leading to a better treatment outcome; in addition, we found that chronic exposure to 
mifepristone after cisplatin enhances the killing efficacy of this cross-linking agent (Freeburg 
et al.,2009b). In this study, although the majority of the cells in the culture succumbed to the 
lethality of cisplatin, there were isolated cells that survived the treatment. These cells, 
because of their scarcity in the culture plate, may be easily missed in routine cell cultures if 
long-term follow-up is not conducted.  When such a population of remnant cells that 
escaped the toxicity of platinum was exposed to cisplatin-free medium, the cells relapsed 
and repopulated the culture.  We were able to document the relapse of highly sensitive 
OV2008 cells after three rounds of cisplatin treatment. The OV2008 cells repopulating after 
cisplatin incorporated more BrdUrd into their DNA when compared with exponentially 
growing, untreated cells, suggesting that an increased number of cells synthesizing DNA 
may be a product of accelerated cell repopulation (Kim&Tannock,2005). When antiprogestin 
mifepristone was utilized chronically in between cisplatin treatment intervals, the cells that 
survived the treatment did not synthesize DNA, did not repopulate, and had a very poor 
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clonogenic survival capacity, suggesting a permanent DNA damage to the cells not 
compatible with their survivability.   
The nature of the cells that escape the lethality of cisplatin remains to be determined. There 
is a possibility that cisplatin is killing only the population of differentiated cancer cells 
representing the bulk of the culture, but not the scarce tumor initiating cells with the 
capacity to regenerate the culture, and that appear to be resistant to most common DNA 
damaging agents (Kvinlaug&Huntly,2007). The presence of tumor initiating cells in ovarian 
cancer cell lines, however, has yet to be confirmed.  
Alternatively, antiprogestins may block repopulation of cells after cisplatin by interfering 
with a cellular process termed reverse polyploidy or neosis (Erenpreisa&Cragg,2007; Illidge 
et al.,2000; Sundaram et al.,2004). Cancer cells develop the capacity to escape DNA damage 
caused by pharmacological doses of platinum agents by reverse polyploidy, leading to the 
formation of diploid, rapid proliferating cells with increased platinum resistance (Puig et 
al.,2008). Thus, it is feasible that antiprogestins, when used chronically, block post-platinum 
repopulation by preventing reverse polyploidy. This hypothesis is based on the observation 
that OV2008 cells repopulating after cisplatin exposure show giant cells together with a 
nascent population of small cells (Freeburg et al.,2009b) that may originate from the likely 
polyploid, giant progenitors. Cultures treated with antiprogestins after platinum do not 
show this small pool of repopulating cells and instead display an overall reduced number of 
cells, with predominance of a giant phenotype that ends up committing suicide as marked 
by cleaved PARP positivity (Freeburg et al.,2009b).  
7.2 Potentiation of platinum induced lethality by antiprogestins 
We proved that intertwining cytostatic concentrations of antiprogestin mifepristone in 
between courses of lethal cisplatin-based chemotherapy not only resulted in an efficacious 
strategy to prevent repopulation of cancer cells in between lethal platinum treatment 
intervals, but it also potentiated the killing efficacy of cisplatin (Freeburg et al.,2009b).  
When ovarian cancer cells are exposed to only mifepristone therapy, the cell cycle is 
arrested in the G1 phase (Goyeneche et al.,2007; Rose&Barnea,1996). However, when 
antiprogestin mifepristone is added after cisplatin, the cells tend to accumulate at the S 
and/or G2/M phases rather than in G1 (Gamarra-Luques&Telleria,2010). This 
phenomenon may provide the rationale for the potentiation of platinum therapy by the 
antiprogestin.  It is known that cisplatin treatment leads to a transitory S or G2 cell cycle 
arrest, which is utilized by the cells as an opportunity to repair any damaged DNA; 
however, if the DNA damage is significant and the DNA repair mechanisms cannot 
operate, the cells usually trigger their own demise (Sorenson et al.,1990). Thus, 
mifepristone may be a disruptor of the DNA damage and repair pathways operating after 
cisplatin exposure. Consequently the cells would enter an unscheduled mitosis with 
damaged DNA, which usually would trigger a cell death mechanism due to mitotic 
failure (Vakifahmetoglu et al.,2008).  Partial support for this hypothesis is that cells 
receiving the combination treatment of cisplatin followed by mifepristone show an 
elevated percentage of cells allocated to the M phase of the cell cycle suggested by 6-fold 
overexpression of the mitotic marker, phospho-histone H3, when compared to cisplatin-
only treated cultures (Freeburg et al.,2009b). This result, together with the data showing 
that the cultures receiving cisplatin followed by mifepristone express 4-fold more cleaved 
PARP compared with cultures receiving only cisplatin (Freeburg et al.,2009b), indicate 
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that cells chronically exposed to mifepristone after receiving lethal platinum therapy not 
only are unable to repopulate, but are also likely to die transiting into an unscheduled 
mitosis that could trigger cell death (i.e. mitotic death).   
Mifepristone may be interfering with early steps in the DNA damage response pathway that 
lead to a failure of cells to arrest in the G2 phase when challenged with cisplatin. This 
rationale is supported by data generated utilizing the Chk-1 kinase inhibitor UCN-01 (7-
hydroxystaurosporine), which as a single agent is able to induce G1 growth arrest in non-
small-cell lung carcinoma similar to the effect observed in ovarian cancer cells treated with 
mifepristone alone (Goyeneche et al.,2007). When UCN-01 was used after cisplatin, 
however, the combination was synergistic in terms of growth inhibition likely by reducing 
the time cells spend in the S or G2 phases to operate the DNA damage check point in order 
to allow repair the DNA damage induced by platinum (Mack et al.,2003).   
We demonstrated that the cytostatic effect of mifepristone in ovarian cancer cells associates 
with an abrupt reduction in the activity of Cdk-2 (Goyeneche et al.,2007). In addition to its 
role in the cell cycle and cell survival previously stated, Cdk-2 has been implicated in DNA 
repair. For instance, the DNA repair machinery is dysfunctional in Cdk-2 deficient cells, and 
cells lacking the DNA repair component of BRCA1 are prone to cell death in response to 
Cdk-2 inhibition (Deans et al.,2006). This role played by Cdk-2 in the DNA repair process 
provides the rationale for a synergistic interaction of Cdk-2 inhibition and DNA damaging 
agents in the killing of cancer cells and could also explain the potentiation by mifepristone 
of platinum-induced lethality of ovarian cancer cells.  
Another hypothesis as to how antiprogestin mifepristone can facilitate the lethal effect of 
cisplatin is based upon its capacity to abrogate the expression of the E2F1 transcription 
factor (Goyeneche et al.,2007). E2F1 is needed to regulate the expression of genes involved in 
the nucleotide excision DNA repair pathway (NER) (Berton et al.,2005), which is a major 
mechanism needed to repair ~90% of the platinum-DNA intrastrand crosslinks (Cepeda et 
al.,2007; Helleday et al.,2008; Kelland,2007; Rabik&Dolan,2007). Because in ovarian cancer 
increased expression of the endonuclease ERCC1 (excision repair cross-complementing-1) 
involved in NER has been correlated with cisplatin resistance (Li et al.,2000), and antisense 
RNA against ERCC1 sensitizes ovarian cancer cells to the lethality of cisplatin 
(Selvakumaran et al.,2003), it is possible that mifepristone potentiates cisplatin lethality by 
interfering with the functionality of the NER pathway. Antiprogestins may also  dysregulate 
the homologous recombination DNA repair pathway responsible to repair the ~10% DNA 
interstrand crosslinks induced by platinum agents; this avenue is of relevance as it is 
apparent that despite the majority of cisplatin binds DNA via intrastrand crosslinks, it is the 
low percentage of DNA interstrand crosslinks which causes most of its lethality 
(Wang&Lippard,2005; Wang et al.,2011). 
8. Clinical relevance of repurposing antiprogestins for ovarian cancer 
treatment 
Based upon the evidence presented earlier in this chapter, antiprogestins—of which 
mifepristone and ulipristal are approved by the United States Food and Drug 
administration for reproductive medicine—can be re-purposed for another modality-of-use 
as part of the chemotherapeutic armamentarium for ovarian cancer patients. The translation 
of antiprogestin therapy to the clinic may have an impact in two manners: (i) adding an 
antiprogestin between rounds of platinum-based therapy should prevent the repopulation 
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of ovarian cancer cells that escape the lethality of the platinum derivative, and improve 
treatment success in a synergistic manner when followed by antiprogestin maintenance 
therapy (compare models in Figs.3A vs.3B); and (ii) working as a single, cytostatic agent, a 
prototypical antiprogestin may be used for chronic maintenance therapy following lethal 
platinum agents to delay or avoid disease recurrence in a similar manner anti-estrogens are 
used to treat some cohorts of breast cancer patients (Osipo et al.,2004) (compare models in 




                                                
 
                                                 
Fig. 3. Clinical translational impact of the use of antiprogestins (AntP) in the context of 
platinum (Pt) based chemotherapy for ovarian cancer 
 




We have described a novel modality of action of antiprogestins acting as cytotoxic agents 
towards ovarian cancer, displaying a cytostatic effect at lower concentrations blocking cell 
growth at the G1 phase of the cell cycle, and a lethal effect at higher doses in association 
with morphological features of apoptosis and fragmentation of the genomic DNA. We have 
distinguished between lethal and cytostatic actions of these synthetic steroids, and provided 
evidence that Cdk-2 is involved as a downstream target of the anti-cancer effect of the 
drugs. Moreover, the remarkable increase in the number of dying cells when antiprogestin 
mifepristone followed cisplatin exposure (Freeburg et al.,2009b; Gamarra-
Luques&Telleria,2010) raises hope that adding antiprogestins to the platinum-based 
chemotherapeutic schedule in ovarian cancer should allow reducing either the number of 
platinum cycles or the dose of platinum without losing efficacy in terms of inhibition of 
tumor growth, yet reducing unwanted side effects. Consequently, the scheduling of 
antiprogestins between and/or after courses of platinum-based therapy for human ovarian 
cancer has reasonable potential for improving treatment success, extending the quality and 
quality of life of patients suffering from this disease. 
We have provided data supporting the feasibility for re-repurposing or re-repositioning of 
antiprogestins originally designed to operate as antiglucocorticoid or antiprogestins, to 
chronically treat ovarian cancer patients, as it is currently done with antiestrogen therapy 
for breast cancer. In particular, the emergent role of ORG-31710 and CDB-2914 having far 
less antiglucocorticoid effects than mifepristone but maintaining its anti-ovarian cancer 
properties is promising for translation to the clinic. 
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1. Introduction 
For early stage (stage I) epithelial ovarian cancer (EOC) surgery may be the sole curative 
therapy. However, the vast majorities of cases are diagnosed in more advanced stages and 
need a multimodal treatment strategy. Therefore, in stage II and higher, surgery with a 
cytoreductive intent, (i.e. to remove as much as possible the macroscopic disease from the 
peritoneal surfaces in adjunct to bilateral salpingo-oophorectomy) is not curative by itself, 
but has to be supplemented by cytotoxic therapy. This is mainly administered as 
intravenously (i.v.) chemotherapy or sometimes as intraperitoneal (i.p.) chemotherapy. 
Although there are trials using whole abdominal or moving-strip external beam 
radiotherapy as adjuvant therapy (Einhorn et al., 2003) or i.p. radiotherapy with colloid 
preparations of 198Au or 32P (Rosenhein et al., 1979; Varia et al., 2003) these have so far not 
presented results to merit a place in the normal therapeutic arsenal, and long term toxicity 
from normal tissues is a major concern.  
Despite extensive cytoreductive surgery and modern chemotherapy, with complete 
remissions (CR) at second look laparotomy (SLL) and normalisation of the serum marker 
cancer antigen 125 (CA-125), approximately 70% of the patients in stage III recur and will 
eventually succumb to their disease. The recurrence pattern is normally the development of 
ascites due to progression of treatment resistant cells growing as peritoneal microscopic 
deposits. From this incurable situation the progression is dominated by a continuous 
accumulation of ascites with intestinal adhesions and bowel obstructions. This progression 
can often be temporarily halted by palliative chemotherapy, or in special occasions, local 
external beam radiotherapy, but will in any event, eventually lead to a great deal of 
suffering and pain from above the abdominal cavity pathology. 
Since the negative impact on survival and the suffering associated with uncontrolled spread 
in the abdominal cavity, efforts have been directed to develop more effective local 
treatments. Such a local more aggressive treatment strategy has proven effective as 
chemotherapy injected locally in the peritoneal cavity (i.p.) could show as a reduction in 
recurrences and a decrease in mortality, although at the expense of clearly increased toxicity 
(Jaaback & Johnson, 2009). The use of 90Y, conjugated to a monoclonal antibody (mAb) and 
studied in a large prospective randomised controlled study, unfortunately did not 
demonstrate a benefit (Oei et al., 2007; Verheijen et al., 2006).  
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These negative results on overall survival of i.p. radioimmunotherapy (RIT) using the β-
emitter 90Y, conjugated to a mAb, are a concern (Verheijen et al., 2006), even if a decreased 
local i.p. recurrence has been seen (Oei et al., 2007). A number of important issues relating to 
this trial including the physical properties of the used nuclide will be discussed in depth, 
which might give clues to optimization of future trials of intraperitoneal RIT. 
2. Radionuclides 
In targeted radionuclide therapy the cytotoxic effect is mediated by a radionuclide, brought 
to the target by the targeting construct (Elgqvist et al., 2010). Below is a list of the 
radionuclides used, in both animal and clinical studies. The list includes a presentation of 
their physical characters, and in which studies they have been used.  
225Ac (Actinium-225). 225Ac decays with a half-life of 10 days and emits four α-particles in a 
serial decay. The α-particle emitted from 225Ac has an energy of 5.8 MeV (mean linear 
energy transfer [LET] ≈ 120 keV/µm) and the daughters are 221Fr (T½ = 4.8 min, E = 6.3 MeV, 
mean LET ≈ 118 keV/µm), 217At (T½ = 32.3 ms, E = 7.1 MeV, mean LET ≈ 109 keV/µm), and 
213Bi (T½ = 45.6 min, E = 8.4 MeV, mean LET ≈ 99 keV/µm). The α-decays are accompanied 
by gamma(γ)-radiation, enabling scintigraphy and dosimetry. 225Ac has been used in one 
animal study (Borchardt et al., 2003). 
 211At (Astatine-211). 211At (an α-particle emitter) is cyclotron produced via the nuclear 
reaction 207Bi(α,2n)211At. 211At decays with a half-life of 7.2 hours in 2 ways: (i) via emission 
of an α-particle (E = 5.9 MeV) to 207Bi, or (ii) via an electron capture process to 211Po. 207Bi 
decays with a half-life of 31.6 y to 207Pb (stable). 211Po decays with a half-life of 0.5 s to 207Pb 
via α-particle emission (E = 7.4 MeV). The 5.9- and 7.4-MeV α-particles have a mean LET of 
~122 and ~106 keV/µm and a particle range in tissue of ~48 and ~70 µm, respectively. The 
decays are accompanied by γ-radiation, enabling scintigraphy and dosimetry. 211At has been 
used in animal studies (Andersson et al., 1999, 2000a, 2000b, 2001; Bäck et al., 2005; Elgqvist 
et al., 2005a, 2005b, 2006a, 2006b, 2006c, 2009a, 2009b; Steffen et al., 2006) and in one clinical 
study (Andersson et al., 2009). 
213Bi (Bismuth-213). 213Bi (an α-particle emitter) is available via a generator based technology 
due to its relatively long-lived parent radionuclide, 225Ac. 213Bi decays with a half-life of 45.6 
min to 209Bi (stable) during which it emits an α-particle of 8.4 MeV (mean LET and particle 
range in tissue: ~99 keV/µm and ~89 µm, respectively). The α-particle emission is 
accompanied by γ-radiation. 213Bi has been used in animal studies (Knör et al., 2008; Song et 
al., 2007). 
90Y (Yttrium-90). 90Y is chemically similar to the lanthanoids and decays with a half-life of 64 
h by the emission of electrons (β) with a maximum energy of ~2.2 MeV (Emean = 933 keV). 
The emitted electrons have a maximum range in tissue of ~12 mm (mean range ≈ 4 mm) and 
a mean LET ≈ 0.2 keV/µm. Due to the emission of Bremsstrahlung, scintigraphy is feasible. 
90Y has been used in one animal study (Buchsbaum et al., 2005) and in clinical studies 
(Alvarez et al., 2002; Epenetos et al., 2000; Grana et al., 2004; Hird et al., 1990; Hnatowich et 
al., 1988; Maraveyas et al., 1994; Oei et al., 2007; Rosenblum et al., 1999; Stewart et al., 1990; 
Verheijen et al., 2006). 
177Lu (Lutetium-177). This radionuclide has a half-life of 6.7 d and decays by the emission 
of β--particles with a maximum energy of 497 keV (Emean = 133 keV), which have a range 
in tissue of ~2 mm (mean range ≈ 0.2 mm), and a mean LET < 0.1 keV/µm. It also emits γ-
radiation (208 keV). 177Lu can be produced in large scale owing to the high thermal 
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neutron capture cross-section of 176Lu (2100 barn) using moderate flux reactors. 177Lu has 
been used in animal studies (Buchsbaum et al., 1999, 2005; Persson et al., 2007; Tolmachev 
et al., 2007) and in clinical studies (Alvarez et al., 1997; Epenetos et al., 1987; Meredith et 
al., 1996, 2001).  
131I (Iodine-131). 131I has a half-life of 8 d and decays by the emission of β-particles with a 
maximum energy of 807 keV (Emean = 182 keV, mean LET ≈ 0.1 keV/µm), which have a 
maximum range in tissue of ~3.6 mm (mean range ≈ 0.4 mm). It emits γ-radiation (364 keV) 
enabling scintigraphy and dosimetry. 131I has been used in animal studies (Kievit et al., 1996; 
Molthoff et al., 1992; Turner et al., 1998) and in clinical studies (Buchsbaum et al., 1999; Buijs 
et al., 1998; Buist et al., 1993; Colcher et al., 1987; Crippa et al., 1995; Epenetos et al., 1987; 
Mahé et al., 1999; Molthoff et al., 1992, 1997; Muto et al., 1992; Stewart et al., 1989a, 1989b; 
Van Zanten-Przybysz et al., 2000, 2001). 
186Re (Rhenium-186) and 188Re (Rhenium-188). 186Re has a half-life of 3.7 d and decays by 
emitting β-particles having a maximum energy of 1.07 MeV (mean LET ≈ 0.1 keV/µm), 90% 
of it delivered within ~1.8 mm. 186Re also emits γ-radiation. 186Re has been used in clinical 
studies (Breitz et al., 1995; Jacobs et al., 1993). 188Re has a half-life of 17 h and decays by 
emitting β-particles having a maximum energy of 795 keV (mean LET ≈ 0.1 keV/µm). The 
emitted γ-radiation enables scintigraphy and dosimetry. 188Re has been used in one clinical 
study (Macey & Meredith, 1999). 
3. Targeting constructs 
In developing treatment strategies against EOC based on the concept of targeted 
radionuclide therapy several candidates as targeting constructs have been evaluated. Below 
follow a compilation of the main targeting constructs that have been used for bringing the 
radionuclide to the target, in animal as well as in clinical studies. 
HMFG1 is a murine monoclonal antibody (mAb) which is directed to an epitope of the 
MUC1 gene product. MUC1 is a large, heavily glycosylated mucin (>400 kDa) expressed on 
the apical surface of the majority of secretory epithelial cells (Gendler, 2001). MUC1 is 
overexpressed in 90% of adenocarcinomas, including cancers of the ovary (Mukherjee et al., 
2003). The extracellular portion of the MUC1 protein mainly consists of a variable number of 
highly conserved 20 amino acid repeats (Verheijen et al., 2006). HMFG1 has been used in 
clinical studies (Epenetos, et al., 1987; Verheijen et al., 2006). 
HMFG2 is a murine mAb that is directed towards a large mucin-like molecule normally 
produced by the lactating breast. The mAbs react with similar components expressed by the 
majority (>90%) of ovarian, breast and other carcinomas (Arklie, et al., 1981). The HMFG2 
epitope is generally expressed at a higher level in tumors (Burchell et al., 1983). HMFG2 has 
been used in one clinical study (Epenetos et al., 1987). 
AUA1 is a murine IgG1 mAb that binds to an antigen expressed by a wide range of 
adenocarcinoma, including the majority (>90%) of carcinomas of the ovary. The antigen is a 
40 kDa glycoprotein (Epenetos et al., 1982). AUA1 has been used in one clinical study 
(Epenetos et al., 1987). 
H17E2 is a murine IgG1 mAb that is directed to placental and placental-like alkaline 
phosphatase (PLAP) (Travers & Bodmer, 1984). This enzyme is expressed as a surface 
membrane antigen (~67 kDa) of many neoplasms, including 60%–85% of ovarian 
carcinomas (Benham et al., 1978; Sunderland et al., 1984). H17E2 has been used in one 
clinical study (Epenetos et al., 1987). 
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phosphatase (PLAP) (Travers & Bodmer, 1984). This enzyme is expressed as a surface 
membrane antigen (~67 kDa) of many neoplasms, including 60%–85% of ovarian 
carcinomas (Benham et al., 1978; Sunderland et al., 1984). H17E2 has been used in one 
clinical study (Epenetos et al., 1987). 
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Hu2PLAP is a human IgG1 κ mAb that has the same specificity as the murine H17E2 mAb 
described above. Hu2PLAP has been used in one clinical study (Kosmas et al., 1998).  
H317 is a murine IgG mAb developed after immunisation with syncytiotrophoblast microvilli 
preparations from term placenta. It is specific for the L-phenylalanine inhibitable placental 
alkaline phosphatase (PLAP). H317 has been used in one clinical study (Kosmas et al., 1998).  
Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a humanized IgG1 mAb 
that recognizes the extracellular domain of the HER-2/neu oncoprotein (Carter et al., 1992). 
Trastuzumab has been used in one animal study (Borchardt et al., 2003). 
Pertuzumab is a human mAb binds to the dimerization domain II of HER-2. Pertuzumab is 
based on the human immunoglobulin IgG1 κ framework sequences, and is produced in 
Chinese hamster ovary cells. It has been used in one animal study (Persson et al., 2007). 
B72.3 is a murine mAb that has been shown to be immunoreactive with the glycoprotein 
complex TAG-72 (>200 kDa) with the characteristics of a mucin (Johnson et al., 1986; Thor et 
al., 1986; Wolf et al., 1989). TAG-72 expression has been shown in the majority of ovarian 
carcinomas tested (Nuti et al., 1982). B72.3 has been used in clinical studies (Colcher et al., 
1987; Rosenblum et al., 1999). 
CC49 is a murine mAb is a high-affinity murine product that reacts with the tumor-
associated glycoprotein TAG-72, which is expressed by the majority of common epithelial 
tumors (Schlom et al., 1990). CC49 has been used in one animal study (Buchsbaum et al., 
2005) and in clinical studies (Alvarez et al., 1997, 2002; Buchsbaum et al., 1999; Macey et al., 
1999; Meredith et al., 1996). 
OC125 is a murine mAb that is directed against the tumor marker CA-125, and has been 
used in clinical studies (Hnatowich et al., 1988; Mahé et al., 1999; Muto et al., 1992). 
MOv18 is a murine mAb that recognizes and reacts with a surface antigen, which is a 
membrane folate-binding glycoprotein of 38 kDa expressed on approximately 90% of all 
human ovarian carcinomas (Boerman et al., 1991; Campbell et al., 1991; Miotti et al., 1987). 
MOv18 (murine and in some cases chimeric) has been used in animal studies (Andersson et 
al., 1999, 2000a, 2000b, 2001) and in clinical studies (Buijs et al., 1998; Buist et al., 1993; 
Molthoff et al., 1992, 1997; Van Zanten-Przybysz et al., 2000, 2001). 
MX35 is a murine IgG1 mAb directed towards a cell-surface glycoprotein of ~95 kDa on 
OVCAR-3 cells (Welshinger et al., 1997) and is expressed strongly and homogeneously on 
~90% of human epithelial ovarian cancers (Rubin et al., 1993). The antigen recognized by 
MX35 is characterized as the sodium-dependent phosphate transport protein 2b (NaPi2b) 
(Yin et al., 2008). MX35 F(ab’)2 has been used in animal studies (Bäck et al., 2005; Elgqvist et 
al., 2006a, 2006b, 2006c, 2009a, 2009b) and in one clinical study (Andersson et al., 2009). 
NR-LU-10 is a IgG2b murine mAb that is reactive with a glycoprotein (~40 kDa) expressed 
on most carcinomas of epithelial origin (Goldrosen et al., 1990; Varki et al., 1984). NR-LU-10 
has been used in clinical studies (Breitz et al., 1995; Jacobs et al., 1993). 
A5B7 is an anti-CEA IgG1 mAb that has been used in one large-animal model (sheep) study 
(Turner et al., 1998). 
17-1A is a chimeric mAb is directed towards a ~39 kDa membrane-associated pancarcinoma 
glycoprotein (Edwards et al., 1986; Koprowski et al., 1979). It has been used in one animal 
study (Kievit et al., 1996). 
323/A3 is a murine mAb that is directed to a ~39 kDa membrane-associated pancarcinoma 
glycoprotein (same as 17-1A) (Edwards et al., 1986; Koprowski et al., 1979). It has been used 
in one animal study (Johnson et al., 1986). 
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hCTMO1 is an antibody that was constructed by taking the short hypervariable regions of 
the murine mAb CTMO1 and grafting them into a human IgG4. It is directed towards a 
glycoprotein expressed on malignant cells of epithelial origin (Baker et al., 1994; Zotter et al., 
1988). hCTMO1 has been used in one clinical study (Davis et al., 1999).  
OV-TL 3 is a murine IgG1 mAb that recognizes a cell-surface antigen highly expressed on 
>90% of ovarian carcinomas (Poels et al., 1986). It has been used in one clinical study (Buist 
et al., 1995). 
139H2 is a IgG1 mAb which binds to a protein determinant of episialin (Hilkens et al., 1988). 
139H2 has been used in one animal study (Molthoff et al., 1992). 
P-P4D is a targeting construct which is a pseudo-symmetrical covalent dimer of the 
monomeric peptide P-P4. It has been used in one animal study (Knör et al., 2008). 
PAI2 is a targeting construct that is a plasminogen activator inhibitor type 2 and which is a 
member of the serine protease inhibitor (Serpin) superfamily and forms SDS-stable 1:1 
complexes with urokinase plasminogen activator (uPA) (Song et al., 2007). It has been used 
in one animal study (Song et al., 2007). 
Affibody molecules are composed of alpha helices and lack disulfide bridges. Two such 
molecular constructs, (ZHER2:4)2 and (ZHER2:342)2 (~15 kDa) have been used in animal studies 
(Steffen et al., 2006a, 2006b; Tolmachev et al., 2007). 
4. Labeling chemistry 
In nuclear medicine targeted therapy all to date approved radiopharmaceuticals are based 
on β-particle emitters. However, an increasing interest has been focused on α-particle 
emitting radionuclides as they offer several advantages over the most commonly used β-
emitters for the treatment of micro-tumors. Unlike medically applied therapeutic 
radionuclides that decay by medium- to high-energy β-particle emissions leading to low-
LET radiation with particle ranges varying from 1 to 10 mm, α-particle emitting 
radionuclides emit high-LET radiation in a small volume determined by the α-particle 
ranges of 50–100 μm. Only a few α-emitters fulfill the criteria for endoradiotherapeutic 
applications, the most studied being 211At, 212Bi, and 213Bi. All these nuclides decay by 100% 
α-particle emission. Astatine-211 decays in two branches, 58% probability through electron 
capture to 211Po which in turn decays through an α-particle emission (7.45 MeV) with a half-
life of 0.52 seconds to the stable 207Pb. The other branch (42%), resulting in an α-particle of 
5.87 MeV, also ends in the stable 207Pb through the daughter 207Bi. The decay of 212Bi is very 
similar to the decay of 213Bi in terms of half-life and energy emitted (T½ for 212Bi = 60.6 min 
versus T½ for 213Bi = 45.6 min, mean Eα of both nuclides ≈ 8–8.5 MeV). However, while 213Bi 
can be isolated as pure nuclide from the 225Ac/213Bi generator, 212Bi is obtained in situ from 
the decay of 212Pb. Lead-212 decays to 212Bi with a half-life of 10.6 h. 
For stable attachment of metals such as 212Pb/212Bi or 213Bi to tumor specific targeting 
constructs an intermediate bifunctional chelating agent is required. A number of different 
chelating derivatives have been developed for conjugate labeling of various carrier 
molecules. Biological targeting constructs such as antibodies and peptides are commonly 
labeled with metal nuclides via chelating agents based on DTPA 
(diethylenetriaminepentaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid). Heat sensitive proteins are preferably labeled with the semi rigid open 
chain DTPA derivatives, e.g. CHX A``DTPA, due to the fast metal coordination reaction 
kinetics at room temperature. DOTA is a versatile chelating agent which shows strong 
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Hu2PLAP is a human IgG1 κ mAb that has the same specificity as the murine H17E2 mAb 
described above. Hu2PLAP has been used in one clinical study (Kosmas et al., 1998).  
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preparations from term placenta. It is specific for the L-phenylalanine inhibitable placental 
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that recognizes the extracellular domain of the HER-2/neu oncoprotein (Carter et al., 1992). 
Trastuzumab has been used in one animal study (Borchardt et al., 2003). 
Pertuzumab is a human mAb binds to the dimerization domain II of HER-2. Pertuzumab is 
based on the human immunoglobulin IgG1 κ framework sequences, and is produced in 
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MX35 is characterized as the sodium-dependent phosphate transport protein 2b (NaPi2b) 
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NR-LU-10 is a IgG2b murine mAb that is reactive with a glycoprotein (~40 kDa) expressed 
on most carcinomas of epithelial origin (Goldrosen et al., 1990; Varki et al., 1984). NR-LU-10 
has been used in clinical studies (Breitz et al., 1995; Jacobs et al., 1993). 
A5B7 is an anti-CEA IgG1 mAb that has been used in one large-animal model (sheep) study 
(Turner et al., 1998). 
17-1A is a chimeric mAb is directed towards a ~39 kDa membrane-associated pancarcinoma 
glycoprotein (Edwards et al., 1986; Koprowski et al., 1979). It has been used in one animal 
study (Kievit et al., 1996). 
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glycoprotein (same as 17-1A) (Edwards et al., 1986; Koprowski et al., 1979). It has been used 
in one animal study (Johnson et al., 1986). 
 
Intraperitoneal Radionuclide Therapy – Clinical and Pre-Clinical Considerations 
 
235 
hCTMO1 is an antibody that was constructed by taking the short hypervariable regions of 
the murine mAb CTMO1 and grafting them into a human IgG4. It is directed towards a 
glycoprotein expressed on malignant cells of epithelial origin (Baker et al., 1994; Zotter et al., 
1988). hCTMO1 has been used in one clinical study (Davis et al., 1999).  
OV-TL 3 is a murine IgG1 mAb that recognizes a cell-surface antigen highly expressed on 
>90% of ovarian carcinomas (Poels et al., 1986). It has been used in one clinical study (Buist 
et al., 1995). 
139H2 is a IgG1 mAb which binds to a protein determinant of episialin (Hilkens et al., 1988). 
139H2 has been used in one animal study (Molthoff et al., 1992). 
P-P4D is a targeting construct which is a pseudo-symmetrical covalent dimer of the 
monomeric peptide P-P4. It has been used in one animal study (Knör et al., 2008). 
PAI2 is a targeting construct that is a plasminogen activator inhibitor type 2 and which is a 
member of the serine protease inhibitor (Serpin) superfamily and forms SDS-stable 1:1 
complexes with urokinase plasminogen activator (uPA) (Song et al., 2007). It has been used 
in one animal study (Song et al., 2007). 
Affibody molecules are composed of alpha helices and lack disulfide bridges. Two such 
molecular constructs, (ZHER2:4)2 and (ZHER2:342)2 (~15 kDa) have been used in animal studies 
(Steffen et al., 2006a, 2006b; Tolmachev et al., 2007). 
4. Labeling chemistry 
In nuclear medicine targeted therapy all to date approved radiopharmaceuticals are based 
on β-particle emitters. However, an increasing interest has been focused on α-particle 
emitting radionuclides as they offer several advantages over the most commonly used β-
emitters for the treatment of micro-tumors. Unlike medically applied therapeutic 
radionuclides that decay by medium- to high-energy β-particle emissions leading to low-
LET radiation with particle ranges varying from 1 to 10 mm, α-particle emitting 
radionuclides emit high-LET radiation in a small volume determined by the α-particle 
ranges of 50–100 μm. Only a few α-emitters fulfill the criteria for endoradiotherapeutic 
applications, the most studied being 211At, 212Bi, and 213Bi. All these nuclides decay by 100% 
α-particle emission. Astatine-211 decays in two branches, 58% probability through electron 
capture to 211Po which in turn decays through an α-particle emission (7.45 MeV) with a half-
life of 0.52 seconds to the stable 207Pb. The other branch (42%), resulting in an α-particle of 
5.87 MeV, also ends in the stable 207Pb through the daughter 207Bi. The decay of 212Bi is very 
similar to the decay of 213Bi in terms of half-life and energy emitted (T½ for 212Bi = 60.6 min 
versus T½ for 213Bi = 45.6 min, mean Eα of both nuclides ≈ 8–8.5 MeV). However, while 213Bi 
can be isolated as pure nuclide from the 225Ac/213Bi generator, 212Bi is obtained in situ from 
the decay of 212Pb. Lead-212 decays to 212Bi with a half-life of 10.6 h. 
For stable attachment of metals such as 212Pb/212Bi or 213Bi to tumor specific targeting 
constructs an intermediate bifunctional chelating agent is required. A number of different 
chelating derivatives have been developed for conjugate labeling of various carrier 
molecules. Biological targeting constructs such as antibodies and peptides are commonly 
labeled with metal nuclides via chelating agents based on DTPA 
(diethylenetriaminepentaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid). Heat sensitive proteins are preferably labeled with the semi rigid open 
chain DTPA derivatives, e.g. CHX A``DTPA, due to the fast metal coordination reaction 
kinetics at room temperature. DOTA is a versatile chelating agent which shows strong 
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binding to a number of different metals, and the rigid structure give a metal-complex 
stronger than that of the corresponding complex to DTPA. However, chelating a metal to 
DOTA require heat or microwave assisted reaction condition, to be completed in reasonable 
times and with good yields, and are therefore more suitable for labeling to small molecules 
and peptides (Cordier et al., 2010).  
The most common functional leaving group of the reagent is succinimidyl ester which is 
directed towards free amines on proteins and peptides, mainly presented on the side chain 
of lysine. For example, an antibody of IgG class has a molecular weight of approximately 
150 kDa, and contains approximately 1200 amino acids, of which a number of lysine is 
randomly distributed. A lysine directed reagent conjugated to the antibody will therefore be 
non-specifically distributed in the protein structure, occasionally including the active 
antigen binding sites. Consequently the antigen binding capacity of the antibody may be 
affected when using lysine amine binding reagents. Site specific conjugation of antibodies 
can be achieved by targeting the sulfhydryl group on the side chain of cystein. In antibodies, 
cystein form disulfide bridges at specific sites within the antibody distant from the antigen 
binding site. The disulfide bridges can chemically be gently disrupted resulting in conjugate 
sites for a labelling reagent, e.g. malemido reagents. In this way the antigen binding of the 
conjugated antibody will not be compromised.  
Independent of chelating moiety the procedure for labeling is conjugation of the chelating 
derivative to the carrier molecule and then labeling to the conjugate. The direct chelating of 
the metal nuclide to the conjugate is a prerequisite when labeling with metal nuclides with 
very short half-lives, e.g. 213Bi. The other α-emitting isotope of bismuth 212Bi is generated in 
the decay of 212Pb. Generally 212Pb or a mixture of 212Pb/212Bi is bound to a DOTA conjugate 
targeting construct. However, it has been reported that a fraction will be dechelated in the 
decay of 212Pb, leaving a free fraction of 212Bi (Su et al., 2005). 
Compared with the 213Bi, 211At is perhaps the most versatile mainly because of its longer half-
life, 7.2 h, which allow time for radiolabeling and quality control, and the time to distribute to 
the target cancer cells. Astatine is the heaviest element in the halogen family and since its 
discovery in 1940 (Corson et al., 1947) it has been proposed for use in nuclear medicine 
applications. Several research and preclinical studies utilising 211At for therapeutic nuclear 
medicine applications have been conducted, including the free halide, and 211At-labeled tumor 
specific targeting constructs (Zalutsky et al., 2000). Many of these studies include tumor 
specific monoclonal antibodies, as they constitute suitable carrier properties for a number of 
different malignancies (Anderson et al., 2000b). Encouraging preclinical results have been 
obtained in radioimmunotherapy with astatinated antibodies and two phase I studies have 
emerged from these studies (Andersson et al., 2009; Zalutsky et al., 2008). However, 211At 
requires a medium energy cyclotron for its production which is a major obstacle hampering 
clinical studies. And of the available cyclotrons having the capacity to produce 211At, only a 
few of those facilities actually produce 211At. Of the available cyclotrons having the capacity to 
produce 211At, only a few of those facilities actually produce 211At. In addition, one of the most 
demanding challenges in 211At-radioimmunotherapy applications has been the development 
of adequate chemical labeling procedures for the production of 211At-labeled antibodies at 
clinical levels of activity. Unlike direct iodination of proteins, astatine cannot be stably attached 
to unmodified antibodies (Visser et al., 1981). A number of different bifunctional labeling 
reagents for astatination of proteins have therefore been developed in which the common 
feature involves an electrophilic substitution reaction of organic tin as leaving group in the 
formation of an aryl-carbon- astatine bond, and a functional group for binding to proteins, 
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commonly N-succinimidyl esters (Wilbur et al., 1989; Yordanov et al., 2001; Zalutsky et al., 
1988). The radiochemistry is in general conducted in two steps, labeling of the reagent and 
conjugation of the labeled reagent to antibody. However, when using this strategy problems 
with yields and the final quality are frequently occurring, and have been recognised being due 
to radiolytic effects within the reacting solvents (Pozzi et al., 2007). Especially at high activity 
concentration conditions the α-particle decay of astatine may during labeling result in a 
considerable absorbed dose to the reaction solvent which can affect the chemistry, i.e. self-
oxidation of astatine, decompose the precursor and/or alter the structural and biological 
integrity of the antibody. In fact, it has been reported that antibodies can be subjected to a 
maximum absorbed dose of approximately 1000 Gy without affecting its immunoreactivity 
(Larsen & Bruland, 1995).  
Similar to metal radiolabeling, in which a bifunctional chelate is conjugated to the protein 
prior to labeling, the ATE reagent can be conjugated to the protein prior to astatination. In 
this way problems related to absorbed dose to reaction volumes, and dependency on protein 
concentration, can be avoided. The resulting yield and specific activities can be kept high 
even at high activity reaction conditions (Lindegren et al., 2008). However, although stable 
in vitro it has been found that the aryl-carbon-astatine bond is not stable in vivo when bound 
to small carrier molecules, e.g. antibody fragments such as F(ab)-fragments and minibodies.   
Based on the higher strength of boron-astatine bonds (Kerr, 1977), new bifunctional reagents 
based on boron-cage structures, nido-carborane and closo-decaborate(2-) have been 
developed to increase the in vivo stability of  astatination of biomolecules (Wilbur et al., 
2004, 2009). The rout for synthesis of astatinated antibodies and fragments with the boron-
cage reagents is, as the in metal radiolabeling, conjugation of the reagent to the antibody and 
subsequently direct radiohalogenation of the immunoconjugate. Halogenation yields are 
therefore generally higher than the yields obtained in two step astatination of the ATE 
reagents. Greater stability to dehalogenation of the astatinated products labeled via boron-
cage chemistry has been confirmed (Wilbur et al., 2004). 
5. Animal studies 
Several animal studies investigating radionuclide therapy have been performed during the 
past couple of years. They have been investigating the pharmacokinetics, toxicity and 
therapeutic efficacy. The studies presented below comprise a selection of these studies using 
different radionuclides as well as different targeting constructs, and are paragraphed based 
on which radionuclide have been used, i.e. 225Ac, 211At, 213Bi, 90Y, 177Lu, or 131I. Some of the 
studies are not in an intraperitoneal setting, but have been mentioned because of their 
importance and relevance. 
5.1 225Ac-Trastuzumab 
One study has investigated the immunoreactivity, internalization, and cytotoxicity using 
SKOV-3 cells (Borchardt et al., 2003). The immunoreactivity was retained (50%–90%) and the 
radioimmunocomplex internalized into the cells (50% at 2 h). Various therapies were 
evaluated, using unlabeled trastuzumab and 8.1, 12.2, or 16.6 kBq of 225Ac-trastuzumab or 
225Ac-labeled control antibody. The therapies were given 9 d after tumor inoculation. 
Groups of control mice and mice administered unlabeled trastuzumab had median survivals 
of 33, 37 or 44 d, respectively. The median survival was 52–126 d using 225Ac-trastuzumab, 
and 48–64 d using the 225Ac-control mAb. Some deaths from toxicity occurred at the highest 
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binding to a number of different metals, and the rigid structure give a metal-complex 
stronger than that of the corresponding complex to DTPA. However, chelating a metal to 
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on which radionuclide have been used, i.e. 225Ac, 211At, 213Bi, 90Y, 177Lu, or 131I. Some of the 
studies are not in an intraperitoneal setting, but have been mentioned because of their 
importance and relevance. 
5.1 225Ac-Trastuzumab 
One study has investigated the immunoreactivity, internalization, and cytotoxicity using 
SKOV-3 cells (Borchardt et al., 2003). The immunoreactivity was retained (50%–90%) and the 
radioimmunocomplex internalized into the cells (50% at 2 h). Various therapies were 
evaluated, using unlabeled trastuzumab and 8.1, 12.2, or 16.6 kBq of 225Ac-trastuzumab or 
225Ac-labeled control antibody. The therapies were given 9 d after tumor inoculation. 
Groups of control mice and mice administered unlabeled trastuzumab had median survivals 
of 33, 37 or 44 d, respectively. The median survival was 52–126 d using 225Ac-trastuzumab, 
and 48–64 d using the 225Ac-control mAb. Some deaths from toxicity occurred at the highest 
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activity levels. The study showed that i.p. administration of 225Ac-trastuzumab extended 
survival in mice at levels that produce no apparent toxicity. An advantage of 225Ac is that it 
emits a cascade of α-particles, implying a very high cytotoxic effect if the α-particle 
emissions occur in close vicinity to the cancer cell nuclei. The disadvantage is that when 
225Ac decays it will be separated from its targeting construct, making the remaining emitted 
α-particles an unspecific irradiation that potentially could lead to both dosimetry and 
toxicity problems. 225Ac should therefore be used with caution in situations other than for 
example during intracavitary treatments or when the radioimmunocomplex is relatively 
rapid internalized into the cancer cells. 
5.2 211At-MOv-18, 211At-MX35 and 211At-Affibody 
Astatine-211 is a very promising radionuclide due to its half-life of 7.2 h and short particle 
range (~70 µm). A drawback is its limited availability due to the fact that it is cyclotron 
produced, and only a few cyclotrons world-wide produce 211At today. The potential 
problem with unspecific irradiation (as described above for 225Ac) is negligible due to the 
fact that the α-particle emanating from the second decay route (from 211Po to 207Pb) occurs 
with a very short half-life (0.5 seconds), i.e. in close vicinity to the targeted cancer cell (Palm 
et al., 2004). Andersson et al. have performed studies investigating the pharmacokinetics 
and therapeutic efficacy of 211At-labeled mAbs (Andersson et al., 1999, 2000a, 2000b, 2001). 
In one of those studies the purpose was to compare the therapeutic efficacy of 211At-MOv18 
and 131I-MOv18 (Andersson et al., 2001). The study used OVCAR-3 cells growing i.p. in 
mice. Two weeks after the i.p. inoculation of 1 × 107 tumor cells twenty mice were treated 
i.p. with MOv18 labeled with either 211At (310–400 kBq) or 131I (5.1–6.2 MBq). The 
pharmacokinetics of the labeled antibody in tumor-free animals was studied and the 
resulting absorbed dose to bone marrow was estimated. When the mice were treated with 
211At-MOv18 nine out of ten mice were free of macro- and microscopic tumors compared to 
three out of ten when 131I-MOv18 was used. The equivalent dose to bone marrow was 2.4–
3.1 Sv from 211At-MOv18 and 3.4–4.1 Sv from 131I-MOv18. The study showed that the 
therapeutic efficacy of 211At-MOv18 was high, and superior to that using 131I-MOv18. 
Other studies using 211At-mAbs have also been completed (Bäck et al., 2005; Elgqvist et al., 
2005a, 2005b, 2006a, 2006b, 2006c, 2009a, 2009b). In one of those studies the purpose was to 
estimate the efficacy of RIT using 211At-MX35 F(ab’)2 or 211At-Rituximab F(ab’)2 (non-
specific) against differently sized ovarian cancer deposits on the peritoneum, and to 
calculate absorbed dose to tumors and critical organs (Elgqvist et al., 2006a). At 1–7 w after 
inoculation animals were i.p. treated with ~400 kBq 211At-MX35 F(ab’)2, ~400 kBq 211At-
Rituximab F(ab’)2, or unlabeled Rituximab F(ab’)2. Eight weeks after each treatment the 
mice were sacrificed and the presence of tumors and ascites was determined. When given 
treatment 1, 3, 4, 5, or 7 w after cell inoculation the tumor-free fraction (TFF) was 0.95, 0.68, 
0.58, 0.47, 0.26, and 1.00, 0.80, 0.20, 0.20, and 0.0 when treated with 211At-MX35 F(ab’)2 or 
211At-Rituximab F(ab’)2, respectively. The conclusion of the study was that treatment with 
211At-MX35 F(ab’)2 or 211At-Rituximab F(ab’)2 resulted in a TFF of 0.95–1.00 when the tumor 
radius was ≤30 µm. The TFF was decreased (TFF ≤ 0.20) for the non-specific 211At-Rituximab 
F(ab’)2 when the tumor radius exceeded the range of the α-particles. The tumor specific 
mAb resulted in a significantly better TFF, for different tumor sizes, explained by a high 
mean absorbed dose (>22 Gy) from the activity bound to the tumor surface, probably in 
addition to some contribution from penetrating activity. 
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Another study (although not i.p.) evaluated the relative biological effectiveness (RBE) of 211At-
mAb (Bäck et al., 2005). The endpoint was growth inhibition (GI) of subcutaneous OVCAR-3 
xenografts. The animals received i.v. injections of 211At-MX35 F(ab’)2 (0.33, 0.65, and 0.90 
MBq). External irradiation of the tumors was performed with a 60Co source. To compare the 
biologic effects of the two radiation qualities, the mean value for GI was plotted for each tumor 
as a function of its corresponding absorbed dose. Exponential fits of these curves were made, 
and the absorbed doses required for a GI of 0.37 (D37) were derived, and also the RBE of 211At 
was determined. Absorbed doses in tumors were 1.35, 2.65, and 3.70 Gy. D37 was determined 
to 1.59 ± 0.08 Gy (mean ± SEM). Tumor growth after irradiation by the 60Co source resulted in 
a D37 of 7.65 ± 1.0 Gy. The RBE of 211At irradiation was calculated to be 4.8 ± 0.7 Gy.  
In yet another study (also not i.p.) HER-2 binding affibody molecules were labeled with 
211At, using the PAB and a decaborate-based linker, and the biodistribution in tumor bearing 
mice was investigated (Steffen et al., 2006a). Compared with a previous biodistribution with 
125I, the 211At biodistribution using the PAB linker showed higher uptake in lungs, stomach, 
thyroid and salivary glands, indicating release of free 211At. When the decaborate-based 
linker was used, the uptake in those organs was decreased, but instead, high uptake in 
kidneys and liver was found. The conclusion of the study was that affibody molecules have 
suitable blood-kinetics for targeted radionuclide therapy with 211At, the labeling chemistry 
however affects the distribution in normal organs to a high degree and needs to be 
improved to allow clinical use. 
5.3 213Bi-P-P4D and 213Bi-PAI2 
Bismuth-213 has a well established chemistry, is available via a generator, and has recently 
achieved an increased attention. A drawback is its short half-life (45.6 min), which necessitates 
a rapid specificity, once injected. Using 213Bi in intracavitary or i.p. applications, or using 
pretargeting techniques, could however overcome this potential problem. A study using 213Bi 
has been performed by Knör et al. developing peptidic radioligands, which targets cancer cell 
urokinase receptors (uPAR, CD87) (Knör et al., 2008). DOTA-conjugated, uPAR-directed 
ligands were synthesised. Biodistribution of 213Bi-P-P4D was analysed in mice 28 d after i.p. 
inoculation of OV-MZ-6 ovarian tumor cells in the absence or presence of the plasma expander 
gelofusine. Binding of 213Bi-P-P4D to monocytoid U937 and OV-MZ-6 cells was shown using 
the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The 
213Bi-P-P4D showed superior binding to OV-MZ-6 cells in vitro, and accumulation of 213Bi-P-
P4D in tumor tissue was shown by biodistribution analysis in mice bearing i.p. OV-MZ-6-
derived tumors. Gelofusine reduced the kidney uptake of 213Bi-P-P4D by 50%. In conclusion, 
ovarian cancer cells overexpressing uPAR were specifically targeted in vitro as well as in vivo 
by 213Bi-P-P4D, and the kidney uptake was reduced by gelofusine. 
An additional study also using 213Bi has been published by Song et al. in which they 
investigated the pharmacokinetics, toxicity and in vivo stability of 213Bi-PAI2, and also 
determined if a prior injection of the metal chelator Ca-DTPA or lysine would reduce the 
toxicity by decreasing the renal uptake (Song et al., 2007). Two different chelators (CHX-A"-
DTPA and cDTPA) were used for the preparation of the 213Bi-PAI2 conjugate; for i.p. 
administration in mice and ear vein injection in rabbits. Neither the mice nor the rabbits 
displayed any short term toxicity over 13 w at 1,420 MBq/kg and 120 MBq/kg 213Bi-PAI2, 
respectively. The kidney uptake was markedly decreased (threefold) by blocking with 
lysine. Nephropathy caused by radiation was observed at 20–30 w in the mice, whereas 
severe renal tubular necrosis was detected at 13 w in the rabbits. In conclusion, the 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
238 
activity levels. The study showed that i.p. administration of 225Ac-trastuzumab extended 
survival in mice at levels that produce no apparent toxicity. An advantage of 225Ac is that it 
emits a cascade of α-particles, implying a very high cytotoxic effect if the α-particle 
emissions occur in close vicinity to the cancer cell nuclei. The disadvantage is that when 
225Ac decays it will be separated from its targeting construct, making the remaining emitted 
α-particles an unspecific irradiation that potentially could lead to both dosimetry and 
toxicity problems. 225Ac should therefore be used with caution in situations other than for 
example during intracavitary treatments or when the radioimmunocomplex is relatively 
rapid internalized into the cancer cells. 
5.2 211At-MOv-18, 211At-MX35 and 211At-Affibody 
Astatine-211 is a very promising radionuclide due to its half-life of 7.2 h and short particle 
range (~70 µm). A drawback is its limited availability due to the fact that it is cyclotron 
produced, and only a few cyclotrons world-wide produce 211At today. The potential 
problem with unspecific irradiation (as described above for 225Ac) is negligible due to the 
fact that the α-particle emanating from the second decay route (from 211Po to 207Pb) occurs 
with a very short half-life (0.5 seconds), i.e. in close vicinity to the targeted cancer cell (Palm 
et al., 2004). Andersson et al. have performed studies investigating the pharmacokinetics 
and therapeutic efficacy of 211At-labeled mAbs (Andersson et al., 1999, 2000a, 2000b, 2001). 
In one of those studies the purpose was to compare the therapeutic efficacy of 211At-MOv18 
and 131I-MOv18 (Andersson et al., 2001). The study used OVCAR-3 cells growing i.p. in 
mice. Two weeks after the i.p. inoculation of 1 × 107 tumor cells twenty mice were treated 
i.p. with MOv18 labeled with either 211At (310–400 kBq) or 131I (5.1–6.2 MBq). The 
pharmacokinetics of the labeled antibody in tumor-free animals was studied and the 
resulting absorbed dose to bone marrow was estimated. When the mice were treated with 
211At-MOv18 nine out of ten mice were free of macro- and microscopic tumors compared to 
three out of ten when 131I-MOv18 was used. The equivalent dose to bone marrow was 2.4–
3.1 Sv from 211At-MOv18 and 3.4–4.1 Sv from 131I-MOv18. The study showed that the 
therapeutic efficacy of 211At-MOv18 was high, and superior to that using 131I-MOv18. 
Other studies using 211At-mAbs have also been completed (Bäck et al., 2005; Elgqvist et al., 
2005a, 2005b, 2006a, 2006b, 2006c, 2009a, 2009b). In one of those studies the purpose was to 
estimate the efficacy of RIT using 211At-MX35 F(ab’)2 or 211At-Rituximab F(ab’)2 (non-
specific) against differently sized ovarian cancer deposits on the peritoneum, and to 
calculate absorbed dose to tumors and critical organs (Elgqvist et al., 2006a). At 1–7 w after 
inoculation animals were i.p. treated with ~400 kBq 211At-MX35 F(ab’)2, ~400 kBq 211At-
Rituximab F(ab’)2, or unlabeled Rituximab F(ab’)2. Eight weeks after each treatment the 
mice were sacrificed and the presence of tumors and ascites was determined. When given 
treatment 1, 3, 4, 5, or 7 w after cell inoculation the tumor-free fraction (TFF) was 0.95, 0.68, 
0.58, 0.47, 0.26, and 1.00, 0.80, 0.20, 0.20, and 0.0 when treated with 211At-MX35 F(ab’)2 or 
211At-Rituximab F(ab’)2, respectively. The conclusion of the study was that treatment with 
211At-MX35 F(ab’)2 or 211At-Rituximab F(ab’)2 resulted in a TFF of 0.95–1.00 when the tumor 
radius was ≤30 µm. The TFF was decreased (TFF ≤ 0.20) for the non-specific 211At-Rituximab 
F(ab’)2 when the tumor radius exceeded the range of the α-particles. The tumor specific 
mAb resulted in a significantly better TFF, for different tumor sizes, explained by a high 
mean absorbed dose (>22 Gy) from the activity bound to the tumor surface, probably in 
addition to some contribution from penetrating activity. 
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Another study (although not i.p.) evaluated the relative biological effectiveness (RBE) of 211At-
mAb (Bäck et al., 2005). The endpoint was growth inhibition (GI) of subcutaneous OVCAR-3 
xenografts. The animals received i.v. injections of 211At-MX35 F(ab’)2 (0.33, 0.65, and 0.90 
MBq). External irradiation of the tumors was performed with a 60Co source. To compare the 
biologic effects of the two radiation qualities, the mean value for GI was plotted for each tumor 
as a function of its corresponding absorbed dose. Exponential fits of these curves were made, 
and the absorbed doses required for a GI of 0.37 (D37) were derived, and also the RBE of 211At 
was determined. Absorbed doses in tumors were 1.35, 2.65, and 3.70 Gy. D37 was determined 
to 1.59 ± 0.08 Gy (mean ± SEM). Tumor growth after irradiation by the 60Co source resulted in 
a D37 of 7.65 ± 1.0 Gy. The RBE of 211At irradiation was calculated to be 4.8 ± 0.7 Gy.  
In yet another study (also not i.p.) HER-2 binding affibody molecules were labeled with 
211At, using the PAB and a decaborate-based linker, and the biodistribution in tumor bearing 
mice was investigated (Steffen et al., 2006a). Compared with a previous biodistribution with 
125I, the 211At biodistribution using the PAB linker showed higher uptake in lungs, stomach, 
thyroid and salivary glands, indicating release of free 211At. When the decaborate-based 
linker was used, the uptake in those organs was decreased, but instead, high uptake in 
kidneys and liver was found. The conclusion of the study was that affibody molecules have 
suitable blood-kinetics for targeted radionuclide therapy with 211At, the labeling chemistry 
however affects the distribution in normal organs to a high degree and needs to be 
improved to allow clinical use. 
5.3 213Bi-P-P4D and 213Bi-PAI2 
Bismuth-213 has a well established chemistry, is available via a generator, and has recently 
achieved an increased attention. A drawback is its short half-life (45.6 min), which necessitates 
a rapid specificity, once injected. Using 213Bi in intracavitary or i.p. applications, or using 
pretargeting techniques, could however overcome this potential problem. A study using 213Bi 
has been performed by Knör et al. developing peptidic radioligands, which targets cancer cell 
urokinase receptors (uPAR, CD87) (Knör et al., 2008). DOTA-conjugated, uPAR-directed 
ligands were synthesised. Biodistribution of 213Bi-P-P4D was analysed in mice 28 d after i.p. 
inoculation of OV-MZ-6 ovarian tumor cells in the absence or presence of the plasma expander 
gelofusine. Binding of 213Bi-P-P4D to monocytoid U937 and OV-MZ-6 cells was shown using 
the natural ligand of uPAR, pro-uPA, or a soluble form of uPAR, suPAR, as competitors. The 
213Bi-P-P4D showed superior binding to OV-MZ-6 cells in vitro, and accumulation of 213Bi-P-
P4D in tumor tissue was shown by biodistribution analysis in mice bearing i.p. OV-MZ-6-
derived tumors. Gelofusine reduced the kidney uptake of 213Bi-P-P4D by 50%. In conclusion, 
ovarian cancer cells overexpressing uPAR were specifically targeted in vitro as well as in vivo 
by 213Bi-P-P4D, and the kidney uptake was reduced by gelofusine. 
An additional study also using 213Bi has been published by Song et al. in which they 
investigated the pharmacokinetics, toxicity and in vivo stability of 213Bi-PAI2, and also 
determined if a prior injection of the metal chelator Ca-DTPA or lysine would reduce the 
toxicity by decreasing the renal uptake (Song et al., 2007). Two different chelators (CHX-A"-
DTPA and cDTPA) were used for the preparation of the 213Bi-PAI2 conjugate; for i.p. 
administration in mice and ear vein injection in rabbits. Neither the mice nor the rabbits 
displayed any short term toxicity over 13 w at 1,420 MBq/kg and 120 MBq/kg 213Bi-PAI2, 
respectively. The kidney uptake was markedly decreased (threefold) by blocking with 
lysine. Nephropathy caused by radiation was observed at 20–30 w in the mice, whereas 
severe renal tubular necrosis was detected at 13 w in the rabbits. In conclusion, the 
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nephropathy was the dose-limiting toxicity, and lysine was effective in reducing the uptake 
in the kidneys. Maximum tolerated doses were 350 and 120 MBq/kg for the mice and 
rabbits, respectively. The same research group has earlier shown the in vitro cytotoxicity and 
in vivo inhibition of tumor growth in breast, prostate, pancreatic, and ovarian cancer (Allen 
et al., 2003; Li et al., 2002; Qu et al., 2005; Ranson et al., 2002; Song et al., 2006). 
5.4 90Y(or 177Lu)-DOTA-biotin-streptavidin-CC49 
Owing to efforts at developing strategies for RIT against ovarian cancer (Alvarez et al., 2002) 
the same research group also investigated pretargeted RIT in an i.p. tumor model (LS174T) 
using four CC49 anti-tumor-associated glycoprotein 72 (TAG-72) single-chain antibodies 
linked to streptavidin as a fusion protein (CC49 fusion protein) (Buchsbaum et al., 2005). A 
synthetic clearing agent was administered i.v. one day later to produce hepatic clearance of 
unbound CC49. A low molecular weight radiolabeled reagent composed of biotin 
conjugated to the chelating agent 7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid 
(DOTA) complexed with 111In-, 90Y-, or 177Lu was injected four hours later. The 
radiolocalization to tumor sites was superior with i.p. administration of radiolabeled DOTA-
biotin as compared to i.v. administration. Imaging and biodistribution studies showed good 
tumor localization with 111In- or 177Lu-DOTA-biotin. Tumor localization of 111In-DOTA-
biotin was 43% ID/g (percentage of injected dose per gram) and 44% ID/g at 4 and 24 hours 
with the highest normal tissue localization in the kidney with 6% ID/g at 48 and 72 h. 90Y-
DOTA-biotin at doses of 14.8–22.2 MBq or 177Lu-DOTA-biotin at doses of 22.2–29.6 MBq 
produced significant prolongation of survival compared with controls (p = 0.03 and p < 
0.01). The conclusion of the study was that pretargeted RIT using regional administration of 
CC49 fusion protein and i.p. 90Y- or 177Lu-DOTA-biotin is a therapeutic strategy in the 
LS174T i.p. tumor model and that this strategy may be applicable to humans. LS174T is a 
human colon cancer cell line, but as it was used in an i.p. setting in this study together with 
CC49 (which reacts with the tumor-associated glycoprotein TAG-72, expressed by the 
majority of common epithelial tumors) we think it is relevant to present the results. 
5.5 177Lu-Pertuzumab and 177Lu-Affibody 
Lutethium-177-Pertuzumab has been used for disseminated HER-2-positive micrometastases 
(Persson et al., 2007), and showed good targeting in mice bearing HER-2-overexpressing 
xenografts. Absorbed radiation dose in tumors was more than 5 to 7 times higher than that in 
blood and in any normal organ. 177Lu-Pertuzumab delayed tumor progression compared with 
controls (no treatment, p < 0.0001; Pertuzumab, p < 0.0001; and 177Lu-labeled irrelevant mAb, p 
< 0.01). Adverse side effects of the treatment could not be detected. In conclusion, the results 
support the possibility using 177Lu-Pertuzumab in clinical studies. 
In a study by Tolmachev et al. a 177Lu-labeled anti-HER-2 affibody molecule (ZHER2:342) 
targeting xenografts was used (Tolmachev et al., 2007). Due to the small size (~7 kDa) of the 
affibody molecule rapid glomerular filtration and high renal accumulation occurred. 
Reversible binding to albumin reduced the renal excretion and uptake though. The affibody 
molecule (ZHER2:342)2 (i.e. dimeric) was fused with the albumin-binding domain (ABD) 
conjugated with the isothiocyanate derivative of CHX-A''-DTPA and thereafter labeled with 
177Lu. Fusion with ABD caused a 25-fold reduction of the renal uptake in comparison with the 
non-fused dimer molecule (ZHER2:342)2. The biodistribution showed high uptake of the 
conjugate in HER-2-expressing tumors. Treatment of SKOV-3 microxenografts (having a high 
HER-2 expression) with 17 or 22 MBq 177Lu-CHX-A''-DTPA-ABD-(ZHER2:342)2 prevented 
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formation of tumors completely. In LS174T xenografts (having a low HER-2 expression), this 
treatment resulted in a small but significant increase of the survival. In conclusion, fusion with 
ABD improved the in vivo biodistribution and indicated 177Lu-CHX-A''-DTPA-ABD-(ZHER2:342)2 
as a candidate for the treatment of disseminated tumors having high HER-2 expression. 
5.6 131I-A5B7 
In a large animal study of human tumors in cyclosporin-immunosuppressed sheep, by 
Turner et al., evaluation and measurement of tumor uptake of 131I-mAbs was done (Turner 
et al., 1998). Human cancer cells were orthotopically inoculated (~107 cells): SKMEL 
melanoma subcutaneously; LS174T and HT29 colon carcinoma into bowel, peritoneum and 
liver; and JAM ovarian carcinoma into the ovary and peritoneum. The tumor xenografts 
grew within 3 w and generally maintained their histological appearance, a few tumor 
deposits showing some degree of dedifferentiation though. Regional lymph node metastases 
were shown for xenografts from the melanoma and ovarian carcinoma. An anti-CEA mAb 
(A5B7) labeled with 131I was administered intravenously. The peak uptake at 5 d in 
orthotopic tumors in the gut was 0.027% ID/g and 0.034% ID/g in hepatic metastases with 
tumor-to-blood ratios of 2.0–2.5. The non-specific uptake in melanoma tumors was 0.003% 
ID/g. In conclusion, the uptake of 131I-mAb in human tumors was comparable to the uptake 
observed in patients, and this sheep model may therefore be more realistic than mice 
xenografts for prediction of the efficacy of RIT.   
6. Clinical studies 
Several clinical protocols have been reported on during the past twenty years, although 
almost all of them have been small phase I radiopharmaceutical biokinetics and absorbed 
dose-finding studies (Alvarez et al., 2002; Jacobs et al., 1993; Macey et al., 1999; Meredith et 
al., 1996, 2001; Van Zanten-Przybysz et al., 2000,2001), or phase I/II studies with no controls 
or at best matched historical cases (Epenetos et al., 1987, 2000; Hird et al., 1990; Nicholson et 
l., 1998; Stewart et al., 1989a, 1989b). Tumor stage and degree of advanced disease have 
varied greatly between, and also within, these studies as have the used targeting constructs 
and the choice of radionuclide. Albeit, these studies are important as they have provided us 
with the necessary starting hubs to the scaffold of knowledge that needs to be acquired. The 
major exception from this is the only randomised phase III study reported by Verheijen et al. 
(Verheijen et al., 2006). Despite its negative results it still holds as the major publication so 
far on intraperitoneal (i.p.) radioimmunotherapy for ovarian cancer and also stresses the 
importance of performing randomized studies. This study was spurred by the positive 
findings in a non-randomized phase I/II trial (Epenetos et al., 2000; Nicholson et al., 1998), 
where prolonged disease free and long term survival was described after one i.p. treatment, 
using 90Y labeled murine HMFG1 antibody, in patients that had received a complete 
response on standard treatment (surgery and primary chemotherapy). Prior to these reports, 
a few other small clinical studies using different radionuclides and targeting constructs, had 
likewise suggested a possibly better treatment effect of i.p. radioimmunotherapy, correlating 
inversely with size of residual disease; 131I (Epenetos et al., 1987; Crippa et al., 1995; Stewart 
et al., 1989a, 1989b); and 186Re (Jacobs et al., 1993).    
Thus, the Verheijen study (Verheijen et al., 2006) finally recruited 447 patients between 
February 1998 and January 2003, with ovarian cancer (FIGO stage Ic-IV) to evaluate if a 
single i.p. infusion of 25 mg of the β-particle emitter 90Y conjugated to the murine HMFG1 
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nephropathy was the dose-limiting toxicity, and lysine was effective in reducing the uptake 
in the kidneys. Maximum tolerated doses were 350 and 120 MBq/kg for the mice and 
rabbits, respectively. The same research group has earlier shown the in vitro cytotoxicity and 
in vivo inhibition of tumor growth in breast, prostate, pancreatic, and ovarian cancer (Allen 
et al., 2003; Li et al., 2002; Qu et al., 2005; Ranson et al., 2002; Song et al., 2006). 
5.4 90Y(or 177Lu)-DOTA-biotin-streptavidin-CC49 
Owing to efforts at developing strategies for RIT against ovarian cancer (Alvarez et al., 2002) 
the same research group also investigated pretargeted RIT in an i.p. tumor model (LS174T) 
using four CC49 anti-tumor-associated glycoprotein 72 (TAG-72) single-chain antibodies 
linked to streptavidin as a fusion protein (CC49 fusion protein) (Buchsbaum et al., 2005). A 
synthetic clearing agent was administered i.v. one day later to produce hepatic clearance of 
unbound CC49. A low molecular weight radiolabeled reagent composed of biotin 
conjugated to the chelating agent 7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid 
(DOTA) complexed with 111In-, 90Y-, or 177Lu was injected four hours later. The 
radiolocalization to tumor sites was superior with i.p. administration of radiolabeled DOTA-
biotin as compared to i.v. administration. Imaging and biodistribution studies showed good 
tumor localization with 111In- or 177Lu-DOTA-biotin. Tumor localization of 111In-DOTA-
biotin was 43% ID/g (percentage of injected dose per gram) and 44% ID/g at 4 and 24 hours 
with the highest normal tissue localization in the kidney with 6% ID/g at 48 and 72 h. 90Y-
DOTA-biotin at doses of 14.8–22.2 MBq or 177Lu-DOTA-biotin at doses of 22.2–29.6 MBq 
produced significant prolongation of survival compared with controls (p = 0.03 and p < 
0.01). The conclusion of the study was that pretargeted RIT using regional administration of 
CC49 fusion protein and i.p. 90Y- or 177Lu-DOTA-biotin is a therapeutic strategy in the 
LS174T i.p. tumor model and that this strategy may be applicable to humans. LS174T is a 
human colon cancer cell line, but as it was used in an i.p. setting in this study together with 
CC49 (which reacts with the tumor-associated glycoprotein TAG-72, expressed by the 
majority of common epithelial tumors) we think it is relevant to present the results. 
5.5 177Lu-Pertuzumab and 177Lu-Affibody 
Lutethium-177-Pertuzumab has been used for disseminated HER-2-positive micrometastases 
(Persson et al., 2007), and showed good targeting in mice bearing HER-2-overexpressing 
xenografts. Absorbed radiation dose in tumors was more than 5 to 7 times higher than that in 
blood and in any normal organ. 177Lu-Pertuzumab delayed tumor progression compared with 
controls (no treatment, p < 0.0001; Pertuzumab, p < 0.0001; and 177Lu-labeled irrelevant mAb, p 
< 0.01). Adverse side effects of the treatment could not be detected. In conclusion, the results 
support the possibility using 177Lu-Pertuzumab in clinical studies. 
In a study by Tolmachev et al. a 177Lu-labeled anti-HER-2 affibody molecule (ZHER2:342) 
targeting xenografts was used (Tolmachev et al., 2007). Due to the small size (~7 kDa) of the 
affibody molecule rapid glomerular filtration and high renal accumulation occurred. 
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formation of tumors completely. In LS174T xenografts (having a low HER-2 expression), this 
treatment resulted in a small but significant increase of the survival. In conclusion, fusion with 
ABD improved the in vivo biodistribution and indicated 177Lu-CHX-A''-DTPA-ABD-(ZHER2:342)2 
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single i.p. infusion of 25 mg of the β-particle emitter 90Y conjugated to the murine HMFG1 
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antibody could prolong survival in patients in complete clinical response (physical 
examination and CT-scan and CA-125) after surgical debulking and finishing standard 
platinum containing chemotherapy and, importantly, with a macroscopically negative 
second-look laparoscopy. However, contrary to the beliefs from the pre-studies this large 
prospective randomized study failed to demonstrate any survival benefit. Using Cox 
proportional hazards analysis of survival, no difference was found, after a median follow-
up of 3.5 years 70/224 patients had died in the active treatment arm compared with 61/223 
in the control arm. Also time to relapse was similar between groups and 104/224 active 
treatment patients experienced relapse compared with 98/223 of controls.  
Although the study was carefully planned and well conducted and performed one should 
consider the following points which could have contributed to conceal positive effects of the 
active treatment. A) Peritoneal adhesions in up to an entire quadrant did not exclude 
patients in this study, which could potentially result in a significant underdosing of ≤ 25% of 
the abdominal cavity. Further, the adhesions were assessed by laparoscopy, CT scan or 
isotope diffusion scan, where only the latter can allow a solid enough assessment of 
adhesions and to discern between one or two quadrants of adhesions. Importantly, it is 
unclear if patients (no adhesions versus one quadrant with adhesions) were stratified 
between each treatment arm. B) A possible skewing of patients with more advanced disease 
characteristics to the treatment arm is evident, e.g. in the active treatment arm there were 8% 
more patients with residual disease after initial surgery (44.2% vs. 35.9%) and there were 3% 
more stage III and IV patients in the treatment arm which also had a higher mean CA-125 
level after laparoscopy (never explained). Furthermore, 7% more patients in the standard 
arm received consolidation chemotherapy (19.7% vs. 12.5%). C) Regarding the 
radioimmunocomplex and their antigenicity towards the cancer cells one may note that the 
overall antibody mass of 25 mg may have been insufficient to provide a concentration 
gradient to help “push” the radiolabeled antibody into the tumors. This can be contrasted to 
the 250 mg/m2 of cold antibody used with Zevalin or the 450 mg total antibody dose used 
with Bexxar. As a multi-center study the radiolabeling process was by necessity performed 
by each institution and although a radiolabeling efficiency of 95% was confirmed with thin-
layer chromatography, a potential loss of affinity of the antibody for the antigen, as a result 
of the radiolabeling process was not addressed. And lastly; D) The impact of a ≤60% MUC1 
staining for 18% of the patients in the treatment arm is grossly unknown.  
Although no survival benefit for 90Y-HMFG1 i.p. instillation as consolidation treatment for 
epithelian ovarian cancer was found, an improved local control of i.p. disease was reported 
on in a pattern of failure analysis (Oei et al., 2007). Of the 104/224 treatment arm and 98/223 
control arm relapses, there were significantly fewer i.p. (40 vs. 69, p < 0.05) and more 
extraperitoneal (47 vs. 13, p < 0.05) relapses in the treatment arm. Correspondingly, time to 
i.p. recurrence was significantly longer (53.4 vs. 46.4 months, p = 0.0019) and time to 
extraperitoneal recurrence was significantly shorter for the treatment arm (51 vs. 63.6 
months, p < 0.001).  
Thus, the main negative result of the Verheijen study balances back somewhat, in that, some 
treatment effects can be seen locally i.p. with a delaying of local relapses which, however, 
could not translate into an effect on survival. Bearing in mind the above listed concerns, it is 
from our research group’s perspective (the Targeted Alpha Therapy Group, 
www.TAT.gu.se), tempting to argue that the failure of the treatment could simply be 
explained by the choice of radionuclide, i.e. when treating microscopic disease with high 
energy β-particles emitted from 90Y, the electron will have too long a range in order to 
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deliver high enough energy to the cancer cell nuclei. It has been modelled that high energy 
β-particle emissions will not deposit large amounts of radiation energy into small 
microscopic tumor spheroids. 
 
 
Fig. 1. Consecutive anteroposterior decay corrected scans (γ-camera) of the abdominal and 
thoracic area of a patient in the study by Andersson et al., 2009. The thyroid uptake, which is 
indicated by a region of interest in each panel, was not blocked in this patient. Images were 
acquired at 1.5 (top left), 5 (top right), 11.5 (bottom left), and 19.5 (bottom right) hours after 
infusion of 211At-MX35 F(ab’)2. The figure is reprinted by permission of the Society of 
Nuclear Medicine from Andersson H, Cederkrantz E, Bäck T, et al. Intraperitoneal α-particle 
radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-
MX35 F(ab´)2 – a phase I study. J Nucl Med 2009;50:1153–1160. 
So far, the only clinical study using an α-particle emitter, 211At, for treating ovarian cancer 
has been performed at our institution (Andersson et al., 2009). In a phase I study the 
pharmacokinetics and toxicity of α-RIT using 211At- MX35 F(ab’)2, in 9 patients with 
relapsed ovarian cancer was studied after 2nd or 3rd line of chemotherapy. Laparoscopy to 
exclude presence of macroscopic tumor growth or adhesions was performed prior to 
infusion with 20.1–101 MBq (0.54–2.73 mCi)/L 211At-MX35 F(ab’)2 via a peritoneal catheter. 
The study demonstrated that it is possible to achieve therapeutic absorbed doses in 
microscopic tumors without significant toxicity using up to 101 MBq. The potential thyroid 
toxicity of 211At could be successfully blocked by potassium perchlorate/iodide, (unblocked 
thyroid, 24.7 ± 11.1 mGy/(MBq/L); blocked thyroid, 1.4 ± 1.6 mGy/(MBq/L)). Two patients 
have no evidence of disease at 39 and 72 months. A multicenter, phase II study is currently 
being planned, intended as an upfront adjuvant treatment for a patient population that has 
received cytoreductive surgery and chemotherapy. 
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6.1 Tolerability and toxicity 
Generally the side effects have been mild, maximum tolerated doses (MTD) depends both 
on the nuclide used and the specific construct. The highest used activities can be infused 
using 131I constructs up to 5–6 GBq have been infused using different antibodies, but due to 
a long half-life (8 days) the bone marrow suppression have been evident (Epenetos et al., 
1987; Crippa et al., 1995; Stewart et al., 1989a, 1989b). The long half-life and gamma emission 
are also a concern regarding the unintentional irradiation of staff, relatives and other 
patients. In modelling bone marrow absorbed doses (Buchsbaum et al., 1999) using the 
CC49 antibody, and based on limiting the bone marrow absorbed dose to 2 Gy, the 
maximum possible administered activity of each of the following radionuclide was 
calculated: 188Re: 6.2 GBq (167.6 mCi), 166Ho: 4.1 GBq (110.8 mCi), 177Lu: 3.9 GBq (105.4 mCi), 
186Re: 2.6 GBq (70.2 mCi), 131I: 2.2 GBq (59.5 mCi), and 90Y: 1.3 GBq (35.1 mCi). Thus, 188Re 
was found to deliver the lowest RM absorbed dose, primarily because it had the shortest 
half-life, whereas 90Y delivered the highest RM dose (high energy, long path-length).  
For 90Y a variation in MTD depending on the used antibody, from 370 MBq with B72.3 
(Rosenblum et al., 1999) up to 895 MBq with CC49 (Alvarez et al., 2002) is described. Prior to 
the large phase III study, a MTD of 685 MBq was found (Hird et al., 1990; Maraveyas et al., 
1994; Stewart et al.,1990) for 90Y using the HFG1-antibody with the bone marrow as dose 
limiting organ.  Subsequently an activity of 666 MBq was used (Nicholson et al., 1998; 
Verheijen et al., 2006), the most common side effects of nausea, fatigue, arthralgia, myalgia 
and abdominal discomfort were transient and mainly mild. The expected bone marrow 
toxicity was evident as thrombocytopenia with as much as 24% of the patients experiencing 
more than grade 3 toxicity, peeking at 6 weeks after treatment and a few cases 2,4% lasting 
until 6 months after treatment (Verheijen et al., 2006). 
Two combined modality treatment protocols have been reported with subcutaneous IFN α2b 
and i.p. paclitaxel (100 mg/m2), combined with i.p. 90Y-CC49, MTD of 895 MBq, (Alvarez et al., 
2002) or i.p. 177Lu-CC49-RIT (Meredith et al., 2001). The addition of IFN increased hematologic 
toxicity such that the MTD of the combination with 177Lu-CC49 was 1.5 GBq/m2 compared to 
1.7 GBq/m2. Considering the much shorter range of the emitted β-particles from 177Lu (mean 
range ≈ 0.2 mm) compared to those emitted from 90Y (mean range ≈ 4 mm), 177Lu theoretically 
has a higher therapeutic index than 90Y for a microscopic disease, due to its ability to more 
specifically irradiate the tumor cells while sparing healthy tissue.  
Strategies to increase the tumor activity and decrease the activity in dose limiting organs 
have been tested also in small clinical studies. Firstly, data have been presented using EDTA 
as an effective myeloprotective drug to suppress the bone uptake (Rosenblum et al., 1999). 
Continuous i.v. infusion of EDTA immediately before i.p. administration of up to 1,665 MBq 
90Y-B72.3 presented the expected dose-limiting toxicities of thrombocytopenia and 
neutropenia but at a higher MTD, and analysis of biopsies demonstrated that the bone and 
marrow content of the 90Y was 15-fold lower (<0.001% ID/g) in the group receiving EDTA 
infusion. Secondly, the concept of pretargeted RIT based on the avidin-biotin system, was 
evaluated in 38 patients (Grana et al., 2004). A three-step protocol: biotinylated mAbs and 
avidin were i.p. injected (first and second step), and 12–18 h later 90Y-biotin (either i.v. or 
i.p.) was injected as the third step. Sixteen were treated by i.p. injection only, whereas 22 
patients received the combined treatment (i.v. + i.p.), doses ranged from 370 to 3,700 MBq of 
90Y-biotin. Both regimens were well tolerated, but two patients showed temporary grade III–
IV hematologic toxicity. In conclusion, excellent tolerability and a good potential therapeutic 
role of pretargeted RIT in advanced ovarian cancer.  
 
Intraperitoneal Radionuclide Therapy – Clinical and Pre-Clinical Considerations 
 
245 
7. Radiation dosimetry in the clinical situation 
Dosimetry is needed to optimize the amount of radiopharmaceutical that should be 
administered to the patient (Palm et al., 2011). This involves estimating the maximum 
administered radioactivity possible at which critical normal organs reach an acceptable 
degree of toxicity. Dosimetric calculations are mostly only needed for a few critical normal 
organs. Derived organ absorbed radiation doses, combined with the knowledge about 
tolerance absorbed doses, provide a guide for estimating the maximum tolerable activity 
(MTA) that should be given. This approach has been applied in the therapy with β-particle–
emitting radiopharmaceuticals when tolerance absorbed doses for critical normal organs 
have been established. An example is the therapy with 177Lu-octreotate, in which the 
administered activity is based on dosimetry for the kidneys (Garkavij et al., 2010). The 
clinical experience with β-particle emitters and estimation of tolerance absorbed doses could 
possibly be used to predict the outcome for the therapy with α-particle emitters. A first 
correction should then be made for the higher relative biological effectiveness (RBE) of α-
particles. In the first clinical studies, an RBE of 5 has been applied for the estimation of 
equivalent absorbed doses (Andersson et al., 2009; Bruland et al., 2006; Sgouros et al., 1999). 
The concept of RBE and the uncertainties of its precise value for α-particles are still under 
debate and investigated. The weighting factors applied for the estimation of the effective 
absorbed dose (where a factor of 20 often is recommended by regulators for α-particle 
radiation) should not be used for predicting therapeutic efficacy and toxicity in patients 
undergoing radionuclide therapy. These weighting factors were conservatively derived for 
the stochastic effects and were never meant for use in estimating the deterministic effects 
relevant for therapy. The clinical experience using α-particles is still very limited, and no 
tolerance absorbed radiation doses in humans have been determined yet. The current 
knowledge is therefore limited to in vitro and in vivo studies. For current and planned 
clinical studies of α-particle–emitting radiopharmaceuticals, it is therefore very important to 
gain more insight into the toxic effects of α-particles and its relationship to absorbed dose 
for different organs. The tolerance absorbed doses found for α-particles could then 
gradually become established and used for the treatment planning of patients. 
Besides the special challenges regarding α-particles, the establishment of pharmacokinetic 
data for dosimetry calculations does not differ from that of the more conventional β-particle 
therapies. Nuclear medicine imaging is often used for the quantification of the dosimetric 
calculations. Much software have been developed for the calculation of the absorbed 
radiation doses to organs and tumors based on serial 3D imaging and anatomical 
information from computed tomography (CT) or magnetic resonance imaging (MRI) 
(Sgouros et al., 2008). Accurate quantification of γ-camera and positron-emission 
tomography (PET) images and measurements of for example the radioactive blood content 
over time, are also becoming increasingly important for many diagnostic nuclear medicine 
procedures. Repeated sample measurements using, for example, a gamma-well counter can 
provide valuable pharmacokinetic data that allow for accurate absorbed dose calculations. 
Blood and urine sampling is often possible for patients undergoing therapy. Repeated 
sampling of peritoneal fluid has also been reported (Andersson et al., 2009). In principle, 
measurements or images of biopsies from organs of interest would be valuable (Bäck et al., 
2010), but the increased dosimetric accuracy gained must be weighed against the discomfort 
such invasive procedures cause the patient. Simple, non-invasive methods using uptake 
probes can also provide important information on the pharmacokinetics for an individual 
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patient. Gaze et al. have demonstrated the usefulness of such an approach for patient 
dosimetry following 131I-MIBG treatments (Gaze et al., 2005).  
Imaging using a γ-camera is commonly used for quantifying the biodistribution of 
therapeutic radiopharmaceuticals. A prerequisite, of course, being the presence of emitted γ-
photons, characteristic X-ray, or bremsstrahlung radiation. The image quality depends on 
photon energy, photon yields, energy settings, and appropriate matching of collimator and 
photon energy. The decay chains of the α-particle emitters used hitherto in clinical studies 
(225Ac, 213Bi, 211At, and 223Ra) all include emissions of photons useful for γ-camera imaging. 
However, the spatial resolution of γ-camera images is inferior to what is needed to resolve 
activity distributions within organ compartments or in small tumors. Administered activity 
and the presence of photons are also much lower compared to the diagnostic situation, 
resulting in a low signal-to-noise ratio. The possibility of serial γ-camera imaging of patients 
receiving α-particle therapy is therefore limited for providing quantitative data for 
dosimetry of whole organs. Low count rates make the preferred 3D SPECT (three 
dimensional single photon-emission computed tomography) imaging of the radionuclide 
distribution very time consuming. Serial imaging might therefore be restricted to planar 
imaging with possibly lower accuracy for the quantification of radioactivity. Such planar 
images can provide useful quantitative information, and the accuracy can also be increased 
by using co-registration with CT images (Sjögren et al., 2002).  
A focus committee of the Society of Nuclear Medicine provided a review in 1995 of the 
different factors affecting quantitative SPECT (Rosenthal et al., 1995). The field has 
developed since then, but the main factors that affect the quantification using SPECT remain 
the same. Many factors influence the accuracy of the quantification of PET/CT images and 
include: correction for attenuation, noise, image resolution, and ROI (region of interest) 
definitions (Alessio et al., 2010; Boellard et al., 2004; Kinahan et al., 1998). Regarding all 
quantifications, it can be very useful to perform phantom measurements mimicking the 
patient situation as good as possible. Measurements of that kind can help in selecting the 
parameters for imaging or probe sessions as well as providing indications of the accuracy 
that possibly can be obtained (He et al., 2005). 
7.1 Tumor and critical organ absorbed doses 
Although the maximum amount of administered activity possible is directly related to the 
absorbed radiation dose to the critical organs, the therapeutic efficacy is determined by the 
absorbed dose to the tumors. If a low tumor absorbed dose can be expected, the therapy 
might not be justified. The tumor absorbed dose should therefore, if at all possible, be 
estimated before treatment. The visualization and quantification using a γ-camera can at 
best give an estimate of the radiopharmaceutical uptake in the organ as a whole and in large 
tumors. The determination of absorbed radiation dose to sub-organ compartments or to 
small tumors or infiltrate cancer cells is though seldom possible. 
Estimating the absorbed dose to tumors following α-particle therapy is particularly difficult. 
Because the targeted tumors often are too small to be detected, at best indirect methods can 
be used for approximating the absorbed radiation dose. Using antibody or peptide-based 
therapies, this approximation can for example involve in vitro studies on the binding 
kinetics to antigens or receptor sites for the relevant cancer cell type. Using radionuclides 
having a decay chain including α-particle–emitting daughters, studies would involve 
investigating the retention of daughter radionuclides on or in the vicinity of the cancer cells. 
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Microdosimetry based on such in vitro studies could then provide the basis for 
investigations of the probability for eradicating or stopping or retarding the growth of the 
tumors. The theoretical basis for such dosimetry has recently been described by Sgouros et 
al. (Sgouros et al., 2011). 
The complexity of the studies and calculations involved for the absorbed dose is 
considerable, particularly when translating the results to the individual patient for an 
outcome prediction. This initial complexity should not though prevent formulation of a first, 
although perhaps rough, estimate. Such estimates, including best-guess information on 
tumor spread and overall tumor burden, targeting ability, and the amount of delivered 
radioactivity, will often provide good insight into the potential usefulness of the treatment 
approach. 
As for radionuclide therapies using β-particle emitters, the absorbed dose to critical organs 
often determines the MTA. The common aim should therefore be to maximize the 
administered activity to near the level of toxicity for these organs, even for therapies using 
α-particles. Therapy planning should include calculation of expected organ absorbed doses 
(Gy) per administered activity (Bq) to identify the optimal amount of activity to be 
administered. The absorbed dose calculations can either be based on pharmacokinetic data 
from previous patients or preferably, data from the specific patient is used. Such data could 
be generated by tracer studies of the actual radiopharmaceutical or a substitute with similar 
pharmacokinetics. If a fractionated or repeated therapy is to be used, the generation of 
pharmacokinetic data from each administration should be used for re-planning the 
remainder. However, differences can arise in the pharmacokinetics between the therapeutic 
radiopharmaceutical and the tracer or between subsequent therapy sessions, and methods 
should therefore be established to detect such changes. 
7.2 General considerations 
The clinical studies using targeted α-particle therapy have their origin in previously 
established strategies involving β-particle emitters. It is assumed that the significantly 
shorter track range of the α-particles compared to β-particles provides a therapeutic 
advantage in that the critical normal organs to a high degree will be spared and a higher 
absorbed radiation dose to microscopic tumors will be reached. An illustration of this fact is 
223Ra therapy for example, in which the bone marrow is less irradiated compared to 
therapies using β-particle emitters. Radium-223 binds to the skeleton, resulting in a high 
absorbed dose to the bone surfaces while the absorbed radiation dose to the bone marrow 
remains relatively low. Consequently, the hematologic toxicity is therefore limited. 
If shifting from a β- to an α-particle emitting radiopharmaceutical, the dosimetry differs not 
only due to the different particles emitted but also due to differences in half-lives and the 
biokinetics of the free radionuclide. When, for example, using 211At-conjugates, 211At can be 
set free and be taken up in the thyroid as a result of the natrium iodine symporter (NIS) 
receptor expressed at the thyroid cells. This process is very similar to that which occurs 
when iodine-based conjugates are used and iodine is set free and taken up by the NIS 
receptor. In both of the clinical studies using 211At, blocking agents like potassium 
perchlorate were used to reduce the uptake in the thyroid cells. This method is well known 
for iodine-based therapies, and both the normal uptake of iodine in the thyroid and the 
blocking effect of, for example, potassium iodide are well established. Regarding 211At, the 
blocking effect can not be considered well established, and careful monitoring is therefore 
necessary for any unwanted uptake in the thyroid despite the use of blocking agents.  
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The physical half-life of α- and β-particle emitters used should ideally be matched with the 
kinetics of the targeting approach. The relatively short half-lives of the α-particle emitters 
211At and 213Bi could in general be a disadvantage therefore, but are a good match for the 
loco-regional therapies such as intraperitoneal. Most of the decays will occur within the 
intraperitoneal cavity before the substance is distributed throughout the body. To be able to 
achieve optimal therapeutic efficacy the maximum safe amount of activity should be 
administered to the patient. The determination of the MTA is typically sought for a patient 
population but should ideally be estimated for each individual patient as mentioned above; 
thus, patient-specific dosimetry is needed.  
Taking a control image with an analogue is relevant for ovarian cancer. In this case, it is 
important to determine if the infused radiopharmaceutical can disperse throughout the 
peritoneal cavity and access all potential microscopic tumors on the peritoneal lining. 
Leakage control, i.e., determining the lymphatic flow out from the peritoneal cavity, can 
also be done using an analogue by monitoring the activity concentration in blood over 
time. Such control images helps manage bone marrow absorbed doses. Pharmacokinetic 
data show that the variation in absorbed dose to bone marrow among patients is around 
20% (Andersson et al., 2009). If the absorbed dose to the bone marrow determines the 
MTA, then a tracer study could be used to estimate the patient-specific MTA. However, 
since the peritoneum might determine the MTA for intraperitoneal therapy, only the 
activity concentration in the peritoneal fluid is probably needed to establish it. In this 
particular situation, the same activity concentration in the injected solution for all patients 
can be reasonable, but it is valid only if the patients are free from ascites at the time of 
injection. 
The phase I study on ovarian cancer has generated interest in an adjuvant-targeted -
particle therapy of earlier-stage cancer patients (Andersson et al., 2009). This population 
would by necessity include patients who would remain disease-free even without the 
adjuvant therapy. In such settings, it is relevant to include stochastic and/or long-term risks 
such as secondary cancers and dysfunction of the peritoneum in the justification for the 
therapy. In this particular case, it is advised that calculation of the equivalent doses to all 
relevant organs is done, including a conservative estimation of the RBE for α-particles. 
8. Future perspectives 
The mortality of EOC has not decreased during the past decades, despite a decline in 
incidence and an intensification of treatment has occurred. The majority of the patients are 
diagnosed at an advanced stage and most of them will therefore succumb, suffering from 
abdominal complications. Using present diagnostics, the screening for early stage EOC has 
not been successful, but efforts in finding proteins in serum indicating early EOC is a vision 
for future improvements in ovarian cancer survival. Additional approaches are for example 
the development of targeted treatments, resulting hopefully in higher efficacy and lower 
toxicity than present day treatments, some of which have been discussed above. Such 
targeted therapies could include substrate analogues, ligands, or antibodies, resulting in up-
regulation of receptors or surface antigens. Antibodies may exhibit a therapeutic effect on 
their own or as conjugates to toxins or radionuclides. Since the clinical situation is 
dominated by spread and complications in the abdominal cavity, such therapeutic 
techniques are primarily directed intraperitoneally. A successful intraperitoneal therapy 
may eradicate abdominal disease and complications, however, extraperitoneal metastases 
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may become revealed. Therefore, a combination of abdominal and systemic modalities is 
most likely required.  
As the current available standard treatments often fail to cure a micrometastatic disease, 
RIT, using short ranged high efficiency α-particles emitted from for example 211At or 213Bi 
and depositing the radiation energy in close vicinity of the targeted cancer cells, is an 
attractive approach, possibly in combination with β-particle emitters aimed at larger tumor 
cell clusters. Such procedures could then be given as a boost after initial cytoreductive 
surgery and systemic chemotherapy, primarily intraperitoneally but possibly also 
intravenously by pretargeting approaches, based for example on the avidin/streptavidin-
biotin system. A systemic adjunctive approach may be of particular value if the disease 
includes retroperitoneal vascularized metastases to the lymph nodes for example 
(Buchsbaum et al., 2005; Frost et al., 2010; Paganelli et al., 1993). Another important concept 
that could potentially improve the therapeutic index would be to use fractionated RIT, 
expectedly resulting in decreased normal tissue toxicity while retaining the therapeutic 
efficacy (Elgqvist et al., 2009b). Auger emitters could also offer an alternative to the 
radionuclides mentioned above, due to the emitted electrons being low energy (<< 1 keV), 
and therefore having a very short path length in tissue. To effectively damage the DNA the 
Auger emitter has to be incorporated into the DNA molecule though, a biological challenge 
that has to be taken into account for this type of treatment. 
The potential disadvantages with a treatment given intraperitoneally are: the i.p. catheter 
could cause pain and discomfort for the patient, the catheter could leak (and possibly 
therefore decreasing the therapeutic efficacy and causing a radiation protection problem for 
the staff), and it could cause an infection and therefore a risk of peritonitis. In order for the 
i.p. treatments to be successful, especially when using radionuclides that emit short-range 
particles such as α-particles, loculation and/or adhesions are undesirable and could 
decrease the therapeutic efficacy. The potential problems of toxicity (especially bone 
marrow, kidney, peritoneum) and HAMA response always needs to be addressed. A 
number of review articles have recently been published, regarding RIT in general and RIT 
against intraperitoneal EOC in particular (Allen, 2004, 2008; Andersson et al., 2003; Chérel, 
2006; Crippa, 1993; Gadducci et al., 2005; Gaze, 1996; Goldenberg, 2002; Goldenberg & 
Sharkey, 2006; Imam, 2001; Kairemo, 1996; Kassis et al., 1996; Meredith et al., 2007; Mulford 
et al., 2005; Muto & Kassis, 1995; Oyen et al., 2007; Sharkey & Goldenberg, 2005; Zalutsky et 
al., 2007). 
Many different parameters could influence the intraperitoneal therapeutic outcome, some of 
which are: the specificity of targeting construct, the degree of antigenic expression (Moltoff 
et al., 1991), loss of immunoreactivity of the targeting construct, amount of unlabeled 
antibody, diffusion barriers for penetration of the targeting construct into cancer cell 
clusters, the choice of radionuclide (half-life and particle range), low specific radioactivity, 
and tumors located extraperitoneally. If treating a microscopic disease the choice of using β-
particle emitters could be problematic due to the inability of the β-particles to deliver high 
enough radiation energy to the target volume, i.e. the cancer cell nuclei. That is probably the 
reason why the clinical studies performed so far using β-particles have failed when trying to 
treat microscopic diseases. 
The proof-of-concept using an intraperitoneal treatment has been shown in a phase III study 
by the Gynecologic Oncology Group that included women undergoing initial therapy for 
advanced ovarian cancer (Armstrong et al., 2006), and the advantage of i.p. compared to i.v. 
administration for the localization of radiolabeled mAbs to microscopic peritoneal disease 
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has been shown in some studies, both in animal models and for humans (Andersson et al., 
2003; Horan Hand et al., 1989; Ward et al., 1987). Finally, in order to be able to compare and 
evaluate different treatment strategies the need to conduct randomized, controlled, 
multicenter clinical studies with large enough patient numbers, enabling statistical 
significance to occur, must be emphasized and aimed at.  
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has been shown in some studies, both in animal models and for humans (Andersson et al., 
2003; Horan Hand et al., 1989; Ward et al., 1987). Finally, in order to be able to compare and 
evaluate different treatment strategies the need to conduct randomized, controlled, 
multicenter clinical studies with large enough patient numbers, enabling statistical 
significance to occur, must be emphasized and aimed at.  
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1. Introduction 
Ovarian cancer is the fifth most common cancer among women and approximately 
200,000 women are diagnosed as ovarian cancer every year in the world (Parkin et al., 
2005). Platinum-containing chemotherapeutic agents such as cisplatin (cis-
diamminedichloroplatinum II) and carboplatin have been most frequently used for the 
treatment of ovarian cancer. These platinum compounds specifically react with guanine 
residues in DNA to form interstrand and intrastrand cross-links in DNA, known as DNA-
adducts. This interferes with mitosis of cancer cells and causes cell death. However, ovarian 
cancer cells can become resistant to cisplatin and the majority of patients develop cisplatin-
resistant disease (Giaccone 2000; Hennessy et al., 2009; Kartalou & Essigmann 2001), and as 
a result, most ovarian cancers relapse. Paclitaxel (taxol) and two analogues of camptothecin, 
irinotecan and topotecan, are the drugs most commonly administered to platinum-resistant 
ovarian cancer patients. Paclitaxel (taxol) binds to -tubulin and stabilizes microtubule 
structure, which causes a G2/M block in the cancer cell cycle. Irinotecan, also known as 
CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin) and 
topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin) inhibit topoisomerase I 
by resealing DNA breaks, which results in the inhibition of cancer cell growth (Bookman et 
al., 1998; Swisher et al., 1997). However, the survival rate for relapsed patients is low; Thus, 
there is an urgent need for more effective chemotherapeutic approaches for ovarian cancer 
treatment. We have previously reported that some ovarian cancer cell lines are remarkably 
sensitive to vitamin K2 (Shibayama-Imazu et al, 2003, 2006, 2008). In this review, strategies 
for developing chemotherapeutic agents for ovarian cancer are described and vitamin K2 is 
proposed as a promising chemotherapeutic agent for ovarian cancer. 
2. Effect of vitamin K2 on cancer cells 
Natural forms of vitamin K such as vitamin K1 (phylloquinone) and vitamin K2 
(menaquinones, MK) are cofactors for the post-translational -carboxylation of glutamate 
residues in vitamin K-dependent proteins (Fig. 1). Vitamin K is mainly used as a hemostatic 
agent because coagulation factors VII, IX, and X, which are critical to blood coagulation, are 
vitamin K-dependent proteins. In addition, vitamin K2 has anti-cancer activity, whereas 
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vitamin K1 does not. This difference arises from structural differences in the side chains 
attached to the parent ring of vitamin K. 
2.1 Structures and fundamental properties of vitamin K 
The parent ring structure of vitamin K is 2-methyl-1,4-naphthoquinone (menadione), which is 
also known as vitamin K3 (Fig. 1). Vitamin K3 does not occur naturally and causes oxidative 
stress in both normal and cancer cells and is toxic to the liver. There are few successful clinical 
applications of vitamin K3. Vitamin K1 has a phythyl side chain at the 3 position of vitamin K3 
and is present mainly in green vegetables. Vitamin K1 is converted to vitamin K2 in animals 
and humans (Thijssen & Drittij-Reijnders, 1996); vitamin K2 has isoprenoid side chains of 
various lengths attached to the 3 position of the vitamin K3 ring structure. The different forms 
of vitamin K2, menaquinone-n (MK-n), are categorized according to the number of repeating 
isoprenoid residues in the side chain. The most common form of vitamin K2 in animals is 
menaquinone-4 (MK-4), which has four isoprenoid residues as its side chain. MK-4 is the most 
biological active form of the vitamin and is produced by intestinal bacteria. Long chain 
menaquinones, MK-7 to MK-10, are synthesized by bacteria and are present in fermented 
products such as cheese (MK-8 and MK-9) and East Asian fermented soybean products, such 
as natto and miso (Shearer et al., 1996; Schurgers & Vermeer, 2000).  
 
 
Fig. 1. Chemical Structures of vitamin K 
Naturally occurring vitamin K1 contains a phytyl group, and vitamin K2 has a repeating 
isoprenoid group at the 3 position of the vitamin K3 menadione ring. In animals, the most 
common and most biologically active form of vitamin K2 is MK-4, which has four 
isoprenoid residues (n = 4). Unlike vitamin K1, vitamin K2 has anti-cancer activity in 
addition to its critical role in blood coagulation and bone metabolism. The isoprenyl side 
chain of vitamin K2 contributes to its unique anti-cancer activity.  
2.2 Growth inhibitory activity of vitamin K2 on cancer cells 
We initially demonstrated vitamin K2-induced differentiation in human leukemia cells 
which was unrelated to its clinical role in blood coagulation and bone metabolism (Sakai I, 
1994). Inhibition of cancerous cell growth and induction of apoptosis by vitamin K2 has 
subsequently been observed in a variety of human cancer cell lines, including liver 
(Nishikawa et al., 1995; Otsuka et al., 2004), pancreatic (Shibayama-Imazu et al., 2003), 
ovarian (Shibayama-Imazu et al., 2003, 2006, 2008), lung (Yoshida et al., 2003; Yokoyama et 
al., 2005), stomach (Tokita et al., 2006), breast (Wu et al., 1993), and leukocyte (Yaguchi, 
1997). The growth-inhibitory effects of vitamin K2 on various human cancer cell lines are 
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et al., 2001), and inhibition of cancerous cell growth was not observed with vitamin K1. 
Therefore, the side chain of vitamin K2 may be important for the anti-cancer activity of 
vitamin K2. The anti-cancer activity of isoprenoids is known to depend on the length of the 
polyprenyl alcohol side chain; polyprenoids with a geranylgeranyl group or a 
geranylisopropyl group have the most potent anticancer activity (Ohizumi et al., 1995). 
Vitamin K2 MK-4 has a geranylgeranyl side chain and is commonly used for the treatment 
of a variety of cancer cells. In this review, vitamin K2 MK-4 is denoted simply as vitamin K2. 
 
 
Table 1. IC50 values for vitamin K2 in various cancer cell lines. IC50 is defined as the 
concentration of vitamin K2 that inhibits cell growth by 50%. The values for SW626 and 
OVCAR3 were estimated from previously published results (Shibayama-Imazu et al., 2008). 
Clinical trials using vitamin K2 that were conducted successfully for leukemia and liver 
cancer patients are indicated by boxes. 
3. Induction of apoptosis in ovarian cells by vitamin K2 
Inhibition of cell growth is a good indicator of the induction of apoptosis in cancer cells by 
chemical agents. A comparison of the inhibition of the growth of various cancer cells by 
vitamin K2 showed that an ovarian cancer cell line PA-1 is the most sensitive to vitamin K2. 
A steroid orphan receptor TR3/Nur77, which regulates cell proliferation and apoptosis, is 
responsible for the induction of apoptosis in ovarian cancer PA-1 cells by vitamin K2. 
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3.1 Growth inhibition of ovarian cancer cells by vitamin K2 
We observed that apoptosis is readily induced in some ovarian cancer cell lines by low 
concentrations of vitamin K2 (Shibayama-Imazu et al, 2003; 2006). Figure 2 shows that 
vitamin K2 is a potent inhibitor of the growth of human ovarian cancer PA-1 cells, with an 
IC50 of 5.0 + 0.7 M. The IC50 value for PA-1 cells is the lowest observed for cancer cell lines 
treated with vitamin K2, indicating that PA-1 cells are the most sensitive to vitamin K2 
(Table 1). In contrast to PA-1 cells, SK-OV-3 cells were resistant to vitamin K2 and no 
significant growth inhibition was observed (Fig. 2). PA-1 and SK-OV-3 cells were used as 
vitamin K2-sensitive and vitamin K2-resistant cells, respectively, in order to examine the 
mechanism of apoptosis induction by vitamin K2. 
 
 
Fig. 2. Effects of vitamin K2 on the growth of human ovarian cancer PA-1 and SK-OV-3 cells. 
Cell proliferation was determined using the XTT assay 96 h after treatment with various 
concentrations of vitamin K2. Each value is represented as mean + SD of the results from 
three independent experiments. Vitamin K2-sensitive PA-1(●); vitamin K2-resistant SK-OV-
3 (○). [Reproduced with permission from Fig. 1 of Shibayama-Imazu et al., 2008.] 
3.2 Mechanism of the induction of apoptosis by vitamin K2  
The induction of apoptosis by vitamin K2 in vitamin K2-sensitive ovarian cancer PA-1 cells 
proceeds slowly. Fragmented nucelosomes were released into the cytosolic fraction 24 h 
after the start of incubation of PA-1 cells with 30 M vitamin K2, and increased until at least 
72 h after the start of incubation (Fig. 3A). After 72 h, the induction of apoptosis was evident 
in approximately 35% of PA-1 cells, as determined by counting apoptotic cells with 
condensed and fragmented nuclei stained with Hoechst 33342 (Shibayama-Imazu et al., 
2008). The slow rate of apoptosis is one of the characteristic features of vitamin K2-induced 
apoptosis, compared to apoptosis induced by conventional anticancer agents such as 
camptothecin and etoposide, and by geranaylgeraniol (Masuda et al., 2000; Shibayama-
Imazu et al., 2003). Mitochondria play a crucial role in the induction of apoptosis by various 
apoptotic agents. Cytochrome c released from mitochondria forms a complex with Apaf-1 
and activates procaspase 9, which activates a downstream caspase cascade. Once the 
caspase cascade has been triggered, nucleases are activated to induce apoptotic chromatin 
condensation and DNA fragmentation. The release of cytochrome c in PA-1 cells was 
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detected 48 h after treatment with 30 M vitamin K2 and the release increased sharply 72 h 





Fig. 3. Induction of apoptosis in ovarian cancer PA-1 and SK-OV-3 cells by vitamin K2. (A) 
Both vitamin K2-sensitive PA-1 (●) and vitamin K2-resistant SK-OV-3 (○) cells were treated 
with 30 M of vitamin K2 for various times. Each value is represented as mean + SD of the 
results from three independent experiments. The percentage of apoptotic cells that 
contained condensed and fragmented chromatin was quantified after staining with Hoechst 
33342 as described previously (Shibayama-Imazu et al., 2008). (B) The panel shows 
immunoblotting analysis of cytochrome c released from mitochondria into the cytoplasm of 
PA-1 cells that had been treated with 30 M vitamin K2 (Shibayama-Imazu et al., 2008). 
[Reproduced with permission from Fig. 6 of Shibayama-Imazu et al., 2008.] 
3.3 Accumulation of TR3/Nur77 in mitochondria after treatment of PA-1 cells with 
vitamin K2 
A steroid orphan receptor TR3/Nur77 is overexpressed in various cancer cells lines, including 
ovarian (Holmes et al., 2002), lung (Li et al., 1998), prostate (Li et al., 2000), colon (Cho et al., 
2007), pancreatic (Chintharlapalli et al., 2005), bladder (Chintharlapalli et al., 2005) and 
stomach (Wu et al., 2002). The expression of TR3/Nur77 is rapidly induced during cancer cell 
apoptosis triggered by various apoptotic agents, such as phorbol ester 12-O-tetradecanoyl 
phobol-13-acetate (Li et al., 2000), etoposide (Li et al., 2000), cytosporone B (Liu et al., 2010), 
and the synthetic retinoid 6-[3-(1-admantyl)]-4-hydroxyphenyl]-2-naphthalene carboxylic acid 
(CD437, Holmes et al., 2004). TR3/Nur77 translocates from the nucleus to mitochondria in 
response to these apoptosis inducers, with the exception of CD437 (Li et al., 2000). TR3/Nur77 
binds to Bcl-2 which switches the function of Bcl-2 from protection to the induction of 
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cytochrome c release from the mitochondria, resulting in the induction of apoptosis (Li et al., 
2000). For CD437, the levels of TR3/Nur77 in the nuclei of various pancreatic cancer cells were 
increased by treatment with this agent, although translocation of TR3/Nur77 from the nuclei 
to the mitochondria was not observed (Chintharlapalli et al., 2005).  
 
 
Fig. 4. Immunoblotting analysis of TR3/Nur77 in vitamin K2-sensitive PA-1 cells and 
vitamin K2-resistant SK-OV-3 cells. Both vitamin K2-sensitive PA-1 and vitamin K2-resistant 
SK-OV-3 cells were treated with 30 M of vitamin K2 for 0 h, 24 h, 48 h, and 72 h. 
TR3/Nur77 in the cell lysates (A) and in the heavy mitochondrial fractions (B) were detected 
by immunoblotting using rabbit TR3/Nur77-specific polyclonal antibody (Shibayama-
Imazu et al., 2008). Two immunostained bands were detected under our electrophoretic 
conditions as previously reported (Chintharlapalli et al., 2005). The more slowly migrating 
minor band is phosphorylated TR3/Nur77 (Pekarsky et al., 2001). The intensities of the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band and the cytochrome oxidase 
subunit Ⅳ (OX) band confirmed that an equal amount of cell lysate proteins and heavy 
mitochondrial fraction proteins, respectively, were loaded in each lane. [Reproduced with 
permission from Fig. 3 and Fig. 6 of Shibayama-Imazu et al., 2008.] 
The level of TR3/Nur77 in vitamin K2-sensitive PA-1 cells was approximately four-fold 
higher than that in vitamin K2-resistant SK-OV-3 cells (Fig. 4A). The level of TR3/Nur77 in 
the cell lysate of PA-1 cells increased markedly in a time-dependent manner after treatment 
with vitamin K2. In contrast, the level of TR3/Nur77 in the cell lysate of vitamin K2-
resistant SK-OV-3 cells was very low and was not significantly affected by treatment with 
vitamin K2. The TR3/Nur77 level in the cell lysate of SK-OV-3 cells did not reach the level 
observed in untreated PA-1 cells, even 72 h after the start of the treatment.  
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In the heavy mitochondrial fraction, which is composed mostly of mitochondria, the level of 
TR3/Nur77 increased sharply 48 h and 72 h after the start of the treatment of PA-1 cells with 
vitamin K2 (Fig. 4B). The percentage of apoptotic cells increased in parallel with the increase 
in TR3/Nur77 in the heavy mitochondrial fraction of PA-1 cells (Fig. 3A). In contrast, the 
level of TR3/Nur77 in the heavy mitochondrial fraction of vitamin K2-resistant SK-OV-3 
cells was unchanged by vitamin K2 treatment (Fig. 4B). Immunofluorescence staining of PA-
1 cells during vitamin K2-induced apoptosis indicates that the amounts of TR3/Nur77 
present in both mitochondria and nuclei as well as in the cytosolic fraction increased after 
vitamin K2 treatment (Shibayama-Imazu et al., 2008). This suggests that TR3/Nur77 
migrated directly from the cytoplasm to the mitochondria and no translocation from the 
nucleus to mitochondria occurred. It should be noted that this effect of vitamin K2 on 
ovarian cancer PA-1 cells is unique and different from that of apoptosis-inducing agents 
such as etoposide (Li et al., 2000) and cytosporone B (Liu et al., 2010) which cause 
translocation of TR3/Nur77 from the nuclei to the mitochondria. 
4. Strategy for the improvement of chemotherapy of ovarian cancer 
Combination treatments with agents that sensitize ovarian cancer cells to platinum 
compounds are an efficient strategy for overcoming chemoresistance acquired by ovarian 
cancer cells. Cancer cell survival signals can be inhibited by chemical agents, or ovarian 
cancer cells can be sensitized to platinum chemotherapeutic agents by preventing the repair 
of platinum-DNA adducts. A further method is to find chemical agents that induce 
apoptosis in ovarian cancer cells by a different mechanism from platinum compounds and 
may therefore exert synergistic apoptotic effects. 
4.1 Inhibition of survival signals  
The balance between cellular survival and induction of apoptosis determines the sensitivity 
of cancer cells to chemotherapeutic drugs. Therefore, blocking survival cascade signals or 
enhancing apoptosis-inducing signals enhances the sensitivity of ovarian cancer cells to 
chemotherapeutic agents (Vivanco & Sawyers, 2002). Topotecan, an inhibitor of 
topoisomerase I, inhibits Akt kinase activity in cisplatin-resistant ovarian cancer Caov-3 cells 
(Tsunetoh et al., 2010). The PI3K-Akt survival cascade signal in cisplatin-resistant ovarian 
cancer cells is inhibited by treatment with a combination of topotecan and cisplatin, which 
enhances the sensitivity to cisplatin in vitro and in vivo (Tsunetoh et al., 2010). The flavonoid 
compound, kaempherol, sensitizes ovarian cancer OVCAR-3 cells to cisplatin by down 
regulation of cMyc, which is involved in proliferation and is commonly activated in human 
cancer cells (Jung et al., 2008; Luo et al., 2010). Treatment of cisplatin resistant A2780CP 
ovarian cancer cells with a polyphenol, curcumin (diferulonyl methane), derived from the 
rhizomes of turmeric Curcuma longa, down regulated the expression of cMyc and pro-
survival proteins such as Bcl-XL and Mcl-1, leading to cisplatin sensitization (Yallapu, 2010). 
Topotecan, kaempherol, and curcumin therefore warrant further investigation as potential 
therapeutic agents for ovarian cancer. 
4.2 Inhibition of platinum-DNA adduct repair 
Inhibitors of DNA synthesis, such as gemcitabine (Touma et al., 2006), cytarabine (Swinnen 
et al., 2008), hydroxyurea (Raymond et al., 2001), and aphidicolin (Sargent et al., 1996), are 
able to inhibit the repair process of platinum-DNA adducts and have been used to increase 
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cytochrome c release from the mitochondria, resulting in the induction of apoptosis (Li et al., 
2000). For CD437, the levels of TR3/Nur77 in the nuclei of various pancreatic cancer cells were 
increased by treatment with this agent, although translocation of TR3/Nur77 from the nuclei 
to the mitochondria was not observed (Chintharlapalli et al., 2005).  
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sensitivity to chemotherapeutic platinum compounds. A phase II study using carboplatin 
followed by gemcitabine and paclitaxel for the treatment of ovarian cancer patients showed 
an improvement in therapeutic efficacy (Harries et al., 2004). However, the pulmonary 
toxicity observed as a side effect of this treatment still needs to be addressed. 
The histone deacetylase inhibitor panobinostat, which affects the expression of various 
genes, showed synergistic cytotoxic effects in conjunction with conventional 
chemotherapeutic agents including carboplatin on ovarian cancer cell lines (Budman et al., 
2010).  
Arsenic trioxide inhibits UV-induced DNA repair processes (Hartwig et al., 1997), and also 
showed additive cytotoxic effects with cisplatin for human ovarian carcinoma cell lines in 
vitro (Uslu et al., 2000). Arsenic trioxide was successfully used for the treatment of all-trans 
retinoic acid resistant acute promyelocytic leukemia (Soignet et al., 1998), which suggests 
that it may be successful in treating cisplatin-resistant ovarian cancer patients. 
4.3 Induction of apoptosis in cancer cells by activating the TR3/Nur77 gene 
Indole -3-carbinol (I3C), contained in cruciferous vegetables such as broccoli, cabbage, and 
cauliflower, and its dimeric product 3,3’-diindolylmethane (DIM) are nontoxic, natural 
compounds with anticancer activities. DIM and its analogues increase the levels of 
TR3/Nur77 and induce apoptosis in various cancer cell lines including colon, pancreas, 
prostate, and breast cancer cells (Banerjee et al., 2009; Cho et al., 2007). Pancreatic cancer 
cells with acquired resistance to chemotherapeutic drugs, such as cisplatin, oxaliplatin, and 
gemcitabin, were sensitized by pretreatment with DIM (Banerjee et al., 2009). Compounds 
that activate the TR3/Nur77 gene and induce apoptosis in cancer cells are proposed as a 
new category of chemotherapeutic drugs, and include an analogue of cytosporone B (Liu et 
al., 2010) and 1,1-bis(3'-indolyl)-1-(p-substituted phenyl) methanes (C-substituted DIMs, 
Chintharlapalli et al., 2005). Acetylshikonin and its derivative 5,8-diacetoxyl-6-(1'-acetoxyl-
4'-methyl-3'-pentenyl)-1,4-naphthaquinones (SK07) increased the level of TR3/Nur77 
through posttranscriptional regulation, and induced apoptosis in various cancer cell lines 
including lung and cervical cancer cells (Liu et al., 2008). The positive correlation of the 
expression of the TR3/Nur77 subfamily member Nor-1 with survival rates of diffuse large 
B-cell lymphoma patients indicates the importance of TR3/Nur77 as a target for anti-cancer 
agents (Shipp et al., 2002). The importance of TR3-Nur77 as a therapeutic target of ovarian 
cancer is also demonstrated by the fact that low expression of TR3/Nur77 in tissue samples 
obtained from various cancer patients is significantly associated with metastasis of primary 
solid cancers (Ramaswamy et al., 2003). 
We discovered that some ovarian cancer cell lines, such as PA-1 cells, are sensitive to 
vitamin K2 and apoptosis induced by stimulation of TR3/Nur77 synthesis and its 
accumulation in mitochondria (Fig. 5). Small interfering RNA (siRNA) directed against TR3-
Nur77 (siRNA-TR3/Nur77) caused a marked decrease in the levels of TR3/Nur77 in the 
lysate of PA-1 cells. When ovarian cancer PA-1 cells after transfection with siRNA-
TR3/Nur77 were treated with vitamin K2, the marked increase in the levels of TR3/Nur77 
observed by vitamin K2 without siRNA-TR3/Nur77 was almost completely abolished 
(Shibayama-Imazu et al., 2008). Induction of apoptosis by vitamin K2 was also significantly 
inhibited by transfection of PA-1 cells with siRNA-TR3/Nur77. Furthermore, 
cycloheximide, an inhibitor of protein synthesis, prevented the increase in TR3/Nur77 
levels, its accumulation in the mitochondria, and the induction of apoptosis in PA-1 cells 
caused by vitamin K2 treatment (Shibayama-Imazu et al., 2008). These results indicate that 
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the synthesis of TR3/Nur77 and its accumulation in mitochondria are required for the 
induction of apoptosis in PA-1 cells by vitamin K2 and also suggest that an increase in the 
level of TR3/Nur77 could be the cause of sensitivity to the induction of apoptosis in PA-1 
cells by vitamin K2 (Fig. 5). 
 
 
Fig. 5. A model for the induction of apoptosis in vitamin K2-sensitive ovarian cancer cells. 
The levels of TR3/Nur77 in vitamin K2-sensitive ovarian cancer cells are increased after 
treatment with vitamin K2. TR3/Nur77 synthesized in the cytoplasm migrates to the 
mitochondria and binds to Bcl-2, which protects the cell from apoptosis. Interaction of 
TR3/Nur77 with Bcl-2 induces a conformational change in Bcl-2, triggering the release of 
cytochrome c, which activates the caspase cascade and thus induces apoptosis. siRNA-
TR3/Nur77 causes degradation of TR3/Nur77 mRNA and cycloheximide inhibits the 
protein synthesis of TR3/Nur77, both leading to inhibition of the induction of apoptosis by 
vitamin K2. 
A combination of vitamin K2 and conventional chemotherapeutic agents for ovarian cancer, 
such as cisplatin and etoposide, which induce apoptosis by different mechanisms, might have 
additive or synergistic apoptotic effects on ovarian cancer cells. In addition, pretreatment with 
vitamin K2 or combination treatment with conventional chemotherapeutic agents could be 
effective for overcoming chemoresistance in ovarian cancer cells.  
5. Vitamin K2 as a promising chemotherapeutic agent for ovarian cancer  
Vitamin K2 induces apoptosis in blastic cells from patients with myelodysplastic syndrome 
(Nishimaki et al., 1999; Yaguchi et al., 1998) and has been successfully used in the clinical 
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(Nishimaki et al., 1999; Yaguchi et al., 1998) and has been successfully used in the clinical 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
268 
treatment of patients with this disorder (Miyazawa et al., 2000; Takami et al., 1999; Yaguchi 
et al., 1998, 1999). Oral administration of vitamin K2 with retinoic acid to a patient with 
relapsed acute promyelocytic leukemia resulted in complete remission (Fujita et al., 1998). In 
addition, oral administration of vitamin K2 also had a suppressive effect on the recurrence 
of hepatocellular carcinoma and improved patient survival rate (Habu et al., 2004; Mizuta et 
al., 2006; Tamori et al., 2007; Yoshiji et al., 2009). A recent cohort study indicates that cancer 
incidence and mortality were significantly decreased by dietary intake of vitamin K2 from 
food sources (Nimptsch et al., 2010). Vitamin K2 is also used clinically as a drug for 
osteoporosis in Asian countries such as Japan, Korea, and Thailand, because it also has a 
significant effect on bone fracture prevention (Cockayne et al., 2006; Olson, 2000; Shiraki et 
al., 2000). This is because calcium-binding proteins such as osteocalcin and calbindin, which 
are involved in calcium uptake and bone mineralization, are vitamin K-dependent proteins. 
A further cohort study indicated that the relative risk of coronary heart disease was also 
reduced by dietary intake of vitamin K2 (Geleijne et al., 2004). This may be because vitamin 
K-dependent proteins are associated with vascular repair processes (Benzakour & Kanthou, 
2000) and the prevention of vascular calcification (Shanahan et al, 1998). No side effects from 
vitamin K2 therapy were observed in any of these clinical studies; even vitamin K2 dosages 
in excess of 40 mg/day did not cause any side effects associated with hypercoagulable states 
(Shiraki et al., 2000), demonstrating its excellent safety profile. However, it is unknown why 
some ovarian cancer cell lines are resistant to vitamin K2. It may be possible to overcome 
vitamin K2 resistance by using it in combination with other agents that increase the level of 
TR3/Nur77 in cancer cells, such as DIM, cytosporone B, and the shikonin derivative SK07. 
SK07 stimulates the protein synthesis of TR3/Nur77 even in cervical cancer HeLa cells, in 
which the basal expression level of TR3/Nur77 is low (Liu et al., 2008). Further pre-clinical 
and clinical evaluation of vitamin K2 is required for its use in chemotherapy for ovarian 
cancers.  
6. Conclusion  
Several ovarian cancer cell lines are sensitive to vitamin K2; the IC50 value of the most vitamin 
K2-sensitive ovarian cancer PA-1 cells is as low as 5 M. Apoptosis is induced in PA-1 cells 
through the stimulation of TR3/Nur77 synthesis and its accumulation in mitochondria, which 
results in the release of cytochrome c and activation of the caspase cascade (Fig. 5). Because 
this mechanism is different from those of conventional chemotherapeutic agents for ovarian 
cancer such as cisplatin and etoposide, the present study demonstrates a new method for 
increasing the sensitivity of cisplatin resistant ovarian cancer cells to chemotherapy. Moreover, 
our observation suggests that the combination of vitamin K2 with cisplatin or etoposide may 
potentially be effective for the treatment of ovarian cancers. None of the clinical trials using 
high doses of vitamin K2 have recorded side effects from the treatment, and oral 
administration of vitamin K2 has already been successfully used for the treatment of acute 
promyelocytic leukemia and haepatocellular carcinoma (Table 1). We therefore propose 
vitamin K2 as a useful chemotherapeutic agent for ovarian cancer.  
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food sources (Nimptsch et al., 2010). Vitamin K2 is also used clinically as a drug for 
osteoporosis in Asian countries such as Japan, Korea, and Thailand, because it also has a 
significant effect on bone fracture prevention (Cockayne et al., 2006; Olson, 2000; Shiraki et 
al., 2000). This is because calcium-binding proteins such as osteocalcin and calbindin, which 
are involved in calcium uptake and bone mineralization, are vitamin K-dependent proteins. 
A further cohort study indicated that the relative risk of coronary heart disease was also 
reduced by dietary intake of vitamin K2 (Geleijne et al., 2004). This may be because vitamin 
K-dependent proteins are associated with vascular repair processes (Benzakour & Kanthou, 
2000) and the prevention of vascular calcification (Shanahan et al, 1998). No side effects from 
vitamin K2 therapy were observed in any of these clinical studies; even vitamin K2 dosages 
in excess of 40 mg/day did not cause any side effects associated with hypercoagulable states 
(Shiraki et al., 2000), demonstrating its excellent safety profile. However, it is unknown why 
some ovarian cancer cell lines are resistant to vitamin K2. It may be possible to overcome 
vitamin K2 resistance by using it in combination with other agents that increase the level of 
TR3/Nur77 in cancer cells, such as DIM, cytosporone B, and the shikonin derivative SK07. 
SK07 stimulates the protein synthesis of TR3/Nur77 even in cervical cancer HeLa cells, in 
which the basal expression level of TR3/Nur77 is low (Liu et al., 2008). Further pre-clinical 
and clinical evaluation of vitamin K2 is required for its use in chemotherapy for ovarian 
cancers.  
6. Conclusion  
Several ovarian cancer cell lines are sensitive to vitamin K2; the IC50 value of the most vitamin 
K2-sensitive ovarian cancer PA-1 cells is as low as 5 M. Apoptosis is induced in PA-1 cells 
through the stimulation of TR3/Nur77 synthesis and its accumulation in mitochondria, which 
results in the release of cytochrome c and activation of the caspase cascade (Fig. 5). Because 
this mechanism is different from those of conventional chemotherapeutic agents for ovarian 
cancer such as cisplatin and etoposide, the present study demonstrates a new method for 
increasing the sensitivity of cisplatin resistant ovarian cancer cells to chemotherapy. Moreover, 
our observation suggests that the combination of vitamin K2 with cisplatin or etoposide may 
potentially be effective for the treatment of ovarian cancers. None of the clinical trials using 
high doses of vitamin K2 have recorded side effects from the treatment, and oral 
administration of vitamin K2 has already been successfully used for the treatment of acute 
promyelocytic leukemia and haepatocellular carcinoma (Table 1). We therefore propose 
vitamin K2 as a useful chemotherapeutic agent for ovarian cancer.  
7. Acknowledgements 
We are grateful for the support from Grants-in-Aid for Scientific Research from the Ministry 
of Education, Cultures, Sports, Science, and Technology, Japan. 
 




Banerjee, S., Wang, Z., Kong, D. & Sarkar, FH. (2009) 3,3'-Diindolylmethane enhances 
chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer 
Research,Vol.69, No.13, (July 2009), pp. 5592-5600, ISSN 1538-7445 
Benzakour, O. & Kanthou, C. (2000) The anticoagulant factor, protein S, is produced by 
cultured human vascular smooth muscle cells and its expression is up-regulated by 
thrombin. Blood. Vol.95, No.6, (March 2000), pp. 2008-2014, ISSN 0006-4971  
Bookman, MA., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, JB. & Fields, SZ. 
(1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-
label phase II study in patients treated after prior chemotherapy that contained 
cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology, Vol.16, No.10, 
(October 1998), pp. 3345-3352, ISSN 0732-183X 
Budman, DR., Tai, J., Calabro, A. & John, V. (2010) The histone deacetylase inhibitor 
panobinostat demonstrates marked synergy with conventional chemotherapeutic 
agents in human ovarian cancer cell lines. Investigational New Drugs, (May 2010), 
published on line: June 9, ISSN 0167-6997  
Chintharlapalli, S., Burghardt, R., Papineni, S., Ramaiah, S., Yoon, K. & Safe, S. (2005) 
Activation of Nur77 by selected 1,1-Bis(3'-indolyl)-1-(p-substituted 
phenyl)methanes induces apoptosis through nuclear pathways. The Journal of 
Biolical Chemistry, Vol.280, No.26, (July 2005), pp. 24903-24914, ISSN 0021-9258  
Cho, SD., Yoon, K., Chintharlapalli, S., Abdelrahim, M., Lei, P., Hamilton, S., Khan, S., 
Ramaiah, SK. & Safe, S. (2007) Nur77 agonists induce proapoptotic genes and 
responses in colon cancer cells through nuclear receptor-dependent and nuclear 
receptor-independent pathways. Cancer Research, Vol.67, No.2, (January 2007), pp. 
674-683, ISSN 1538-7445 
Cockayne, S., Adamson, J., Lanham-New, S., Shearer, MJ., Gilbody, S. & Torgerson, DJ. 
(2006) Vitamin K and the prevention of fractures: systematic review and meta-
analysis of randomized controlled trials. Archives of  Internal Medicine, Vol.166, 
No.12, (June 2006), pp. 1256-1261, ISSN 0003-9926  
Fujita, H., Tomiyama, J. & Tanaka, T. (1998) Vitamin K2 combined with all-trans retinoic 
acid induced complete remission of relapsing acute promyelocytic leukemia. British 
Journal of Haematology, Vol.103, No.2, (November 1998), pp. 584-585, ISSN 0007-1048  
Geleijnse, JM., Vermeer, C., Grobbee, DE., Schurgers, LJ., Knapen, MH., van der Meer, IM., 
Hofman, A. & Witteman, JC. (2004) Dietary intake of menaquinone is associated 
with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of 
Nutrition, Vol.134, No.11, (November 2004), pp. 3100-3015, ISSN 0022-3166 
Giaccone, G. (2000) Clinical perspectives on platinum resistance. Drugs, Vol.59, Suppl. 4, pp. 
9-17, ISSN 0012-6667 
Habu, D., Shiomi, S., Tamori, A., Takeda, T., Tanaka, T., Kubo, S. & Nishiguchi, S. (2004) 
Role of vitamin K2 in the development of hepatocellular carcinoma in women with 
viral cirrhosis of the liver. The Journal of the Amerian Medical Association, Vol.292, 
No.3, (July 2004), pp. 358-361, ISSN 0098-7484 
Harries, M., Moss, C., Perren, T., Gore, M., Hall, G., Everard, M., A'Hern, R., Gibbens, I., 
Jenkin, A., Shah, R., Cole, C., Pizzada, O. & Kaye, S. (2004) A phase II feasibility 
study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
270 
first-line treatment for ovarian cancer. British Journal of Cancer, Vol.91, No.4, 
(August 2004), pp. 627-632, ISSN 0007-0920 
Hartwig, A., Groblinghoff, UD., Beyersmann, D., Natarajan, AT., Filon, R. & Mullenders, 
LH. (1997) Interaction of arsenic (III) with nucleotide excision repair in UV-
irradiated human fibroblasts. Carcinogenesis, Vol.18, No.2, (February 1997), pp. 399-
405, ISSN 0143-3334 
Hennessy, BT., Coleman, RL. & Markman, M. (2009) Ovarian cancer. Lancet, Vol.374, 
No.9698, (October 2009), pp. 1371-1382, ISSN 0140-6736 
Holmes, WF., Soprano, DR. & Soprano, KJ. (2002) Elucidation of molecular events mediating 
induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian 
carcinoma cell line. The Journal of Biological Chemistry, Vol.277, No.47, (November 
2002), pp. 45408-45419, ISSN 0021-9258 
Holmes, WF., Soprano, DR &, Soprano, KJ. (2004) Synthetic retinoids as inducers of 
apoptosis in ovarian carcinoma cell lines. Journal of Cellular Physiology, Vol.199, 
No.3, (June 2004), pp. 317-329, ISSN 0021-9541 
Jung, P., Menssen, A., Mayr, D. & Hermeking, H. (2008) AP4 encodes a c-MYC-inducible 
repressor of p21. Proceedings of the Nationall Academy of Sciences of the United States of 
America, Vol.105, No.39, (September 2008), pp. 15046-15051, ISSN 0027-8424 
Kartalou, M. & Essigmann, JM. (2001) Mechanisms of resistance to cisplatin. Mutation 
Research, Vol.478, No. 1-2, (July 2001), pp. 23-43, ISSN 0027-5107 
Li, H., Kolluri, SK., Gu, J., Dawson, MI., Cao, X., Hobbs, PD., Lin, B., Chen, G., Lu, J., Lin, F., 
Xie, Z., Fontana, JA., Reed, JC. & Zhang, X. (2000) Cytochrome c release and 
apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. 
Science. Vol.289, No.5482, (August 2000), pp. 1159-1164, ISSN 1095-9203 
Li, Y., Lin, B., Agadir, A., Liu, R., Dawson, MI., Reed, JC., Fontana, JA., Bost, F., Hobbs, PD., 
Zheng, Y., Chen, GQ., Shroot, B., Mercola, D. & Zhang, XK. (1998) Molecular 
determinants of AHPN (CD437)-induced growth arrest and apoptosis in human 
lung cancer cell lines. Molecular and Cellular Biology, Vol.18, No.8, (August 1998), pp. 
4719-4731, ISSN 0270-7306 
Liu, J., Zhou, W., Li, SS., Sun, Z., Lin, B., Lang, YY., He, JY., Cao, X., Yan, T., Wang, L., Lu, J., Han, 
YH., Cao, Zhang, XK. & Zeng, JZ. (2008) Modulation of orphan nuclear receptor Nur77-
mediated apoptotic pathway by acetylshikonin and analogues. Cancer Research, Vol.68, 
No.21, (November 2008), pp. 8871-8880, ISSN 1538-7445 
Liu, JJ., Zeng, HN., Zhang, LR., Zhan, YY., Chen, Y., Wang, Y., Wang, J., Xiang, SH., Liu, 
WJ., Wang, WJ., Chen, HZ., Shen, YM., Su, WJ., Huang, PQ., Zhang, HK. & Wu, Q. 
(2010) A unique pharmacophore for activation of the nuclear orphan receptor 
Nur77 in vivo and in vitro. Cancer Research, Vol.70, No.9, (May 2010), pp. 3628-3637, 
ISSN 1538-7445 
Luo, H., Daddysman, MK., Rankin, GO., Jiang, BH. & Chen, YC. (2010) Kaempferol 
enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis 
caused by down regulation of cMyc. Cancer Cell International, Vol. 10, (May 2010), 
pp. 16-25, ISSN 1475-2867 
Masuda, Y., Nakaya, M., Aiuchi, T., Hashimoto, S., Nakajo, S. & Nakaya, K. (2000) The 
mechanism of geranylgeraniol-induced apoptosis involves activation, by a caspase-
3-like protease, of a c-jun N-terminal kinase signaling cascade and differs from 
 
Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer 
 
271 
mechanisms of apoptosis induced by conventional chemotherapeutic drugs. 
Leukemia Research, Vol.24, No.11, (November 2000), pp. 937-950, ISSN 0145-2126 
Miyazawa, K., Nishimaki, .J, Ohyashiki, K., Enomoto, S., Kuriya, S., Fukuda, R., Hotta, T., 
Teramura, M., Mizoguchi, H., Uchiyama, T. & Omine, M. (2000) Vitamin K2 
therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid 
leukemia: information through a questionnaire survey of multi-center pilot studies 
in Japan. Leukemia, Vol.14, No.6, (June 2000), pp. 1156-1157, ISSN 0887-6924 
Miyazawa, K., Yaguchi, M., Funato, K., Gotoh, A., Kawanishi, Y., Nishizawa,Y., You, A. & 
Ohyashiki, K. (2001) Apoptosis/differentiation-inducing effects of vitamin K2 on 
HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia, Vol.15, 
No.7, (July 2001), pp. 1111-1117, ISSN 0887-6924 
Mizuta, T., Ozaki, I., Eguchi, Y., Yasutake, T., Kawazoe, S., Fujimoto, K. & Yamamoto, K. 
(2006) The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and 
survival in patients with hepatocellular carcinoma after curative treatment: a pilot 
study. Cancer, Vol.106, No.4, (February 2006), pp. 867-872, ISSN 0008-543X 
Nimptsch, K., Rohrmann, S., Kaaks, R. & Linseisen, J. (2010) Dietary vitamin K intake in 
relation to cancer incidence and mortality: results from the Heidelberg cohort of the 
European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). 
The American Journal of Clinical Nutrition, Vol.91, No.5, (May 2010), pp. 1348-1358, 
ISSN 0002-9165  
Nishikawa, Y., Carr, BI., Wang, M., Kar, S., Finn, F., Dowd, P., Zheng, ZB., Kerns, J. & 
Naganathan S. (1995) Growth inhibition of hepatoma cells induced by vitamin K 
and its analogs. The Jounal of Biological Chemistry, Vol.270, No.47, (November 1995), 
pp. 28304-28310, ISSN 0021-9258 
Nishimaki, J., Miyazawa, K., Yaguchi, M., Katagiri, T., Kawanishi, Y., Toyama, K., 
Ohyashiki, K., Hashimoto, S., Nakaya, K. & Takiguchi, T. (1999) Vitamin K2 
induces apoptosis of a novel cell line established from patient with myelodysplastic 
syndrome in blastic transformation. Leukemia, Vol.13, No.9, (September 1999), pp. 
1399-1405, ISSN 0887-6924 
Ohizumi, H., Masuda, Y., Nakajo, S., Sakai, I., Ohsawa, S. & Nakaya, K. (1995) 
Geranylgeraniol is a potent inducer of apoptosis in tumor cells. Journal of 
Biochemistry, Vol.117, No.1, (January 1995), pp. 11-13, ISSN 0021-924X 
Olson, RE. (2000) Osteoporosis and vitamin K intake. The American Journal of Clinical 
Nutrition, Vol.71, No.5, (May 2000), pp. 1031-1032, ISSN 0002-9165 
Otsuka, M., Kato, N., Shao, RX., Hoshida, Y., Ijichi, H., Koike, Y., Taniguchi, H., Moriyama, 
M., Shiratori, Y., Kawabe, T. & Omata, M. (2004) Vitamin K2 inhibits the growth 
and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. 
Hepatology, Vol.40, No.1, (July 2004), pp. 243-251, ISSN 0270-9139 
Parkin, DM., Bray, F., Ferlay, J. & Pisani, P. (2005) Global Cancer Statics, 2002. A Cancer 
Journal for Clinicians, Vol.55, No. 2, (March-April 2005), pp. 74-108, ISSN 0007-9235 
Pekarsky, Y., Hallas, C., Palamarchuk, A., Koval, A., Bullrich, F., Hirata, Y., Bichi, R., 
Letofsky, J. & Croce, CM. (2001) Akt phosphorylates and regulates the orphan 
nuclear receptor Nur77. Proceedings of the National Academy of  Sciences United States 
of America, Vol. 98, No. 7, (March 2001), pp. 3690-3694, ISSN 0027-8424 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
270 
first-line treatment for ovarian cancer. British Journal of Cancer, Vol.91, No.4, 
(August 2004), pp. 627-632, ISSN 0007-0920 
Hartwig, A., Groblinghoff, UD., Beyersmann, D., Natarajan, AT., Filon, R. & Mullenders, 
LH. (1997) Interaction of arsenic (III) with nucleotide excision repair in UV-
irradiated human fibroblasts. Carcinogenesis, Vol.18, No.2, (February 1997), pp. 399-
405, ISSN 0143-3334 
Hennessy, BT., Coleman, RL. & Markman, M. (2009) Ovarian cancer. Lancet, Vol.374, 
No.9698, (October 2009), pp. 1371-1382, ISSN 0140-6736 
Holmes, WF., Soprano, DR. & Soprano, KJ. (2002) Elucidation of molecular events mediating 
induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian 
carcinoma cell line. The Journal of Biological Chemistry, Vol.277, No.47, (November 
2002), pp. 45408-45419, ISSN 0021-9258 
Holmes, WF., Soprano, DR &, Soprano, KJ. (2004) Synthetic retinoids as inducers of 
apoptosis in ovarian carcinoma cell lines. Journal of Cellular Physiology, Vol.199, 
No.3, (June 2004), pp. 317-329, ISSN 0021-9541 
Jung, P., Menssen, A., Mayr, D. & Hermeking, H. (2008) AP4 encodes a c-MYC-inducible 
repressor of p21. Proceedings of the Nationall Academy of Sciences of the United States of 
America, Vol.105, No.39, (September 2008), pp. 15046-15051, ISSN 0027-8424 
Kartalou, M. & Essigmann, JM. (2001) Mechanisms of resistance to cisplatin. Mutation 
Research, Vol.478, No. 1-2, (July 2001), pp. 23-43, ISSN 0027-5107 
Li, H., Kolluri, SK., Gu, J., Dawson, MI., Cao, X., Hobbs, PD., Lin, B., Chen, G., Lu, J., Lin, F., 
Xie, Z., Fontana, JA., Reed, JC. & Zhang, X. (2000) Cytochrome c release and 
apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. 
Science. Vol.289, No.5482, (August 2000), pp. 1159-1164, ISSN 1095-9203 
Li, Y., Lin, B., Agadir, A., Liu, R., Dawson, MI., Reed, JC., Fontana, JA., Bost, F., Hobbs, PD., 
Zheng, Y., Chen, GQ., Shroot, B., Mercola, D. & Zhang, XK. (1998) Molecular 
determinants of AHPN (CD437)-induced growth arrest and apoptosis in human 
lung cancer cell lines. Molecular and Cellular Biology, Vol.18, No.8, (August 1998), pp. 
4719-4731, ISSN 0270-7306 
Liu, J., Zhou, W., Li, SS., Sun, Z., Lin, B., Lang, YY., He, JY., Cao, X., Yan, T., Wang, L., Lu, J., Han, 
YH., Cao, Zhang, XK. & Zeng, JZ. (2008) Modulation of orphan nuclear receptor Nur77-
mediated apoptotic pathway by acetylshikonin and analogues. Cancer Research, Vol.68, 
No.21, (November 2008), pp. 8871-8880, ISSN 1538-7445 
Liu, JJ., Zeng, HN., Zhang, LR., Zhan, YY., Chen, Y., Wang, Y., Wang, J., Xiang, SH., Liu, 
WJ., Wang, WJ., Chen, HZ., Shen, YM., Su, WJ., Huang, PQ., Zhang, HK. & Wu, Q. 
(2010) A unique pharmacophore for activation of the nuclear orphan receptor 
Nur77 in vivo and in vitro. Cancer Research, Vol.70, No.9, (May 2010), pp. 3628-3637, 
ISSN 1538-7445 
Luo, H., Daddysman, MK., Rankin, GO., Jiang, BH. & Chen, YC. (2010) Kaempferol 
enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis 
caused by down regulation of cMyc. Cancer Cell International, Vol. 10, (May 2010), 
pp. 16-25, ISSN 1475-2867 
Masuda, Y., Nakaya, M., Aiuchi, T., Hashimoto, S., Nakajo, S. & Nakaya, K. (2000) The 
mechanism of geranylgeraniol-induced apoptosis involves activation, by a caspase-
3-like protease, of a c-jun N-terminal kinase signaling cascade and differs from 
 
Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer 
 
271 
mechanisms of apoptosis induced by conventional chemotherapeutic drugs. 
Leukemia Research, Vol.24, No.11, (November 2000), pp. 937-950, ISSN 0145-2126 
Miyazawa, K., Nishimaki, .J, Ohyashiki, K., Enomoto, S., Kuriya, S., Fukuda, R., Hotta, T., 
Teramura, M., Mizoguchi, H., Uchiyama, T. & Omine, M. (2000) Vitamin K2 
therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid 
leukemia: information through a questionnaire survey of multi-center pilot studies 
in Japan. Leukemia, Vol.14, No.6, (June 2000), pp. 1156-1157, ISSN 0887-6924 
Miyazawa, K., Yaguchi, M., Funato, K., Gotoh, A., Kawanishi, Y., Nishizawa,Y., You, A. & 
Ohyashiki, K. (2001) Apoptosis/differentiation-inducing effects of vitamin K2 on 
HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia, Vol.15, 
No.7, (July 2001), pp. 1111-1117, ISSN 0887-6924 
Mizuta, T., Ozaki, I., Eguchi, Y., Yasutake, T., Kawazoe, S., Fujimoto, K. & Yamamoto, K. 
(2006) The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and 
survival in patients with hepatocellular carcinoma after curative treatment: a pilot 
study. Cancer, Vol.106, No.4, (February 2006), pp. 867-872, ISSN 0008-543X 
Nimptsch, K., Rohrmann, S., Kaaks, R. & Linseisen, J. (2010) Dietary vitamin K intake in 
relation to cancer incidence and mortality: results from the Heidelberg cohort of the 
European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). 
The American Journal of Clinical Nutrition, Vol.91, No.5, (May 2010), pp. 1348-1358, 
ISSN 0002-9165  
Nishikawa, Y., Carr, BI., Wang, M., Kar, S., Finn, F., Dowd, P., Zheng, ZB., Kerns, J. & 
Naganathan S. (1995) Growth inhibition of hepatoma cells induced by vitamin K 
and its analogs. The Jounal of Biological Chemistry, Vol.270, No.47, (November 1995), 
pp. 28304-28310, ISSN 0021-9258 
Nishimaki, J., Miyazawa, K., Yaguchi, M., Katagiri, T., Kawanishi, Y., Toyama, K., 
Ohyashiki, K., Hashimoto, S., Nakaya, K. & Takiguchi, T. (1999) Vitamin K2 
induces apoptosis of a novel cell line established from patient with myelodysplastic 
syndrome in blastic transformation. Leukemia, Vol.13, No.9, (September 1999), pp. 
1399-1405, ISSN 0887-6924 
Ohizumi, H., Masuda, Y., Nakajo, S., Sakai, I., Ohsawa, S. & Nakaya, K. (1995) 
Geranylgeraniol is a potent inducer of apoptosis in tumor cells. Journal of 
Biochemistry, Vol.117, No.1, (January 1995), pp. 11-13, ISSN 0021-924X 
Olson, RE. (2000) Osteoporosis and vitamin K intake. The American Journal of Clinical 
Nutrition, Vol.71, No.5, (May 2000), pp. 1031-1032, ISSN 0002-9165 
Otsuka, M., Kato, N., Shao, RX., Hoshida, Y., Ijichi, H., Koike, Y., Taniguchi, H., Moriyama, 
M., Shiratori, Y., Kawabe, T. & Omata, M. (2004) Vitamin K2 inhibits the growth 
and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. 
Hepatology, Vol.40, No.1, (July 2004), pp. 243-251, ISSN 0270-9139 
Parkin, DM., Bray, F., Ferlay, J. & Pisani, P. (2005) Global Cancer Statics, 2002. A Cancer 
Journal for Clinicians, Vol.55, No. 2, (March-April 2005), pp. 74-108, ISSN 0007-9235 
Pekarsky, Y., Hallas, C., Palamarchuk, A., Koval, A., Bullrich, F., Hirata, Y., Bichi, R., 
Letofsky, J. & Croce, CM. (2001) Akt phosphorylates and regulates the orphan 
nuclear receptor Nur77. Proceedings of the National Academy of  Sciences United States 
of America, Vol. 98, No. 7, (March 2001), pp. 3690-3694, ISSN 0027-8424 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
272 
Ramaswamy, S., Ross, KN., Lander, ES. & Golub, TR. (2003) A molecular signature of 
metastasis in primary solid tumors. Nature Genetics, Vol.33, No.1, (January 2003), 
pp. 49-54, ISSN 1061-4036 
Raymond, E., Faivre, S., Weiss, G., McGill, J., Davidson, K., Izbicka, E., Kuhn, JG., Allred, C., 
Clark, GM. & Von Hoff, DD. (2001) Effects of hydroxyurea on extrachromosomal 
DNA in patients with advanced ovarian carcinomas. Clinical Cancer Research, Vol.7, 
No.5, (May 2001), pp. 1171-1180, ISSN 1078-0432 
Sakai, I., Hashimoto, S., Yoda, M., Hida, T., Ohsawa, S., Nakajo, S. & Nakaya, K. (1994) 
Novel role of vitamin K2: a potent inducer of differentiation of various human 
myeloid leukemia cell lines. Biochemical and Biophysical Research Communications, 
Vol.205, No.2, (December 1994), pp. 1305-1310, ISSN 0006-291X 
Sargent, JM., Elgie, AW., Williamson, CJ. & Taylor, CG. (1996) Aphidicolin markedly 
increases the platinum sensitivity of cells from primary ovarian tumours. British 
Journal of Cancer, Vol.74, No.11, (December 1996), pp. 1730-1733, ISSN 0007-0920 
Shanahan, CM., Proudfoot, D., Farzaneh-Far, A. & Weissberg, PL. (1998) The role of Gla 
proteins in vascular calcification. Critical Reviews in Eukaryotic Gene Expression, 
Vol.8, No.3-4, (1998), pp. 357-375, ISSN 1045-4403 
Shearer, MJ., Bach, A. & Kohlmeier, M. (1996) Chemistry, nutritional sources, tissue 
distribution and metabolism of vitamin K with special reference to bone health. 
The Journal of Nutrition, Vol.126, Suppl.4, (April 1996), pp. 1181S-1186S, ISSN 0022-
3166 
Schurgers, LJ. & Vermeer, C.(2000) Determination of phylloquinone and menaquinones in 
food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis, 
Vol.30, No.6, (November-December 2000), pp. 298-307, ISSN 0301-0147 
Shibayama-Imazu, T., Sakairi, S., Watanabe, A., Aiuchi, T., Nakajo, S. & Nakaya, K. (2003) 
Vitamin K2 selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA 
PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from 
geranylgeraniol. Journal of Cancer Research and Clinical Oncology, Vol.129, No.1, 
(January 2003), pp. 1-11, ISSN 0170-5216 
Shibayama-Imazu, T., Sonoda, I., Sakairi, S., Aiuchi, T., Ann, WW., Nakajo, S., Itabe, H. & 
Nakaya, K. (2006) Production of superoxide and dissipation of mitochondrial 
transmembrane potential by vitamin K2 trigger apoptosis in human ovarian cancer 
TYK-nu cells. Apoptosis, Vol.11, No.9, (September 2006 ), pp. 1535-1543, ISSN 1360-
8185 
Shibayama-Imazu, T., Fujisawa, Y., Masuda, Y., Aiuchi, T., Nakajo, S., Itabe, H. & Nakaya, 
K. (2008) Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is 
associated with an increase in the level of TR3/Nur77 and its accumulation in 
mitochondria and nuclei. Journal of Cancer Research and Clinical Oncology, Vol.134, 
No.7, (January 2008), pp. 803-812, ISSN 0170-52168  
Shipp, MA., Ross, KN., Tamayo, P., Weng, AP., Kutok, JL., Aguiar, RC., Gaasenbeek, M., 
Angelo, M., Reich, M., Pinkus, GS., Ray, TS., Koval, MA., Last, KW., Norton, A., 
Lister, TA., Mesirov, J., Neuber, DS., Lander, ES., Aster, JC. & Golub, TR. (2002) 
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling 
and supervised machine learning. Nature Medicine, Vol.8, No.1, (January 2002), pp. 
68-74, ISSN 1078-8956 
 
Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer 
 
273 
Shiraki, M., Shiraki, Y., Aoki, C. & Miura, M. (2000) Vitamin K2 (menatetrenone) effectively 
prevents fractures and sustains lumbar bone mineral density in osteoporosis. 
Journsl of Bone and Mineral Research, Vol.15, No.3, (March 2000), pp. 515-521, ISSN 
0884-0431 
Soignet, SL., Maslak, P., Wang, ZG., Jhanwar, S., Calleja, E., Dardashti, LJ., Corso, D., 
DeBlasio, A., Gabrilove, J., Scheinberg, DA., Pandolfi, PP. & Warrell, RP. Jr. (1998) 
Complete remission after treatment of acute promyelocytic leukemia with arsenic 
trioxide. The New England Journal of Medicine, Vol.339, No.19, (November 1998), pp. 
1341-1348, ISSN 0028-4793 
Swinnen, LJ., Rankin, C., Carraway, H., Albain, KS., Townsend, JJ., Budd, GT., Kish, JA., 
Rivkin, SE. & Blumenthal, DT. (2008) A phase II study of cisplatin preceded by a 
12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside 
(Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group 
S9149). Journal of Neuro-oncology, Vol.86, No.3, (February 2008), pp. 353-358, ISSN 
0167-594X 
Swisher, EM., Mutch, DG., Rader, JS., Elbendary, A. & Herzog, TJ. (1997) Topotecan in 
platinum- and paclitaxel-resistant ovarian cancer. Gynecologic Oncology. Vol.66, 
No.3, (September 1997), pp. 480-486, ISSN 0090-8258 
Takami, A., Nakao, S., Ontachi, Y., Yamauchi, H. & Matsuda, T. (1999) Successful therapy of 
myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. International 
Journal of Hematology, Vol.69, No.1, (January 1999), pp. 24-26, ISSN 0925-5710 
Tamori, A., Habu, D., Shiomi, S., Kubo, S. & Nishiguchi, S. (2007) Potential role of vitamin 
K2 as a chemopreventive agent against hepatocellular carcinoma. Hepatology 
Research, Vol.37, Suppl.2, (September 2007), pp. S303-S307, ISSN 1386-6346 
Thijssen, HH. & Drittij-Reijnders, MJ. (1996) Vitamin K status in human tissues: tissue-
specific accumulation of phylloquinone and menaquinone-4. British Journal of 
Nutrition, Vol.75, No.1, (January 1996), pp. 121-127 
Tokita, H., Tsuchida, A., Miyazawa, K., Ohyashiki, K., Katayanagi, S., Sudo, H., Enomoto, 
M., Takagi, Y. & Aoki, T. (2006) Vitamin K2-induced antitumor effects via cell-cycle 
arrest and apoptosis in gastric cancer cell lines. International Journal of Molecular 
Medicine. Vol.17, No.2, (February 2006), pp. 235-243, ISSN 1107-3756 
Touma, R., Kartarius, S., Harlozinska, A., Götz, C. & Montenarh, M. (2006) Growth 
inhibition and apoptosis induction in ovarian cancer cells. International Journal of 
Oncology, Vol.29, No.2, (August 2006), pp. 481-488, ISSN 1019-6439 
Tsunetoh, S., Terai, Y., Sasaki, H., Tanabe, A., Tanaka, Y., Sekijima, T., Fujioka, S., 
Kawaguchi, H., Kanemura, M., Yamashita, Y. & Ohmichi, M. (2010) Topotecan as a 
molecular targeting agent which blocks the Akt and VEGF cascade in platinum-
resistant ovarian cancers. Cancer Biology & Therapy. Vol. 10, No.11, (December 2010), 
pp. 1137-1146, ISSN 1538-4047 
Uslu, R., Sanli, UA., Sezgin, C., Karabulut, B, Terzioglu, E., Omay, SB. & Goker, E. (2000) 
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian 
carcinoma cell lines. Clinical Cancer Research, Vol.6, No.12, (December 2000), pp. 
4957-4964, ISSN 1078-0432 
Vivanco, I. & Sawyers, CL. (2002) The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nature Reviews. Cancer. Vol.2, No.7, (July 2002), pp. 489-501, ISSN 
1474-175X 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
272 
Ramaswamy, S., Ross, KN., Lander, ES. & Golub, TR. (2003) A molecular signature of 
metastasis in primary solid tumors. Nature Genetics, Vol.33, No.1, (January 2003), 
pp. 49-54, ISSN 1061-4036 
Raymond, E., Faivre, S., Weiss, G., McGill, J., Davidson, K., Izbicka, E., Kuhn, JG., Allred, C., 
Clark, GM. & Von Hoff, DD. (2001) Effects of hydroxyurea on extrachromosomal 
DNA in patients with advanced ovarian carcinomas. Clinical Cancer Research, Vol.7, 
No.5, (May 2001), pp. 1171-1180, ISSN 1078-0432 
Sakai, I., Hashimoto, S., Yoda, M., Hida, T., Ohsawa, S., Nakajo, S. & Nakaya, K. (1994) 
Novel role of vitamin K2: a potent inducer of differentiation of various human 
myeloid leukemia cell lines. Biochemical and Biophysical Research Communications, 
Vol.205, No.2, (December 1994), pp. 1305-1310, ISSN 0006-291X 
Sargent, JM., Elgie, AW., Williamson, CJ. & Taylor, CG. (1996) Aphidicolin markedly 
increases the platinum sensitivity of cells from primary ovarian tumours. British 
Journal of Cancer, Vol.74, No.11, (December 1996), pp. 1730-1733, ISSN 0007-0920 
Shanahan, CM., Proudfoot, D., Farzaneh-Far, A. & Weissberg, PL. (1998) The role of Gla 
proteins in vascular calcification. Critical Reviews in Eukaryotic Gene Expression, 
Vol.8, No.3-4, (1998), pp. 357-375, ISSN 1045-4403 
Shearer, MJ., Bach, A. & Kohlmeier, M. (1996) Chemistry, nutritional sources, tissue 
distribution and metabolism of vitamin K with special reference to bone health. 
The Journal of Nutrition, Vol.126, Suppl.4, (April 1996), pp. 1181S-1186S, ISSN 0022-
3166 
Schurgers, LJ. & Vermeer, C.(2000) Determination of phylloquinone and menaquinones in 
food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis, 
Vol.30, No.6, (November-December 2000), pp. 298-307, ISSN 0301-0147 
Shibayama-Imazu, T., Sakairi, S., Watanabe, A., Aiuchi, T., Nakajo, S. & Nakaya, K. (2003) 
Vitamin K2 selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA 
PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from 
geranylgeraniol. Journal of Cancer Research and Clinical Oncology, Vol.129, No.1, 
(January 2003), pp. 1-11, ISSN 0170-5216 
Shibayama-Imazu, T., Sonoda, I., Sakairi, S., Aiuchi, T., Ann, WW., Nakajo, S., Itabe, H. & 
Nakaya, K. (2006) Production of superoxide and dissipation of mitochondrial 
transmembrane potential by vitamin K2 trigger apoptosis in human ovarian cancer 
TYK-nu cells. Apoptosis, Vol.11, No.9, (September 2006 ), pp. 1535-1543, ISSN 1360-
8185 
Shibayama-Imazu, T., Fujisawa, Y., Masuda, Y., Aiuchi, T., Nakajo, S., Itabe, H. & Nakaya, 
K. (2008) Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is 
associated with an increase in the level of TR3/Nur77 and its accumulation in 
mitochondria and nuclei. Journal of Cancer Research and Clinical Oncology, Vol.134, 
No.7, (January 2008), pp. 803-812, ISSN 0170-52168  
Shipp, MA., Ross, KN., Tamayo, P., Weng, AP., Kutok, JL., Aguiar, RC., Gaasenbeek, M., 
Angelo, M., Reich, M., Pinkus, GS., Ray, TS., Koval, MA., Last, KW., Norton, A., 
Lister, TA., Mesirov, J., Neuber, DS., Lander, ES., Aster, JC. & Golub, TR. (2002) 
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling 
and supervised machine learning. Nature Medicine, Vol.8, No.1, (January 2002), pp. 
68-74, ISSN 1078-8956 
 
Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer 
 
273 
Shiraki, M., Shiraki, Y., Aoki, C. & Miura, M. (2000) Vitamin K2 (menatetrenone) effectively 
prevents fractures and sustains lumbar bone mineral density in osteoporosis. 
Journsl of Bone and Mineral Research, Vol.15, No.3, (March 2000), pp. 515-521, ISSN 
0884-0431 
Soignet, SL., Maslak, P., Wang, ZG., Jhanwar, S., Calleja, E., Dardashti, LJ., Corso, D., 
DeBlasio, A., Gabrilove, J., Scheinberg, DA., Pandolfi, PP. & Warrell, RP. Jr. (1998) 
Complete remission after treatment of acute promyelocytic leukemia with arsenic 
trioxide. The New England Journal of Medicine, Vol.339, No.19, (November 1998), pp. 
1341-1348, ISSN 0028-4793 
Swinnen, LJ., Rankin, C., Carraway, H., Albain, KS., Townsend, JJ., Budd, GT., Kish, JA., 
Rivkin, SE. & Blumenthal, DT. (2008) A phase II study of cisplatin preceded by a 
12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside 
(Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group 
S9149). Journal of Neuro-oncology, Vol.86, No.3, (February 2008), pp. 353-358, ISSN 
0167-594X 
Swisher, EM., Mutch, DG., Rader, JS., Elbendary, A. & Herzog, TJ. (1997) Topotecan in 
platinum- and paclitaxel-resistant ovarian cancer. Gynecologic Oncology. Vol.66, 
No.3, (September 1997), pp. 480-486, ISSN 0090-8258 
Takami, A., Nakao, S., Ontachi, Y., Yamauchi, H. & Matsuda, T. (1999) Successful therapy of 
myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. International 
Journal of Hematology, Vol.69, No.1, (January 1999), pp. 24-26, ISSN 0925-5710 
Tamori, A., Habu, D., Shiomi, S., Kubo, S. & Nishiguchi, S. (2007) Potential role of vitamin 
K2 as a chemopreventive agent against hepatocellular carcinoma. Hepatology 
Research, Vol.37, Suppl.2, (September 2007), pp. S303-S307, ISSN 1386-6346 
Thijssen, HH. & Drittij-Reijnders, MJ. (1996) Vitamin K status in human tissues: tissue-
specific accumulation of phylloquinone and menaquinone-4. British Journal of 
Nutrition, Vol.75, No.1, (January 1996), pp. 121-127 
Tokita, H., Tsuchida, A., Miyazawa, K., Ohyashiki, K., Katayanagi, S., Sudo, H., Enomoto, 
M., Takagi, Y. & Aoki, T. (2006) Vitamin K2-induced antitumor effects via cell-cycle 
arrest and apoptosis in gastric cancer cell lines. International Journal of Molecular 
Medicine. Vol.17, No.2, (February 2006), pp. 235-243, ISSN 1107-3756 
Touma, R., Kartarius, S., Harlozinska, A., Götz, C. & Montenarh, M. (2006) Growth 
inhibition and apoptosis induction in ovarian cancer cells. International Journal of 
Oncology, Vol.29, No.2, (August 2006), pp. 481-488, ISSN 1019-6439 
Tsunetoh, S., Terai, Y., Sasaki, H., Tanabe, A., Tanaka, Y., Sekijima, T., Fujioka, S., 
Kawaguchi, H., Kanemura, M., Yamashita, Y. & Ohmichi, M. (2010) Topotecan as a 
molecular targeting agent which blocks the Akt and VEGF cascade in platinum-
resistant ovarian cancers. Cancer Biology & Therapy. Vol. 10, No.11, (December 2010), 
pp. 1137-1146, ISSN 1538-4047 
Uslu, R., Sanli, UA., Sezgin, C., Karabulut, B, Terzioglu, E., Omay, SB. & Goker, E. (2000) 
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian 
carcinoma cell lines. Clinical Cancer Research, Vol.6, No.12, (December 2000), pp. 
4957-4964, ISSN 1078-0432 
Vivanco, I. & Sawyers, CL. (2002) The phosphatidylinositol 3-Kinase AKT pathway in 
human cancer. Nature Reviews. Cancer. Vol.2, No.7, (July 2002), pp. 489-501, ISSN 
1474-175X 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
274 
Wu, FY., Liao, WC. & Chang, HM. (1993) Comparison of antitumor activity of vitamins K1, 
K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life 
Sciences, Vol.52, No.22, (March 1993), pp. 1797-1804, ISSN 0024-3205 
Wu, Q., Liu, S., Ye, XF., Huang, ZW. & Su, WJ. (2002) Dual roles of Nur77 in selective 
regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. 
Carcinogenesis, Vol.23, No.10, (October 2002), pp. 1583-1592, ISSN 0143-3334 
Yaguchi, M., Miyazawa, K., Katagiri, T., Nishimaki, J., Kizaki, M., Tohyama, K. & Toyama, 
K. (1997) Vitamin K2 and its derivatives induce apoptosis in leukemia cells and 
enhance the effect of all-trans retinoic acid. Leukemia, Vol.11, No.6, (June 1997), pp. 
779-787, ISSN 0887-6924  
Yaguchi, M., Miyazawa, K., Otawa, M., Katagiri, T., Nishimaki, J., Uchida, Y., Iwase, O., 
Gotoh, A., Kawanishi, Y. & Toyama, K. (1998) Vitamin K2 selectively induces 
apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of 
apoptotic cells using APO2.7 monoclonal antibody. Leukemia, Vol.12, No.9, 
(September 1998), pp. 1392-1397, ISSN 0887-6924 
Yaguchi, M., Miyazawa, K., Otawa, M., Ito, Y., Kawanishi, Y. & Toyama, K. (1999) Vitamin 
K2 therapy for a patient with myelodysplastic syndrome. Leukemia, Vol.13, No.1, 
(January 1999), pp. 144-145, ISSN 0887-6924 
Yallapu, MM., Maher, DM., Sundram, V., Bell, MC., Jaggi, M. & Chauhan, SC. (2010) 
Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin 
nanoparticles inhibit ovarian cancer cell growth. Journal of Ovarian Research, Vol.3, 
(April 2010), pp. 11-23, ISSN 1757-2215 
Yokoyama, T., Miyazawa, K., Yoshida, T. & Ohyashiki, K. (2005) Combination of vitamin K2 
plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer 
cell lines. International Journal of Oncology, Vol.26, No.1, (January 2005), pp. 33-40, 
ISSN 1019-6439 
Yoshiji, H., Noguchi, R., Toyohara, M., Ikenaka, Y., Kitade, M., Kaji, K., Yamazaki, M., 
Yamao, J., Mitoro, A., Sawai, M., Yoshida, M., Fujimoto, M., Tsujimoto, T., 
Kawaratani, H., Uemura, M. & Fukui, H. (2009) Combination of vitamin K2 and 
angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of 
hepatocellular carcinoma. Journal of Hepatology, Vol.51, No.2, (August 2009), pp. 
315-321, ISSN 0168-8278 
Yoshida, T., Miyazawa, K., Kasuga, I., Yokoyama, T., Minemura, K., Ustumi, K., Aoshima, 
M. & Ohyashiki, K. (2003) Apoptosis induction of vitamin K2 in lung carcinoma 
cell lines: the possibility of vitamin K2 therapy for lung cancer. International Journal 
of Oncoogy, Vol.23, No.3, (September 2003), pp. 627-632, ISSN 1019-6439 
14 
Second-Line Chemotherapy for  
Platinum- and Taxane-Resistant Epithelial 
Ovarian Cancer: Pegylated Liposomal 
Doxorubicin (PLD), Irinotecan, and  
Combination Therapies at Lower Doses 
Toru Sugiyama 
Obstetrics and Gynecology, Iwate Medical University  
School of Medicine, Morioka City 
Japan 
1. Introduction 
Epithelial ovarian cancer is sensitive to chemotherapy and approximately 75% of patients 
achieve complete clinical remission after the initial treatment. However, most develop a 
recurrence which results in death after a chronic course. Therefore, most patients are 
candidates for second-line chemotherapy, including approximately 20% among of these 
patients with platinum- and taxane-resistant disease. Patients with platinum-and taxane-
resistant disease have poor outcomes, and most would like to prolong their survival with 
relieved symptoms and the best possible quality of life (QOL). The effects of several drugs 
which are being used for these purposes are similar, but it is usually difficult to relieve 
recurrent disease with one drug. Monotherapy has been generally chosen for having the 
most favorable toxicity profile in patients with platinum- and taxane-resistant disease. 
However, it is not clear whether this strategy is optimal with the various novel anticancer 
drugs and targeted agents under development. In this article, pegylated liposomal 
doxorubicin (PLD), which is used worldwide, and irinotecan, the predominant agent in 
Japan for the treatment of platinum- and taxane-resistant ovarian cancer, are evaluated for 
their effects and toxicity in monotherapy and in combination at lower doses with other 
drugs. 
2. Objectives 
Platinum- and taxane-resistant epithelial ovarian cancer is not curable; therefore, patients 
give fully informed consent and are treated to maintain their QOL. The initial treatment 
aims to cure cancer while the second-line chemotherapy seeks palliation as the primary goal. 
To be specific, the aim is to balance toxicity and the beneficial effects, and considering the 
toxicities after the initial treatment and patient’s desires, more convenient and less toxic 
agents should be chosen. Second-line chemotherapy is intended to prevent deterioration of 
cancer lesions and to relieve symptoms.  
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3. Principle for choosing therapy 
In the treatment of recurrent ovarian cancer, the issues to consider are the treatment-free 
interval (TFI), toxicity continuously observed from the initial treatment, recurrent tumor 
diameter and increased CA125. The TFI is the most important for selecting regimens, and 
the longer the TFI, the higher the response rate (Figure 1).1,2) In selecting regimens, when the 
TFI is 6 months or longer, the tumor is considered to be sensitive to chemotherapy. In 
contrast, when the TFI is less than 6 months, the tumor is considered to be resistant to 
chemotherapy. For patients with a platinum- and taxane- resistant disease, a drug without 
cross-resistance to paclitaxel and carboplatin must be selected. On the other hand, 
recommended therapies for tumors sensitive to drugs, based on the results of randomized 
controlled trials and meta-analyses, are carboplatin- combination therapy with or without a 
targeted agent. However, 6-12 months of TFI is considered to be a gray zone (platinum-
resistant factor remains; partially sensitive) and more careful consideration should be 
needed in choosing regimens.  
 
 
Fig. 1. Principle for choosing therapy. 
Pegylated liposomal doxorubicin (PLD), topotecan, and weekly paclitaxel are the drugs 
approved by the Food and Drug Administration (FDA), and gemcitabine (GEM), oral 
etoposide, and docetaxel can also be used. In Japan, weekly irinotecan is frequently used. The 
effects of drugs on patients with platinum- and taxane-resistant disease are similar and no 
drug can complete the treatment in most patients. Based on the performance status (PS) and 
toxicity persisting from the initial treatment and the bone-marrow function of an individual 
patient, drugs to be administered should be presented to the patient. PLD is safer for heavily 
pretreated patients than topotecan and GEM due to mild bone-marrow toxicity, however, 
nonhematotoxity such as hand-foot syndrome (HFS), stomatitis and mucositis frequently 
develop, patient’s desire is considered, finally, the drugs are selected. 3) However, it is usually 
difficult to completely relieve cancer with one drug with high efficacy and low toxicity, and 
the drugs are therefore changed as required while assessing the effect and toxicity. 
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4. Effects and toxicities 
4.1 Effects 
The response rate of anticancer drugs in platinum-resistant ovarian cancer ranges from 12% 
to 32%, and the survival (median) is around 8–10 months. The effect of anticancer drugs is 
generally evaluated by the change in tumor diameter; i.e., if the tumor diameter increases, 
outcomes are judged to be progressive disease (PD) and the treatment is discontinued or 
changed, and if the tumor diameter decreases, the treatment is evaluated to be effective and 
continued if no toxicity-related problem occurs. However, it was shown in several studies 
that such direct evaluation results of tumor diameter do not always correlate with survival 
time. We investigated the relationship between the drug-induced change in tumor diameter 
and survival, albeit in a small-size population, and showed that there was no difference in 
the survival time between the patients with complete response (CR) or partial response (PR) 
and those with stable disease (SD), and that only patients with PD showed particularly poor 
outcomes (the IGCS Symposium, Edinburgh, 2004). Cesano et al. showed similar results. 4) 
Rose et al. recently analyzed outcomes of patients with platinum-resistant ovarian ovarian 
cancer who were enrolled in 11 GOG phase II clinical trials (1996–2004) and compared the 
survival time between the CR/PR, SD and PD groups (Figure 2). 5)  The results showed no 
difference between the CR/PR and the SD groups while the overall survival (OS) in the PD 
group was significantly poorer than that in the CR/PR/SD group (p<0.001). Given these 
corroborating results, it is important to evaluate the effect of treatment by the total percent 
of responders and patients with SD who have no increase in tumor size (disease control 
rate) in treatments of patients with platinum-resistant disease. This percent is expressed as 
the clinical benefit. Consequently, it is considered that patients with platinum- and taxane- 
resistant ovarian cancer who have tumors evaluable as SD as well as CR/PR are given 





Fig. 2. Survival by tumor response status (landmark analysis) 
Rose PG, et al. Gynecol Oncol. 2010;17:324-329 
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TFI is 6 months or longer, the tumor is considered to be sensitive to chemotherapy. In 
contrast, when the TFI is less than 6 months, the tumor is considered to be resistant to 
chemotherapy. For patients with a platinum- and taxane- resistant disease, a drug without 
cross-resistance to paclitaxel and carboplatin must be selected. On the other hand, 
recommended therapies for tumors sensitive to drugs, based on the results of randomized 
controlled trials and meta-analyses, are carboplatin- combination therapy with or without a 
targeted agent. However, 6-12 months of TFI is considered to be a gray zone (platinum-
resistant factor remains; partially sensitive) and more careful consideration should be 
needed in choosing regimens.  
 
 
Fig. 1. Principle for choosing therapy. 
Pegylated liposomal doxorubicin (PLD), topotecan, and weekly paclitaxel are the drugs 
approved by the Food and Drug Administration (FDA), and gemcitabine (GEM), oral 
etoposide, and docetaxel can also be used. In Japan, weekly irinotecan is frequently used. The 
effects of drugs on patients with platinum- and taxane-resistant disease are similar and no 
drug can complete the treatment in most patients. Based on the performance status (PS) and 
toxicity persisting from the initial treatment and the bone-marrow function of an individual 
patient, drugs to be administered should be presented to the patient. PLD is safer for heavily 
pretreated patients than topotecan and GEM due to mild bone-marrow toxicity, however, 
nonhematotoxity such as hand-foot syndrome (HFS), stomatitis and mucositis frequently 
develop, patient’s desire is considered, finally, the drugs are selected. 3) However, it is usually 
difficult to completely relieve cancer with one drug with high efficacy and low toxicity, and 
the drugs are therefore changed as required while assessing the effect and toxicity. 
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4. Effects and toxicities 
4.1 Effects 
The response rate of anticancer drugs in platinum-resistant ovarian cancer ranges from 12% 
to 32%, and the survival (median) is around 8–10 months. The effect of anticancer drugs is 
generally evaluated by the change in tumor diameter; i.e., if the tumor diameter increases, 
outcomes are judged to be progressive disease (PD) and the treatment is discontinued or 
changed, and if the tumor diameter decreases, the treatment is evaluated to be effective and 
continued if no toxicity-related problem occurs. However, it was shown in several studies 
that such direct evaluation results of tumor diameter do not always correlate with survival 
time. We investigated the relationship between the drug-induced change in tumor diameter 
and survival, albeit in a small-size population, and showed that there was no difference in 
the survival time between the patients with complete response (CR) or partial response (PR) 
and those with stable disease (SD), and that only patients with PD showed particularly poor 
outcomes (the IGCS Symposium, Edinburgh, 2004). Cesano et al. showed similar results. 4) 
Rose et al. recently analyzed outcomes of patients with platinum-resistant ovarian ovarian 
cancer who were enrolled in 11 GOG phase II clinical trials (1996–2004) and compared the 
survival time between the CR/PR, SD and PD groups (Figure 2). 5)  The results showed no 
difference between the CR/PR and the SD groups while the overall survival (OS) in the PD 
group was significantly poorer than that in the CR/PR/SD group (p<0.001). Given these 
corroborating results, it is important to evaluate the effect of treatment by the total percent 
of responders and patients with SD who have no increase in tumor size (disease control 
rate) in treatments of patients with platinum-resistant disease. This percent is expressed as 
the clinical benefit. Consequently, it is considered that patients with platinum- and taxane- 
resistant ovarian cancer who have tumors evaluable as SD as well as CR/PR are given 





Fig. 2. Survival by tumor response status (landmark analysis) 
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4.2 Toxicity 
The toxicity depends on agents but generally tends to increase with the frequency of 
chemotherapy. Therefore, in the treatment of platinum- and taxane- resistant ovarian cancer, 
much attention should be given to the occurrence of toxicities. Topotecan, GEM, docetaxel 
are highly hemotoxic, and patients using PLD, irinotecan, or weekly paclitaxel should be 
monitored for non-hemotoxic events that reduce the QOL. There is concern about HFS 
occurring in treatment with PLD, diarrhea with irinotecan, and peripheral neuropathy and 
arthralgia during weekly paclitaxel therapy. When a patient is treated with irinotecan, 
diarrhea is frequently induced, therefore, informed consent for determination of UGT1A1 
polymorphism should be obtained from the patient and the assay is carried out as needed. 6,7) 
5. Pgylated liposomal doxorubicin (PLD) 
PLD was approved in 1999 by the FDA and in 2000 by the European Medicines Evaluation 
Agency as treatment for chemorefractory and chemoresistant epithelial ovarian cancer and 
has been used as the first option for patients with chemorefractory and chemoresistant 
epithelial ovarian cancer over the world.  
5.1 Efficacy 
The results of phase II/III studies of PLD showed response rates to platinum-resistant 
disease ranging from 8.7% to 31.4%, SD rates from 18.2% to 51.3% and a high clinical benefit 
around 60%, and no difference in the efficacy between 50 and 40 mg/m2 of PLD. A phase II 
study has recently been completed in Japan and the response rate for recurrent platinum-
resistant ovarian cancer was 21.0%, the SD rate was 40.3% and the clinical benefit was 61.3%, 
which was similar to those in the studies in Europe and the United States. 8-15) 
5.2 Safety 
The data in Europe and the United States show that PLD is accompanied by a low incidence 
and low severity of hematotoxicities such as neutropenia. The incidence of neutropenia of 
grade 3/4 ranges from 10% to 20%, and granulocyte colony stimulating factor (G-CSF) 
drugs are seldom needed. The incidence of thrombopenia is lower. On the other hand, PLD 
is accompanied by high incidences of subjective non-hematotoxities including HFS and 
stomatitis at FDA-approved doses and schedules. HFS and stomatitis developed in 
approximately 40% of patients; however, HFS of grade 2 or higher were found in 19.8% to 
31.5% of patients treated with PLD at a dose of 50 mg/m2 and 2.8% to 15.5% (less than half 
as frequently) at doses of 40 mg/m2 and less. Stomatitis of grade 2 or higher developed in 
14% to 38% or more of patients treated with PLD at a dose of 50 mg/m2 and in 8.0% of those 
treated with 40 mg/m2. 8-15) We showed the efficacy of cooling the wrists and ankles during 
infusion to prevent HFS (ESMO, Milan, 2010). We are currently conducting a clinical trial of 
stomatitis prevention.  
Based on the review of previous studies, no difference in the efficacy between 50 and 40 
mg/m2 of PLD, therefore, a dose of 40 mg/m2 is preferable for patients with platinum-
resistant disease to reduce adverse events. To scientifically confirm the dosage, the Japanese 
Gynecologic Oncology Group (JGOG) has started a randomized comparative study of 50 
and 40 mg/m2 of PLD in patients with platinum-and taxane- resistant ovarian cancer (TFI < 
6 months). 
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5.3 Japanese-specific toxicity 
The incidences and severity of PLD-induced toxicity in the Japanese population are different 
from those in European and the United States populations. In a Phase II trial in Japan, the 
incidence of HFS was 78% (Grade 2 or more: 51%) and that of neutropenia of grade 3 or 
more was 68%, suggesting the necessity of toxicity monitoring and treatment. 16) 
5.4 Comparison with other drugs in Phase III trials 
 Topotecan: The response rate of topotecan was around 14% in patients with platinum- 
and taxane-resistant ovarian cancer. In a phase III comparative study with paclitaxel, 
the response rate of topotecan was 13.3% in the platinum-resistant ovarian cancer 
group, better than paclitaxel’s rate of 6.7%.17) The time to progression in the topotecan 
group was significantly better than that in the paclitaxel group; consequently, topotecan 
was confirmed to have at least an equivalent effect to paclitaxel. In comparison with 
PLD, topotecan had a tendency of being more effective in terms of the progression free 
survival (PFS) and overall survival (OS) in the platinum-resistant ovarian cancer group; 
on the other hand, PLD was significantly more effective than topotecan in the platinum-
sensitive ovarian cancer group (Table 1). 18)  
 
 
Table 1. Survival of Randomized studies. 
 Gemcitabine: The response rate at doses of 800-1,000 mg/m2/week and the schedule of 
days 1, 8 and 15 and one-week withdrawal was 13-14% in the platinum-resistant 
ovarian cancer group. Mutch et al. conducted a phase III comparative study with 
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31.5% of patients treated with PLD at a dose of 50 mg/m2 and 2.8% to 15.5% (less than half 
as frequently) at doses of 40 mg/m2 and less. Stomatitis of grade 2 or higher developed in 
14% to 38% or more of patients treated with PLD at a dose of 50 mg/m2 and in 8.0% of those 
treated with 40 mg/m2. 8-15) We showed the efficacy of cooling the wrists and ankles during 
infusion to prevent HFS (ESMO, Milan, 2010). We are currently conducting a clinical trial of 
stomatitis prevention.  
Based on the review of previous studies, no difference in the efficacy between 50 and 40 
mg/m2 of PLD, therefore, a dose of 40 mg/m2 is preferable for patients with platinum-
resistant disease to reduce adverse events. To scientifically confirm the dosage, the Japanese 
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gemcitabine (GEM) that showed no significant differences in PFS and OS between PLD 
and GEM. 14)  Ferrandina et al. reported no differences in PFS between PLD and GEM in 
relapsed patients with a treatment-free interval (TFI) of 12 months or less, but a 
significant efficacy in OS with PLD compared to GEM (Table 1). 15) From the results of 
the above phase III studies, PLD was considered to have similar efficacy as other novel 
drugs on platinum-resistant disease; however, it was more effective at improving the 
survival rate in patients with recurrent ovarian cancer, including platinum-sensitive 
cancer, than other drugs. 
 Difference in toxicity: The results of phase III comparative studies with topotecan or 
GEM confirmed that HFS and stomatitis significantly developed in patients treated 
with 50 mg/m2 of PLD while the incidence of HFS was slightly higher in patients 
treated with 40 mg/m2 of PLD compared with those treated with GEM and no 
difference was found in the incidence of stomatitis between PLD and GEM. On the 
other hand, PLD induced hematotoxicity less than topotecan and gemcitabine. 
Although neutropenia of grade 3 or more developed in 10% to 20% of patients treated 
with 50 mg/m2 of PLD, febrile neutropenia was rarely found. The incidence of 
thrombocytopenia was further less. 13-15) 
5.5 Combination with other drugs 
In multidrug therapy, toxicity is often increased by the combination of multiple drugs at doses 
recommended for monotherapy. In contrast to initial chemotherapy, which aims to cure 
cancer, second-line chemotherapy aims to combine drugs at lower doses, considering the 
toxicity based on the results of phase I clinical studies. In particular, drugs with non-
hematotoxicity such as PLD should be used in accordance with the above consideration. 3) In 
fact, in phase II clinical trials, the incidence and severity of PLD-specific non-hematotoxicities 
(HFS, stomatitis) were reduced without loss of efficacy when PLD was administered at lower 
doses in combination with GEM, topotecan, vinorelbine, and oxaliplatin. 
In vitro data suggested a potential synergistic interaction between PLD and GEM. 19) 
Combination chemotherapy of PLD and GEM achieved good response rates ranging from 
22% to 33%, however, the clinical benefit was between 28% and 61%, which was similar to 
PLD monotherapy. 20-23) As for hematotoxicity, neutropenia of grade 3/4 was slightly higher 
and HFS of grade 2/3 was slightly less. The combination of PLD and GEM is an active and 
acceptably tolerated option in the treatment of patients with platinum-resistant ovarian 
cancer (Table 2). The combination at the dosages chosen seems suitable for this patient 
population. Synergism between PLD and topotecan was demonstrated in platinum-resistant 
disease. 24) A median total response rate of 28% and clinical benefit of 72% were 
demonstrated, with a median TTP of 30+weeks in the combination of PLD and topotecan for 
platinum-resistant disease (Table 3).25) These data compare favorably to the data of both the 
drugs administered as single agent. In comparison of two studies of combination 
chemotherapy of PLD and oxaliplatin, the response rates for platinum-resistant disease were 
28.6% and 38.5% and the clinical benefit was 71.4% and 76.9%, suggesting the higher 
efficacy compared with PLD monotherapy. 26,27) Furthermore, the response rates for 
platinum-sensitive disease were 66.7% and 81.5% and the clinical benefit was 82.8% and 
100%, showing the efficacy similar or more to other platinum combination chemotherapy 
(Table 3). The incidence of HFS was low and no marked increase in hematotoxicity was 
found, consequently, it was considered to be controllable. Consequently, PLD, with its low 
hematotoxicity but specific non-hematotoxicities, is recommended for use not as a 
monotherapy but in low-doses combinations for improved patient QOL. 
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(HFS, stomatitis) were reduced without loss of efficacy when PLD was administered at lower 
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cancer (Table 2). The combination at the dosages chosen seems suitable for this patient 
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demonstrated, with a median TTP of 30+weeks in the combination of PLD and topotecan for 
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found, consequently, it was considered to be controllable. Consequently, PLD, with its low 
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ovarian cancer. 30) Regarding dose-limiting toxicity, although neutropenia and diarrhea were 
observed, diarrhea was thought to cause no remarkable problems in the combination 
regimen examined. Based on these results, irinitecan is considered to be useful drug in 
chemotherapy for ovarian cancer. There were two phase II studies of single agent of 
irinotecan for platinum- and taxane-resistant ovarian cancer. Matsumoto et al. treated 28 
patients with platinum- and taxane-resistant or refractory ovarian cancer with irinotecan 
(irinotecan 100mg/m2, days 1,8,15, every 4 weeks), and they observed a response rate of 
28.5% with a SD rate of 32.1%, and the clinical benefit was obtained in 60.7% of the patients. 
31) Grade3 or 4 neutropenia and diarrhea were shown in 17.9% and 10.7% of the patients, 
respectively. They concluded that the weekly dosing schedule of irinotecan seems to be 
effective and safe salvage chemotherapy regimen for platinum- and taxane-resisitant or 
refractory epithelial ovarian cancer. There are few studies of irinotecan, commonly used in 
Japan for second-line chemotherapy, from Europe and the United States. Bodurka et al. 
conducted a clinical trial of irinotecan at a dose of 300 mg/m2 every 3 weeks in 31 platinum-
resistant and platinum-refractory patients. 32) The response rate was 17% and lower than that 
Matsumoto et al. reported; however, irinotecan had at least an equivalent effect to topotecan 
and GEM. Furthermore, 14 (48%) patients had stable disease (SD) and 65% showed a clinical 
benefit, which was similar to the result of Matsumoto et al. There are no data directly 
comparing irinotecan and topotecan, which have similar active mechanism; however, in a 
comparison between the results of a phase II study in Japanese patients with recurrent 
ovarian cancer (topotecan: 1.2 mg/m2, days 1–5, every 3 weeks), 33) the results of Matsumoto 
et al. (irinotecan: 100 mg/m2, days 1, 8 and 15, every 4 weeks), 31) and the results of Bodurka 
et al. (irinotecan: 300 mg/m2, every 3 weeks), 32) toxicities markedly differed. The incidences 
of hematotoxicity of grade 3 or more were higher in the topotecan group; i.e., the incidence 
of neutropenia of grade 3 or more was 95.8% in the topotecan group, but 17.9% and 35.5% in 
the irinotecan groups of Matsumoto et al. and Bodurka et al., respectively. Furthermore, 
thrombopenia occurred in 97% of the topotecan group, but rarely in the irinotecan groups 
(0% and 6.5% in studies of Matsumoto et al. and Bodurka et al., respectively). Diarrhea 
frequently occurred in the irinotecan groups with ≥grade 3 incidences of 10.7% and 32.3% in 
Matsumoto et al. and Bodurka et al., respectively. On the other hand, the incidence in the 
topotecan group was low (7.1%). As shown above, in treatment with topotecan and 
irinotecan for patients with recurrent ovarian cancer, hematotoxicity and diarrhea should be 
monitored, respectively.  
6.1 Combination with cisplatin 
The synergism between irinotecan and cisplatin, 34) the different mechanism of action 
between the two drugs, 35) some lack of cross-resistance, 36) and the relative absence of 
overlapping principal toxicities support the rationale behind considering combination 
therapy with these agents. Minagwa et al. reported that in cisplatin-resistant Hela cells 
cisplatin showed a collateral sensitivity to SN-38, an active metabolite of irinotecan. 37) 
Furthermore, isobologram analysis indicated synergistic interaction of cisplatin and SN-38 
for cisplatin-resistant Hela cells. Based on the results of a phase I study, our group 
conducted a phase II study with irinotecan and cisplatin. 29) Twenty-five patients with 
recurrent ovarian cancer who had previously undergone platinum-based combination 
chemotherapy received this treatment consisting of 50 or 60mg/m2 of irinotecan on days 1, 
8, and 15, and 50 or 60mg/m2 of cisplatin on day1 every 4 weeks administrated 
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intravenously. The overall response rate was 40%.  Even when the analysis was limited to 21 
platinum-resistant cases, the response rate was 33.3% with a stable disease (SD) rate of 
38.1%, and the clinical benefit was obtained in 15/21 (71.4%) patients (Table 4). Neutropenia 
occurred in 54.5% of cycles and 64% of patients. Although diarrhea was observed in 31.8% 
of the courses, there were only a few severe cases (3.0%), and this condition could be 
managed with the administration of loperamide and/or Kanpo medicine along with  
adequate hydration. Irinotecan/cisplatin represented a useful doublet regimen for 
platinum-resistant disease because high clinical benefit was shown, and irinotecan may 
induce relatively mild hematologic toxicity, particularly, thrombocytopenia, compared with 
topotecan. Neutropenia was reserved by short-term G-CSF. Although diarrhea frequently 
occurs during irinitecan monotherapy, it is no longer thought to be a serious toxicity in 
combination chemotherapy due to irinotecan dose reduction. 
 
 
Table 4. Phase II studies of irinotecan-combinations in patients with platinum-resistant 
disease. 
6.2 Combination with oral etoposide 
Etoposide, a topoisomerase-II inhibitor, has high antitumor activity against various animal 
and human malignancies. The efficacy of etoposide may be regimen-dependent, since 
prolonged oral administration has yielded better results than intravenous administration. 
The largest study to date, performed by the Gynecologic Oncology Group (GOG), reported a 
response rate of 8.3%.38) Rose et al. gave oral etoposide (50mg/kg of body weight) from days 
1 to 21 every 4 weeks to 41 patients with platinum–resistant or 25 patients with platinum-
/taxane-resistant ovarian cancer and obtained response rates of 26.8% and 32%, 
respectively. 39)  
DNA topoisomerase-I and –II are nuclear enzymes that participate in various genetic 
processes, including transcription, replication, recombination and chromosome segregation 
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ovarian cancer. 30) Regarding dose-limiting toxicity, although neutropenia and diarrhea were 
observed, diarrhea was thought to cause no remarkable problems in the combination 
regimen examined. Based on these results, irinitecan is considered to be useful drug in 
chemotherapy for ovarian cancer. There were two phase II studies of single agent of 
irinotecan for platinum- and taxane-resistant ovarian cancer. Matsumoto et al. treated 28 
patients with platinum- and taxane-resistant or refractory ovarian cancer with irinotecan 
(irinotecan 100mg/m2, days 1,8,15, every 4 weeks), and they observed a response rate of 
28.5% with a SD rate of 32.1%, and the clinical benefit was obtained in 60.7% of the patients. 
31) Grade3 or 4 neutropenia and diarrhea were shown in 17.9% and 10.7% of the patients, 
respectively. They concluded that the weekly dosing schedule of irinotecan seems to be 
effective and safe salvage chemotherapy regimen for platinum- and taxane-resisitant or 
refractory epithelial ovarian cancer. There are few studies of irinotecan, commonly used in 
Japan for second-line chemotherapy, from Europe and the United States. Bodurka et al. 
conducted a clinical trial of irinotecan at a dose of 300 mg/m2 every 3 weeks in 31 platinum-
resistant and platinum-refractory patients. 32) The response rate was 17% and lower than that 
Matsumoto et al. reported; however, irinotecan had at least an equivalent effect to topotecan 
and GEM. Furthermore, 14 (48%) patients had stable disease (SD) and 65% showed a clinical 
benefit, which was similar to the result of Matsumoto et al. There are no data directly 
comparing irinotecan and topotecan, which have similar active mechanism; however, in a 
comparison between the results of a phase II study in Japanese patients with recurrent 
ovarian cancer (topotecan: 1.2 mg/m2, days 1–5, every 3 weeks), 33) the results of Matsumoto 
et al. (irinotecan: 100 mg/m2, days 1, 8 and 15, every 4 weeks), 31) and the results of Bodurka 
et al. (irinotecan: 300 mg/m2, every 3 weeks), 32) toxicities markedly differed. The incidences 
of hematotoxicity of grade 3 or more were higher in the topotecan group; i.e., the incidence 
of neutropenia of grade 3 or more was 95.8% in the topotecan group, but 17.9% and 35.5% in 
the irinotecan groups of Matsumoto et al. and Bodurka et al., respectively. Furthermore, 
thrombopenia occurred in 97% of the topotecan group, but rarely in the irinotecan groups 
(0% and 6.5% in studies of Matsumoto et al. and Bodurka et al., respectively). Diarrhea 
frequently occurred in the irinotecan groups with ≥grade 3 incidences of 10.7% and 32.3% in 
Matsumoto et al. and Bodurka et al., respectively. On the other hand, the incidence in the 
topotecan group was low (7.1%). As shown above, in treatment with topotecan and 
irinotecan for patients with recurrent ovarian cancer, hematotoxicity and diarrhea should be 
monitored, respectively.  
6.1 Combination with cisplatin 
The synergism between irinotecan and cisplatin, 34) the different mechanism of action 
between the two drugs, 35) some lack of cross-resistance, 36) and the relative absence of 
overlapping principal toxicities support the rationale behind considering combination 
therapy with these agents. Minagwa et al. reported that in cisplatin-resistant Hela cells 
cisplatin showed a collateral sensitivity to SN-38, an active metabolite of irinotecan. 37) 
Furthermore, isobologram analysis indicated synergistic interaction of cisplatin and SN-38 
for cisplatin-resistant Hela cells. Based on the results of a phase I study, our group 
conducted a phase II study with irinotecan and cisplatin. 29) Twenty-five patients with 
recurrent ovarian cancer who had previously undergone platinum-based combination 
chemotherapy received this treatment consisting of 50 or 60mg/m2 of irinotecan on days 1, 
8, and 15, and 50 or 60mg/m2 of cisplatin on day1 every 4 weeks administrated 
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intravenously. The overall response rate was 40%.  Even when the analysis was limited to 21 
platinum-resistant cases, the response rate was 33.3% with a stable disease (SD) rate of 
38.1%, and the clinical benefit was obtained in 15/21 (71.4%) patients (Table 4). Neutropenia 
occurred in 54.5% of cycles and 64% of patients. Although diarrhea was observed in 31.8% 
of the courses, there were only a few severe cases (3.0%), and this condition could be 
managed with the administration of loperamide and/or Kanpo medicine along with  
adequate hydration. Irinotecan/cisplatin represented a useful doublet regimen for 
platinum-resistant disease because high clinical benefit was shown, and irinotecan may 
induce relatively mild hematologic toxicity, particularly, thrombocytopenia, compared with 
topotecan. Neutropenia was reserved by short-term G-CSF. Although diarrhea frequently 
occurs during irinitecan monotherapy, it is no longer thought to be a serious toxicity in 
combination chemotherapy due to irinotecan dose reduction. 
 
 
Table 4. Phase II studies of irinotecan-combinations in patients with platinum-resistant 
disease. 
6.2 Combination with oral etoposide 
Etoposide, a topoisomerase-II inhibitor, has high antitumor activity against various animal 
and human malignancies. The efficacy of etoposide may be regimen-dependent, since 
prolonged oral administration has yielded better results than intravenous administration. 
The largest study to date, performed by the Gynecologic Oncology Group (GOG), reported a 
response rate of 8.3%.38) Rose et al. gave oral etoposide (50mg/kg of body weight) from days 
1 to 21 every 4 weeks to 41 patients with platinum–resistant or 25 patients with platinum-
/taxane-resistant ovarian cancer and obtained response rates of 26.8% and 32%, 
respectively. 39)  
DNA topoisomerase-I and –II are nuclear enzymes that participate in various genetic 
processes, including transcription, replication, recombination and chromosome segregation 
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at mitosis. 40) These two DNA topoisomerases are functionally related and act in concert. 
Both seem to be essential for maintaining cell viability throughout the cell cycle. 
Topoisomerase-I treatment induces an increase in the S-phase cell population with an 
increase in topoisomerase-II mRNA expression. Thus, topoisomerase-I can modulate 
topoisomerase-II levels to enhance the effect of topoisomerase-II inhibitors. 41,42) Therefore, 
combined use of topoisomerase-I and-II targeting agents could theoretically inhibit both 
DNA and RNA synthesis completely, resulting in synergistic cytotoxicity.  
We undertook a pilot study and a phase II study to evaluate the antitumor efficacy and 
toxicity of a combination of irinotecan and oral etoposide in women with platinum- and 
taxane-resistant ovarian cancer. 43,44)  In both studies, irinotecan was administered in an 
intravenous dose of 60 or 70mg/m2 as a 90-min infusion on days 1 and 15 of a 28-day cycle, 
and etoposide was administered in an oral dose of 50mg/body on days 1 to 21. The two 
studies showed very similar results for efficacy (according to the RECIST and CA125 
criteria) and toxicity (Table 4). A pilot study of irinotecan and oral etoposide in platinum- 
and taxane-resistant ovarian cancer reported an overall response rate of 44.4% in 
12/27cases, and the median duration of response was 11 months. 43)  Adding 11 patients 
with SD, a high clinical benefit was shown in 23/27 cases (85.1%). The median time to 
progression and the median survival in the study group as a whole was 9 months and 17 
months, respectively. The major toxicity was neutropenia (grade 3/4, 59%), but was 
managed easily by administration of short-term G-CSF. Febrile neutropenia was observed in 
only one patient. Diarrhea was infrequent and mild. The other study was conducted in the 
northern area of Japan (Tohoku Gynecologic Cancer Unit).44) Forty-two patients with 
recurrent epithelial ovarian cancer who had previously undergone platinum-based 
combination chemotherapy were registered in this study, and the overall response rate was 
50.0%. Even when the analysis was limited to 31 platinum-resistant cases, a response rate of 
41.9% and clinical benefit of 77.4% were achieved. As for toxicity, grade 3/4 neutropenia 
was observed in 22 patients (52.4%) and febrile neutropenia in 3 patients (7.1%). Grade 3/4 
diarrhea occurred in only two patients (4.8%). Acute myeloid leukemia (AML) developed as 
a secondary malignancy in one patient in each study. Topoisomerase-II-related AML, 
initially noted as a therapy-related complication of childhood leukemia, is characterized by 
the lack of a myelodysplastic phase, no dysplastic change in diagnostic bone marrow 
specimens, balanced chromosomal translocations involving 11q23, and variable 
chemosensitivity. This leukemia is characteristically related to the cumulative dose of 
etoposide and has a shorter latency period (median, 24 to 30 months) than the AML 
associated with alkylating agent therapy. In general, a total dose of etoposide of more than 
6g may be associated with an increased risk of developing leukemia. The total dose of 
etoposide received by the two patients who had AML in the two studies was 10.5g and 
14.2g, respectively. We strongly recommended that this regimen not be given for more than 
6 cycles, even if the response or stable disease is sustained. These results of the two studies 
justify further studies of irinotecan plus oral etoposide in patients with platinum- and 
taxane-resistant epithelial ovarian cancer. 
7. Conclusions 
In the treatment of platinum- and taxane- resistant recurrent ovarian cancer, monotherapy is 
recommended from the perspective of toxicity. However, monotherapy of PLD and 
irinotecan, which have specific non-hematotoxicities, increases the incidence and severity of 
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HFS, stomatitis and diarrhea, resulting in a decreased patient QOL. We investigated 
whether combination therapy of these drugs with other drugs would exploit their 
advantages at lower doses. The results of studies of combination therapy of PLD or 
irinotecan showed lower incidences of the non-hematotoxicities specific to these drugs at the 
same time good patient QOL was maintained; furthermore, a good clinical benefit was 
shown without loss of the effect in comparison with that of monotherapy. In conclusion, we 
propose the use of combination therapy using PLD or irinotecan in the treatment of 
platinum- and taxane- resistant recurrent ovarian cancer. 
8. Summary 
In the treatment of platinum- and taxane-resistant recurrent cancer, monotherapy is 
recommended as the standard treatment from the perspective of toxicity. However, 
pegylated liposomal doxorubicin (PLD) and irinotecan have specific non-hematotoxicities 
that impair the quality of life (QOL) of patients; therefore, combination therapy at lower 
doses may provide better clinical benefit than monotherapy, especially as it can be 
maintained for a longer time because the lowering of the doses decreases the specific 
toxicities.  
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at mitosis. 40) These two DNA topoisomerases are functionally related and act in concert. 
Both seem to be essential for maintaining cell viability throughout the cell cycle. 
Topoisomerase-I treatment induces an increase in the S-phase cell population with an 
increase in topoisomerase-II mRNA expression. Thus, topoisomerase-I can modulate 
topoisomerase-II levels to enhance the effect of topoisomerase-II inhibitors. 41,42) Therefore, 
combined use of topoisomerase-I and-II targeting agents could theoretically inhibit both 
DNA and RNA synthesis completely, resulting in synergistic cytotoxicity.  
We undertook a pilot study and a phase II study to evaluate the antitumor efficacy and 
toxicity of a combination of irinotecan and oral etoposide in women with platinum- and 
taxane-resistant ovarian cancer. 43,44)  In both studies, irinotecan was administered in an 
intravenous dose of 60 or 70mg/m2 as a 90-min infusion on days 1 and 15 of a 28-day cycle, 
and etoposide was administered in an oral dose of 50mg/body on days 1 to 21. The two 
studies showed very similar results for efficacy (according to the RECIST and CA125 
criteria) and toxicity (Table 4). A pilot study of irinotecan and oral etoposide in platinum- 
and taxane-resistant ovarian cancer reported an overall response rate of 44.4% in 
12/27cases, and the median duration of response was 11 months. 43)  Adding 11 patients 
with SD, a high clinical benefit was shown in 23/27 cases (85.1%). The median time to 
progression and the median survival in the study group as a whole was 9 months and 17 
months, respectively. The major toxicity was neutropenia (grade 3/4, 59%), but was 
managed easily by administration of short-term G-CSF. Febrile neutropenia was observed in 
only one patient. Diarrhea was infrequent and mild. The other study was conducted in the 
northern area of Japan (Tohoku Gynecologic Cancer Unit).44) Forty-two patients with 
recurrent epithelial ovarian cancer who had previously undergone platinum-based 
combination chemotherapy were registered in this study, and the overall response rate was 
50.0%. Even when the analysis was limited to 31 platinum-resistant cases, a response rate of 
41.9% and clinical benefit of 77.4% were achieved. As for toxicity, grade 3/4 neutropenia 
was observed in 22 patients (52.4%) and febrile neutropenia in 3 patients (7.1%). Grade 3/4 
diarrhea occurred in only two patients (4.8%). Acute myeloid leukemia (AML) developed as 
a secondary malignancy in one patient in each study. Topoisomerase-II-related AML, 
initially noted as a therapy-related complication of childhood leukemia, is characterized by 
the lack of a myelodysplastic phase, no dysplastic change in diagnostic bone marrow 
specimens, balanced chromosomal translocations involving 11q23, and variable 
chemosensitivity. This leukemia is characteristically related to the cumulative dose of 
etoposide and has a shorter latency period (median, 24 to 30 months) than the AML 
associated with alkylating agent therapy. In general, a total dose of etoposide of more than 
6g may be associated with an increased risk of developing leukemia. The total dose of 
etoposide received by the two patients who had AML in the two studies was 10.5g and 
14.2g, respectively. We strongly recommended that this regimen not be given for more than 
6 cycles, even if the response or stable disease is sustained. These results of the two studies 
justify further studies of irinotecan plus oral etoposide in patients with platinum- and 
taxane-resistant epithelial ovarian cancer. 
7. Conclusions 
In the treatment of platinum- and taxane- resistant recurrent ovarian cancer, monotherapy is 
recommended from the perspective of toxicity. However, monotherapy of PLD and 
irinotecan, which have specific non-hematotoxicities, increases the incidence and severity of 
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HFS, stomatitis and diarrhea, resulting in a decreased patient QOL. We investigated 
whether combination therapy of these drugs with other drugs would exploit their 
advantages at lower doses. The results of studies of combination therapy of PLD or 
irinotecan showed lower incidences of the non-hematotoxicities specific to these drugs at the 
same time good patient QOL was maintained; furthermore, a good clinical benefit was 
shown without loss of the effect in comparison with that of monotherapy. In conclusion, we 
propose the use of combination therapy using PLD or irinotecan in the treatment of 
platinum- and taxane- resistant recurrent ovarian cancer. 
8. Summary 
In the treatment of platinum- and taxane-resistant recurrent cancer, monotherapy is 
recommended as the standard treatment from the perspective of toxicity. However, 
pegylated liposomal doxorubicin (PLD) and irinotecan have specific non-hematotoxicities 
that impair the quality of life (QOL) of patients; therefore, combination therapy at lower 
doses may provide better clinical benefit than monotherapy, especially as it can be 
maintained for a longer time because the lowering of the doses decreases the specific 
toxicities.  
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1. Introduction 
Members of the human epidermal growth factor receptor (HER) family—epidermal growth 
factor receptor (EGFR, HER1), HER2, HER3, and HER4—are transmembrane tyrosine kinase 
receptors that are important mediators of cell growth, development, and survival. 
Activation of the HER tyrosine kinases triggers intracellular signaling pathways, including 
the MAPK and PI3K-Akt pathways (Olayioye et al., 2000) (Figure 1). 
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Fig. 1. Dimerization of HER2–HER3 initiates the PI3K and MAPK signaling pathways. 
Ligand binding to HER1, 3, and 4 results in a conformational change in the extracellular 
domain of each protein that opens a dimerization domain and allows the receptor to form 
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either a homo- or heterodimer with another member of the HER family (Cho & Leahy, 2002; 
Zhang et al., 2006). No ligand has been identified for HER2, and it exists in a conformation 
that is constitutively available for dimerization (Garrett et al., 2003). HER2 is therefore the 
preferred dimer partner of other HER family members (Graus-Porta et al., 1997). While 
HER2 has no known ligand, HER3 lacks intracellular tyrosine kinase activity, rendering 
HER2–HER3 signaling dependent on heterodimerization (Yarden & Sliwkowski, 2001). 
HER2–HER3 dimerization results in phosphorylation of the tyrosine kinase domain, which 
in turn activates intracellular signaling pathways (Zhang et al., 2006). The effect of these 
signaling pathways on gene transcription determines how the cell responds to the ligand 
activation. 
HER family members can also be activated by ligand-independent mechanisms, including 
activation by other tyrosine kinase receptors, G-protein coupled receptors, and adhesion 
proteins (Siwak et al., 2010). 
1.1 Role of HER2 in oncology 
Members of the HER family were first associated with oncogenesis after the discovery that 
the sequence of the EGFR receptor was found to be very similar to that of v-ErbB, a 
transforming retroviral oncogene carried by the avian erythroblastosis virus (Downward et 
al., 1984). The v-ErbB oncogene encodes a truncated form of EGFR that can form ligand-
independent dimers, thereby initiating cell signaling pathways and inducing cellular 
proliferation in the absence of ligand stimulation (Adelsman et al., 1996). Examination of a 
series of rat neuro/gliobalstomas revealed a commonly transforming gene, neu, encoding a 
protein serologically related to ErbB (EGFR), subsequently shown to be the HER2 
oncoprotein (Coussens et al., 1985; Schechter et al., 1984). 
HER2 expression is frequently dysregulated in several types of human tumors including 
those of the breast, head and neck, prostate, and ovary (Hynes, 1993). Of particular 
significance was the discovery that the HER2 protein was overexpressed, commonly by 
gene amplification, in about 30% of breast cancers. These studies also showed that 
overexpression of HER2 indicated  an aggressive subtype of breast cancers with a 
particularly poor prognosis for the patient (Slamon et al., 1987, 1989). Overexpression of 
HER2 facilitates the formation of HER2 heterodimers, which trigger HER2 signaling 
pathways (Yarden and Sliwkowski, 2001), with excess HER2 signaling resulting in signaling 
cascades that promote oncogenic cell survival and proliferation (Olayioye et al., 2000; 
Rowinsky, 2004).  
HER2 amplification /overexpression has also been reported in patients with gastric tumors 
where it is again linked to a poor prognosis (Jaehne et al., 1992). In addition, increased HER2 
levels have been reported in some patients with salivary gland tumors (Cornolti et al., 2007) 
and non-small cell lung cancer (NSCLC) (Cappuzzo et al., 2006). Mutations in tumor 
suppressor genes may be partly responsible for the aberrant expression of HER2 in these 
tumors. Foe example, one tumor suppressor, FOXP3, normally maintains low levels of 
HER2 in normal cells; however, in breast cancer models the absence of FOXP3 results in 
high expression of HER2 (Zuo et al., 2007). 
Overexpression of HER2 is only one of several mechanisms, albeit the most frequent, by 
which HER2 signaling can be activated in oncogenesis. Mutations in the kinase domain of 
HER2 can potentially trigger signaling that is independent of ligand binding or dimerization 
(Anglesio et al., 2008). Ligand-dependent activation of HER2 via dimerization with other 
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HER family members may also play a role in HER2 oncogenesis. Of all of the different HER 
family dimers, the HER2–HER3 heterodimer appears to have the most potent signaling 
effects in cancer cells (Tzahar et al., 1996).. It appears that HER3 is crucial for mediating the 
dysregulated signaling in tumors overexpressing HER2 (Lee-Hoeflich et al., 2008). Cancers 
with HER2 amplification are frequently observed to have increased Akt activity even 
though HER2 cannot directly activate the PI3K–Akt pathway (Hsieh & Moasser, 2007). 
However, the intracellular domain of HER3 contains several binding sites for PI3K, enabling 
direct activation of the PI3K–Akt pathway (Figure 1), which may explain the mitogenic 
activity of HER2–HER3 dimers (Hsieh & Moasser, 2007). HER2 can also form a dimer with 
EGFR, which initiates intracellular signaling via the MAPK pathway (Campiglio et al., 1999). 
In summary, while HER2 amplification leading to overexpression is clearly linked to 
activation of HER2 in some tumor cells, activating mutations in HER2, as well as ligand-
dependent activation of HER2 signaling, are also likely important mechanisms leading to 
HER2 oncogenesis. 
2. HER2 in ovarian cancer 
The HER family are important mediators of normal ovarian follicle development, and 
regulate the growth of ovarian epithelial cells (Conti et al., 2006). Dysregulation of HER 
signaling in the ovary due to overexpression of, or mutations in HER family members have 
been linked to the growth and proliferation of ovarian tumors. 
2.1 HER2 overexpression in ovarian cancer 
The proportion of ovarian cancers overexpressing HER2 is a matter of debate (Sheng & Liu, 
2011). Various studies have reported that between 5% and 35% of ovarian tumors 
overexpress HER2 (Table 1). Some of these differences are likely to be attributable to the 
diagnostic technique used to measure HER2 expression. HER2 protein expression is 
commonly measured using immunohistochemistry (IHC), whereas HER2 gene amplification 
is typically measured using hybridization techniques, such as fluorescence in situ 
hybridization (FISH) (Wolff et al., 2007). Recent technical improvements also enable 
measurement of HER2 mRNA expression levels using the quantitative real time-polymerase 
chain reaction (qRT-PCR) in archival samples (Muller et al., 2011).  
However, the reported levels of HER2 overexpression and/or amplification may be affected 
by other factors including variable definitions of overexpression, small sample sizes, and 
variable testing conditions or assay performance (Wolff et al., 2007). It should also be noted 
that studies investigating only HER2 gene amplification are likely to account for only a 
proportion of cancers that overexpress of the protein without amplification of the gene 
(Mano et al., 2004). 
In a  recent study of somatic copy number alterations in 489 ovarian cancer samples using 
multiple microarray-based platforms, 63 regions of recurrent focal amplification were 
identified, of which 26 regions encoded eight or fewer genes. The most common focal 
amplifications encoded CCNE1, MYC, and MECOM, each of which was highly amplified in 
more than 20% of tumors. By contrast, HER2 was highly amplified in 3.1% of tumors, and a 
further 7% of tumors had a more moderate level of HER2 amplification. The correlation 
between HER2 copy number and mRNA expression was 0.59 (Cancer Genome Atlas 
Research Network, 2011). 
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Study Method of assay 
Pts with HER2-








Rubin et al., 
1993 IHC 
36/105 (34) 2+ or 3+ membrane staining No†‡ NA 12/105 (11) 1+ membrane staining 
Meden et al., 
1994 IHC 51/275 (19) NS Yes 
p=0.001† 
p=0.006‡ 
Meden et al., 
1995 IHC 48/266 (18) NS Yes
 p=0.002† 
p=0.012‡ 
Meden et al., 
1998 IHC 46/208 (22) 
>5% cells had membrane 




al., 2003 IHC 95/837 (11) 2+ or 3+ membrane staining NA NA 
Hogdall et al., 
2003 IHC 
24/181 (13) 2+ or 3+ membrane staining Yes p=0.003‡ 71/181 (39) 1+ membrane staining 
Cloven et al., 
2004 IHC 227/1420 (16) ≥1+ staining NA NA 
Lassus et al., 
20042 
IHC 66/390 (17) 2+ or 3+ membrane staining Yes p<0.0001† 
CISH 
26/381 (7) >5 copies of HER2 per nucleus Yes p<0.0001
† 
p<0.006‡ 55/381 (14) 3–5 copies of HER2 per nucleus 
Kupryjanczyk 
et al., 2004 IHC 
63/233 (27) 2+ or 3+ membrane staining No NA 
35/233 (15) 1+ membrane staining 
Nielsen et al., 
2004  IHC 272/783 (35) 
2+ or 3+ staining of 
cytoplasm or membrane Yes/No 
p=0.021†3 
p=0.76‡ 
Lee et al., 
2005 IHC 5/102 (5) ≥1+ staining NA NA 
Verri et al., 
2005 IHC 
27/194 (14) 2+ or 3+ membrane staining Yes/No p=0.04
† 




18/160 (11) 2+ or 3+ membrane staining 
Yes p=0.03† 39/160 (24) 1+ membrane staining 
FISH 10/145 (7) HER2:CEP17 ratio >2 No p=0.39† 
Tuefferd et 
al., 2007 IHC 41/320 (13) 2+ or 3+ membrane staining No 
p=0.6† 
p=0.152‡ 
Farley et al., 
2009 FISH 
9/133 (7) HER2:CEP17 ratio >2 No p=0.12
† 
p=0.152‡ 
12/133 (9) HER2:nuclei ratio >4 No p=0.42
† 
p=0.980‡ 
CEP17, chromosome enumeration probe 17; CISH, chromogenic in situ hybridization; FISH; 
fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, 
immunohistochemistry; NA, not applicable; NS, not specified; Pts, patients. 
1 Overall survival of patients with HER2 positive tumors versus those with HER2 negative tumors. † 
Univariate analysis; ‡ Multivariate analysis.  
2 Not all IHC samples were analyzable by CISH/FISH due to DNA degradation. 
3 Patients with HER2 positive tumors had increased survival versus those with HER2 negative tumors. 
Table 1. Expression level of HER2 in ovarian tumors in studies with >100 patients. 
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The HER2 mRNA level in samples taken from ovarian tumors of patients who were enrolled 
in a clinical trial studying platinum-sensitive disease (Kaye et al., 2008) showed a 
dichotomous distribution of HER2 mRNA expression (Figure 2A) similar to that observed in 
tumor samples from a study of patients with breast cancer (Figure 2B) (Burris et al., 2011). 
The prevalence of mRNA overexpression in the ovarian cancer samples was approximately 








Fig. 2. Distribution of HER2 mRNA expression levels in (A) ovarian cancer and (B) breast 
cancer (Yulei Wang & Lukas Amler, unpublished data).  
Samples from ovarian tumors were randomly chosen from archived samples collected 
during a clinical trial (Kaye et al., 2008). Samples from breast tumors were also collected 
during a clinical trial (Burris et al., 2011) but had known HER2 status (75% were HER2 
negative, 25% were HER2 positive by IHC). HER2 mRNA levels in both data sets were 
determined by qRT-PCR (method as published in Makhija et al., 2010).  
The CR of HER2:G6PDH expression was plotted as a histogram, and a smooth curve was 
fitted over the histogram. The ovarian cancer samples show a bimodal distribution of HER2 
expression, with a small peak indicating the population of tumors that overexpress HER2 
mRNA. 
(BC, breast cancer; CR, concentration ratio; HER2, human epidermal growth factor 
receptor 2; G6PDH, glucose-6-phosphate dehydrogenase; IHC, immunohistochemistry; 
qRT-PCR, quantitative real time-polymerase chain reaction). 
Steffenson et al. also used qRT-PCR to measure HER2 mRNA expression in 99 ovarian 
tumors and found that the tumor tissue had an average 5.7-fold higher level of HER2 
mRNA compared with normal ovarian tissue. IHC showed HER2 overexpression (2+/3+ 
staining) in 11% (11/99) of tumors with a further 33% (33/99) of tumors showing 1+ 
staining. In contrast, all samples from normal ovarian tissue (n=23) were shown to be 
negative for HER2 staining (Steffensen et al., 2008). 
Several studies have shown that overexpression of HER2 in ovarian tumors is an 
independent predictor of shorter progression-free survival and/or overall survival after 
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2 Not all IHC samples were analyzable by CISH/FISH due to DNA degradation. 
3 Patients with HER2 positive tumors had increased survival versus those with HER2 negative tumors. 
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multivariate analysis. However, this has not been supported by other studies (Table 1) 
(Serrano-Olvera et al., 2006). This discrepancy may indicate that while HER2 overexpression 
is of prognostic value in some groups of patients, this is not true for all patients in whom 
other biomarkers may be more significant. Assay quality, execution, and interpretation of 
data, as discussed above, may also explain differences in the observed levels of HER2 
expression and its prognostic value. 
2.2 Activation of HER2 in ovarian cancer 
HER2 amplification and/or overexpression occurs in relatively few patients with ovarian 
cancer, although “normal” expression of HER2 measured by IHC 1+ staining is relatively 
common (Table 1). Other mechanisms, such as mutations in HER2 or ligand-dependent 
activation of HER2, may play a role in HER2 oncogenesis. 
Mutations in the HER2 kinase domain are indeed found in ovarian tumors (Table 2), and the 
pattern of these in-frame insertions and missense mutations is similar to activating 
mutations found in other kinases, strongly suggesting that these mutations activate the 
HER2 kinase. For example, mutations in HER2 are adjacent to or overlap with the analogous 
structural region of EGFR in-frame deletions that are associated with some lung tumors 
(Stephens et al., 2004). One study found that 6% of serous borderline ovarian tumors of low 
malignant potential (LMP) expressed a mutated version of HER2. LMP ovarian tumors also 
have a high rate of KRAS (18%) and BRAF (48%) mutations indicating that constitutive 
activation of the RAS–MAPK pathway may be one of the key mechanisms in the 
development of this type of ovarian tumor (Anglesio et al., 2008).  
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Ligand-dependent signaling via HER2–HER3 or HER2–EGFR dimers may also be important 
in ovarian cancer (Amler, 2010; Campiglio et al., 1999; Lewis et al., 1996). To investigate this 
hypothesis, Gordon et al. measured activated phosphorylated (p)HER2 by enzyme-linked 
immunosorbent assay and HER2 gene amplification by FISH in 20 fresh ovarian tumor 
biopsies. They found that while only two tumors had HER2 gene amplification (10%), 
pHER2 was detected in 45% of tumors (Gordon et al., 2006), indicating that activation of 
HER2 signaling probably occurs independently of gene amplification. 
2.3 Biomarkers to identify HER2 activated or dependent ovarian tumors 
Cumulative evidence over the past decade has demonstrated that in most cases, tumors 
from the same anatomic site of origin can be sub-classified into distinct molecular subsets 
driven by different underlying biological mechanisms and with distinct prognoses. This is 
best exemplified in breast cancer, where at least four distinct subtypes have been identified 
(Onitilo et al., 2009). Biomarkers that can differentiate between these distinct biological 
subsets of tumors can be used to predict the prognosis of a patient and potentially identify 
those who will derive the most benefit from targeted therapies (Carden et al., 2009). In 
breast cancer, such relevant biomarkers include measuring the expression of estrogen 
receptor α and the progesterone receptor to identify patients who would be sensitive to 
hormonal therapies, and HER2 to identify patients who would benefit from treatment with 
HER2-targeted therapies (Labuhn et al., 2006). Likewise, biomarkers are also used to 
determine the best course of treatment in a variety of other cancers. For example, patients 
with NSCLC or colorectal cancer (CRC) are screened for mutations in EGFR and KRAS, 
respectively, to determine whether they would benefit from EGFR inhibitors (Catenacci et 
al., 2011; Domingo et al., 2010). Mutations in both of these oncogenes are likely 
representative of distinct biological subsets of disease. For example, patients whose tumors 
harbor EGFR mutations are typically non-smokers, often female and of Asian ethnicity, and 
generally have a better prognosis than non-EGFR mutant NSCLC (Coate et al., 2009). 
The identification of patients with ovarian tumors that express either high levels of HER2, 
HER2 with activating mutations, or biomarkers that indicate activated HER2 signaling, such 
as pHER2, could enable the patients who would derive the greatest therapeutic benefit to 
receive HER2-targeted therapies. Measuring the expression status of genes regulated by 
HER2 signaling could also identify tumors with activated HER2 signaling.  
The importance of HER2–HER3 heterodimers in the HER2 signaling pathway has led to the 
investigation of HER3 as a prognostic biomarker in ovarian cancer (Amler, 2010). In one 
study of patients with ovarian cancer, those with high (≥ median; n=62) expression of HER3 
protein had significantly decreased survival compared with those with low (< median; 
n=54) expression levels (1.80 versus 3.31 years; p=0.0034) following surgery and 
chemotherapy. In multivariate analysis, high HER3 expression significantly increased the 
risk of mortality compared with low HER3 expression (p=0.018) (Tanner et al., 2006). In 
contrast, patients with ovarian cancer receiving gemcitabine who had low HER3 mRNA 
expression (< median; n=35) had a significantly decreased progression-free survival 
(p=0.0002) and overall survival (p=0.003) than patients with high HER3 (≥ median; n= 24) 
mRNA levels. These data suggest that HER3 may be a prognostic biomarker in ovarian 
cancer (Makhija et al., 2010). 
Interestingly, two separate studies have demonstrated that HER3 mRNA and protein levels 
in ovarian cancer cell lines were reduced on addition of heregulin, a ligand for HER3 
(Makhija et al., 2010; Nagumo et al., 2009). The modulation of HER3 mRNA levels was 
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multivariate analysis. However, this has not been supported by other studies (Table 1) 
(Serrano-Olvera et al., 2006). This discrepancy may indicate that while HER2 overexpression 
is of prognostic value in some groups of patients, this is not true for all patients in whom 
other biomarkers may be more significant. Assay quality, execution, and interpretation of 
data, as discussed above, may also explain differences in the observed levels of HER2 
expression and its prognostic value. 
2.2 Activation of HER2 in ovarian cancer 
HER2 amplification and/or overexpression occurs in relatively few patients with ovarian 
cancer, although “normal” expression of HER2 measured by IHC 1+ staining is relatively 
common (Table 1). Other mechanisms, such as mutations in HER2 or ligand-dependent 
activation of HER2, may play a role in HER2 oncogenesis. 
Mutations in the HER2 kinase domain are indeed found in ovarian tumors (Table 2), and the 
pattern of these in-frame insertions and missense mutations is similar to activating 
mutations found in other kinases, strongly suggesting that these mutations activate the 
HER2 kinase. For example, mutations in HER2 are adjacent to or overlap with the analogous 
structural region of EGFR in-frame deletions that are associated with some lung tumors 
(Stephens et al., 2004). One study found that 6% of serous borderline ovarian tumors of low 
malignant potential (LMP) expressed a mutated version of HER2. LMP ovarian tumors also 
have a high rate of KRAS (18%) and BRAF (48%) mutations indicating that constitutive 
activation of the RAS–MAPK pathway may be one of the key mechanisms in the 
development of this type of ovarian tumor (Anglesio et al., 2008).  
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Ligand-dependent signaling via HER2–HER3 or HER2–EGFR dimers may also be important 
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hypothesis, Gordon et al. measured activated phosphorylated (p)HER2 by enzyme-linked 
immunosorbent assay and HER2 gene amplification by FISH in 20 fresh ovarian tumor 
biopsies. They found that while only two tumors had HER2 gene amplification (10%), 
pHER2 was detected in 45% of tumors (Gordon et al., 2006), indicating that activation of 
HER2 signaling probably occurs independently of gene amplification. 
2.3 Biomarkers to identify HER2 activated or dependent ovarian tumors 
Cumulative evidence over the past decade has demonstrated that in most cases, tumors 
from the same anatomic site of origin can be sub-classified into distinct molecular subsets 
driven by different underlying biological mechanisms and with distinct prognoses. This is 
best exemplified in breast cancer, where at least four distinct subtypes have been identified 
(Onitilo et al., 2009). Biomarkers that can differentiate between these distinct biological 
subsets of tumors can be used to predict the prognosis of a patient and potentially identify 
those who will derive the most benefit from targeted therapies (Carden et al., 2009). In 
breast cancer, such relevant biomarkers include measuring the expression of estrogen 
receptor α and the progesterone receptor to identify patients who would be sensitive to 
hormonal therapies, and HER2 to identify patients who would benefit from treatment with 
HER2-targeted therapies (Labuhn et al., 2006). Likewise, biomarkers are also used to 
determine the best course of treatment in a variety of other cancers. For example, patients 
with NSCLC or colorectal cancer (CRC) are screened for mutations in EGFR and KRAS, 
respectively, to determine whether they would benefit from EGFR inhibitors (Catenacci et 
al., 2011; Domingo et al., 2010). Mutations in both of these oncogenes are likely 
representative of distinct biological subsets of disease. For example, patients whose tumors 
harbor EGFR mutations are typically non-smokers, often female and of Asian ethnicity, and 
generally have a better prognosis than non-EGFR mutant NSCLC (Coate et al., 2009). 
The identification of patients with ovarian tumors that express either high levels of HER2, 
HER2 with activating mutations, or biomarkers that indicate activated HER2 signaling, such 
as pHER2, could enable the patients who would derive the greatest therapeutic benefit to 
receive HER2-targeted therapies. Measuring the expression status of genes regulated by 
HER2 signaling could also identify tumors with activated HER2 signaling.  
The importance of HER2–HER3 heterodimers in the HER2 signaling pathway has led to the 
investigation of HER3 as a prognostic biomarker in ovarian cancer (Amler, 2010). In one 
study of patients with ovarian cancer, those with high (≥ median; n=62) expression of HER3 
protein had significantly decreased survival compared with those with low (< median; 
n=54) expression levels (1.80 versus 3.31 years; p=0.0034) following surgery and 
chemotherapy. In multivariate analysis, high HER3 expression significantly increased the 
risk of mortality compared with low HER3 expression (p=0.018) (Tanner et al., 2006). In 
contrast, patients with ovarian cancer receiving gemcitabine who had low HER3 mRNA 
expression (< median; n=35) had a significantly decreased progression-free survival 
(p=0.0002) and overall survival (p=0.003) than patients with high HER3 (≥ median; n= 24) 
mRNA levels. These data suggest that HER3 may be a prognostic biomarker in ovarian 
cancer (Makhija et al., 2010). 
Interestingly, two separate studies have demonstrated that HER3 mRNA and protein levels 
in ovarian cancer cell lines were reduced on addition of heregulin, a ligand for HER3 
(Makhija et al., 2010; Nagumo et al., 2009). The modulation of HER3 mRNA levels was 
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found to be inversely proportional to activation of the downstream signaling molecules Akt 
and ERK1/2, critical components of the PI3K–Akt pathway (Nagumo et al., 2009). This 
suggests that low HER3 mRNA levels in HER2-positive tumors are associated with a high 
level of HER2–HER3 signaling. Overall these results point to a negative feedback loop that 
responds to the activation of HER3 by downregulation of HER3 mRNA expression (Makhija 
et al., 2010; Nagumo et al., 2009), and suggests that HER3 protein or mRNA levels may be a 
useful prognostic biomarker in patients with ovarian cancer. 
3. HER2 as a drug target in human cancer 
3.1 Clinical evidence for HER2 as a drug target in solid tumors 
Trastuzumab (Herceptin) is a monoclonal antibody that binds to HER2 in the 
juxtamembrane region of the extracellular domain (Cho et al., 2003). Trastuzumab is 
licensed for use as a first-line treatment in combination with other chemotherapeutic agents 
in patients with HER2-positive breast cancer or gastric cancer in the USA and Europe. It has 
also been licensed for use as a single agent in patients with breast cancer who have not 
responded to previous chemotherapy (Genentech Inc., 2011). A trial of trastuzumab in 
combination with other chemotherapies in 3351 patients with breast cancer demonstrated 
significant improvements in disease-free survival (p<0.0001) and overall survival (p=0.015) 
compared with patients receiving chemotherapeutic agents alone (Romond et al., 2005). 
Patients who received trastuzumab after chemotherapy also exhibited a significant 
improvement in disease-free survival compared with those who did not (p<0.0001) (Piccart-
Gebhart et al., 2005). In a Phase III trial of 584 patients with gastric cancer, the addition of 
trastuzumab to other chemotherapeutic agents significantly improved survival versus 
chemotherapy alone (p=0.0046) (Bang et al., 2010).  
Lapatinib (Tyverb/Tykerb) is a small molecule inhibitor that targets the tyrosine kinase 
domain of HER2 and EGFR, thereby inhibiting downstream signaling from both receptors. 
In a Phase III trial, lapatinib increased the time to disease progression from 4.4 months in 
patients on capecitabine monotherapy (n=161) to 8.4 months in patients on a combination of 
the two drugs (n=163; p<0.001) (Geyer et al., 2006). The addition of lapatinib to letrozole also 
significantly reduced the risk of disease progression versus letrozole monotherapy (p=0.019) 
in 219 patients with HER2-positive breast tumors (Johnston et al., 2009). Following these 
trials, lapatinib was licensed for use in combination with letrozole as a first-line treatment 
for HER2-positive breast cancer, and in combination with capecitabine as a second-line 
treatment for breast cancer in the USA and Europe (GlaxoSmithKline, 2011).  
A third agent targeting the HER2 signaling pathway, pertuzumab, is another monoclonal 
antibody that binds to the extracellular domain of HER2 and inhibits HER2 dimerization. 
The clinical development of pertuzumab is most advanced in breast cancer. In a Phase II 
trial of 66 patients with HER2-positive advanced breast cancer whose disease had 
progressed while on trastuzumab monotherapy, pertuzumab in combination with 
trastuzumab resulted in a complete response for 6% of patients. An additional 18% of 
patients had a partial response to therapy and 26% achieved stable disease for ≥6 months. 
Overall, 50% of patients benefited from the pertuzumab–trastuzumab combination (Baselga 
et al., 2010). Pertuzumab is currently undergoing several clinical trials for the treatment of 
HER2-positive breast cancer in combination with various other agents including 
trastuzumab (clinicaltrials.gov; Baselga & Swain, 2010). 
Other HER2-targeted therapies in development for cancer are shown in Table 3. 
 


















































CRC, colorectal cancer; EGFR, epidermal growth factor receptor; HER2/4, human epidermal growth 
factor receptor 2/4; mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; TKI, tyrosine 
kinase inhibitor. 
Table 3. HER2-targeted therapies in clinical testing for the treatment of cancer (data from 
clinicaltrials.gov). 
3.2 Preclinical evidence for HER2 as a target in ovarian cancer 
Trastuzumab, pertuzumab, and lapatinib have all been studied in cell and animal models of 
ovarian cancer, demonstrating the potential use of these therapies to treat patients.  
For example, in SKOV3 cells, a cell line derived from the ascites of an ovarian 
adenocarcinoma, trastuzumab has been shown to reduce pHER2 and pAkt levels, indicating 
that trastuzumab reduced the activation of HER2 signaling pathways (Larbouret et al., 
2007). Moreover, both trastuzumab and lapatinib have been shown to reduce the ability of 
SKOV3 cells to form spheres in a dose-dependent manner, suggesting that both agents have 
an effect on the growth or viability of ovarian cancer cells (Magnifico et al., 2009). 
Pertuzumab and trastuzumab have been shown to reduce HER2–EGFR dimerization in 
SKOV3 cells by 24% and 44%, respectively, while lapatinib had little effect on dimerization 
(Gaborit et al., 2011). Finally, trastuzumab was shown to reduce tumor progression of 
SKOV3 xenografts in mice (Larbouret et al., 2007; Magnifico et al., 2009).  
A number of studies have also investigated the effect of HER2 inhibitors on ligand-dependent 
signaling. Pertuzumab has been shown to reverse ligand-stimulated growth by inhibiting the 
phosphorylation of HER2 and subsequent activation of downstream signaling pathways 
(Mullen et al., 2007). Makhija et al. showed that HER3 mRNA expression was reduced by 
ligand stimulation in six of the eight ovarian cell lines tested. This effect was reversed by the 
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found to be inversely proportional to activation of the downstream signaling molecules Akt 
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signaling. Pertuzumab has been shown to reverse ligand-stimulated growth by inhibiting the 
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(Mullen et al., 2007). Makhija et al. showed that HER3 mRNA expression was reduced by 
ligand stimulation in six of the eight ovarian cell lines tested. This effect was reversed by the 
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addition of pertuzumab, small interfering RNAs (siRNAs) targeting the HER2 transcript, or 
inhibition of PI3K activity using a small molecule inhibitor. In contrast, siRNAs targeting the 
EGFR transcript, or a MEK inhibitor were not able to suppress ligand stimulation, indicating 
that pertuzumab inhibits HER2–HER3 signaling (Makhija et al., 2010). In a separate study, 
down-regulation of HER3 mRNA by heregulin-dependent activation of HER3 was reversed by 
pertuzumab. These authors also demonstrated that a change in HER3 mRNA levels was 
accompanied by changes in Akt and ERK signaling (Nagumo et al., 2009).  
Other preclinical studies have suggested that levels of the HER2 extracellular domain may 
be a biomarker of response or resistance to some therapies used to treat ovarian cancer 
(Vazquez-Martin et al., 2011). 
3.3 Clinical evidence for HER2 as a target in ovarian cancer 
Trastuzumab, pertuzumab and lapatinib have also been studied in a number of clinical trials 
of ovarian cancer (Table 4). 
 
Drug Combination No. pts Clinical stage Reference 
Trastuzumab Monotherapy 41 Phase II Bookman et al., 2003 
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Carboplatin 11 Phase I Kimball et al., 2008 
Carboplatin and 
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Table 4. A summary of completed clinical trials of trastuzumab, lapatinib, and pertuzumab 
in HER2-positive ovarian cancer. 
3.3.1 Trastuzumab  
In HER2-positive ovarian cancer (2+/3+ staining by IHC), a Phase II trial of trastuzumab in 
41 patients demonstrated an overall response rate of 7% (3 patients). One patient had a 
complete response to trastuzumab, and two patients had partial responses to treatment, 
while a further 16 patients (39%) achieved stable disease (Bookman et al., 2003). There are no 
reports of further development of trastuzumab for the treatment of ovarian cancer. 
3.3.2 Lapatinib 
Although studies of lapatinib for the treatment of ovarian cancer are at a relatively early 
stage, available evidence suggests that lapatinib may be effective in some patients with 
ovarian cancer. Of 11 patients with platinum-sensitive ovarian cancer receiving lapatinib 
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plus carboplatin in a Phase Ib trial, three (27%) had a partial response to treatment and a 
further three patients achieved stable disease (Kimball et al., 2008). Rivkin et al. reported 
preliminary results from a Phase I/II study of lapatinib in combination with carboplatin and 
paclitaxel in 21 patients with ovarian cancer. Complete responses were observed in 21% of 
patients, with a further 29% of patients experiencing a partial response and 29% achieving 
stable disease (Rivkin et al., 2008). Lapatinib has also been studied in ovarian cancer in 
combination with topotecan. Results from this Phase II trial with 18 patients showed that 
four patients (22%) experienced clinical benefit from the combination (one partial response 
and three patients who achieved stable disease) (Weroha et al., 2011). In terms of further 
development, a Phase I trial is underway of lapatinib in combination with paclitaxel in 
patients with advanced solid tumors including ovarian tumors (clinicaltrials.gov identifier 
NCT00313599). 
3.3.3 Pertuzumab 
Pertuzumab has been more extensively studied in patients with ovarian cancer than other 
HER2-targeted agents. Studies have included trials of pertuzumab monotherapy as well as 
trials of pertuzumab in combination with other agents (Langdon et al., 2010). In a Phase II 
trial of pertuzumab alone, a partial response was observed in 4% of patients with a further 
7% achieving stable disease for ≥6 months. Interestingly, patients with tumors that had a 
detectable level of HER2 phosphorylation (eight out of 28 tumors tested), had longer 
progression-free survival following pertuzumab treatment than those who did not express 
pHER2 (20.9 vs 5.8 weeks), although this difference was not statistically significant (p=0.14) 
(Gordon et al., 2006). These results, while very preliminary, suggest that pHER2 may 
indicate active HER2 signaling in these tumors and thus benefit from HER2 targeted 
therapy. 
In trials of pertuzumab in combination with carboplatin, gemcitabine, or paclitaxel, patients 
with platinum-sensitive ovarian cancer achieved a 64% response rate compared with 52% for 
patients receiving chemotherapy alone (Kaye et al., 2008; Langdon et al., 2010). Pertuzumab 
has also been tested in combination with gemcitabine versus gemcitabine alone in 130 patients 
with ovarian cancer. A partial response was observed in 14% of patients receiving the 
combination therapy versus 5% receiving gemcitabine alone (Makhija et al., 2010).  
Exploratory biomarker analyses in the Makhija and Kaye studies demonstrated that patients 
with ovarian tumors that express a low level of HER3 mRNA have a better response to 
pertuzumab than those with higher HER3 mRNA levels. Makhija et al. observed that 
patients with low (< median) HER3 mRNA levels receiving pertuzumab and gemcitabine 
demonstrated better response rates than those receiving gemcitabine alone (p=0.0002) 
(Makhija et al., 2010). Kaye et al. reported that in patients with tumors expressing a low level 
of HER3 mRNA who had a treatment-free interval of 6–12 months, those receiving 
pertuzumab had a longer progression-free survival time compared with those who received 
chemotherapy alone; however, this difference was not statistically significant (hazard ratio 
0.55; p=0.16) (Amler, 2010; Kaye et al., 2008).  
3.4 Summary 
Preclinical data demonstrate that HER2 inhibitors reduce tumor cell signaling via HER2 in 
ovarian cancer cells and tumor models. In the clinic, a subset of patients with HER2-positive 
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ovarian tumors responds to HER2-targeted treatment. Studies by Makhija et al. and Kaye et 
al. suggest that measuring the HER3 mRNA level may help to identify a subset of patients 
with ligand-dependent activation of HER2 signaling pathways who may benefit from 
treatment with a combination of pertuzumab and chemotherapy.  
4. The future of the HER family as targets in oncology 
Clinical validation of HER2 as a relevant target in ovarian cancer opens up several 
possibilities for therapeutic development in this area. These include the use of HER family 
antibody conjugates, bispecific antibodies, and novel targeted combinations, all of which are 
likely to require advanced and clinically integrated biomarker strategies to identify 
appropriate patient subsets for treatment.  
HER2 antibodies can be conjugated with other anticancer drugs or radioactive entities to 
target chemotherapy and radiotherapy to cancerous cells that express HER2. Radiolabeled 
trastuzumab and pertuzumab have both been shown to delay tumor progression in mice 
with SKOV3 xenografts (Palm et al., 2007; Persson et al., 2007) and reduce the growth of 
SKOV3 cells in vitro (Heyerdahl et al., 2011), while trastuzumab–platinum (II) conjugates 
have been shown to increase SKOV3 cell death in vitro (Gao et al., 2008). Trastuzumab–DM1 
(T-DM1) conjugates enable the targeted delivery of the antimicrotubule agent DM1 to cancer 
cells overexpressing HER2. In a single-arm Phase II study of T-DM1 therapy, a response rate 
of 26% was observed in 112 patients with HER2-positive metastatic breast cancer (Burris et 
al., 2011). 
The bispecific, trifunctional antibody ertumaxomab, targets HER2 expressed on cancer cells 
and CD3 on T cells, and binds to Fcγ type I/III receptors via its Fc portion. In this way, 
ertumaxomab brings HER2-expressing cells into close contact with T cells and macrophages, 
facilitating antibody-dependent cellular cytotoxicity (ADCC) (Kiewe et al., 2006). In vitro 
studies have also demonstrated that ertumaxomab is able to kill cell lines with low HER2 
expression derived from breast, lung, and colorectal cancers, whereas trastuzumab had no 
cytotoxic effect in these cells (Jager et al., 2009). In a Phase I trial of ertumaxomab in patients 
with HER2-positive metastatic breast cancer, five of 15 patients experienced an antitumor 
response (Kiewe et al., 2006).  
Tumor cells commonly develop resistance to single-agent targeted therapies, thus 
combinations of agents that target different mechanisms of cell proliferation and survival 
often improve response compared with monotherapy alone. For example, the combination 
of trastuzumab with chA21 significantly reduced tumor size in mice with SKOV3 xenografts 
compared with antibody monotherapy (p<0.05) (A. Zhang et al., 2010). Similar results were 
observed with pertuzumab–trastuzumab combinations (Faratian et al., 2011) that have 
shown promise in the clinic (see Section 3.1) (Baselga et al., 2010). However, early clinical 
results for lapatinib and trastuzumab are not as promising. In a clinical trial of 282 patients 
with breast cancer, the combination of 1000 mg lapatinib with trastuzumab did not improve 
progression-free survival compared with 1500 mg lapatinib alone (16.3 versus 12.3 weeks; 
p=0.18) (Wu et al., 2011). Clinical trials of trastuzumab combined with pertuzumab (Baselga 
& Swain, 2010) and T-DM1 combined with pertuzumab (clinicaltrials.gov identifier 
NCT01120184) are ongoing in breast cancer. 
Therapies targeting HER2 can also be combined with EGFR inhibitors in order to block 
multiple signaling pathways. Addition of matuzumab, an EGFR inhibitor, to trastuzumab 
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was shown to reduce tumor progression in mice with SKOV3 xenografts to a greater extent 
than either antibody alone (Larbouret et al., 2007). The combination of trastuzumab or 
pertuzumab with another EGFR inhibitor, cetuximab, significantly inhibited cell growth in 
OVCAR-3 and IGROV-1 cells, although this effect was not observed in SKOV3 cells, 
possibly because of high basal levels of pERK and pAkt (Bijman et al., 2009). A combination 
of cetuximab and trastuzumab has also been shown to inhibit HER2–EGFR dimerization in 
SKOV3 cells, and this effect was shown to improve median survival and the percentage of 
tumor-free animals in a mouse model of ovarian cancer (Gaborit et al., 2011). 
To date, clinical trials of anti-HER2/EGFR combinations have only been performed in non-
ovarian cancer. Trastuzumab has been studies in breast cancer in combination with the 
EGFR inhibitors, gefitinib (Arteaga et al., 2008) and erlotinib (Britten et al., 2009). However, 
the trial of trastuzumab with erlotinib was terminated early, and the study with gefitinib 
showed increased toxicity with no apparent increase in the expected clinical benefit with 
trastuzumab monotherapy. Currently, there is one ongoing Phase I trial of trastuzumab with 
cetuximab in breast cancer (clinicaltrials.gov identifier NCT00367250). Trials are also 
underway to evaluate pertuzumab in combination with erlotinib or cetuximab in several 
types of cancer (clinicaltrials.gov identifiers NCT00947167, NCT01108458, NCT00855894, 
NCT00551421) and patients with CRC are being recruited for a trial of lapatinib in 
combination with cetuximab (clinicaltrials.gov identifier NCT01184482). 
Combining agents that target HER2 with inhibitors of downstream signaling pathway 
components, such as PI3K, mTOR, or MEK, may also lead to increased clinical activity. A 
preclinical study investigating the PI3K inhibitor PKI-587 demonstrated tumor regression in 
xenograft models of breast cancer, which was enhanced when PKI-587 was combined with 
the dual HER2/EGFR tyrosine kinase inhibitor neratinib or a MEK inhibitor, PD0325901 
(Mallon et al., 2011). A number of clinical trials are underway in breast cancer to investigate 
the efficacy of combining trastuzumab with PI3K inhibitors, including BKM120 
(clinicaltrials.gov identifier NCT01132664) and XL-147 (clinicaltrials.gov identifier 
NCT01042925), as well as the combination of neratinib and temsirolimus, an allosteric 
mTOR inhibitor (clinicaltrials.gov identifier NCT01111825). 
Preclinical and early clinical data suggest that targeting HER3 directly may also be 
therapeutically relevant in several types of cancer, including ovarian. The HER3 monoclonal 
antibody MM-121 has been shown to inhibit ovarian tumor growth in vivo (Sheng et al., 
2010) and in vitro studies of another antibody, MM-111, have demonstrated that it inhibits 
cell growth alone and in combination with lapatinib (Oyama et al., 2010) and trastuzumab 
(Huhalov et al., 2010). A Phase I trial of U3-1287 in 31 patients with solid tumors, including 
one patient with ovarian cancer, showed that 26% of patients achieved stable disease for 
≥70 days (Berlin et al., 2011). These antibodies are undergoing early-stage clinical testing in 
combination with other agents including HER2 and EGFR inhibitors (clinicaltrials.gov). 
MEHD7945A a dual-specific antibody targeting HER3 and EGFR has also shown in vivo 
activity in an ovarian xenograft model suggesting a potential benefit of combined inhibition 
of ErbB members (Schaefer et al., 2011).   
4.1 The future use of biomarkers in ovarian cancer 
Preclinical and clinical data suggest that amplification and overexpression of HER2 protein 
or mRNA, while infrequent, clearly exists in some ovarian tumors. Treatment with 
trastuzumab or a HER2 antibody–drug conjugate could be a potential option for these 
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trastuzumab or a HER2 antibody–drug conjugate could be a potential option for these 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
302 
patients. Rare mutations in the HER2 gene may be of particular relevance in ovarian LMP 
tumors where mutations in the BRAF and KRAS oncogenes are also common (see Section 
2.2) (Anglesio et al., 2008). LMP tumors are usually treated successfully with surgery; 
however treatment options are limited in patients who relapse following surgery as this 
tumor type does not respond well to currently available chemotherapy. Further clinical 
evaluation with agents that inhibit HER2 signaling, such as lapatinib or trastuzumab, are 
warranted to determine the benefit of these agents to patients with progressed LMP lesions.  
Based on the available data, it appears that ligand-dependent activation of HER2 signaling 
could be a more important mechanism for HER2 oncogenesis in ovarian cancer. Expression 
of pHER2 or HER3 may also be biomarkers that could identify tumors with oncogenic 
ligand-dependent HER2-activation. Further studies with inhibitors of HER2 dimerization, 
such as pertuzumab, will be useful in assessing their clinical potential in patients with 
ligand-dependent activation of the pathway.  
5. Conclusion 
Targeting HER2 with trastuzumab and lapatinib has proven successful in treating HER2-
positive breast cancer. Other molecules, such as pertuzumab, are in advanced clinical 
development for the treatment of this indication, further validating the clinical relevance 
and importance of this target. In contrast to breast cancer, in which HER2 is overexpressed 
in up to 30% of cases, a much lower proportion of ovarian tumors show activation of HER2 
by this mechanism. Nonetheless, trials of HER2-targeted agents in patients identified with 
HER2-positive ovarian tumors have shown improved progression-free survival and overall 
survival in a small proportion of patients. 
Importantly, there are patients with ovarian tumors with no evidence of HER2 amplification 
or overexpression, but in whom HER2-targted therapeutics appear to be beneficial. In these 
patients, activating mutations in HER2 or high levels of ligand-dependent activation of 
HER2/HER3 signaling may play a more important role in mediating HER2 oncogenesis. 
Identifying these patients through the use of novel biomarkers, such as assessment of HER3 
mRNA levels, could significantly improve the clinical benefit of HER2-targeted therapies in 
this setting. 
In conclusion, the use of targeted HER2 therapies in ovarian cancer warrants further 
investigation, particularly with regard to the development and validation of appropriate 
diagnostic tests. 
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patients. Rare mutations in the HER2 gene may be of particular relevance in ovarian LMP 
tumors where mutations in the BRAF and KRAS oncogenes are also common (see Section 
2.2) (Anglesio et al., 2008). LMP tumors are usually treated successfully with surgery; 
however treatment options are limited in patients who relapse following surgery as this 
tumor type does not respond well to currently available chemotherapy. Further clinical 
evaluation with agents that inhibit HER2 signaling, such as lapatinib or trastuzumab, are 
warranted to determine the benefit of these agents to patients with progressed LMP lesions.  
Based on the available data, it appears that ligand-dependent activation of HER2 signaling 
could be a more important mechanism for HER2 oncogenesis in ovarian cancer. Expression 
of pHER2 or HER3 may also be biomarkers that could identify tumors with oncogenic 
ligand-dependent HER2-activation. Further studies with inhibitors of HER2 dimerization, 
such as pertuzumab, will be useful in assessing their clinical potential in patients with 
ligand-dependent activation of the pathway.  
5. Conclusion 
Targeting HER2 with trastuzumab and lapatinib has proven successful in treating HER2-
positive breast cancer. Other molecules, such as pertuzumab, are in advanced clinical 
development for the treatment of this indication, further validating the clinical relevance 
and importance of this target. In contrast to breast cancer, in which HER2 is overexpressed 
in up to 30% of cases, a much lower proportion of ovarian tumors show activation of HER2 
by this mechanism. Nonetheless, trials of HER2-targeted agents in patients identified with 
HER2-positive ovarian tumors have shown improved progression-free survival and overall 
survival in a small proportion of patients. 
Importantly, there are patients with ovarian tumors with no evidence of HER2 amplification 
or overexpression, but in whom HER2-targted therapeutics appear to be beneficial. In these 
patients, activating mutations in HER2 or high levels of ligand-dependent activation of 
HER2/HER3 signaling may play a more important role in mediating HER2 oncogenesis. 
Identifying these patients through the use of novel biomarkers, such as assessment of HER3 
mRNA levels, could significantly improve the clinical benefit of HER2-targeted therapies in 
this setting. 
In conclusion, the use of targeted HER2 therapies in ovarian cancer warrants further 
investigation, particularly with regard to the development and validation of appropriate 
diagnostic tests. 
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1. Introduction 
Patients who are diagnosed with cancer are mainly concerned about the chance of being 
cured. Long-term aspects of quality of life seem second rate at this moment due to the fear 
of death and sickness and the patient´s urgent desire to survive. Interests or aims in life, 
which were important before the diagnosis of a life threatening disease can be completely 
changed. Doctors tend to concentrate on the necessary therapeutic steps and do not want to 
overrun the patient with assumed “unimportant” information e.g. the influence of the 
disease and treatment on sexual function.  
Approximately 10% of patients get confronted with ovarian cancer when they are 
premenopausal (Edmondson et al. 2001). Also for older patients an active sexual life can be 
important and might be impaired by the disease and therapy (Braehler et al. 1994).  
Sexuality can imply different things to different people, the extent to which patients are 
affected varies significantly, and health care professionals should assess each patient 
carefully according to her needs (Jefferies et al. 2004, Aerts et al. 2009). 
In an evaluation by Stead, although most health care professionals thought that the majority 
of women with ovarian cancer would experience a sexual problem, only one out of four 
doctors and one of five nurses discussed sexual topics with their patients. Reasons for not 
addressing these problems included embarrassment, lack of knowledge of the topic, lack of 
experience discussing the topic and lack of resources, such as professionals with training in 
sexual medicine to provide support, if needed (Stead et al. 2003, Hasenburg et al. 2011). 
Important elements of quality of life may be affected by ovarian cancer. The impact of the 
disease on sexuality is determined by multiple factors. Not only can the diagnosis and 
treatment of ovarian cancer cause sexual problems, but also psychological distress, 
vulnerable body image and an altered relationship with a partner can diminish overall 
sexual well-being (Sadovsky et al. 2009).  
For example, 62% of patients complain of dyspareunia and 75% of orgasmic dysfunction 
after therapy for ovarian cancer (Taylor et al. 2004). The significance of radical pelvic and 
para-aortal lymph node dissection with regard to sexual arousal disorders is not yet well 
defined. Depending on the patient´s individual history and present circumstances in life 
(married, single etc.) these effects can differ considerably.  
A small percentage of patients desire pregnancy. They are especially affected. Only in 
selected cases a fertility preserving therapy can be offered. Patients with borderline 
tumors of the ovary have a much better overall survival but often still need a bilateral 
salpingo-oophorectomy with long-term consequences (GCP Guideline on ovarian cancer 
2007, in German).  
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experience discussing the topic and lack of resources, such as professionals with training in 
sexual medicine to provide support, if needed (Stead et al. 2003, Hasenburg et al. 2011). 
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after therapy for ovarian cancer (Taylor et al. 2004). The significance of radical pelvic and 
para-aortal lymph node dissection with regard to sexual arousal disorders is not yet well 
defined. Depending on the patient´s individual history and present circumstances in life 
(married, single etc.) these effects can differ considerably.  
A small percentage of patients desire pregnancy. They are especially affected. Only in 
selected cases a fertility preserving therapy can be offered. Patients with borderline 
tumors of the ovary have a much better overall survival but often still need a bilateral 
salpingo-oophorectomy with long-term consequences (GCP Guideline on ovarian cancer 
2007, in German).  
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This chapter will elucidate the impact of ovarian cancer and the necessary therapy on 
women´s quality of life and sexuality and will give helpful recommendations how treating 
physicians can include this aspect. The aim of this article is to call attention to the subject of 
sexual function in cancer patients and to provide management strategies. The general and 
disease-specific changes of sexual function caused by oncologic therapies are outlined.  
2. Ovarian cancer (OC) therapy 
Apart from the psychological aspects of the diagnosis, there are many physical changes due 
to OC therapy. OC still being the most aggressive tumor of the female genital tract is a very 
severe threat to the woman´s life and in many cases it cannot be cured. Due to the lack of 
screening possibilities, OC in most cases is diagnosed at an advanced stage (Jemal et al. 
2010). State of the art treatment includes optimal tumor debulking with a following 
combination therapy of taxol and carboplatinum (GCP Guideline on ovarian cancer 2007, in 
German). Overall survival with this therapy has been mostly unchanged over the years and 
is the worst among gynaecological tumors (Jemal et al. 2010). In advanced stages the five 
year survival does not exceed 40% (Hanker et al. 2010) Therapy is long and strenuous but it 
is the only chance for cure. After relapse, many patients have to live with ovarian cancer as a 
chronic disease for many years, but most of the time they are under therapy. Therefore, 
aspects of quality of life are of major importance. 
2.1 Surgical therapy: Influence on sexuality 
It is widely accepted that the radicality of the surgical approach increases the chance of the 
patient to be cured (Bristow et al. 2002). Optimal tumor debulking should be the goal of 
every surgery. The surgical approach for OC comprises a longitudinal laparotomy from the 
symphysis to the xyphoid, hysterectomy, bilateral salpingoophorectomy, infragastric 
omentectomy, pelvic and paraaortal lymphadenectomy and, if necessary bowel resection 
etc. (GCP Guideline on ovarian cancer 2007, in German). The operation results in a sudden 
onset of menopause in premenopausal patients, but also has negative side effects on the 
sexuality of postmenopausal patients. Thus, prior to therapy, it is important to inform the 
patient about all possible side effects including those on sexual function. Many patients will 
experience the side effects of their therapy without prior counselling in the course of their 
disease.  
After therapy of ovarian cancer, 75% of patients have difficulties to reach orgasm (Taylor et 
al. 2004). It has not been clarified whether this results from the severity of the disease, the 
chemotherapy or from the pelvic and para-aortic lymphadenectomy. The latter could cause 
damage to the autonomic nerves, comparable to prostate cancer surgery in men (Madeb et 
al. 2007). A current study from the “AGO-Ovar” (working group on gynecological 
oncology) is supposed to resolve this question: the LION-PAW study, a substudy of the 
LION Study (Lymphadenectomy In Ovarian Neoplasm) – (PAW = Pleasure Ability of 
Women), has the aim to clarify to which extent a radical lymphadenectomy affects the 
women's sexual function (ClinicalTrials.gov Identifier: NCT00712218). 
If the patient seems to be dissatisfied with her sexual life, it has to be evaluated whether she 
suffers from a hypoactive sexual desire disorder (HSDD, American Psychiatric Association, 
1987), which is defined as a deficiency or absence of sexual fantasies and desire for sexual 
activity. There is little initiative on the patient´s side, and sexual intercourse is rare. Stead 
(2003) and Taylor (2004) reported a prevalence of HSDD between 47% and 67% in clinical 
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studies of ovarian cancer patients. Interestingly, Raboch et al. (1985) even saw a decrease of 
libido of 42% and of sexual intercourse of 30% in women after hysterectomy and salpingo-
ophorectomy for benign causes. Therefore it seems that sexual problems are mainly 
influenced by the salpingo-oophorectomy and the following loss of hormone production 
and are not only due to the diagnosis of cancer. 
A large study about sexual activity in patients after ovarian cancer therapy was performed 
by Taylor et al. (2004) at the MD Anderson Cancer Center. Patients who contacted the center 
during or after ovarian cancer therapy filled in the Sexual Activity Questionnaire (SAQ). 
This questionnaire comprises questions about pleasure, arousal, orgasm or sexual activity in 
general. 50% of the 233 women, who were included, were sexually active at least once a 
month, especially if they were married (p < 0.001) and under 56 years of age (p< 0.001) and 
did not receive cancer specific therapy at this time. Identification with the own body also 
had a positive impact on sexual activity (p < 0.004). 80% of the sexually active women 
reported vaginal dryness, 40% very strong. 62% complained about pain or discomfort 
during intercourse. 75% had problems with orgasm, a third of the women almost always. 
Correlating these results with the physical performance status of the women, lower sexual 
activity correlated with low performance status and depressive disorders. Regarding 
vaginal dryness and problems with penetration there was no difference whether the patients 
were currently under therapy or not. Those patients who were sexually inactive had the 
following reasons for being inactive: 44% missing partner, 38% lack of interest, 23% physical 
problems, 10% suffered from the fatigue syndrome (Taylor et al. 2004).  
Aerts et al. showed in a retrospective study of fifty women after pelvic surgery for 
gynaecological cancer that significantly more patients reported sexual problems than controls 
(83% vs 20%), including decreased desire and impaired vaginal lubrication. Pelvic surgery was 
specifically related to changed intensity of orgasm, reduced vaginal sensitivity and elasticity, 
dyspareunia and vaginal narrowing and shortening (Aerts et al 2009, Hasenburg et al. 2011). 
2.2 Chemotherapy: Influence on sexuality 
Chemotherapy or, in advanced stages, anti-hormonal therapy are a very important part of 
ovarian cancer therapy. Side effects such as the fatigue syndrome in at least 10% of the 
women or coexisting depressive disorders are common in 21-25% of the patients and may 
additionally affect the sexual life of a patient (Taylor et al. 2004, Arden-Close et al. 2008, 
Reich et al. 2008). Other side effects are nausea and vomiting, weight loss, and also pain 
(Oskay-Oezcelik et al. 2010). Obviously, in this situation, sexual life becomes less important. 
But even if the woman does not suffer from a lack of desire, a changed body image due to a 
long scar on her abdomen or more importantly alopecia may make her feel less attractive. 
Also with her long-term partner she may be uncomfortable and afraid to present herself. 
3. Special patient groups 
3.1 The premenopausal patient 
Cancer affecting young women prior to completing family planning represents a struggle 
for the patient and her partner as well as for the caring physician. Cancer treatment does not 
only impair sexual function and body image, but also the reproductive function with a 
premature menopause, e.g. the onset of menopause before the age of 40 (Beckmann et al. 
2006). Women who are premenopausal at the time of diagnosis are especially affected as the 
physical changes are more pronounced than in older patients. A sudden onset of 
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menopause has a much higher occurrence of depression, hot flashes and other 
postmenopausal symptoms than in the natural course of menopause (Gupta et al. 2006). 
Patients may experience premature menopause including symptoms such as mood swings, 
hot flashes, libido loss and insufficient lubrication. Therefore, a hormone replacement 
therapy should be recommended (Michaelson-Cohen et al 2009). 
A fertility conserving approach is possible for selected patients with early stage ovarian 
cancer and with germ cell tumors of the ovary (Gershenson et al. 2007, Wright et al. 2009). 
However, young patients are often faced with the fact that fertility cannot be preserved and 
the wish to have children cannot be fulfilled. Aims in life have to be changed and the whole 
concept of life has to be reconsidered. In this situation sexuality at first sight is out of focus.  
Especially for women, who were either planning to have children or had not given family 
planning much thought yet, especially if they were single at the time of diagnosis, it is the 
clinician’s responsibility to communicate the cancer-associated issues but also the 
consequences the therapeutic interventions may have on the patient’s fertility. A 
multidisciplinary approach is necessary and the patient should be advised to visit a fertility 
centre prior to therapy initiation. Information about different fertility preservation options 
and contact data of fertility centres can be obtained from the network FertiPROTEKT 
(www.fertiprotekt.de, in German). 
The emotional and physical impact of loss of fertility can be complex and long lasting for 
women, who are experiencing high levels of distress, menopausal symptoms, and changes 
in sexual function persisting into survivorship. Alternative family-building strategies like 
adoption have to be explored before and/or during treatment (Carter et al. 2010). Especially 
for these patients psycho-oncological counselling should be offered (Hasenburg et al. 2011). 
3.2 Borderline tumors of the ovary (BOT) 
Patients with borderline tumors of the ovary have a much better prognosis and a higher 
chance of being cured than patients with ovarian cancer. Therefore, the long-term aspects of 
therapy are especially important. Most of the patients do not receive chemotherapy, but in 
most cases both ovaries and the uterus have to be removed (Cadron et al. 2009). For some 
cases, a fertility preserving operation is possible, but close follow-up is necessary. 
3.3 Palliation 
Even with the therapeutic progress for ovarian cancer during the last decade, most patients 
with advanced disease cannot be cured and often live in a palliative situation for months 
and years. They receive chemotherapy with the possible side effects of fatigue syndrome, 
sleeping disorders, nausea and vomiting, depression etc. which are additionally aggravated 
by the consuming disease itself.  
The idea of palliation is to maintain quality of life with all aspects as long as possible. Just 
because a patient has a life threatening disease does no imply that she does not longer wish 
to live her sexual feelings or to convey expressions of her sexuality (Jefferies et al. 2004). 
The importance of sexuality even in a palliative situation was recently described by Vitrano 
et al. (2011). 65 patients admitted to an acute pain relief or palliative care unit were asked 
about the role of sexuality in their lives. The patients had a mean Karnofsky index of 58 
(range 40-70) and a mean well-being sensation of 5.67 (range 2-10). In summary, 60% of 
patients did not feel to be less attractive with their disease, 30% of patients felt a little, and 
only 10% very much less attractive. Most patients (86.4%) considered a dialogue about 
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sexuality and to face such an issue with skilled people as important. About half of the 
patients (47%) reported that sexuality was very important for their psychological well-being. 
Only 7.6% of patients had satisfactory sexual intercourse, 15.2% had little activity, 39.4% had 
an insufficient activity, and 37.8% did not have any activity. A significant relationship was 
observed with age (p= 0.002), Karnofsky status (p = .024), and well-being (p = .004). Only 
12.1% of patients were sexually satisfied, 12.1% experienced a mild satisfaction, 30.3% had 
insufficient satisfaction, and 45.5% had no sexual satisfaction. Only 3% of patients had a 
satisfactory frequency of intercourse, 45.5% had a low or limited frequency, and 51.5% had 
no sexual intercourse. For 50% of the patients emotional aspects were very important and 
for 12.1% important. The emotional aspects had a relevant role in sexuality, possibly as a 
surrogate of impaired physical activity (Vitrano et al. 2011). This survey clearly shows the 
ongoing importance of maintaining sexual life, even in a palliative situation.  
Understanding palliation “as making life easier” and more valuable for a person with a non-
curable disease, is an important mission.  
4. Changes due to therapy (surgery and chemotherapy) 
4.1 Impairment of body image  
Treatment of ovarian cancer is multimodal, which makes it necessary to differentiate 
between the side effects of the various therapeutic interventions. Stigmata may be obvious 
to others like alopecia, scars, a preternatural anus or a urostomy. These can greatly alter the 
patient's body image and self-esteem. The patient’s situation before the disease - whether 
the integrity of the body has been an important aspect for the woman - may have an impact 
on the coping process.  
Somatic and psychological problems of sexual dysfunction are difficult to differentiate and are 
inter-dependent. If the patient manages to accept the disease and the associated physical 
changes, it is easier for her to return to a satisfactory quality of life including sexual function. 
The mental situation of the patient can be especially impaired, if there had been psychological 
injuries or traumata in the past, which can be reactivated during her course of the disease, 
especially if there is a lack of help by the partner, family or friends (Hasenburg 2008).  
A partner can often be affected by helplessness and passivity. Due to false considerations, 
the couple might not talk about these issues, thus, a vicious circle may develop (see Fig. 1). 
On the other hand, the disease can be used as a chance to intensify the relationship 
(Rowland et al. 2009).  
4.2 Psychological problems 
A co-existing depression should be thoroughly assessed. Approximately one out of four 
cancer patients has any type of depression and at least half of those are willing to accept 
professional help or referral for this issue (Curry et al. 2002, Passik et al. 1998).  
It might be difficult to differentiate between a fatigue syndrome or depressive symptoms. 
Patients suffering from depression should be offered antidepressive therapy. Some of the 
antidepressive agents can induce a lack of desire, but a severe depression can also impair 
sexual functioning. Specific pharmacotherapy may be necessary and the depression should 
not be treated with hormones alone. Often it is sufficient to take the antidepressive 
medication for a few weeks and both the mental situation as well as the sexual desire can 
improve over the course of treatment. If overall well-being increases, sexual life and the 
relationship may experience benefit (Hasenburg et al. 2008).  
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to intend to have a child is difficult due to the fear of recurrence (Bhatti et al. 2011).  
Glantz et al. (2009) described that the risk of being abandoned by the partner after surviving 
a severe disease is especially higher for women (20.8%) than for men (2.9%). When 
counselling a patient with cancer, the partner should not be neglected, who often does not 
know how to support his wife. This may lead to misunderstandings, and a vicious cycle. As 
reported by Hasenburg et al. (2011) women with gynaecological cancer often report being 
fearful of signalling (unintentionally) a desire for sexual intimacy, when they are merely 
attempting to create emotional proximity in their partner relationship. In order to avoid this 
miscommunication, women distance themselves from their wish for emotional intimacy, 
often resulting in an increased sense of loneliness during illness and the period of recovery, 
and hence reduced quality of life. Most women would also have appreciated their partner 
being informed about the possible side-effects on sexuality and partner relationship (Corney 
et al. 1994). Raising the topic of psychological, relational and sexual functioning by health 
care providers could help to ease the way for a more freely flowing discussion of this topic 
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opportunity to improve their coping strategies and reduce anxiety (Janda et al. 2004). 
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The aspect of sexual minority women (SMW) like patients with homosexual relationships 
should not be ignored. There has been some research in this field, and the review of 
Boehmer et al. (2009) indicated that partnerships of SMW are not directly comparable with 
heterosexual ones. It seems that SMW may experience less disruption in their sexual 
relationships like fewer sexual problems such as decreased lubrication, reduced quality and 
quantity of orgasm, impaired body image, and experience more understanding and 
supportive partners compared to heterosexual women (Boehmer et al. 2009). However, in 
SMW there can be problems to obtain information and support from medical professionals 
with respect to sexual functioning. Sexual functioning may be worse among subgroups of 
sexual minority women (Boehmer et al. 2009). For example, Mc Gregor found that 
internalized homophobia was associated with a higher level of distress in lesbians with 
breast cancer (Mc Gregor et al. 2001). 
5. What can the physician do? 
Counselling ovarian cancer patients about sexuality, the first step is to evaluate the 
patient´s sexual life before the onset of the disease. Cancer and cancer treatment can 
exacerbate former sexual function problems and can also create new ones. As sexual 
dysfunction may be present in healthy individuals, these issues can often be overlooked 
initially. Awareness of these potential problems will help the patient to adapt to post 
treatment difficulties such as fatigue syndrome, and body image impairment by the above 
mentioned reasons. A pretreatment discussion of sexuality and intimacy provides a 
baseline for comparison with the subsequent re-evaluation during and after treatment 
(Grzankowski 2011).  
People have different opinions about what is normal, so the doctor has to evaluate whether 
the patient has been satisfied with her sexual life in the past. Questions like “Has anything 
changed in your sexuality after the diagnosis of your disease?” are very helpful to ascertain 
if there is any need to go deeper into this topic. Asking “How were your sexual desires 
recently? How was it on your partner´s side?” also help to start talking. For some patients 
the cancer diagnosis can even be used as an excuse to refrain from being sexually active, 
they therefore refuse professional help (Hasenburg et al. 2011). 
According to the Pfizer Global Study (2002) 80% of cancer patients would like to have 
more information about the impact of their illness and subsequent therapy on their 
sexuality. 91% of the cancer patients were afraid to ask their treating physician about 
sexual problems, and even 97% of the doctors did not inform their patients about possible 
sexual dysfunction. These findings emphasize that there is a great need for intensive 
training in communication skills. Physicians have to learn how to actively approach this 
distressing issue. Furthermore they have to be aware that the way of addressing sexual 
problems and counselling might be influenced by their own sexual experience 
(Hasenburg et al. 2008). When talking about sexuality issues, the doctor should try to find 
the patients language and wording, so that it is easier for her to talk about these problems. 
Medical technical terms should be avoided, if possible.  
For women, sexuality might stand for intimacy and tenderness, instead for sexual 
intercourse only. The treating physician has to identify the special problem for each 
woman and can help her to cope with losing sexual and erotic potency (Hasenburg et al. 
2008).  
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It is of major importance to sensitize physicians working with ovarian cancer patients to the 
issues of quality of life and sexuality. Each patient has to be informed about the long-term 
consequences of the disease and the scheduled therapy. Although sexuality is a taboo 
subject, the potential long-term consequences of oncological therapy on sexual function, 
possibly on fertility and quality of life have to be considered and discussed with the patient. 
Patients need to understand that problems in sexual function do not imply a general failure 
of the person. 
The doctor has a role-model function and should address these issues frankly, making it 
clear to the patient that sexuality is an important aspect of quality of life. A special training 
in sexual medicine may be helpful but it is not mandatory.  
5.1 Hormone Replacement Therapy (HRT) 
The role of hormone replacement therapy is often controversially discussed (Jefferies et al. 
2004, Mørch et al. 2009). After ovarian cancer therapy, premenopausal patients are likely to 
suffer from premature onset of menopause, while postmenopausal patients may suffer from 
libido loss. Sudden onset of menopause can cause more severe symptoms such as 
postoperative depressive episodes, hot flashes, mood changes and long-term consequences 
such as osteoporosis or sexual dysfunction due to sudden hormone deprivation than the 
gradually beginning menopause. This implies that in these patients a hormone replacement 
therapy should be considered and discussed even prior to surgery.  
In older patients a reduction of desire can be due to the lack of androgens after bilateral 
salpingo-oophorectomy. The stromal cells and the hilar interstitial cells in the ovaries are 
essential for the synthesis of androgens (testosterone and androstendione) which, among 
other factors, preserve a woman’s libido after menopause (Fogle et al. 2007). Thus, the side 
effects of cancer treatment on the gonads can hurt all age groups. Androgens can be 
replaced by transdermal testosterone substitution (Buster et al. 2005, Davis et al. 2008). In 
the study of Shifren et al. (2009) a significant rise in sexual interest and activity could be 
shown after androgen replacement for women after hysterectomy and bilateral salpingo-
oophorectomy for benign disease. However, oncological safety is yet unclear and androgen 
replacement can not be recommended up to now. 
Estrogen substitution is important to ameliorate hot flashes, osteoporosis, vaginal dryness 
and other postmenopausal symptoms. The largest study on this topic from Sweden on 649 
patients with OC and 150 with borderline tumors of the ovary, aged between 50 and 74 
years showed that neither pre- nor postoperative HRT affected overall survival, nor the 
kind of HRT administered (multivariate hazard ratio = 0.57; 95%-CI: 0.42-0.78), 
(Mascarenhas et al. 2006). In a second study of postmenopausal patients with ovarian 
cancer, HRT treatment was also not associated with an increased risk of recurrence 
(Michaelson-Cohen et al. 2009).  
As an alternative to orally administered HRT, estradiol can be substituted with oestrogen 
patches or a vaginal ring (Estring®). The systemic effects with the latter are reduced while 
local oestrogen effects are sufficient (Henriksson et al. 1996). Serum levels are higher with 
oestrogen patches than with the vaginal ring (Gupta et al. 2008). In ovarian cancer, there is 
no contraindication for local oestrogen therapy (GCP Guideline on ovarian cancer 2007, in 
German). 
If the quality of life is reduced due to oestrogen deprivation secondary to ovarian cancer, 
hormone therapy with sex steroids can be initiated after a careful risk-benefit assessment 
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(Michaelson-Cohen et al. 2009). In patients with an endometrioid histology, low-dose-
oestrogens should be combined with a progesterone therapy (GCP Guideline on ovarian 
cancer 2007, in German).  
5.2 Alternatives for HRT  
For patients suffering from postmenopausal symptoms with a contraindication against HRT 
or who refuse HRT, there are alternative therapeutic options. The main symptoms need to 
be identified, so these can specifically be addressed.  
There is a great choice of herbal and homeopathic medicines with a significant placebo 
effect leading to a reduction of postmenopausal symptoms in up to 20% of the patients 
(Tempfer et al. 2007). However, alternative drugs should not be taken without medical 
advice. The risks and side effects of these medications have not been completely 
investigated. Food supplements containing isoflavone in soy or red clover could slightly 
improve hot flashes (GCP guideline on hormone replacement therapy by the German 
Society of Gynecology & Obstetrics, in German; Wuttke et al. 2008, Haimov-Kochmann et 
al. 2008).  
In order to prevent osteoporosis in premenopausal patients with a sudden onset of 
menopause vitamin D (1000 IE/d), a daily supplement of calcium (1500mg/d), physical 
exercise and abstinence from nicotine are recommended (GCP guideline on osteoporosis 
2009, in German). In patients with preexisting osteoporosis bisphosphonates should be 
administered (Reid 2009). 
5.3 Pharmaceutical alternatives 
If hot flashes and sleep disorders persist, antidepressants can be an option (selective 
serotonin reuptake inhibitors, SSRI) (Bordeleau et al. 2010). With e.g. 75 mg venlafaxine 
daily a reduction of hot flashes of approximately 60% was observed compared to 20% with 
placebo (Pachman et al. 2010). Another possibility are anticonvulsive (e.g. gabapentin) or 
antihypertensive agents (clonidin, methyldopa) (Hall et al. 2011).  
A survey of the medications showed the following reductions of hot flashes (Sideras et al. 
2010): 
 Venlafaxine: 33% reduction of symptoms; 37.5 bis 75mg/d 
 Paroxetine: 41% reduction of symptoms; 20mg/d 
 Fluoxetine: 13% reduction of symptoms; 20mg/d 
 Sertraline: 3 to 18% reduction of symptoms, 50mg/d 
 Gabapentin: 45 to 50% reduction of symptoms, 900mg/d 
5.4 Vaginal dilators 
Patients who have undergone surgical shortening of the vagina, radiation therapy of the 
pelvis or brachy-therapy should be informed about the available treatment options for 
vaginal strictures or adhesions to preserve the patient’s ability for cohabitation. These 
include the use of vaginal dilators or bepanthen tampons which can be combined with 
oestrogen-containing lotions or lubricants. Treatment can be initiated four to six weeks after 
therapy (GCP Guideline on diagnosis and therapy of cervical cancer 2008, in German). It is 
important to use the vaginal dilators regularly (e.g. Dilator Set®), even if the patient is not in 
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a relationship, because dilatation becomes increasingly difficult with time. Accompanying 
pelvic floor muscle training can be recommended and results in gain over muscle 
identification, control and strength (Derzko et al. 2007). Possible fears of the patient such as 
manipulating her own genitals or resuming of sexual intercourse should be actively 
discussed.  
6. Conclusion  
The potential impact of ovarian cancer therapy such as surgery, chemotherapy or even 
radiation therapy on sexual function and fertility needs to be discussed with each patient. 
Even for women in a palliative setting, sexuality and intimacy should be an issue.  
Impaired sexual function after treatment of ovarian cancer is a common problem and 
represents a significant limitation of quality of life. While for younger patients infertility and 
early postmenopausal symptoms may be of major concern, postmenopausal women might 
consider the loss of the remaining androgen function of the ovaries as most striking. The 
significance of radical pelvic and para-aortic lymphadenectomy for sexual function remains 
unclear.  
Local or systemic oestrogen therapy subsequent to treatment of ovarian cancer is considered 
an adequate treatment of postmenopausal symptoms. Apart from symptomatic therapy, 
physical interventions (e.g. physiotherapy) and physical activity should be included as 
supportive actions. For patients with an underlying depressive condition an antidepressive 
medication should be taken into account, even if only for a limited time. 
Health care providers have a model function when discussing therapy-induced changes of 
sexual function and should regard sexuality as an essential element of quality of life. 
Therefore, the possible treatment side effects, including therapeutic or preventive options, 
and the quality of life after cancer must be discussed with the patient prior to therapy 
initiation. By understanding that sexuality is an important and normal aspect of life and 
not a “luxury issue” even for patients with a non-curable disease, treating physicians can 
support their patients and help them to maintain a good or at least acceptable quality of 
life. 
7. GCP guidelines 
1. Interdisciplinary guideline of the German Cancer society and the German Society of 
Gynecology and Obstetrics on diagnosis and therapy of malignant ovarian tumors. In 
German, 2007. www.awmf.org/leitlinien/detail/ll/032-035.html 
2. Interdisciplinary guideline of the German Cancer society and the German Society of 
Gynecology and Obstetrics on diagnosis and therapy of cervical cancer. In German, 
2008. www.awmf.org/leitlinien/detail/ll/032-033.html 
3. Interdisciplinary guideline of the German Osteoporosis Society on prophylaxis, 
diagnosis and therapy of osteoporosis. In German, 2009. 
ww.awmf.org/leitlinien/detail/ll/034-003.html 
4. Interdisciplinary guideline of the German Society of Gynecology and Obstetrics on 
hormone therapy in peri- and postmenopausal women. In German, 2009. 
ww.awmf.org/leitlinien/detail/ll/ 015-062.html 
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a relationship, because dilatation becomes increasingly difficult with time. Accompanying 
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supportive actions. For patients with an underlying depressive condition an antidepressive 
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Health care providers have a model function when discussing therapy-induced changes of 
sexual function and should regard sexuality as an essential element of quality of life. 
Therefore, the possible treatment side effects, including therapeutic or preventive options, 
and the quality of life after cancer must be discussed with the patient prior to therapy 
initiation. By understanding that sexuality is an important and normal aspect of life and 
not a “luxury issue” even for patients with a non-curable disease, treating physicians can 
support their patients and help them to maintain a good or at least acceptable quality of 
life. 
7. GCP guidelines 
1. Interdisciplinary guideline of the German Cancer society and the German Society of 
Gynecology and Obstetrics on diagnosis and therapy of malignant ovarian tumors. In 
German, 2007. www.awmf.org/leitlinien/detail/ll/032-035.html 
2. Interdisciplinary guideline of the German Cancer society and the German Society of 
Gynecology and Obstetrics on diagnosis and therapy of cervical cancer. In German, 
2008. www.awmf.org/leitlinien/detail/ll/032-033.html 
3. Interdisciplinary guideline of the German Osteoporosis Society on prophylaxis, 
diagnosis and therapy of osteoporosis. In German, 2009. 
ww.awmf.org/leitlinien/detail/ll/034-003.html 
4. Interdisciplinary guideline of the German Society of Gynecology and Obstetrics on 
hormone therapy in peri- and postmenopausal women. In German, 2009. 
ww.awmf.org/leitlinien/detail/ll/ 015-062.html 
 




[1] Aerts L, Enzlin P, Verhaeghe J et al. Sexual and psychological functioning in women 
after pelvic surgery for gynaecological cancer. European journal of gynaecological 
oncology. 2009;30: 652-6. 
[2] Arden-Close E, Gidron Y, Moss-Morris R. Psychological distress and its correlates in 
ovarian cancer: a systematic review. Psychooncology. 2008 Nov;17(11):1061-72. 
Review. 
[3] Bhatti Z, Salek M, Finlay A. Chronic diseases influence major life changing decisions: a 
new domain in quality of life research. J R Soc Med. 2011 Jun;104(6):241-50. 
[4] Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in 
surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105: 944-
952. 
[5] Boehmer U, Potter J, Bowen DJ. Sexual functioning after cancer in sexual minority 
women. Cancer J. 2009 Jan-Feb;15(1):65-9. 
[6] Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, Haq R, Goodwin 
PJ. Multicenter, randomized, cross-over clinical trial of venlafaxine versus 
gabapentin for the management of hot flashes in breast cancer survivors. J Clin 
Oncol. 2010 Dec 10;28(35):5147-52. Epub 2010 Nov 8. 
[7] Brähler E, Unger U. Sexual activity in advanced age in the context of gender, family 
status and personality aspects-results of a representative survey. Z Gerontol. 1994 
Mar-Apr;27(2):110-5.  
[8] Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of 
maximal cytoreductive surgery for advanced ovarian carcinoma during the 
platinum era: a meta-analysis. J Clin Oncol. 2002 Mar 1;20(5):1248-59. 
[9] Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of 
borderline ovarian neoplasms. J Clin Oncol. 2007 Jul 10;25(20):2928-37. Review. 
[10] Carter J, Goldfrank D, Schover LR. J Sex Med. Simple strategies for vaginal health 
promotion in cancer survivors. 2011 Feb;8(2):549-59. doi: 10.1111/j.1743-
6109.2010.01988.x. Epub 2010 Aug 16. 
[11] Carter J, Chi DS, Brown CL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Levine DA, 
Baser RE, Raviv L, Barakat RR. Cancer-related infertility in survivorship. Int J 
Gynecol Cancer. 2010 Jan;20(1):2-8. Review. 
[12] Corney RH, Crowther ME, Everett H et al. Psychosexual dysfunction in women with 
gynaecological cancer following radical pelvic surgery. British journal of obstetrics 
and gynaecology. 1993;100: 73-8. 
[13] Curry C, Cossich T, Matthews JP et al. Uptake of psychosocial referrals in an outpatient 
cancer setting: improving service accessibility via the referral process. Support Care 
Cancer. 2002;10: 549-55. 
[14] Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, 
Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J; APHRODITE 
Study Team. Testosterone for low libido in postmenopausal women not taking 
estrogen. N Engl J Med. 2008 Nov 6;359(19):2005-17. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
324 
[15] Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal 
breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 
2007 Dec;14 Suppl 1:S20-40. 
[16] Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol 
Cancer. 2001 Nov-Dec;11(6):423-9. Review. 
[17] Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in 
postmenopausal women. J Clin Endocrinol Metab. 2007 Aug;92(8):3040-3. Epub 
2007 May 22.  
[18] Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007; 25: 2938–
2943.  
[19] Glantz MJ, Chamberlain MC, Liu Q, Hsieh CC, Edwards KR, Van Horn A, Recht L. 
Gender disparity in the rate of partner abandonment in patients with serious 
medical illness. Cancer. 2009 Nov 15;115(22):5237-42. 
[20] Grzankowski KS, Carney M. Quality of life in ovarian cancer. Cancer Control. 2011 
Jan;18(1):52-8. Review. 
[21] Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for 
breast cancer: the prevalence and severity of symptoms and their perceived effects 
on quality of life. Climacteric 2006;9(1):49–58. 
[22] Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr. The effect of transdermal and 
vaginal estrogen therapy on markers of postmenopausal estrogen status. 
Menopause. 2008 Jan-Feb;15(1):94-7. 
[23] Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor 
symptoms: a critical review. Drugs. 2011 Feb 12;71(3):287-304. Review. 
[24] Hanker LC, Kaufmann M. Problematik des Ovarialkarzinoms: oft zu spät erkannt, oft 
untertherapiert. Gyn (15) 2010. 
[25] Hasenburg A, Amant F, Aerts L, Pascal A, Achimas-Cadariu P, Kesic V. Psycho-
Oncology: Structure and profiles of European centres treating patients with 
gynecological cancer. Int J Gynecol Cancer 2011, accepted. 
[26] Hasenburg A, Gabriel B, Einig E-M. Sexualität nach Therapie eines Ovarialkarzinoms. 
Geburtsh Frauenheilk 2008; 68: 994-997. 
[27] Henriksson L, Stjernquist M, Boquist L et al. A one year multi-center study of efficacy 
and safety of a continuous, low dose estradiol releasing vaginal ring (Estring) in 
postmenopausal women with symptoms and signs of urogenital aging. Am J 
Obstet Gynecol 1996; 174: 85–92.  
[28] Janda M, Obermair A, Cella D et al. Vulvar cancer patients' quality of life: a qualitative 
assessment. Int J Gynecol Cancer. 2004;14: 875-81. 
[29] Jefferies H, Groves J. In: Gynecologic Cancer: Controversies in Management. Edited by 
David Gershenson, McGuire and Gore von Churchill Livingstone. 2004, ISBN 0-
443-07142-X. 
[30] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-
Oct;60(5):277-300. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-
Apr;61(2):133-4. 
 
Sexuality After Ovarian Cancer Therapy 
 
325 
[31] Madeb R, Golijanin D, Knopf J, Vicente I, Erturk E, Patel HR, Joseph JV. Patient-
reported validated functional outcome after extraperitoneal robotic-assisted nerve-
sparing radical prostatectomy. JSLS. 2007 Oct-Dec;11(4):443-8. Review.  
[32] Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E. 
Use of hormone replacement therapy before and after ovarian cancer diagnosis and 
ovarian cancer survival. Int J Cancer. 2006 Dec 15;119(12):2907-15. 
[33] McGregor BA, Carver CS, Antoni MH, et al. Distress and internalized homophobia 
among lesbian women treated for early stage breast cancer. Psychol Women Quart. 
2001;25:1–9. 
[34] Michaelson-Cohen R, Beller U. Managing menopausal symptoms after gynecological 
cancer. Curr Opin Oncol. 2009 Jul 7. [Epub ahead of print].  
[35] Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone 
therapy and ovarian cancer. JAMA. 2009 Jul 15;302(3):298-305. 
[36] Oskay-Oezcelik G, Neubert S, Munstedt K, Liebrich K, Hanker LC, Lorenz R, 
Wimberger P, Mahner S, Hindenburg HJ, Sehouli J. What do primary and recurrent 
ovarian cancer (OC) patients expect from their doctors? Final results of a german 
survey in 676 patients. A Study of The North-Eastern German Society of 
Gynaecological Oncology (NOGGO). ASCO 2010. 
[37] Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor 
symptoms: Current treatment options, challenges and future directions. Int J 
Womens Health. 2010 Aug 9;2:123-35.  
[38] Passik SD, Dugan W, McDonald MV et al. Oncologists' recognition of depression in 
their patients with cancer. J Clin Oncol. 1998;16: 1594-600. 
[39] Raboch J, Boudnik V, Raboch Jr J. Sex life following hysterectomy. Geburtsh 
Frauenheilk 1985; 45: 48–50 
[40] Reid DM. Prevention of osteoporosis after breast cancer. Maturitas. 2009 Sep 20;64(1):4-
8. Epub 2009 Aug 25. 
[41] Sadovsky R, Basson R, Krychman M et al. Cancer and sexual problems. The journal of 
sexual medicine. 2009;7: 349-73. 
[42] Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in 
women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 
682–688 
[43] Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk 
reduction therapy. J Natl Compr Canc Netw. 2010 Oct;8(10):1171-9. 
[44] Sitruk-Ware R. Estrogen therapy during menopause. Practical treatment 
recommendations. Drugs 1990; 39: 203–217.  
[45] Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between 
healthcare professionals and women with ovarian cancer about sexual issues. Br J 
Cancer 2003; 88: 666–671 
[46] Taylor C. Predictors of sexual functioning in ovarian-cancer patients. J of Clin Oncol 
2004; 22: 881–889.  
[47] Vitrano V, Catania V, Mercadante S. Sexuality in patients with advanced cancer: a 
prospective study in a population admitted to an acute pain relief and palliative 
care unit. Am J Hosp Palliat Care. 2011 May;28(3):198-202. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
324 
[15] Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal 
breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 
2007 Dec;14 Suppl 1:S20-40. 
[16] Edmondson RJ, Monaghan JM. The epidemiology of ovarian cancer. Int J Gynecol 
Cancer. 2001 Nov-Dec;11(6):423-9. Review. 
[17] Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in 
postmenopausal women. J Clin Endocrinol Metab. 2007 Aug;92(8):3040-3. Epub 
2007 May 22.  
[18] Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007; 25: 2938–
2943.  
[19] Glantz MJ, Chamberlain MC, Liu Q, Hsieh CC, Edwards KR, Van Horn A, Recht L. 
Gender disparity in the rate of partner abandonment in patients with serious 
medical illness. Cancer. 2009 Nov 15;115(22):5237-42. 
[20] Grzankowski KS, Carney M. Quality of life in ovarian cancer. Cancer Control. 2011 
Jan;18(1):52-8. Review. 
[21] Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for 
breast cancer: the prevalence and severity of symptoms and their perceived effects 
on quality of life. Climacteric 2006;9(1):49–58. 
[22] Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr. The effect of transdermal and 
vaginal estrogen therapy on markers of postmenopausal estrogen status. 
Menopause. 2008 Jan-Feb;15(1):94-7. 
[23] Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor 
symptoms: a critical review. Drugs. 2011 Feb 12;71(3):287-304. Review. 
[24] Hanker LC, Kaufmann M. Problematik des Ovarialkarzinoms: oft zu spät erkannt, oft 
untertherapiert. Gyn (15) 2010. 
[25] Hasenburg A, Amant F, Aerts L, Pascal A, Achimas-Cadariu P, Kesic V. Psycho-
Oncology: Structure and profiles of European centres treating patients with 
gynecological cancer. Int J Gynecol Cancer 2011, accepted. 
[26] Hasenburg A, Gabriel B, Einig E-M. Sexualität nach Therapie eines Ovarialkarzinoms. 
Geburtsh Frauenheilk 2008; 68: 994-997. 
[27] Henriksson L, Stjernquist M, Boquist L et al. A one year multi-center study of efficacy 
and safety of a continuous, low dose estradiol releasing vaginal ring (Estring) in 
postmenopausal women with symptoms and signs of urogenital aging. Am J 
Obstet Gynecol 1996; 174: 85–92.  
[28] Janda M, Obermair A, Cella D et al. Vulvar cancer patients' quality of life: a qualitative 
assessment. Int J Gynecol Cancer. 2004;14: 875-81. 
[29] Jefferies H, Groves J. In: Gynecologic Cancer: Controversies in Management. Edited by 
David Gershenson, McGuire and Gore von Churchill Livingstone. 2004, ISBN 0-
443-07142-X. 
[30] Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-
Oct;60(5):277-300. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-
Apr;61(2):133-4. 
 
Sexuality After Ovarian Cancer Therapy 
 
325 
[31] Madeb R, Golijanin D, Knopf J, Vicente I, Erturk E, Patel HR, Joseph JV. Patient-
reported validated functional outcome after extraperitoneal robotic-assisted nerve-
sparing radical prostatectomy. JSLS. 2007 Oct-Dec;11(4):443-8. Review.  
[32] Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E. 
Use of hormone replacement therapy before and after ovarian cancer diagnosis and 
ovarian cancer survival. Int J Cancer. 2006 Dec 15;119(12):2907-15. 
[33] McGregor BA, Carver CS, Antoni MH, et al. Distress and internalized homophobia 
among lesbian women treated for early stage breast cancer. Psychol Women Quart. 
2001;25:1–9. 
[34] Michaelson-Cohen R, Beller U. Managing menopausal symptoms after gynecological 
cancer. Curr Opin Oncol. 2009 Jul 7. [Epub ahead of print].  
[35] Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone 
therapy and ovarian cancer. JAMA. 2009 Jul 15;302(3):298-305. 
[36] Oskay-Oezcelik G, Neubert S, Munstedt K, Liebrich K, Hanker LC, Lorenz R, 
Wimberger P, Mahner S, Hindenburg HJ, Sehouli J. What do primary and recurrent 
ovarian cancer (OC) patients expect from their doctors? Final results of a german 
survey in 676 patients. A Study of The North-Eastern German Society of 
Gynaecological Oncology (NOGGO). ASCO 2010. 
[37] Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor 
symptoms: Current treatment options, challenges and future directions. Int J 
Womens Health. 2010 Aug 9;2:123-35.  
[38] Passik SD, Dugan W, McDonald MV et al. Oncologists' recognition of depression in 
their patients with cancer. J Clin Oncol. 1998;16: 1594-600. 
[39] Raboch J, Boudnik V, Raboch Jr J. Sex life following hysterectomy. Geburtsh 
Frauenheilk 1985; 45: 48–50 
[40] Reid DM. Prevention of osteoporosis after breast cancer. Maturitas. 2009 Sep 20;64(1):4-
8. Epub 2009 Aug 25. 
[41] Sadovsky R, Basson R, Krychman M et al. Cancer and sexual problems. The journal of 
sexual medicine. 2009;7: 349-73. 
[42] Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in 
women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 
682–688 
[43] Sideras K, Loprinzi CL. Nonhormonal management of hot flashes for women on risk 
reduction therapy. J Natl Compr Canc Netw. 2010 Oct;8(10):1171-9. 
[44] Sitruk-Ware R. Estrogen therapy during menopause. Practical treatment 
recommendations. Drugs 1990; 39: 203–217.  
[45] Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between 
healthcare professionals and women with ovarian cancer about sexual issues. Br J 
Cancer 2003; 88: 666–671 
[46] Taylor C. Predictors of sexual functioning in ovarian-cancer patients. J of Clin Oncol 
2004; 22: 881–889.  
[47] Vitrano V, Catania V, Mercadante S. Sexuality in patients with advanced cancer: a 
prospective study in a population admitted to an acute pain relief and palliative 
care unit. Am J Hosp Palliat Care. 2011 May;28(3):198-202. 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
326 
[48] Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog 
TJ. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 
2009 Sep 15;115(18):4118-26. 
17 
Quality of Life of Patients with Ovarian Cancer 
Wei-Chu Chie1 and Elfriede Greimel2 
1Institute of Epidemiology and Preventive Medicine,  
College of Public Health, National Taiwan University  




1.1 Current status of ovarian cancer 
Ovarian cancer is one of the leading female cancers around the world (International Agency 
for Research on Cancer, 2011). Up to now, there is no effective method of early detection (US 
Task Force of Preventive Services, 2011). When detected, the stages are usually advanced, 
and patients have poor prognosis and poor health-related quality of life (HRQoL). Patient-
reported outcomes have been recommended as endpoints of clinical trials by the U.S. Food 
and Drug Administration (FDA) (2011). Therefore, besides improving survival, a better 
HRQoL is a major goal for the development of methods for new detection and treatments. 
1.2 The impacts of the disease 
Patients with ovarian cancer share general functioning and systemic problems with patients 
with other cancers (Cella et al., 1993; Cain et al., 1998; Base-Enquist et al., 2001; Aaronson et al., 
1993). Regarding disease-specific problems, abdominal / gastrointestinal symptoms because of 
the space-occupying nature of the tumor and the malignant ascites from the tumor in the 
pelvic and abdominal cavity are most important issues (Cain et al., 1998; Base-Enquist et al., 
2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). The disease recurs easily. Patients may 
suffer repeating debulking surgeries and chemotherapies that affect their HRQoL. 
1.3 The impacts of the treatments 
The standard treatment of this disease is debulking (cytoreduction) surgery followed by 
platinum-based chemotherapy (du Bois at al., 2005), while a new approach of neoadjuvant 
chemotherapy followed by debulking surgery (Brisow & Chi, 2006). These treatments, no 
matter which comes first, can improve survival and improve HRQoL of patients by 
reducing tumor size and ascites, and also patients’ psychological distress. But they may also 
have negative impacts on HRQoL of patients because of the adverse effects of chemotherapy 
and surgery. 
1.4 Other important aspects of HRQoL 
The life-threatening nature of the illness can also cause psychological distress (Cull et al., 
2001; Greimel et al., 2003a, 2003b). As all other gynecological cancers, patients with ovarian 
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cancer suffer from body image concerns and problems in sexual life (Cain et al., 1998; Base-
Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2. Domains of HRQoL affected by disease and treatments of ovarian cancer 
2.1 Disease-related problems 
2.1.1 General functioning and systemic symptoms 
General functioning including physical, emotional, social, etc. (Cella et al., 1993; Aaronson et 
al., 1993) and ability of getting around (independence) are major issues in this category 
(Cain et al., 1998; Base-Enquist et al., 2001). Weight loss is also seen as a disease-related 
systemic symptom for advanced tumor (Cain et al., 1998; Base-Enquist et al., 2001). 
2.1.2 Abdominal (gastrointestinal) symptoms 
Abdominal (gastrointestinal) symptoms are major disease-related HRQoL problems of 
patients with ovarian cancer. These symptoms may include abdominal swelling, fullness, 
pain or cramps, indigestion, change of bowel habit, etc. Abdominal pain and bowel habit 
change can also arise from treatment (Cain et al., 1998; Base-Enquist et al., 2001; Cull et al., 
2001; Greimel et al., 2003a, 2003b). 
2.2. Treatment-related problems 
2.2.1 Urological and gynecological symptoms 
The urological or gynecological symptoms are not as common as other gynecological 
cancers, and they are usually caused by treatment. Urinary frequency and dry vagina are 
often complained of (Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2.2.2 Chemotherapy side effects 
Chemotherapy can cause nausea and vomiting, poor appetite (Cella et al., 1993; Cain et al., 
1998; Base-Enquist et al., 2001; Aaronson et al., 1993), hair loss (Cain et al., 1998; Base-
Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b), peripheral neuropathy 
including numbness and weakness, other sensory change, skin problems and muscle pain 
(Cull et al., 2001; Greimel et al., 2003a, 2003b). Urinary frequency can also be attributed to 
chemotherapy (Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2.2.3 Termination of reproductive ability and menopausal symptoms 
For women of reproductive age, both surgical treatment and chemotherapy can cause early 
menopause and the termination of reproductive ability (Cain et al., 1998; Base-Enquist et al., 
2001). Menopausal symptoms caused by hormonal depletion, including hot flush (flash) and 
night sweats, are also experienced by these patients (Cull et al., 2001; Greimel et al., 2003a, 
2003b). 
2.3 Other important aspects in HRQoL 
2.3.1 Body image and psychological problems 
Like all other gynecological cancer, ovarian cancer per se and its treatment can cause body 
image and psychological problems. For the body image problems, patients may feel less 
attractive, less like a woman, dissatisfied with body or appearance, etc. (Cain et al., 1998; 
Base-Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). For the psychological 
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problem, patients may have negative emotions (Cella et al., 1993; Aaronson et al., 1993), or 
suffer from burdens of and worries about disease or treatment (Cull et al., 2001; Greimel et 
al., 2003a, 2003b). 
2.3.2 Sexuality 
Like all other gynecological cancers, sexuality is negatively affected. Issues include interest 
in sex, real sexual activity and enjoyment (Cain et al., 1998; Base-Enquist et al., 2001; Cull et 
al., 2001; Greimel et al., 2003a, 2003b). Dry vagina during intercourse, a result of hormonal 
depletion, can also be classified in this category (Cull et al., 2001; Greimel et al., 2003a, 
2003b). 
3. Existing instruments for assessment of HRQoL 
We have at present two systems of disease-specific instruments for assessment of HRQoL of 
patients with ovarian cancer: the Functional Assessment of Cancer Therapy (FACT) and the 
European Organisation for Research and Treatment of Cancer (EORTC). Both have a generic 
core questionnaire, the FACT-G and the EORTC QLQ-C30, and a disease-specific 
supplementary questionnaire, the FACT-O and the EORTC QLQ-OV28.  
3.1 The FACT system: FACT-G and FACT-O 
3.1.1 The scale structure of the FACT system 
The FACT-G was developed as a general measure for HRQoL of patients with cancer in 1987 
(Cella et al., 1993) and validated in patients with different cancers before the development of 
ovarian specific scale (Weitzner et al., 1995; Cella, 1995; List at al., 1996; Brady at al., 1997; 
Esper at al., 1997; Yellen at al., 1997; McQuellon et al., 1997; Ward at al., 1999). The 
instrument contains four domains and 27 questions: physical well-being (PWB), 7 questions; 
social / family well-being (SWB), 7 questions; emotional well-being (EWB), 6 questions; and 
functional well-being (FWB), 7 questions (Cella et al., 1993). Each question has 5 options: 0 
(not at all), 1 (a little bit), 3 (quite a bit), and 4 (very much). All item scores are recoded to 
make a high score corresponding to better HRQoL. It can be seen either as a disease-specific 
instrument vs. other diseases or a generic instrument for all patients with cancer. An ovarian 
cancer-specific subscale (OCS) was developed in 1998 using the same option format (Cain et 
al., 1998) and was reported to have good reliability and validity in 2001 (Base-Enquist et al., 
2001). The questionnaire contains one domain, originally 12 questions: stomach swelling, 
losing weight, vomiting, hair loss, stomach cramping, and concerns about fertility (negative 
questions); bowel control, good appetite, appearance, getting around, feel like a woman, and 
interested in sex (positive questions, reverse coded). One question (concerns about fertility) 
was deleted because most patients are beyond childbearing age. The two instruments are 
used together when assessing HRQoL of patients with ovarian cancer. The score of each 
scale is a summation of recoded question scores within each scale. The total score is a 
summation of all scores of all 38 (27 and 11) questions together. 
3.1.2 Reliability and validity of the FACT system in patients with ovarian cancer 
Reliability and validity of the FACT-O with FACT-G were reported by Base-Enquist et al. 
(2001). The internal consistency (Cronbach’s alpha) coefficient of the 11 questions in FACT-
O was 0.92, and test-retest correlation coefficient of the total FACT-O score was 0.81. The 
correlation coefficients between the total FACT-O score, subscale scores of FACT-G, and 
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cancer suffer from body image concerns and problems in sexual life (Cain et al., 1998; Base-
Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). 
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2001; Greimel et al., 2003a, 2003b). 
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2.2.2 Chemotherapy side effects 
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Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b), peripheral neuropathy 
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chemotherapy (Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2.2.3 Termination of reproductive ability and menopausal symptoms 
For women of reproductive age, both surgical treatment and chemotherapy can cause early 
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problem, patients may have negative emotions (Cella et al., 1993; Aaronson et al., 1993), or 
suffer from burdens of and worries about disease or treatment (Cull et al., 2001; Greimel et 
al., 2003a, 2003b). 
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2003b). 
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patients with ovarian cancer: the Functional Assessment of Cancer Therapy (FACT) and the 
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ovarian specific scale (Weitzner et al., 1995; Cella, 1995; List at al., 1996; Brady at al., 1997; 
Esper at al., 1997; Yellen at al., 1997; McQuellon et al., 1997; Ward at al., 1999). The 
instrument contains four domains and 27 questions: physical well-being (PWB), 7 questions; 
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functional well-being (FWB), 7 questions (Cella et al., 1993). Each question has 5 options: 0 
(not at all), 1 (a little bit), 3 (quite a bit), and 4 (very much). All item scores are recoded to 
make a high score corresponding to better HRQoL. It can be seen either as a disease-specific 
instrument vs. other diseases or a generic instrument for all patients with cancer. An ovarian 
cancer-specific subscale (OCS) was developed in 1998 using the same option format (Cain et 
al., 1998) and was reported to have good reliability and validity in 2001 (Base-Enquist et al., 
2001). The questionnaire contains one domain, originally 12 questions: stomach swelling, 
losing weight, vomiting, hair loss, stomach cramping, and concerns about fertility (negative 
questions); bowel control, good appetite, appearance, getting around, feel like a woman, and 
interested in sex (positive questions, reverse coded). One question (concerns about fertility) 
was deleted because most patients are beyond childbearing age. The two instruments are 
used together when assessing HRQoL of patients with ovarian cancer. The score of each 
scale is a summation of recoded question scores within each scale. The total score is a 
summation of all scores of all 38 (27 and 11) questions together. 
3.1.2 Reliability and validity of the FACT system in patients with ovarian cancer 
Reliability and validity of the FACT-O with FACT-G were reported by Base-Enquist et al. 
(2001). The internal consistency (Cronbach’s alpha) coefficient of the 11 questions in FACT-
O was 0.92, and test-retest correlation coefficient of the total FACT-O score was 0.81. The 
correlation coefficients between the total FACT-O score, subscale scores of FACT-G, and 
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
330 
subscale scores of other related instruments were as expected (good convergent and 
divergent validity). The scores of subscales of the FACT-G and the total FACT-O score were 
significantly different in different performance and treatment status, and were sensitive to 
changes of performance status. According to the validation results, the FACT-O is a reliable 
and valid instrument used with the FACT-G in assessment of ovarian cancer-specific 
HRQoL as a whole for patients with ovarian cancer. 
3.2 The EORTC system: QLQ-C30 and QLQ-OV28 
3.2.1 The scale structure of the EORTC system 
The development of the EORTC QLQ-C30 can be traced back in 1986. The questionnaire was 
designed for the measurement of general HRQoL issued for patients with cancer (Aaronson 
et al., 1993). It can also be seen either as a disease-specific instrument vs. other diseases or a 
generic instrument for all patients with cancer. The questionnaire contains 30 questions 
belonging to five functional scales (physical, role, emotional, social, and cognitive), nine 
symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite 
loss, constipation, and diarrhea), financial difficulty in the past week, and one global health 
status (overall health and quality of life) scale. Each question has 4 options: 1 (not at all), 2 (a 
little), 3 (quite a bit), and 4 (very much). Each scale is scored separately. There is no total 
score. All scale scores are transformed into 0-100 from a recoded summation of item scores 
in each scale. For all functional scales, a higher score represents a better HRQoL. For all 
symptom scales and financial difficulty, a higher score means a poorer HRQoL. Previous 
studies showed good reliability and validity for different cancer diagnoses (Bjordal & Kaasa, 
1992; Aaronson et al., 1993; Hjermstad et al., 1995; Groenvold et al., 1997; Kobayashi et al., 
1998). 
The EORTC QLQ-OV28 was designed as a supplement to the EORTC QLQ-C30 for the use 
in ovarian cancer clinical trials and related studies (Cull et al., 2001; Greimel et al., 2003a, 
2003b). It contains seven subscales and 28 questions – abdominal / gastrointestinal 
symptoms (7 questions: abdominal pain, feeling bloated, clothes too tight, changed bowel 
habit, flatulence, fullness when eating, indigestion), peripheral neuropathy (4 questions: 
tingling, numbness, and weakness), other chemotherapy side-effects (7 questions: hair loss 
and upset by hair loss, taste change, muscle pain, hearing problem, urinary frequency, and 
skin problem), hormonal / menopausal (2 questions: hot flushes and night sweat), body 
image (2 questions: less attractive, dissatisfied with body), attitude to disease and treatment 
(3 questions: disease burden, treatment burden, and worry about future), and sexual 
function (4 questions: interest in sex, sexual activity, enjoyment of sex, and dry vagina). Each 
scale is scored separately as that of the EORTC QLQ-C30. For symptom scales, a higher 
score means a poorer HRQoL. For function scales (body image and sexual function), a 
higher score represent a better HRQoL. In addition to the cross-cultural validation of the 
EORTC, Chie et al. (2010) reported the translation and validation of the EORTC QLQ-OV28 
in Taiwan and found a relatively low importance of body image, menopausal, and sexuality 
problems because of low emphasis on attractiveness and avoidance of sexual activity after 
having cancer. 
3.2.2 Reliability and validity of the EORTC system in patients with ovarian cancer 
Greimel et al. (2003b) reported the result of cross-cultural validation of the EORTC QLQ-
OV28 used with the EORTC QLQ-C30. The internal consistency (Cronbach’s alpha) 
coefficients of all subscales except body image (0.58) were above 0.70 (ranging from 0.77 to 
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0.90). There was no scaling error except the subscale of other chemotherapy side effects 
(5/42). The intraclass correlation coefficients for test-retest of all subscales ranged from 0.74 
to 0.94. The correlation coefficients between subscales of the EORTC QLQ-OV28 and EORTC 
QLQ-C30 were as expected. For responsiveness, scores of abdominal symptoms, peripheral 
neuropathy, other chemotherapy side effects, and disease burden responded significantly 
after treatment. For sensitivity (known-groups comparison), subscale scores differed most 
significantly between patients with primary and recurrent tumors. According to the 
validation report, the EORTC QLQ-OV28 is a reliable and valid multi-dimensional 
instrument used with the EORTC QLQ-C30 for the assessment of HRQoL of multiple 
aspects for patients with ovarian cancer. 
3.3 Comparison of scale structures of the two systems 
The comparison of the two sets of instruments is shown in Tables 1 and 2. The functional 
scales of the FACT-G and the EORTC QLQ-C30 are similar. Both include physical, mental 
or emotional, social, and role or functional subscales. The FACT-G emphasizes familial 
functioning, while the EORTC QLQ-C30 includes cognitive functioning. Both have an 
overall measure for HRQoL: the FACT-G uses a summation of all scores, while the 
EORTC QLQ-C30 measures it separately. The EORTC QLQ-C30 also has symptom and 
financial difficulty subscales. The FACT-G includes some symptoms in physical or 
function subscales (Table 1). The contents of the FACT-O and the EORTC QLQ-OV28 are 
similar. However, the FACT-O has only one overall scale for ovarian cancer, while the 
EORTC QLQ-OV28 has seven subscales covering problems of different organ-systems or 
aspects of HRQoL (Table 2). 
 
FACT EORTC 
Physical  Energy Physical  Strenuous activity 
 Nausea   Long walk 
 Family needs   Short walk 
 Pain   Stay in chair 
 Side effects  Self-care 
 Feel ill   
 Bed-ridden   
Social /family Close to friends Social  Interfere with family life 
 Family support  With social activities  
 Friends’ support   
 Family comm. illness   
 Close to partner   
 Sexual life   
Emotional  Feel sad Emotional  Tense 
 Satisfied with coping  Worry  
 Losing hope  Irritable  
 Feel nervous  Depressed  
 Worry / dying Cognitive  Concentration  
 Worry / getting worse  Remembering  
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subscale scores of other related instruments were as expected (good convergent and 
divergent validity). The scores of subscales of the FACT-G and the total FACT-O score were 
significantly different in different performance and treatment status, and were sensitive to 
changes of performance status. According to the validation results, the FACT-O is a reliable 
and valid instrument used with the FACT-G in assessment of ovarian cancer-specific 
HRQoL as a whole for patients with ovarian cancer. 
3.2 The EORTC system: QLQ-C30 and QLQ-OV28 
3.2.1 The scale structure of the EORTC system 
The development of the EORTC QLQ-C30 can be traced back in 1986. The questionnaire was 
designed for the measurement of general HRQoL issued for patients with cancer (Aaronson 
et al., 1993). It can also be seen either as a disease-specific instrument vs. other diseases or a 
generic instrument for all patients with cancer. The questionnaire contains 30 questions 
belonging to five functional scales (physical, role, emotional, social, and cognitive), nine 
symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite 
loss, constipation, and diarrhea), financial difficulty in the past week, and one global health 
status (overall health and quality of life) scale. Each question has 4 options: 1 (not at all), 2 (a 
little), 3 (quite a bit), and 4 (very much). Each scale is scored separately. There is no total 
score. All scale scores are transformed into 0-100 from a recoded summation of item scores 
in each scale. For all functional scales, a higher score represents a better HRQoL. For all 
symptom scales and financial difficulty, a higher score means a poorer HRQoL. Previous 
studies showed good reliability and validity for different cancer diagnoses (Bjordal & Kaasa, 
1992; Aaronson et al., 1993; Hjermstad et al., 1995; Groenvold et al., 1997; Kobayashi et al., 
1998). 
The EORTC QLQ-OV28 was designed as a supplement to the EORTC QLQ-C30 for the use 
in ovarian cancer clinical trials and related studies (Cull et al., 2001; Greimel et al., 2003a, 
2003b). It contains seven subscales and 28 questions – abdominal / gastrointestinal 
symptoms (7 questions: abdominal pain, feeling bloated, clothes too tight, changed bowel 
habit, flatulence, fullness when eating, indigestion), peripheral neuropathy (4 questions: 
tingling, numbness, and weakness), other chemotherapy side-effects (7 questions: hair loss 
and upset by hair loss, taste change, muscle pain, hearing problem, urinary frequency, and 
skin problem), hormonal / menopausal (2 questions: hot flushes and night sweat), body 
image (2 questions: less attractive, dissatisfied with body), attitude to disease and treatment 
(3 questions: disease burden, treatment burden, and worry about future), and sexual 
function (4 questions: interest in sex, sexual activity, enjoyment of sex, and dry vagina). Each 
scale is scored separately as that of the EORTC QLQ-C30. For symptom scales, a higher 
score means a poorer HRQoL. For function scales (body image and sexual function), a 
higher score represent a better HRQoL. In addition to the cross-cultural validation of the 
EORTC, Chie et al. (2010) reported the translation and validation of the EORTC QLQ-OV28 
in Taiwan and found a relatively low importance of body image, menopausal, and sexuality 
problems because of low emphasis on attractiveness and avoidance of sexual activity after 
having cancer. 
3.2.2 Reliability and validity of the EORTC system in patients with ovarian cancer 
Greimel et al. (2003b) reported the result of cross-cultural validation of the EORTC QLQ-
OV28 used with the EORTC QLQ-C30. The internal consistency (Cronbach’s alpha) 
coefficients of all subscales except body image (0.58) were above 0.70 (ranging from 0.77 to 
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0.90). There was no scaling error except the subscale of other chemotherapy side effects 
(5/42). The intraclass correlation coefficients for test-retest of all subscales ranged from 0.74 
to 0.94. The correlation coefficients between subscales of the EORTC QLQ-OV28 and EORTC 
QLQ-C30 were as expected. For responsiveness, scores of abdominal symptoms, peripheral 
neuropathy, other chemotherapy side effects, and disease burden responded significantly 
after treatment. For sensitivity (known-groups comparison), subscale scores differed most 
significantly between patients with primary and recurrent tumors. According to the 
validation report, the EORTC QLQ-OV28 is a reliable and valid multi-dimensional 
instrument used with the EORTC QLQ-C30 for the assessment of HRQoL of multiple 
aspects for patients with ovarian cancer. 
3.3 Comparison of scale structures of the two systems 
The comparison of the two sets of instruments is shown in Tables 1 and 2. The functional 
scales of the FACT-G and the EORTC QLQ-C30 are similar. Both include physical, mental 
or emotional, social, and role or functional subscales. The FACT-G emphasizes familial 
functioning, while the EORTC QLQ-C30 includes cognitive functioning. Both have an 
overall measure for HRQoL: the FACT-G uses a summation of all scores, while the 
EORTC QLQ-C30 measures it separately. The EORTC QLQ-C30 also has symptom and 
financial difficulty subscales. The FACT-G includes some symptoms in physical or 
function subscales (Table 1). The contents of the FACT-O and the EORTC QLQ-OV28 are 
similar. However, the FACT-O has only one overall scale for ovarian cancer, while the 
EORTC QLQ-OV28 has seven subscales covering problems of different organ-systems or 
aspects of HRQoL (Table 2). 
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Functional  Able to work Role  Limited work 
 Work fulfilling  Limited leisure 
 Enjoy life   
 Sleep well    
 Enjoy pleasure   
 Content with QOL Overall  Health  
   QOL 
Symptoms   Pain, Fatigue, Nausea & vomiting 
Dyspnea, Sleep, Appetite, constipation, 
diarrhea  
Other scale(s)  Financial difficulty 
Table 1. Comparison of FACT-G and the EORTC QLQ-C30. 
 
FACT EORTC 
FACT-O (one scale) 
Stomach swelling, losing weight, bowel 
control, vomiting, hair loss, good appetite, 
appearance, getting around, feel like a 
woman, stomach cramping, interested in sex, 
concerns about fertility (deleted) 
























Treatment burden,  
Worry about future 
Sexual function Interest in sex, 
Sexual activity, Sex 
enjoyment,  Dry 
vagina 
Table 2. Comparison of FACT-O and the EORTC QLQ-OV28. 
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4. Equivalence of the FACT and the EORTC systems 
Are the results of the two systems equivalent? Hozner et al. (2006) reported a study on 737 
patients with different cancers for the equivalence of the FACT-G and the EORTC QLQ-C30, 
the core content of the two systems. Both classical test theory and Rasch measurement 
model were used. Three of the four subscales common to the two systems are equating: 
physical, emotional, and role / functional, but not the social / family subscale. A converting 
table was generated according to the results. No such study was conducted for the FACT-O 
and the EORTC QLQ-OV28 because the FACT-O has only one subscale, therefore the two 
site-specific questionnaires have no common subscales to study. 
5. Application of two systems in assessing HRQoL of patients with ovarian 
cancer undergoing different treatments across different cultures 
5.1 The application of the FACT system 
The two systems of instruments measuring HRQoL of patients with ovarian cancer were 
used in clinical trials and non-trial clinical studies. The FACT system was more widely used 
because the FACT-O was developed earlier than the EORTC QLQ-OV28. The FACT-O has 
been applied in studies assessing palliative chemotherapy for advanced ovarian cancer 
(using EORTC QLQ-C30 and FACT-O) (Doyle et al., 2001), general chemotherapy ( Le et al., 
2004), adjuvant and salvage chemotherapy for advanced ovarian cancer (Le et al., 2005), 
interval cytoreduction in advanced ovarian cancer (Wenzel et al., 2005), active coping 
(Canada et al., 2006), Thallidomide therapy (Gordinier et al., 2007), phase I/II gemcitabine 
and doxirubicine (Goff et al., 2003)] and phase II gemicitabine and topotecan trials for 
platinum-refractory ovarian cancers (Goff et al., 2008), and factors for decreased QoL (von 
Gruenigen et al., 2009). In summary, the FACT-O and FACT-G scores became better when 
there was response to treatment, active coping can improve HRQoL, and factors causing 
decreased HRQoL can be detected and managed in advance. 
5.2 The application of the EORTC system 
The use of the EORTC QLQ-OV28 with the EORTC QLQ-C30 was less common because it 
was developed later than the FACT-O. The two questionnaires were first used in a study 
assessing HRQoL for patients after pelvic exenteration in 2004 (Roos et al., 2004) where more 
physical, social, and sexual problems, especially for young patients were reported after 
surgery. A comparison of HRQoL of patients with early vs. advanced ovarian cancer 
(Mirabeau-Beale et al., 2009) found comparable HRQoL in two groups. A clinical trial of 
neoadjuvant platinum-based chemotherapy followed by (interval) debulking surgery vs. 
standard care of primary debulking surgery followed by platinum-based chemotherapy in 
stage IIIC or IV ovarian cancer used the two questionnaires did not detect any difference 
between the two arms in HRQoL (Vergote et al., 2010). The EORTC QLQ-C30 alone without 
the EORTC QLQ-OV28 has been used in a randomized trial of cisplatin / paclitaxel vs. 
carboplatin / paclitaxel and found patients undergoing carboplatin / paclitaxel treatment 
had better HRQoL (Greimel et al., 2006). Another study using the EORTC QLQ-C30 
assessing the HRQoL of long-term survivors of ovarian cancer found long-term survivors 
had better HRQoL scores before treatment than short-term survivors, and long-term 
survivors had significant improvement of HRQoL in emotional and global health scores 1 
year after treatment and remained stable. The scores of all domains but dyspnea were 
comparable with women without cancer (Greimel et al., 2011). 
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4. Equivalence of the FACT and the EORTC systems 
Are the results of the two systems equivalent? Hozner et al. (2006) reported a study on 737 
patients with different cancers for the equivalence of the FACT-G and the EORTC QLQ-C30, 
the core content of the two systems. Both classical test theory and Rasch measurement 
model were used. Three of the four subscales common to the two systems are equating: 
physical, emotional, and role / functional, but not the social / family subscale. A converting 
table was generated according to the results. No such study was conducted for the FACT-O 
and the EORTC QLQ-OV28 because the FACT-O has only one subscale, therefore the two 
site-specific questionnaires have no common subscales to study. 
5. Application of two systems in assessing HRQoL of patients with ovarian 
cancer undergoing different treatments across different cultures 
5.1 The application of the FACT system 
The two systems of instruments measuring HRQoL of patients with ovarian cancer were 
used in clinical trials and non-trial clinical studies. The FACT system was more widely used 
because the FACT-O was developed earlier than the EORTC QLQ-OV28. The FACT-O has 
been applied in studies assessing palliative chemotherapy for advanced ovarian cancer 
(using EORTC QLQ-C30 and FACT-O) (Doyle et al., 2001), general chemotherapy ( Le et al., 
2004), adjuvant and salvage chemotherapy for advanced ovarian cancer (Le et al., 2005), 
interval cytoreduction in advanced ovarian cancer (Wenzel et al., 2005), active coping 
(Canada et al., 2006), Thallidomide therapy (Gordinier et al., 2007), phase I/II gemcitabine 
and doxirubicine (Goff et al., 2003)] and phase II gemicitabine and topotecan trials for 
platinum-refractory ovarian cancers (Goff et al., 2008), and factors for decreased QoL (von 
Gruenigen et al., 2009). In summary, the FACT-O and FACT-G scores became better when 
there was response to treatment, active coping can improve HRQoL, and factors causing 
decreased HRQoL can be detected and managed in advance. 
5.2 The application of the EORTC system 
The use of the EORTC QLQ-OV28 with the EORTC QLQ-C30 was less common because it 
was developed later than the FACT-O. The two questionnaires were first used in a study 
assessing HRQoL for patients after pelvic exenteration in 2004 (Roos et al., 2004) where more 
physical, social, and sexual problems, especially for young patients were reported after 
surgery. A comparison of HRQoL of patients with early vs. advanced ovarian cancer 
(Mirabeau-Beale et al., 2009) found comparable HRQoL in two groups. A clinical trial of 
neoadjuvant platinum-based chemotherapy followed by (interval) debulking surgery vs. 
standard care of primary debulking surgery followed by platinum-based chemotherapy in 
stage IIIC or IV ovarian cancer used the two questionnaires did not detect any difference 
between the two arms in HRQoL (Vergote et al., 2010). The EORTC QLQ-C30 alone without 
the EORTC QLQ-OV28 has been used in a randomized trial of cisplatin / paclitaxel vs. 
carboplatin / paclitaxel and found patients undergoing carboplatin / paclitaxel treatment 
had better HRQoL (Greimel et al., 2006). Another study using the EORTC QLQ-C30 
assessing the HRQoL of long-term survivors of ovarian cancer found long-term survivors 
had better HRQoL scores before treatment than short-term survivors, and long-term 
survivors had significant improvement of HRQoL in emotional and global health scores 1 
year after treatment and remained stable. The scores of all domains but dyspnea were 
comparable with women without cancer (Greimel et al., 2011). 
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5.3 A comparison of the two systems in HRQoL assessment 
A review article in 2010 commented after comparing all generic and specific questionnaires 
for HRQoL of patients with gynecologic cancers that there is little evidence that disease-, 
symptom- or treatment-specific instruments are more responsive or sensitive than generic or 
cancer-specific questionnaires, and a superior quality and quantity data reported for the 
FACT system compared with the EORTC system (Luckett et al., 2010). Nordin and Greimel 
on behalf of the EORTC Quality of Life Gynecology Group (2010) responded in a letter that 
such comments are not substantiated and provided examples of good results of cross-
cultural validation. In addition to the cross-cultural nature, the multi-dimensional structure 
of the EORTC system may also help clinical researchers and practitioners conduct more 
detailed assessment of different aspects of HRQoL of patients. 
6. Future development 
Ovarian cancer is an important gynecological cancer which affects the survival and HRQoL 
of patients (International Agency for Research on Cancer, 2011). The keys to improve both 
survival and HRQoL are methods of early detection (US Task Force of Preventive Services, 
2011) and effective treatment (du Bois at al., 2005; Brisow & Chi, 2006). We expect 
breakthroughs in both early detection and effective treatment in the near future. Patient-
reported outcomes have been recommended as endpoints of clinical trials by the U.S. Food 
and Drug Administration (FDA) (2011). To evaluate the effectiveness of these methods, 
HRQoL is an essential primary endpoint. Two systems of HRQoL assessment, i.e. the FACT 
and the EORTC systems are available. Both cover major issues of HRQoL and show good 
reliability and validity in previous reports and are used widely around the world in clinical 
trials and clinical studies. Therefore, we expect that the assessment of HRQoL of patients 
can be routinely included in clinical researches and practice, to understand and further 
improve patients’ HRQoL. 
7. Conclusions 
Ovarian cancer is one of the leading female cancers around the world. There is no effective 
method of early detection. When detected, the stages are usually advanced, and patients 
have poor health-related quality of life (HRQoL). The standard treatments of this disease 
including debulking surgery and chemotherapy can improve survival and may have either 
positive or negative impacts on HRQoL of patients. The disease recurs easily. Patients may 
suffer repeating debulking surgeries and chemotherapies that affect their HRQoL. In this 
chapter, we introduced and reviewed the scale structures, psychometric properties and 
clinical validities of existing instruments – the FACT system and the EORTC system for the 
assessment of HRQoL for patients with ovarian cancer, and report the results of their 
application in clinical trials and observational studies. We hope that HRQoL can be 
emphasized and routinely assessed for all patients with ovarian cancer in future clinical 
researches and practice. 
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